<SEC-DOCUMENT>0001570562-17-000005.txt : 20180108
<SEC-HEADER>0001570562-17-000005.hdr.sgml : 20180108
<ACCEPTANCE-DATETIME>20170828142846
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001570562-17-000005
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20170828
<PUBLIC-REL-DATE>20180108
DATE AS OF CHANGE:		20170926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01693
		FILM NUMBER:		171054243

	BUSINESS ADDRESS:	
		STREET 1:		17901 VON KARMAN AVENUE, SUITE 150
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		17901 VON KARMAN AVENUE, SUITE 150
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s88340233DD1A57E945111527CB97F068"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Confidential Draft No. 1, as confidentially submitted to the Securities and Exchange Commission on August 28, 2017</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Registration No. 333-</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;font-weight:bold;">FORM S-1</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;font-weight:bold;">REGISTRATION STATEMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;font-weight:bold;">UNDER</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;font-weight:bold;">THE SECURITIES ACT OF 1933</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:20pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:20pt;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:7pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">2834</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">46-1385614</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(State or other jurisdiction of </font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(Primary Standard Industrial</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Classification Code Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1027 Garden Street </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Santa Barbara, California 93101</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(949) 284-4555</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Murthy Simhambhatla, Ph.D.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#32;Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1027 Garden Street </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Santa Barbara, California 93101</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7.5pt;font-weight:bold;">(949) 284-4555</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-style:italic;font-weight:bold;">Copies to:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Michael A. Hedge</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">David C. Lee</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">K&amp;L Gates LLP</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1 Park Plaza </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Twelfth Floor </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Irvine, California 92614</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(949) 253-0900</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Jeffrey J. Plumer, Vice President, Legal</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Evolus, Inc.</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1027 Garden Street</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Santa Barbara, California 93101</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(949) 284-4555</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Michael J. Zeidel</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Skadden, Arps, Slate, Meagher &amp; Flom LLP</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">4 Times Square</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">New York, New York 10036</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(212) 735-3000</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">___________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Approximate date of commencement of proposed sale to the public:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">As soon as practicable after the effective date of this Registration Statement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:18%;"></td><td style="width:26%;"></td><td style="width:26%;"></td><td style="width:12%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box. &#9744;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Non-accelerated filer</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9746; (Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">Emerging Growth Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9746; </font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. </font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">&#9746; </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">CALCULATION OF REGISTRATION FEE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:64%;"></td><td style="width:18%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Title of Each Class of Securities to be Registered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #231f20;border-right:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Proposed Maximum Aggregate Offering Price(1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Amount of </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Registration Fee(2)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #231f20;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Common Stock, $0.00001 par value per share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #231f20;border-right:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">$</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Includes the offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sBEE17A5DE014084AAD201527CBB76CD7"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#d81e05;font-weight:bold;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#d81e05;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;color:#de1a1e;font-style:normal;font-weight:normal;">SUBJECT TO COMPLETION, DATED&#160;&#160;&#160;&#160;&#160;, 2017       </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;">PRELIMINARY PROSPECTUS</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</font><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;text-align:center;"><img src="higherreslogowithtma01.jpg" alt="higherreslogowithtma01.jpg" style="height:80px;width:296px;"></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Evolus, Inc.</font><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</font><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">_____________________________</font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. We expect the initial public offering price to be between $&#160;&#160;&#160;&#160;&#160;&#160;&#160;and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. We intend to apply to have our common stock listed on the Nasdaq Global Market, or Nasdaq, under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;.&#8221;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon completion of this offering, our parent company, ALPHAEON Corporation, or ALPHAEON, will own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our outstanding common stock, representing approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total voting power of our outstanding common stock (or approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total voting power of our outstanding common stock, if the underwriters exercise in full their option to purchase additional shares of our common stock in this offering). As a result of ALPHAEON&#8217;s ownership of our common stock following this offering, we will be a &#8220;controlled company&#8221; under the listing requirements of Nasdaq, or the Nasdaq Marketplace Rules. We have elected not to take advantage of the &#8220;controlled company&#8221; exemptions under the Nasdaq Marketplace Rules. See &#8220;Management&#8212;Controlled Company.&#8221;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are an &#8220;emerging growth company&#8221; under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. See &#8220;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company.&#8221;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Investing in our common stock involves a high degree of risk. Please read &#8220;Risk Factors&#8221; beginning on page 10 of this prospectus.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:5%;"></td><td style="width:57%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">PER SHARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Public Offering Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Underwriting Discounts and Commissions</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Proceeds to Evolus, Inc. (before expenses)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">(1) See &#8220;Underwriting&#8221; beginning on page 117 of</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">this prospectus for a description of compensation payable to the underwriters.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Delivery of the shares of common stock is expected to be made on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017. We have granted the underwriters an option for a period of 30 days to purchase an additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and the total proceeds to us, before expenses, will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#231f20;font-weight:bold;">Jefferies</font></div><div style="text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#231f20;font-weight:bold;">Mizuho Securities</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Prospectus dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sCC3D72A337DC44D8C4551527CC0B909C"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:94%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s6D39B55A3FFFF3FF58731527CC3D9765"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">PROSPECTUS SUMMARY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s6D39B55A3FFFF3FF58731527CC3D9765">1</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD8E40018058C18D91D811527CCBF4C02"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD8E40018058C18D91D811527CCBF4C02">10</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s01D94DB6758416D45CC61527CCE38B87"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FORWARD-LOOKING STATEMENTS AND STATISTICAL DATA</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s01D94DB6758416D45CC61527CCE38B87">45</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sF7806717EB3FCABEAD431527CD052FD7"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sF7806717EB3FCABEAD431527CD052FD7">47</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sFB45FDAB2ABFA6A8F9A51527CD3864FB"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">DIVIDEND POLICY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sFB45FDAB2ABFA6A8F9A51527CD3864FB">48</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s01AA43A51F52EDD89E571527CD5989A1"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">CAPITALIZATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s01AA43A51F52EDD89E571527CD5989A1">49</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD4A250275719E13D8DD71527CD9EBECA"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">DILUTION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD4A250275719E13D8DD71527CD9EBECA">51</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s1E4B0BD2C4E93D4AB47E1527C9F8587C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">SELECTED FINANCIAL DATA</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s1E4B0BD2C4E93D4AB47E1527C9F8587C">53</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s85E56E8A756D5FD53ABE1527CE521C25"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s85E56E8A756D5FD53ABE1527CE521C25">55</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sBF4353BE1C0F0392CEE61527CFD17063"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">BUSINESS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sBF4353BE1C0F0392CEE61527CFD17063">67</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sAB77F3F9243F371485571527CFF4F211"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">MANAGEMENT</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sAB77F3F9243F371485571527CFF4F211">91</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s9C81D7BFE8EF94F11B9C1527C9F97A27"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">EXECUTIVE AND DIRECTOR COMPENSATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s9C81D7BFE8EF94F11B9C1527C9F97A27">95</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD5CCBCB08077A63A1A911527D048FCA4"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD5CCBCB08077A63A1A911527D048FCA4">101</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sA6CBE56B911E203A57851527D078846F"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">PRINCIPAL STOCKHOLDERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sA6CBE56B911E203A57851527D078846F">105</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sC683F5846D8BB95184871527D0993F6D"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">DESCRIPTION OF CAPITAL STOCK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sC683F5846D8BB95184871527D0993F6D">107</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s4589D3ADD2480F89F82C1527D0CB3233"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">SHARES ELIGIBLE FOR FUTURE SALE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s4589D3ADD2480F89F82C1527D0CB3233">111</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sAF5774588E1EADEF04CB1527D0ED0960"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sAF5774588E1EADEF04CB1527D0ED0960">113</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s2170E55753FB8BF06E9B1527D11FBC91"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">UNDERWRITING</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s2170E55753FB8BF06E9B1527D11FBC91">117</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sDF68F2F7775C56F142A11527D1406881"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sDF68F2F7775C56F142A11527D1406881">123</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sDC15F5A5591F249C6A1E1527D17242B0"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">EXPERTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sDC15F5A5591F249C6A1E1527D17242B0">123</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCDD7DCB13D91B42E638B1527D194D92C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCDD7DCB13D91B42E638B1527D194D92C">123</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD7CB316810488F8690321527D1C6DF67"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">INDEX TO THE FINANCIAL STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD7CB316810488F8690321527D1C6DF67">F-1</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">___________________</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under the circumstances and in the jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Through and including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017 (25 days after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States.</font></div><div><br></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">i</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">EVOLUS&#8482; is one of our trademarks that is used in this prospectus. This prospectus also includes trademarks, trade names and service marks that are the property of other organizations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">, such as BOTOX</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#174;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;and BOTOX</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#174;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;Cosmetic, which we refer to throughout this prospectus as BOTOX</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">&#174; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div><br></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ii</font></div></div><hr style="page-break-after:always"><div><a name="s6D39B55A3FFFF3FF58731527CC3D9765"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">PROSPECTUS SUMMARY</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider in making your investment decision. Before deciding to invest in shares of our common stock, you should read this summary with the more detailed information appearing elsewhere in this prospectus. You should read the entire prospectus carefully, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the financial statements and the related notes, before making an investment decision regarding our common stock. Unless the context requires otherwise, references in this prospectus to &#8220;Evolus,&#8221; &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. We focus on the self-pay aesthetic market and our first product candidate, DWP-450, is an injectable 900 kilodalton, or kDa, botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We believe we will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; between the eyebrows, in the United States, European Union, or EU, and Canada. The U.S. Food and Drug Administration, or FDA, issued a Prescription Drug User Fee Act, or PDUFA, date of May 15, 2018 for completion of its review of our Biologics License Application, or BLA. We submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and it was accepted for review in July 2017 with a decision expected by the third quarter of 2018.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We successfully completed a comprehensive five-study DWP-450 clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU and a New Drug Submission, or NDS, in Canada, for the treatment of moderate to severe glabellar lines. The program, which was developed in consultation with the FDA and European regulatory bodies, included three multicenter, randomized, controlled, single dose Phase III studies and two open label, multiple dose, long-term Phase II studies. Over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in the program. All three Phase III studies successfully met their respective primary endpoints.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to patients or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Within the self-pay aesthetic market, the global aesthetic neurotoxin market is estimated to generate approximately $1.8 billion of revenue in 2017 and is estimated to grow to approximately $2.3 billion in 2020. The United States is the largest portion of this market and is estimated to generate approximately $941 million of revenue in 2017 and is expected to grow to approximately $1.2 billion in 2020. We believe the continued growth of the aesthetic neurotoxin market will be driven by an aging population, increased use by individuals between the ages of 19 and 34, whom we refer to as Millennials, rising disposable income, improved accessibility to these products and treatments due to an increase in the number of physicians who perform these procedures, continued innovation, and an increasing acceptance and utilization of elective or minimally invasive aesthetic procedures.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If approved, we plan to launch DWP-450 in the United States by building a commercialization infrastructure, including a specialty sales force of approximately 65 sales representatives at commercial launch and growing to 150 sales representatives over time. We intend for our sales force to market the product to aesthetic practices, beginning with U.S. board certified dermatologists, plastic surgeons, facial plastic surgeons and oculoplastic surgeons at launch and expanding to the broader aesthetic injector market over time. We intend to establish brand awareness for DWP-450 through national public relations, social media and direct-to-consumer media campaigns, which are widely-used commercialization channels for aesthetic neurotoxin products. In the long-term, we plan to capitalize on our commercialization infrastructure and our relationships with key aesthetic physicians to provide a comprehensive medical aesthetics portfolio over time, thereby driving continued revenue growth without a proportional increase in our selling, general and administrative expenses. Outside of the United States, we plan to market and sell DWP-450 through distributors in the territories in which we have the right to sell it.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">1</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co., Ltd., or Daewoong, a South Korean pharmaceutical manufacturer, for aesthetic indications in the United States, EU, Switzerland, Canada, Australia, Russia, Commonwealth of Independent States, or C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. We also have an option to exercise a similar license in these territories for therapeutic indications by the end of 2018. DWP-450 will be manufactured by Daewoong in a recently constructed facility in South Korea that is designed with the intention of complying with FDA and EMA current Good Manufacturing Practice, or cGMP, requirements. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than DWP-450) in a territory covered by the license.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Competitive Strengths</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe we will offer physicians and patients a compelling value proposition beginning with the launch of DWP-450, if approved, for the following reasons:</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">DWP-450 will offer the U.S. market the first known 900 kDa neurotoxin alternative to BOTOX</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. Both DWP-450 and BOTOX manufacturing start with a 900 kDa complex, include adding the excipients human serum albumin</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and sodium chloride, and are finished by vacuum drying. If approved, DWP-450 is expected to be the only known neurotoxin product in the United States with a 900 kDa neurotoxin complex other than BOTOX. We believe an important component of competitiveness in the neurotoxin market relates to the characteristics associated with the 900 kDa complex and the potential of the accessory proteins to increase the effectiveness of the active toxin portion of the complex.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">DWP-450 may be easily integrated into existing aesthetic physician practices.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;DWP-450 was clinically tested with one DWP-450 unit compared to one BOTOX unit. In the study, both products were stored, prepared and injected identically. We believe aesthetic physicians&#8217; familiarity with the 900 kDa neurotoxin complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of DWP-450 into their practices.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Enhanced level of physician-customer interaction through an aesthetic-only marketing strategy. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have elected to specifically target the self-pay aesthetic market. With a reduced regulatory burden compared to third-party payor reimbursed markets, we believe we will achieve a number of benefits that market participants in reimbursed markets are unable to achieve, such as an enhanced level of interaction with our physician-customers. It is expected that upon U.S. approval, DWP-450 will be the only U.S. neurotoxin without a therapeutic indication. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. We intend to utilize this flexibility to drive market adoption through programs such as promotional events, sampling programs and pricing strategies.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">We have strong relationships with aesthetic key opinion leaders, or KOLs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. We have established relationships with aesthetic KOLs as a result of our management team&#8217;s industry experience and engagement of our clinical trial investigators. In addition, there are approximately 250 KOLs who have invested in our parent organizations, creating financial alignment with our success. KOLs are important information resources to the general physician-customer market due to their clinical expertise, academic reputations, active clinical practices and their status as medical innovators. The broader physician community often looks to KOLs for their experience with products and procedures as part of their new product and procedure adoption process.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Our management team has significant experience and expertise in medical aesthetics</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. Our management team has extensive experience in self-pay healthcare markets, in the development, market launch and commercialization of major medical products, execution and integration of business development transactions, identification of and partnerships with KOLs, and understanding of the regulatory environment of the healthcare markets. Key members of our leadership team have also served in relevant senior leadership positions with leading aesthetic companies.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our near-term strategy is to enter the U.S. medical aesthetic neurotoxin market with DWP-450. We plan to expand our product offerings over time through in-licensing, partnerships and acquisitions. The key components of our strategy are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Achieve regulatory approval of DWP-450;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Launch the first known 900 kDa neurotoxin in the United States since BOTOX was launched 15 years ago;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Pursue an aesthetic-only marketing strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Leverage our strong KOL relationships in medical aesthetics for our commercial launch;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Build a commercialization infrastructure with specialized sales and marketing functions; and</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Establish a leading medical aesthetics company by in-licensing technology, developing partnerships and potentially acquiring products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Market</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our primary market is self-pay healthcare, which includes medical products purchased by physicians that are then sold to patients or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. By focusing on the self-pay medical aesthetics market, we believe we will not be exposed to reimbursement risk associated with a reliance on payments from such third-party payors and we will be subject to fewer regulations that place limits on the types of marketing and other interactions we can have with physicians. For example, the federal Anti-Kickback Statute, or the Anti-Kickback Statute, imposes significant restrictions on the ability of healthcare manufacturers who have products or services reimbursed by a federal healthcare program to interact with physicians in relation to the marketing of their products. We believe our clinical data and clinical testing of one DWP-450 unit to one BOTOX unit, together with the reduced regulatory burden and related flexibility in marketing and pricing, will improve our ability to generate product demand for DWP-450.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The global self-pay medical aesthetics neurotoxin market is estimated to generate approximately $1.8 billion of revenue in 2017 and is estimated to grow to approximately $2.3 billion in 2020. The global self-pay medical aesthetics market was estimated to have generated approximately $9.3 billion of revenue in 2015 and is estimated to grow to approximately $15.1 billion in 2020, representing a 10% compound annual growth rate, or CAGR, of which the United States comprises the largest portion of the market at an estimated $3.9 billion of revenue in 2015, and is estimated to grow at an 11% CAGR during the same period. We believe the growth in both the self-pay medical aesthetics neurotoxin market and the overall self-pay medical aesthetics market is being driven by a number of factors, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an aging population consisting of both Generation X, comprised of individuals between the ages of 35 and 50, and Baby Boomers, comprised of individuals between the ages of 51 and 64;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the Millennial generation seeking to prophylactically delay the appearance of aging and utilizing neurotoxins as an entry point for aesthetic procedures due to its minimally invasive nature;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an increasing life expectancy, which is resulting in patients with a desire for improved appearance and well-being;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">rising disposable income, with the U.S. Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 17% from March 2012 to March 2017;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">growing awareness and acceptance of aesthetic procedures;&#160;and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">continued innovation and improved accessibility to these treatments due to an increase in the number of physicians who perform these procedu</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">res.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe the demand for aesthetic treatment for facial lines has stimulated growth in the use of botulinum toxin type A, given the neurotoxin&#8217;s minimally invasive nature of the treatment, effectiveness, ease of use, and safety profile. Additionally, a patient is able to have the procedure performed with minimal interruption to daily life primarily because most treatments require less than 30 minutes to be completed and have little to no recovery period. In general, the results of neurotoxin treatments may last up to four months but are not permanent. As a result, patients may seek repeat procedures to maintain the product&#8217;s effect, which translates into recurring revenue generation for manufacturers and physicians.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The large and established U.S. aesthetic neurotoxin market includes a wide range of age groups. In 2016, approximately 39% of total U.S. nonsurgical procedures were performed on Generation X patients and approximately 31% were performed on Baby Boomer patients. Millennial patients represent a growing segment of the market with data from the American Society of Plastic Surgeons showing a 49% increase between 2009 and 2016 in the number of botulinum toxin type A procedures in patients aged 20 to 29, which is the younger subset of the age 19 to 34 Millennial generation. In 2016, this 20 to 29 age group made up approximately 16% of total U.S. nonsurgical procedures in 2016, and we believe provides a source of future growth.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Presently, BOTOX, Dysport and Xeomin represent a majority of the medical aesthetics botulinum toxin type A market. In 2016, BOTOX sales represented 84.5% of the U.S. market share and 73.1% of the worldwide market share, and generated approximately $729.2 million of revenue in the United States. In the same year, Dysport and Xeomin sales represented 13.5% and 2.0% of the U.S. market share, respectively, and 18.5% and 7.1% of the worldwide market share, respectively, and generated approximately $116.5 million and $17.3 million of revenue in the United States, respectively. </font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">BOTOX prices have increased consistently in recent years. According to The Centers for Medicare and Medicaid Services, the average sales price, or ASP, for BOTOX was approximately $599 per 100 unit vial as of June 2017, up nearly 8% or over $40, from its July 2014 ASP of approximately $557 per 100 unit vial.&#160;Many physicians have expressed frustration with increasing neurotoxin prices. According to a physician survey conducted by Bernstein Research in the second quarter of 2017, approximately 41% of physicians surveyed stated that they would be willing to try a new neurotoxin with a material discount strategy.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">DWP-450 Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We licensed DWP-450 from Daewoong in September 2013 and commenced clinical trials in 2014. DWP-450 is an injectable formulation of a 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">DWP-450 contains a 900 kDa botulinum toxin type A produced by the bacterium </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Clostridium botulinum.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;DWP-450 neurotoxin complex has the same molecular weight as the neurotoxin in BOTOX, 900 kDa. The active neurotoxin is the 150 kDa component, and the rest of the complex is made up of accessory proteins that we believe help with the function of the active portion of the toxin. DWP-450 has the same mechanism of action as other type A botulinum toxins. When injected intramuscularly at therapeutic doses, botulinum toxin produces chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We successfully completed a comprehensive five-study DWP-450 clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada, for the treatment of moderate to severe glabellar lines. Our program was developed in consultation with the FDA and European regulatory bodies. These regulatory bodies provided the critical endpoints and statistical methodology required to develop the safety and efficacy endpoints that would support this indication&#8217;s approval. A BLA and MAA seeking approval for the treatment of adult patients with glabellar lines was accepted and validated by the FDA and EMA, respectively, in July 2017. The FDA issued a PDUFA date of May 15, 2018 for completion of its review of our BLA. If approved, DWP-450 is expected to be the first known 900 kDa neurotoxin product in the United States since BOTOX was approved for the treatment of glabellar lines in 2002.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">All five studies contributed data to the evaluation of efficacy and safety. In the three multicenter, randomized, double-blind, controlled, single dose Phase III studies (EV-001, EV-002 and EVB&#8209;003), 1,194 subjects participated. The two identical placebo-controlled U.S. pivotal studies, EV-001 and EV-002, enrolled 654 subjects in total. The placebo and active controlled EU pivotal study, EVB-003, enrolled 540 subjects. 20 units of BOTOX served as the active control in EVB-003. In addition, 922 subjects participated in the two multicenter, open label, multiple dose, long-term U.S. Phase II safety studies, EV-004 and EV-006, in which up to a total of four treatments were allowed over the course of one year.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">All three Phase III studies met their respective primary endpoints, EV-001 and EV-002 studies demonstrated superiority over placebo, and the EVB-003 study demonstrated non-inferiority to BOTOX and superiority over placebo. The EV-004 and EV-006 safety studies had no drug-related serious adverse events.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Relationship with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are a wholly-owned subsidiary of ALPHAEON Corporation, or ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON is majority-owned by AEON-SCH, LLC, formerly known as Strathspey Crown Holdings, LLC, or SCH. Upon completion of this offering (including the automatic conversion of all outstanding shares of our Series A preferred stock into shares of our common stock), ALPHAEON will own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our outstanding common stock, representing approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total voting power of our outstanding common stock (or approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total voting power of our outstanding common stock, if the underwriters exercise in full their option to purchase additional shares of our common stock in this offering). </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Immediately prior to the completion of this offering, we and ALPHAEON intend to enter into, or will have entered into, certain agreements that will provide a framework for our ongoing relationship with ALPHAEON. For a description of these agreements, see &#8220;Certain Relationships and Related Party Transactions</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Relationships with ALPHAEON Corporation.&#8221;</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Implications of Being an Emerging Growth Company </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to &#8220;opt out&#8221; of this provision and to comply with new or revised accounting standards as required of publicly-traded companies generally. This decision to opt out of the extended transition period is irrevocable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will remain an emerging growth company until the earliest of (i) the end of the fiscal year following the fifth anniversary of the completion of this offering, (ii) the first fiscal year after our annual gross revenues exceed $1.07 billion, (iii) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeds $700 million as of the end of the second quarter of that fiscal year.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Associated with Our Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled &#8220;Risk Factors&#8221; immediately following this prospectus summary. These risks include, among others, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have a limited operating history and have incurred significant losses since our inception, and anticipate that we will continue to incur losses for the foreseeable future. We have only one product candidate and no commercial sales, which, together with our limited operating history, make it difficult to assess our future viability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently depend entirely on the successful and timely regulatory approval and commercialization of our only product candidate,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;DWP</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">-450. DWP-450 may not receive regulatory approval or, if it does receive regulatory approval, we may not be able to successfully commercialize it.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may be unable to obtain regulatory approval for DWP-450 or any future product candidates under applicable regulatory requirements. The FDA, EMA and other similar regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of product candidates. The delay, limitation or denial of any regulatory approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our operating results.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We rely on the Daewoong Agreement, which is defined below, to provide us exclusive rights to distribute DWP-450 in certain</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;territories</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of DWP-450.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently rely solely on Daewoong to manufacture DWP-450, and as such, any production or other problems with Daewoong could </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adversely</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;affect us.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may require additional financing to fund our future operations, and a failure to obtain additional capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:normal;font-weight:normal;">We have concluded that we do not have sufficient cash to fund our operations through December 31, 2017, and, as a result, there is substantial doubt about our ability to continue as a going concern</font><font style="font-family:Times New Roman;font-size:9pt;font-style:normal;font-weight:normal;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even if DWP-450 or future product candidates, if any, receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even if DWP-450 is approved for commercialization, if there is not sufficient patient demand for DWP-450, our financial results and future prospects will be harmed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will face significant competition in the aesthetic neurotoxin and broader self-pay healthcare market and our </font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-left:48px;padding-bottom:2px;padding-top:0px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">failure to effectively compete may prevent us from achieving significant market penetration and expansion.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we are unable to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">establish</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize DWP-450 or any other future product candidates, if approved, or generate product revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we or any of our current or future licensors, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">including</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;Daewoong, are unable to maintain, obtain or protect intellectual property rights related to DWP-450 or any of our future product candidates</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">we may no</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;be able to compete effectively in our market.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">ALPHAEON controls the direction of our business, and the concentrated ownership of our common stock and certain contractual rights of ALPHAEON may prevent you and other stockholders from influencing significant decisions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We were incorporated in the State of Delaware in November 2012. Our principal executive offices are located at 1027 Garden Street, Santa Barbara, California 93101 and our telephone number is (949) 284-4555. Our website is www.evolus.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><a name="s24EB688139593DBA97011527CC7D197B"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">THE OFFERING</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:37%;"></td><td style="width:63%;"></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Common stock offered by us</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares</font></div><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Common stock to be outstanding after this offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares</font></div><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Option to purchase additional shares</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The underwriters have the option to purchase from us up to a maximum of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common stock. The underwriters can exercise this option at any time within 30 days from the date of this prospectus.</font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Use of proceeds </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We estimate that the net proceeds to us from this offering will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million (or approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million if the underwriters exercise their option to purchase additional shares in full), based on an assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We intend to use the net proceeds from this offering to satisfy requirements of the FDA and other regulatory agencies related to the approval of DWP-450, to fund commercialization activities for DWP-450, for payment of certain milestone payments owed upon marketing approval of DWP-450 in the United States and EU, and for other general corporate purposes. </font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">See &#8220;Use of Proceeds&#8221; for more information.</font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Proposed Nasdaq Global Market symbol </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8221;</font></div><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk factors </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">See &#8220;Risk Factors&#8221; for a discussion of certain factors to consider carefully before deciding to purchase any shares of our common stock.</font></div><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The number of shares of our common stock to be outstanding after this offering is based on 11,250,000 shares of common stock outstanding as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">after giving effect to the conversion of all of our outstanding Series A preferred stock, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and excludes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Equity Incentive Plan, or the 2017 plan, as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock reserved for future issuance under the 2017 plan as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Unless otherwise indicated, all information contained in this prospectus assumes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no exercise by the underwriters of their option to purchase up to an additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no exercise of the outstanding stock options described above; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a one-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reverse stock split of our common stock to be effected before the completion of this offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the automatic conversion of all outstanding shares of our Series A preferred stock into 1,250,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of common stock immediately prior to the completion of this offering; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the filing of our amended and restated certificate of incorporation, or our certificate of incorporation, and the adoption of our amended and restated bylaws, or our bylaws, immediately prior to the completion of this offering.</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><a name="s6AD645E008B6180AC4B21527CA189F68"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;SUMMARY FINANCIAL DATA</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following tables contain a summary of our financial data as of, and for the periods ended on, the dates indicated. The summary statements of operations data for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;are derived from our audited financial statements and related notes appearing elsewhere in this prospectus. The summary statements of operations for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the summary balance sheet data as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, are derived from our unaudited financial statements appearing elsewhere in this prospectus. We have prepared the unaudited interim financial information on the same basis as the audited financial statements and have included all adjustments, consisting only of normal recurring adjustments, that we consider necessary for a fair statement of our financial and operating results for such period. The summary financial data below should be read together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in conjunction with the financial statements, related notes and other information included elsewhere in this prospectus.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our historical results are not necessarily indicative of the results that may be expected or may actually occur in the future, and our interim results are not necessarily indicative of the expected results for future interim periods or the full year.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our historical financial statements have been prepared on a standalone basis and are derived from the financial statements and accounting records of ALPHAEON and prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The financial statements reflect amounts attributable to our business, including the costs ALPHAEON incurred for the development, commercialization and the Daewoong Agreement. We have calculated our income tax amounts using a separate return methodology and have presented these amounts as if we were a separate taxpayer from ALPHAEON in each jurisdiction for each period pr</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">esented. Our management believes that the allocations and results are reasonable for all periods presented. However, allocations may not be indicative of the actual expense we would have incurred had we operated as an independent company for the periods presented and, accordingly, our historical financial statements may not reflect what our actual financial position, results of operations and cash flows would have been if we had been an independent company for the periods presented. </font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table is presented in thousands, except for share and per share data:</font></div><div style="line-height:125%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Statement of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">12,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">4,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">9,883</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">7,033</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">5,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">2,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:0px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(31,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(19,972</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,254</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">93</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">93</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">56</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(31,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(20,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss per share, basic and diluted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(3.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(2.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(1.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Weighted-average shares used to compute basic and diluted net loss per share</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Pro forma net loss per share, basic and diluted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2) </sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1.78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(0.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Pro forma weighted-average shares used to compute basic and diluted net loss per share</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2) </sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">See Note 2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the net loss per share and the number of shares used in the computation of the per share amounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The pro forma net loss per share of common stock, basic and diluted, for the year ended December&#160;31, 2016 and the six months ended June 30, 2017 reflects the automatic conversion of all outstanding shares of our Series A preferred stock into 1,250,000 shares of common stock and the filing and effectiveness of our certificate of incorporation, each of which will occur immediately prior to the completion of this offering. The pro forma net loss </font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="padding:24px 24px 24px 24px; border:1pt solid #000000;"><div style="line-height:120%;padding-left:24px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">per share of common stock, basic and diluted, does not give effect to the issuance of shares from the proposed initial public offering nor do they give effect to potential dilutive securities where the impact would be anti-dilutive.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table is presented in thousands:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Actual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Pro Forma</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Pro Forma as Adjusted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Related party receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Note obligation</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">122,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(73,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stockholders&#8217; deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(67,008</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gives effect to the automatic conversion of all outstanding shares of our Series A preferred stock into an aggregate of 1,250,000 shares of our common stock and the filing and effectiveness of our certificate of incorporation, each of which will occur immediately prior to the completion of this offering.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Reflects, in addition to the pro forma adjustment set forth in footnote 1, the sale of&#160;&#160;&#160;&#160;&#160;shares of our common stock in this offering at an assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A $1.00 increase (decrease) in the assumed initial public offering price would increase (decrease) each of cash, total assets and total stockholders&#8217; (deficit) equity by $&#160;&#160;&#160;&#160;&#160;million, assuming the number of shares offered by us as stated on the cover page of this prospectus remains unchanged and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 1,000,000 share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, total assets and total stockholders&#8217; (deficit) equity by $&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the mid-point of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Represents our obligations as a guarantor of ALPHAEON&#8217;s convertible promissory notes and convertible bridge note.  For a further explanation, including the resulting impact on the related party receivable and total stockholders&#8217; deficit, see the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Guarantee of ALPHAEON&#8217;s Convertible Notes and Intercreditor Agreement.&#8221;</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><a name="sD8E40018058C18D91D811527CCBF4C02"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this prospectus, including our financial statements, the notes thereto and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, reputation, financial condition, results of operations and future growth prospects, as well as our ability to accomplish our strategic objectives. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and stock price.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to our Business and Strategy</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We have a limited operating history and have incurred significant losses since our inception, and anticipate that we will continue to incur losses for the foreseeable future. We have only one product candidate and no commercial sales, which, together with our limited operating history, make it difficult to assess our future viability. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are a medical aesthetics company with a limited operating history. Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have invested substantially all of our efforts and financial resources in the clinical development and regulatory approval of, and commercial planning for, DWP-450, which is currently our only product candidate. We are not profitable and have incurred losses in each year since our inception in 2012. We have a limited operating history upon which you can evaluate our business and prospects.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or an approved product on the market. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. To date, we have not obtained any regulatory approvals for DWP-450 or generated any revenue from product sales relating to DWP-450. We continue to incur significant expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">related</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to reg</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ulatory approval and commercialization operations of DWP-450. We have recorded net losses of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">31.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">20.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">6.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;the years ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and for the six months ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, and had an accumulated deficit during our development stage through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">73.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to seek regulatory approval for, and begin to commercialize, DWP-450, if approved.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our ability to achieve revenue and profitability is dependent on our ability to obtain necessary regulatory approvals and successfully market and commercialize DWP-450. We have limited experience in successfully commercializing a product candidate once approved. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We currently depend entirely on the successful and timely regulatory approval and commercialization of our only product candidate, DWP-450. DWP-450 may not receive regulatory approval or, if it does receive regulatory approval, we may not be able to successfully commercialize it.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently have only one product candidate, DWP-450, and our business presently depends entirely on our ability to obtain regulatory approval for DWP-450 and to successfully commercialize it in a timely manner. We have no products currently approved for sale and we may never be able to develop marketable products. We are not permitted to market DWP-450 in the United States until we receive approval of a BLA from the FDA, in the EU until we receive approval of a MAA from the EMA, in Canada until we receive approval of a NDS from Health Canada or in any other countries permitted under the Daewoong Agreement until we receive the requisite approval from the applicable regulatory authorities in such countries. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The FDA issued a PDUFA date of May 15, 2018 for completion of its review of our BLA. We submitted a MAA to the EMA and it was accepted for review in July 2017 with a decision expected by the third quarter of 2018. We also submitted a NDS to Health Canada in July 2017. We do not know if or when we will receive any such approvals, or whether we will need to make modifications or significant additional expenditures to obtain any such approvals. In addition, if we receive approval in one country, we may not receive a similar approval in any other jurisdiction.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our near-term prospects, including our ability to finance our company and generate revenue, as well as our future growth, depend entirely on the successful and timely regulatory approval and commercialization of DWP-450. The regulatory and commercial success of DWP-450 will depend on a number of factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether we are required by the FDA, EMA or other similar regulatory authorities to conduct additional clinical trials to support the approval of DWP-450;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our success in educating physicians and patients about the benefits, administration and use of DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the prevalence, duration and severity of potential side effects experienced with DWP-450&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timely receipt of necessary marketing approvals from the FDA, EMA and other similar regulatory authorities&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">achieving and maintaining compliance with all regulatory requirements applicable to DWP-450;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability to raise additional capital on acceptable terms, or at all, if needed, to support the commercial launch of DWP-450&#894; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the acceptance by physicians and patients of the safety and efficacy of DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully commercialize DWP-450, if approved, whether alone or in collaboration with others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability of our current manufacturer and any third parties with whom we may contract to manufacture DWP-450 to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to obtain regulatory approvals or commercialize DWP-450. Even if regulatory approvals are obtained, we may never be able to successfully commercialize DWP-450 or any future product candidates. In addition, we will need to transition at some point from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. Accordingly, we may not be able to generate sufficient revenue through the sale of DWP-450 or any future product candidates to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may be unable to obtain regulatory approval for DWP-450 or any future product candidates under applicable regulatory requirements. The FDA, EMA and other similar regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of product candidates. The delay, limitation or denial of any regulatory approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our operating results.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize DWP-450 or any future product candidates. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to DWP-450 and any future product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and in other countries, and such regulations differ from country to country. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">To gain approval to market a biologic product such as DWP-450, we must provide the FDA, the EMA and other similar regulatory authorities with clinical data that adequately demonstrates the safety, efficacy, purity and potency of the product for the intended indication applied for in a BLA, a MAA or other respective regulatory filing. The development and approval of biologic products is a long, expensive and uncertain process, and delay or failure can occur at any stage. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The approval process across jurisdictions is also not necessarily the same in time or scope.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The regulatory review and approval processes are expensive and lengthy, and their outcome is inherently uncertain. Although we have completed a comprehensive five-study clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada for DWP-450 for the treatment of moderate to severe glabellar lines, we may not receive marketing approval for DWP-450 in one or more of the countries in which marketing approval is sought.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;In addition, any future product candidates will require extensive clinical testing and will be subject to the numerous risks inherent with the regulatory approval process, including development delay or failure after commencement of a clinical trial</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A number of companies in the pharmaceutical and biopharmaceutical industry have suffered significant setbacks in clinical trials, including in Phase III clinical development, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">parties may not be indicative of the results in trials we or our partners may conduct. We may experience these setbacks during the clinical trial process for any of our future product candidates. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any such setbacks could also result in negative publicity which could damage our reputation in jurisdictions in which we have been approved.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The FDA, the EMA and other similar regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of product candidates for many reasons, including, without limitation:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may disagree with the design or implementation of one or more clinical trials&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may not deem a product candidate safe and effective for its proposed indication, or may deem a product candidate&#8217;s safety or other perceived risks to outweigh its clinical or other benefits&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may not find the data from preclinical studies and clinical trials sufficient to support approval, or the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA, the EMA or any similar regulatory authorities for approval&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials performed by us or third parties&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the data collected from clinical trials may not be sufficient to support the submission of a BLA, a MAA, a NDS, or other applicable regulatory filing&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may require additional preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may identify deficiencies in the formulation, quality control, labeling or specifications of DWP-450 or future product candidates&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may grant approval contingent on the performance of costly additional post approval clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities also may approve DWP-450 or any future product candidates for a more limited indication or a narrower patient population than we originally requested;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA&#8217;s, the EMA&#8217;s or other similar regulatory authority&#8217;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may change its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA, the EMA or other similar regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Therefore, even if we comply with all FDA, EMA or other similar regulatory requirements, the regulatory body may determine that DWP-450 or any of our future product candidates are not safe or effective, and we may never obtain regulatory approval for such product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval for DWP-450 or any of our future product candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our business, results of operations and prospects. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additionally, any negative publicity or safety concerns related to our competitors&#8217; products could cause further scrutiny and delay of our products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We rely on the Daewoong Agreement to provide us exclusive rights to distribute DWP-450 in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of DWP-450. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the Daewoong Agreement, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit DWP-450 for aesthetic indications in the United States, EU, Switzerland, Canada, Australia, Russia, C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of DWP-450, obtain from Daewoong all of our product supply requirements for DWP-450 and pay to Daewoong regulatory milestone payments and other cash payments in connection with the net sales of DWP-450. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a Joint Steering Committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of DWP-450, any disagreement among the JSC would be referred to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong&#8217;s and our respective senior management for resolution </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">if the JSC is unable to reach a decision within thirty days, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">After the commercial launch of DWP-450, if it occurs, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license if we fail to achieve minimum annual purchase targets of DWP-450. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The initial term of the Daewoong Agreement will expire on the later of September 30, 2023 or the fifth anniversary of our receipt of marketing approval in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights (including exclusivity) under the Daewoong Agreement would materially and adversely affect our ability to develop and commercialize DWP-450, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals which may never be obtained </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. If we were to commercialize DWP-450 and later experienced delays as a result of a dispute with Daewoong, the demand for DWP-450 could be materially and adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We currently rely solely on Daewoong to manufacture DWP-450, and as such, any production or other problems with Daewoong could adversely affect us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We depend solely upon Daewoong for the manufacturing of DWP-450. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New suppliers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of DWP-450. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, upon completion of inspections, Daewoong&#8217;s recently constructed manufacturing facility will be Daewoong&#8217;s only facility meeting FDA and EMA cGMP requirements. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality may harm our abiltity to compete in our market.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any failure or refusal to supply DWP-450 or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may require additional financing to fund our future operations, and a failure to obtain additional capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We presently are entirely dependent on cash from ALPHAEON, and as of June 30, 2017, we did not have any cash or cash equivalents. We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of DWP-450 initially in the United States, EU and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to finalize regulatory approval for DWP-450, to commercialize DWP-450, for the development of any other indications of DWP-450, and for the clinical development of any additional product candidates we may choose to pursue. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the near term, these expenditures will include costs associated with the development and expansion of our sales force and commercialization infrastructure in connection with commercializing DWP-450, if approved. In the long term, these expenditures will include costs associated with the continued commercialization of DWP-450, if approved, and any of our future product candidates, such as research and development, conducting preclinical studies and clinical trials, and manufacturing and supplying as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the regulatory approval process and commercialization expenditures needed to meet our sales objectives is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of DWP-450 or any future product candidates. Upon the closing of this offering, we expect to incur additional costs associated with operating as a public company, hiring additional personnel and expanding our operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Based on our estimated use of proceeds, we anticipate that the net proceeds of this offering, together with resources from ALPHAEON (including the payment of certain expenses on our behalf that we will evidence as related party borrowings from ALPHAEON), will be sufficient to fund our operating plan through the launch and initial commercialization of DWP-450, if approved by the FDA. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available capital resources much faster than we currently expect or require more capital to fund our operations than we currently expect. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For example, we may require additional funds earlier than we currently expect in the event that we are required to conduct additional clinical trials, experience a delay in receiving marketing approval of DWP-450 or market acceptance of DWP-450 is slower than expected. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our currently anticipated expenditures for the commercialization of DWP-450 may exceed the net proceeds from this offering and our </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">resources from ALPHAEON and we may need to seek additional financing</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have historically funded our operations through the support of ALPHAEON, from which funding may not be available after the completion of this offering. We may need to raise additional capital following the completion of this offering to fund our operations and continue to support both our near and long-term expenditures. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our future capital requirements depend on many factors, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of, and the costs involved in, obtaining regulatory approvals for DWP-450 or any future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the cost of commercialization activities if DWP-450 or any future product candidates are approved for sale, including marketing, sales and distribution costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the scope, progress, results and costs of researching and developing any future product candidates, and conducting preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">costs under our third-party manufacturing and supply arrangements for our current and any future product candidates and any products we commercialize&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the degree and rate of market acceptance of DWP-450 or any future approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">costs of operating as a public company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">costs associated with any acquisition or in-license of products and product candidates, technologies or businesses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to commercialize our product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets. If we do not raise capital, whether in this offering or otherwise, there will remain substantial doubt about our ability to continue as a going concern. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement. In addition, if we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We have concluded that we do not have sufficient cash to fund our operations through December 31, 2017, and as a result, there is substantial doubt about our ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our ability to continue as a going concern is an issue raised as a result of ongoing operating losses and a lack of financing commitments to meet cash requirements. We have incurred recurring losses from operations in fiscal years </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the six months ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, and we had negative working capital as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Our ability to continue as a going concern is subject to our ability to generate a profit or obtain appropriate financing from outside sources, including obtaining additional funding from the sale of our securities, increasing sales of our products or obtaining loans from third parties where possible. If we cannot continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that our stockholders may lose some or all of their investment in us. After this offering, we may not raise the funding we require such that substantial doubt about our ability to continue as a going concern continues. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Even if DWP-450 or future product candidates, if any, receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Even if DWP-450 receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients and others in the medical aesthetics community. The commercial success of DWP-450 and any future product candidates, if approved, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of DWP-450, the treatment of glabellar lines and other aesthetic and therapeutic indications that we may seek to pursue. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The degree and rate of physician adoption of DWP-450 and any future product candidates, if approved, depend on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the effectiveness, ease of use, and safety of DWP-450 and any future product candidates as compared to existing products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">physician and patient willingness to adopt DWP-450 to treat glabellar lines or other aesthetic and therapeutic indications we may pursue over products and brands with which patients and physicians may have more familiarity or recognition </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">or additional approved uses</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">overcoming any biases physicians or patients may have toward the use, safety and efficacy of existing products or treatments </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and successful marketing of the benefits of a 900 kDa botulinum toxin type A complex</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the cost of DWP-450 and any future product candidates in relation to alternative products or treatments and willingness to pay for the product or treatment, if approved, on the part of patients&#894;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">proper training and administration of DWP-450 and any future product candidates by physicians and medical staff&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">patient satisfaction with the results and administration of DWP-450 and any future product candidates and overall treatment experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">changes in pricing and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">promotional</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;efforts by competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">patient demand for the treatment of glabellar lines or other aesthetic indications that may be approved in the future, and patient need for therapeutic indications that may be approved in the future; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the willingness of patients to pay for DWP-450 and any future product candidates relative to other discretionary items, especially during economically challenging times&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the revenue and profitability that DWP-450 and any future product candidates may offer a physician as compared to alternative products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the effectiveness of our sales, marketing and distribution efforts&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any adverse impact on our brand resulting from KOL relationships with our parent organizations, whether or not related to us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">adverse </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">publicity </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">about our product candidates, competitive products, or the industry as a whole, or favorable publicity about competitive products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, in its clinical trials, DWP-450 was clinically tested with one DWP-450 unit compared to one BOTOX unit. If approved, DWP-450 is expected to be the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of DWP-450 into their practices. However, the ease of integration of DWP-450 into a physician&#8217;s practice may not be as seamless as we anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If DWP-450 or any future product candidates are approved for use but fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Even if DWP-450 is approved for commercialization, if there is not sufficient patient demand for DWP-450, our financial results and future prospects will be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Treatment of glabellar lines with DWP-450 is an elective procedure, the cost of which must be borne by the patient, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a patient to elect to undergo treatment with DWP-450 for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience and are still in the process of planning and developing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the extent to which physicians recommend DWP-450 to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the extent to which DWP-450 satisfies patient expectations </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and overcoming patient loyalty with existing products and brands</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to properly train physicians in the use of DWP-450 such that their patients do not experience excessive discomfort during treatment or adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the cost, safety and effectiveness of DWP-450 versus other aesthetic treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the development </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;availability of alternative products and treatments that seek to address similar goals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">consumer sentiment about the benefits and risks of aesthetic procedures generally and DWP-450 in particular;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the success of any direct-to-consumer marketing efforts that we may initiate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability and ease with which physicians are able to incorporate DWP-450 into their practices; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in demographic and social trends; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">general consumer </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">confidence</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which may be impacted by economic and political conditions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">It is expected that upon U.S. approval, DWP-450 will be the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to DWP-450, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with DWP-450 on </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient patient demand for DWP-450, if approved.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">DWP-450 and any future product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:normal;font-weight:normal;">In the near term, we expect to enter into the highly competitive aesthetic neurotoxin market through the commercial launch of DWP-450, if approved. In the long term, we expect to expand our focus to the broader self-pay healthcare market. While numerous companies are engaged in the development, patenting, manufacture and marketing of aesthetic neurotoxin products competitive with DWP-450, Allergan plc, or Allergan, through its product BOTOX, held approximately 73.1% of the global market share in the aesthetic neurotoxin market by revenue in 2016. Allergan and many of these potential competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These competitors may also try to compete with DWP-450 on price both directly, through rebates and promotional programs to high volume physicians and coupons to patients, and indirectly, through attractive product bundling with complimentary products such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger competitors may also be able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant amount of studies and research papers that they could use to compete with us. We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our planned strategy to compete in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event we elect to seek approval for and market reimbursed indications, including a therapeutic indication for DWP-450 or in the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material affect on our business, financial condition and results of operations. In addition, if we pursue a therapeutic indication for DWP-450, we will face significant additional competition relating to the development, patenting, manufacture and marketing of a neurotoxin used for such indication.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon marketing approval, the first expected use of DWP-450 will be in aesthetic medicine. The aesthetic product market, and the facial aesthetic market in particular, is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We are seeking regulatory approval of DWP-450 for the treatment of glabellar lines. We anticipate that DWP-450, if approved, will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. If approved, DWP-450 may also compete with unapproved and off-label treatments. In addition, competitors may develop new technologies within the aesthetic market which may be superior in safety and efficacy to DWP-450 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">or offer alternatives to the use of toxins, including surgical and radio frequency techniques</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. To compete successfully in the aesthetic market, we will have to demonstrate that DWP-450 is at least as safe and effective as current products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we face more competition in these markets than in the United States. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than DWP-450 or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing our products and attracting physician and patient demand.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">DWP-450 or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen&#8217;s Petition requesting that FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe that DWP-450 should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">DWP-450 is manufactured exclusively in one facility located in South Korea, and we plan to utilize this facility in the future to support commercial production if DWP-450 is approved. If this facility were damaged or destroyed, or if there occurs a significant disruption in operations at this facility for any reason, our ability to continue to operate our business would be materially harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong developed the manufacturing process for DWP-450 and manufactures DWP-450 in a recently constructed facility located in South Korea, which was completed in 2016 with the intention to comply with FDA and EMA regulations and is now fully validated by Daewoong under cGMP requirements. FDA and EMA approval of the facility is pending review and expected to occur in the fourth quarter of 2017 or the first quarter of 2018. Any delay or failure to obtain these approvals may result in delays in the initiation of commercial production of DWP-450, which could have an adverse effect on our business and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We plan to utilize Daewoong&#8217;s facility in the future for commercial production if DWP-450 is approved. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could, if DWP-450 is approved, jeopardize Daewoong&#8217;s ability to manufacture DWP-450 as promptly as we or our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if Daewoong is unable to manufacture DWP-450 within a timeframe that meets ours and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If these disruptions exceed coverage provided by Daewoong&#8217;s insurance policies, Daewoong may be unable to satisfy their obligations to us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters or political unrest and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or political unrest. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong, the sole manufacturer of DWP-450, manufactures DWP-450 in a facility located in South Korea. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, the underlying drug substance for DWP-450 is also manufactured in a separate facility on the same campus. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The risk of extreme weather and earthquakes in the Pacific Rim region is significant due to the proximity of major earthquake fault lines. There is also a level of political unrest or uncertainty in South Korea and the broader region. Natural disasters or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">political unrest could severely disrupt Daewoong&#8217;s operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If a natural disaster, political unrest, power outage or other event occurred that prevented Daewoong from using all or a significant portion of its manufacturing facility, or prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because Daewoong manufactures DWP-450 in its facility, in the event of a natural disaster, political unrest, power outage or other event affecting this facility, we would be required to seek additional manufacturing facilities and capabilities that have obtained the necessary approvals required by state, federal or other applicable authorities in order to continue or resume manufacturing activities, which we may not be able to do on commercially reasonable terms if at all. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our ability to market DWP-450, if approved, will be limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market DWP-450, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are currently seeking regulatory approval for DWP-450 in the United States, EU and Canada for the treatment of moderate to severe glabellar lines. If DWP-450 is approved for this indication, the terms of that approval will restrict our ability to market or advertise DWP-450 for other indications, which could limit physician and patient adoption. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market DWP-450 for approved indications. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin product and may be able to market such product for use in a way we cannot. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For example, we are aware that one of our competitors, Allergan, has obtained and plans to obtain additional indications for their neurotoxin product within medical aesthetics and therefore is able to market their product across all approved indications. If we are unable to obtain approval for indications in addition to our anticipated approval for glabellar lines, our marketing efforts for DWP-450 will be severely limited. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result, we may not generate physician and patient demand or approval of DWP-450. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, pursuant to the Daewoong Agreement, we have an option to expand our license to include therapeutic indications for which we paid a total of $1.0 million. This option expires on December 31, 2018 and is exercisable by us upon payment of a confidential option exercise price. We may attempt to develop, promote and commercialize new treatment indications and protocols for DWP-450 in the future, but we may not receive the regulatory approvals required to do so in a timely manner, if at all. In addition, if we were to pursue regulatory approvals for additional indications, we would be required to conduct additional clinical trials or studies to support such indications, which would be time consuming and expensive, and may produce results that do not support such regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we do not obtain additional regulatory approvals for therapeutic indications of DWP-450, our ability to expand our business into therapeutic indications will be limited. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If DWP-450 or any of our future product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as DWP-450, if approved. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">other similar regulatory authorities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as reflected in the product&#8217;s approved labeling. If we receive marketing approval for DWP-450 for the treatment of moderate to severe glabellar lines, which is the first indication that we are pursuing, physicians could use DWP-450 on their patients in a manner that is inconsistent with the approved label, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from the FDA, EMA and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Physicians may also misuse DWP-450 or any future product candidates, if approved, or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If DWP-450 or any future product candidates, if approved, are misused or used with improper techniques </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">or are determined to cause or contribute to patient harm</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of DWP-450 or any future product candidates, if approved, for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. Any of these events could harm our business and results of operations and cause our stock price to decline. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">DWP-450 or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling or result in post-approval regulatory action.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Unforeseen side effects from DWP-450 or our future product candidates could arise either during clinical development or, if approved, after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">or similar regulatory authorities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, EMA </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">or similar regulatory authorities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by DWP-450, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may withdraw their approval of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may require a recall of the product or we may voluntarily recall a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may require us to create a medication guide outlining the risks of such side effects for distribution to patients or institute a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Risk Evaluation and Mitigation Strategies, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">REMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we may be subject to limitations as to how we promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we may be required to change the way the product is administered or modify the product in some other way;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">our brand </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our products. The demand for DWP-450 could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Although a substantial amount of our effort will focus on the potential regulatory approval and commercialization of DWP-450, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">portfolio of products to serve the self-pay aesthetic market, which may include dermal fillers, aesthetic lasers and energy devices, and breast implants. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize DWP-450 or any other future product candidates, if approved, or generate product revenue. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently have limited marketing capabilities and no sales organization. To commercialize DWP-450 or any other future product candidates, if approved, in the United States, EU, Canada and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If DWP-450 receives regulatory approval, we expect to market DWP-450 in the United States through an internal specialized sales force and outside the United States through distributors, which will be expensive and time consuming. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize DWP-450 or any future product candidates. To the extent we commercialize our product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which case our future revenues would depend heavily on the success of the efforts of these third parties. If we are not successful in commercializing DWP-450 or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We will need to increase the size of our organization, and we may experience difficulties in managing this growth. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of&#160;August 28, 2017, we had 22 employees, all of whom constitute full-time employees of ALPHAEON, 11 of whom have been assigned to work full time at our company and 11 of whom have been assigned to work part time at our company.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;We will need to continue to expand our managerial, operational, finance and other resources to manage our operations, commercialize DWP-450 or any other product candidates, if approved, and continue our development activities. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">manage any of our future clinical trials effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">identify, recruit, retain, incentivize and integrate additional employees;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">continue</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to improve our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates applicable regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory agencies, manufacturing standards, and federal and state healthcare laws and regulations. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Although our strategy to focus only on the self-pay market will reduce our risk under the Anti-Kickback Statute, we could face liability under similar state laws that are not limited to products reimbursed by the government or if we obtain regulatory approval for products reimbursed by federal healthcare programs in the future. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, referrals, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">In the future, we may rely on third parties and consultants to conduct all of our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the future, we may rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">clinical research organizations, or CROs,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to conduct clinical trials on our product candidates. The third parties with whom we may contract for execution of any of our future clinical trials may play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, any of these third parties may not be our employees, and except for contractual duties and obligations, we would have limited ability to control the amount or timing of resources that they devote to any of our future programs. Although we may rely on these third parties to conduct our preclinical studies and clinical trials, we would remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the investigational plan and protocol. Moreover, the FDA and other similar regulatory authorities require us to comply with good clinical practices, or GCP, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We may also rely on consultants to assist in the execution, including data collection and analysis, of any of our future clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for and will not be able to, or may be delayed in our efforts to, successfully commercialize any future product candidates being tested in such trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We plan to rely on third-party distribution partners for the distribution of our products, product candidates and services, which could delay or limit our ability to generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">With respect to certain markets for our products, product candidates and services, we plan to retain third-party service providers to perform functions related to the marketing, distribution and sale of DWP-450 and any future product candidates. Key aspects of those functions may be out of our direct control, including regulatory compliance, warehousing and inventory management, distribution, contract administration, accounts receivable management and call center management. Any future distribution partners may hold significant control over important aspects of the commercialization of our products, including market identification, regulatory compliance, marketing methods, pricing, composition of sales force and promotional activities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may not be able to control the amount and timing of resources that any future third-party distribution partners may devote to our products, or prevent any third-party from pursuing the development of alternative technologies or products that compete with our products, except to the extent our contractual arrangements protect us against such activities. Also, we may not be able to prevent any other third-party from withdrawing its support of our products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities or otherwise fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver product to meet commercial demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample accountability and regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we could be subject to regulatory sanctions </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and any indemnity we may receive from such third-party service providers could be limited by such provider&#8217;s ability to pay and otherwise might not be sufficient to cover all losses we may experience</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We will forecast the demand for commercial quantities of our products, and if our forecasts are incorrect, we may experience delays in shipments or increased inventory costs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If DWP-450 is approved, we will purchase the product from Daewoong. Pursuant to the Daewoong Agreement, we will submit forecasts of anticipated product orders to Daewoong and may from time to time submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a DWP-450 formulation, from this facility. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate our component and material requirements, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our proposed international operations will expose us to risks and failure to manage these risks may adversely affect our operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We expect to have operations both inside and outside the United States. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">requirements or preferences for domestic products or solutions, which could reduce demand for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">differing existing or future regulatory and certification requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">management communication and integration problems resulting from cultural and geographic dispersion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">greater difficulty in collecting accounts receivable and longer collection periods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">difficulties in enforcing contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">difficulties and costs of staffing and managing non-U.S. operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the uncertainty of protection for intellectual property rights in some countries;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">tariffs and trade barriers, export regulations and other regulatory and contractual limitations on our ability to sell our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">more stringent data protection standards in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">greater risk of a failure of foreign employees to comply with both U.S. and foreign laws, including export and antitrust regulations, the U.S. Foreign Corrupt Practices Act, or the FCPA, quality assurance and other healthcare regulatory requirements and any trade regulations ensuring fair trade practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">foreign currency exchange rates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">potentially adverse tax consequences, including multiple and possibly overlapping tax structures and difficulties relating to repatriation of cash; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">political and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">economic</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;instability, political unrest and terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operations results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">A perception of a conflict of interest of our indirect physician investors by other physicians or patients could negatively impact our future product sales or product approvals.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have been indirectly funded through investments in our parent organizations, ALPHAEON, and its majority stockholder, SCH, by leading physicians in the self-pay healthcare market and these physicians have an indirect financial interest in our success. As a result, other physicians will be aware of their additional incentives in recommending DWP-450 and any of our future product candidates, if approved. If physicians perceive this to be a significant conflict, they may be unwilling to purchase DWP-450 or any of our future product candidates without obtaining additional third-party evidence of their benefits and efficacy. If patients perceive these physicians have a conflict of interest in recommending DWP-450 or any of our future product candidates, they may be unwilling to purchase DWP-450 or any of our future product candidates </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and may have a negative view of our brand which could harm our reputation in the market</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. If physicians do not recommend DWP-450 or any of our future product candidates or patients choose not to purchase any of our products as a result of these conflicts of interest, it could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, clinical investigators for any of our future pivotal or non-pivotal clinical trials may be indirect investors in our company. We believe it is likely that they will be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of one or more of our future product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We face an inherent risk of product liability as a result of the clinical testing of DWP-450 and any of our future product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">decreased demand for DWP-450 or any future product candidates or products we develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">significant costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a diversion of management&#8217;s time and our resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">loss of revenue; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the inability to commercialize any products we develop; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">a decline in our share price.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of DWP-450 or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing DWP-450, we intend to expand our insurance coverage to include the sale of DWP-450; however, we may be unable to obtain this liability insurance on commercially reasonable terms. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop DWP-450 or any future product candidates, conduct our clinical trials and commercialize DWP-450 or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly Murthy Simhambhatla, Ph.D., our Chief Executive Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of DWP-450 or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel, including experienced sales representatives, as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the market for aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect DWP-450 for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, our product candidate will be wholly-paid for by the patient. Demand for this product will be tied to discretionary spending levels of our targeted patient population. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decline in the discretionary spending of our target patient population, which could lead to a weakened demand for DWP-450 or any future product candidates, if approved. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A severe or prolonged economic down turn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of DWP-450 or any of our future product candidates could differ materially from our projections if our assumptions are incorrect. In addition, our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability. For example, to maintain the marketing and pricing flexibility we believe results from offering products and procedures that are not reimbursed by third-party payors, we cannot offer products or services available in the broader healthcare market that are reimbursed by third-party payors. This eliminates our ability to offer a substantial number of products. In the event that we elect to seek regulatory approval for and market therapeutic </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">indications of DWP-450 or any other product candidate, we will be subject to regulations governing the marketing and pricing of products which are reimbursed by third-party payors which may have a adverse affect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our near-term strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we cannot offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">However, pursuant to the Daewoong Agreement, we have an option to expand our license to include therapeutic indications. We may attempt to develop, promote and commercialize new treatment indications and protocols for DWP-450 in the future, but we may not receive the regulatory approvals required to do so in a timely manner, if at all. In addition, if we were to pursue regulatory approvals for additional indications, we would be required to conduct additional clinical trials or studies to support such indications, which would be time consuming and expensive, and may produce results that do not support such regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business into therapeutic indications will be limited. Further, we would not be able to benefit from the pricing and marketing flexibility we currently enjoy due to our exclusive focus on the aesthetic self-pay healthcare market. We will be required to calculate DWP-450&#8217;s ASP, inclusive of both aesthetic and therapeutic sales, for purposes of therapeutic reimbursement. As a result, we may limit our aesthetic neurotoxin discounting to protect our therapeutic neurotoxin reimbursement rate, which many of our competitors currently do. Additional regulations would also impose limits on the permitted interaction with our physician-customers. This would require us to compete without using pricing and marketing flexibility, which we may not be successful at, if at all. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market, or Nasdaq, and the rules of the Securities and Exchange Commission, or SEC, require that we satisfy certain corporate governance requirements. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">After this offering, we will be subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In order to maintain effective internal controls, we will need to assume certain functions that have historically been provided by ALPHAEON and we will need additional financial personnel, systems and resources. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Beginning with the second annual report on Form 10-K that we will be required to file with the SEC, Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (i) following the fifth anniversary of the completion of this offering, (ii) in which we have total annual gross revenue of at least $1.07 billion, or (iii) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">To date, we have never conducted a review of our internal controls for the purpose of providing the reports required by these rules. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from Nasdaq or other adverse consequences that would materially harm our business and reputation. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of DWP-450, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of DWP-450 and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">candidates or bring them to market and generate revenue.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we had $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">44.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">63.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of federal and state NOLs, respectively, available to offset our future taxable income, if any. These federal NOLs and research and development tax credit carryforwards expire at various dates beginning in 2025. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or future product development programs. For example, the loss of clinical trial data from completed or any future ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation, and the further development of our product candidates could be delayed.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">If we or any of our current </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">or</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">&#32;future licensors</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to DWP-450 or any of our future product candidates, we may not be able to compete effectively in our market.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We and our current licensor Daewoong currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Clostridium</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">botulinum</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented and for which Daewoong obtained a U.S. patent. Under the Daewoong Agreement, we license the trademark associated with DWP-450. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to DWP-450 to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are reliant on the ability of Daewoong, as the licensor of our only product candidate, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over Daewoong&#8217;s or our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications currently being prosecuted may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may issue on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims, including Daewoong&#8217;s defense in connection with the Medytox Litigation, which is defined below. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgement or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">, including the Medytox Litigation, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">may prevent or delay our development and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, aesthetic medicine and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing DWP-450. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Third parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of DWP-450 or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that DWP-450 or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of DWP-450 or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of our product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used us toward the maintenance of our own intellectual property and the development and commercialization of our product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. Presently, we, ALPHAEON, SCH and Daewoong are defendants to a lawsuit brought by Medytox, Inc., or Medytox, alleging, among other things, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">manufacture DWP-450 (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture DWP-450, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing DWP-450, and (v) attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Medytox Litigation and any other similar claims, suits, government investigations, and proceedings are inherently uncertain and their results may not be favorable for us. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For example, if the Medytox Litigation has a negative outcome for us, ALPHAEON or Daewoong, it could result in us losing access to DWP-450 and the manufacturing process and require us to negotiate a new license with Medytox for continued access to DWP-450. We may not be able to successfully negotiate such license on terms acceptable to us or at all. If we are unable to license DWP-450, we may not be able to find a replacement product, if at all, without expending significant resources and being required to seek additional regulatory approvals, which would be uncertain, time consuming and costly. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Regardless of the outcome, such proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">An adverse ruling against either us or one of the other defendants </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">of any such proceedings could adversely affect our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">which may not be commercially or more available</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of DWP-450 or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist which might be enforced against our products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to seeking patents for our </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">product</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We employ individuals who were previously employed at other pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A third-party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third-party were able to establish that our trademarks or trade names were infringing their marks, that third-party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third-party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our business and products are subject to extensive government regulation. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event our products receive regulatory approval, we, and our direct and indirect suppliers, including Daewoong, will remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may not obtain regulatory approval for the commercialization of DWP-450 or any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. Neither we nor any collaboration partner is permitted to market DWP-450 or any future product candidates in the United States until we receive approval of a BLA from the FDA. We submitted a BLA to the FDA in May 2017, a MAA to the EMA in June 2017, and a NDS to Health Canada in July 2017 for DWP-450 for the treatment of glabellar lines. Our BLA and MAA were accepted for review by the FDA and EMA, respectively, in July 2017. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">commence criminal investigations and prosecutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">impose injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">impose other civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">suspend any ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">delay or refuse to approve pending applications or supplements to approved applications filed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">refuse to permit drugs or active ingredients to be imported or exported to or from the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">seize or detain products or require us to initiate a product recall.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborator believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Regulatory approval of a BLA or BLA supplement, MAA, NDS or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA, EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a product candidate may not be deemed safe, effective, pure or potent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the data from preclinical studies and clinical trials may not be deemed sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a general requirement intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">FDA</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;or other regulatory authorities may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If DWP-450 or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Even if we receive regulatory approval for DWP-450 or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Once regulatory approval has been granted, DWP-450 or any other approved product will be subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any regulatory approvals that we or our collaborators receive for DWP-450 or any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, if the applicable regulatory agency approves DWP-450 or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and GCPs, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with DWP-450 or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">fines, warning letters or holds on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">refusal by the FDA, EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators, or suspension or revocation of product license approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">product seizure or detention, or refusal to permit the import or export of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">injunctions or the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">imposition</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If we fail to obtain regulatory approvals in foreign jurisdictions for DWP-450 or any future product candidates, we will be unable to market our products outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If approved, DWP-450 or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Some participants in our clinical trials have reported adverse events after being treated with DWP-450. If we are successful in commercializing DWP-450 or any other products, FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authority could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">While we do not expect that DWP-450, if approved for the treatment of moderate to severe glabellar lines, will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of DWP-450 or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of DWP-450 or any future product candidates. Such changes could, among other things, require: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes to manufacturing or marketing methods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes to product labeling or promotional materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">recall, replacement, or discontinuance of one or more of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">additional recordkeeping.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related To Our Relationship with Alphaeon </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">ALPHAEON controls the direction of our business, and the concentrated ownership of our common stock and certain contractual rights of ALPHAEON may prevent you and other stockholders from influencing significant decisions. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, immediately following the completion of this offering, ALPHAEON, which is majority-owned by SCH, will own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our outstanding shares of common stock (or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% if the underwriters exercise their option to purchase additional shares in full). As long as ALPHAEON beneficially owns a majority of the voting power of our outstanding common stock, it will generally be able to determine the outcome of all corporate actions requiring stockholder approval, including the election and removal of directors. Even if ALPHAEON were to beneficially own less than a majority of the voting power of our outstanding common stock, it may have the ability to influence the outcome of such corporate actions if it owns a significant portion of our common stock. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, if SCH chooses to sell some or all of its controlling interest in ALPHAEON, it could result in a change-of-control of ALPHAEON which could result in us being indirectly controlled by an unknown third-party.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result, ALPHAEON has the ability to control the direction of our business and the concentrated ownership of our common stock, and the contractual rights described above will prevent you and other stockholders from influencing significant decisions. In addition, we may take actions that stockholders other than ALPHAEON do not view as beneficial. This voting control may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If ALPHAEON sells a controlling interest in our company to a third-party in a private transaction, you may not realize any change-of-control premium on shares of our common stock and we may become subject to the control of a presently unknown third-party. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon completion of this offering, ALPHAEON will continue to control a majority of the voting power of our outstanding common stock. ALPHAEON will have the ability after the lock-up period of 180 days, should it choose to do so, to sell some or all of its shares of our common stock in a privately negotiated transaction, which, if sufficient in size, could result in a change-of-control of our company without your approval and without providing for a purchase of your shares.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, ALPHAEON entered into two substantially similar pledge and security agreements whereby ALPHAEON pledged and granted a continuing first priority lien and security interest in and to all of ALPHAEON&#8217;s right, title and interest in, among other items, securities and all other investment property held by ALPHAEON, including ALPHAEON&#8217;s entire ownership of our capital stock, or the collateral. The collateral secures the payment and performance of the obligations of ALPHAEON under certain convertible notes issued by ALPHAEON and other related agreements.&#160;Upon certain events of default, these secured lenders may take possession, hold, collect, sell, lease, deliver, grant options to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">purchase or otherwise retain, liquidate or dispose of all or any portion of the collateral, and as such, a change-of-control of our company may result. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have no obligation to maintain ALPHAEON&#8217;s financial viability and ALPHAEON may not remain current on such obligations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The ability of ALPHAEON to privately sell its shares of our common stock, with no requirement for a concurrent offer to be made to acquire your shares of our common stock could prevent you from realizing any change-of-control premium on your shares of our common stock that may otherwise accrue to ALPHAEON on its private sale of our common stock. Additionally, if ALPHAEON privately sells its significant equity interest in our company, we may become subject to the control of a presently unknown third-party. Such third-party may have conflicts of interest with those of other stockholders. In addition, if ALPHAEON sells a controlling interest in our company to a third-party, any future indebtedness we have may be subject to acceleration, and our other commercial agreements and relationships could be impacted, all of which may adversely affect our ability to run our business as described herein and may have a material adverse effect on our operating results and financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We will be a &#8220;controlled company&#8221; within the meaning of the Nasdaq Marketplace Rules, and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon completion of this offering, ALPHAEON will continue to control a majority of the voting power of our outstanding common stock. As a result, we will be a &#8220;controlled company&#8221; within the meaning of the Nasdaq Marketplace Rules. Under these rules, a listed company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the requirement that a majority of our board of directors consist of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the requirement that our nominating and corporate governance committee be comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the requirement that our compensation committee be comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">requirement</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for an annual performance evaluation of our corporate governance and compensation committees.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Presently, we intend to comply with all of the corporate governance requirements of Nasdaq. However, while ALPHAEON controls a majority of the voting power of our outstanding common stock, we may elect to not have a majority of independent directors or our nominating and corporate governance and compensation committees consisting entirely of independent directors and we will not be required to have written charters addressing these committees&#8217; purposes and responsibilities or have annual performance evaluations of these committees. Accordingly, if we elect not to comply with all of the corporate governance requirements, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Following this offering,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;will serve on our board of directors. Such directors may own shares of common stock or preferred stock of ALPHAEON, debt instruments convertible into equity interests of ALPHAEON, options to purchase shares of common stock or other equity awards of ALPHAEON. These individuals&#8217; holdings of ALPHAEON debt or equity securities, options to purchase shares of ALPHAEON or other equity awards may be significant for some of these persons compared to these persons&#8217; total assets. Their positions at ALPHAEON and the ownership of any ALPHAEON equity or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for ALPHAEON than the decisions have for us. These decisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">corporate opportunities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the impact that operating decisions for our business may have on ALPHAEON&#8217;s consolidated financial statements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on ALPHAEON&#8217;s current or future indebtedness or the covenants under that indebtedness; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">business combinations involving us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our dividend policy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">management stock ownership; and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the intercompany services </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;agreements between ALPHAEON and us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Potential conflicts of interest could also arise if we decide to enter into any new commercial arrangements with ALPHAEON or SCH in the future or in connection with ALPHAEON&#8217;s desire to enter into new commercial arrangements with third parties.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Furthermore, disputes may arise between ALPHAEON and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">indemnification and other matters arising from this offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the nature, quality and pricing of services ALPHAEON agrees to provide to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">sales or other disposal by ALPHAEON of all or a portion of its ownership interest in us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">business</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;combinations involving us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are controlled by ALPHAEON, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third-party.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">ALPHAEON and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation will provide that, subject to any contractual provision to the contrary, ALPHAEON will have no obligation to refrain from: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">engaging in the same or similar business activities or lines of business as we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">doing business with any of our clients or consumers; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">employing or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">otherwise</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;engaging any of our officers or employees.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation will provide for the allocation of certain corporate opportunities between us and ALPHAEON. Under these provisions, neither ALPHAEON or its other affiliates, nor any of their officers, directors, agents or stockholders, will have any obligation to present to us certain corporate opportunities. For example, a director of our company who also serves as a director, officer or employee of ALPHAEON or any of its other affiliates may present to ALPHAEON certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to ALPHAEON or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, under our certificate of incorporation, neither ALPHAEON nor any officer or director of ALPHAEON, except as will be provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary duty by reason of any of these activities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">ALPHAEON currently performs or supports many of our important corporate functions and if we are unable to replicate or replace these functions, our operations could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will need to replicate or replace certain functions, systems and infrastructure to which we will no longer have the same access after this offering. We may also need to make investments or hire additional employees to operate without the same access to ALPHAEON&#8217;s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these services on an allocation basis. Following this offering, many of these services will be governed by our services agreement with ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including cost, comparable to those that we will receive from ALPHAEON under our services agreement. Additionally, after the agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from ALPHAEON. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">may decline. In addition, we have historically received informal support from ALPHAEON, which may not be addressed in our services agreement. The level of this informal support will diminish or be eliminated following this offering. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to This Offering and Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not develop. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock was determined through negotiations between us and the underwriters and may bear no relationship to the price at which the common stock will trade upon the closing of this offering. An active trading market for our shares may never develop or be sustained following this offering. In addition, since ALPHAEON will remain a majority stockholder after we complete this offering, an active trading market may never develop or be sustained. If an active trading market for our common stock does not develop, it may be difficult for you to sell the shares that you purchase in this offering without depressing the market price for the common stock or to sell your shares at all. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">The trading price of our common stock is likely to be volatile, and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our stock price is likely to be volatile. The stock market in general and the market for pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements of regulatory approval or disapproval of DWP-450 or any future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adverse results from or delays in clinical trials of any of our future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">unanticipated safety concerns related to the use of DWP-450 or any of our future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any termination or loss of rights under the Daewoong Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adverse developments concerning our manufacturer or any future strategic partnerships&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">success or failure of competitive products or medical aesthetic products generally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">market conditions in the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">quarterly variations in our results of operations or those of our future competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">rumors and market speculation involving us or other companies in our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">sales of substantial amounts of our stock by ALPHAEON or other significant stockholders or our insiders, or the expectation that such sales might occur;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">general economic, industry and market conditions, including the size and growth, if any, of the medical aesthetics market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">additions or departures of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements or actions taken by ALPHAEON as our principal stockholder, including sales of substantial amounts of our common stock by ALPHAEON; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in accounting standards, policies, guidelines, interpretations or principles; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">other factors </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">described</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The trading market for our common stock will rely in part on the research and reports that equity research analysts publish about us and our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock after the closing of this offering, and such lack of research coverage may adversely affect the market price of our common stock. In the event we obtain equity research analyst coverage, we will not have any control of the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our common stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our historical financial data is not necessarily representative of the results that we would have achieved as a stand-alone company and may not be a reliable indicator of our future results.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our historical financial data included in this prospectus does not reflect the financial condition, results of operations or cash flows that we would have achieved as a stand-alone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our historical financial data reflects expense allocations for certain support functions that are provided on a centralized basis within ALPHAEON, such as expenses for business technology, facilities, legal, finance, human resources and business development that may be higher or lower than the comparable expenses that we would have actually incurred, or will incur in the future, as a stand-alone company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">significant</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;increases will occur in our cost structure as a result of this offering, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of the separation from ALPHAEON, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Future sales of common stock by ALPHAEON or others of our common stock, or the perception that such sales may occur, could depress the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, immediately following the completion of this offering, ALPHAEON will own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our outstanding shares of common stock (or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% if the underwriters exercise their option to purchase additional shares in full). Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to the volume and other restrictions of Rule 144 under the Securities Act of 1933, as amended, or the Securities Act, for so long as ALPHAEON is deemed to be our affiliate, unless the shares to be sold are registered with the SEC. The sale by ALPHAEON of a substantial number of shares after this offering, or a perception that such sales could occur, could significantly reduce the market price of our common stock. Upon completion of this offering, except as otherwise described herein, all shares that are being offered hereby will be freely tradable without restriction, assuming they are not held by our affiliates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We, our officers and directors, and ALPHAEON have agreed with the underwriters that, without the prior written consent of the representative of the underwriters, we and they will not, subject to certain exceptions and extensions, during the period ending 180 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock. The representative of the underwriters may, in its sole discretion and at any time without notice, release all or any portion of the shares of our common stock subject to the lock-up.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Following this offering, we intend to file one or more registration statements with the SEC covering shares of our common stock available for future issuance under the 2017 plan or any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the lock-up agreements referred to above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market could have an adverse effect on the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Because the initial public offering price of our common stock will be substantially higher than the pro forma net tangible book value per share of our outstanding common stock following this offering, new investors will experience immediate and substantial dilution.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The initial public offering price will be substantially higher than the pro forma net tangible book value per share of our common stock immediately following this offering based on the total value of our tangible assets less our total liabilities. Therefore, if you purchase shares of our common stock in this offering, you will experience immediate dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, based on an assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, and our pro forma as adjusted net tangible book value per share as of June 30, 2017. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation, bylaws, and Delaware law, contain provisions or will contain provisions that might enable our management to resist a takeover, and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;our</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, our certificate of incorporation will specify that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Our management will have broad discretion over the actual amounts and timing of the expenditure of the proceeds of this offering and might not apply the proceeds in ways that enhance our operating results or increase the value of your investment.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to allocate a significant amount of the net proceeds of this offering to the commercial launch of DWP-450, and also for general corporate purposes, including working capital. Our management will have broad discretion over the actual amounts and timing of the expenditure of the net proceeds of this offering within those categories, and accordingly investors in this offering will need to rely upon the judgment of our management with respect to the use of proceeds, with only limited information concerning management&#8217;s specific intentions. Our management might not apply the proceeds in ways that enhance our operating results or increase the value of your investment. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pending our use of the net proceeds from this offering, we plan to invest the net proceeds in a variety of capital preservation investments, including short and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation and bylaws will provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into, or will enter into, with our directors and officers may, among other things provide that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The rights conferred in our bylaws will not be exclusive. W</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">e may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We will incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies in the United States, which may adversely affect our operating results. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a public company listed in the United States, we will incur significant additional legal, accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Failure to comply with these rules might also make it more difficult for us to obtain certain types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a public company, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We also expect that being a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><a name="s01D94DB6758416D45CC61527CCE38B87"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS AND STATISTICAL DATA</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This prospectus contains forward-looking statements that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to obtain and maintain regulatory approval of DWP-450, and any related restrictions, limitations and/or warnings in the label of DWP-450;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully commercialize DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the potential market size, opportunity and growth potential for DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the attractiveness of DWP-450&#8217;s characteristics (including the benefits of a 900 kDa botulinum toxin type A complex) and the rate and degree of physician and patient acceptance of DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize DWP-450, if approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the pricing of DWP-450, if approved, and the flexibility of our pricing and marketing strategy compared to our competitors&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the performance of our third-party licensors, suppliers, manufacturers and distributors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our expectations regarding our future development of DWP-450 for other indications, including therapeutic indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing or likelihood of regulatory filings and approvals or clearances for DWP-450;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory developments in the United States, EU, Canada and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">developments and projections relating to our competitors and our industry, including competing products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the loss of key management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">o</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">ur future financial performance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">he results of the Medytox Litigation and any future legal proceedings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our use of the net proceeds from this offering.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions described under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained in this prospectus.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements may never be achieved or occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement on Form S-1, of which this prospectus is a part, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Statistical Data</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the section entitled "Risk Factors." These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><a name="sF7806717EB3FCABEAD431527CD052FD7"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We estimate that we will receive net proceeds of approximately $&#160;&#160;&#160;&#160;&#160;million (or approximately $&#160;&#160;&#160;&#160;&#160;million if the underwriters&#8217; option to purchase additional shares is exercised in full) from the sale of the shares of common stock offered by us in this offering, based on an assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A $1.00 increase (decrease) in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share would increase (decrease) the net proceeds to us from this offering by approximately $&#160;&#160;&#160;&#160;&#160;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The principal purposes of this offering are to increase our financial flexibility to support our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. We intend to use the net proceeds from this offering as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">up to $&#160;&#160;&#160;&#160; million </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to obtain marketing approval for DWP-450 in the United States and other territories, including to satisfy various regulatory requirements related to the approval of DWP-450 in these territories</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">approximately $&#160;&#160;&#160;&#160;&#160;million </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to conduct pre-commercial launch activities, including building our commercialization infrastructure to support our specialty sales force and developing physician education, brand awareness campaigns and other marketing efforts</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">approximately $&#160;&#160;&#160;&#160;&#160;million </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to hire, train and deploy our specialty sales force and to launch marketing efforts if DWP-450 is approved</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the remainder for working capital and general corporate purposes.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, we intend to use a portion of the net proceeds from this offering to pay certain milestone payments to Daewoong and certain former stockholders of our company upon U.S. and EU regulatory approval of DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The costs and timing of biological product development, marketing approval and product launch are highly uncertain, are subject to substantial risks and can often change. The amounts and timing of our actual expenditures will depend upon numerous factors, including the FDA's review of our BLA, the EMA&#8217;s review of our MAA and Health Canada&#8217;s review of our NDS, the scale of our initial commercial launch, whether or not we enter into distribution arrangements for DWP-450 with third parties outside of the United States, our operating costs and expenditures and the other factors described under the section entitled "Risk Factors" in this prospectus. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and investors will be relying on our judgment regarding the application of the aggregate net proceeds</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Based on our estimated use of proceeds, we anticipate that the net proceeds of this offering and resources from ALPHAEON (including the payment of certain expenses on our behalf that we will evidence as related party borrowings from ALPHAEON) will be sufficient to fund our launch and initial commercialization of DWP-450, if approved. However, we may require additional funds earlier than we currently expect if, in the event that we are required to conduct additional clinical trials, we experience a delay in receiving marketing approval of DWP-450 or market acceptance of DWP-450 is slower than expected. We may seek any necessary funds through a combination of private and public equity offerings, debt financings and collaborations, strategic partnerships and licensing arrangements. Additional financing may not be available when we need it or may not be available on terms that are favorable to us. Because of the risks and uncertainties associated with the development and commercialization of DWP-450, we may not have or be able to obtain all of the funds required to&#160;commercialize&#160;DWP-450. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pending our use of the net proceeds from this offering, we plan to invest the net proceeds in a variety of capital preservation investments, including short and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><a name="sFB45FDAB2ABFA6A8F9A51527CD3864FB"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">DIVIDEND POLICY</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since inception, we have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, tax considerations, legal or contractual restrictions, business prospects, the requirements of current or then-existing debt instruments, general economic conditions and other factors our board of directors may deem relevant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><a name="s01AA43A51F52EDD89E571527CD5989A1"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">CAPITALIZATION</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table sets forth our cash and cash equivalents and capitalization as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">on an actual basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">on a pro forma basis to reflect (i) the automatic conversion of all outstanding shares of our Series A preferred stock into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,250,000 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of our common stock, which will occur immediately prior to the completion of this offering, and (ii) the filing and effectiveness of our certificate of incorporation, which will occur immediately prior to the completion of this offering; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">on a pro forma as adjusted basis to give further effect to our issuance and sale of</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of common stock in this offering at an assumed initial public offering price of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The pro forma and pro forma as adjusted information below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the initial public offering price of our common stock and other terms of this offering determined at pricing. You should read the following table in conjunction with &#8220;Use of Proceeds,&#8221; &#8220;Selected Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and other financial information contained in this prospectus, including the financial statements and related notes appearing elsewhere in this prospectus.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table is presented in thousands, except for share data:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">As of June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Actual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Pro Forma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Pro Forma As Adjusted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Related party receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">68,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">68,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Note obligation</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">122,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Series A preferred stock, $0.00001 par value; 2,500,000 shares authorized and 1,250,000 shares issued and outstanding, actual; no shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Stockholders&#8217; deficit:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Preferred stock, $0.00001 par value; no shares authorized, issued and outstanding, actual; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized and&#160;no shares issued and outstanding, pro forma and pro forma as adjusted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Common stock, $0.00001 par value; 20,000,000 shares authorized and 10,000,000 shares issued and outstanding, actual; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, pro forma;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, pro forma as adjusted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(73,100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stockholders&#8217; (deficit) equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(67,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total capitalization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">55,429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A $1.00 increase (decrease) in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash, additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#160;&#160;&#160;&#160;&#160;million, assuming the number of </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:24px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares offered by us as stated on the cover page of this prospectus remains unchanged and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional paid-in capital, total stockholders&#8217; equity and total capitalization by $&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Represents our obligations as a guarantor of ALPHAEON&#8217;s convertible promissory notes and convertible bridge note.  For a further explanation, including the resulting impact on the related party receivable and total stockholders&#8217; deficit, see the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Guarantee of ALPHAEON&#8217;s Convertible Notes and Intercreditor Agreement.&#8221;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The number of shares of common stock shown as issued and outstanding in the table excludes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon the exercise of outstanding stock options under the 2017 plan as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock reserved for future issuance under the 2017 plan as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><a name="sD4A250275719E13D8DD71527CD9EBECA"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">DILUTION</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our historical net tangible book value (deficit) is the amount of our total tangible assets less our liabilities and preferred stock. Our historical net tangible book value (deficit) per share is our historical net tangible book value (deficit) divided by the number of shares of common stock outstanding as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Our historical net tangible book value (deficit) as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;or $(&#160;&#160;&#160;&#160;&#160;) per share of common stock. Our pro forma net tangible book value (deficit) as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was $(&#160;&#160;&#160;&#160;&#160;) million, or $(&#160;&#160;&#160;&#160;&#160;) per share of common stock, after giving effect to the automatic conversion of all our outstanding shares of Series A preferred stock into 1,250,000 shares of common stock upon the completion of this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pro forma as adjusted net tangible book value (deficit) is our pro forma net tangible book value, after giving further effect to the sale of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock in this offering at an assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. This amount represents an immediate increase in pro forma net tangible book value (deficit) of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share to our existing stockholder, and an immediate dilution of $&#160;&#160;&#160;&#160;&#160;per share to investors purchasing in this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table illustrates this dilution on a per share basis to new investors:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:75%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assumed initial public offering price per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Historical net tangible book value (deficit) per share as of June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Increase in pro forma net tangible book value (deficit) attributable to conversion of our Series A preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Pro forma net tangible book value (deficit) per share as of June&#160;30, 2017, before giving effect to this offering</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Increase in pro forma net tangible book value (deficit) per share attributable to new investors participating in this offering</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Pro forma as adjusted net tangible book value (deficit) per share after this offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dilution in pro forma net tangible book value (deficit) per share to investors purchasing in this offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A $1.00 increase (decrease) in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value (deficit) per share after this offering by approximately $&#160;&#160;&#160;&#160;&#160;per share and the dilution in pro forma net tangible book value (deficit) per share to investors purchasing in this offering by approximately $&#160;&#160;&#160;&#160;&#160;per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 1,000,000 share increase in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value (deficit) per share after this offering by approximately $&#160;&#160;&#160;&#160;&#160;and decrease the dilution in pro forma net tangible book value (deficit) per share to investors purchasing in this offering by approximately $&#160;&#160;&#160;&#160;&#160;, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1,000,000 share decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value (deficit) per share after this offering by $&#160;&#160;&#160;&#160;&#160;and increase the dilution in pro forma net tangible book value (deficit) per share to investors purchasing in this offering by approximately $&#160;&#160;&#160;&#160;&#160;per share, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma information discussed above is illustrative </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">only and will change based on the actual initial public offering price, number of shares and other terms of this offering determined at pricing.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If the underwriters exercise in full their option to purchase&#160;&#160;&#160;&#160;&#160;additional shares of our common stock in this offering, the pro forma as adjusted net tangible book value will increase to $&#160;&#160;&#160;&#160;&#160;per share, representing an immediate increase in pro forma net tangible book value to our existing stockholder of $&#160;&#160;&#160;&#160;&#160;per share and an immediate dilution of $&#160;&#160;&#160;&#160;&#160;per share to new investors purchasing in this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table summarizes, as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, on the pro forma as adjusted basis described above, the difference between our existing stockholder and the investors purchasing in this offering with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the average price paid per share paid to us, based on an assumed initial public offering price of $&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:46%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Percent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Percent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Existing stockholder</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">New investors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If the underwriters exercise in full their option to purchase additional shares of our common stock in this offering, the number of shares held by our existing stockholder will be reduced to&#160;&#160;&#160;&#160;&#160;% of the total number of shares of common stock outstanding upon completion of this offering, and the number of shares of common stock held by new investors participating in this offering will be further increased to&#160;&#160;&#160;&#160;&#160;% of the total number of shares of common stock to be outstanding upon completion of the offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A $1.00 increase (decrease) in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) total consideration paid by new investors by $&#160;&#160;&#160;&#160;&#160;million, assuming the number of shares we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) total consideration paid by new investors by $&#160;&#160;&#160;&#160;&#160;million, assuming that the assumed initial price to the public remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The foregoing tables and calculations excludes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon the exercise of outstanding stock options under the 2017 plan, as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock reserved for future issuance under the 2017 plan as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Furthermore, we may choose to raise additional capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that any outstanding stock options are exercised, new stock options are issued under our 2017 plan or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors purchasing in this offering.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><a name="s1E4B0BD2C4E93D4AB47E1527C9F8587C"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following tables contain selected portions of our financial data. We derived the selected statements of operations data for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and the selected balance sheets data as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and 2016, from our audited financial statements and related notes appearing elsewhere in this prospectus. We derived the selected statements of operations data for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and selected balance sheet data as of June 30, 2017 from our unaudited interim financial statements that are included elsewhere in this prospectus. We have prepared this unaudited information on the same basis as the audited financial statements and have included all adjustments, consisting only of normal recurring adjustments, that we consider necessary for a fair statement of our financial position and operating results for such period. Our historical results are not necessarily indicative of the results that may be expected or may actually occur in the future, and our interim results are not necessarily indicative of the expected results for future interim periods or the full year. The selected financial data should be read together with our financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; appearing elsewhere in this prospectus.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our historical financial statements have been prepared on a standalone basis and are derived from the financial statements and accounting records of Evolus and prepared in accordance with GAAP. The financial statements reflect amounts attributable to our business, including the costs Evolus incurred for the development, commercialization and license agreement with Daewoong. We have calculated our income tax amounts using a separate return methodology and have presented these amounts as if we were a separate taxpayer from ALPHAEON in each jurisdiction for each period presented. Our management believes that the allocations and results are reasonable for all periods presented. However, allocations may not be indicative of the actual expense we would have incurred had we operated as an independent company for the periods presented and, accordingly, our historical financial statements may not reflect what our actual financial position, results of operations and cash flows would have been if we had been an independent company for the periods presented.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table is presented in thousands, except for share and per share data:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Statements of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">20,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">12,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">6,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">4,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">9,883</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">7,033</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">5,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">2,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:0px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(31,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(19,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(31,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(20,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(12,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Net loss per share, basic and diluted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(3.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(2.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(1.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Weighted-average shares used to compute basic and diluted net loss per share</font><font style="font-family:Trade Gothic,sans-serif;font-size:1pt;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Pro forma net loss per share, basic and diluted</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2) </sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(1.78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(0.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Pro forma weighted-average shares used to compute basic and diluted net loss per share</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)(2) </sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">See Note 2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the basic and diluted net loss per common share and the shares used in the computation of the per share amounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The pro forma net loss per share of common stock, basic and diluted, for the year ended December&#160;31, 2016 and the six months ended June 30, 2017 reflects the automatic conversion of all outstanding shares of our Series A preferred stock into 1,250,000 shares of common stock and the filing and effectiveness of our certificate of incorporation, each of which will occur in connection with this offering. The pro forma net loss per share of common </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:24px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">stock, basic and diluted, does not give effect to the issuance of shares from the proposed initial public offering nor do they give effect to potential dilutive securities where the impact would be anti-dilutive.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table is presented in thousands:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Related party receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">68,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">46,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">59,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">68,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,152</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">21,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Note obligation</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">122,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Series A preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">58,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">59,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(46,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(66,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(73,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Total stockholder&#8217;s equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">12,002</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(7,106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(67,008</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Represents our obligations as a guarantor of ALPHAEON&#8217;s convertible promissory notes and convertible bridge note.  For a further explanation, including the resulting impact on the related party receivable and total stockholder&#8217;s deficit, see the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Guarantee of ALPHAEON&#8217;s Convertible Notes and Intercreditor Agreement.&#8221;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><a name="s85E56E8A756D5FD53ABE1527CE521C25"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS</font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">The following discussion and analysis should be read in conjunction with &#8220;Selected Financial Data&#8221; and our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Forward-Looking Statements and Statistical Data&#8221; in this prospectus.</font></div><div><a name="s628F6D0909AA9DAF2EEE1527CE84C156"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. We focus on the self-pay aesthetic market and our first product candidate, DWP-450, is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We believe we will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; between the eyebrows in the United States, EU and Canada. The FDA issued a PDUFA date of May 15, 2018 for completion of its review of our BLA. We submitted a MAA to the EMA and it was accepted for review in July 2017 with a decision expected by the third quarter of 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since our inception in 2012, we have devoted substantially all our efforts to identify and recruit personnel, conduct clinical trials, and seek regulatory approval for our DWP-450 product candidate. Our resources have largely been devoted to the clinical development of DWP-450. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On September 30, 2013, we entered into the Daewoong Agreement pursuant to which Daewoong agreed to manufacture and supply us with DWP-450 and granted us an exclusive license to develop, distribute, market and sell the product in the United States, EU, Switzerland, Canada, Australia, Russia, C.I.S., and South Africa, or the covered territories. Daewoong also granted us a non-exclusive license to do the same in Japan.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In a series of related transactions in 2013, SCH acquired all of our outstanding equity in exchange for </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">membership interests in SCH</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. In 2014, SCH contributed our equity that it had acquired in 2013 to ALPHAEON</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of these transactions, we became a wholly-owned subsidiary of ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have never been profitable and, as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$73.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. We have never generated revenue from DWP-450 and we incurred net losses of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$31.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$20.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$12.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$6.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. In addition, we have concluded that we do not have sufficient cash to fund our operations through December 31, 2017 and as a result there is substantial doubt about our ability to continue as a going concern.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not expect to receive any revenue from DWP-450 or any future product candidates that we develop unless and until we obtain regulatory approval and commercialize DWP-450 or any future product candidates, or enter into collaborative arrangements with third parties. We expect to continue to incur </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">significant expenses and increasing </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">net operating losses for the foreseeable future as we seek regulatory approval, prepare for and, if approved, proceed to commercialization. We utilized CROs to carry out our clinical development and we do not yet have a sales organization. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We expect to incur significant expenses related to building our commercialization infrastructure, including marketing, sales and distribution functions, inventory build prior to commercial launch and training and deploying a specialty sales force and implementing a targeted marketing campaign. We plan to launch DWP-450, if approved, in the United States by building a commercialization infrastructure with a specialty sales force of approximately 65 sales representatives at commercial launch and growing to 150 sales representatives over time. We also expect to incur additional costs associated with operating as a public company and in building our internal resources to become less reliant on ALPHAEON. Based on our estimated use of proceeds, we anticipate that the net proceeds of this offering, together with resources from ALPHAEON (including the payment of certain expenses on our behalf that we will evidence as related party borrowings from ALPHAEON), will be sufficient to fund our operating plan through the launch and initial commercialization of DWP-450, if approved by the FDA. However, we may require additional funds earlier than we currently expect if, in the event that we are required to conduct additional clinical trials, we experience a delay in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">receiving marketing approval of DWP-450 or market acceptance of DWP-450 is slower than expected. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Adequate funding may not be available to us on acceptable terms, or at all, which could have a material adverse effect on our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On September 30, 2013, we entered into the Daewoong Agreement pursuant to which Daewoong agreed to manufacture and supply us with DWP-450 and granted us an exclusive license to develop, distribute, market and sell the product in the covered territories. Daewoong also granted us a non-exclusive license to do the same in Japan. We have the option, subject to certain payment conditions, to expand the permitted use of the product beyond aesthetic indications and into therapeutic indications. Under the Daewoong Agreement, we are required to make certain minimum annual purchases in order to maintain the exclusivity of the license.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million. We further agreed to make milestone payments upon certain confidential development and commercial milestones</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, including a confidential payment to Daewoong upon FDA and EMA approval of DWP-450</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of DWP-450, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">During the term of the Daewoong Agreement, we will not purchase, sell or distribute any competing products in any covered territory or Japan or sell the product subject to the Daewoong Agreement outside the covered territory or Japan. The initial term of the Daewoong Agreement is from September 30, 2013 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell the product or by (ii) September 30, 2023, and automatically renews for additional three-year terms if we meet certain performance requirements. Either party may terminate the Daewoong Agreement with written notice upon a continuing uncured default by the other party. The Daewoong Agreement terminates without notice upon our bankruptcy or insolvency. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For additional information about the Daewoong Agreement, see &#8220;Business</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Third Party Licenses and Arrangements-Daewoong License and Supply Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Payment Obligation Related to our Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As part of our acquisition by SCH, certain of our former stockholders, or the Evolus contributors, were issued Class D units which contained certain rights and privileges that provide the Evolus contributors with a 10% economic interest in our company, and a right to compel SCH to sell to ALPHAEON this 10% interest in our company in exchange for certain payment obligations by ALPHAEON to SCH which were ultimately allocable solely to the Evolus contributors. The payment obligations include (i) a $10.0 million up-front payment upon obtaining FDA approval for DWP-450 for the treatment of glabellar lines, (ii) </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">perpetual quarterly royalties of a mid-teen percentage of net sales of the product within the United States and (iii) a high-single digit percentages of net sales of the product outside of the United States. As these future royalty streams are perpetual, ALPHAEON had the right to terminate any future payments for a one-time lump sum payment to SCH of $145.0 million.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of this offering, we intend to enter into an agreement under which we will either directly assume the obligations set forth above, as they may be amended, to the Evolus contributors or indirectly, by entering into an agreement with ALPHAEON to reimburse them for the payments to the Evolus contributors. As a result of a series of agreements, we will become either directly or indirectly obligated to make specified payments to the Evolus contributors.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:normal;font-weight:bold;">&#32;Relationship with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since our acquisition in 2014, we have funded our operations primarily through contributions and related party borrowings from ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have derived the financial statements we present in this registration statement by allocating expenses associated with DWP-450 from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON&#8217;s </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">consolidated financial statements in accordance with applicable accounting standards and SEC regulations. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our management believes that the allocations and results are reasonable for all periods presented in our financial statements. However, allocations may not be indicative of the actual expense we would have incurred had we operated as an independent company for the periods presented and do not include additional expenses we expect to incur in connection with the commercialization of DWP-450, including the creation of a commercialization infrastructure and hiring of our sales force.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to enter</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;into a services agreement with ALPHAEON, or the services agreement, which will become effective upon completion of this offering. The services agreement will set forth certain agreements between ALPHAEON and us that will govern the relationship between ALPHAEON and us following this offering</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently incur obligations to ALPHAEON for the research and development expenses it incurs on our behalf, which include both external and internal expenses. External research and development expenses include costs for CROs to conduct nonclinical and clinical studies on our product candidate, costs to acquire and evaluate clinical study data such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. Internal development expenses include costs for the work that ALPHAEON's development employees perform for us. All ALPHAEON-provided research and development expenses shown in our financial statements for </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the six months ended June 30, 2017 and all internal research and development expenses for the same periods were recorded as related party borrowings </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">from ALPHAEON in the amounts of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$20.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$12.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$4.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON also provides us certain services, including, without limitation, general and administrative support services and development support services. We currently pay ALPHAEON for our share of the internal and external expenses for each of these functions based on our relative use of each function, plus an allocation of facility-related expenses, including depreciation and amortization and rent expense. All ALPHAEON-provided general and administrative expenses shown in our financial statements for </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the six months ended June 30, 2017 were recorded as related party borrowings from ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">in the amounts of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$10.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$7.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As our business grows and we assume increasing responsibility from ALPHAEON, we will assume direct responsibility for procuring and financing the services we currently receive from ALPHAEON and ALPHAEON's responsibility to provide us with these services will decrease. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not pay a mark-up or profit on the external or internal expenses ALPHAEON bills to us. For example, we do not have to pay for a full time person if we only need the person's skills for 50% of the time. In this way, we can increase our headcount as our requirements grow and as we assume increasing responsibility for our product candidate from ALPHAEON, rather than building capabilities and capacity in advance of full utilization. We believe that our expenses reasonably reflect the expenses we would have incurred if we had the capabilities and capacity in place to perform this work ourselves. Further, we do not believe that our expenses representing functions historically reimbursed by ALPHAEON will increase significantly as we assume development, regulatory, manufacturing and administrative responsibilities from ALPHAEON because we will only assume these functions when we believe we can do so in a cost-efficient manner.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;However, we do expect that our future expenses will increase from our historical expenses as we move towards commercialization of DWP-450 and transition to a public company.</font></div><div><a name="sAFF42727B5446921B0361527CA026A76"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Financial Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We derived the full year </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;financial results on a standalone basis from ALPHAEON&#8217;s financial statements and accounting records and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">prepared them in accordance with generally accepted accounting principles, or GAAP</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The full year </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and 2017 financial results reflect amounts attributable to our business, including the costs that ALPHAEON incurred for the development, commercialization and license agreement with Daewoong. M</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">anagement believes that the allocations and results are reasonable for all periods presented. However, allocations may not be indicative of the actual expense we would have incurred had the business operated as an independent company for the periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following is a description of the components of our results of operations:</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our general and administrative expenses consist of salaries and personnel-related costs (other than research personnel), including stock-based compensation of ALPHAEON&#8217;s stock, for our employees in executive and administrative functions. Our general and administrative expenses also include professional fees for accounting, auditing and consulting services, legal services, investor relations, travel and facilities. As described above, ALPHAEON charges us for many of the expenses associated with these functions, including, among others, accounting, human resources, legal and investor relations. We expect to assume responsibility from ALPHAEON for these general and administrative functions as our business grows and we build our internal development and commercialization capabilities. ALPHAEON has historically charged us market rates for the portion of the resources that we use. Accordingly, we do not expect the overall general and administrative expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">representing functions historically reimbursed by ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to change significantly as we transition functions from ALPHAEON to us, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">however we do expect such expenses to increase as described below</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We anticipate our general and administrative expenses to increase in the future to support our continued development and potential commercialization of DWP-450. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, if DWP-450 obtains regulatory approval, we expect that we will incur expenses associated with building a sales and marketing team. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Increases over and above the level of work that ALPHAEON is currently performing on our behalf will result in an increase in general and administrative expenses and could include costs related to hiring additional personnel, increased office space, implementing new information technology systems and other costs associated with expanding our general and administrative functions. Our general and administrative expenses will also increase due to the costs of operating as a public company</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and may further increase when we are no longer able to rely on certain &#8220;emerging growth company&#8221; exemptions we are afforded under the JOBS Act.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since our inception, we have focused on developing DWP-450. Our research and development expenses primarily consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">personnel costs, which include salaries and related expenses for research and development personnel, including expenses related to stock-based compensation granted to personnel in development functions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">fees paid to clinical study sites and vendors, including CROs, in connection with our clinical studies, costs of acquiring and evaluating clinical study data such as investigator grants, patient screening fees, laboratory work and statistical compilation and analysis, and fees paid to clinical consultants related to the execution of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expenses to acquire clinical study materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">other consulting fees paid to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expenses related to compliance with drug development regulatory requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">travel, facilities, which includes cost associated with rent, maintenance and related facilities costs as well as depreciation and amortization, insurance and other expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As described above, ALPHAEON charges us for many of the expenses associated with these functions, including, among others, costs for CROs to conduct nonclinical and clinical studies on our product candidate, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. We expect to assume responsibility from ALPHAEON for these research and development functions as our business grows and we build our internal research and development capabilities. ALPHAEON has historically charged us market rates for the portion of the resources that we use. Accordingly, we do not expect our overall research and development expenses representing functions historically reimbursed by ALPHAEON to change significantly as we transition functions from ALPHAEON to us, however we expect our overall research and development expenses to increase as we seek to develop future product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Following this offering, we will expense our research and development costs as we incur them. Our expenses related to clinical studies are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with CROs that we may use to conduct and manage our clinical studies on our behalf. We generally accrue expenses related to clinical studies based on contracted amounts applied to the level of patient enrollment and activity. If we modify timelines or contracts based upon changes in the clinical study protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Six Months Ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">The following table summarizes our results of operations for the periods indicated (in thousands):</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(dollars)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">6,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">4,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(2,852</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">General and administrative</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">5,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(3,104</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;padding-left:9px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(5,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(12,106</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(6,252</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">5,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Other expense, net </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Loss before taxes </font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(12,106</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(6,254</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">5,852</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Provision for income taxes </font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(16</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(12,162</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(6,294</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">5,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Research and development expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">decreased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$6.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$4.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease was primarily attributable to a reduction in our clinical trial costs associated with the completion of our Phase III clinical trials in 2016. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Amounts incurred in 2017 were primarily attributable to costs related to the preparation of our regulatory filings with the FDA and EMA. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">General and administrative expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">decreased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$3.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$5.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease was attributable to a reduction in ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">expenses allocated to us, reflecting an overall decrease in ALPHAEON operations and personnel in 2017 compared with 2016, for services provided to us by its employees, including salaries and benefits of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$483,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, third-party service costs of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$3.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and partially offset by an increase in office expense of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$592,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Depreciation and Amortization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Depreciation and amortization expense </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">increased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$102,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$116,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$218,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The increase was attributable to related </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">expenses allocated to us from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Provision for Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Income tax expense was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$40,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;compared with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$56,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The expense for both periods is primarily attributable to the book to tax difference for intangible amortization of the in-process research and development, or IPR&amp;D, asset representing research and development relating to DWP-450. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">The following table summarizes our results of operations for the periods indicated (in thousands):</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(dollars)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">20,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">12,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(8,074</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">General and administrative</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">9,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">7,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(2,850</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(90</font></div></td><td style="vertical-align:top;border-bottom:1px solid #231f20;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(11,014</font></div></td><td style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(30,980</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(19,966</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">11,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Other expense, net </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(33</font></div></td><td style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Loss before taxes </font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(31,019</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(19,972</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">11,047</font></div></td><td style="vertical-align:bottom;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Provision for income taxes </font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(31,112</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(20,065</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">11,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Research and development expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">decreased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$20.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$12.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease was primarily attributable to a reduction in our clinical trial costs associated with completion of our Phase III clinical trials. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">General and administrative expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">decreased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$9.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$7.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease was attributable to a reduction in ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">expenses allocated to us, reflecting an overall decrease in ALPHAEON operations and personnel in 2017, compared to 2016, for services provided to us by its employees, including third-party service costs of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, stock-based compensation expense of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$479,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and office related expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$342,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Depreciation and Amortization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Depreciation and amortization expense </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">decreased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$90,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, from </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$416,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$326,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease was attributable to a reduction in related </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">expenses allocated to us from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Provision for Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Income tax expense was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$93,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;compared with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$93,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The expense for both years is primarily attributable to the book to tax difference for intangible amortization of the IPR&amp;D asset. </font></div><div><a name="s0FACA24E93842EA754851527CA4D5ABE"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we had no cash or cash equivalents and a stockholder&#8217;s deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$67.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we had </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$4.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, in restricted cash, representing an escrow account with funds set aside for research and development.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since our acquisition in 2014, we have funded our operations primarily through contributions and related party borrowings from ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have no revenue, incurred operating losses and have an accumulated deficit as a result of ongoing efforts to develop our product DWP-450, including conducting nonclinical and clinical trials and providing general and administrative support for these operations. We had an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$66.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$73.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and negative working capital as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$69.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. We had net losses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$20.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$31.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$6.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$12.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. We used net cash in operating activities of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$13.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$36.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. We anticipate that operating losses and net cash used in operating activities will increase over the next several years as we commercialize DWP-450, if approved.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Based on our estimated use of proceeds, we anticipate that the net proceeds of this offering, together with resources from ALPHAEON (including the payment of certain expenses on our behalf that we will evidence as related party borrowings from ALPHAEON), will be sufficient to fund our operating plan through the launch and initial commercialization of DWP-450, if approved by the FDA. However, we may require additional funds earlier than we currently expect if, in the event that we are required to conduct additional clinical trials, we experience a delay in receiving marketing approval of DWP-450 or market acceptance of DWP-450 is slower than expected. In addition, we expect to incur significant expenses related to building our commercialization infrastructure, including marketing, sales and distribution functions, inventory build prior to commercial launch and training and deploying a specialty sales force and implementing a targeted marketing campaign. We also expect to incur additional costs associated with operating as a public company and in building our internal resources to become less reliant on ALPHAEON. If such financing is not available at adequate levels or on acceptable terms, we could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of our development programs or commercialization efforts or other aspects of our business plan, out-license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above, any of which could significantly limit our ability to achieve profitability or to respond to competitive pressures and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.&#160; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is&#160;probable that we will be unable to meet our obligations as they become due within one year after the date that the&#160;financial statements are issued. The financial information throughout this prospectus and the financial statements included elsewhere in this prospectus have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.&#160;This financial information and these financial statements do not include any adjustments that may result from an unfavorable outcome of this uncertainty. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish our business plans and secure sources of financing and ultimately attain profitable operations.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">The following table summarizes our cash flows for the periods indicated (in thousands):</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:1px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Operating activities </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(36,384</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(13,267</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(8,839</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">(8,605</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Investing activities </font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Financing activities </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">36,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">13,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">8,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">8,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Net change in cash and cash equivalents </font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Operating Activities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our cash used in operating activities is primarily driven by our net loss and related party borrowings from ALPHAEON for expenses paid on our behalf.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Operating activities used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from our net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$6.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and a decrease of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$3.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in our net operating assets and liabilities, partially offset by non-cash charges of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;Non-cash charges included depreciation and amortization of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and non-cash stock-based compensation allocated from ALPHAEON of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease in our net operating assets and liabilities was primarily driven by a decrease in accounts payable and accrued expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, partially offset by a release of our restricted cash of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Operating activities used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$13.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from our net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$20.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which was partially offset by non-cash charges of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and an increase in our net operating assets and liabilities of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Non-cash charges included depreciation and amortization of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and non-cash stock-based compensation of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The increase in our net operating assets and liabilities was primarily driven by the release of our restricted cash of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and an increase in accounts payable of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, partially offset by a decrease in accrued expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Operating activities used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$36.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from our net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$31.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and a decrease of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$3.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in our net operating assets and liabilities, partially offset by non-cash charges of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Non-cash charges included depreciation and amortization of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and non-cash stock-based compensation of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The decrease in our net operating assets and liabilities was primarily driven by the replenishment of our restricted cash of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$4.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and a decrease in accrued expenses and accounts payable of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$1.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We had no investing activity during the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our cash provided from financing activities is primarily driven by changes in our related party borrowings from ALPHAEON for expenses paid on our behalf.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Financing activities provided </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from the change in our related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Financing activities provided </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$13.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from the change in our related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Financing activities provided </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$36.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of cash in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, primarily resulting from the change in our related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON provides us certain services, including, without limitation, general and administrative support services and research and development support services. ALPHAEON has allocated a certain percentage of personnel to perform the services that it provides to us based on its good faith estimate of the required services. We intend to pay ALPHAEON for these allocated costs, which reflect the ALPHAEON full-time equivalent, or FTE, rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing us these services. We do not pay a mark-up or profit on the external or internal expenses ALPHAEON allocates to it. All ALPHAEON-provided operating expenses shown in our financial statements for </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;were treated as related party borrowings from ALPHAEON to us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we owed ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$46.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$59.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:normal;font-weight:bold;">Guarantee of ALPHAEON&#8217;s Convertible Notes and Intercreditor Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON is, as of June 30, 2017, the borrower under (i) certain convertible promissory notes issued by ALPHAEON for an aggregate principal amount of approximately $46.5 million, or the convertible promissory notes, and (ii) a certain convertible bridge note issued by ALPHAEON for a principal amount of $2.5 million, or the convertible bridge note, collectively, the Notes. ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of our capital stock, granted by ALPHAEON to Dental Innovations BVBA, or DI, as collateral agent for the holders of the convertible promissory notes, and Longitude Venture Partners II, L.P., or Longitude, as the holder of the convertible bridge note, pursuant to separate pledge and security agreements, or the ALPHAEON security agreements. In April 2017, we agreed to unconditionally guarantee ALPHAEON&#8217;s obligations under the Notes and we granted to Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, a first priority lien and security interest in substantially all of our assets pursuant to separate guaranty and security agreements, or the Evolus security agreements. We refer to the ALPHAEON security agreements and the Evolus security agreements collectively as the convertible notes security agreements. In April 2017, we, as guarantor, also entered into an amended and restated intercreditor agreement with ALPHAEON, as borrower, Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, or the intercreditor agreement. The intercreditor agreement sets forth certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">rights of Longitude and DI in connection with the convertible bridge note, the convertible promissory notes and the collateral pledged pursuant to the convertible notes security agreements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The intercreditor agreement and Evolus security agreements stipulate that any payment by us under their terms shall result in a dollar-for-dollar offset and reduction in the amount of intercompany loans owed by us to ALPHAEON. The Evolus security agreements will terminate upon the earlier of (i) the date on which all secured obligations described under the Evolus security agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or into unsecured notes pursuant to the terms of the Notes if not paid by ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Concurrent with the execution of the Evolus security agreements with the holders of the Notes in April 2017, we severally agreed to pay the redemption amount of 2.5 times the principal amount of the Notes upon maturity. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a co-obligor to these Notes, we are required to measure obligations resulting from joint and several liability arrangements as the sum of the amount that we have (i) contractually agreed to pay on the basis of our arrangement with our co-obligors and (ii) any additional amount that we expect to pay on behalf of our co-obligors. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We recorded this joint and several liability as Note obligations and recorded a corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity as of April 2017 to reflect the joint and several liability. As we and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, we developed a range of amounts that we expect to pay under the c</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">onvertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and selected the amount from within that range that we determined to be the best estimate, which equaled </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. As provided for within the intercreditor agreement and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">convertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, in conjunction with our recognition of the joint and several liability, we also recorded a receivable from ALPHAEON, which equals the current balance of the amounts we owe to ALPHAEON under our intercompany borrowing arrangements. No amounts have been paid under this joint and several liability by us in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the liability recorded by us to the Note holders pursuant to the above joint and several liability was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date) and the related party receivable was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, representing the amount by which related party borrowings could be reduced pursuant to the terms of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">convertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The difference between the amount of the joint and several liability and the related party receivable of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$53.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was recorded as a deemed distribution to ALPHAEON, which caused a corresponding reduction in additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In July 2017, ALPHAEON issued an additional $5 million of convertible promissory notes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As a result of this additional issuance, the total note obligations under all the Notes increased to $134.9 million (2.5 times the total outstanding principal amount of the Notes).  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of the offering, we and ALPHAEON intend to enter into amendments with each of Longitude</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, as the holder of the convertible bridge note,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and DI, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">as collateral agent for the holders of the convertible promissory notes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, releasing our guarantee of the Notes and the security interest in our assets and terminating the Evolus security agreements.</font></div><div><a name="sBC6AA1AC48EB5F4B23061527CEF92AFA"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><a name="s55CE57226265FCBD613D1527CA4A7FBC"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table summarizes our principal contractual obligations as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which consist of our operating lease for our Santa Barbara, California office facility </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">encompassing approximately 4,450 square feet of space, and expiring on May 31, 2020</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Contractual Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">1 &#8211; 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Operating lease obligation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">584</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The table above does not reflect our outstanding related party borrowings from ALPHAEON of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$59.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we owed ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">From time to time we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims, including the Daewoong Agreement and certain real estate leases, supply purchase agreements, and agreements with directors and officers. The terms of such obligations vary by contract and in most instances a maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted thus no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The table above also does not include potential milestone payments that we may be required to pay Daewoong, $10.0 million that we may be required to pay to the Evolus contributors upon marketing approval of DWP-450 in the U.S. and the EU and certain amounts that may be payable to Daewoong upon certain commercialization milestones. We have not included these potential obligations in the table above because they are contingent upon the occurrence of future events, and we do not know the timing of such potential obligations with certainty. We describe our contingent milestone payment in more detail in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Note 5</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to our financial statements.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The table above does not reflect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">certain minimum annual purchases we are required to make under the Daewoong Agreement in order to maintain the exclusivity of the license.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;We may, however, meet these minimum purchase obligations by achieving certain market share in our licensed territories. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have not included these potential minimum purchase obligations in the table above because they are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions, and we do not know the timing of such potential obligations with certainty.</font></div><div><a name="s54261C722BCA5D37B22A1527CF4CF322"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this prospectus, we believe the following accounting policies to be most critical for fully understanding and evaluating our financial condition and results of operations, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:justify;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Joint and Several Liability Assessment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We measure obligations resulting from joint and several liability arrangements as the sum of the amount that we have (i) agreed to pay on the basis of our arrangement among our co-obligors, and (ii) any additional amounts that we expect to pay on behalf of our co-obligors. The </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">determination of the &#8220;best estimate&#8221; from within the range of amounts that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">might be paid involves substantial judgment by our management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Research and development expenses are expensed as incurred. Non-refundable advance payments for goods and services that will be used or rendered for future research and development activities are recorded as a prepaid expense and recognized as an expense as the related goods are delivered or the related services are performed. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by CROs in connection with research and development activities for which we have not yet been invoiced.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting expense amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. However, due to the nature of these estimates, we can not assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies or other research activity.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Impairment Evaluations of Goodwill and Acquired Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but we perform an annual qualitative assessment of our goodwill during the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, we perform a two-step process. The first step involves comparing the fair value of our reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, we have determined that we have one reporting unit. There has been no impairment of goodwill for any periods presented. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Intangible assets represent IPR&amp;D projects acquired in an acquisition that have not yet been completed. IPR&amp;D</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;assets with indefinite useful lives that are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">IPR&amp;D</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;assets are either amortized over their estimated useful lives or written-off immediately.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation Expense Allocated by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">have</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;not granted stock-based compensation for the periods presented. However, we </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">recognize t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">he fair value of the expense allocated to us </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">for all ALPHAEON stock-based grant arrangements with our employees, including members of ALPHAEON&#8217;s board of directors. </font></div><div><a name="sE96B2EC064141162CEE91527CF7E6F27"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosure About Market Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We did not have any cash or other financial instruments as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><a name="s9D68B619BA2E03749D981527CF9E4906"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In August 2016, the Financial Accounting Standards Board, or FASB, issued new guidance that clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The guidance is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not believe the adoption of the standard will have a material impact on the Company&#8217;s statement of cash flow. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In March 2016, FASB issued Accounting Standards Update, or ASU, No. 2016-09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, or ASU No. 2016-09, which is intended to simplify several areas of accounting for share-based payment arrangements. The amendments in this update cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. ASU No. 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. We adopted this standard in the first quarter of 2017. We had no excess tax benefits for which a benefit could not previously be recognized as of December 31, 2016. Upon adoption, the balance of the unrecognized excess tax benefits is reversed with the impact recorded to (accumulated deficit) retained earnings, including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets as of December 31, 2016, there was no impact to the financial statements as a result of this adoption in the first half of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In February 2016, FASB issued final guidance for lease accounting. The new guidance requires lessees to put most leases on their balance sheet but to recognize expenses on their income statement in a manner similar to current accounting principles. The new guidance also eliminates the current real estate-specific provisions for all entities. The standard is effective for public companies for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are in the process of assessing the impact of the adoption of the standard on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In April 2015, the FASB issued ASU No. 2015-03, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the corresponding debt liability rather than as an asset. Management adopted this accounting pronouncement as of December 31, 2016. The adoption of the standard did not have a material effect on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on our present or future financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">JOBS Act</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an &#8220;emerging growth company,&#8221; or EGC, can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC, we intend to rely on certain of these exemptions, including exemptions from the requirement to provide an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an EGC until the earlier of: the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more; the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><a name="sBF4353BE1C0F0392CEE61527CFD17063"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">BUSINESS</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. We focus on the self-pay aesthetic market and our first product candidate, DWP-450, is an injectable 900 kilodalton, or kDa, botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We believe we will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; between the eyebrows, in the United States, European Union, or EU, and Canada. The U.S. Food and Drug Administration, or FDA, issued a Prescription Drug User Fee Act, or PDUFA, date of May 15, 2018 for completion of its review of our Biologics License Application, or BLA. We submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and it was accepted for review in July 2017 with a decision expected by the third quarter of 2018.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We successfully completed a comprehensive five-study DWP-450 clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU and a New Drug Submission, or NDS, in Canada, for the treatment of moderate to severe glabellar lines. The program, which was developed in consultation with the FDA and European regulatory bodies, included three multicenter, randomized, controlled, single dose Phase III studies and two open label, multiple dose, long-term Phase II studies. Over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in the program. All three Phase III studies successfully met their respective primary endpoints.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to patients or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Within the self-pay aesthetic market, the global aesthetic neurotoxin market is estimated to generate approximately $1.8 billion of revenue in 2017 and is estimated to grow to approximately $2.3 billion in 2020. The United States is the largest portion of this market and is estimated to generate approximately $941 million of revenue in 2017 and is expected to grow to approximately $1.2 billion in 2020. We believe the continued growth of the aesthetic neurotoxin market will be driven by an aging population, increased use by individuals between the ages of 19 and 34, whom we refer to as Millennials, rising disposable income, improved accessibility to these products and treatments due to an increase in the number of physicians who perform these procedures, continued innovation, and an increasing acceptance and utilization of elective or minimally invasive aesthetic procedures.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If approved, we plan to launch DWP-450 in the United States by building a commercialization infrastructure, including a specialty sales force of approximately 65 sales representatives at commercial launch and growing to 150 sales representatives over time. We intend for our sales force to market the product to aesthetic practices, beginning with U.S. board certified dermatologists, plastic surgeons, facial plastic surgeons and oculoplastic surgeons at launch and expanding to the broader aesthetic injector market over time. We intend to establish brand awareness for DWP-450 through national public relations, social media and direct-to-consumer media campaigns, which are widely-used commercialization channels for aesthetic neurotoxin products. In the long-term, we plan to capitalize on our commercialization infrastructure and our relationships with key aesthetic physicians to provide a comprehensive medical aesthetics portfolio over time, thereby driving continued revenue growth without a proportional increase in our selling, general and administrative expenses. Outside of the United States, we plan to market and sell DWP-450 through distributors in the territories in which we have the right to sell it.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co., Ltd., or Daewoong, a South Korean pharmaceutical manufacturer, for aesthetic indications in the United States, EU, Switzerland, Canada, Australia, Russia, Commonwealth of Independent States, or C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. We also have an option to exercise a similar license in these territories for therapeutic indications by the end of 2018. DWP-450 will be manufactured by Daewoong in a recently constructed facility in South Korea that is designed with the intention of complying with FDA and EMA current Good Manufacturing Practice, or cGMP, requirements. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than DWP-450) in a territory covered by the license.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Competitive Strengths</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe we will offer physicians and patients a compelling value proposition beginning with the launch of DWP-450, if approved, for the following reasons:</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">DWP-450 will offer the U.S. market the first known 900 kDa neurotoxin alternative to BOTOX</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. Both DWP-450 and BOTOX manufacturing start with a 900 kDa complex, include adding the excipients human serum albumin</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or HSA, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and sodium chloride, and are finished by vacuum drying. If approved, DWP-450 is expected to be the only known neurotoxin product in the United States with a 900 kDa neurotoxin complex other than BOTOX. We believe an important component of competitiveness in the neurotoxin market relates to the characteristics associated with the 900 kDa complex and the potential of the accessory proteins to increase the effectiveness of the active toxin portion of the complex.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">DWP-450 may be easily integrated into existing aesthetic physician practices.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;DWP-450 was clinically tested with one DWP-450 unit compared to one BOTOX unit. In the study, both products were stored, prepared and injected identically. We believe aesthetic physicians&#8217; familiarity with the 900 kDa neurotoxin complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of DWP-450 into their practices.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Enhanced level of physician-customer interaction through an aesthetic-only marketing strategy. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have elected to specifically target the self-pay aesthetic market. With a reduced regulatory burden compared to third-party payor reimbursed markets, we believe we will achieve a number of benefits that market participants in reimbursed markets are unable to achieve, such as an enhanced level of interaction with our physician-customers. It is expected that upon U.S. approval, DWP-450 will be the only U.S. neurotoxin without a therapeutic indication. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. We intend to utilize this flexibility to drive market adoption through programs such as promotional events, sampling programs and pricing strategies.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">We have strong relationships with aesthetic key opinion leaders, or KOLs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. We have established relationships with aesthetic KOLs as a result of our management team&#8217;s industry experience and engagement of our clinical trial investigators. In addition, there are approximately 250 KOLs who have invested in our parent organizations, creating financial alignment with our success. KOLs are important information resources to the general physician-customer market due to their clinical expertise, academic reputations, active clinical practices and their status as medical innovators. The broader physician community often looks to KOLs for their experience with products and procedures as part of their new product and procedure adoption process.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Our management team has significant experience and expertise in medical aesthetics</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. Our management team has extensive experience in self-pay healthcare markets, in the development, market launch and commercialization of major medical products, execution and integration of business development transactions, identification of and partnerships with KOLs, and understanding of the regulatory environment of the healthcare markets. Key members of our leadership team have also served in relevant senior leadership positions with leading aesthetic companies.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our near-term strategy is to enter the U.S. medical aesthetic neurotoxin market with DWP-450. We plan to expand our product offerings over time through in-licensing, partnerships and acquisitions. The key components of our strategy are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Achieve regulatory approval of DWP-450.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;We believe the experience of our management team improves our ability to advance DWP-450 through the development phase and increases the likelihood of successfully obtaining approval for our product candidate. We also believe the completion of our clinical development program for the glabellar line indication and the acceptance of our BLA within three years of enrollment of the first patient demonstrates our ability to execute an effective development plan. In addition, we have worked with Daewoong to build a custom facility designed for neurotoxin manufacturing under FDA and EMA cGMP requirements during this pre-commercialization period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Launch the first known 900 kDa neurotoxin in the United States since BOTOX was launched 15 years ago. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The U.S. aesthetic neurotoxin market has been dominated by BOTOX since it received FDA approval for the treatment of glabellar lines in 2002. As the only known commercially approved 900 kDa neurotoxin for the last 15 years, BOTOX has flourished in an economic market structure with only one 900 kDa product option and significant barriers to entry, including a strenuous regulatory approval process. DWP-450, if approved, is expected to be the only known BOTOX alternative in the United States with a 900 kDa complex and Phase III clinical testing of one DWP-450 unit to one BOTOX unit. We believe these product characteristics will enable aesthetic physicians who use BOTOX to more easily incorporate DWP-450 in their practices.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Pursue an aesthetic-only marketing strategy</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. It is expected that upon U.S. approval, DWP-450 will be the only U.S. neurotoxin without a therapeutic indication. An aesthetic-only indication is an important strategic advantage because it provides greater flexibility around pricing and marketing strategies compared to neurotoxin manufacturers with aesthetic and therapeutic sales. Current U.S. neurotoxin manufacturers are required to calculate their neurotoxin&#8217;s average sales price, or ASP, inclusive of both aesthetic and therapeutic sales, for purposes of therapeutic reimbursement. As a result, we believe that U.S. neurotoxin manufacturers limit aesthetic neurotoxin discounting to protect their therapeutic neurotoxin reimbursement rate, with therapeutic sales representing approximately 60% of all U.S. neurotoxin sales in 2016. By contrast, we will not have a therapeutic indication for DWP-450 upon commercialization and therefore will have greater flexibility in our pricing strategies. We will utilize this flexibility to create a compelling value proposition for aesthetic physicians. Additionally, our aesthetic-only focus will allow us marketing flexibility and the ability to pursue our neurotoxin commercial strategy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leverage our strong KOL relationships in medical aesthetics for our commercial launch. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will utilize our strong KOL relationships to facilitate the awareness of the DWP-450 clinical evidence to the broader aesthetic physician community. Since KOLs opinions are valued due to their clinical expertise, academic reputations, active clinical practices and status as medical innovators, we believe the aesthetic KOLs, including our indirect investors, will be important in influencing aesthetic physician buying decisions. We plan to utilize our KOLs to assist in scientific presentations, publications and other methods by which we will drive awareness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Build a commercialization infrastructure with specialized sales and marketing functions. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We intend to establish a commercial infrastructure targeting board certified dermatologists, plastic surgeons, facial plastic surgeons and oculoplastic surgeons at launch and expanding to the broader aesthetic injector market over time. We will hire experienced sales professionals who will reflect our commitment to serving physicians and their patients with a high level of service and engagement. We will partner with established distributors outside the United States to reach and serve physicians and patients in those territories.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Establish a leading medical aesthetics company by in-licensing technology, developing partnerships and potentially acquiring products. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our long-term strategy is to build our company into a leading medical aesthetics company. We believe that an aesthetic neurotoxin is an attractive entry point for building a medical aesthetic portfolio as the aesthetic neurotoxin segment is one of the largest product segments in the self-pay medical aesthetics market. We intend to add additional self-pay medical aesthetics products that yield high patient satisfaction. We will use the insights of our management team to develop partnerships, in-license technology and potentially acquire products to expand our medical aesthetics product offerings over time. These products may include dermal fillers, aesthetic lasers, energy devices, and breast implants. We believe that we will create a commercial infrastructure and maintain relationships with key aesthetic physicians that can be leveraged over time to offer a medical aesthetics portfolio to our customers to drive growth without a significant increase in our selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Market</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our primary market is self-pay healthcare, which includes medical products purchased by physicians that are then sold to patients or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. By focusing on the self-pay medical aesthetics market, we believe we will not be exposed to reimbursement risk associated with a reliance on payments from such third-party payors and we will be subject to fewer regulations that place limits on the types of marketing and other interactions we can have with physicians. For example, the federal Anti-Kickback Statute, or the Anti-Kickback Statute, imposes significant restrictions on the ability of healthcare manufacturers who have products or services reimbursed by a federal healthcare program to interact with physicians in relation to the marketing of their products. We believe our clinical data and clinical testing of one DWP-450 unit to one BOTOX unit, together with the reduced regulatory burden and related flexibility in marketing and pricing, will improve our ability to generate product demand for DWP-450.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The global self-pay medical aesthetics neurotoxin market is estimated to generate approximately $1.8 billion of revenue in 2017 and is estimated to grow to approximately $2.3 billion in 2020. The global self-pay medical aesthetics market was estimated to have generated approximately $9.3 billion of revenue in 2015 and is estimated to grow to approximately $15.1 billion in 2020, representing a 10% compound annual growth rate, or CAGR, of which the United States comprises the largest portion of the market at an estimated $3.9 billion of revenue in 2015, and is estimated to grow at an 11% CAGR during the same period. We believe the growth in both the self-pay medical aesthetics neurotoxin market and the overall self-pay medical aesthetics market is being driven by a number of factors, including:&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an aging population consisting of both Generation X, comprised of individuals between the ages of 35 and 50, and Baby Boomers, comprised of individuals between the ages of 51 and 64;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the Millennial generation seeking to prophylactically delay the appearance of aging and utilizing neurotoxins as an entry point for aesthetic procedures due to its minimally invasive nature;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an increasing life expectancy, which is resulting in patients with a desire for improved appearance and well-being;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">rising disposable income, with the U.S. Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 17% from March 2012 to March 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">growing awareness and acceptance of aesthetic procedures;&#160;and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">continued innovation and improved accessibility to these treatments due to an increase in the number of physicians who perform these procedu</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">res.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe the demand for aesthetic treatment for facial lines has stimulated growth in the use of botulinum toxin type A, given the neurotoxin&#8217;s minimally invasive nature of the treatment, effectiveness, ease of use, and safety profile. Additionally, a patient is able to have the procedure performed with minimal interruption to daily life primarily because most treatments require less than 30 minutes to be completed and have little to no recovery period. In general, the results of neurotoxin treatments may last up to four months but are not permanent. As a result, patients may seek repeat procedures to maintain the product&#8217;s effect, which translates into recurring revenue generation for manufacturers and physicians.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The large and established U.S. aesthetic neurotoxin market includes a wide range of age groups. In 2016, approximately 39% of total U.S. nonsurgical procedures were performed on Generation X patients and approximately 31% were performed on Baby Boomer patients. Millennial patients represent a growing segment of the market with data from the American Society of Plastic Surgeons showing a 49% increase between 2009 and 2016 in the number of botulinum toxin type A procedures in patients aged 20 to 29, which is the younger subset of the age 19 to 34 Millennial generation. In 2016, this 20 to 29 age group made up approximately 16% of total U.S. nonsurgical procedures in 2016, and we believe provides a source of future growth.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The current medical aesthetics botulinum toxin type A market is set forth in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="image34.jpg" alt="image34.jpg" style="height:226px;width:394px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">BOTOX prices have increased consistently in recent years. According to The Centers for Medicare and Medicaid Services, or CMS, the ASP of BOTOX was approximately $599 per 100 unit vial as of June 2017, up nearly 8% or over $40, from its July 2014 ASP of approximately $557 per 100 unit vial.&#160;Many physicians have expressed frustration with increasing neurotoxin prices. According to a physician survey conducted by Bernstein Research in the second quarter of 2017, approximately 41% of physicians surveyed stated that they would be willing to try a new neurotoxin with a material discount strategy.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">DWP-450 Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We licensed DWP-450 from Daewoong in September 2013 and commenced clinical trials in 2014. DWP-450 is an injectable formulation of a 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We completed a comprehensive five-study DWP-450 clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada, for the treatment of moderate to severe glabellar lines. Our program was developed in consultation with the FDA and European regulatory bodies. These regulatory bodies provided guidance and feedback on the critical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">endpoints and statistical methodology required to develop the safety and efficacy endpoints that would support this indication&#8217;s approval.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The clinical program included three randomized, controlled, single dose Phase III studies, and two open label, multiple dose, long-term Phase II safety studies. Over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in the program. All three Phase III studies successfully met their respective primary endpoints. A BLA and MAA seeking approval for the treatment of adult patients with glabellar lines was accepted and validated by the FDA and EMA, respectively, in July 2017 on the basis of these studies. The FDA issued a PDUFA date of May 15, 2018 for completion of its review of our BLA. If approved, DWP-450 is expected to be the first known 900 kDa neurotoxin product in the United States since BOTOX was approved for the treatment of glabellar lines in 2002. Our MAA </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">was accepted for review in July 2017 with a decision expected by the third quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As demonstrated in the figure below, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">DWP-450 contains a 900 kDa botulinum toxin type A complex produced by the bacterium </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Clostridium botulinum.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;The active part of the neurotoxin is the 150 kDa component, and the remaining 750 kDA of the complex is made up of accessory proteins that we believe help with the function of the active portion of the toxin. DWP-450 has the same mechanism of action as other type A botulinum toxins. When injected intramuscularly at therapeutic doses, botulinum toxin causes a chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Diagram of Botulinum Toxin Type A</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="image1a05.jpg" alt="image1a05.jpg" style="height:310px;width:205px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table provides a summary of the botulinum toxin type A complex composition for DWP-450 and available toxins in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="image2a04.jpg" alt="image2a04.jpg" style="height:190px;width:398px;"></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Daewoong South Korean Clinical Development for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In South Korea, two DWP-450 clinical studies were used to support Daewoong&#8217;s BLA to the Korean Ministry of Food and Drug Safety, or MFDS, including one Phase I study and one Phase III study. Both studies were double blind, randomized trials with an active control. Both compared 20 units of Nabota, a DWP-450 formulation, with 20 units of BOTOX (onabotulinumtoxinA), injected as 4 units per 0.1 milliliters, or mL, into each of five target sites in the glabellar region of adult subjects with moderate to severe glabellar lines. Both the Phase I and Phase III study used the investigator&#8217;s assessment of the improvement of glabellar lines at maximum frown on a four-point Glabellar Line Severity scale to evaluate efficacy, where 0 = none, 1 = mild, 2 = moderate and 3 = severe glabellar lines at maximum frown.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Phase I Clinical Trial. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Phase I study included 20 randomized subjects, with 10 subjects receiving Nabota and 10 subject receiving BOTOX. The average ages, ratios of males to females, and the rating of glabellar lines at maximum frown and at rest at 4 weeks were similar between the two groups. Two adverse events, or AEs, were reported: a mild case of dizziness in a Nabota subject and a mild case of headache in a BOTOX subject.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Phase III Clinical Trial. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Phase III study included 268 randomized subjects, with 135 subjects receiving Nabota and 133 subjects receiving BOTOX. The primary efficacy endpoint was the responder rate at maximum frown at 4 weeks. A responder was defined as a subject with a Glabellar Line Severity scale score of none (0) or mild (1), based on the investigator&#8217;s assessment of glabellar lines. In a per protocol analysis , the responder rate was 93.9% in the Nabota group and 88.6% in the BOTOX group. The difference between these groups was 5.3% and the lower limit of the 97.5% one-sided confidence interval was -1.53%. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence that the result lies. In this Phase III study, the results indicate that there is a 97.5% level of confidence that the difference between the Nabota and BOTOX responder rates was between -1.53% and 5.26%, which we express as: 97.5% CI (-1.53, 5.26). </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Based on the lower limit of the confidence interval surpassing a pre-determined -15.0% threshold for non-inferiority, the Nabota treatment group was determined to be non-inferior to BOTOX.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-style:italic;">Korean Phase III Primary Endpoint - Responder Rates at Week 4, Glabellar Line Severity at Maximum Frown by Investigator Assessment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-style:italic;">Korean Phase III Primary Endpoint - Non-Inferiority, Glabellar Line Severity at Maximum Frown by Investigator Assessment</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="slide4.jpg" alt="slide4.jpg" style="height:197px;width:226px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:205px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="slide42.jpg" alt="slide42.jpg" style="height:114px;width:325px;"></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A secondary efficacy endpoint was the responder rate at maximum frown at 4 weeks, 8 weeks, 12 weeks and 16 weeks, with a responder defined as a subject with a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Glabellar Line Severity scale</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;score of none (0) or mild (1), based on the investigator&#8217;s assessment of glabellar lines. The responder rates for the Nabota group were 93.6%, 83.9%, 75.6% and 62.1% at 4 weeks, 8 weeks, 12 weeks and 16 weeks, respectively. For the BOTOX group, the responder rates were 89.3%, 82.6%, 70.0% and 54.6% at 4 weeks, 8 weeks, 12 weeks and 16 weeks, respectively. The overall AE rate was 20.0% and 18.1% in the Nabota and BOTOX groups respectively, and the drug related AE rate was 5.9% and 4.5% in the Nabota and BOTOX groups respectively. There was one serious adverse event, or SAE, in the trial and it was assessed as not study drug related.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Korean Phase III Secondary Endpoint - Improvement in Rates for Glabellar Lines Severity at Maximum Frown by Investigator Assessment</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide6.jpg" alt="slide6.jpg" style="height:202px;width:442px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">South Korean Approval. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Nabota was approved by the MFDS for marketing on November 29, 2013 for the treatment of glabellar lines. The Nabota DWP-450 formulation in the South Korean study and that is currently being commercialized by Daewoong is slightly different than the formulation used in our sponsored studies. The HSA used in our formulation is licensed and approved by the FDA and is certified by the EMA, whereas the HSA currently used in the Nabota formulation is not. In addition, the Nabota formulation is lyophilized, or freeze dried, whereas the product we intend to commercialize, if approved, is vacuum dried. See the section entitled &#8220;Additional Safety Evaluations&#8221; below for additional information.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Evolus Clinical Development for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In 2014, we initiated a comprehensive five-study DWP-450 clinical development program in the United States, EU and Canada to meet the regulatory requirements for a BLA in the United States, a MAA in the EU, and a NDS in Canada, for the treatment of moderate to severe glabellar lines. The program, which was developed in consultation with the FDA and European regulatory bodies, included three multicenter, randomized, double-blinded, controlled, single dose Phase III studies titled EV-001, EV-002 and EVB-003. Each Phase III study lasted 150 days. We also completed two open label, multiple dose, long-term Phase II studies titled EV-004 and EV-006, each lasting one year. Between September 2014 and August 2016, over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in this program.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In our clinical trials, subjects received intramuscular injections in five target sites in muscles that contribute to the formation of glabelllar lines: the midline of the procerus, the inferomedial aspect of each corrugator, and the superior middle aspect of each corrugator. Each of the five target sites was injected with 0.1mL for a total of 0.5mL. Subjects assigned (in the open label studies) or randomized (in the controlled studies) to DWP-450 received a total of 20&#160;units per treatment, administered as 4 units per 0.1 mL and those subjects who were randomized to the placebo group received 0.5 mL saline. In our EVB-003 Phase III trial, the only study of the five with both a placebo and active control arm, subjects randomized to the active control received a total of 20 units of BOTOX administered as 4&#160;units per 0.1&#160;mL. As in the Korean studies, 20 units of BOTOX served as the active control in EVB-003. In the multiple dose studies, eligible subjects could receive up to four treatments of 20 units of DWP-450 each.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">All five studies contributed data to the evaluation of efficacy and safety. The table below summarizes our five-study DWP-450 clinical development program.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Listing of the Five U.S./EU DWP-450 Clinical Studies - Design Features and Efficacy Assessments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:12%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:20%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">EV-001</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">EV-002</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">EVB-003</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">EV-004</font></div></td><td style="vertical-align:bottom;background-color:#f3f3f3;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">EV-006</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Study</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">U.S. Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">U.S. Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">EU Pivotal Phase III Safety and Efficacy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">U.S. Phase II Long-term Safety</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">U.S. Phase II Long-term Safety</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Population</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (Glabellar Line Scale, or GLS, score &#8805;2) at maximum frown, as independently assessed by </font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">both</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;Investigator Assessment (IA) and Subject Assessment(SA)</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown, as independently assessed by </font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">both</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;IA and SA</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown assessed by IA </font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">only</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;and who felt that their glabellar lines had an important psychological impact</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown assessed by IA </font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">only</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Healthy adults (&#8805;18 years) who had moderate to severe glabellar lines (GLS score &#8805;2) at maximum frown, as independently agreed by </font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">both</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;IA and SA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Design, including Duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Randomized (3:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Placebo controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Randomized (3:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Placebo controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Randomized (5:5:1)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Double blind</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Placebo and active controlled</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single dose</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">150 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Non-randomized</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Open label</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multiple dose (initial treatment plus up to three repeat treatments)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;365 days duration</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multicenter</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Non-randomized</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Open label</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Multiple dose (initial treatment plus up to three repeat treatments)</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">365 days duration</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Treatments</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single treatment of:</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of DWP-450 or</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single treatment of:</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of DWP-450 or</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Single treatment of:</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of DWP-450 or</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of BOTOX or</font></div><div style="text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">0.5mL saline (Placebo)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of DWP-450/treatment, up to a maximum of 4 treatments</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">20 units of DWP-450/treatment, up to a maximum of 4 treatments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Subjects</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">330 randomized (3:1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">324 randomized (3:1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">540 randomized (5:5:1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">352 treated with DWP-450</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">570 treated with DWP-450</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Location of Sites</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Canada;</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#ff0000;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">France; Germany; Sweden; United Kingdom</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">United States</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Primary Endpoint</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Proportion of subjects classified as responders on Day 30;</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">A composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">A responder was a subject with a &#8805;2 point improvement on the GLS from Day 0 to Day 30 at maximum frown</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Proportion of subjects classified as responders on Day 30</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">A composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">A responder was a subject with a &#8805;2 point improvement on the GLS from Day 0 to Day 30 at maximum frown</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Proportion of subjects classified as responders on Day 30</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;text-decoration:underline;">Not</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;a composite endpoint</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">A responder was a subject with a GLS score of 0 or 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">None, all efficacy endpoints were exploratory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">None, all efficacy endpoints were exploratory</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Phase III U.S. Based Clinical Trials. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The two identical U.S. Phase III studies, EV-001 and EV-002, enrolled subjects who were selected from a population of healthy adults, at least 18 years of age, who had moderate to severe glabellar lines at maximum frown, as independently assessed by the investigator and subject using the 4-point photonumeric Glabellar Line Scale, or GLS, where 0=no lines, 1=mild lines, 2=moderate lines and 3=severe lines. On Day 0, eligible subjects were randomly assigned in a 3:1 ratio to receive a single treatment of either DWP-450 or placebo. Subjects were followed for 150 days.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. This was a composite endpoint in which a responder was a subject with a 2 point improvement or greater on the GLS from Day 0 to Day 30 at maximum frown, only if independently agreed by both investigator and subject assessment. In keeping with the FDA guidance, this was deemed to be a clinically meaningful composite primary efficacy endpoint.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Both studies met the primary endpoint of superiority over placebo. The percentages of responders in the intent to treat population for the composite primary endpoint, a two point or greater score composite improvement, in each of the two controlled single dose studies were:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">EV-001: 1.2% placebo, 67.5% DWP-450, with an absolute difference between the groups of 66.3%, 95% CI (59.0, 72.4)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">EV-002: 1.3% placebo, 70.4% DWP-450, with an absolute difference between the groups of 69.1%, 95% CI (61.5, 75.1)</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">U.S. Phase III Primary Endpoint - Composite Score &#8805; 2 Point GLS Improvement at Maximum Frown on Day 30</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide7.jpg" alt="slide7.jpg" style="height:198px;width:464px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since a two point or greater composite score requires both the investigator and subject to agree simultaneously, studies using this definition generally have a lower responder rates than non-composite studies. Xeomin and Dysport represent two botulinum toxin type A products who also conducted trials using a two point or grater composite responder rate. The Xeomin two point or greater responder rates in their Phase III studies, per FDA labels, were 48% and 60%, and the Dysport rates were 52%, 55% and 60%. Importantly, no comparison across any of the studies can be made. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">U.S. Phase III Primary Endpoint - Components of Composite Score, &#8805; 2 Point GLS Improvement at Maximum Frown on Day 30 by Investigator and Subject Assessment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide8.jpg" alt="slide8.jpg" style="height:205px;width:365px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the EV-001 study, analysis of the secondary endpoints investigated the response at maximum frown beyond Day 30 using a two point composite score. For the composite endpoint, the absolute differences in the percentages of responders between the DWP-450 and placebo groups were 25.2%, 7.0% and 4.6%, for Day 90 (post hoc), Day 120 and Day 150 or early termination, respectively (all p&lt;0.05), indicating that DWP-450 was superior to placebo. The p value, expressed in the previous sentence as p&lt;0.05, is the probability that the difference between two data sets was due to chance. The smaller the p value, the more likely the differences are not due to chance alone. In general, if the p value is less than or equal to 0.05, the outcome is statistically significant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The results were similar in the EV-002 study to the EV-001 study for the secondary endpoints. For the</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;composite endpoint, the absolute differences in the percentages of responders between groups were 25.8%, 12.4% and 4.6%, for Day 90 (post hoc), Day 120 and Day 150 or early termination, respectively (all p&lt;0.05).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additional exploratory efficacy analyses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">in the EV-001 and EV-002 studies </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">were conducted where DWP-450 was investigated for a one point or greater improvement as assessed by either the subject or investigator at various days at maximum frown based on the GLS. DWP-450 was compared against a placebo at 2 days, 7 days, 14 days, 30 days, 90 days, 120 days and 150 days or early termination.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">U.S. Phase III Exploratory Endpoints - &#8805; 1 Point Improvement GLS at Maximum Frown</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide91.jpg" alt="slide91.jpg" style="height:238px;width:454px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide101.jpg" alt="slide101.jpg" style="height:237px;width:453px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In each of the EV-001 and EV-002 studies, we also assessed as an exploratory endpoint investigator and patient assessments on the Global Aesthetic Improvement Scale, or the GAIS. The GAIS is a five-point scale on which an evaluator, the subject or investigator, can determine the aesthetic outcome for the subject from: much improved, improved, no change, worse or much worse. The rate of positive responders, those who were assessed by either the subject or the investigator as much improved or improved, over the course of the study is provided below.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">U.S. Phase III studies Exploratory Endpoint - Global Aesthetic Improvement Responders (Much Improved/Improved)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide11.jpg" alt="slide11.jpg" style="height:222px;width:417px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide12.jpg" alt="slide12.jpg" style="height:222px;width:418px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">EV-002 Subject - Glabellar Lines at Maximum Frown</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide13.jpg" alt="slide13.jpg" style="height:288px;width:374px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the EV-001 study, the AE rate was 32.1% in the placebo group and 38.2% in the DWP-450 group. Placebo and DWP-450 groups were similar in the overall incidence of subjects who experienced one or more AEs. Three DWP-450 subjects (3/246, 1.2%) experienced SAEs, none were assessed as study drug related. Placebo and DWP-450 groups were also similar in the percentages of subjects who experienced AEs assessed by the investigator as study drug related: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">13.1% of placebo subjects and 15.4% of DWP-450 subjects. The eyelid and eyebrow ptosis rates, the drooping of an upper eyelid or eyebrow, respectively, in the DWP-450 group was 0.4% for each.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the EV-002 study, the AE rate was 26.9% in the placebo group and 28.5% in the DWP-450 group. Placebo and DWP-450 groups were similar in the overall incidence of subjects who experienced one or more AEs. Four DWP-450 subjects (4/246, 1.6%) experienced a SAE, none were assessed as study drug related. Placebo and DWP-450 groups were also similar in the percentages of subjects who experienced an AE assessed by the investigator as study drug related: 7.7% of placebo subjects and 9.8% of DWP-450 subjects. The eyelid and eyebrow ptosis rates in the DWP-450 arm were 1.2% and 0.4% respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">U.S. Phase III Trials - Adverse Event Rate Summary</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide14.jpg" alt="slide14.jpg" style="height:88px;width:488px;"></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Phase III European Clinical Trial for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The EVB-003 study was the third Phase III safety and efficacy study in the DWP-450 clinical development program, and was conducted in Europe and Canada. 540 subjects with moderate to severe glabellar lines, or a GLS score of 2 or 3, as assessed by the investigator, were eligible to be enrolled provided that subjects also felt their glabellar lines had an important psychological impact, such as on their mood, anxiety or depressive symptoms. On Day 0, eligible subjects were randomly assigned in a 5:5:1 ratio to receive a single treatment of 20 units of DWP-450, 20 units of BOTOX or placebo. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. A responder was a subject with a GLS score of 0 or 1, as assessed by the investigator at maximum frown. The primary analysis of the primary efficacy endpoint in the EVB-003 study showed DWP-450&#8217;s superiority over placebo, and established DWP-450&#8217;s non-inferiority to BOTOX. The percentages of responders for the primary efficacy endpoint were:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.2% in the placebo group, 95% CI (0.0, 9.8);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">82.8% in the BOTOX group, 95% CI (78.1, 87.5); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">87.2% in the DWP-450 group, 95% CI (83.0, 91.5).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The absolute differences between the treatment groups were:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">83.1% between DWP-450 and placebo groups, 95% CI (70.3, 89.4), (p&lt;0.001), indicating DWP-450 was superior to placebo; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.4% between DWP-450 and BOTOX groups, 95% CI (-1.9, 10.8), with non&#8209;inferiority of DWP-450 versus BOTOX concluded based on the lower bound of the 95% CI for the absolute difference exceeding -10.0%.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">EU Phase III Primary Endpoint - Responder Rates at Maximum Frown on Day 30 (GLS = 0 or 1) by Investigator Assessment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">EU Phase III Primary Endpoint - Non-Inferiority, at Maximum Frown on Day 30 by Investigator Assessment</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="slide151.jpg" alt="slide151.jpg" style="height:180px;width:256px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:188px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="slide161.jpg" alt="slide161.jpg" style="height:117px;width:325px;"></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As presented in the table below, within each group, 32.7% of placebo subjects, 41.9% of BOTOX subjects and 37.6% of DWP-450 subjects experienced AEs. One placebo subject (1/49, 2.0%), one BOTOX subject (1/246, 0.4%) and three DWP-450 subjects (3/245, 1.2%) experienced a total of 11 SAEs and none were assessed as study drug related. The eyelid ptosis rate were 1.6% in the DWP-450 arm, 0% in the BOTOX arm and the eyebrow ptosis rates were 0% in the DWP-450 arm and 0.4% in the BOTOX arm.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">EU Phase III Trial - Adverse Event Rate Summary</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="slide17.jpg" alt="slide17.jpg" style="height:88px;width:436px;"></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Phase II Repeat Dose Clinical Trial for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The primary objective of the Phase II EV-004 study was to demonstrate the safety of DWP-450 in adult subjects receiving repeat doses of DWP-450 for the treatment of moderate to severe glabellar lines. This multi-dose study lasted one year. Subjects were selected from a population of healthy adults at least 18 years of age who had moderate to severe glabellar lines at maximum frown, as assessed by the investigator. On Day 0, eligible subjects were administered a single treatment, 20 units of DWP-450. On and after Day 90, subjects were eligible for a repeat treatment if their GLS score was 2 or greater at maximum frown, as assessed by the investigator. If a subject did not have a GLS score of 2 or greater, they were followed monthly until eligible for a repeat treatment or until the study ended on Day 365. The test product in this study was different from all the other Evolus sponsored studies because each vial contained lyophilized, instead of vacuum dried, DWP-450. See the section entitled &#8220;Additional Safety Evaluations&#8221; below for additional information. All other studies in the Evolus sponsored program used vials containing vacuum dried DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Over the course of the one year study, the 352 subjects in the study received a median total dose of 60 units, or 3 treatments. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Total AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">148 subjects (148/352, 42.0%) experienced a total of 265 AEs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7 subjects (7/352, 2.0%) experienced a total of 9 SAEs, none assessed as study drug related.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Study Drug Related AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">51 subjects (51/352, 14.5%) experienced a total of 59 AEs (59/265 events, 22.3%) assessed by the investigator as study drug related.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">39 subjects (39/352, 11.1%) experienced a study drug related AE following the initial treatment visit, representing 76.5% of all subjects who experienced study drug related AEs (39/51). Progressively lower percentages of subjects experienced study drug related AEs following each repeat treatment: 3.4% (11/319) after the first repeat treatment, 1.5% (4/262) after the second repeat treatment, and none after the third repeat treatment.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Phase II, EV-006 study&#8217;s primary objective was also to demonstrate the safety of DWP-450 in adult subjects receiving repeat doses of DWP-450 for the treatment of moderate to severe glabellar lines. Like EV-004, the EV-006 was a multi-dose study that lasted one year. Subjects were selected from a population of healthy adults at least 18 years of age who had moderate to severe glabellar lines at maximum frown, agreed by both the investigator and the subject, as opposed to the sole assessment of the investigator in the EV-004 study. On Day 0, eligible subjects were administered a single treatment of 20 units of DWP-450. On and after Day 90, subjects were eligible for repeat treatment if their GLS score was a 2 or greater at maximum frown, as assessed by the investigator. If a subject did not have a GLS score &#8805;2, they were followed monthly until eligible for repeat treatment or until the study ended on Day 365.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Over the course of the one-year study, the 570 subjects in the study received a median total dose of 60 units, or 3 treatments. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Total AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">235 subjects (235/570, 41.2%) experienced a total of 475 AEs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Seven subjects (7/570, 1.2%) experienced eight SAEs, none of the SAEs were assessed as study drug related. One death (1/570, 0.2%) was reported during the study, a SAE, this event was not related to study drug</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Study Drug Related AEs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">61 subjects (61/570, 10.7%) experienced a total of 91 AEs (91/473 events, 19.2%) assessed by the investigator as study drug related.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">37 subjects (37/570, 6.5%) experienced 46 study drug related AEs following the initial treatment visit, representing 60.7% of all subjects who experienced study drug related AEs (37/61). Progressively lower percentages of subjects experienced study drug related AEs following each repeat treatment: 3.6% (19/524) after the first repeat treatment, 3.2% (14/431) after the second repeat treatment, and 1.9% (4/214) after the third repeat treatment</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The combined eyelid ptosis rate for the EV-004 and EV-006 studies was 0.9%. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Additional Safety Evaluations</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;five Evolus sponsored studies, EV-001, EV-002, EVB-003, EV-004 and EV-006, assessed the vital signs of subjects, and there were no notable differences found between the DWP-450 group and placebo. In the U.S.-based studies, EV-001, EV-002, EV-004 and EV-006, additional testing was conducted such as chemistry, hematology, urinalysis, and electrocardiograms, and these additional tests did not reveal any notable differences between the DWP-450 and placebo groups. During the course of the U.S.-based studies, testing was also conducted looking for subjects who developed antibotulinum toxin antibodies, or cases of seroconversion in these subjects. There were two cases of seroconversion in the EV-004 repeat dose study. The DWP-450 formulation in the EV-004 study was not the same as the formulation used in all the other Evolus studies. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Specifically, the DWP-450 formulation for the EV-004 study used a lyophilizing, or freeze drying, method for removing water. The pivotal studies EV-001 and EV-002, and the repeat dose study EV-006, used a DWP-450 formulation that was vacuum dried, and there were no cases of seroconversion in any subjects. This vacuum dried formulation was tested for antibotulinum antibody formations in 1,739 DWP-450 treatments in the 570 subjects in the repeat treatment EV-006 trial, and 492 DWP-450 treatments in the two U.S. single treatment Phase III trials, EV-001 and EV-002. If approved, we plan to commercialize the vacuum dried formulation of DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Testing for neutralizing antibody formation was also conducted in the Daewoong Nabota DWP-450 studies and there were no cases of seroconversion. The Nabota DWP-450 formulation in the South Korean studies is slightly different than the formulation used in the Evolus sponsored studies. The HSA used in the Evolus formulation is licensed and approved by the FDA and certified by the EMA. Additionally, the Nabota product is lyophilized, whereas the Evolus product intended for commercialization is vacuum dried.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Additional Daewoong Clinical Trials</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Phase III Post Stroke Upper Limb Spasticity Clinical Trial. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong has also conducted a post-stroke upper limb spasticity Phase III comparator study. It was a randomized, double blind, multi-center, active drug controlled, Phase III clinical trial to compare the safety and efficacy of Nabota versus BOTOX conducted in South Korea. This study was the basis for registration and approval of Nabota with the MFPS for the post-stroke upper limb spasticity indication in South Korea.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Patients diagnosed with a stroke at least six weeks prior to the start date of the study and found to be eligible based on the screening test result, were randomized to either Nabota or BOTOX. Treatment consisted of intramuscular injections of up to 360 units to the wrist flexor, elbow flexor, finger flexor or thumb-in-palm; the total dose depended on the existent and severity of spasticity. In order to assess efficacy and safety after the treatment, follow-up visits were performed at 4, 8, and 12 weeks.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The primary endpoint compared the evaluations of the changes in muscle tension values as measured by the Modified Ashworth Scale, or MAS, scores of wrist flexors at 4 weeks after the injection compared to the scores before treatment. The changes in the wrist flexor MAS assessed by the investigator at 4 weeks after treatment compared to the baseline in the per protocol analysis group for the primary efficacy assessment were -1.44&#177;0.72 points and -1.46&#177;0.77 points in the Nabota and BOTOX group, respectively. Both groups demonstrated statistically significant decreases (p&lt;0.0001) in muscle tension as measured on the MAS. The difference between the Nabota and BOTOX groups was 0.0129, with a 95% CI (-0.2062, 0.2319). Since the upper limit of the 97.5% one-sided confidence interval of the difference in changes was 0.2319, Nabota was found to be non-inferior to BOTOX. As a secondary endpoint, the average change in in muscle tension as measured on the MAS of both groups as compared to baseline, when measured at Week 8 and Week 12, remained statistically significant at all points in time.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">After administration of the treatment, AEs occurred in 19.6% of the subjects in the Nabota group and 19.4% of the subjects in the BOTOX group. Adverse drug reactions occurred in 3.1% of the subjects in the Nabota group and in 4.1% of the subjects of the BOTOX group. There was one SAE</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">a radius fracture that occurred in the Nabota group, and was assessed as not study drug related. Botulinum neutralizing antibody testing was conducted using mouse bio-assay, and there were no &#8220;positive&#8221; subjects found in either group. Nabota is now approved for this indication in South Korea.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong has agreed to manufacture and supply us with DWP-450. Daewoong has over 70 years of experience manufacturing pharmaceutical products and is one of the largest pharmaceutical drug companies in South Korea. Daewoong has recently constructed a facility for the purposes of producing DWP-450 drug product. The facility is located in Gyeonggi-do, South Korea. This facility was completed in 2016 with the intention to comply with FDA and EMA regulations and is now fully validated by Daewoong under cGMP requirements. We believe this facility will be sufficient to meet demand for DWP-450 for the foreseeable future. FDA and EMA inspection of the manufacturing sites are expected to occur in the fourth quarter of 2017 or the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong manufactures the DWP-450 drug substance in a separate facility on the same campus. The manufacture of DWP-450 drug substance is based on the fermentation of Daewoong&#8217;s </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">C.botulinum</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;cell line, followed by isolation and purification of the drug substance. Daewoong has received a U.S. patent for the production process. The DWP-450 drug substance production facility was renovated to comply with FDA and EMA cGMP requirements.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commercialization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We plan to use the proceeds of this offering, in part, to build the sales and marketing infrastructure required to successfully commercialize DWP-450 in anticipation of FDA approval. We plan to launch with our own sales force in the United States, which will initially focus on core aesthetic physicians (dermatologists, plastic surgeons, facial plastic surgeons and oculoplastic surgeons), as these physicians perform a significant proportion of the aesthetic procedure volume in the United States. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe a scientifically oriented, customer-focused specialty sales force initially consisting of approximately 65 sales representatives and growing to 150 sales representatives over time would allow us to establish the necessary relationships and achieve market presence. We intend to seek distribution partners for commercialization of DWP-450 in markets outside the United States.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">It is expected that upon U.S. approval, DWP-450 will be the only neurotoxin approved for marketing in the United States without a therapeutic indication. We believe pursuing an aesthetic-only strategy will allow for meaningful strategic advantages in the United States. The CMS establishes the reimbursement rates for Medicare Part B drugs based on the drugs&#8217; ASP of both the aesthetic and therapeutic sales. Current U.S. neurotoxins manufacturers&#8217; products are used for both aesthetic and therapeutic treatments. As a result, these U.S. manufacturers are required to calculate their neurotoxin&#8217;s ASP inclusive of both aesthetic and therapeutic sales, which we believe will cause these manufacturers to limit their aesthetic neurotoxin discounting to protect their therapeutic neurotoxin reimbursement rate. This is due to therapeutic neurotoxins representing approximately 60% of all U.S. neurotoxin sales in 2016. By contrast, we will not have a therapeutic indication for DWP-450 upon commercialization and therefore will have greater flexibility in our discounting strategies relative to other U.S. neurotoxin manufacturers. We will utilize this flexibility to appropriately incentivize aesthetic physicians to incorporate DWP-450 into their practices. We expect our pricing flexibility will continue until we have approval for a U.S. therapeutic indication, which we believe would require at least five years from the start of the clinical program to complete, if we were to pursue it.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to establish brand awareness for DWP-450 through national public relations, social media and direct-to-consumer media campaigns. We will launch a comprehensive, multi-year communication campaign to drive brand awareness for DWP-450 upon FDA approval. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will increase brand awareness through patient marketing initiatives including consumer electronic applications that will help connect aesthetic patients with board-certified aesthetic physicians, high quality content and other self-pay patients. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The campaign will also leverage targeted communication channels to reach Baby Boomers, the Generation X and the fastest growing segment of the market, the Millennials. We expect our communications strategy will help facilitate patient transitions from other neurotoxin products to DWP-450 and motivate non-neurotoxin patients to experience the benefits of the aesthetic neurotoxin procedure. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our History</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We were incorporated in November 2012 and are headquartered in Santa Barbara, California. In a series of related transactions in 2013, AEON-SCH, LLC (formerly known as Strathspey Crown Holdings, LLC), or SCH, acquired all of our outstanding equity in exchange for </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">membership interests in SCH</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. In 2014, SCH contributed our equity that it had acquired in 2013 to ALPHAEON in exchange for the payments described in the section entitled </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8220;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;Payment Obligation Related to our Acquisition by ALPHAEON.&#8221; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of these transactions, we became a wholly-owned subsidiary of ALPHAEON. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On September 30, 2013, we entered into a license and supply agreement, or the Daewoong Agreement, with Daewoong, pursuant to which Daewoong agreed to manufacture and supply DWP-450 and grant us an exclusive license to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit DWP-450 in the United States, EU, Switzerland, Canada, Australia, Russia, C.I.S., and South Africa, each, a covered territory. Daewoong also granted us a non-exclusive license to do the same in Japan. In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million. We further agreed to make milestone payments upon certain confidential development and commercial milestones</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, including a confidential payment to Daewoong upon FDA and EMA approval of DWP-450</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of DWP-450, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of DWP-450.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the Daewoong Agreement, Daewoong has agreed to supply us with DWP-450 at an agreed-upon, transfer price, and we have agreed to make milestone payments upon completion of certain confidential development and commercial milestones. Our exclusivity is subject to certain minimum annual purchases, irrespective of aesthetic or therapeutic indications, and if we fail to meet these targets, Daewoong may, at its option, convert the exclusive license to a non-exclusive license. During the term of the Daewoong Agreement, we cannot purchase, sell or distribute any competing products in a covered territory or Japan or sell DWP-450 outside a covered territory or Japan. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The initial term of the Daewoong Agreement is from September 30, 2013 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell DWP-450 or by (ii) September 30, 2023, and automatically renews for unlimited additional three-year terms if we meet certain performance requirements. The Daewoong Agreement will terminate (A) upon written notice by either us or Daewoong upon a continuing uncured default by the other party, or (B) without notice upon the bankruptcy or insolvency of our company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to the aesthetic use of DWP-450, Daewoong has granted us an option to expand our exclusive license to include therapeutic indications, for which we paid a total of $1.0 million. This option expires on December 31, 2018 and is exercisable by us upon payment of a confidential option exercise price. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than DWP-450) in a covered territory or Japan. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will be the sole owner of any marketing authorization and clinical trial results we pursue in a covered territory. This will include ownership of the BLA we submitted to the FDA in May 2017, the MAA that was accepted for review by the EMA in July 2017, and any other approvals we receive in a covered territory. However, if we do not renew the Daewoong Agreement or upon termination of the Daewoong Agreement due to a breach by us, we are obligated to transfer our rights to Daewoong. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the Daewoong Agreement, a Joint Steering Committee, or the JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, shall review and provide input on our commercialization plan for DWP-450, although we have final decision-making power regarding the marketing, promotion, sale and/or distribution of DWP-450. A disagreement among the JSC will be referred to senior management of Daewoong and us for resolution if the JSC is unable to reach a decision within 30 days. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We plan to market DWP-450 under a name approved by relevant regulatory agencies. Daewoong currently markets DWP-450 in South Korea under its own brand name, Nabota.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Daewoong Agreement also provides that Daewoong will indemnify us for any losses arising out of (i) Daewoong&#8217;s willful misconduct or gross negligence in performing its obligations under the agreement, (ii) Daewoong&#8217;s breach of the agreement, or (iii) any allegation that DWP-450 or Daewoong&#8217;s trademark infringes or misappropriates the rights of a third party, except, in each case, as a result of our willful misconduct or gross negligence. We have agreed to indemnify Daewoong for any losses arising out of (i) our willful misconduct or gross negligence in performing our obligations under the agreement, or (ii) our breach of the agreement, except, in each case, as a result of Daewoong&#8217;s willful misconduct or gross negligence. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our primary competitors in the pharmaceutical market are companies offering injectable dose forms of botulinum toxin. There are only three approved injectable botulinum toxin type A neurotoxins in the United States. There are also other injectable botulinum toxin type A products being developed in the United States, however, we believe our product, DWP-450, is further along in its clinical development than other products and the only product with an accepted BLA in the United States. We believe the primary products in this market include BOTOX, Dysport and Xeomin:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">BOTOX, marketed by Allergan, received FDA approval in 2002 for glabellar lines. Allergan was the first company to market neurotoxins for aesthetic purposes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dysport, marketed by Galderma S.A., or Galderma, received FDA approval in 2009 for glabellar lines.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Xeomin, marketed by Merz Pharma GmbH &amp; Co., or Merz, received FDA approval in 20</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">11 for glabellar lines</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to the companies commercializing neurotoxins, there are other products and treatments that may indirectly compete with DWP-450, such as dermal fillers, laser treatments, brow lifts, chemical peels, fat injections and cold therapy. We compete with various companies that have products in these medical aesthetic categories. Among these companies are Allergan, Sanofi, Sun Pharma, Valeant Pharmaceuticals International, Inc., or Valeant, Mentor Worldwide LLC, a division of Johnson &amp; Johnson, Merz, Galderma, and Skinceuticals, a division of L&#8217;Oreal SA. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Many of our competitors have substantially greater technological, financial, research and development, manufacturing, personnel and marketing resources than we do. We believe that we have competitive strengths that position us favorably in our markets. However, our industry is evolving rapidly and is becoming increasingly competitive. Larger and more established companies may acquire or in-license aesthetic products and could directly compete with us. These competitors may also try to compete with DWP-450 on price both directly, through rebates and promotional programs to high volume physicians and coupons to patients, and indirectly, through attractive product bundling with complimentary products such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. Larger competitors may also be able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. Our competitors may seek to discredit our product by challenging our short operating history or relatively limited number of scientific studies and publications. Smaller companies could also launch new products and services that we do not offer and that could gain market acceptance quickly. Additionally, certain of our competitors may be able to develop competing or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors, including competing botulinum toxin type A formulations that may be administered in higher doses and may result in higher response rates and longer durations of effect than our product such as advances in surgical or radio frequency techniques. As more companies develop new intellectual property in our markets, the possibility of a competitor acquiring patents or other rights that may limit demand for DWP-450 or our future products.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Government Regulation Applicable to Us</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our present and future business has been, and will continue to be, subject to a variety of laws including the Federal Food Drug and Cosmetic Act, or FFDCA, and the Public Health Service Act, or PHS Act, among others. Biologics and medical devices are subject to regulation under the FFDCA and PHS Act.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the United States, cosmetics, dietary supplements, biopharmaceutical products and medical devices are subject to extensive regulation by the FDA. The FFDCA, PHS Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, regulatory approval, license or clearance, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of these products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending license or marketing applications, warning letters and other enforcement actions, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">U.S. Biological Products Development Process</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">submission to the FDA of an investigative new drug application, or IND, which must become effective before human clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed biological product for its intended use, according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements including those for the protection of human research subjects and their health and other personal information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">purity and potency from results of nonclinical testing and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices for the use of human cellular and tissue products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">potential FDA audits of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FDA review and approval of the BLA</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Preclinical Studies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Biological product development in the United States typically involves preclinical laboratory and animal tests. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs, among other requirements. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not objected to the IND within this 30-day period, the clinical trial proposed in the IND may begin.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Studies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our clinical trials for our DWP-450 product candidate involved the administration of the investigational biologic to subjects under the supervision of one or more qualified investigators. Clinical trials must be conducted pursuant to an IND and in compliance with federal regulations and GCPs, an international standard meant to protect the rights and health of subjects and to define the roles of clinical trial sponsors, administrators, and monitors, as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other requirements or sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. The clinical trial protocol, any protocol amendments, and informed consent information for subjects in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. The IRB also approves the form and content of the informed consent form that must be signed by each clinical trial subject or his or her legal representative, and the IRB must monitor the clinical trial until completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase I. The product candidate is initially introduced into a limited population of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for some diseases, or when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the disease or condition for which the product candidate is intended to gain an early indication of its effectiveness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase II. The product candidate is evaluated in a limited patient population, but larger than in Phase I, to identify possible adverse events and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to assess dosage tolerance, optimal dosage and dosing schedule.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase III. Clinical trials are undertaken to further evaluate dosage, and provide substantial evidence of clinical efficacy and safety in an expanded patient population, such as several hundred to several thousand subjects, at geographically dispersed clinical trial sites. Phase III clinical trials are typically conducted when Phase II clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety profile. These trials typically have at least 2 groups of patients who, in a blinded fashion, receive either the product or a placebo. Phase III clinical trials are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase III clinical trials are required by the FDA for approval of a BLA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase IV. In some cases, the FDA may condition approval of a BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the product. Such post-approval studies are typically referred to as Phase IV clinical trials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Marketing Approval</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Clinical trials to support BLAs which are applications for marketing approval, are typically conducted in three sequential phases, but the phases may overlap. In Phase I, the initial introduction of the investigational biologic candidate into patients, the investigational biologic is tested to assess side effects and, if possible, early evidence on effectiveness. Phase II usually involves trials in a limited subject population, to determine the effectiveness of the investigational biologic for a particular indication or indications, and identify common adverse effects and safety risks.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If an investigational biologic demonstrates evidence of effectiveness and an acceptable safety profile in Phase II evaluations, Phase III clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of subjects, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the investigational product and to provide adequate information for its labeling. In most cases, the FDA requires two adequate and well-controlled Phase III clinical trials to demonstrate the efficacy and safety of the biologic for use in a specific indication or population. A single Phase III clinical trial with other confirmatory evidence may be sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s manufacture and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application fee, and the manufacturer or sponsor under an approved BLA are also subject to annual FDA product and establishment user fees.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications for standard review biologics products are reviewed within twelve months of submission; most applications for priority review biologics are reviewed within eight months of submission. Priority review for biologics is limited to those products intended to treat a serious or life-threatening disease with unmet medical need relative to the currently approved products. The review process may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel biologics products or biologics products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the BLA unless it determines that compliance with cGMP is satisfactory. Manufacturers of biologics also must comply with the FDA&#8217;s general biological product standards. After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing, including additional large-scale clinical testing or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">monitor the product&#8217;s safety or efficacy and may impose other conditions, including labeling restrictions, which can materially affect the product&#8217;s potential market and profitability. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems or safety issues are identified following initial marketing. Changes to some of the conditions established in an approved application, including changes in indications, labeling, ingredients or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Post-Approval Requirements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase IV testing, Risk Evaluation and Mitigation Strategies, or REMS, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with applicable regulations such as cGMP and the Quality System Regulation. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Biosimilar Approval Process</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on their similarity to existing brand product.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a BLA. However, an application may be submitted after four years. The BPCIA is complex and is still in the process of being interpreted and implemented by the FDA. As a result, its ultimate impact and implementation are subject to uncertainty.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Government Regulation in Europe</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the European Economic Area, or EEA (which is composed of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There are two types of MAs:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when the authorization of a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. Under the accelerated procedure the standard 210 days review period is reduced to 150 days.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Because we are a biotechnology medicinal products company, we are eligible for a Community MA under the Centralized Procedure.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Product Approval Process Outside the United States and Europe</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to regulations in the United States and EU, we will be subject to a variety of regulations in other jurisdictions governing manufacturing, clinical trials, commercial sales and distribution of our future products.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Whether or not we obtain FDA approval or MA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval or MA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Federal and State Fraud and Abuse</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">While we do not currently have plans for our neurotoxin product candidate to be covered by insurance or government reimbursement programs, if we were to offer reimbursable products, we could be subject to federal laws and regulations covering reimbursable products, such as the Anti-Kickback Statute, Stark Law and Physician Payment Sunshine Act. These laws that may affect our ability to operate include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving any remuneration (including any ownership, kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return, for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, service or item for which payment is made, in whole or in part, under a federal health care program. The Anti-Kickback Statute has been interpreted to apply, among others, to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for a statutory exception or a regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Violations of the Anti-Kickback Statute may result in substantial civil or criminal penalties, including criminal fines of up to $25,000 for each violation and imprisonment of up to five years for each violation. Violations are also subject to sanctions under the Civil Monetary Penalties Law, including penalties of up to $50,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act of up to $11,000 for each claim submitted, plus up to three times the amounts paid for such claims, and exclusion from participation in the Medicare and Medicaid programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the federal False Claims Act, which prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. Suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the False Claims Act, the government may impose penalties of not less than $5,500 and not more than $11,000 per claim, plus up to three times the amount of damages which the government sustains because of the submission of a false claim, and may exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. Recently, the civil False Claims Act has been used to assert liability on the basis of kickbacks and improper referrals, improperly reported government pricing metrics such as Medicaid Best Price or Average Manufacturer Price, improper use of supplier or provider Medicare numbers when detailing a provider of services, improper promotion of drugs or off-label uses not </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:2px;padding-top:0px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expressly approved by the FDA in a drug&#8217;s label, and misrepresentations with respect to the services rendered or items provided, among other issues;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. Significantly, the HIPAA provisions apply not only to federal programs, but also to private health benefit programs. HIPAA also broadened the authority of the Office of Inspector General to exclude participants from federal healthcare programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers or self-pay patients; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require pharmaceutical manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the federal Physician Payments Sunshine Act, and its implementing regulations, which require that certain manufacturers of drugs, medical devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report to the CMS information related to certain payments or other transfers of value made or distributed to physicians, which is defined broadly to include other healthcare providers, teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. Manufacturers are required to submit reports to CMS by the 90th day of each calendar year. Failure to submit the required information may result in civil monetary penalties up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for &#8220;knowing failures&#8221;) for all payments, transfers of value or ownership or investment interests not reported in an annual submission, and may result in liability under other federal laws or regulations. Some state laws require biopharmaceutical companies to adopt or disclose specific compliance policies to regulate a company&#8217;s interactions with healthcare professionals. Moreover, some states, such as Minnesota and Vermont, also impose an outright ban on certain gifts to physicians</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, we may be subject to, or our marketing activities may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct our business. The risk that we would be found to be in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Moreover, recent healthcare reform legislation has strengthened many of these laws.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Due to the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors, it is possible that some of our business activities would not satisfy the statutory exceptions or regulatory safe harbors and we could be subject to challenge under one or more of such laws. State law equivalents to these federal laws may also apply to our current arrangements. Such a challenge could have a material adverse effect on our business, financial condition and results of operations. Violations of these laws may result in substantial fines and other consequences. To the extent that such laws are applicable, they would affect our promotional or other activities by limiting the kinds of interactions we may have with hospitals, physicians or other potential purchasers or users of our products. Certain disclosure laws and gift bans could impose additional administrative and compliance burdens on us. Although we seek to structure our interactions in compliance with all applicable requirements, many of these laws are broadly written, and it is often difficult to determine precisely how a law will be applied in specific circumstances. If an employee were to offer an inappropriate gift to a customer, we could be subject to a claim under an applicable federal or state law. Similarly if we fail to comply with reporting or other requirements, we could be subject to penalties under applicable federal or state </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">laws including, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in government healthcare programs (to the extent that this is applicable to our business in the future), contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. In addition to the federal and state disclosure and gift ban laws, certain countries outside of the United States have similarly enacted disclosure laws for which the company in its activities may be subjected to from time to time.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Data Privacy and Security Laws and Regulations</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are also subject to data privacy and security regulation by both the federal government, states and non-U.S. jurisdictions in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state and non-U.S. laws govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities now and in the future could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion of products from reimbursement under government programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Environmental Regulation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, manufacturing practices, fire hazard control, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous substances and biological materials. Some of these laws and regulations require us to obtain licenses or permits to conduct our operations. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. Although the costs to comply with applicable laws and regulations, including requirements in Canada relating to the restriction of use of hazardous substances in products, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of&#160;August 28, 2017, we had 22 employees, all of whom constitute full-time employees of ALPHAEON, 11 of whom have been assigned to work full time at our company and 11 of whom have been assigned to work part time at our company. In connection with this offering ALPHAEON intends to transfer certain employees to us. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Facilities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our corporate headquarters are located at 1027 Garden Street, Santa Barbara, California, 93101, in a facility we lease encompassing approximately 4,450 square feet of space. The lease for this facility expires on May 31, 2020. We believe our facilities are sufficient for our current needs. When our lease expires, we may exercise our renewal option or look for additional or alternate space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms. In addition, ALPHAEON&#8217;s headquarters are located at 17901 Von Karman Avenue, Suite 150, Irvine, California 92614, in a facility it leases encompassing approximately 3,639 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">square feet of space. The lease for this facility expires on November 1, 2018. In the future, we may sublease this space from ALPHAEON, as certain of our executive, legal and financial personnel will be located in this space. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On June 7, 2017, Medytox Inc., or Medytox, filed an initial complaint in the Superior Court of the State of California, or the Medytox Litigation, against, us, ALPHAEON, SCH, Daewoong, Byung Kook Lee, Jae Chun Yoon, Jae Seung Yoon and Chang Woo Suh, among others, or collectively, the defendants. On August 14, 2017, Medytox filed an amended complaint against the defendants, or the amended complaint. The amended complaint alleges, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture DWP-450 (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture DWP-450, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing DWP-450, and (v) attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are vigorously defending Medytox&#8217;s claims against us. Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us. The litigation could go on for an extended period of time and require us to dedicate significant financial and management time to those efforts. While we are entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. An adverse ruling against either us or one of the other defendants could materially and adversely affect our business, consolidated financial position, results of operations, or cash flows and could also result in reputational harm. Even if we are successful, the litigation may result in delays in our product development, reputational damage or other collateral consequences. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In January 2017, Medytox initiated a criminal investigation into the foregoing matter in South Korea, which appears to target one or more of the above defendants, but does not appear to target us, ALPHAEON, or SCH. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition to the Medytox Litigation, from time to time, we may be subject to other legal proceedings and claims in the ordinary course of business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">90</font></div></div><hr style="page-break-after:always"><div><a name="sAB77F3F9243F371485571527CFF4F211"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">MANAGEMENT</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Executive Officers and Directors </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table sets forth certain information regarding our executive officers and directors as of August&#160;22, 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Position(s)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;font-style:italic;font-weight:bold;">Executive Officers and Directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Murthy Simhambhatla, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Chief Executive Officer, Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">J. Christopher Marmo, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Chief Operating Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Rui Avelar, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Murthy Simhambhatla</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Ph.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, has served as our </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Chief Executive Officer, and as a member of our board of directors, since November 2016. He has also served as President and Chief Executive Officer of ALPHAEON since August 2016. From January 2016 to August 2016, he was a Senior Partner with SCH, a growth equity firm focused on self-pay healthcare companies and a majority owner of ALPHAEON. From January 2013 to January 2016, he was a Senior Vice President at Abbott Laboratories and from April 2006 to January 2013, he was the President of Abbott Medical Optics Inc. Mr. Simhambhatla holds a B.Tech. degree in chemical engineering from Anna University in India and a M.S. and Ph.D. in polymer engineering from the University of Akron. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe that Mr. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Simhambhatla</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;is qualified to serve as a member of our board of directors because of the perspective he brings as our Chief Executive Officer and his management and operational experience in the life science industry.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">J. Christopher Marmo, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Ph.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, has served as our Chief Operating Officer since November 2016. He has also served as the President, Beauty of ALPHAEON, a position he has held since April 2014. From November 2012 to August 2016, Mr. Marmo was our Chief Executive Officer. From December 2007 to November 2012, Mr. Marmo was the Senior Vice President of Research and Development at Allergan. Mr. Marmo holds a B.S. in chemistry from Union College and a Ph.D. in chemistry from the University of Florida. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Rui Avelar, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, has served as our Chief Medical Officer</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and as the Chief Medical Officer of ALPHAEON, since January 2014. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of this offering, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">we will appoint a principal financial officer and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;enter into employment agreements with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">each of Messrs. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Simhambhatla</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, Marmo and Avelar. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Non-Employee Directors</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently do not have any non-employee directors on our board of directors. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Board Composition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Murthy Simhambhatla, Ph.D. is currently the only member of our board of directors. Prior to the completion of this offering, we intend to expand our board of directors to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;members</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. In connection with this offering, we intend to enter into a stockholder agreement, which will provide ALPHAEON with certain rights relating to the composition of our board of directors. See &#8220;Certain Relationships and Related Party Transactions&#8212;Relationships with ALPHAEON Corporation.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Director Independence</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our board of directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors determined that all directors, other than Mr. Simhambhatla and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, are &#8220;independent directors&#8221; as defined under the listing requirements of Nasdaq, or the Nasdaq Marketplace Rules. In making these determinations, our board of directors reviewed and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management, including the beneficial ownership of our capital stock by each non-employee director and the transactions involving them described in the section entitled &#8220;Certain Relationships and Related Party Transactions.&#8221; In addition to determining whether each director satisfies the director independence requirements set forth in the Nasdaq Marketplace Rules, in the case of members of the audit committee and compensation committee, our board of directors will also make an affirmative determination that such members also satisfy separate independence requirements and current standards imposed by the SEC and Nasdaq Marketplace Rules for audit committee members and by the SEC, the Nasdaq Marketplace Rules and the Internal Revenue Service for compensation committee members. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There are no family relationships among any of our directors or executive officers.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Controlled Company</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon completion of this offering, ALPHAEON will continue to control a majority of the voting power of our outstanding common stock. As a result, we will be a &#8220;controlled company&#8221; for purposes of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Nasdaq Marketplace Rules</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As a controlled company, the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Nasdaq Marketplace Rules provide an exemption </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">from the obligation to comply with certain corporate governance requirements, including the requirements:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">that a majority of the board of directors consists of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">that we have a nominating and corporate governance committee that is comprised entirely of independent directors </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">with a written charter addressing the committee&#8217;s purpose and responsibilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">that we have a compensation committee that is comprised entirely of independent directors </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">with a written charter addressing the committee&#8217;s purpose and responsibilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not currently intend to utilize these exemptions. However, we may use these exemptions in the future, and as a result, we could choose not to have a majority of independent directors on our board of directors, or fully independent directors on our nominating and corporate governance and compensation committees. If that were the case, you would not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Nasdaq Marketplace Rules</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. In any case, these exemptions do not modify the independence requirements for our audit committee, and we intend to comply with the requirements of Rule 10A-3 of the Exchange Act, and Nasdaq Marketplace Rules within the applicable time frame.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Board Leadership Structure</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a general policy, we believe that separation of the positions of Chairman of our board of directors and our Chief Executive Officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of management&#8217;s performance and enhances the effectiveness of our board of directors as a whole. As such, Mr. Simhambhatla, our Chief Executive Officer, will not serve as our Chairman of the board of directors following this offering. However, we will reevaluate this policy from time to time and may in the future elect to combine the roles of Chief Executive Officer and Chairman of the board if our board of directors believes it is in the best interest of our stockholders.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Role of the Board in Risk Oversight</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">One of the key functions of our board of directors is overseeing our risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee, nominating and corporate governance committee and compensation committee support our board of directors in discharging its oversight duties and address risks inherent in their respective areas. We believe this division of responsibilities is an effective approach for addressing the risks we face and that our board leadership structure supports this approach.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Board Committees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Each committee operates under a charter that has been approved by our board of directors. Prior to the completion of this offering, copies of each committee&#8217;s charter will be posted on the Investor Relations section of our website, which is located at www.evolus.com. Each committee has the composition and responsibilities described below. Our board of directors may from time to time establish other committees.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our audit committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, who is the chair of the committee, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of directors has determined that each of the members of our audit committee satisfies the Nasdaq Marketplace Rules and SEC independence requirements. The functions of this committee include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">evaluating the performance, independence and qualifications of our independent registered public accounting firm and determining whether to retain our existing independent registered public accounting firm or engage new independent registered public accounting firm;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent registered public accounting firm and management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing with our independent registered public accounting firm and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and approving related party transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our board of directors has determined that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Marketplace Rules. In making this determination, our board has considered&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;extensive financial experience and business background. Both our independent registered public accounting firm and management periodically meet privately with our audit committee.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our compensation committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, who is the chair of the committee and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of directors has determined that each of the members of our compensation committee is an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, and satisfies the Nasdaq Marketplace Rules independence requirements and is a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act. The functions of this committee include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment of our executive officers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviewing with management and approving our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in our periodic reports or proxy statements to be filed with the SEC; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">preparing the report that the SEC requires in our annual proxy statement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Nominating and Corporate Governance Committee</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our nominating and corporate governance committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of directors has determined that each of the members of the nominating and corporate governance committee satisfies the Nasdaq Marketplace Rules independence requirements.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;serves as the chair of our nominating and corporate governance committee. The functions of this committee include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">evaluating, nominating and recommending individuals for membership on our board of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">evaluating nominations by stockholders of candidates for election to our board of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have established a compensation committee which has and will make decisions relating to compensation of our executive officers, consisting of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and none of such members of the compensation committee is, or ever has been, an officer or employee of ours nor had any relationship requiring disclosure by us under any paragraph of Item 404 of Regulation S-K of the SEC. None of our executive officers currently serves on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our board of directors or compensation committee.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Code of Business Conduct and Ethics</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of this offering, we will adopt a code of business conduct and ethics that will apply to all of our employees, officers and directors, including those officers responsible for financial reporting, which will be available on our website, which is located at www.evolus.com. We expect that any amendments to the code, or any waivers of its requirements, will be disclosed on our website.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">94</font></div></div><hr style="page-break-after:always"><div><a name="s9C81D7BFE8EF94F11B9C1527C9F97A27"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">EXECUTIVE AND DIRECTOR COMPENSATION</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our named executive officers, which consist of our principal executive officer and our two other most highly compensated officers for the year ended December 31, 2016, are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Murthy Simhambhatla, Ph.D., our Chief Executive Officer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">J. Christopher Marmo, Ph.D., our Chief Operating Officer; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Rui Avelar, M.D., our Chief Medical Officer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned programs summarized in this discussion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As noted above, we are an &#8220;emerging growth company,&#8221; as that term is used in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the JOBS Act</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table sets forth total compensation paid to our named executive officers for the fiscal year ended December 31, 2016.</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Murthy Simhambhatla, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">169,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">169,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">J. Christopher Marmo, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">407,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">152,831</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">560,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chief Operating Officer</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Rui Avelar, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">325,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">81,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">406,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The amount reported represents the full amount paid to Mr. Simhambhatla by ALPHAEON. D</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">uring 2016, Mr. Simhambhatla split his time between ALPHAEON and our company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mr. Marmo served as our Chief Executive Officer until November 2016. Mr. Simhambhatla was appointed our Chief Executive Officer in November 2016. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The amounts reported represent the amounts paid to Messrs. Marmo and Avelar by ALPHAEON. In 2016, each of Messrs. Marmo and Avelar spent near 100% of their time at our company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Annual Base Salary</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The annual base salaries of our named executive officers will generally be determined and approved at the beginning of each year, or, if later, in connection with the commencement of employment of the executive, by our board of directors or our compensation committee. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As reflected in the table below, the annual base salaries of our named executive officers did not change at the beginning of 2017. Mr. Simhambhalta receives his base salary for his services as our Chief Executive Officer and also for his services as Chief Executive Officer of ALPHAEON</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017 Base Salary</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Murthy Simhambhatla, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">J. Christopher Marmo, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">407,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Rui Avelar, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">325,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Bonus Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not currently have an established plan or policy with regard to bonuses for our executive officers. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">From time to time, our board of directors or compensation committee may approve bonuses for our named executive officers based on individual performance, company performance or as otherwise determined appropriate in their sole discretion. ALPHAEON&#8217;s</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;board of directors determined that Messrs. Marmo and Avelar should receive discretionary retention bonuses of $152,831 and $81,250 (representing 37.5% and 25% of their base salaries, respectively) based on their qualitative assessment of our and our officers&#8217; performance, which bonuses were paid to Messrs. Marmo and Avelar in 2016.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Equity-Based Incentive Awards</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our equity-based incentive awards are designed to align our interests and the interests of our current and future stockholders with those of our employees and consultants, including our named executive officers. Our board of directors is responsible for approving equity grants.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Initially, we will use stock options as the primary incentive for long-term compensation to our named executive officers because the officers are able to profit from stock options only if our stock price increases relative to the stock option&#8217;s exercise price, which exercise price will be set at the fair market value of our common stock at the date of grant. We may grant equity awards at such times as our board of directors determines appropriate. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will grant all equity compensation awards pursuant to the 2017 plan. The terms of the 2017 plan are described below under &#8220;&#8212;Equity Compensation Plans.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Agreements with Our Named Executive Officers</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not currently have employment agreements with our named executive officers. Mr. Simhambhatla has an employment agreement with ALPHAEON, which agreement governs the terms and conditions of his employment with ALPHAEON (and pursuant to which he will be entitled to receive restricted stock units of ALPHAEON upon consummation of this offering). Mr. Marmo has an employment agreement with SCH that governs the terms and conditions of his employment with SCH and has since been assigned to ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We plan to enter into employment agreements with certain of our executive officers (including all of our named executive officers) prior to completion of this offering, which agreements will supersede the terms of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">any existing employment agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, where applicable. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Potential Payments upon Termination or Change in Control</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We currently do not have any agreements with our named executive officers that provide for payment at, following or in connection with, their resignation, retirement or other termination of employment, or a change in control of us. As noted above, we plan to enter into employment agreements with each of our named executive officers prior to completion of this offering, which agreements may contain employment termination and change in control provisions.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at 2016 Fiscal Year-End</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">None of our named executive officers held outstanding equity awards related to our stock as of December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Perquisites and Health and Welfare Benefits</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our named executive officers are eligible to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">receive employee benefits</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, including medical, dental, vision, group life, disability and accidental death and dismemberment insurance, in each case on the same basis as all of our other employees.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not provide perquisites or personal benefits to our named executive officers. Our board of directors may elect to adopt qualified or non-qualified benefit plans in the future if it determines that doing so is in our best interests.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Equity Compensation Plans</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In connection with this offering, we intend to adopt and ask our stockholder to approve the 2017 plan, under which we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2017 plan, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and implementing the 2017 plan and, accordingly, this summary is subject to change.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Stock Awards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. ISOs may be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">granted only to employees. All other awards may be granted to our and our affiliates&#8217; employees, non- employee directors, consultants and other service providers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Administration, Amendment and Termination. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan is administered by our board of directors or a committee of the board designated by the board to administer the plan. Our board of directors has designated the compensation committee to administer the 2017 plan, but the board has retained the right to exercise the authority of the committee under the plan to the extent consistent with applicable law and the applicable requirements of any stock exchange.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Subject to the terms of the 2017 plan, the plan administrator has the authority (1) to grant and amend awards, which includes determining the type, form, terms and conditions and number of shares subject to any award, (2) to interpret any provision of the 2017 plan, any award or any award agreement and (3) to make all determinations and decisions necessary for the administration of the plan. All determinations and decisions by the plan administrator under the 2017 plan are in its sole discretion and are final and binding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Securities to be Offered. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for awards based on shares of our common stock. The total number of shares that may be issued pursuant to the 2017 plan is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any award settled in cash will not be counted as issued shares for any purpose under the 2017 plan. If any award expires, or is terminated, surrendered or forfeited, the unissued shares covered by the award will again be available for the grant of awards. If shares issued pursuant to the 2017 plan are repurchased by, or are surrendered or forfeited to the Company, at no more than cost, those shares will again be available for the grant of awards. If shares issuable upon exercise, vesting or settlement of an award or shares owned by a grantee are surrendered or tendered to the Company in payment of the purchase price of an award or any taxes required to be withheld for an award, those surrendered or tendered shares will again be available for the grant of awards.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Substitute awards will not be counted against the number of shares available for the grant of awards under the 2017 plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Eligibility. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Eligibility to participate in the 2017 plan is limited to such of our and our affiliates&#8217; employees, officers, non-employee directors, consultants and advisors as determined from time to time by the plan administrator.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Stock Options. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of options to purchase shares of common stock at exercise prices, and subject to terms, conditions and limitations, determined by the plan administrator and set forth in an option agreement delivered to the optionee.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">An option that the plan administrator intends to be an &#8220;incentive stock option&#8221; as defined in Section 422 of the Code, or an ISO, will be granted only to our employees and will be subject to and be construed consistently with the requirements of Section 422 of the Code. An option that does not qualify as an ISO is referred to as a &#8220;non-qualified stock option.&#8221; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Stock Appreciation Rights. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of stock appreciation rights, or SARs, which may be awarded either alone or in tandem with, or as a component of, other awards. The applicable award agreement will include information about the terms and conditions under which a SAR will be exercisable, including any performance requirements. A SAR confers on the participant a right to receive, upon exercise, a payment of the excess of (1) the fair market value of one share of our stock on the date of exercise over (2) the grant price of the SAR as determined by the plan administrator (which will be equal to at least fair market value on the grant date).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Restricted Stock Awards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of restricted stock awards. In general, a restricted stock award is an award of actual shares of common stock issued in the participant&#8217;s name that are subject to certain vesting requirements and that we may hold until the applicable vesting date, at which time the shares are released to the participant. Alternatively, at the discretion of the plan administrator, we may issue a restricted stock certificate bearing the legends required by applicable securities laws.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The plan administrator will determine the terms and conditions of any restricted stock award, which will be set forth in the restricted stock agreement delivered to the participant. A restricted stock award holder will have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in the restricted stock agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Restricted Stock Units. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of restricted stock units, or RSUs. An RSU represents the right to receive one share of common stock upon the applicable vesting date, but no share is actually issued until vesting. An RSU may be settled in cash rather than stock to the extent provided in the applicable award agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The plan administrator will determine the terms and conditions of any RSUs granted under the 2017 plan. In general, a holder of RSUs will not have any rights of a stockholder but the plan administrator may provide that the holder is entitled to receive dividend equivalent rights.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Stock-Based Performance Awards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The 2017 plan provides for the grant of awards based on various performance conditions as may be specified by the plan administrator. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Settlement of performance awards may be in cash, shares, other awards or other property, in the discretion of the plan administrator. The plan administrator may reduce the amount of a settlement otherwise to be made in connection with performance awards.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Other Stock-Based Awards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The plan administrator may grant other stock-based awards, either alone or in addition to or in conjunction with other awards under the 2017 plan, based upon the common stock, having terms and conditions as the plan administrator may determine.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Transferability of Awards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A participant may not assign or transfer an award under the 2017 plan, except by will or as permitted under the laws of descent and distribution. During a participant&#8217;s lifetime, only the participant personally (or his or her personal representative) may exercise rights under the 2017 plan. However, if authorized by the applicable award agreement, a participant may transfer, not for value, all or part of an award (other than an ISO) to certain family members, in accordance with the terms of the 2017 plan. After a permitted transfer, the award will continue to be subject to the same terms and conditions as it was before the transfer. Subsequent transfers of the award are only permitted if made to another family member as described above.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Rights as Stockholder. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Unless an applicable award agreement states otherwise, a 2017 plan participant will have no rights as a stockholder with respect to any shares covered by an award until he or she becomes the record holder of the shares.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Withholding for Payment of Taxes. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We may deduct from payments of any kind otherwise due to a 2017 plan participant any federal, state or local taxes of any kind required by law to be withheld in connection with the vesting of or other lapse of restrictions applicable to an award or upon the issuance of any shares of stock upon the exercise of an option or pursuant to an award.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Effect of Certain Transactions. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Subject to any required action by our stockholders, in the event of any change in our common stock effected without receipt of consideration by us, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in our capital structure, or in the event of payment of a dividend or distribution to our stockholders in a form other than our common stock (excepting normal cash dividends) that has a material effect on the fair market value of our common stock, appropriate and proportionate adjustments will be made in the number and class of shares subject to the 2017 plan and to any outstanding awards, and in the option exercise price, SAR exercise price or purchase price per share of any outstanding awards in order to prevent dilution or enlargement of participant rights under the 2017 plan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If a majority of our shares of common stock are exchanged for, converted into, or otherwise become shares of another corporation, the plan administrator may unilaterally amend outstanding awards under the 2017 plan to provide that such awards are for new shares. In the event of any such amendment, the number of shares subject to, and the option exercise price, SAR exercise price or purchase price per share of, the outstanding awards will be adjusted in a fair and equitable manner as determined by the plan administrator. The plan administrator may also make such adjustments in the terms of any award to reflect, or related to, such changes in our capital structure or distributions as it deems appropriate.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Change in Control. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event of a &#8220;change in control&#8221; (as defined in the 2017 plan), outstanding awards under the 2017 plan will remain our obligation or be assumed by the surviving or acquiring entity, and there will be automatically substituted for our shares then subject to awards the consideration payable with respect to our outstanding shares in connection with the change in control. However, if such consideration is not solely common stock of the acquiror, the plan administrator may, with the consent of the acquiror, provide for the consideration to be received upon the exercise or settlement of awards, for each share subject to the award, to consist solely of common stock of the acquiror equal in fair market value to the per share consideration received by our stockholders pursuant to the change in control. If any portion of the consideration may be received by our stockholders pursuant to the change in control on a contingent or delayed basis, the plan administrator may determine such fair market value per share as of the time of the change in control on the basis of the plan administrator&#8217;s good faith estimate of the present value of the probable future payment of such consideration.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any award that is not assumed or continued by the acquiror in connection with the change in control nor exercised or settled as of the change in control will terminate and cease to be outstanding effective as of the time of the change in control.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additionally, the plan administrator may, without participant consent, determine that upon the occurrence of a change in control each or any award outstanding under the 2017 plan immediately prior to the change in control and not previously exercised or settled will be canceled in exchange for a payment with respect to each vested share (and each unvested share, if so determined by the plan administrator) subject to the canceled award in (1) cash, (2) our stock or stock of a corporation or other business entity a party to the change in control or (3) other property that will be in an amount having a fair market value equal to the fair market value of the consideration to be paid per share of our common stock in the change in control, reduced by the exercise or purchase price per share, if any, under such award.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Amendment and Termination. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The plan administrator may amend, suspend or terminate the 2017 plan as to any awards that have not been made. No amendment, suspension or termination of the 2017 plan may, without participant consent, materially impair rights or obligations under any outstanding award. The plan administrator may amend, modify or supplement the terms of any outstanding award, including modification of awards to foreign nationals or individuals who are employed outside the United States to recognize differences in local law, tax policy or custom.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">401(k) Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON maintains a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officers are eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a tax-qualified plan under Section 401(k) of the Code. The 401(k) plan provides that each participant may contribute up to the lesser of 100% of his or her compensation or the statutory limit, which was $18,000 for calendar year 2016 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">(and 2017)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Participants who are 50 years or older can also make &#8220;catch- up&#8221; contributions, which in calendar year 2016 was up to an additional $6,000 above the statutory limit </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">(and stayed the same for 2017)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. We currently do not make matching contributions into the 401(k) plan on behalf of participants. Participant contributions are held and invested, pursuant to the participant&#8217;s instructions, by the plan&#8217;s trustee.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Nonqualified Deferred Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide our officers and other employees with non-qualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Director Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We did not pay any compensation to any member of our board of directors for their service on our board during the year ended December 31, 2016. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We do not currently have an established plan or policy with regard to compensation of members of our board of directors. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Limitations on Liability and Indemnification Matters</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation will contain provisions that limit the personal liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for any of the following: (i) </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">breach of the director&#8217;s duty of loyalty to us or our stockholders; (ii) an </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; (iii) unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or (iv) a transaction from which the director derives an improper personal benefit.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our bylaws will provide that we must indemnify our directors and other officers, and may indemnify our employees or agents, to the maximum extent permitted by Section 145 of the DGCL.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have entered into or intend to enter into separate indemnification agreements with our directors and executive officers</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, in addition to the indemnification that will be provided for in our </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">certificate of incorporation and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">bylaws, as they will be in effect upon completion of this offering. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We believe that these provisions in our certificate of incorporation, bylaws and indemnification agreements will be necessary to attract and retain qualified persons as directors and officers.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The limitation of liability and indemnification provisions that will be set forth in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. To the extent we pay the costs of settlement or a damage award against any director or officer pursuant to these indemnification provisions, our stockholders&#8217; investment may be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Except as otherwise disclosed under the heading &#8220;Legal Proceedings&#8221; in the &#8220;Business&#8221; section of this prospectus, there is at present no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">100</font></div></div><hr style="page-break-after:always"><div><a name="sD5CCBCB08077A63A1A911527D048FCA4"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following includes a summary of transactions since January 1, 2014 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">and each currently proposed transaction </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to which we have been or are a party, in which the amount involved in the transaction exceeded or will exceed $120,000, and in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than compensation arrangements for our directors and executive officers, which are described in &#8220;Executive and Director Compensation.&#8221; </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Relationships with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of this offering, we were a wholly-owned subsidiary of ALPHAEON and an indirectly owned subsidiary, through ALPHAEON, of SCH. Immediately following the completion of this offering, ALPHAEON will own</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">% of our outstanding shares of common stock (or approximately &#160;&#160;&#160;&#160;&#160;% of our common stock, if the underwriters exercise in full their option to purchase additional shares of our common stock in this offering), and as a result, ALPHAEON will continue to have significant control of our business, including pursuant to the agreements described below. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In connection with this offering, we and ALPHAEON intend to enter into, or have entered into, certain agreements that relate to our relationship with ALPHAEON prior to this offering or will provide a framework for our ongoing relationship with ALPHAEON following the completion of the offering. Of the agreements summarized below, the material agreements are filed as exhibits to the registration statement of which this prospectus is a part, and the summaries of these agreements set forth the terms of the agreements that we believe are material. These summaries are qualified in their entirety by reference to the full text of such agreements.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Contribution Agreement and Related Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On October 3, 2013, we entered into a contribution agreement with SCH, the Evolus contributors, and J. Christopher Marmo, as the Evolus contributors&#8217; representative, or the contribution agreement, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">which was amended in 2014, 2015 and 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Pursuant to the contribution agreement, the Evolus contributors contributed to SCH 10,000,000 shares of our common stock, and 1,250,000 shares of our Series A preferred stock, constituting all of our then outstanding capital stock. As consideration, the Evolus contributors received membership interests in SCH. In addition, under the contribution agreement, the Evolus contributors had the option to require SCH to sell to ALPHAEON 1,000,000 shares of our common stock and 125,000 shares of our Series A preferred stock, which option was exercised in full in 2014. We refer to this option as the Evolus contributors&#8217; put option.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the exercise of the Evolus contributors&#8217; put option, SCH and ALPHAEON entered into a contribution agreement on March 28, 2014 whereby SCH contributed 9,000,000 shares of our common stock and 1,125,000 shares of our Series A preferred stock to ALPHAEON, representing 90% of our then outstanding capital stock. In exchange, ALPHAEON issued shares of its equity to SCH. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of the exercise of the contributors&#8217; put option, SCH and ALPHAEON entered into a stock purchase agreement. Under the stock purchase agreement, SCH sold and ALPHAEON purchased 1,000,000 shares of our common stock and 125,000 shares of our Series A preferred stock, representing 10% of our then outstanding capital stock. As consideration, ALPHAEON agreed to make certain lump sum and royalty payments to SCH, which are ultimately allocable to the Evolus contributors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The payment obligations include (i) a $10.0 million up-front payment upon obtaining FDA approval for DWP-450 for the treatment of glabellar lines, (ii) </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">perpetual quarterly royalties of a mid-teen percentage of net sales of the product within the United States and (iii) a high-single digit percentages of net sales of the product outside of the United States. As these future royalty streams are perpetual, ALPHAEON had the right to terminate any future payments for a one-time lump sum payment to SCH of $145.0 million.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the consummation of this offering, we intend to enter into an agreement under which we will either directly assume the obligations set forth above, as they may be amended, to the Evolus contributors or indirectly, by entering into an agreement with ALPHAEON to reimburse it for the payments to the Evolus contributors. As a result of a series of agreements, we will become either directly or indirectly obligated to make specified payments to the Evolus contributors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a result of the transactions contemplated by the foregoing agreements, ALPHAEON held 10,000,000 shares of our common stock and 1,250,000 shares of our Series A preferred stock, representing all of our outstanding shares of our capital stock. In connection with this offering, all of our issued and outstanding shares of Series A preferred stock will convert into 1,250,000 shares of our common stock. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Guarantee</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">&#32;of ALPHAEON&#8217;s Convertible Notes and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Intercreditor Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON is, as of June 30, 2017, the borrower under (i) certain convertible promissory notes issued by ALPHAEON for an aggregate principal amount of approximately $46.5 million, or the convertible promissory notes, and (ii) a certain convertible bridge note issued by ALPHAEON for a principal amount of $2.5 million, or the convertible bridge note, collectively, the Notes. ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of our capital stock, granted by ALPHAEON to Dental Innovations BVBA, or DI, as collateral agent for the holders of the convertible promissory notes, and Longitude Venture Partners II, L.P., or Longitude, as the holder of the convertible bridge note, pursuant to separate pledge and security agreements, or the ALPHAEON security agreements. In April 2017, we agreed to unconditionally guarantee ALPHAEON&#8217;s obligations under the Notes and we granted to Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, a first priority lien and security interest in substantially all of our assets pursuant to separate guaranty and security agreements, or the Evolus security agreements. We refer to the ALPHAEON security agreements and the Evolus security agreements collectively as the convertible notes security agreements. In April 2017, we, as guarantor, also entered into an amended and restated intercreditor agreement with ALPHAEON, as borrower, Longitude, as the holder of the convertible bridge note, and DI, as collateral agent for the holders of the convertible promissory notes, or the intercreditor agreement. The intercreditor agreement sets forth certain rights of Longitude and DI in connection with the convertible bridge note, the convertible promissory notes and the collateral pledged pursuant to the convertible notes security agreements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The intercreditor agreement and Evolus security agreements stipulate that any payment by us under their terms shall result in a dollar-for-dollar offset and reduction in the amount of intercompany loans owed by us to ALPHAEON. The Evolus security agreements will terminate upon the earlier of (i) the date on which all secured obligations described under the Evolus security agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or into unsecured notes pursuant to the terms of the Notes if not paid by ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Concurrent with the execution of the Evolus security agreements with the holders of the Notes in April 2017, we severally agreed to pay the redemption amount of 2.5 times the principal amount of the Notes upon maturity. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a co-obligor to these Notes, we are required to measure obligations resulting from joint and several liability arrangements as the sum of the amount that we have (i) contractually agreed to pay on the basis of our arrangement with our co-obligors and (ii) any additional amount that we expect to pay on behalf of our co-obligors. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We recorded this joint and several liability as Note obligations and recorded a corresponding deemed distribution to ALPHAEON as a reduction to additional paid-in-capital in equity as of April 2017 to reflect the joint and several liability.  As we and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, we developed a range of amounts that we expect to pay under the c</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">onvertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and selected the amount from within that range that we determined to be the best estimate, which equaled </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. As provided for within the intercreditor agreement and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">convertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, in conjunction with our recognition of the joint and several liability, we also recorded a receivable from ALPHAEON, which equals the current balance of the amounts we owe to ALPHAEON under our intercompany borrowing arrangements. No amounts have been paid under this joint and several liability by us in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the liability recorded by us to the Note holders pursuant to the above joint and several liability was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date) and the related party receivable was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, representing the amount by which related party borrowings could be reduced pursuant to the terms of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">convertible notes security agreements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The difference between the amount of the joint and several liability and the related party receivable of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$53.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was recorded as a deemed distribution to ALPHAEON, which caused a corresponding reduction in additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In July 2017, ALPHAEON issued an additional $5 million of convertible promissory notes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.  As a result of this additional issuance, the total note obligations under all the Notes increased to $134.9 million (2.5 times the total outstanding principal amount of the Notes).  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of the offering, we and ALPHAEON intend to enter into amendments with each of Longitude</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, as the holder of the convertible bridge note,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and DI, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">as collateral agent for the holders of the convertible promissory notes,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;releasing our guarantee of the Notes and the security interest in our assets and terminating the Evolus security agreements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">102</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Stockholder Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to enter into a stockholder agreement with ALPHAEON, which will become effective upon completion of this offering. The stockholder agreement will provide ALPHAEON with certain registration rights. At any time beginning 180 days after the effective date of the registration statement of which this prospectus forms a part, ALPHAEON may request that we register for resale all or a portion of its shares of common stock. Any such request must cover a quantity of shares with an anticipated aggregate offering price of at least $&#160;&#160;&#160;&#160;&#160;&#160;million. ALPHAEON may also request that we file an automatic shelf registration statement on Form S-3 that covers the registrable securities requested to be registered, to the extent we are eligible to do so. Depending on certain conditions, we may defer a demand registration for up to 90 days in any twelve-month period. ALPHAEON will agree pursuant to a contractual lock-up not to exercise any of its rights under the stockholder agreement during the 180-day restricted period described under the section entitled &#8220;Underwriting.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event that we propose to register any of our securities under the Securities Act, either for our account or for the account of our other security holders, ALPHAEON will be entitled to certain piggyback registration rights allowing each to include its shares in the registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, ALPHAEON is entitled to notice of the registration.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The stockholder agreement will provide that we must pay all registration expenses (other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The stockholder agreement will contain customary indemnification and contribution provisions </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">by us for the benefit of ALPHAEON and its affiliates and, in limited situations, by ALPHAEON for the benefit of us and any underwriters with respect to written information furnished to us by ALPHAEON and stated by ALPHAEON to be specifically included in any registration statement, prospectus or related document.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The registration rights will remain in effect with respect to any shares covered by the stockholder agreement until (i) all of ALPHAEON&#8217;s shares have been sold pursuant to an effective registration statement under the Securities Act, (ii) all of ALPHAEON&#8217;s shares have been sold to the public pursuant to Rule 144 under the Securities Act, or (iii) ALPHAEON owns less than&#160;&#160;&#160;&#160;&#160;&#160;% of our then outstanding shares of our common stock.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Services Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to enter into a services agreement with ALPHAEON, or the services agreement, which will become effective upon completion of this offering. The services agreement will set forth certain agreements between ALPHAEON and us that will govern the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">respective rights, responsibilities and obligations </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">between ALPHAEON and us </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">that will govern the relationship between ALPHAEON and us following this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the services agreement, ALPHAEON will agree to provide us with certain administrative and support services on a transitional basis after completion of this offering. We expect that the fees to be charged to us for transition services furnished pursuant to the services agreement will remain consistent with our current practice and will approximate the actual cost incurred by ALPHAEON in providing the transition services to us for the relevant period. In addition, pursuant to the services agreement, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">we may sublease from ALPHAEON its lease for its headquarters encompassing approximately 3,639 square feet of space, as certain of our executive, legal and financial personnel will be located at ALPHAEON&#8217;s headquarters.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Outstanding Payable - Related Party Borrowings</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, we owed ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$59.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, representing related party borrowings from ALPHAEON as consideration for certain expenses incurred on our behalf, including research and development expenses, general and administrative support services and development support services. There is currently no written agreement in place governing the terms of our related party borrowings to ALPHAEON, and as such, we may elect to remunerate ALPHAEON through a variety of methods. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have entered into or intend to enter into separate indemnification agreements with our directors and officers. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For more information regarding these agreements, see the section entitled &#8220;Executive and Director Compensation</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8212;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Limitations on Liability and Indemnification Matters.&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Policies and Procedures for Transactions with Related Persons</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to the completion of this offering, we plan to adopt a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration, ratification and oversight of &#8220;related-person transactions.&#8221; For purposes of our policy only, a &#8220;related-person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceeds $120,000.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director or a holder of more than 5% of any class of our equity, including any of their immediate family members and any entity owned or controlled by such persons.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review, consideration and approval. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related persons, the benefits of the transaction to us and whether any alternative transactions are available. To identify related-person transactions in advance, we will rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our audit committee or other independent body of our board of directors shall take into account the relevant available facts and circumstances including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the risks, costs and benefits to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the terms of the transaction;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the availability of other sources for comparable services or products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the terms available to or from, as the case may be, unrelated third parties or to or from our employees generally.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">104</font></div></div><hr style="page-break-after:always"><div><a name="sA6CBE56B911E203A57851527D078846F"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">PRINCIPAL STOCKHOLDERS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table sets forth information regarding beneficial ownership of our capital stock by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each of our directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each of our named executive officers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">all of our executive officers and directors as a group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The ownership information under the column entitled &#8220;Shares Beneficially Owned Prior to this Offering&#8221; is based on 11,250,000 shares of common stock. The number of shares of common stock includes 1,250,000 shares of common stock issuable upon the automatic conversion of all outstanding shares of Series A preferred stock upon the closing of this offering, as if the conversion had occurred as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable on or before&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017 which is 60 days after&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Evolus, Inc., 1027 Garden Street, Santa Barbara, California 93101.</font></div><div style="line-height:100%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name and address of</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">beneficial owner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Common Stock Beneficially Owned Prior to this Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Common Stock Beneficially Owned After this Offering </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Named Executive Officers and Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;">Murthy Simhambhatla, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;">J. Christopher Marmo, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;">Rui Avelar, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;">All directors and executive officers as a group (3&#160;persons)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Greater than 5% Holders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;">ALPHAEON Corporation</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;color:#231f20;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">11,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Less than 1%.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Consists of 10,000,000 shares of our common stock and 1,250,000 shares of our Series A preferred stock, which will be automatically converted into 1,250,000 shares of our common stock prior to the completion of this offering. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The address of ALPHAEON is 17901 Von Karman Avenue, Suite 150, Irvine, California 92614. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Changes in Control</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In 2016, ALPHAEON entered into two substantially similar pledge and security agreements with DI and Longitude, respectively. Pursuant to the pledge and security agreements, ALPHAEON pledged and granted to DI, as collateral agent for several debt holders, and Longitude a continuing first priority lien and security interest in and to all of ALPHAEON&#8217;s right, title and interest in, among other items, securities and all other investment property held by ALPHAEON, including ALPHAEON&#8217;s entire ownership of our capital stock, or the collateral. The collateral secures the payment and performance of the obligations of ALPHAEON under certain convertible notes issued by ALPHAEON and other related agreements.&#160;Upon certain events of default, DI and Longitude may take possession, hold, collect, sell, lease, deliver, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">105</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">grant options to purchase or otherwise retain, liquidate or dispose of all or any portion of the collateral. In the event DI or Longitude exercises such rights, upon an event of default, a change-of-control of our company may result.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">106</font></div></div><hr style="page-break-after:always"><div><a name="sC683F5846D8BB95184871527D0993F6D"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following is a summary of the rights of our common stock and preferred stock, certain provisions of our amended and restated certificate of incorporation, or certification of incorporation, and our amended and restated bylaws, or bylaws, as they will be in effect upon completion of this offering, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which will be filed as exhibits to the registration statement of which this prospectus forms a part.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon the completion of this offering, our authorized capital stock will consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock, par value $0.00001 per share; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of preferred stock, par value $0.00001 per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of June 30, 2017, and after giving effect to the automatic conversion of all of our outstanding Series A preferred stock into common stock in connection with this offering, there were outstanding 11,250,000 shares of our common stock, all of which were owned by our sole record holder, ALPHAEON</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As of that date, there were no outstanding stock options.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Immediately after the completion of this offering,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">shares of common stock will be outstanding, assuming the underwriters&#8217; option to purchase additional shares is not exercised, and no shares of preferred stock will be outstanding.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following summarizes the rights of holders of our common stock:</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Voting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The holders of our common stock are entitled to one vote per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of our capital stock entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Subject to preferences that may be applicable to the holders of outstanding shares of preferred stock, the holders of common stock are entitled to share equally, on a per share basis, in any dividends when, as and if declared by our board of directors out of assets legally available for dividends (except that in the event a dividend or distribution is paid in the form of common stock (or rights to acquire such stock), then holders of common stock shall receive common stock (or rights to acquire such stock, as the case may be).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As a Delaware corporation, we will be subject to certain restrictions on dividends under the DGCL. Generally, a Delaware corporation may only pay dividends either out of "surplus" or out of the current or the immediately preceding year's net profits. Surplus is defined as the excess, if any, at any given time, of the total assets of a corporation over its total liabilities and statutory capital. The value of a corporation&#8217;s assets can be measured in a number of ways and may not necessarily equal their book value.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation Rights</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon our liquidation, dissolution or winding up, after satisfaction of all our liabilities and the payment of any liquidation preference of any outstanding preferred stock, the holders of shares of common stock will be entitled to share equally, on a per share basis, in all of our assets legally remaining for distribution after payment of all debt and other liabilities.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Redemption Rights</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There are no redemption or sinking fund provisions applicable to our common stock.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Preemptive Rights and Conversion Rights</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There are no preemptive or conversion rights applicable to our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">107</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon the completion of this offering, we will have no shares of our preferred stock outstanding, but our board of directors will be authorized, without further action by our stockholders, to create and issue one or more series of preferred stock and to fix the rights, preferences and privileges thereof. Among other rights, our board of directors may determine, without further vote or action by our stockholders:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the number of shares constituting the series and the distinctive designation of the series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the dividend rate on the shares of the series, whether dividends will be cumulative, and if so, from which date or dates, and the relative rights of priority, if any, of payment of dividends on shares of the series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether the series will have voting rights in addition to the voting rights provided by law and, if so, the terms of the voting rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether the series will have conversion privileges and, if so, the terms and conditions of conversion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether or not the shares of the series will be redeemable or exchangeable, and, if so, the dates, terms and conditions of redemption or exchange, as the case may be;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether the series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of the sinking fund; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the rights of the shares of the series in the event of our voluntary or involuntary liquidation, dissolution or winding up and the relative rights or priority, if any, of payment of shares of the series.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Any future issuance of shares of preferred stock, or the issuance of rights to purchase shares of preferred stock, could, among other things, decrease the amount of earnings and assets available for distribution to the holders of common stock or could adversely affect the rights and powers, including voting rights, of the holders of the common stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Options</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock subject to outstanding stock options under the 2017 plan.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Registration Rights</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We will enter into the stockholder agreement with ALPHAEON prior to the completion of this offering that will provide ALPHAEON with registration rights relating to shares of our common stock held by it after this offering. See &#8220;Certain Relationships and Related Party Transactions&#8212;Relationships with ALPHAEON Corporation&#8212;Stockholder Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Provisions of our Certificate of Incorporation, Bylaws and Delaware Law</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Delaware Anti-Takeover Law</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are subject to Section 203 of the DGCL, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that such stockholder became an interested stockholder, unless:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In general, Section 203 defines a business combination to include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">108</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In general, Section 203 defines an interested stockholder as any entity (other than the corporation and any direct or indirect majority-owned subsidiary of the corporation) or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, associated with or controlling or controlled by such entity or person.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following provisions of our&#160;certificate of incorporation and bylaws may make a change in control of our business more difficult and could delay, defer or prevent a tender offer or other takeover attempt that a stockholder might consider to be in its best interest, including takeover attempts that might result in the payment of a premium to stockholders over the market price for their shares. These provisions also may promote the continuity of our management by making it more difficult for a person to remove or change the incumbent members of our board of directors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Authorized but Unissued Shares; Undesignated Preferred Stock</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;The authorized but unissued shares of our common stock will be available for future issuance without stockholder approval. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions and employee benefit plans. In addition, our board of directors may authorize, without stockholder approval, the issuance of undesignated preferred stock with voting rights or other rights or preferences designated from time to time by our board of directors (including the right to approve an acquisition or other change in our control). The existence of authorized but unissued shares of common stock or preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Election and Removal of Directors</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Our board of directors will consist of not less than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;nor more than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;directors. The exact number of directors will be fixed from time to time only by resolution of our board of directors. Our board of directors will initially have&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;members.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our certificate of incorporation will provide that directors may be removed only for cause and only by the affirmative vote of holders of a majority of our then outstanding stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Classified Board of Directors</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Our certificate of incorporation and bylaws&#160;will provide that our board of directors will be classified with approximately&#160;one-third&#160;of the directors elected each year. The number of directors will be fixed from time to time by a majority of the total number of directors that we would have at the time such number is fixed if there were no vacancies. The directors will be divided into three classes, designated class I, class II and class III. Each class will consist, as nearly as may be possible, of&#160;one-third&#160;of the total number of directors constituting the entire board of directors. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term and until their successors are duly elected and qualified. In addition, if the number of directors is changed, any increase or decrease will be apportioned by our board of directors among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, disability, resignation or disqualification of a director or other cause will hold office for a term that will coincide with the remaining term of that class, but in no case will a decrease in the number of directors have the effect of removing or shortening the term of any incumbent director.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Director Vacancies</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our certificate of incorporation will authorize only our board of directors to fill vacant directorships.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">No Cumulative Voting</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our certificate of incorporation will provide that stockholders do not have the right to cumulate votes in the election of directors (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Special Meetings of Stockholders</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our&#160;certificate of incorporation and bylaws will provide that special meetings of our stockholders may only be called by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">109</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Advance Notice Procedures for Director Nominations</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our&#160;bylaws&#160;will establish advance notice procedures for stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders. Although our&#160;bylaws&#160;will not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, our&#160;bylaws&#160;may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Action by Written Consent</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our&#160;certificate of incorporation will provide that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Amending Our Certificate of Incorporation and Bylaws</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;At any time after ALPHAEON beneficially owns less than 50% of our then-outstanding common stock, our&#160;certificate of incorporation and bylaws may be amended by the affirmative vote of the holders of at least&#160;66 2/3% of our then-outstanding common stock. Prior to such time, our certificate of incorporation and bylaws may be amended by the affirmative vote of the holders of a majority of the voting power of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Exclusive Jurisdiction</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.&#160;Our certificate of incorporation and bylaws will provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or other employees to us or to our stockholders, any action asserting a claim arising pursuant to the DGCL, or any action asserting a claim governed by the internal affairs doctrine.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Conflicts of Interest</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. Our certificate of incorporation will, to the maximum extent permitted from time to time by Delaware law, renounce any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to our officers, directors or stockholders or their respective affiliates, other than those officers, directors, stockholders or affiliates who are our employees. Our certificate of incorporation will provide that, to the fullest extent permitted by law, none of ALPHAEON or any of its affiliates or any director who is not employed by us or his or her affiliates will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar lines of business in which we or our affiliates now engage or propose to engage or (ii)&#160;otherwise competing with us or our affiliates. In addition, to the fullest extent permitted by law, in the event that ALPHAEON or any&#160;non-employee&#160;director acquires knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us or our affiliates, such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our affiliates and they may take any such opportunity for themselves or offer it to another person or entity. Our certificate of incorporation will not renounce our interest in any business opportunity that is expressly offered to a&#160;non-employee&#160;director solely in his or her capacity as a director of our company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our certificate of incorporation, we have sufficient financial resources to undertake the opportunity and the opportunity would be in line with our business.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Nasdaq Global Market Listing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to apply for listing of our common stock on the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Nasdaq Global Market</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The transfer agent and registrar for our common stock is</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The transfer agent and registrar&#8217;s address is</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">110</font></div></div><hr style="page-break-after:always"><div><a name="s4589D3ADD2480F89F82C1527D0CB3233"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">SHARES ELIGIBLE FOR FUTURE SALE</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Immediately prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below, sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Based on the number of shares outstanding as of&#160;June 30, 2017, upon completion of this offering, we will have outstanding an aggregate&#160;&#160;&#160;&#160;&#160;shares of common stock (or &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares if the underwriters exercise in full their option to purchase additional shares of our common stock). This includes shares of common stock that we are selling in this offering, which shares may be resold in the public market immediately following this offering, and assumes (i) the automatic conversion of all outstanding shares of Series A preferred stock into common stock and (ii) no exercise of outstanding stock options prior to completion of this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The remaining&#160;&#160;&#160;&#160;&#160;shares of common stock that were not offered and sold in this offering, all of which are beneficially owned by ALPHAEON, and&#160;&#160;&#160;&#160;&#160;shares subject to employee stock options will be &#8220;restricted securities,&#8221; as that term is defined in Rule 144 under the Securities Act. All of these restricted securities will be subject to the 180-day lock-up period described below. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which are summarized below, or any other exemption and, if subject to lock-up agreements, may only be sold after the expiration of the 180-day lock-up period.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Rule 144</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In general, under Rule 144 as currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this offering without regard to whether current public information about us is available. Beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1% of the number of shares of our common stock then outstanding, which will equal approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares immediately after this offering; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Sales of restricted shares under Rule 144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions applicable to restricted shares, other than the holding period requirement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Notwithstanding the availability of Rule 144, the holders of substantially all of our shares have entered into lock-up agreements as described below and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Rule 701</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under Rule 701, shares of our common stock acquired upon the exercise of currently outstanding stock options or pursuant to other rights granted under our stock plans may be resold by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule 144; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">111</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017, options to purchase a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock were outstanding, of which&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;were vested. Of the total number of shares of our common stock issuable under these options, substantially all are subject to contractual lock-up agreements with us or the underwriters described below and will become eligible for sale at the expiration of those agreements unless held by an affiliate of ours.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Lock-Up Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We, along with our directors, executive officers and ALPHAEON have agreed that for a period of 180 days after the date of this prospectus, subject to specified exceptions, we or they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock without prior consent. Upon expiration of the &#8220;lock-up&#8221; period, ALPHAEON will have the right to require us to register its shares under the Securities Act. See &#8220;Registration Rights&#8221; below.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See &#8220;Underwriting&#8221; for a more complete description of the lock-up agreements that we, our directors, executive officers, ALPHAEON and all of our optionholders will enter into in connection with this offering.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock reserved for issuance under the 2017 plan. The registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up agreements described above, if applicable.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Registration Rights</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Upon completion of this offering, ALPHAEON will be entitled to various rights with respect to the registration of its shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming freely tradeable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#8220;Certain Relationships and Related Party Transactions&#8212;Relationship with ALPHAEON Corporation&#8212;Stockholder Agreement.&#8221; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the lock-up agreements described above, ALPHAEON will agree not to exercise these rights during the lock-up period.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Potential Future Sale or Distribution of Common Stock Held by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">After the completion of this offering, ALPHAEON will beneficially own &#160;&#160;&#160;&#160;% of our outstanding common stock, assuming the underwriters&#8217; option to purchase additional shares of common stock from us is exercised. ALPHAEON has indicated that after this offering it intends, over time, to sell or distribute its equity ownership in the Company. After the expiration of the &#8220;lock-up period&#8221; ALPHAEON intends to explore options in order to provide their stockholders liquidity including open market sales or underwritten offerings of the common stock it holds in us, a tax-free merger, or tax-free or tax-advantaged distributions of the shares it holds in us to its stockholders. These transaction are subject to various conditions, including receipt of any necessary bank regulatory and other approvals, the existence of satisfactory market conditions, and, in the case of a tax-free transaction, a private letter ruling from the U.S. International Revenue Service, or the IRS, as to certain issues relating to, and an opinion of counsel confirming, the tax-free treatment of the transaction to us and our stockholders. The conditions to any transaction ALPHAEON may contemplate may not be satisfied and ALPHAEON may decide for any reason not to consummate any of the transactions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are unable to predict whether significant numbers of shares will be sold in the open market or otherwise in anticipation of or following any exchange, distribution or sales of our shares by&#160;ALPHAEON.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">112</font></div></div><hr style="page-break-after:always"><div><a name="sAF5774588E1EADEF04CB1527D0ED0960"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following discussion describes the material U.S. federal income tax considerations for Non-U.S. Holders (as defined below) with respect to the acquisition, ownership and disposition of our common stock acquired in this offering. This discussion does not address all aspects of U.S. federal income tax law that may be relevant to Non-U.S. Holders in light of their particular circumstances, nor does it address any U.S. federal estate or gift tax, or any state, local or non-U.S. tax consequences or U.S. federal tax consequences other than income taxes. Non-U.S. Holders should consult their tax advisors as to these matters. Rules different from those described below may apply to certain Non-U.S. Holders that are subject to special treatment under the Code such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">banks, financial institutions, or insurance companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">tax-exempt organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">tax-qualified retirement plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">broker-dealers and traders in securities, commodities or currencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">certain former citizens or long-term residents of the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persons that own, or are deemed to own, more than five percent of our common stock (except to the extent specifically set forth below);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulated investment companies or real estate investment trusts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; or corporations that accumulate earnings to avoid U.S. federal income tax;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persons that hold our common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or other integrated investment or risk reduction strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">holders deemed to sell our common stock under the constructive sale provisions of the Code;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">holders who are subject to the alternative minimum tax or Medicare contribution tax; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">partnerships and other pass-through entities, and investors in such pass-through entities or entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their places of organization or formation).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Such Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and Treasury regulations, published administrative pronouncements, rulings and judicial decisions thereunder as of the date hereof. Such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary. In addition, the IRS could challenge one or more of the tax consequences described herein. This discussion assumes that the Non-U.S. Holder holds our common stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following discussion is for general information only and is not tax advice for any Non-U.S. Holders under their particular circumstances. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction or under any applicable tax treaty, including any state, local and non-U.S. tax consequences and any U.S. federal non-income tax consequences.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For the purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is, for U.S. federal income tax purposes, a beneficial owner of our common stock that is not a U.S. Holder. A &#8220;U.S. Holder&#8221; means a beneficial owner of our common stock that is, for U.S. federal income tax purposes, (a) an individual who is a citizen or resident of the United States, (b) a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust if it (1) is subject to the primary supervision of a court within the United States and one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a United States person. Also, partnerships, or other entities that are treated as partnerships for U.S. federal income tax purposes (regardless of their </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">113</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">place of organization or formation) and entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their place of organization or formation), are not addressed by this discussion and are, therefore, not considered to be Non-U.S. Holders for the purposes of this discussion. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Distributions on Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As described in the section entitled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, distributions of cash or property, if any, made on our common stock to a Non-U.S. Holder of our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide us with a properly executed IRS Form W-8BEN or IRS Form W-8BEN-E, or other appropriate form, certifying the Non-U.S. Holder&#8217;s entitlement to benefits under that treaty. In the case of a Non-U.S. Holder that is an entity, Treasury regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder&#8217;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#8217;s agent will then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you should consult with your tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We generally are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates, unless a specific treaty exemption applies. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce your adjusted basis in our common stock as a non-taxable return of capital, but not below zero, and then any excess will be treated as gain and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Gain on Disposition of Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Subject to the discussion below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a) the gain is effectively connected with a trade or business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), (b) the Non-U.S. Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c) we are or have been a United States real property holding corporation, or a USRPHC, within the meaning of Code Section 897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder&#8217;s holding period for the relevant shares of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the case of gain described in (a) above, a Non-U.S. Holder generally will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, unless a specific treaty exemption applies, and a corporate Non-U.S. Holder may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. An individual Non-U.S. Holder described in (b) above generally will be subject to U.S. federal income tax at a rate of 30% on the gain derived from the sale (or such lower rate as may be specified by an applicable income tax treaty), which gain may be offset by certain of the Non-U.S. Holder&#8217;s U.S. source capital losses (even though the Non-U.S. Holder is not considered a resident of the United States), provided the Non-U.S. Holder timely files U.S. federal income tax returns with respect to such losses. With respect to (c) above, in general, we would be a USRPHC if our interests in U.S. real property interests constituted (by fair market value) at least </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">114</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">half of our assets. We believe that we are not, and do not anticipate becoming, a USRPHC; however, there can be no assurance that we will not become a USRPHC in the future. Even if we are treated as a USRPHC, gain realized by a Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1) the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a) the five-year period preceding the disposition or (b) the holder&#8217;s holding period for the relevant shares of our common stock and (2) our common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury regulations, on an established securities market. There can be no assurance that our common stock will qualify as regularly traded on an established securities market.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Information Reporting Requirements and Backup Withholding</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our common stock, including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#8217;s country of residence.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Dividends paid by us (or our paying agents) to a Non-U.S. Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to a Non-U.S. Holder that provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E, or other appropriate form, or otherwise establishes an exemption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under current U.S. federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected by or through a U.S. office of any broker, U.S. or non-U.S., unless the holder provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E, IRS Form W-8ECI or other appropriate form, or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a non-U.S. broker. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a Non-U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. Non-U.S. Holders you should consult with their tax advisors to determine if they are eligible to obtain a tax refund or credit with respect to amounts withheld under the backup withholding rules.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Foreign Accounts</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a U.S. federal withholding tax of 30% may apply to dividends on, and the gross proceeds of, a disposition of our common stock paid to a foreign financial institution (as specifically defined by applicable rules), including when the foreign financial institution holds our common stock on behalf of a Non-U.S. Holder, unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which may include certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing these withholding and reporting requirements may be subject to different rules. FATCA withholding tax will also apply to dividends on, and the gross proceeds of, a disposition of our common stock paid to a non-financial foreign entity (as specifically defined by applicable rules) unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. Withholding under FATCA will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules. Under certain circumstances, a Non-U.S. Holder might be eligible for refunds or credits of such taxes. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The withholding provisions described in the preceding paragraph will generally apply to payments of dividends and will begin to apply to payments of gross proceeds from a sale or other disposition of our common stock on or after January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">115</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL NON- INCOME TAX LAWS.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">116</font></div></div><hr style="page-break-after:always"><div><a name="s2170E55753FB8BF06E9B1527D11FBC91"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">UNDERWRITING</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Subject to the terms and conditions set forth in the underwriting agreement, dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2017, among us and Jefferies LLC and Mizuho Securities USA LLC, as the representatives of the underwriters named below and the joint book-running managers of this offering, or the underwriting agreement, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Underwriter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Jefferies LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mizuho Securities USA LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers&#8217; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commission and Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of common stock. After the offering, the initial public offering price and concession to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">117</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:49%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Without Option to Purchase Additional Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">With Option to Purchase Additional Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Without Option to Purchase Additional Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">With Option to Purchase Additional Shares</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Public offering price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Underwriting discounts and commissions paid by us</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Proceeds to us, before expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, incurred in connection with review by the Financial Industry Regulatory Authority, Inc. of the terms of this offering, as set forth in the underwriting agreement. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Determination of Offering Price</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Listing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We intend to apply to have our common stock listed on the Nasdaq Global Market under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stamp Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Option to Purchase Additional Shares</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#8217;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">No Sales of Similar Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We, our officers, directors and holders of all of our outstanding capital stock and other securities have agreed, subject to specified exceptions, not to directly or indirectly:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-l(h) under the Exchange Act, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This restriction terminates after the close of trading of the common stock on and including the 180th day after the date of this prospectus. The shares of our common stock that ALPHAEON owns are currently pledged to secure its obligations under ALPHAEON&#8217;s convertible promissory notes and convertible bridge note.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Jefferies LLC may, in its sole discretion and at any time or from time to time before the termination of the 180-day period release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and ALPHAEON providing consent to the sale of shares prior to the expiration of the lock-up period.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stabilization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriters have advised us that they, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8220;Naked&#8221; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#8217;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Electronic Distribution</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#8217; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Other Activities and Relationships</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">119</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Disclaimers About Non-U.S. Jurisdictions </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">European Economic Area</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or as to each, a Relative Member State, an offer to the public of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common stock may be made at any time under the following exemptions under the Prospectus Directive:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To any legal entity which is a qualified investor as defined in the Prospectus Directive; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representatives for any such offer; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In any other circumstances falling within Article 3(2) of the Prospectus Directive;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">provided that no such offer or shares of our common stock shall result in a requirement for the publication by us of a prospectus pursuant to Article 3 of the Prospectus Directive.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For the purposes of this provision, the expression an &#8220;offer to public&#8221; in relation to our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common stock to be offered so as to enable an investor to decide to purchase our common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (as amended), including by Directive 2010/73/EU and includes any relevant implementing measure in the Relevant Member State. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This European Economic Area selling restriction is in addition to any other selling restrictions set out below. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">United Kingdom</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the United Kingdom, this prospectus is only addressed to and directed as qualified investors who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order; or (ii) high net worth entities and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). Any investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged with relevant persons. Any person who is not a relevant person should not act or relay on this prospectus or any of its contents. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Canada</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our common stock may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of our common stock must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a legal advisor.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Hong Kong</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our common stock may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong), or the Companies (Winding Up and Miscellaneous Provisions) Ordinance, or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the Securities and Futures Ordinance, or (ii) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to our common stock may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Singapore</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of our common stock may not be circulated or distributed, nor may our common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined under Section 4A of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA) under Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Where our common stock are subscribed or purchased under Section 275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired our common stock under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#8217;s securities pursuant to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore, or Regulation 32.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Where our common stock are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired our common stock under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Japan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our common stock has not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended), or the FIEA. Our common stock may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">121</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">122</font></div></div><hr style="page-break-after:always"><div><a name="sDF68F2F7775C56F142A11527D1406881"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by K&amp;L Gates LLP, Irvine, California.&#160;Skadden, Arps, Slate, Meagher &amp; Flom LLP, New York, New York, is acting as counsel for the underwriters in connection with this offering.</font></div><div><a name="sDC15F5A5591F249C6A1E1527D17242B0"></a></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The financial statements of Evolus, Inc. at December 31, 2016 and 2015, and for each of the two years in the period ended December 31, 2016, appearing in this Prospectus and Registration Statement have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</font></div><div><a name="sCDD7DCB13D91B42E638B1527D194D92C"></a></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement and its exhibits. For further information with respect to us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. Upon completion of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. You may read and copy this information at the Public Reference Room of the SEC, 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is http://www.sec.gov. We also maintain a website at www.evolus.com, at which, following the completion of this offering, you may access our SEC filings free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. You may also request a copy of these filings, at no cost, by writing us at 1027 Garden Street, Santa Barbara, California, 93101, Attention: Vice President, Legal or telephoning us at (949) 284-4555.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">123</font></div></div><hr style="page-break-after:always"><div><a name="sD7CB316810488F8690321527D1C6DF67"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Index to Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Years ended December 31, 2015 and 2016 and Six Months ended June 30, 2016 and 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s5C38304D5D19D4D224691527D1E731A4"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s5C38304D5D19D4D224691527D1E731A4">F-2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Financial Statements:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s8ABD20BC0EF0219AC10F1527CA031F8A"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s8ABD20BC0EF0219AC10F1527CA031F8A">F-3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s74C58A14840D956F9C921527CA015076"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Operations and Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s74C58A14840D956F9C921527CA015076">F-4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s14873D07859E1E7F3A971527CA0061C6"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Convertible Preferred Stock and Stockholder&#8217;s Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s14873D07859E1E7F3A971527CA0061C6">F-5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD8110A3180B27636CF8E1527C9F7D4AD"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sD8110A3180B27636CF8E1527C9F7D4AD">F-6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s2564CE5E752C72968E611527D2E1E99A"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s2564CE5E752C72968E611527D2E1E99A">F-7</a></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s5C38304D5D19D4D224691527D1E731A4"></a></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Board of Directors and Stockholder of Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have audited the accompanying balance sheets of Evolus, Inc. as of December 31, 2016 and December 31, 2015 and the related statements of operations and comprehensive loss, convertible preferred stock and stockholder&#8217;s equity (deficit) and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States) and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Evolus, Inc. at December 31, 2016 and December 31, 2015, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:right;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:right;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:right;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Irvine, California</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">August 28, 2017</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s8ABD20BC0EF0219AC10F1527CA031F8A"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Balance Sheets</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Pro Forma</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">4,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">4,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">113</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Related party receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">68,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">81,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">77,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">146,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDER&#8217;S EQUITY (DEFICIT)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Current Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">2,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">46,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">59,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">68,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">48,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">63,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">69,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">21,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Note obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">122,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">69,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">84,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">213,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Commitments and contingencies (Note 5)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Convertible Preferred Series A, $0.00001 par value; 2,500,000 shares authorized; 1,250,000 shares issued and outstanding at December 31, 2015, 2016 and at June 30, 2017 (unaudited); no shares authorized and no shares issued and outstanding, pro forma (unaudited)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Stockholder&#8217;s equity (deficit)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Common Stock, $0.00001 par value; 20,000,000 shares authorized; 10,000,000 shares issued and outstanding at December 31, 2015, 2016 and at June 30, 2017 (unaudited); 11,250,000 shares issued and outstanding, pro forma (unaudited)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">58,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">59,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">6,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(46,741</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(66,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(73,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total stockholder&#8217;s equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">12,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(7,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(67,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Total liabilities, convertible preferred stock and stockholder&#8217;s equity (deficit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">81,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">77,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">146,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s74C58A14840D956F9C921527CA015076"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">20,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">12,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">6,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">4,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">9,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">7,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">5,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">2,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">116</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">30,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(30,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(19,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(12,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(6,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Other expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(31,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(19,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(12,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(6,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(31,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(20,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(12,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(3.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(2.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Weighted-average shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Pro forma net loss per share, basic and diluted (unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1.78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(0.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Pro forma weighted-average shares used to compute basic and diluted net loss per share (unaudited)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">11,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="s14873D07859E1E7F3A971527CA0061C6"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Statements of Convertible Preferred Stock and Stockholder&#8217;s Equity (Deficit) </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.84567901234568%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:36%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Convertible Series A Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Additional Paid in Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total equity (deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Balance as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">57,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(15,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">41,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Capital contribution - stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(31,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(31,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">58,743</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(46,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">12,002</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Capital contribution - stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(20,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(20,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">59,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(66,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(7,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Capital contribution - stock-based compensation (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deemed distribution to Parent - note obligation (unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(53,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(53,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(6,294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(6,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Balance at June 30, 2017 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">10,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">6,092</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(73,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(67,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="sD8110A3180B27636CF8E1527C9F7D4AD"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Statements of Cash Flows </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(31,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(20,065</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(12,162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(6,294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Adjustments to reconcile net loss to net cash used in operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">116</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Changes in assets and liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(Payment) release of restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">3,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(157</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1,373</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">2,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">1,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(2,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(1,029</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(104</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(408</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">46</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:72px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(36,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(13,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(8,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">(8,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">36,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">13,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">8,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">8,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">36,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">13,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">8,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">8,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Effect of exchange rates on cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;font-weight:bold;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Noncash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Related party receivable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(68,583</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Note obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">122,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">Deemed distribution</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(53,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s2564CE5E752C72968E611527D2E1E99A"></a></div><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s22B76C0B76398D896C1D1527D3139F76"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 1.&#160;&#160;&#160;&#160;Organization</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Evolus, Inc. (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. The Company&#8217;s focus is on the self-pay aesthetic market and its first product candidate, DWP-450, is an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Evolus was incorporated in Delaware in November 2012. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In October 2013, AEON-SCH, LLC (formerly known as Strathspey Crown Holdings, LLC) (&#8220;SCH&#8221;) acquired all of the Company&#8217;s outstanding equity in exchange for 15,000 Class AA units of SCH and 15,000 Class D units of SCH. On June 30, 2014, SCH contributed 90% of the Company&#8217;s then outstanding equity that it had acquired in October 2013 to ALPHAEON Corporation (&#8220;ALPHAEON&#8221;). On September 30, 2014, certain former stockholders of the Company (&#8220;Evolus contributors&#8221;) exercised a right held with the Class D units to compel SCH to sell the remaining 10% of the outstanding shares of the Company to ALPHAEON in exchange for certain payments required to be made by ALPHAEON. As a result of these transactions, Evolus became a wholly-owned subsidiary of ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company is headquartered in Santa Barbara, California.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Management Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company has adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Presentation of Financial Statements &#8211; Going Concern</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which requires that management evaluate whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity&#8217;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. However, t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">he Company has incurred operating losses since its inception and as reflected in the accompanying financial statements. The Company has an accumulated deficit of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">66.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which includes a net loss of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">20.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Additionally, the Company used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$13.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in cash for operations in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;2016 and the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. As of June 30, 2017, the Company has an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$73.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which includes a net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$6.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As a result of these conditions, management has concluded that, substantial doubt about the Company&#8217;s ability to continue as a going concern exists as conditions and events, considered in the aggregate indicate that it is probable that the Company will not be able to meet its obligations as they become due within one year after the date the financial statements are issued.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company&#8217;s management believes that it will be necessary to raise additional funding in the form of an equity financing from the sale of capital stock. The Company may in the future seek additional capital from public or private offerings of its capital stock or it may elect to borrow additional amounts under new credit lines or from other sources. If the Company issues equity or debt securities to raise additional funds, its existing stockholder may experience dilution, it may incur significant financing costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of its existing stockholder. The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise significant additional capital, of which there can be no assurance. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern, and do not include any adjustments that may result from&#160;the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the&#160;Company&#8217;s&#160;liabilities&#160;and commitments&#160;in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and&#160;classification of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The audit report covering these accompanying financial statements includes an explanatory paragraph that describes conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-7</font></div></div><hr style="page-break-after:always"><div><a name="sF85C8701EB172E1071181527CA11EC78"></a></div><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For comparative purposes, the Company derived its full year 2015 and 2016 and six months ended June 30, 2016 and 2017 financial results on a standalone basis from ALPHAEON&#8217;s financial statements and accounting records and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. These results reflect amounts attributable to the Company&#8217;s business, including the costs ALPHAEON incurred for the development, commercialization and license agreement with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Daewoong Pharmaceuticals Co. LTD. (&#8220;Daewoong&#8221;), a South Korean pharmaceutical manufacturer </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">described below in Note 4, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Related Party Transaction</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON charges the Company external and internal administrative and research and development expenses ALPHAEON incurs on the Company's behalf. External research and development expenses charged to the Company include costs for contract research organizations (&#8220;CROs&#8221;), costs to conduct nonclinical and clinical studies on its product, DWP-450, costs to acquire and evaluate clinical study data such as investigator grants, patient screening fees and laboratory work, and fees paid to consultants. ALPHAEON charges these costs to the Company at the same costs that ALPHAEON incurs. Internal development expenses include costs for the work that ALPHAEON development employees perform for the Company. ALPHAEON charges the Company a full-time equivalent rate that covers personnel-related expenses, including salaries and benefits, plus an allocation of facility-related expenses, including rent, utilities, depreciation, insurance and property taxes, for those research and development employees who work either directly or indirectly on the development of the Company's drugs and certain administrative employees. ALPHAEON calculates the facility-related expenses to the Company based on a percentage of aggregate expenses incurred at ALPHAEON. ALPHAEON calculates depreciation expense of property and equipment using the straight-line method over the estimated useful lives of its assets of 3 to 5 years.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company currently incurs related party borrowings from ALPHAEON for its share of the internal and external expenses for each of these functions based on the Company&#8217;s relative use of each function, plus an allocation of facility-related expenses. The Company&#8217;s management believes that the allocations and results are reasonable for all periods presented. However, allocations may not be indicative of actual expense Evolus would have incurred had it operated as an independent company for the periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has calculated its income tax amounts using a separate return methodology and has presented these amounts as if it were a separate taxpayer from ALPHAEON in each jurisdiction for each period the Company presented.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ materially from those estimates. The Company&#8217;s management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company&#8217;s management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, joint and several liability obligations, and realizability of income taxes, among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has not commenced principal operations in the form of commercialized product sales. The product candidate being developed by the Company requires approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency, and other similar regulatory authorities prior to commercial sales. There can be no </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">assurance that the Company&#8217;s current and any future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The accompanying interim balance sheet as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the statements of operations and comprehensive loss and cash flows for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the statements of convertible preferred stock and stockholder&#8217;s equity (deficit) for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared in accordance with GAAP and, in management&#8217;s opinion, on a basis consistent with the audited financial statements and reflect all adjustments, which only include normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and its results of operations and comprehensive loss and cash flows for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the statements of convertible preferred stock and stockholder&#8217;s equity (deficit) for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The results for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;are not necessarily indicative of the results to be expected for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">year ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;or for any other interim period.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Pro Forma Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The unaudited pro forma information in the accompanying balance sheet as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;assumes the conversion of all outstanding shares of Series A convertible preferred stock into common stock upon the closing of the of the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The pro forma balance sheet assumes that the completion of the IPO had occurred as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and excludes shares of common stock issued in the proposed IPO and any related net proceeds therefrom. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The unaudited pro forma net loss per share information for the six months ended June 30, 2017 assumes the conversion of 1,250,000 shares of Series&#160;A convertible preferred stock into 1,250,000 shares of the Company's common stock at the beginning of the period presented.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has determined that it operates in a single reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Restricted cash of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">4.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;at </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, represents cash required to be reserved to fund certain specified research and development activities related to the Company&#8217;s rights acquired pursuant to the contribution agreement; the restriction was released in 2016. Restricted cash of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;at </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, reserved pursuant to a contractual agreement amending the Evolus acquisition agreement, represents cash reserved for Evolus development costs and the advance of the product through the regulatory approval process at the FDA for the neuromodulator.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Rent</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company leases its Santa Barbara, California facilities under a non-cancelable operating lease. This lease is classified as an operating lease. For leases that contain rent escalation rent concession provisions, the Company records the total rent expense on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the anticipated lease term. The Company records the difference between the rent paid and the straight-line rent as deferred rent on the accompanying balance sheets. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There has been no impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The intangible asset in the accompanying balance sheets represents in-process research and development projects acquired that have not yet been completed. In-process research and development assets with indefinite useful lives that are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the in-process research and development assets are either amortized over their estimated useful lives or written-off immediately. There has been no impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Initial Public Offering Costs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Deferred offering costs, which primarily consist of direct incremental legal and accounting fees relating to the IPO, are capitalized. The deferred offering costs will be offset against IPO proceeds upon the effectiveness of the IPO. In the event the IPO is terminated, deferred offering costs would be expensed. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;of deferred offering costs were capitalized in &#8220;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Other assets</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#8221; on the accompanying balance sheet. No deferred offering costs were capitalized and deferred as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:justify;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Joint and Several Liability Assessment</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has (i) agreed to pay on the basis of its arrangement among its co-obligors, and (ii) any additional amounts that the Company expects to pay on behalf of its co-obligors. The </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">determination of the &#8220;best estimate&#8221; from within the range of amounts that might be paid involves substantial judgment by the Company&#8217;s management. These estimates are subject to periodic revisions at each period as the joint and several liability is re-measured. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel and personnel-related costs; costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product; internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings; overhead costs, including allocated facility related expenses. During the year ended December 31, 2015, $3.5 million of research and development expenses were reimbursed by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Teoxane Laboratories, SA (&#8220;Teoxane&#8221;)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, a related party as described in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Note 4, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Related Party Transaction</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. There have been no further reimbursements of research and development expenses through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">At each financial reporting date, the Company accrues and expenses the estimated costs of clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates based upon a review of the agreements, data collected by internal and external personnel regarding the progress or stage of completion of trials or services. This progress or stage of completion of trials or services is monitored pursuant to contracts with clinical research organizations and other service providers. The agreed-upon fee to be paid for such services are based upon facts and circumstances known to the Company at each financial reporting date. If the actual performance of activities varies from the assumptions used in the estimates, the accruals are adjusted accordingly. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has not granted stock-based compensation for the periods presented. However, the Company recognizes the fair value of the expense allocated to Evolus for all ALPHAEON stock-based grant arrangements with Evolus employees, including members of ALPHAEON&#8217;s board of directors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Compensation cost related to the grant of ALPHAEON awards to the Company&#8217;s employees is recognized in the statements of convertible preferred stock and stockholder&#8217;s equity (deficit) as a capital contribution. The Company recorded stock-based compensation expense for the years ended December 31, 2015, 2016, and the six months ended June 30, 2017 of $1.5 million, $1.0 million and $0.2 million, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Share-based compensation expense is allocated to the Company by ALPHAEON based upon the relative percentage of time utilized by ALPHAEON employees on Company matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The ALPHAEON common share awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service period. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">E</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">stimates were used to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">determine</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;the fair value of these awards, as they are not publicly traded. ALPHAEON common share awards are subject to specified vesting schedules and requirements. The Company estimated the fair value of each ALPHAEON option on the date of grant using the Black-Scholes model.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Compensation expense is allocated to the Company over the required service period over which these ALPHAEON common share awards and options would vest and is based upon the relative percentage of time utilized by ALPHAEON employees on Company matters.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, by the Company when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Basic and diluted net income per common stock are presented in conformity with the two-class method required for participating securities. All dividends shall be declared pro rata on the common stock and preferred stock on a pari passu basis according to the number of shares of common stock held by such holders.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Under the two-class method, net income attributable to common stockholders is determined by allocating undistributed earnings between common stock and Series A convertible preferred stock. In computing diluted net income attributable to common stockholders, undistributed earnings are reallocated to reflect the potential impact of dilutive securities. Basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In August 2016, the FASB issued new guidance that clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The guidance is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those years. The Company does not believe the adoption of the standard will have a material impact on the Company&#8217;s statement of cash flow. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In March 2016, FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Compensation - Stock Compensation Topic 718</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(&#8220;ASU 2016-09&#8221;), which is intended to simplify several areas of accounting for share-based payment arrangements. The amendments in this update cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted this standard in the first quarter of 2017. The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">had no excess tax benefits for which a benefit could not previously be recognized as of December 31, 2016.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;Upon adoption, the balance of the unrecognized excess tax benefits is reversed with the impact recorded to (accumulated deficit) retained earnings, including any change to the valuation allowance as a result of the adoption. Due to the full valuation allowance on the U.S. deferred tax assets as of December 31, 2016, there was no impact to the financial statements as a result of this adoption in the first half of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In February 2016, FASB issued final guidance for lease accounting. The new guidance requires lessees to put most leases on their balance sheet but to recognize expenses on their income statement in a manner similar to current accounting principles. The new guidance also eliminates the current real estate-specific provisions for all entities. The standard is effective for public companies for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is in the process of assessing the impact of the adoption of the standard on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In April 2015, the FASB issued ASU No. 2015-03,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">&#32;Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the corresponding debt liability rather than as an asset. Management adopted this accounting pronouncement as of December 31, 2016. The adoption did not have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(&#8220;ASU 2015-17&#8221;), which requires entities to present deferred tax assets (&#8220;DTAs&#8221;) and deferred tax liabilities (&#8220;DTLs&#8221;) as noncurrent in a classified balance sheet. The ASU simplified the previous guidance, which required entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. The adoption of ASU 2015-17 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Early adoption is permitted. The Company elected to early-adopt this guidance and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">applied it retrospectively to periods presented in the financial statements.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;The </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">adoption did not have a material impact on the accompanying financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on our present or future financial position, results of operations or cash flows.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-13</font></div></div><hr style="page-break-after:always"><div><a name="s9D14624E7B1B2D41B3AB1527CA100D62"></a></div><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 3.&#160;&#160;&#160;&#160;Goodwill and Intangible Asset</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There was no change in the carrying value of the goodwill </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">for all periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There was no impairment loss recognized during the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Asset</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company&#8217;s intangible asset consists solely of in-process research and development projects acquired in an acquisition. There was no change in the carrying value of the intangible asset for all periods presented. There was no impairment loss recognized during the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The intangible asset is recorded as an indefinite lived asset and therefore, no </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">amortization was expensed during the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, or the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Amortization expense will commence upon FDA approval of the DWP-450.</font></div><div><a name="sC9EFFE0DCDDF184274131527CA39402B"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 4</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Services with ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Since </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">becoming a wholly-owned subsidiary of ALPHAEON</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;in 2014, the Company has funded its operations primarily through contributions and related party borrowings from ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON provides Evolus certain services, including, without limitation, research and development, general and administrative support services and support services. ALPHAEON has allocated a certain percentage of personnel to perform the services that it provides to the Company based on its good faith estimate of the required services. Evolus pays ALPHAEON for these allocated costs, which reflect the ALPHAEON full-time equivalent (&#8220;FTE&#8221;), rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing Evolus these services. Evolus does not pay a mark-up or profit on the external or internal expenses ALPHAEON allocates to it. All research and development, general and administrative, and other support services expenses shown in the Company's financial statements for 2015 and 2016, and the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, excluding stock-based compensation which is treated as a capital contribution, were treated as related party borrowings from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In addition, as long as ALPHAEON continues to consolidate Evolus&#8217; financial statements, Evolus will comply with ALPHAEON's policies and procedures and internal controls. As long as Evolus is consolidated into ALPHAEON's financial statements under GAAP, Evolus will continue to obtain these services from ALPHAEON.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, Evolus owed ALPHAEON </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$46.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$59.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table summarizes the amounts included in Evolus&#8217; general and administrative expenses that were generated by transactions with ALPHAEON for the following periods (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Compensation &amp; Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Third party service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">5,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">3,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">3,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Office related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">510</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">179</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">10,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Teoxane Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In April 2014, ALPHAEON and Evolus entered into an agreement with Teoxane, SA (&#8220;Teoxane&#8221;), for the rights of its license, distribution and development of DWP-450 in the European Union. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">During the year ended December 31, 2015, $3.5 million of Evolus research and development expenses was reimbursed by Teoxane. There have been no further reimbursements of research and development expenses through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Teoxane&#8217;s Chief Executive Officer was a member of ALPHAEON&#8217;s board of directors from January 2014 through July 2016.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Evolus Contributors</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Certain of the Evolus contributors, from whom SCH purchased its equity interests include individuals employed by the Company in operational roles, including J. Christopher Marmo, Ph.D., the Company&#8217;s Chief Operating Officer. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Note Obligation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In 2016, ALPHAEON entered into two separate debt transactions: (i) a convertible note with one of its shareholders, also a related party (the &#8220;Bridge Note&#8221;) with a principal amount of $2.5 million and (ii) a Secured Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which ALPHAEON could issue up to an aggregate of $55.0 million (&#8220;Note Facility&#8221; and together with the Bridge Note, the &#8220;Notes&#8221;). As of December 31, 2016, the principal drawn on the Notes was $24.0 million. The Notes have substantially similar terms and accrue simple interest at a rate of ten percent (10%) per annum, subject to adjustment pursuant to terms of the Notes. The Notes may be paid at a redemption price equal to 2.5 times the face amount of the Note less any prepayment of principal and any principal amount of the Notes that may convert into shares of ALPHAEON on (i) maturity in December 2018, (ii) a required prepayment event, or (iii) prepayment at any time at ALPHAEON&#8217;s election. Upon the occurrence of certain corporate events at ALPHAEON, at the election of the holder, the Notes will convert into a variable number of shares of ALPHAEON with an aggregate fair value equaling the principal value of the Notes or such Notes will continue to maturity as unsecured promissory notes with a reduced interest rate.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ALPHAEON&#8217;s obligations under the Notes are secured by a first priority lien and security interest in substantially all of ALPHAEON&#8217;s assets, including all of the shares of the Company&#8217;s capital stock held by ALPHAEON, which as of December 31, 2016 represented all of our outstanding capital stock, as collateral for the holders of the Notes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In April 2017, ALPHAEON entered into an Amended and Restated Secured Convertible Note Purchase Agreement with the Note holders to amend and restate the terms of the Purchase Agreement and the outstanding Notes and form of Notes to be issued. In addition, the Purchase Agreement was amended and restated to, among other things, set forth the terms for the issuance of up to an additional $30.0 million in principal amount of Notes. Concurrent with the amendment and restatement of the Purchase Agreement, the Company also executed two substantially similar guaranty and security agreements (the &#8220;Guarantee Agreements&#8221;), with the holders of the Notes. Pursuant to the Guarantee Agreements, the Company absolutely, unconditionally and irrevocably guaranteed, as primary obligor and not merely as surety, the full and punctual payment when due, whether at stated maturity or earlier, by reason of acceleration all the obligations of the Notes. In addition, pursuant to the Guarantee Agreements, the Company agreed to a first priority lien and security interest in and to all its right, title and interest in the assets of the Company.  As a result of executing the Guarantee Agreements, there is no requirement that the holders of the Notes first seek payment from ALPHAEON. Instead, they may demand payment from the Company, from ALPHAEON or from both simultaneously.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Amended and Restated Secured Note Purchase Agreement and Guarantee Agreements stipulate that any payment by the Company under their terms shall result in a dollar-for-dollar offset and reduction in the amount of intercompany loans owed by the Company to ALPHAEON. The Guarantee Agreements will terminate upon the earlier of (i) the date on which all secured obligations under the Guarantee Agreements have been paid and performed in full and (ii) the date on which the entire outstanding principal amount of the Notes has been either converted into equity or unsecured notes pursuant to the terms of the Notes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Concurrent with the execution of the Guarantee Agreements with the holders of the Notes in April 2017, the Company jointly and severally agreed to pay the redemption amount of 2.5 times the principal amount of the Notes upon maturity if not paid by ALPHAEON. As a co-obligor to these Notes, the Company applied the accounting guidance provided in ASC 405-40, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Obligations Resulting from Joint and Several Liability Arrangements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. This guidance requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount that the entity has (a) agreed to pay on the basis of its arrangement with its co-obligors and (b) any additional amount that the entity expects to pay on behalf of its co-obligors. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company recorded a liability and corresponding deemed distribution to its parent as a reduction to additional paid-in-capital in equity as of April 2017 to reflect the joint and several liability.  As the Company and ALPHAEON had not agreed to what portion of this joint and several liability each would pay, the Company developed a range of amounts that it expects to pay under the Guarantee Agreement and selected the amount from within that range that it determined to be the best estimate, which equaled </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date), representing the total principal amount due to the Note holders upon redemption of the Notes at maturity. As provided for within the Amended and Restated Secured Convertible Note Purchase Agreement and Guarantee Agreements, in conjunction with its recognition of the joint and several liability, the Company also recorded a receivable from ALPHAEON, which equals the current balance of the amounts it owes to ALPHAEON under its intercompany borrowing arrangements. No amounts have been paid under this joint and several liability by the Company in the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">six months ended June 30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the liability recorded by the Company to the Note holders pursuant to the above joint and several liability was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$122.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(2.5 times the outstanding principal amount of the Notes as of that date) and the related party receivable was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$68.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, representing the amount by which related party borrowings could be reduced purs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">uant to the terms of the Amended and Restated Secured Convertible Note Purchase Agreement and Guarantee Agreements. The difference between the amount of the joint and several liability and the related party receivable of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$53.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was recorded as a deemed distribution to ALPHAEON, which caused a corresponding reduction in additional paid in capital.</font></div><div><a name="s2287F0E969F06DFD977C1527CACCE90A"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 5</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company leases its Santa Barbara, California office under an operating lease. The office lease is with a third-party vendor under a non-cancelable operating lease. The office lease includes rent escalation clauses which are recorded on straight-line basis with t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">he difference between the rent expense accounted for over the term of the lease and actual amounts paid</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Rental</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;expense for the years ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and the six months ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$0.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Future minimum payments under operating lease agreements with non-cancelable terms greater than one year as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;color:#231f20;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2018</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2019</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;">584</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">FDA Milestone Payments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In connection with a license and supply agreement, as described in detail below, the Company is obligated to make future milestone payments for certain confidential development and commercial milestones associated with DWP-450. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In October 2013, SCH entered into a license and supply agreement with Daewoong. Pursuant to the license and supply agreement (&#8220;Daewoong Agreement&#8221;), the Company has an exclusive distribution license to DWP-450 from Daewoong for aesthetic indications in the United States, European Union, Switzerland, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Company also has an option to exercise a similar license in these territories for therapeutic indications by the end of 2018. DWP-450 will be manufactured by Daewoong in a recently constructed facility in South Korea that is designed with the intention of complying with FDA and the European Medicines Agency&#8217;s current Good Manufacturing Practice requirements. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than DWP-450), in a territory covered by the Daewoong Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Daewoong Agreement also includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;The Company may, however, meet these minimum purchase obligations by achieving certain market share in its licensed territories. T</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">hese potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. The Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. No amounts were accrued as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company, ALPHAEON, SCH and Daewoong are defendants to a lawsuit brought by Medytox, Inc.(&#8220;Medytox&#8221;) alleging, among other things, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture DWP-450. The Company intends to vigorously defend Medytox&#8217;s claims. Given the early stage in the Medytox litigation, the Company is unable to determine the likelihood of success of Medytox&#8217;s claims against Evolus. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In accordance with the Company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">as they will be in effect upon completion of this offering, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date and the Company has a director and officer insurance policy that may enable it to recover a portion of any amounts paid for future claims.</font></div><div><a name="sF5A4A42F1DCECA6FE11F1527C9FEC370"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 6.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company&#8217;s loss before income taxes generated from its operations were (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Loss before income taxes:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">United States</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(31,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(19,972</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total loss before taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(31,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(19,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total current provision</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total deferred provision</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company has federal NOL carryforwards of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">44.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">63.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;respectively, which will begin to expire in year 2034. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company has stated NOL carryforwards of $44.0 million and $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">63.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, which will begin to expire in year 2034. NOL carryforwards generated by the Company have been included in the consolidated and unitary income tax returns of ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As of December 31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of $0.6 million and $0.9 millions, respectively, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of $0.6 million and $0.9 million, respectively, which has an indefinite carryforward period. Deferred tax assets in the accompanying financial statements are presented as if the Company filed separate income tax returns. Accordingly, the NOL and credit carryforwards allocable to the Company based on ALPHAEON&#8217;s consolidated and unitary income tax returns may ultimately differ from those presented in the financial statements on a separate return methodology.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The deferred expense for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">U.S. Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">U.S. State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total deferred provision</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period (a &#8220;Section 382 ownership change&#8221;), utilization of its pre-change NOL carryforwards and the R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards and R&amp;D credit carryforwards before utilization and may be substantial. As of December 31, 2016, the Company has not determined if ownership change has occurred which would limit the Company&#8217;s utilization of its NOL carryovers and R&amp;D credit carryforwards.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The components of deferred tax assets and liabilities were as follows </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">(in thousands)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred income tax assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">27,291</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Intangible asset</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,054</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(29,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,245</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(21,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company recorded deferred tax assets of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">21.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">29.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively, which have been fully offset by a valuation allowance. The valuation allowance </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">increased</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$8.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$14.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, during </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, respectively. The increase in the valuation allowance in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;was due to an increase in net operating loss carryforwards from operating losses and stock-based compensation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">A reconciliation of the difference between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows for the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">years ended December 31,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(10,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(6,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Income tax provision</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The tax-effected amount that would reduce the Company&#8217;s effective income tax rate if recognized is $0.0 million. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,812</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There was no accrued interest and penalties associated with uncertain tax positions as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The Company&#8217;s tax returns for all years since inception are open for audit. </font></div><div><a name="sA4393FD12A585D1DD3D21527CA3C50BB"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 7.&#160;&#160;&#160;&#160;Stockholder&#8217;s Equity (Deficit)</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Series A Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company had 2,500,000 shares of Series A convertible preferred stock authorized, of which </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">1,250,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;were issued or outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The holder of Series A convertible preferred stock has the following rights and preferences for all periods presented:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Dividends</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The holder of Series A convertible preferred stock is entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company&#8217;s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock. Such dividends are noncumulative. The dividend rate for the Series A convertible preferred stock per share per annum is $0.032. To date, the Company&#8217;s board of directors has not declared any dividends.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Conversion</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. Each share of Series A convertible preferred stock is convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, into fully paid and nonassessable shares of the Company&#8217;s common stock. Conversion of all shares of Series A convertible preferred stock is automatic upon (i) the closing of a public offering of common stock with gross cash proceeds of at least $15.0 million; or (ii) affirmative election of at least a majority of the shares of preferred stock outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The number of shares of common stock to which a preferred stockholder is entitled is the product obtained by multiplying the convertible preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the Amended and Restated Certificate of Incorporation. As of December 31, 2015 and 2016, all shares of Series A convertible preferred stock were convertible into common stock on a one-for-one basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Series A convertible preferred stock conversion rates are subject to adjustment in accordance with the Amended and Restated Certificate of Incorporation. Adjustments include any future stock splits or stock combinations, reclassifications or exchanges of similar shares, or upon a reorganization, merger or consolidation of the Company. In addition, the Series A convertible preferred stock is subject to adjustment upon a future equity issuance at a price per share below the stated conversion price for the Series A convertible preferred stock, subject to certain exceptions in the Amended and Restated Certificate of Incorporation. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Redemption</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The Series A convertible preferred stock is not mandatorily redeemable, as it does not have a set redemption date or a date after which the shares may be redeemed by the holders. However, the Company has classified the Series A convertible preferred stock as temporary equity on the balance sheet as these shares can be redeemed upon the occurrence of certain change in control events that are outside the Company&#8217;s control, including liquidation, sale or transfer of the Company. The Company has elected not to adjust the carrying values of the Series A convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">occur that would obligate the Company to pay the liquidation preferences to the holder of shares of Series A convertible preferred stock and at the balance sheet dates, these circumstances were not probable. Subsequent adjustments to the carrying values of liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. &#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Voting and protective provisions</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. The holder of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which each share of preferred stock is convertible as of the record date for the vote and votes together as one class with the common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As long as any shares of Series A convertible preferred stock remain outstanding, the holder of Series A convertible preferred stock and the holders of common stock, voting together as a single class, will be allowed to elect three directors of the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As long as any shares of Series A convertible preferred stock are outstanding, the Company is required to obtain approval by a majority of the holders of the Series A convertible preferred stock prior to such actions as a liquidation event, amendment to the underlying certificate of incorporation, declaration of a dividend, issuance of any equity security with preference above or parity to the existing preferred stock and other matters. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Liquidation preferences. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In the event of a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily, and upon certain other defined events, the holder of Series A convertible preferred stock is also entitled to receive a liquidation preference in amounts per share equal to the original issue price plus the amount of any declared and unpaid dividends on such shares of Series A convertible preferred stock. Liquidation preferences are made in preference to any payments to the holders of common stock. If the funds or assets from the liquidation event are insufficient to pay the holder of Series A convertible preferred stock its full liquidation preference, then all the funds or assets would be distributed to the holder of Series A convertible preferred stock, or among the holders of Series A convertible preferred stock on a pro rata, pari passu basis, according to the liquidation preference, if there is more than one holder of Series A convertible preferred stock. If there are funds remaining after the payment of the liquidation preference to the holder or holders of the Series A convertible preferred stock, as the case may be, then all remaining funds shall be distributed to the holders of the common stock, pro rata based on the number of shares held by each such holder.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, the Company had 20,000,000 shares of common stock authorized, of which </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">10,000,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;were issued or outstanding.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Allocated to the Company</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has not granted stock-based compensation for the periods presented. However, t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">he Company recognizes t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">he fair value of the expense allocated to Evolus </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">for all ALPHAEON stock-based grant arrangements with Evolus employees, including members of ALPHAEON&#8217;s board of directors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table summarizes stock-based compensation expense (in thousands) which was allocated to Evolus by ALPHAEON:</font></div><div style="line-height:125%;padding-bottom:12px;padding-top:9px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#333333;">1,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Deemed Distribution</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">On April 19, 2017 and as a result of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the Guaranty Agreement, as described in Note 4, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">Related Party Transaction</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">the Company recorded a non-cash deemed distribution&#160;in the amount of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">$53.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">to ALPHAEON. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">This amount was the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-weight:bold;">(Information as of June 30, 2017 and thereafter and for the six months ended June 30, 2016 and 2017 is unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">difference between the amount of the joint and several liability and the related party receivable, which caused a corresponding reduction in additional paid in capital. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">As ALPHAEON&#160;is the sole stockholder of the Company, there were no earnings per share adjustments considered necessary.</font></div><div><a name="sE6B0E875A7232B6D7E4C1527D55B874E"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Note 8.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The Company has evaluated subsequent events through August 28, 2017. After review and evaluation, management has concluded that there were no material subsequent events as of the date that the financial statements were available to be issued, other than as noted below. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In July 2017, ALPHAEON issued an additional $5.0 million of convertible promissory notes under the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Amended and Restated Secured Note Purchase Agreement</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">. As a result of this additional issuance, the total note obligations under all the Notes increased to $134.9 million (2.5 times the total outstanding principal amount of the Notes).  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">F-22</font></div></div><hr style="page-break-after:always"><div><a name="s382E80537809CA9E9EAF1527DE990CAD"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="higherreslogowithtma01.jpg" alt="higherreslogowithtma01.jpg" style="height:80px;width:296px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;____________________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PRELIMINARY PROSPECTUS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">____________________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:125%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#231f20;font-weight:bold;">Jefferies</font></div><div style="text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#231f20;font-weight:bold;">Mizuho Securities</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">, 2017</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sFBB4EE69350D599680841527DECBFEEB"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div><div><a name="s5E34863DAA465982CA6E1527DEEA62F0"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 13.&#160;&#160;&#160;&#160;Other Expenses of Issuance and Distribution.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market listing fee. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:82%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amount to be paid</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">SEC registration fee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FINRA filing fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Nasdaq Global Market listing fee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Blue sky qualification fees and expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Printing and engraving expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Legal fees and expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accounting fees and expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Transfer agent and registrar fees and expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Miscellaneous expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To be provided by amendment.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s6A9BF52F8A9D9CCEE8FB1527DF1E31F0"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 14.&#160;&#160;&#160;&#160;Indemnification of Directors and Officers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We are incorporated under the laws of the State of Delaware. Section 145 of the DGCL provides that a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. Except in the case of an action by or in the right of the corporation (</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;">i.e.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">, a derivative action), the indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. With respect to an action by or in the right of the corporation, the indemnity may only include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except that no indemnification is permitted without judicial approval if such person is adjudged to be liable, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">unless the Delaware Court of Chancery, or the court in which such action or suit was brought, determines that despite the adjudication of liability, such person is fairly and reasonably entitled to indemnity for such expenses. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Where a present or former officer or director is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above, the corporation must indemnify him or her against the expenses (including attorneys&#8217; fees) by him or her in connection therewith. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our amended and restated certificate of incorporation and amended and restated bylaws, each of which will become effective upon the completion of this offering, will provide for the indemnification of our directors and officers to the fullest extent permitted under the DGCL.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">II-1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">transaction from which the director derives an improper personal benefit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">willful or negligent violations of Delaware law governing the authorizations of dividends, stock repurchases, and redemptions, as provided in Section 174 of the DGCL; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:7pt;color:#000000;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">breach of a director&#8217;s duty of loyalty to the corporation or its stockholders.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Our amended and restated certificate of incorporation will include such a provision. Expenses incurred by any of our officers or directors in defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Section 174 of DGCL provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of such action.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We have entered into or intend to enter into separate indemnification agreements with our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or as a director, officer, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">employee or agent </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">of any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Except as otherwise disclosed under the heading &#8220;Legal Proceedings&#8221; in the &#8220;Business&#8221; section of this registration statement, there is at present no pending or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers and we intend to maintain such insurance coverage. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities. </font></div><div><a name="sF665A4959AFD90906E541527DF3E03CF"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 15.&#160;&#160;&#160;&#160;Recent Sales of Unregistered Securities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">There have been&#160;no sales&#160;of unregistered securities since January 1, 2014</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">.</font></div><div><a name="sE57338135F20EF4F02D41527DF716CB9"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 16.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Exhibits.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">See the Exhibit Index attached to this registration statement, which is incorporated by reference herein.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Financial Statement Schedules.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</font></div><div><a name="s4A75F4FCE64E24798E741527DF934CEF"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 17.&#160;&#160;&#160;&#160;Undertakings.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">II-2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">The undersigned hereby undertakes that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">II-3</font></div></div><hr style="page-break-after:always"><div><a name="s4D68B9E48DDB960359E41527DFC58421"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Barbara, State of California, on the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;day of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:328px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:43.05555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#231f20;font-weight:bold;">EVOLUS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Murthy Simhambhatla, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Murthy Simhambhatla, Ph.D. and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Chief Executive Officer and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Member of the Board of Directors</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Murthy Simhambhatla, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6C5EC9CBB0D9F8F928951527DFE65DEF"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sCC3D72A337DC44D8C4551527CC0B909C"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Title</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Underwriting Agreement.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amended and Restated Certificate of Incorporation, as currently in effect.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Amended and Restated Certificate of Incorporation, to be effective in connection with the completion of this offering.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.3*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Bylaws, as currently in effect.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.4*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Amended and Restated Bylaws, to be effective in connection with the completion of this offering.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Specimen certificate evidencing shares of common stock of the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Stockholder Agreement by and between ALPHAEON Corporation and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Opinion of K&amp;L Gates LLP.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.1&#8224;*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Contribution Agreement, dated as of October 3, 2013, by and among Strathspey Crown Holdings, LLC, the Registrant, the Shareholders of the Registrant, and J. Christopher Marmo, as the Shareholders&#8217; Representative.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.2&#8224;*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.3&#8224;*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.4&#8224;*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.5+*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2017 Equity Incentive Plan, and Form of Incentive Stock Option Agreement, Nonstatutory Stock Option Agreement and Restricted Stock Purchase Agreement.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.6+*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Indemnification Agreement by and between the Registrant and its directors and officers.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Services Agreement by and between ALPHAEON Corporation and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.8*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Lease, dated February 5, 2015, by and between J. Carol Duncan, Tyler J. Duncan and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amended and Restated Intercreditor Agreement, amended and restated as of April 19, 2017, by and among Longitude Venture Partners II, L.P., Dental Innovations BVBA, ALPHAEON Corporation and the Registrant. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.10*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Guaranty and Security Agreement, dated as of April 19, 2017, by and between Dental Innovations BVBA and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.11*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Guaranty and Security Agreement, dated as of April 19, 2017, by and between Longitude Venture Partners II, L.P. and the Registrant.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">List of subsidiaries.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">23.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consent of Ernst &amp; Young LLP, an independent registered public accounting firm.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">23.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consent of K&amp;L Gates LLP (included in Exhibit 5.1).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">24.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Power of Attorney (included on signature page hereto).</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:195px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:194px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To be filed by amendment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">+</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicates management contract or compensatory plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Registrant intends to seek confidential treatment with respect to certain omitted portions of this exhibit.</font></div></td></tr></table><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>higherreslogowithtma01.jpg
<TEXT>
begin 644 higherreslogowithtma01.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_XGT024-#7U!23T9)3$4  1(
M"(!P041"10(0  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03
M  !!1$)%                        ]M8  0    #3+4%$0D4
M                                                      ID97-C
M    _    '1C<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!
M,D(R   !L   H@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  "
M.+1",D$R  6W*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E
M8B!#;V%T960@*%-73U I('8R
M
M         '1E>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@
M26YC+@  6%E:(        +5:  "\9P  DC!M9G0R      0#"0   0
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M_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ
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MN7U2DHL9/'W&CO#UA7JJNEW=67J?M$C$IWJSKHNK?'KPJ3V1XGM,I$YWLGO
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MB'Q02H?+AW8T=H=YAP4.^HE6AKO81X\(FY+#+HTRF'NM@8N&E9>7'HH3DOV
M%XCHD+YH4X?FCKQ/6X<3C/\SG8;"C!T.%(@HB836Z8Y*IA7!T8QXHB:L)(K4
MGG.5THEHFPI^YH@RE^IG2X<^E2U.?89ODLPRV88<D<$-3H<EB/_5IXVQL,?
MFXOBK "J]HH^IW>4M(C6HT%]XH>DGUQF6(:GF]I-M87=F/DR+(6*E_(,J(9+
MB(_4D(TSNZ6_DHMGM@6I\HG"L*:3OHA;JZ1]"H<PIPAEGH8VHN=-#(5?GZ\Q
MG84+G3\,'H67B#'3HXS+QL>^LXL#P$FI%HE>NA22YX?TM$E\0H;,KP1D]H7<
MJG=,AX4%IV4Q)(2BH3H+KH4$A^;2X(QRTE>]^XJPRO&H78D-P^&2,8>CO5-[
MG89ZMWQD:86+LL=,#82]KF<PMX1<H/ +582.AZG,^YOR>UNXDYE'>R&C]I:X
M>PF.WI1@>R9Y%9)%>WAB:9!E>_E*<H[:?),O8XXU?7X*?I ??\#+.IKBA/VW
M9I@C@^>C 969@OR-^I--@DMX*Y%#@=AA?(]U@9I)?HWW@8$N>8U7@>,)SXZ;
M@PC)TYG?CJVV')<EC,*AY928BOB,X9);B8EW(9!>B%1@@XZ>AUY(F(TJAJ M
MIXR,AIT)-8U'A>C(J)CGF(ZTXY8]E<Z@IY.]DS2+NY%RD.UV X^&CO]??XW2
MC5)'L8QFB_LLWHO,B\T(KXP?A=_'?)@LHH:SQI6$GOJ?>Y,+FZR*A)#2F*IT
M[([9E?1>CXTQDZ!&[HO%D<0L.XLGD;X(/(LAA9'&7Y>;K*6RLI3UJ%F>;))^
MI$J)A)!*H(UT 8Y3G2-=N(R=FB=&08LTE_<KKHJ4ESL'VXI,A5#%9I<FMNRQ
MR92 L=Z=B9((K0Z(JH_5J)IS0(WEI(]=$XPPH1-%L8JTGM,K.HH2F\@'BXF;
MA1K$DI;#P7BQ!Y0>NZ6<R9&GMA:'[H]RL.YRCXV%K%5<?8O:J)E%/HI<ID$J
MV8FHG/D'2HD+A.[#XI9NS'FP9Y/*Q=B<*)%6OX6'3H\CN;-Q_HTVM*I< XN-
ML1-$U8H:K$(J?(EIG+H'%HB9A,N]/Z70>GJJ'*)H>DV6T9\<>D6#%)P(>G)N
MG9DX>M19+):R>V1"4Y2B? HG\Y/S?/T$JI-_?Z:[LZ3B@Y2I*J%:@IR6%9X*
M@=""8)K]@3YMVY@Z@.M88Y7"@,Y!@I.\@-LG-),+@74$:)(#@IJZB*/KC,*H
M%Z!HBP&5))T5B6Z!:YH7B"EL\9==AR=7BI3OAF9 O)+NA>@FCI(XAEL$+Y"T
M@M2Y?*,;E?6F_9^CDWJ3_YQ9D3F 7YE.CS-K]9:=C9%6K90TC#%  I(TBSDE
M^9%WB]D#_8^2@K*XEJ)5GVBF"I[IG#.2_INJF3]_5IBFEHMK!)78E"Y5V9-\
MDC\_4I%^D.PE;I"_D58#TXZ9@I:WHZ'(J0*E-9Y5I162+IL1H6M^@I@1GAEJ
M.956FR)5(I+KF*P^PY#LES\E 9 GE@L#KXW(@GVVRZ%7LKVD;9WAKAZ1;)J=
MJ<9]RI>@I=%IEI3KHE)4EI* GX,^3Y!LGE0DK(^@F,P#D8T:@FFV#Z#^O+:C
MQIV"MV&0RIH]LEQ]+)<_K<QI 92.J>!4%Y(MIPT][Y 2I,,D98\PF)L#>8R-
M@EFU<:"OQRRC/)TMP1>009GJNU]\I9;PMC]HB)1 LA)3LY'@KT<]FX_2J:@D
M'X[TF&P#98P=@DRN'J_^>>2<*:O>>;:*$*?>>;)WBJ07>>9D1Z"8>E!/^9US
M>N8Z'YKV>XT@*9J8?'$  )73?\JLSJ\H@H.;:*KD@9F)?J;:@.!V^Z,3@&-C
MJ)^;@"9/4YQ_@",Y=)H%@$P?H9F6@1<  )2.@ "KWZX]BRZ:BJG^B8V(O:7M
MB!IV,:(PAOMBY)Z\AB!.GYNFA8XXU9DLA4L?+IBKAD8  )-P@ "K$JUJD^>9
MJJDWD9J'S*4PCX1U4*%HC;UB$IW\C%%-Z)KHBS@X09AJBJ(>RI?7B[,  ))X
M@ "J0:S*G+28VJB8F<*&\Z24EQ=T=:#/E,!A39U+DK!-0IH]D2@WOY>XD&L>
M=9<4D&$ "Y&2@ >ID*PLI<R8+Z?\HC&&2*/YGN)SRJ UF^]@JIRRF5Q,KYF/
MEVLW39<*EN4>*)9?E%@ &Y#$@!*HXJNYKP.7HJ=]JKB%PJ-RIL-S0)^LHT-@
M*9PVH$],09D<GCLV]I: G7T=\Y7(E$  *) 9@!NH0JMAN'27&:<;LWN%0Z,-
MKN=RR)](JN1?NYO6IZE+X9C%I>,VL)8CHNL=S)5/E"8 ,X^/@"*GN:L5PEZ6
MIJ;$O*N$UJ*VMW%R8I[VLOI?8YN&K[I+G)AUK1\V>Y7=I-8=IY4)E T /(\@
M@"B?L+J$>72.U;6K>3I]T;#\>3)L9*R+>6=:.*AD>=1&[Z2N>FHQZZ'F>P<7
M\*)R>[X  )$H@ ">IKFV@:2.0K3"@+U]8K %@ UK\ZN,?YY9N*=D?W)&;*.N
M?X,Q;*#>?\$7L*$[@+H  )!N@ "=][C+B=6-FK/>B$E\SZ\:ANYK5:JCA>U9
M'J9ZA31%X:+&A,PP^I_LA,07@: <A@0  (_+@ "=:+?SDA",^+,/C^=\&JY2
MC?MJJJG.C&-8?:6KBRU%6:'VBE<PE9\3BBP77)\<BK   (\^@ "<U;=&FFF,
M8K)AEZ9[>ZVFE31J!JDDDQA7[:3PD5U$X:$_D#4P/IY2D"H7/IXVCK@  ([$
M@ "<.[:_HNZ+V;'1GY)Z^JT/G(]IBZB/F?A7>:1:E]9$?:"2EG O^)V>EJ07
M)YUGCZ@  (Y>@ ";R+8VJZ"+<+%$IZ5ZF*R"I!-I+Z@$H057):/4GI=$.: (
MG4DOQ)SPG"<7%9RHCYL  (X*@ ";2K77M(R+(K#4K]MZ5ZP#JZMHZ:=YJ#%6
MWZ-+I;!#_)^5I)XOG)R&H#$7%9P7CYL  (W%@ ":V;6&O>N*R[!TN(-Z#JNA
ML[9HK*<;K^-6LJ+OK:!#WY\XJJ<OD9POH"D7'YNVCZ(  (V.@ "1\\5C>1B"
M'[_2>,MR%KI\>+EAH[5I>.I0<;"G>5,^"ZQS>>0IIJF6>FH/9JM9>PL  (U#
M@ "1-\2+@.:!MK[S?_AQPKF0?TIA2K1M?N)0#:^>?L0]K:M??N4I7:AF?S(/
MA:G#@$0  (S^@ "0S<.2B*B!1[X(AR=Q7KB>A=Q@V[-UA/-/H:Z?A%D]4JI:
MA!DI(Z=*A$X/KZA/A.X  (S!@ "0@<*ID&N Z+TCCE]PZ;>\C)5@:[*&BR9/
M.JVRBB4] *EJB9,H]J9(B>,/VJ<$B0(  (R,@ "0+,'HF$^ E+Q;E;5PDK;P
MDW1@"[&[D95.Z*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&*
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M<'S#>HIWNWT[>Q9<]GW#>ZH_UGYX?%P;%G_1?0_P7'F0A._9.GH'@^C!<7J
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MFAM0.'WYEPLT7GXRE5\.>WZ B<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB"
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M?W<;?:Z2?ZL$EZQ)@'4  (,A@ ![<,?HB11M?<)SAYY?%[T1AF=0);?4A85
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MG-,<>*C@DT &AZ7KA&H  (,<@ !ZW,2=KSYM/K[AJY-?";DXJ%M0*K/,IC-
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MKGU0"G2.JDDT8W3]HR@.]'2?BAS6%7\.<;;!Y7\0<LJL]'\=<\^7'W\U=-&
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MM*"D=X5ZPYW!=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P  (4
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M!:6*I+UKYZ'DH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P  (
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M!;)Q@[!BQJX]@O%3RJHX@F9#R::6@A0R<J.D@? >I*)B@A8&MJ%_@>0  (
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MT*\KJ59AA*K!IEU29*:"H^M"D**MHL,QE)^/G_,>=IW)E)D'H)O%A2@  (
M@ !RK\5(;-YEI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@
M *LI='L  (  @ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_
M=B$5%:_$=;L #ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<Z
MB+$#>Q(IGJWR>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ
M@4))J+/2@,PZ9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME
M7[P'B,A7P+=%A[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (
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MI()@LS.$7H%\KNMR/("IJJ!??( 0IN]+UW^OI'HVS7]8H7D=GG\-E <  (
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M (WBC!![^(Q>BNEK"(KVB;]9+8FUB+)&'(B^A]PQ68@7AU 7L(C&AU@  (
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MUYQ,:HUSWYH";#1CQ)?O;<52AY8+;TD_[)2&<+$K2I/H<;,0;);><2\  (
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M%Y9XD<MP 90\D$!@"I(?CKI/,Y SC6 ])8Z?C&HI(HVVC%T/BX[ B9$  (
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MWJ36<4=GK:'G<BQ8@9\G<Q9(,)RK<_XV9YK#=,LB*YI'=1X(@)MT=3$  (
M@ ""EJ:6>&AU/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(
MG9EG>J<  (  @ "" *5"@%!TD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I
M?U\AH9=U?U@(KI>+?Y,  (  @ "!9*0EB$=S\*$DAWAEM9X\AJU6GYMYA?%&
MEICZA5PU&Y</A0(A6I9"A10(O)7?@]$  (  @ " V*-+D%]S:*!.CQEE+IUA
MC<M6%9J8C(]&$Y@2BX@TR)8'BO$A*Y4DBV((S)1@A?,  (  @ " ;:*0F(=R
M]Y^9ELYDN)RHE0)5G9G:DTU%II=1D?(T=Y4\D5LA%90>D.@(XI,.A@(  (
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M8*W8=QM< JI'=V!-H*;K=\,^**/L>"TM$*''>(08[J'I>%0"7IWY>E@  (
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ML:DMFSM:,J6&F59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0  (
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M8;=F?!Y0A[-=>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (
M@ !I>KHQ@W]=-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X
M )IL@    (  @ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<Z
MA\ /YJ>KAK@  )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS
M\:B;C>$CIZ8RCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9
MEE5"DJM-E0@SY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=
M([,3GTE04:ZUG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (
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M9H&(=XN!78$[>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (
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MMGO<HU5\CGNGH&MK=WMYG7)9B7MQFLE&CWN#F,,R'WMME_D9('K$D/T  (
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M"XBR?B1T\H?!?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (
M@ "1,(A,ALR##X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2
M=X3H@X8  (  @ "05X<[C[Z"5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$
MB@ KTH+]B9X2'X-GB#H  (  @ "/J(9BF+6!FH5XEQ=RA82)E3EB9X.IDT91
M;8+RD8H_58)ED$(K;X'[D!T1Y8(>C!D  (  @ "/((6\H;Z!"839GY9QZ8/A
MG1MAS(+TFHM0U8(WF%H^N8&REO0J\($ZED81LH$1B_<  (  @ ".OH5%JO>
MEX1EJ%=Q8X-BI45A/X)BHB%06(&7GY@^5H$*GF4JFX".FS41<8!%B\L  (
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M*I"QA =H^(\8@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X  (
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M$Z F9)5@JYWN9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (
M?]!Y_*%!:GMMH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$
M()80<=(  (  @ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q
M=?X<-I8%=?L$4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ
M[)6!>QTOTY0\>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U
M@79/R)83@2U :)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J
M^IESB3A=DY<PB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (
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MNJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2<:(M;HH  )<M<VD  (
M@ !M%ZJ!<+-A.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@
M )6@>#   (  @ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<
M>6P2EYXR>/4  )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W
M,9S0?O0FG9MP?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'
MA>1%A9X+A5 VV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?
MD:+2C:]2WY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (
M@ !K)*4/EA!?5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,
M ) G@    (  @ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=J
MEN<2JI>IC)X "X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,M
MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5
M:C@\;ZX+:V8MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5
M=[*_;Y))7:]R<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (
M@ !@JK1D==A5);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@
M (^_?Q8  (  @ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.
M?)D)ZJ6(?1D  ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M
M;Z5(@H,=):00@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?
MB;P[BZ;AB0@M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94
MLJS+D7Y(F*E(D'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (
M@ !?P:_=F:!4NZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8
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M>G>O8;J&-'A<9'1TIWD49OMA\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (
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M(&WOCCY_^&\3C/=NS7 LBYU<O7%%BE5)C7),B38TVW+RB&,;[W'+B$L  (
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M1GTY::1Z 7UD:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (
M>F>6.7K7<+Z( 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5
MQ7U(=H4  (  ??.5!7C$>>>&O'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K
M>]PO"7L;? H59GL=>Z8  (  @ "3TW<'@PZ%KG=_@O-VA'?J@K!F37A2@E)5
M'WC'@?M"EGE(@;0N5WF2@784Z7E-@5,  (  @ "2U'6DC$N$J78FBX=UA':7
MBI%E6'<&B8-4.G=^B(-!X'?VAZXMQG@PART4@7?&AJ8  (  @ "2!W2"E8F#
MVW4,E"-TMW5]DGQDD77ND,%3?79LCRE!07;BC>$M6G;\C5,4.79^BQ8  (
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M'8.D<*-M[8-"<=M>=X+S<OI-WX*[= L[V(*Q=/HGLX+W=8<-GH/G=.\  (
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MYWS[F41IL'RWEU]:>7QOE6)*27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8  (
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M1(KN=JIAWHGY=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (
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M4H6^G<M>ZH2XF\90@H.EF:)!-H+"F"4PAH(FE[8=@8&OD_,&?8$4A&,  (
M@ !QKYO87+)E\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<
M ),-:;\  (  ?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N
M;*L6,)47;)0 +Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[
M-)(1<0DJ5I&"<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'
M=65)C9&/=A(ZF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C
M%Y,,>^)6<9&"?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (
M@ !N,I-;@UIB?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@
MX(DG@)<  (  @ !MK))/BR=A]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=
MB%$5=8OCB 0! X??@*\  (  @ !M0I&+DPIAL9 7DC55$HYYD0%':8S3C[$X
MO(MTCM,H<(J>CP05&8K'C* !&H;1@+X  (  @ !L[Y#XFPYA7X]]F?A4N8W4
MF%]'$(P@EK$X<HJQE=$H.8G%E2<4_(G)CC !)X8#@,@  (  @ !E8J976[!:
M$J0?7A5-\*(C8&5 JZ!;8HTQ\I\%9&@@YY\398H+^Z&[91H  (V4;=(  (
M@ !DLZ3,8R=9IJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T
M (O[<LP  (  @ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!
M;Y4,?9QL;P8  (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q
M$9E(=(T@D)C>=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[
M>:T^XYD_>>PPM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97
M<9P6@&%+=9GX@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (
M@ !B)ITMA[]7&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T
M (7.@    (  @ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^
MC*\,B9,EB'H  (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPO
MJY-*DV<?L9);D>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T9
M7JHUG*L88)XG+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-
MNJWB8QM"(ZMJ9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (
M@ !8"*Z2:&A-2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@
M (9G>MT  (  @ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.
M<:L$A*%<<OP  (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,F
MNJ'U=VT6":)==RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=
M?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,
M*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (
M@ !6A:?2BT-,$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8
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M9V>F?SQX,VE>?T9G^&KY?SE6QFR(?RQ$.6WM?R@P&FZ>?QX74FX&?O   (
M@ "4>V/JB)*&3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6
MZ6QRA,   (  @ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKT
MBU8O%6MJBJP6G6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I4
M7FAMDSU"+VG2D;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0I
MGX1DV676G)Q3V&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!
M)WE27 ERMWGA7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (
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M1VWCA7IM#F[_A0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (
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M:'[*8U]FU'[M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H  (
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M9G40BMYB#'6)BA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54  (
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MK(4^:;-;"X3I:V9-(X2A;/D]^(1X;F0M!X2A;WT9 (69;Z "3H43<38  (
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MUWTOCW)717T CF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (
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M7HR>;O]/8HO)<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (
M@ !EKXM]=4Q:EHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0
M (%.?.4  (  @ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,
M?:,/"__B?1!)0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M9
M4H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (
M@ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(
M (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+M
MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@K
MB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT
M87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0
M]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (
M@ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",
M (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<
M=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,I
MF) $>M\9<9 M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J
M@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.
M+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (
M@ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D
M (  @    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC
M70@  * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@
M6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K
M91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$
MHZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (
M@ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D
M (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI
M=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/?; LMYHW?9X?
M)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#2IQSA'$X@9JV
MA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (  @ !,\9TIBX]#
M*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8  (  @    (
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MI&1E5UA^]F:56P9N.FBW7HA<86K%8>9)46RI91<TLVX&9^T;UVV":9L  (
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M/%4!A&1X*U@Q@_IH%5LE@X)7#%WC@Q)$U6 D@KDQ&F#T@H$92&&E@J$  (
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M4V? 7[=SMFFA8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (
M=I6.2V(J9B" W61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143
M$FY=<0\  (  >K.,MU[H;VY_4V%H<-=P_F.K<B5AH67&<UA0_F?#='@_&VEC
M=8 K<6GK=D42DFQ'=@P  (  ?D>+15P,>+A]\EZU>6EOK6$@>?Q@8&-9>G50
M$&5L>N8^1V<7>U$JT&=H>YT2-&IZ>V\  (  @ "*$5F@@@A\TEQJ@@=NHE[R
M@=]?96%&@:!/)V-G@60]G64+@3LJ364D@2P1YFCW@3L  (  @ ")&5>9BT][
MYUI]BIYMQ5T8B;Q>EE]_B,A.9&&NA^T\^F-+AT(IZ6,GAO\1LV>PAD,  (
M@ "(7%7VE()[,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1
M@F:JBF(  (  @ "'V52ZG9EZJE>]FY]L@EIGF59=7ES2EPA-15\#E18[^F"/
MD],I"5_ODV@1)&7OBY<  (  @ "%,'&24T!X:G*65O-JI7.S6GA;I7387<E+
M7G7W8.<YEW<.8[LEF7?Y9=<+NGK$9@(  (  =<*#QVW27 YW-V\P7P-I@7"$
M8<Y:I7'-9'-*@G,&9NTXX70B:20E"W3(:K8+C7?W:JH  (  >>&"<&I=9-UU
MTFP!9Q=H6&V#:3)9C6[N:RE)F'! ;/\X(W%>;IXD@G&\;[(+976";XH  (
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MLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*LVWJASP  (
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M<W$Z;7U<NG)/;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (
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MA&@:E(Y8]VEPDR)+96J#D9X\O6M8D( LBFN%D%\9T&JTCH@$;'B'@OT  (
M@ !LQ8+94GMA@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894
M (,Z9:X  (  ? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K
M9D02UX+[9E\  ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XW
MBWWX:B<FZGZ*:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%
M;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=
M5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (
M@ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V
M (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O
M@601J77:@8D  (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T
M9W.[AXLD<G.)AYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@
MC]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6
M!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (
M?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T
M (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U
M:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM
M58.);9P<XX0D;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<
M<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11
MB'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (
M@ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,
M (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:
MA1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K
M)WIUBT@;8GG9BS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/
M5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])
MO)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (
M@ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<
M (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3
M:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXB
MXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]
M=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&
M#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (
M@ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74
M (  @    (  @ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=
MAR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9
MPZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:
M6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]
M-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (
M@ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP
M (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/
M;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7
MN)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N
M=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z
M;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (
M@ !#@)$$A,8Z)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@
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MQ4S;=7MPDE"M=F-A8%0L=SQ1-%=<> T_E%F[>-0L<5FZ>7L4U5_G>:P  (
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MPV0'4AULL68F5A==FV@Y6>Q-5FHN79$[I&O:8.\G\FR88ZD.DW#K9&@  (
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M@%#A?!=F-E1'?&]7WU=6?+5(>UGV?/DWLEN0?4,D]EK,?8D-4FE\?@D  (
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MG&:W6=QA@VBI70M36&I]8!5#XFPA8NHRTFUE96@?1&U/9PH''W3J9[\  (
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M8%7/@<9;X5BQ@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (
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M4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (
M?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD
M\WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#
M<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6=_]%]&1<>) W
MS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=[5WC?O12&V ?
M?PQ%-F'R?PLW&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (  @ !H)5D#AL!=
M1%N[AH]1>5X+AA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X  (
M@ !GGE<MCL9<Q5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!
M#WXU@+@  (  @ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z
M70T,S("@77@  (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@Q
MR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G02
M89 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6
M&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (
M@ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X
M (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;
M=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N
M,VGH?(L>>FD=?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A
M@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2
M)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (
M@ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(
M (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S
M7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G
M4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE5
M9>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=*
M*752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (
M@ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\
M (  @    (  @ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F
M>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD
M96]2?XD40G Z?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!
MAG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#
M8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (
M@ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\
M (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>
M8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<
M((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^
M:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^
M37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (
M@ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<
M (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO
M?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:
M)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB4
M3M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V
M5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (
M@  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,
M (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&
M8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/
MIXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE
M:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ
M](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (
M@  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @
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M:D)K4FQ>;6=N<6]Z<(-QC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N
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M*^HLURW$+K$OGC",,7DR9S-5-$0U,C8B-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI
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MG2%Z^%L%F/![P$H)E*!\L3EJD!%]_RG0BQQ_Q*]<K5*"9I[4J-F!@HX&I(2
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M>C2#RL,J>K."Z*O/>SN",I0T>]"!JGR(?':!0F3A?2Z XTU5?A" GS8!?SJ
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M6H]TA"E[I7O-@YM\"F@!@R%\BU1?@K1]($#N@F9]W"XG@CI^R\6SA.&$RK0
MA"V$ J&B@X&#0HY:@O6"GGK%@GF"&F<;@A>!K%.?@<J!1$!A@9V YBW>@8Z
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MMX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU* 6#1%F+" 62J8D<^ ?B)YBM^
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MCAF#<H)TC&Z"[G,DBM*":F-DB5"!^U.EA]B!ED1#AE^!-#59A/> U2>D@Y&
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M/3YGB#B);S&&A?Z&@"81@\:#A)"KEB>@YH.&D[B=WW7*D32:?&>JCK*6Y%F
MC%*32DN$BA"/ISXIA\2+]C%YA9"((B8D@VR$3Y!=E<ZH/X,ODUZDAG5GD-&@
M2V=&CD6;RUDJB^"724M$B:&2P3W[AV..+3%CA4")@"8T@R6$](B IFQIIWQ1
MHOAK@6^CGZ5M76)VG$EO1U4%F,IQ4$>5E2ESA3JAD69UXBX[C7]XD",AB8![
MDX@2I5=Q;'O\H>AR<V]'GH)SC6(CFQ9TPU2\EY1V'$=?D_MWG3J$D$-Y/BY/
MC&]['"-YB(1],8>@I IX\GMKH*IY16[,G41YJV&HF=UZ,E17EF9ZV4<7DMY[
MHCI@CSA\@"Y<BWI]AR/&AZA^K(<6HL2 2GK-GVR  &X@G!)_OV$@F+)_EE/B
ME4U_B$;&D=A_CSHWCD=_HRYEBJ!_RR0(ANF  H:%H;.'D7H\GF.&KVV+FQ"%
MRV",E[.$ZU-YE%&$'D9WD/"#7CH0C7&"H"YLB>"!YB1 AD:!,H8%H.&.SGG"
MG9>-5&T5FD&+PV 8EN2**%,2DX.(D$8]D!R&_CGWC*^%;2YSB3B#TB1OA;R"
M.X6BH"V5YGE<G.N3SVRLF921B5^SEC:/*E*\DMF,R48%CWB*93GJC *'_2Y^
MB*6%B"26A4N#'(50G[:<UWDLG'2:*6QZF0Z7(%]TE9B3Y5)ZDC:0L$7#CNF-
M?SF_BX6*32Z!B#"'""2UA.^#V842GV&CG'CNG!6@2VPTF*.<=U\KE2288E(]
MD;Z45T68CG.04CFGBQ^,3RY^A]N(1B3.A*6$<GR^K^MI/W%+J]=K"V6+I\)L
MZ%E\HX)NWTU(GP1P_$$OFDQS236GE6-UORK.D$1XA"%7BPQ[C7QMKP-PG7$E
MJMAQG65HIIURP5EBHD)T"TTWG;MU@4$MF0IW)36[E"QXZRL+CQ]Z[B'.B@%]
M'WPEK;]WK'#(J9EX!64?I5AX?%D:H/QY)$T"G'UY\D$2E]QZZ#7 DP][^2L]
MCAI]-2(VB1E^BWO.K'%^A'!>J%%^362HI!E^*EC"G\1^+$RYFU5^4T#IEL9^
MDS6]D@U^Y2MFC3)_5"*/B%!_TGMPJU6%27  ISR$BF1'HPB#TUA=GK:#)TQZ
MFDJ"F$# E<^"'S6WD2F!K"N'C&>!22+;AZ6 \WL9JGZ,!F^SIF6*OF/^HBR)
M9%@6G=B("4P[F6^&NT"AE/*%?36SD%Z$12NCB[:#$2,:AQ:![7K0J=>2EF]Y
MI;N0PV/&H7J.P5?<G1^,K4P$F+N*HT"#E$6(HC6WCZR&I2N]BQV$IB-.AJ&"
MP7J?J4^8[V]+I2^6BF.3H.B3W5>IG(B1#$O5F"2.0D!7D[R+?#6HCR6(P"O7
MBIR&!2-XAD&#<7ITJ/F?)F]-I,F<.6./H&R8QU>.F_*5%TO#EX*1@D!6DQ^.
M #6SCJB*D2OIBD"'*2.:A?6$ '&!N:-HW&:KM01JDEO%L#%L;5#*JO]N<$70
MI6EPHCL-GX%S"S#RF5AUG">CDNEX>A_"C')[AW%$N.1OUV:KM!)PR%O4KP)Q
M\5#DJ:IS3D7QI ATXSL]GB5VK#$UF 9XF2@*D:YZQ"!7BU=]#7$HMZ)V<V:
MLLIVR5NZK;!W3%#,J$]X$T7KHK-Y"CM.G-YZ,3%CEM)[=BA?D)5\Z"#7BF)^
M;7$'MD-\SV9,L6]\HEMYK%M\F5"CIP-\PT72H71]'SM/F[)]FS&%E;Q^+RBF
MCYU^Y"%%B9!_IW#>M12#%&8FL$*"<%M1JR^!X%!TI=N!9T7!H%.!&#M0FJ:
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M:1N&"J0Y:T2%%I#K;6B$-7TI;YR#=FE.<>J"OU6E=%B" T)%=O^!/2^W>?>
M5L>G95"1>[5Q9Z:/BZ*V:>6-GH]\;!Z+NWOU;F^)Z&A,<..(*%3B<W6&4T'!
M=D"$6B]R>5B"&\9?9!R;UK0R9GV9 Z%]:,:6&HY-:Q"3+WKA;7203&=D;_Z-
M:E0S<K**>$%+=9R'22\X>,^#M,5;8R:F$K,U98^B6Z!]9]R><HU1:BZ:>'G]
M;*66AF:E;T22B%.?<@R.9$#J=1*)_B\(>%R%'<298G"P(+)V9-RK@9^R9R6F
ME(R :7>AA'DS:_B<>67X;JR78E,?<8F2$T"7=*",;R[@=_V&5<0:8?>YZ['T
M9&"T4I\99I^N5XO8:.BH+7B1:VNB!V5M;BF;T%*G<1657$ _=$".C"[ =["'
M6L""=/]F-*^/=?YHIIWE=O]J]8MX> %M,'B*>0YO<V5K>BYQT%)\>VET4#_$
M?-9W%"W3?I!Z2[\G<LAP>ZZ!<_]QU)SC=2-S'HJ$=D9T9W>C=W1UO62=>+YW
M*E'/>B5XKC]%>\1Z8BV.?:]\6+VO<-%ZGZSJ<B=Z\IMS<VI[0(DH=*][F79X
M=@5\ V.C=WE\?U$'>0I]!#ZZ>M-]G"U2?.1^2+PH;Q>$F:M9<(*#_IGI<=V#
M7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#" &+J[;9^.>ZGX
M;QN-!)B-<(N+>H:-<@")Z'0_<Y.(7F',=5&&XD^F=RN%5#W4>3Z#J"SO>Y.!
MPKF2;'684ZC4;?R6 )=O;W63AH5[</J0^7-'<J".;&$!='&+W4\0=FN)/SUT
M>)V&:BS)>PV#0+BF:XBB"Z?H;1:>W):";I*;;(26<!^7W7)X<=B436!7<[R0
MKTZ3=<B,[STF>!6(\2RI>IV$C[?W:M>KF*<T;&>GB)7!;>&C'(/4;VV>@G&_
M<3"9Y5^Y<RJ5.4X@=4F07SSB=Z6+-BR/>D"%K[>&:F&TZ*:S:^VO[94I;5RJ
M?(,R;N"DSW$I<*6?(%\\<JJ98$VV=-J3;#R5=TJ-*2QZ>?6&GK+5?2%EI*-U
M?41H+),Y?8%JB8(<?=!LSW!P?BYO'UZ2?IUQCDSP?R%T(CN-?\]W 2L(@+IZ
M5;'$>PQO2Z)J>VEPSY(;>\=R/H$3?#)SIV^$?*UU'5W*?4!VK$Q/?>IX5#LB
M?L)Z+2KF?]5\3+"<>2AXX:$J>:MY<I$->B1Y^8 ">JMZ?FZ5>T1[%%T%>_I[
MO$NZ?,M\<CK#?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%
M>@.! EPG>MV O$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/=KJ*CHYF=V")
M7'VD>!*(%VR5>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!:ZSZ=/B4\)V(
M=:B3#HUF=E:0^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\>YN%C"J$?3&"
MT*PF=!2>'YRQ=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.V$F=>92+?#F
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MB'A^,"+5A:1^_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J
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M<D:[>!2!UC=T>B&!,"E9?&F >**%;<>.9Y0W;RV-+X4V<(F+PW6=<?6*-F7
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MAT.%3&CAAC^$O5RZA3B$#5!YA$*#6$1+@VB"M3A_@JR"&"U=@@^!<B.P@8B
MQW],AT:-!70UAEZ,"FAWA5J*OUP_A$^)0$_]@V>'P4/I@J&&3CA:@>^$WRU:
M@7&#5R/3@0J!RG[8AHR4)W/!A:N2D&@"A*60A5O4@Y>.-$^<@K.+YD.+@@&)
MGC@@@5Z'7BU9@.Z% 2/O@*."HWY_A@&;%'-EA2*8Y&>?A!>6$EMU@P.2YD]/
M@AR/P4-7@7&,I3@#@.")CRU3@(B&9B0%@%&#57@SF69?*6V_ES)B"&+!E2%D
MZ5<ZDP5GUDMOD,1JWC^OCFQN%S1]C AQ?2GIB:IU/2"JAVAY4'>.E[AFGVU&
ME:5HQ6).DY!J]U;BD6UM/$LRCS-OGS^0C/%R+#1^BJ=TWRH7B&EWVB$2AD9[
M#7;WE>%MX6R9D^]O96'"D>MP\%9@C]9RD4K3C;-T2C]8BXYV*#1RB65X(RH\
MATIZ4R%MA4A\I'9.E"!T^6OBDD%UZ6$"D%1VV%72CE9WTTIAC%%XX#\2BDMZ
M!S19B$1[0RI5ADQ\HR&[A&U^$W6FDJ=\ &M D-E\86!ECOE\LU4[C0=\_4G_
MBQ1]5S[-B2]]Q#0\AT9^/2IFA6Y^R"'^@[%_6G43D7Z"_&JYC[Z"SU_IC>."
M>U3%B_:"$$F9B@Z!JCZBB"^!530KAF2!"RIUA*Z P"(U@Q2 =W2;D(:)RFI#
MCM2)"U]WC/V(#%19BQ2&YTD]B3:%PSYGAV>$JC0KA9^#FRJ(A F"@2)C@I*!
M:G0\C]&0;&H(CBF/*%\_C$J-=%0>BD^+?4D)B&^)DCXMAK>'MC0#A0:%Z2J4
M@X&$"R*(@BB"-7/RCTF6UFG!C9Z5"%[UB[F2FE/9B;F/UTC3A]B-(CX+AB6*
M?S/VA(:'["J;@QF%4B*F@=."VVU"HF]>L&-XGZ1A@%E:G-9D8T[FF=IG8D1,
MEJ)JASG1DT%MXB_UC\EQ:2;/C$MU0A\'B/)Y5&RIH/QEO6,<GC1GXED/FU!J
M(TZVF$1L@T0VE0QO"CG8D;QQP3 <CEMTGB<?BOMWOA^(A\)[ FPQGSILC6*9
MG(5N'5BLF:QOPDY>EJEQB4/^DX5S<#G%D$]U@3 QC0QWL2=AB<]Z%!_WAKE\
MBFNUG7QS,&(1FMAT.5@=F!%U3$W\E2)V=T.TDAEWOCFBCP%Y(S YB]YZH">5
MB,5\02!7A=5]ZFLXG !YPV&<F6QZ2E>MEJ]ZS$V-D\M[4$-VD--[[CE^C=I\
MI3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU DK* %$,V
MC\1__#EHC--__# \B>N ""?>AQ: &R#MA'" ,&IMF>F&I&#SEV:&+%<7E*J%
M=$T!D<F$GD+YCN6#TSE&C .#&3!'B2&";B?^AFN!OR$E@^F!%6HGF2J,OV"R
MEJR+PU;6D_"*:4S&D0V(WT+'CBV'7CD5BUV%ZS WB(2$CB@>A=V#*R%2@WR!
MU&GOF**2LF"GEB*125;+DUF/.TRRD&",W$+%C76*F3DJBJV(<S!0A_2&9R@V
MA6^$6B%V@R6"<&*LJ\I>&EE]J'-@UU WI.-CO4;1H/%FT#UIG*5J&30XF!UM
MG2NUDW=Q32/ZCL=U11V5BE1Y56(5JI!DP5DOIR)FX5 $HV=I,$:]GUQKKSUQ
MFPIN8C1?EHYQ2RO\D?MT6B1HC6AWHQXMB19Z^&&]J-YK)%C4I71LO$_%H<!N
M>$:+G;AP:CU=F7=RAS1ME1-TU2PQD)QW0"3%C"QYV1ZPB )\<V%PIQIQ5EA]
MH[QR<T]IH!5SJ493G"-U"3T[E_IVDC1MD[5X/2Q7CU]Z 241BQ5[YA\@AQ5]
MQ6$CI9)W>%@XHD%X(4\IGJ)XTT83FKEYE#TEEJ5Z?C1LDGU[ABQVCD=\G251
MBB-]RA]_ADM^[V#=I%U]DE@*H0Y]RD\&G7%][47TF8U^$#T-E81^2C1UD6E^
MI"R5C5%_#B6(B5)_@A_/A:-_\&"CHV:#>E?JH!6#04[PG'6"T47@F)2"3SS[
ME):!X31UD(N!B2RTC'Z!126YB**!!B 0A1B RF!VHJB)*E?8GT^(@$[EFZB'
M>$76E\2&2CSND\R%+S1HC]>$*BR\B]N#/B7@B!&"5R!$A*B!?V!9HAB.I%?3
MGJ^-AT[BFO^+X473EQ>* #SSDR&(-#1YCS>&@RS*BU"$[27UAY^#:2!NA$Z"
M$;=98K=:Z:;W95Y>6)8K9_9AN83.:HUE#7+^;3IH9V$ < UKVT]&<PUO>3W<
M=EMS:"UQ>@IWX[5R7VIE5*5^8F1GN93@94-J%X.L:!YL=7'[:Q%NVV ?;BUQ
M6TZ,<7AS^SU==1-VX"U&>0YZ++.I7(%OI*/.7[EQ 9-Q8M5R7()69>MSQ7#3
M:1MU/%\K;'IVR$W2< IX;#SG<^UZ0"TA>"M\5;'D6>EYQJ(9759Z*Y'-8*%Z
ME8#Y8^M[!V^B9UI[C5XV:O9\(TT>;L9\Q3QY<NE]@BT =V-^6[!!5ZN#Q*"7
M6T6#1)!@7KR"P7^?8B^"0&Z49<R!R5U6::2!9$Q];:V _CP9<@B G2SD=K2
M-Z[E5=.-J9];68^,2(\]72:*UGZ38+Z)76VA9(&'Z%R<:'^&>TOT;+V%"SO%
M<4F#ARS,=A^!XZW.5$^79IY=6">5'XY36]22MWV[7X>00VS=8VV-TUO[9Y"+
M7TN&:_&(VCN$<*B&-"RY=:*#6ZS[4R&@YYV<5PN=LHV:6L::3WT-7HB6VVP\
M8H>3;5MM9LV/]DL>:U",8SM,<".(FRRI=3N$GJQS4DFJ#)T85CREV(T36?BA
M<WR(7;^= 6O%8<N8F%L-9B:4(DK*:L./ACL/;[6*K2R<=.B%K*K<:@Q:K)OZ
M:_U>-8QV;?%AGGP\;^YD\VN$<@1H4%JA=#]KRTH+=J1O=#G2>5-S=2JN?%IX
M *E:9O!DDYK=:31G'(MW:V1IDWM;;9EL FJ\;^AN>EGZ<F1Q#DF,=0]SQCF%
M> IVQRJ?>UIZ,*?,9"5N5IE!9J9OZXH-:0UQ=7H*:WIR_VF?;@9TEUD2<,)V
M1$C><ZYX##D?=NEZ!2J1>G9\/Z8W8:AW[9>Q9%EXH8B-9NYY27C2:8IY[6B.
M;%%ZGU@Z;TA[84A%<G%\,CC(=>E]'RJ%>:Q^*:2_7X&!:9938EJ!1X<_91F!
M#W>59]V RV>>:L^ CE=T;?Z 8$>[<5Z -3A]=0N #RIZ>/U_Z:.*7;R*T94Q
M8+.)V(8R8Y"(NW:<9G>'BV:_:8V&6U;/;.&%,D=&<'&$"#@\=$V"SBIR>&B!
M>J*47$F4#Y1(7UB2.X568DF0-'7094J.$V8(:(*+\E8]:_F)S4;J;ZB'G3@*
M<ZV%3RIK=^N"V*'<6RB=$9.57D6:7X2D84*7:'4H9%*44&5K9Z.1.56T:SN.
M'$:+;PN*ZC?><RJ'C"IE=X6$!*%C6EFEO9,577RB*(0:8'J>.W2@8XZ:*63U
M9NR6'%58:IF2!T8Z;H.-UC>F<L")=2I@=S.$_IZE<9A:CI$B<LU>'X+;=!AA
MBG/$=7=DWV0H=NYH/51D>(=KOT3Y>D9O<C7U?$ES@2@6?IEX&IUB;J5CVI &
M<"QF?H&_<:]I"G+)<T%KC&-2=.YN&E.X=L-PQT1[>,!SF36S>P5VM"@A?9-Z
M,9P::_5M%8ZY;;QNUX"W;W)PBG',<3-R-&* <Q)S[%,6=2%UO40/=UMWJ35_
M>>!YR"@K?*I\)YJP:8]V)HU6:X1W&G],;6=W^7"F;U-XSF%_<6UYK%),<[1Z
MG$."=BA[G34X>.1\NR@S>]U]]YEA9X!_'(P5:9E_2GX::Z)_5V^);;5_4&"M
M;_5_35&@<G%_6$,/=1A_:34!> 9_@2@Z>RQ_G9A,9<^( HL.: .'9GTF:B:&
MFVZF;%J%M%_C;KR$RE$1<5F#YD*N="V#!#31=TB"%2A >I6!%9=O9&R0O8HY
M9K2/57Q::.N-K&WJ:S:+WU\[;;B*#E".<'6(.T)B<V6&832O=J>$;2A%>AB"
M6Y;)8U69/(F39:R7!WNS9^Z4?&U-:D:1P5ZH;-^/!5 .;[V,1$(-<LJ)=32/
M=B2&@2A)>;&#<9998HJA;HD99.F>:WLN9RR:]VS):8F73%XY;"V3H$^Z;QZ/
M\$'#<D:,+#1==;V(12A->5^$6)*N>6%:B(9->=Q>$'DB>G]A=VLJ>SMDS%RR
M? MH+TX:?/5KNC_H??UO=C(L?T!SDB6I@,)X+Y&7=I1C1(5-=V%E\W@C>#EH
MBVI)>2%K'EOW>A]MOTV)>SYP@3^&?']S:S(&??QVGR7/?[-Z,)!X= 9KXX05
M=1!MQW<>=A1OFVE6=RAQ:%LS>%9S0TSW>:MU-S\I>R-W23'E?-EYCR7P?L-\
M#X]%<;1T<H+><NUUE77O=!MVH6A[=55WJ%IY=K5XLTQR>#QYT3[<>>E[ S'+
M>]9\528,??%]QHX:;[U\YX';<1A]4W3P<FA]G6=T<\1]T%FS=4A^"$O.=P-^
M33YO>.!^FC&?>OE^\R8E?3U_5(TB;B&%2(#I;Y.$^G0-</R$>6:D<G6#V%C_
M=!>#-$M3=>Z"F#X@=_6!_S%_>CJ!7B8Y?*. LXQ:;,Z-?( I;E2,<G-6;\V+
M(67[<5J)IUAI<QF(*$KA=0Z&ISWE=RV%)#%K>9>#C29*?"2!Y(O!:\*5=G^0
M;5>3KW*];MJ1BF5M<'*/+U?E<D:,STIN=%F*;#V;=I*( C%7>1&%>R98>[R"
MYHM4:OJ=)G\=;)F:IG)!;A^7J&3T;[N49U>!<9>1(DHD<[R-VCU;=A"*AC$O
M>*R'&R9C>VF#NX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AK
MMCKA@<=O?BZ @C)SIB-L@L]X087Y?M!BN'JI?NAE:6Z'?PYH"V')?T%JKE2?
M?X)M8T=F?]IP/3JF@$IS0"Y\@.IVCB.L@;5Z+H3^?&!JTGF7?+-LR&V@?0)N
MM&#S?5QPG5/S?<ARF4;I?E%TL3I>?O1VZ"YP?\5Y52/C@+U[]H/S>BYRRWB)
M>JAT%&R/>QYU36 N>YAV?E-+?#1WND9T?.QY"CH??;]Z;BYG?L%[]203?^1]
MEX+R>$1ZO7>0>.![66NF>75[V%]5>@]\15+(>L=\ND83>ZY].SGM?*U]R"YC
M?=U^9B0\?RI_#H(5=KR"GG;8=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!
M1CFJ>\. ^2Y0?1N JB1??HV 6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<
M>*.&/$5">;Z%$CE\>OF#ZBY(?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.
ME5V4=M>,F%$L=]2*ED3?>0J(E#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T
M=)>6Y&EB=5F45%TK=B61?%#7=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#
M*7MYB<%::7#DB.9=S66VB#1A*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'
MA1)SN2%DA+=X3WJ;AUQB'G NAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO
M\S7NA!9S$BLC@\)V?"&]@Y%Z*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>
M@UUQYD$,@P9T)37)@KUVA2LU@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S
M\E@$@A%U3DQ,@=)VN4"J@:5X/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.
M@/IY9&*;@,=Z%E=%@)-ZO4O9@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^
MS'=&?YM_]&S=?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5
M?]U__"*U@$V  W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL ?D&$1S_<?F^#
M>35,?K6"LRM:?S.!X2+<?\>!#78I?7*.%VOH?8N-#V$8?7J+HE7I?6*)^DJE
M?72(5S^)?;J&O34=?A6%+"M??J>#BR+\?UJ!['7(?+:4RVN(?->3+V"X?,J1
M!%60?+2.C4I@?,N,&S];?1V)M#4 ?8Z'52M7?CN$[B,5?P."HW!UDEY:'F:L
MD-I=<%QMCW-@RE&SC@1D-D:YC'IGQ#O/BN-KAC%ZB4UO>"?9A\MSQ1^9AG%X
M6F^ID#1A8&84CN!D#5ODC8EFQE%,C"1IDD9TBJYL?3NQB3EOES&&A\ARV2@4
MAG!V92 )A3YZ(V[VC?YH@&55C-=JDEM,BYQLK%#$BE%NV$84B/UQ'SM\AZ]S
MC#&!AF=V&RA"A3MXXB!JA#%[QFX[B_!O@F23BN9Q %J)B<ER?U WB)UT"D6E
MAV]UJ3LZADIW9#%OA2UY.2ABA"M[-2"^@TA]0&V%BBQV<&/HB3UW7EGFB#9X
M04^?AQ]Y($5)A@UZ$CK]A0][&3%<A!A\,"A]@SU]7R$%@H%^D6SDB+I]36-9
MA^)]KUEHANE][T\MA>%^'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B% @=I_
MMFQ:AX6#\F+4AL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR
M@;V!'"%Q@5& L&ONAIB*=6*:A>R)Q%B^A0&(JDZ4@_2'541U@P:&$SJ*@DF$
MYS%+@9Z#TBC#@2J"JR&9@."!@FN8A>&0OV))A3F/BEAMA%.-NDY-@TB+G$1!
M@EN)F#IM@::'K3%&@0^%URC1@+B#]B&X@(>"+67>FS%9H5SGF0A<Y5.9EN=@
M04GME)]COT 9DB)G:#9FCXEK3"U7C.=O7R4#BE=SQQX'A_QX8F4BF4=@?5QK
MES]C*5,NE1IE\4FEDLQHVC_UD%AKZ39JC=EO*RV$BU=RER5;B.YV2AZ,AKMZ
M'624ER=G+%O4E3]I3%*WDS-K@$D]D/EMUC^TCJ%P2C96C$1RZBV?B>EUK"6D
MAZQXIA\ A:-[L&0$E1IMMULXDTMO4%(6D5EP]TC-CSURM3]DC0ITCC8RBM5V
MARVJB*1XFB7<AI%ZV!]CA+)]&V-SDU=T,UJPD:)U25&:C\!V8$A8C;9W>C\D
MBZ!XL#8/B9%Z BVLAX=[9"8'A9Q\XA^W@^1^6V+PD>IZI5H]D$M[.E$WCG5[
MN$@%C'=\*S[BBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GB
MCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV ;BV[A;. ;B9(A!2 :2 W@JF
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MEN>#6TC>E#B"[D#%D3V"93C0CC&!]3$PBSB!GBI?B$N!7R1*A:6!&A];@V.
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M7_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N Z3]2<0: N3*@=2F BR=/>6N
M78VI6OZ*:8%[7DV)F'2Q88:(D6=79-2';5FZ:%V&24PA;"B%*3\4<"J$##**
M='V"XB==>.B!JXSY69"2K(#47/J1$G008$R/+V;$8[6-)UDS9V"+(4NK:U6)
M'#[);WV'%#)T<^^$]2=I>'V"QHQ_6'R:E8!96_F8-W.07UF5=F9*8M*2AEC0
M9I*/FTMD:J*,LCZ*;NR)P#)+<X*&MB=R>">#L8H'<K95@'Y,<]Y9<7'G=2E=
M3V30=HYA(U=&> ME"$FF>:QI&3QZ>W5M82_7?85R$22!?]1W1XBY;T]>!7TU
M<-EA+W#E<FQD2F/U= YG8E:6=<UJBDDC=[=MUSPG><MQ4B_"?"9U(B2W?K5Y
M5H=];#1F>WOP;@YHXV_>;]YK/V,'<;YMEU7:<[YO_4B;=>YR@CO8>$IU*B^O
M>NQX$R3F?;A[0(8V:6)NXWJP:WUPC6ZN;8AR)V(T;YYSOE4L<=]U6D@E=%%W
M#CN:=O%XW2^D>=5ZVB4/?-Q] H3]9O5W,7FD:4)X)6VM:W]X_V$O;<9YR51P
M<#QZF4>+<O![?#LY=<Q\;B^$>.A]>B4R?!U^F8/Z9.I_9WBN9UY_I&S,:<)_
MMV!D;#=_LE/#;ME_KD<<<;=_MSKV=,I_RR]P>!M_Y25/>WV  (,I8S:':7?K
M9<J&[VP9:$V&.%_":N2%7U,S;:^$AT:R<+>#M#K(<^V"Z"]G=VR"%"5H>O>!
M-X*&8=6/*W=19(2-^VN#9QZ,=E\Z:<V*Q%*W;+B)$T9&;^>'9CJ&<T"%O2];
M=MR$ 25[>HJ"/X(18,>6FW;=8XJ4O&L+9C*29U[(:.^/UU);:^V-2D8&;S:*
MPCI.<K"(."\Y=F^%H"6+>C.#&'[2>GQ5GW0$>P%9?6B;>[!=45R/?'-A)5 @
M?4-E$$.H?BQI*C>Q?S1M>RQ7@'5R-")8@>=W7WVF=TI=G7,3>"M@QV>_>19C
MZ%O=>@UG#4^7>Q9J1T-+?$!MJ3>$?8MQ.BQB?Q%U'R*D@+UY6'R,=%)ECW'R
M=8!H!F;2=J9J=UL(=]-LZ$[P>1AO;4+6>H1R$S='?!%TWBQC?=5WZ2+G?[=[
M+'MP<:1M9W#8<PIO,V6]=&5P]%I&=<-RLDY-=TAT?$)J>/%V7S<2>KYX7BQD
M?+YZBB,A?M-\UWI<;TQU-6_2<.)V5&3.<FIW8%EL<_9X7DW0=:AY9T(1=XUZ
M@S;K>9)[L2QL>\E\^R-3?@]^5WEQ;5E\[V\0;Q=]:&0C<,%]NEC <G-]\TTS
M=$U^,4&M=EI^@3:Q>)!^W2QA>OI_0B-\?6I_J'BQ:[>$=&Y:;9.$16-\;UJ#
MV5@J<2R#2TRO<RF"P$%/=5R"0#:-=[*!R"QB>DB!3".>?.& RW@::F2+M6W-
M;%J*X6+U;C:)M5>R<!V(6TQ#<C>' T#P=(Z%LC98=P2$:BQB>;6#%B.Z?'*!
MP7>I:5R2KFU@:V:1.V*';5&/35=,;T6-($OS<7"*]4"\<]Z(U#8L=G6&MRQ+
M>4>$E2//?!F"BG/,@HQ5FFG?@G%99U]L@GM=-%1L@H]A#4D;@J%E!#W1@K]I
M,#,6@O%MD2D+@T]R5"!C@]1W<W*^?Y)='&D,?\I@1EZO@ 9C;U/9@$-FI4BR
M@(1I]CV4@-MM=#,*@4EQ'RDT@>-U&R#&@IUY67'*?+YDD&@2?3QG%EWG?:QI
MG5,G?AEL+$@N?I!NTCU!?R)QGC+M?\QTD"E0@*!WOR$;@8U[&'#3>BUK[F<9
M>MYMU5ST>WUOMU)U?!MQGD>>?,MSECSC?9=UJS+%?GMWW"E@?X9Z.B%E@*%\
MKF_H=_)S.&9!>,UT@UPJ>91UP%&S>EMV]D<P>S-X.3R6?#=YE#*G?5![ 2ER
M?HY\B2&D?]9^&6\4=@MZ<V5]=PY[(5M[=_=[L%$F>-Y\+$:]>=M\L#QI>P!]
M2S*:?$A]\RF$?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94
M>+J ]3P<>@. S#*&>VB KRF0?0* C2($?I^ :&W<<S*(2F1O='.'R5J)=8J&
M\5!.=I>%[$7Z=\R$\3O/>3:$ S)<>K:#(BF9?&R"."(G?BV!36UR<C".TF0*
M<X6-P%HG=*R,,$_X=<:*8T6Z=PF(H3NH>(>&[3)#>B6%12F3>_N#FR)#?=&"
M"&D@BN157& ,BB-9'%:-B7U<Z4R9B-!@S4)EB ]DVCA)ATUI("[)AI9MFR8)
MA?]R;QZHA9%W@V@NB"!<;5]4AZI?F57IARIBT4P=AIMF'D(6A@%ICC@IA6]M
M+R[;A.MP_29-A(IU%1\?A$UY6&=?A6QC:UY_A3-F U5!A.)HHTN+A'UK5T&Q
MA!)N)C?S@[9Q("[:@VET/2:!@S]WE1^&@S)[!&:1@O!J4UVO@N1L6%1T@KUN
M8$KX@H5P=T$^@D]RHS>R@BET\"[,@A)W62:G@AQY[!_?@CU\B&7'@,=Q+%SQ
M@.-RH%/"@.!T#4I7@,IU>D#?@+YW #=S@,MXGBZ[@.9Z3B;%@2!\&2 J@6Q]
MX643?O5W\EQ-?S5XUE,S?T]YHTG9?UAZ9D![?VI[-S=2?Y1\'RZW?]Q]%2;A
M@$5^%B!I@+Q_#61V?61^?5N[?<M^TE*R?@%^^TEM?B%_$4 D?E!_,#<H?IA_
M7R[0?O1_GR<$?XE_W""=@"N #F/[?"B$WUMJ?+2$KU)Q?/N$*DD^?1R#>T (
M?56"X3<&?;^"6RZT?CV!ZB<7?N^!:R#'?[6 Y6.:>RJ+!5L/>\J*3U(=?".)
M&DCY?%&'K#_;?)6&53;P?0Z%%BZQ?::#ZB<D?GB"MR#H?U>!E%[CDXA4V5:>
MDA58DTX*D*I<9D4=CR5@83P$C7YDCC,4B\AH^BK+BA9MF"--B']RA1TFAQQW
MD%X(D/M;@U7WC\9>MTUWCG9B T2QC09E<#O(BWEI"3,*B>ILV"KVB&1PTB.J
MAOYU#!VOA<MY55U8CF=B%55%C61DPTSKC#UG@T0ZBN]J8CM]B8UM9#+PB"YP
ME2L0AMESYR/UA:=W;!XFA*5Z\ERQB_MHDE2;BR!JN$Q#BAYLZT/(B/MO-CLK
MA\AQH3+,AIMT+BL=A7IVUB0PA'MYHQZ-@ZA\95P-B=IO U0"B29PHDNWB$5R
M14-+AT%S\3KKAC5UOC*KA3AWIRLDA$9YH"1A@W=[L![C@M!]KEMUB MU85-[
MAWYV?$M'AKIWB$+OA=!XE3JFA.!YMC*?@_]Z]BLQ@S=\0"2)@I=]D!\K@AM^
MS%KRAH=[C5,-AA]\)TKMA7-\F$*IA)M\_CIN@\-]=S*%@OY^""M'@DU^IR2P
M@=A_/!]G@85_OUJ'A4:!<%*EA/V!@4J/A&B!5$)<@Z*!$CHT@MV Y3)0@C>
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ML9QW28-M58[B3GQO!8#64UAPNG)46$AR<F-(77ET.%0O8O)V%T6,:+-X%3>
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M8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V
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M8YQ_&5S'9KE_-5)E:>!_0$??;3%_5SUY<+5_@C.Z=%=_O2J9>"A__2+<>]&
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M:>Z"K%0O;'R"7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^ ^R%L?1J
MP65R9<N)'%S0:*2(@U/+:UB'@$J';?N&4T$X<+>%.S@7<Z6$.R^I=J6#3"?Q
M><B"7R&+?+J!@&*$@MQ0X5GT@O%4]U$4@R!9*D?3@TM=@SY;@VYB#34#@YMF
MUBQ-@]MKV"1BA$-Q-1W5A,1VQV%#?VI7MUD#?]U;3U!'@$I>^T<V@*IBQ#WT
M@0AFMC35@7MJWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!D
MN4:/?BYG[#V ?M!K0S28?XQNR2Q:@%QR=B3B@4]V81Z^@DEZ6U]4>0YE7E<B
M>A=GV4ZE>P-J7T7P>^1L^CT'?,YOLC14?=)RD2Q.?NEUCR4-@!QXNQ\<@4E[
MYUYP=D]L'U9.=YAN!DWC>,%O\T5&>=QQZCRE>P9T #07?$YV-BQ"?:-X@24P
M?Q%ZZA]K@&Y]1UVE<^1RRU67=6QT(4U'=LYU;D3">"%VP3Q!>7YX*#/Z>O1Y
MKBQ%?(%[1B53?BA\Z1^M?[=^>EST<<EY1%3R<X]Z"$RW=2AZLD1.=JM[63OJ
M>#5\%#/0>=A\YBQ=>X5]RB5Y?5]^KQ_C?Q]_@%QF< )_C%2(<@=_QTQG<]%_
MQD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2 7%O\;I"%FE0D
M<+^%3$P+<K2$GD//='B#T3N7=CR#(S.1>"F"CRP]>B*"#R6;?$*!C" R?D*!
M#UB*BSI085#XBI14@4D:B@!8OD#=B5Y=*SAQB*=ATS RA^YFP2B=AT)KY"'8
MAK9Q51Q@AE%VV5=QA_U6UU 5A[A:@4A,AUI>14 ^AN)B+C@0AEAF2# 2A==J
MGBB_A69O("(UA1MSXASMA/%XIU:8A-5=24\[A-A@=4><A+ACLS^HA'9G$S>O
MA"AJG"_J@^AN6"C5@[ER-B*!@Z]V1AUG@[YZ3%72@=UCKTYV@AUF4T;<@C=I
M!S\C@C1KV#=0@BANSR^_@BQQ["C@@C]U)2*^@G)X@1W0@K9[QU41?REJ#4W!
M?ZML)D8Y?_YN3#Z7@#%P@C<*@&%RX2^;@*1U7RCH@/1W[B+Q@6!ZD1XI@=1]
M%U1??,1P6TT=?8IQZD6Q?A=S>CXM?GQU%3:^?MQVS2^(?TUXIRCS?])ZBR,<
M@'1\=!YS@1=^.U/%>K-V>4R4>[AW@$5"?'MX=#W9?0QY;C9[?9=Z@R]K?C)[
MLBD(?M9\[B-$?ZI^(1ZP@'M_,U-!>.=\64P6>B]\UD35>R9]+3V&>^!]@C9
M?(Q]\B\Z?5)^>"D#?@]_#B-O?O]_EA[A?_V  U+@=W&"'DO,>/:"%T2@>A^!
MOSUQ>NV!6#95>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB K$[8D_U/HTA*
MDH13TD%QD1%8'3H]CX5<I#+AC=EA=BN[C"-FDR5!BGIKY!^4B/9Q;QL9A[1V
MYTW,D/I5N4=2C^U9?4" CJ]=7SE]C3]A<3)LBZUEP2N6BAUJ3R5LB)]O R
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M,0     #!"$   $                    !                     0
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MSHBHALZ(J(;.B*B&SHBHALZ(J(;._ZDV,O^E0DO_JD%<]K([:NZ]-G?HRS.
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MDM. I)+3@*22TX"DDM. I)+3_Z4W*O^A1$'_I451_JQ"7_6T/VSMO#YXY\=
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MG\!EK9FZ<K66MGNZE+."OI*RA<"-L8;!B;"'PX:OB,2"KHK%@*Z,Q8"NC,6
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MHS0:_ZTS'OZX,B#PQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW
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M4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC
M[B87M/ R**CN.SB<[4-&D>Q+4H;L4EQ\ZUED<^M>:VKJ9'!EZ&QU8>9T>%[D
M?'M;XH-]6>"+?U;?DH%5WIJ#4]ZB@U+=JH11W;:$4=V_A%'=OX11W;^$4=V_
MA%'=OX11W;^$4=V_A%'=OX11W;^$_Y\A!O^P&P7IQ0T#T-D+ L#N& RS]B8<
MI_4Q+)OU.SJ0]41'A?5,47SU4UIS]5E@:_-?9F7P9FIA[6UM7>MT<%KJ>G-8
MZ(%T5N>'=E3FC7A3Y91Y4>2;>E#DH7M/XZI\3N.P?$[CL'Q.X[!\3N.P?$[C
ML'Q.X[!\3N.P?$[CL'Q.X[!\_Z@< NN\# '-S D P> ,!++Z&1"E_"<@FOTR
M+H_]/3N%_D5%>_]-3G+_5%5K^UI:9/A@7V#V9V)<]&UE6?)R9U?Q>&E5\'YJ
M4^^#;%'NB6U0[8]N3NR4;TWKFG!,ZZ%Q2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+
MZJ9R2^JF<DOJIG)+ZJ9R][,- ,S#" "_T0@ L>\.!J3_&Q.9_RDACO\T+H3_
M/SE[_T=!<?].2&K_5$YC_UI27OY@5EK\9EA7^VQ:5?IQ7%/Y=EY1^'I?3_=_
M8$[VA&%,]8EB2_6.8TKTE&1)\YIE2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF
M2/.>9DCSGF9(\YYFS;L% +W'!@"QV <!H_\0")C_'Q2-_RP@@_\W*WK_031P
M_T<[:/]-06'_5$5<_UI)6/]?2U7_94U2_VI/4/]N44[_<E),_W=32_][5$G_
M?U5(_H161_Z(5T;]C5=$_9-81/R6643\EEE$_)991/R6643\EEE$_)991/R6
M643\EEE$_)99O;\$ +#.! "BX 8"E_\3"(S_(A.#_RX=>?\X)6[_/BUF_T4R
M7_],-UG_4CM5_U@^4?]=0$__8D),_V9#2O]J1$G_;D5'_W)&1O]V1T7_>DA#
M_WY(0O^"24'_ADI _XM+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2S__
MCTL__X]+K\8" *+6 @"6]PH"B_\6!X+_) ]W_RT7;/\S'F/_.B1<_T(H5O])
M+%'_3R]._U4Q2_]:,TC_7C5&_V(V1/]F-T/_:3A!_VPX0/]P.3__<SH^_W<Z
M/?][.SS_?CPZ_X,\.O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ
M_X8]_W4D!O]V-1#_=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S
M@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+
M@>9>U8'@8-N!UV+>@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!
M_W4D!O]V-1#_=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT
M;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>
MU8'@8-N!UV+>@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D
M!O]V-1#_=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN
M\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@
M8-N!UV+>@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W8D!O]W
M-1#_>4(<_X)))_^'43+_B%@]_X=?2/^#9E'_?FY:^WEW8O=U@FGT<8IN\6V2
M<^YKF7;L:)]YZV:D>^IDJGWI8Z]_Z&*U@.=AO('G8,2"YE_.@N-?UX/<8=N#
MTF/=@\]DW8//9-V#SV3=@\]DW8//9-V#SV3=@\]DW8//9-V#_W<D!O]X-1#_
M?$$<_X5()_^*3S+_C%8]_XM=1_^'9%'_@FQ:^WQT8O=X?VGS=(AO\'"0=.UL
MEWCK:IY[Z6>D?NAFJH#G9+""YF*V@^5AOH3E8,>%Y6#3A=UBV8739-R%S&7;
MALEEVX;)9=N&R67;ALEEVX;)9=N&R67;ALEEVX;)9=N&_W@D!O]X-1#_?D ;
M_XA')O^-3C'_CU4\_XY;1O^+8E#_AFE9_(!Q8O=[>VGS=H5P[W*.=>QNE7GJ
M:YQ]Z&FC@.=FJ8+E9;"$Y&.WA>1BP(?C8<N'WV+5A]5DVH?-9=F(QF?9B<1G
MV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G$9]B)_WDC!O]Y-!#_@#\;_XI&
M)O^033#_DE,[_Y%:1?^/8$__BF=9_(1N8?=^>&GR>8)P[W2+=NMPDWOI;9M_
MYVJB@N5GJ83D9;"&XV2YB.)BPXGB8M"*V&38BLYFV(K'9]>+P&C6C+YIUHR^
M:=:,OFG6C+YIUHR^:=:,OFG6C+YIUHR^:=:,_WDC!O]Z-!#_@SX;_XU%)?^3
M3"__E5$Z_Y171/^274[_CF58_(AK8?>"=&GR?']P[G>(=NMSD7SH;YF YFNA
MA.1HJ8?B9K&)X62[B^!CQXS<8]2,SV;6C,=HU8W :=2.NFK4CKAKU(ZX:]2.
MN&O4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2._WHC!O][-!#_A3T:_X]$)/^62B[_
METXX_Y=40O^56DS_DF%6_(YI7_:'<&CR@7IP[7N%=^IVCGSF<9>!XVV?AN!J
MJ(G=9[",VF:[C=9EQX[19M2/QVC3C[]JTY"Y:]*1LVS2D;)MTI&R;=*1LFW2
MD;)MTI&R;=*1LFW2D;)MTI&R;=*1_WLC!O]\-!'_B#P:_Y)#)/^82"W_FDPW
M_YI20?^96$K\EU]4]I-F7?"-;F;KAW=OYH"!=N%[BWW<=9.#UW&<A])NI(O/
M:ZR.S&FUD<EHP)+':,^3OVO1D[ALT).R;="4K6_0DZMOT9.K;]&3JV_1DZMO
MT9.K;]&3JV_1DZMOT9.K;]&3_WPC!O]]-!'_BCL9_Y1!(_^:1BS_G$LU_YU0
M/_^=5DCXFUU1\9AC6^N3:V3DC75MWH9^==B AWS1>H^#S':7B<=RGXW$;Z>1
MP&VPD[YLNY6[:\B6MFW/EK!OSI:K<,^6IG'/E:5RSY6E<L^5I7+/E:5RSY6E
M<L^5I7+/E:5RSY6E<L^5_WPC!O]]-!'_C#H9_Y= (O^<12O_GTDT_Z!.//NA
M5$7TH%I.[)UA6.69:6'>DW-JU8Q[=,Z%@WW(?XN$PGJ3BKYVFX^Z<Z.3MG&K
MEK-OMIBQ;\*8K7#-F*ARS9BD<\V8H'3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7
MGW3.EY]TSI>?=,Z7_WTC!O]_,Q'_CCD8_YD_(?^>0RG_H4<R_Z-,.OBE4D/P
MI%A+Z*-?5.&?:%W7F'!HSI%X=,:*@'W A(B%NG^/B[5[EY"Q=Y^4K76GEZIS
ML9FG<[V;I7/+FZ!URYJ==LR:FG?-F9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-
MF)EWS9B9=\V8_WXB!O^ ,A#_D#@8_YL_(/^@0BC_I$8P_J9+./2H4$#LJ5='
MY*E=4-RE9EK0G6YHQY5U<[^.?7VYB82%LX.,C*U_DY&I?)N5I'FDF:%WK9N>
M=[F<G'?(G)EXRIR7><N;E7K,FI1ZS)F4>LR9E'K,F91ZS)F4>LR9E'K,F91Z
MS)F4>LR9_WXB!O^",A#_DC<7_YP]'_^A0"?_ID0N^ZE)-?&L3SSIKE5#X:]=
M2]6H9%G+H6MGPIES<[F3>GVRC8&%K(B)C*:$D)&A@)B6G7V@FIE\JIR6>[:=
ME'O$GI)\RIV1?<J<CWW+FX]]S)J/?<R:CWW,FH]]S)J/?<R:CWW,FH]]S)J/
M?<R:_W\B!O^$,1#_DS87_YX\'O^C/R7_J$(L^*U',N^P33GFM%0_W;-;2="L
M8EG&I&IFO)UQ<K27=WRLD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[*>C8#!
MGHR R9Z+@,J=BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;
M_W\B!O^%, __E386_Y\['?^E/23_JT$J];!%+^RU3#3CNE0YV+=92,NO85C!
MJ&AFMZ%O<J^;=7RGE7R$H)&#BYJ-BY&4BI.6CX>;FHN%I9V(A+"?AH2^GX6%
MR9Z%A,F=A83*G(6$RYN%A,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;_X B
M!O^'+P__ES46_Z Z'/^G/"+^K3\G\[-$+.FZ2S#AOU(UT[I81\>S7U>\K&9E
MLJ5M<:F?<WNAFGJ$FI:!BY22B)&.CY"6B8R9FH2*HIV!BJV??XJ[GWZ*R)Y_
MB<F=@(C*G("(RYN B,N;@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;_X$B!O^)
M+@__F345_Z(X&_^I.B#[L#TD\+A"*.:_2BK=PT\TSKU61L*V7E:WL&5DK:EK
M<*2D<7J<GWB#E)M^BHZ7AI"(E8Z5@I*6F7Z0H)QZCZN>>(^XGW>0R9YYCLJ=
M>HS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;_X$B!O^++0[_
MFS04_Z0W&?^L.![XM#HA[;U (^3&22/7QTPSR<%51;VZ7%6RM&-CJ*YI;Y^I
M;WF6I7:"CJ%\B8>=@X^!FXN4?)B4F'>7G9MSEJB=<9:UGG"6QIURE,J<=)++
MFW61RYIUD<N:=9'+FG61RYIUD<N:=9'+FG61RYIUD<N:_X(B!O^-+ W_G303
M_Z8T&/^O-1OTN#<<Z<,^'.#-11_1RTLRQ,540[B_6U.MN6%AHK1H;9FO;G>0
MJW2 B*=ZAX&D@8U[HHF2=:"1EG">FYEMG::;:IVSG&F>PYQKG,N;;IC,FF^7
MS)EOE\R9;Y?,F6^7S)EOE\R9;Y?,F6^7S)EOE\R9_X,A!O^0*PW_H#,1_ZDR
M%?VS,1?POC07Y<L[%=K4/QW+STDPOLE20K+$65&GOV!?G+IF:Y*V;'6)LG)^
M@:]XA7JL?XMTJH>0;ZB/DVJGF99GIJ289*:QF6.GP9EDI<V89Z#-F&B?S9=H
MG\V7:)_-EVB?S9=HG\V7:)_-EVB?S9=HG\V7_X0A!O^3*0O_HC /_ZTN$OBX
M+!+KQB\0X-4X"]+:/1S%U$@NN,]00*S*6$^@Q5Y=E<%D:(N]:G*#NG!Z>[=V
M@72U?8=NLX6+:+*.CV2QF))AL*.47K"PE5VQOY5=L="48*K0E&&HT)1AJ-"4
M8:C0E&&HT)1AJ-"48:C0E&&HT)1AJ-"4_X8A!O^7* K_IBP-_[$H#O+ )@SC
MT"@'U-\R"\G?/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W
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M0_^154+^F%9!_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A
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MASTX_XP]-_^3/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0
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M_Z5*.?^M2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+OK4" +#
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M,2W_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXRI,(  );/  "(WP
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M6SC_=V-!_W!L2/]L=T__9X)4_V.-6?U@EES\79]?^ENG8OA9KF3W6+9F]5?
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M23K\STDY_.-).?SC23G\XTDY_.-).?SC23G\XTDY_.-)QZT  +>W @"JPP(
MGM $ )/C"0",_1@"A/XG!WO_,0]R_S@6:?] '&+_1B)<_TTF5O]3*E+_62U.
M_U\P2O]E,D?_:S1$_W$U0?]Y-S__@3@\_XHZ.O^3.SC_G3PV_Z<]-?^Q/C3_
MOCXS_\H_,__*/S/_RC\S_\H_,__*/S/_RC\S_\H_N+(  *J]  "=R@  D=@"
M (C[#0%__QD"=O\D!F[_+0QF_S427_\\%UC_0QM3_TD>3O]/(4K_521&_ULF
M0_]@)T#_9BD^_VLJ._]R*SG_>2TV_X$N-/^*+S'_E# P_YPQ+O^E,BW_KS,L
M_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS,L_[<SJ[@  )[%  "0T@  @^   'W_
M#P%R_Q8":/\>!&'_)PA:_R\,5/\W$$[_/A-)_T061?]*&$'_3QD^_U4;._]9
M'#G_7QTV_V0>-/]I'S+_<" O_W<A+?]_(BO_AR,H_Y D)_^9)2;_H28E_Z<F
M)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<FG\   )'-  "#VP  >/8" &__#0%D
M_Q("7/\9 U3_( 1._R<&2/\O"$/_-@H__SP,//]"#CC_1P\U_TP0,_]1$3#_
M5A(N_UH3+/]?%"K_910H_VL5)O]Q%B/_>1<B_X$8(/^)&![_D1D=_Y<9'?^7
M&1W_EQD=_Y<9'?^7&1W_EQD=_Y<9_U8G!/]1,@7_5C4'_U\]#O]D11;_9DX?
M_V18)_]A8B__7FXU_UIY._]7A#__5(]#_U&81O]/H$C_3J=*_TVN2_],M4S_
M2[Q-_TK$3O])SD__2=Y/_TCI4/](\E#\2?90]TOY4/%,^D_K3OM0ZD_[4.I/
M^U#J3_M0ZD_[4.I/^U#J3_M0_U8G!/]1,@7_6#0'_V([#O]G1!;_:4T?_V=6
M)_]C8"__8&LU_UQW._]8@D#_58U$_U.61_]0GTG_3Z9+_TZM3?]-M$[_3+Q/
M_TO%4/]*SU'_2>!1_TGK4?Y)\E+Y2_=2\TWY4?_B?1!)0T-?4%)/1DE,10 %
M$NU/^E'F4/I2Y5#Z4N50^E+E4/I2Y5#Z4N50^E+E4/I2_U<G _]2,07_6C('
M_V0Z#O]J0A;_;$L?_VI4)_]G7B__8F@V_UYT//]:@$'_5XM%_U252/]2G4K_
M4*5,_T^M3O].M$__3;Q1_TS%4?]+T5+_2N)3_TGM4_M+\U/U3/=3[D_X4^A0
M^5/A4OI4X%+Z5>!2^E7@4OI5X%+Z5>!2^E7@4OI5_U@F _]4, 7_73$'_V<X
M#O]M0!;_;TD>_VY2)_]J7"__968V_V%Q//]=?4'_68A&_U:22?]4G$S_4J1.
M_U"K4/]/LU'_3KM2_TW$4_]-SU3^3.!5^TSK5?A,]%7P3_=5Z5'X5>)2^%;;
M5/E7V53Y5]E4^5?95/E7V53Y5]E4^5?95/E7_UDF _]7+@7_8"\'_VHV#?]Q
M/A7_<T@>_W)1)O]O6B[_:F,V_V5N//]A>D+_785'_UJ/2O]7F$W_5:!0_U2H
M4OY2KU/]4;=5_%# 5OI/RU;X3]Q7]4_I5_)/\U?J4O97X5/W6-I5^%G15OA:
MSU;X6L]6^%K/5OA:SU;X6L]6^%K/5OA:_UDF _]:+ 7_9"T'_VXS#?]U/17_
M>$8=_W=/)?]T6"W_<& U_VIJ//]F=D+_8H%'_EZ+2_M;E$_Y69U2^%>D5/96
MK%;U5+17\U.\6/)3QUGP4M5:[%+F6NE3\EGA5/5;UU;V7,]7]UW(6?A=QUGX
M7<=9^%W'6?A=QUGX7<=9^%W'6?A=_UHE _]=*@7_9RH&_W(R#/]Y.Q3_?$4<
M_WQ-)/]Z52S_=5XT_V]G//QJ<D+Y9GU(]F.'3/-?D%#Q79E3[UNA5NU9J%CK
M6+!:ZE>Y6^A6PUSF5M%<XU;D7-]6\%W55_5?S%GV8,9:]F# 6_9AOESV8;Y<
M]F&^7/9AOESV8;Y<]F&^7/9A_ULE _]@* 7_:R@&_W<P"_]^.A/_@4,:_X)+
M(O]_4RK_>ULS^79D.O5P;D'Q;'E([6B#3>IDC%'G8955Y5^=6.-=I5KA6ZU<
MWEJV7MQ9P%_:6<Y@U5GB8-%9[V'*6O1BPEST8[Q=]&2W7O-DME_S9+9?\V2V
M7_-DME_S9+9?\V2V7_-D_UPD _]C)@3_;R8%_WLO"_^".1'_AD$8_X=)(/^%
M42CX@EDP\GU@..UW:D#H<G5'Y&Y_3>%IB%+=9I%7V6.96M5@H5W27ZA@SUVQ
M8LU<NV/+7,=DR5S;9<5=ZV6_7?)FN%_Q9[-@\6>O8?%GKF+Q9ZYB\6>N8O%G
MKF+Q9ZYB\6>N8O%G_UTD _]F) 3_<B0%_WXN"O^'-Q#_BS\6_XQ''?F+3R7R
MB%8M[(-=-N9^9S[@>'%&VW-[3=5N@U/0:HQ8S&>47<EEG&#&8Z-CPV&L9<%@
MM6>_7\%HO5_0:;I@YFFU8>]JKV+O:JMC[VJG9.]IIF7P::9E\&FF9?!IIF7P
M::9E\&FF9?!I_UXC _]I(@3_=B,$_X(L"?^+-@[_CSX4_9%%&_213"+MCE,J
MYHI:,M^%93O7?FU%T'AV3<MT?U3&<(=:PFR/7K]IEV*[9Y]EN&6G:+9DL&JS
M8[MKL6/*;*]CX6RK9.UMIF;M;*-G[6R@:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H
M[FN?:.YK_U\C _]K( /_>2($_X4K"/^.- S_DSP2^)9#&.^62A[GE5 FX)%8
M+M>*83K.A&I%R'YS3<)Y>U6^=8-;N7&+8+5NDF2R;)IGKVJC:JQHK&RI9[9N
MIV?$;Z5GVF^B:.MOGFGL;YMJ[&Z9:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6V8
M:^UM_U\C _]N'@/_>R$$_X@J!_^1,@O_ESH/])I!%>N;1QKCFTTAVI95+<^/
M7CG(B6=$P8-O3;M^=U6V>7];L7:'8*USCV6I<)9HIFZ?;*-LJ&Z@:[)PG6O
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M<&>.ZG!GCNIP9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0 _*,5 .JP$@#9O@P
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MI#H[]K [.O>_/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH
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M&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP
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M9'5\\V1U?/-D=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8
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MKDM(Q;]+1\;82T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY
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M+S?ST"\W\^<O-O'S+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP
MDL8  (;0 0![W04 =/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(
M^U461?M;&$+[8AI _&@</?QP'3K]>!\X_8(@-OV-(C3^F",R_J0D,?^Q)3#_
MOR8O_\\F+O_C)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT
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M5X)O_5>";_U7@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@
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M0$7 Z#]$OO9!0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0
MK:X  **V  "8OP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'04QI<
MSUL?6,]B(U3.:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_--4'.
MZ#5 S?4W/\O^.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,
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M&RO[ZQLK^^L;*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@
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M2))@_T>28/]'DF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT
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M2%&8YDA1E_5(49?_1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0
MOYL! +2B  "KJ   H;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%M
MJUPG:*EC+&2H:C!@IW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRC
MY$-+H?1#2Z#_1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\
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M+3S%_RX\Q?\N/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP
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M"1S_W0D<_]T)F+   (JZ  !\Q   ;\T  &+8  !5W@  2>0  $3[!0 __PX
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M_S^"9/\__UD. /]D"P#_;@H ZG<( -M]" #4@@H S(02 ,.%) &[@S0%LX!
M#*U\2Q2F>50;H79<(9QS9":8<6LKE&]R+Y%M>3..:X$VBVJ).8AHDCR%9YL_
M@F:F08!FLD-^9L%$?6;91'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\
M:/\__UL, /]G"0#W<0< WGH% -2 !P#.A0D QX<1 +Z((@&VAS$$KX0^"ZB!
M21.B?5(:G'I:()=W82:3=6@KCW-O+XMQ=S.(;WXVA6Z&.H)MCSU_:YD_?&NC
M0GEJL$-X:K]$=FK4179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/]
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M1%]]Y4-@??9"8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P
MQX@! +Z/ @"VE0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4A9-0&G^16"!Z
MCU\E=HUE*G*+;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$
MXT):@_1!6X/_0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP
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M.$F;_SE)F_\Y29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@
MD:P  (>Q" "!LA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-BKU887JY='%JM9"!7
MK&LC5*QS)E"K?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F
M_S-#I?\T0Z7_-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(
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M&C/._QHSSO\:LYD  *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @
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M:@(0_W@"#O^' @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8
M 'F_  !KR0  7M,  %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q,
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M.FQJY#IM:_4X;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0
MS'D  ,-^ @"[@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=O
MXCIG;_0X:&__-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P
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M-EA^_S58?O\U6'[_-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0
MGI0  ):6#@"1EQP BY<K H66-P5_E$$*>9-)$'22415PD%@9;(]?'6B.9B%E
MC&TE88MT*%Z*?2Q;B8<O6(B2,56'GS-3AZTU4H>^-5&'UC51ANXU4H7[-%*%
M_S12A?\S4H7_,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD
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M*4"@_RE H/\IR7X  +J+  "OE   HYH  )B@  "-I0  @JH  '6P  !LLPP
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MC04JW)T&*=RM!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T
M )BE  "+K0  ?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8
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M 0?_D $%_Z !!/^N 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@
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M+GI:XRYZ6_4M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9
MSVH  ,=N @# < 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.
M9F,8BV5I&XAC<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>
MX2]T7_,N=%__+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT
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M+61K_RUE:_\L96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@
MIGX! )]_$ "9@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP
M=&X?;7-V(FIR?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O
M_RQ@;_\L8&__+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(
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M*4^ _RE/@/\IVVH  ,=U  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!(
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MD14ZJZ 6.:NP%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0
M *Z/  "BE@  EYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0
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M B'5N0(AU=("(-/K B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0
M>;$  &VX  !@O@  5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  B
MWR4 (> N "#@-P ?X4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;F
MK $5YL !%.?= 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD
M &'   !4Q@  2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\
M%^XF !7N+0 4[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *
M]:X "?;"  GVV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)
M  !'S@  .](  #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=
M  W](P ,_2D "OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL
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M'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5
MV5D  ,]; P#*6P8 Q%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<
M4V@1F5)O$Y=1=A654'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.
MXB&$3_,@@T__((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T
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MI")Y5K$C=U;!)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT
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M)F1BSR9D8NHF96+Z)&5C_R-E8_\B96/_(F5C_R)E8_\BZU4  -A@  #(:
MO&X  +-Q  "K<P  HG$  )MR#@"5<QP D'0J 8IS-@*%<D %@7!("'UO4 MY
M;5<.=FQ>$7-K9!1P:FP7;6ES&FMI?!QH:(8?9F>0(61GG"-B9JDE8&:Y)E]F
MS29?9N@F8&;Y)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$
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M(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M  "X=@  KGT  *6"  ":@P
MC8,  (2$ P!]A1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<
M@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[
M_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@
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M%SB5_Q<XE?\7NWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I
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M>@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD
M (^?  ""I@  =:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8
M&=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0
MWGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G
M  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X&
M !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX
M >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !K
MMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV
M"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N
M  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P
M4L@  $3-   WT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P
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M N$5_P+A%?\"X!7_ N 5_P+@%?\"_R4; /\F%P#_)!8 _R4< /\F)0#_)#
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M"ZTP_PNM,/\+_S,, /\V!@#_/ D _SX, /T]$ #O/!4 Y#D? -LY+0#2.CP
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MJ!2,1;05BT7$%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\
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M&W%2S1QP4N@;<%/Y&G!3_QIP4_\9<%/_&'!3_QAP4_\8[TD  -U3  #+6@
MP%\  +=B  "O80  J%X" *%?$ ";8!X EF L )%@. &-7D(#B5U+!85<4@>"
M6UD*@%I@#'U99PY[6&X0>%AU$G97?11T5X<6<E:1&&]6G!IN5JD;;%:X'&M6
MRQUJ5N8<:E?W&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(
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M'%MB_QM<8O\:7&+_&EQB_QI<8O\:X%4  ,M?  "]9P  LFP  *EP  "?;P
ME&P  (QM" "&;A, @F\A 'UO+0%Y;S@"=6Y! W)M205N;% ':VM7"FEK7@QF
M:F4.9&EL$6%I=!-?:'X676>)&%MGE1I99J(;5V:P'%9FPQU69M\=5F;S'%=F
M_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW
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M%T=U_Q='=?\7R64  +IO  "N=P  I'T  )A_  "+?P  ?G\  '.!  !L@PD
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M@P8QH)(',*"B""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX
M *.)  "7C@  C9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0
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M !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@
M<:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .
MT1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74
MF  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$
M %FX  !,O0  /\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T
M!-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB
MY)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!
M  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-
M  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH
M /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   S
MS0  )]$  !W6   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P
M"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)
M  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C<
M_P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_
M *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X
M_P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI!
M /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX
M]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F
M!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.
M20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA
M .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\
MVPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^
M$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/
MI0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_
M <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L
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MK@6H+[H%IB_*!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S
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M#X1 SP^"0>D/@4'Y#X!!_P^ 0O\.@$+_#H!"_PZ 0O\.^CL  .5$  #32P
MQTX  +Y/  "X3   LDD) *M)%0"E2R, H$LQ )Q+/0&82D<"E4E/ Y))5P20
M2%X%CD=E!HM':P>)1G()B$9Y"H9%@@N$18H-@D64#H!$GP]^1*L0?$6Y$7M%
MRQ%Z1>81>4;W$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,
M +A4  "Q4@  JTX% *1.$0">3R  F5 M )50.0&23T,!CDY, XM-4P2)35H%
MADQA!H1+: B"2VX)@$IV"WY*?@Q\28<.>DF1#WA)G!!V2:@2=$FV$G-)R!-R
M2N,3<4KU$G%*_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,  -E,  #(4P  O5<  +18
M  "L5P  I5(! )Y3#P"85!P DU0I (]4-0"+4T !B%-( H524 2"45<%?U!>
M!GU09 A[3VL)>4]R"W=.>PUU3H0.<TV.$'%-F1%O3:43;4VS%&Q-Q11K3N$4
M:T[T$VM._Q)K3O\2:T[_$6M._Q%K3O\1Z$8  --0  #$5@  N5H  +!<  "F
M6@  GU8  )A6#0"25QD CE@F (E8,@"&6#T!@E=% G]630-\550%>51;!G=4
M80AU4V@)<U-P"W%2> UO4H$/;5*+$&M1EQ)I4:,39U&Q%&91PQ5E4MX595+R
M%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  # 6@  M5X  *Q@  "B7@
MFED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:2P-V65($=%A8!G%87P=O
M5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O%6%5P19@5=L68%;Q%6!6
M_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T
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M$E-A_Q)38?\2T58  ,!?  "S9@  J6L  )QK  "0:@  A6<  'UI  !W:@T
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MA@L_>Y0-/GNC#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@
M *]R  "D>0  EGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB
M3X8J $Z'- !,ASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@Y
MA9$*.(2@"S:$L0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX
M  "??P  D'X  (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E
M $60+P!$D#@ 0I!  $"01P$_D$\!/9!6 CN07P(YD&@#-X]S!#6/@ 4SCXX&
M,8^>!S".KP<OCL,'+X[A!R^,] @OB_\(+XK_""^*_PDOBO\)L'8  *5_  "8
MA   BH0  'V%  !PAP  98H  %J.  !/D@  1I4  $&8#  ^F!0 /9D? #N9
M*  ZFC$ .9HZ #>:0@ VFDH -9I2 3.:6@$QFF0!+YIO BV:>P(LFHH#*IJ:
M RF:K 0HFL $)YG> R>7\@0GEOT%)Y7_!2>5_P4GE?\%J7X  )Z%  "2B0
MA(H  ':,  !JCP  7I,  %27  !)FP  0)\  #>B!  RHPX ,:,7 #"D(0 N
MI"H +:0R "RE.@ KI4, *J5+ "FE5  HI5X )J5I "6E=@$CI84!(J66 2"F
MJ $?I;L!'J77 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$
M &^4  !CF   5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$
M(+ I !^P,0 >L#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4
MLK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?
M  !;HP  4*@  $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP>
M !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP
M![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3
MKP  1[,  #RV   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)
M'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS
M  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N
M.[L  #"^   FP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%
MU1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>
MM@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0
M "3'   ;RP  $\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(
M .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0
M[K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1
M   1U@  "]L   />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/
M  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(
M /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_
M %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8
MIP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_
M .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8
M_P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M
M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$
M_P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!<
M /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@
MXP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4
M _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&
M80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M
M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\
M_QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A
M#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.
MM #(#L  Q@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\*
M /\<! #_'P@ _Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\
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M I\HU0*<*>P#FBKZ Y@J_P27*O\$ERK_!)8J_P26*O\$_R@  /4N  #E,P
MVC4  - S 0#,+08 QBH0 +XM'@"X+BP LR\Z *\O10"L,$\ J2]8 *<O7P&E
M+V8!HR]M :$O<P*@+GH"GBZ! ITNB0*;+I$#F2Z: Y@NI 26+Z\$E2^]!),O
MSP21,.@%CS#X!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT
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M"W)!_PIR0?\*<D'_"7)!_PER0?\)Z3P  -5%  #%2P  NDX  +!.  "G2P
MHD8  )M&#@"61QH D4@G (Y(,P"*2#T AT=& 81'3@&"1E4"@$9< WY%8@1\
M16D$>D5P!7A$> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$P QM1=D-;$7O#&M%
M_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH
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M#%M1_PM;4?\+UDH  ,-3  "V60  JUP  )Y:  "360  BU0  (16 P!^5A
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MA@I+8I0+26*B#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@
M +5@  "J9@  FV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24
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M"#=UK0@W=< (-G7>"#=T\@@W<_X(-W+_"#=R_P@W<O\(M68  *EO  ":<0
MBW$  'YQ  !S<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#
M@#4 0H ] $& 10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^
MJ@8P?KT&,'[:!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4
M 'EV  !N=P  8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3
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M !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP
M4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5
MJC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJ
MWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\
M #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB<
M";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP
MMN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O
M   LL@  ([4  !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F
M  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$
M ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   B
MO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/
M)   T"T  -(X  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.
M  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@
M$,D   K,   "T    -0   #7    V    -H%  #;"P  W X  -X3  #?&0
MX2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #J
MPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0
M  #9    W0   .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4
M / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L
M^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\
M:P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P
M .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\
M_PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W
M &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8
MM #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3
M /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L
M[ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8
M +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.
M#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M
M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@
MR #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_
M$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $
M;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;"
M +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@,
M_Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"
M#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0
MU "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD
M .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L
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M H<J_P*&*O\"ABK_ H8J_P*&*O\"]"@  .,Q  #1-@  Q3@  +PV  "V,
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M!F5 _P5E0/\%W#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q(
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MA@944),'4E"A"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L
M +E3  "K5P  G%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"<
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M!T-=K ="7;X(0EW:"$)<\0="7/X'0UO_!D-;_P9#6_\&O54  *]=  "?7P
MD%X  (->  !X70  ;5P  &5=  !?7P  6F , %=A% !58AX 4F(H %%C,0!/
M8SD 3F-! $QC2 !+8T\!26-6 4=C7@)%8V<"1&-Q T)C?01 8HL%/V*:!CYB
MJ@8]8KP'/&+6!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$
M ']A  !T80  :6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38
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M BIWZ@(J=OD#*G7_ RIT_P,J=/\#JFH  )IM  ");   ?&T  '!M  !F;@
M6W$  %!U  !(>   07L  #I^!0 V?PX -( 6 #.!(  R@2@ ,($P "^".  N
M@D  +8)( "R"4  K@EH *H)D "B"<  F@G\!)8*/ 22"H $C@K(!(H+) 2*!
MYP$B?_<!(G[_ B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@
M $Q\  !#@   .X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D
M(XQ" "*-2@ AC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9
MBO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$
M   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z
M !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO(
M$)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   V
MDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD
M.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S
M  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@
M)J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@
ML#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N
M]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX
M !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$
M +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP
MO>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\
M   )OP   L(   #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP
M  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L
M=YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'
MR@   ,X   #0    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@
M+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4
M %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V
M -P   #?    WP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@
M\2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\
M%0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V
M /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T
MZ@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_
M !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /
M>0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#&
M -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T
M_P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C
M 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P
MT0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P /
M /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4
MT@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"]
M ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!
M$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V
M ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\
ML 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B
M 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%
M=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP
M *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L
MS@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J
M#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3
M_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 .
M +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G(
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M 74K_P%U*O\!Y2P  - T  #!.   LS@  *@U  "B,0  G2T  )DJ#@"4*Q@
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MA@)>/I,#7#Z@ UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\
M +Q&  "K2   G$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H
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M!$Q+J@1+2[P$2DO3!4I+[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P
MD4\  (5.  ![30  <TD  &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!6
M33H 5$U! %-.2 !23D\ 4$Y7 4].7P%.3F<!3$YR DM.?0))3HL#2$Z9!$=/
MJ 1&3[H$1D_1!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$
M (%1  !W4   ;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@
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M S9<Z ,W7/D#-UO_ SA;_P,X6O\#LE<  *!:  "/60  @5D  '59  !K60
M8%H  %9;  !170  3%X" $A@#0!%8!0 1&$> $)B)@! 8BX /V(V #YC/@ ]
M8T4 /&-- #MC50 Y8UX .&-H 39C= $U8X$!,V.1 C)CH0(Q8[,",6/( C%B
MYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X
M %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$
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M !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9;   3V\  $5S   ]=P
M-7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8
MADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"
M_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,
M ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40
M#I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (
MC?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1
M   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(
M  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@
M@GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2
MH   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I
M2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8
M &^!  !AA   58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K
M!Z\   "R    LP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0
MN$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+
M  !:D   3I8  $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P
M  "^    O@   +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(
M ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3
MG@  1J0  #JK   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*
M    R@   ,P   #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#
M  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0
M/[0  #*X   DO   &+\  !##   (QP   ,H   #-    T0   -4   #8
MV0   -L   #=    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q
M1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5
M /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X
M] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C
M .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\
M&P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_
M .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@
MT@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[
M "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H
M@ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R
M ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T
MZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#(
M (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0
M^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B
M -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L
MN0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G
M /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,<
M)P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\
M *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\
MF@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W
M RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(
M?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_
M (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20
MJ XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2
M$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5
M_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J
M )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P
MA1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X
M'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>
M+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"!
M 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\
MW2D  ,@P  "W,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@""
M)30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\H
MB !N*)0 ;"BA &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\
M ,(V  "O-@  H34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\
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M 54YJ )4.;D"4SK/ E,ZZP)3.OL!4SK_ 5,Y_P%3.?\!Q#P  +)!  "@0
MDD   (8_  !^/0  >#H  ',X  !N.0@ :CD1 &<Y&@!D.B0 8CHL & Z- !>
M.CP 73M# %L[2@!:.U  6#M7 %<[7P!6/&< 5#QQ 5,\? %2/8D!43V7 4\]
MI@)./K<"3C[- DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,
M ()"  !Z0   <ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD
M5SY  %4_1@!4/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))
M0K4"24++ DE"Z ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%
M  !V0P  ;T   &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(]
M $]"0P!/0TL 3D-2 $U$6@!,1&, 2D1M 4E%> %(184!1T64 45%HP)%1K0"
M1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8  *9(  "42   AD@  'M'  !R
M1@  :D(  &-#  !>1   6D4+ %9%$@!41AL 448C $]&*P!.1C, 3$<Z $M'
M00!*1TD 24A0 $A(6 !'2&$ 1DEK $1)=@%#28,!0DF2 4%)H@) 2;,"/TK'
M C]*Y0(_2?<"0$G_ D!(_P) 2/\!MDD  *)*  "12@  @TH  '=*  !N20
M944  %Y'  !92   54D( %%*$ !/2A@ 3$HA $I+*0!)2S$ 1TLX $9,/P!%
M3$8 1$Q. $--5@!"35\ 04UH $!-= $^38$!/4V0 3Q-H $[3K$".D[& CI.
MY ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H
M %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440
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M 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6  !>5@  5%<  $Q9  !%6P
M/UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J
M9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A
M_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,
M #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\
M(FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <
M:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M
M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714
M !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\
MCF   'U@  !O80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B
M>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_
M6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4
M '=E  !J90  868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0
M%80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $
MB6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J
M  !G:P  6VP  %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\
M  R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED
M )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@
M<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2=
M P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?
M  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P
M38   $*%   XBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J
MJP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R
M9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT
M #N3   PF0  )IX  !RC   3IP  #:L   >N    L@   +4   "W    N
M +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@
MPVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B
M   HJ   ':T  !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8
M  #'    R00  ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\
M -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @
MMP  %;L   V^   $P@   ,4   #)    S0   -    #2    T@   -4   #6
M    V0   -L   #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE
M  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D
M_P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N
M (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T
M_P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q
M /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4
MX "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+
M /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\
M-P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"%
M ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\
MO #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#;
M #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X
MA@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_
M *T _P"M /\ _P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8
MQ0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N
M (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *
M_P"@ /\ _P   /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z
M +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A ((
MH "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2
M /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *<
M/0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"&
M )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\
M[P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9
M"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+
MC "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<
M -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D
MC!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z
M$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E
M  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\
M ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I
M;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K
M*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>
M/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*:
M &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P
MEB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K
M)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LI
MI0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,
M (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT
M8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3
M+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U
M  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]
M %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$
M333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T
M-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T
M0P!2-$H 4310 % U6 !.-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC#
M 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@
M:C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,
M.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X  13N. $0\G@!#/*X!0CS" 4(]
MWP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH
M & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0
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M #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@
M2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U
M2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+
M_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL
M #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45(
M+E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J
M3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2
M @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9
M "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\
MEDT  (1.  !U3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O
M6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>
M80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$
M 'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 ,
M)&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 7
M96H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5
M  !K50  8%8  %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H'
M !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4
M!Q(2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS
M  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@
M*FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *
M=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T
M]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(
M !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8
M ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@
M?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>
M   1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY
M  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8
M;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,
MCP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<
M.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT
M %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G
M *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0
MJSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y
M  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X
M  "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,
M +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$
MBP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
M    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U
M  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@
M,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-
MS0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G
M.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0
M /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4
M[@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#;
M .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\
M%0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U
M -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T
MR #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q
M !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P
M=0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K
M +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8
MVP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[
M '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@
M]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP <
M ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\
MJ@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9
M /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +,
M( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N
M )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@
MC #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D
M "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\
M;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_
M '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T
ME0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"!
M W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*
M_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@
M (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X
M=0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I
M$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0
M) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S
M &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\
MQR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q
M%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9
M>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<
M *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2,
M9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6
M(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L
M  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G
M %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\
M3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".
M,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H
M*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+
M $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P
M?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.
M+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$Q
MF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38
M &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P
M1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [
M-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX
M  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O
M $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4
M-CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?
M.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ
M-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV
M #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0
M53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U
M/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"
MRP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\
M $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8
M+T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F
M1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"
M   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ
M "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8
M(4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \
M2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0
M/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V
M !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3
M,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :
M5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15
M_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0
M "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D
M$5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .
M7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=
M   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%
M  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P
M=U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   9
M9P  $VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P
M2@  <%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8
M &-6  !95@  45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<
M#G,   MV!  %> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1
M>E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];
M  !66P  3%P  $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X
M  2! @  @@@  (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD
M (=7  "':   AWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !1
M80  1F0  #QI   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-
M    C@0  (X)  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.
M  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@
M/VX  #5T   K>0  (7\  !F$   1B0  #(T   :1    E    )@   ":
MFP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F
M50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L
M "V!   CAP  &8T  !&2   +EP  !)P   "@    HP   *8   "H    J0
M *H   "L    K00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P
MN%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0
M   ;EP  $IT   RB   #IP   *L   "N    L@   +8   "X    N    +H
M  "[    O0   +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%
M ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3
MI@  #*P   .Q    M@   +H   "^    P@   ,8   #(    R    ,H   #+
M    S0   ,X   #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56
M  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$
M_P M /\ . #] $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G
M '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -(
M_P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H
M /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H
MU !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#
M /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .(
M+@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z
M ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\
MKP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #)
M #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$
M>@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_
M *  _P"A /\ _P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P
MM  V +( /P"O $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@
M 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )(
M_P"1 /\ ]P   .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P
M *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0
MD !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"#
M /\ [    -,   #! 0  M    *P   "F  < H  . )T %@": "  EP I )4
M,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W
M (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\
MW@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "'
M #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8
M>P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA
M +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX
M>@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J
M!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7
M  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP
M &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$
M7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4
M'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81
M,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+
M %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@
M@2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<
M%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;
MEP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<
M '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#
M4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$
M(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ
M  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S
M $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z,
M/B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A
M+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F
M-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR
M #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P
M6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]
M*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(P
MQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$
M $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8
M-C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M
M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR
M  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[
M # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..(
M*3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"
M-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY
M00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST
M "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0
M.3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E
M/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !]
M_@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X
M #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0
M'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :
M1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$
M   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+
M !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\
M?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C
M2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%1
M4@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,
M &I$  !=1   4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40
M&E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *
M6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'
M  !92   4$@  $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H
M !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4
M &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !5
M2P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE
M!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=
M  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P
M2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !
M< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S
M9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154
M #M8   R7   *F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8
M 'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P
M@'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A
M   L90  (VH  !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&
M  "("@  B0T  (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@
M (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D
M<0  ''<  !1\   .@0  "(4   ")    C0   )    "2    DP   )0   "6
M P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T
M  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P
M%(4   V+   &D    )0   "8    G    )\   "A    H@   *0   "E
MIP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R
M@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4
M  ::    GP   *0   "H    K    *\   "Q    L0   +,   "U    M@
M +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@
MQXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J
M    KP   +,   "W    O    +\   #!    P@   ,0   #%    QP   ,D
M  #+    S0   ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L
M .&1  #BH@  XJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[
M #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .
MA0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_
M ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D
MZ !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#*
M (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H
M_P"V /\ _P   /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ]
M ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (
MM@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J
M /\ _P   /T   #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L
M/P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"!
M *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\
M_@   .X   #>    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G
M $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4
MA "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \
M -L   #'    N@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L
ME@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"%
M (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8
M  "U    J@   *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [
M (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (,
M=@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G
M!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H
M/ !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"*
M &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@
MCPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N
M #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"
ME0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,
M 'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C<
M8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4
M"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08
M  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY
M %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*(
M2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F
M'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1
M.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P
M $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0
M7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)
M%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<
MPP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,
M %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D
M0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U
M(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D
M  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$]
M #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP
M,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !(
M)0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F
M00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ
M "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*
M/R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M
M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N
M_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP
M #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4
M)S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B
M,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P
M   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1,
M "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\
M@C   '$R  !C,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K
M-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ
M5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(
M &TT  !@-0  538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@
M(SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4
M/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW
M  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$
M !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L
M#D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8
M.P  3SL  $<\  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5(
M"  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD
M  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@
M2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .
M40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2
M;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$
M $%!   [0@  -$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H
M!E@.  )8$@  61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0
M67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%
M   W1P  +TD  "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -
M  !@$   810  &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8
M &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R
M30  *E   "-3   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I
M#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$
M  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5
M)%@  !U<   68   $&0   QG   ':P   6X   !P    <@,  '('  !S"P
M=0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !Y
ME   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(
M !9G   0:P  "V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H
M (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP
MB*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T
M   *>0   GT   "!    A0   (@   "*    C    (T   "/    D 0  )((
M  "3#   E1   )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH
M )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !
MB    (P   "1    E0   )@   ":    FP   )T   "?    H    *(   "D
M!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG
M  "KN@  J\L 168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F
M )T   "A    I0   *@   "K    JP   *X   "O    L0   +,   "U
MMP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!
MK0  P;P /G(  #)X   G@   '(@  !*0   *EP   )T   "C    J    *T
M  "R    M@   +D   "[    O    +X   #     P@   ,0   #&    R
M ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP
MW*L _P   /\   #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /
M2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ".
M -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\
M_P   /\   #_    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9
M $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\
MD "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P
M /\   #X    [0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $<
MP !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K
M )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8
M  #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!(
M *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X
MF0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0
M    P0   +<  @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L
M2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3
M (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\
MKP   *8   ">  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"*
M $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H
MF@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP
M )<   "0  ( BP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$
M>P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K
M *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@
M  "#    ?P & 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!!
M &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\
M7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W
M!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &,
M00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K
M %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@
M:0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8
M $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%
MO !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$
M %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X
M3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"
M#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83
M  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY!
M $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8
M.A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.
M%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\2
M1  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N
M #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@
M1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W
M%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;
M^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L
M #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8
M+QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I
M'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>
M   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%,
M "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\
M@B,  '$E  !C)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R
M(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F
M5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4
M &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@,
M*R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =
M*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ
M  !=*P  4RP  $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL(
M ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP
M%R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:
M+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q
M#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G
M !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,
M33   $4P   ^,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7
M-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ
M=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,
M $(S   [,P  -C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P
M$#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &
M/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U
M   Y-0  -#4  "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.
M  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P
M $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W
M.   ,3@  "LY   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+
M$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,
M  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P
M+CP  "<^   B00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$
M4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2
MG   4K$  %'*  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(
M "-$   =1P  %TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$
M %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP
M6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,
M   73P  $E,   Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01
M  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@
M &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   2
M60  #5P   A@   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P
M$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X
M  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9
M!V@   !K    ;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@
M@!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  "
MR0  @.4 2DX  #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4
M  !Y    ?0   ($   "#    A0   (8   "(    B0   (L$  "-"   CPT
M )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0
MDM4 1%4  #E9   O70  )&,  !II   2;P  #'4   1[    @    (4   ")
M    C0   )$   "3    E    )8   "8    F@   )P   ">    H 8  *(+
M  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<<
M/EX  #)C   G:@  '7   !-X   ,?P   X4   "+    D0   )8   ";
MGP   *(   "D    I0   *<   "I    JP   *T   "P    L@   +4"  "W
M"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH
M "MP   @>   %H    V(   %CP   )8   "<    H@   *<   "L    L
M +,   "V    MP   +D   "[    O0   +\   #"    Q0   ,@   #*
MS@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\
M  #_    _P % /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3
M .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P
MQ@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_
M    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L
M5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A
M +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R
MY@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U
M %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$
MJ "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S
M ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T
MH !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0".
M +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P
M  "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !,
M (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D
M?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4
M  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\
M2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T
M &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&
M@0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P
M $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$
MP@!A .0 80#X &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 #
M '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4
M8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6
M -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &<
M!P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !%
M %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T
M3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!<
M 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X
M1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F
M $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0
M4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$
M TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'
M\P Z"/P CA   'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT&
M $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D<
M/ I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R
M#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,.
M" !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y-
M #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\
M@Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [
M$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T3
M5  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD
M &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0<
M-!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F
M&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>
M  !='P  4R   $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+
M "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L
M'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:
M(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=
M#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F
M !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P
M320  $4E   ^)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @
M(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F
M<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8
M $(G   \)@  -B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X
M&2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /
M*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I
M   Y*   -"@  "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1
M !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\
M"B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W
M*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R
M$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..
M  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0
M+RP  "LL   F+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 )
M.!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   X
MGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\
M "DO   D,   'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0
M #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G
M/K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R
M   @-   &S8  !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46
M  !%'0  120  $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T
M $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =
M.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-
M&0  3B   $XH  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!
M  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80
M$T,   ]&   +20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0
M5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3
MW0  4_  2SP  $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL
M  M/   %40   %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8
M &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U
M7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18
M    6P   %X   !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7
M  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@
M1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D
M9P   &L   !M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^
M&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<
M #E)   O3   )5   !Q5   46P  #F    =E    :@   &X   !R    =@
M 'D   !\    ?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0
MDAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1
M   H5@  'EP  !5B   .:   !VX   !T    >0   'X   ""    A@   (D
M  ",    C@   )    "2    E    )8   "8    FP   )X&  "A#   I!$
M *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A
M8@  %VD   ]P   '=P   'X   "$    B@   (\   "4    F    )L   ">
M    GP   *(   "D    I@   *@   "K    K0   +    "S!   MPP  +L2
M  "['P  NS   +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<
M$'@   F     B    (\   "6    FP   *$   "F    J@   *X   "P
ML0   +0   "V    N    +L   "]    P    ,,   #'    RP,  ,\,  #3
M%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P #
M /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D
MV0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\
M ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T
M!P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8
M +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T
MIP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*
M  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L
M5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#-
M )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @
MK0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6
M %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0
MY@"# /T A #_ (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  ,
M )8 $0"4 !D DP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\
MA !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S
M /0 = #_ '0 _P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (,
M#@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !.
M ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H
M9@#_ &8 _P!G /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R
M !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4
M3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X
M %H _P!: /\ J    )4   "'    >P   ',   !N    :@ ! &< " !E  X
M9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8
M $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X
M_P!/ /\ G    (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 /
M %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L
M30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!%
M /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\
M$ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!.
M $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\
MB0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!&
M !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H
M4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T
M '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X
M/@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q
M!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1
M  !?$P  5!0  $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0
M #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD
M*0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;
M%@  41<  $@7  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -
M$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E
M "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&
M31D  $49   _&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I
M$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3
M<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL
M $(<   \&P  -AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q
M(A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5
M&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>
M   Y'0  -!T  "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2
M !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\
M$!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V
M'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<
M%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/
M  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0
M+R$  "H@   F'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1
M(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <D
MG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",
M "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8
M#"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !
M**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D
M   B(P  'R,  !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:
M  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T
M "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A
M)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R
M'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!
M   QWP  ,?  5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0
M&BH  !8L   2+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@
M."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   W
MW@  -O  42L  $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\
M !,Q   0,P  #34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X
M $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W
M/?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W
M   ,.@  "3P   4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A
M  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/
M2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (
M0@   T0   !&    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2
M)0  4C   %(\  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8
M #LV   T-0  +S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@
M $T   !/    40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P
M72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y
M   S.   *SD  ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<
M  !:    7    %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,
M &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N
M/0  )4   !U$   620  $$T   I1   $50   %H   !=    8    &,   !F
M    :    &H   !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG
M  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10
M($H  !=.   05   "ED   )>    8P   &<   !K    ;P   '(   !U
M=P   'D   ![    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".
M*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54
M !!;   *80   6<   !M    <@   '<   ![    ?P   (,   "&    B
M (H   "-    CP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0
MI#$  *-$  "B60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI
M   !<    '<   !]    @P   (@   "-    D0   )4   "8    F@   )P
M  "?    H0   *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<
M +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y
M@0   (D   "/    E@   )L   "@    I    *@   "K    K    *\   "R
M    M    +8   "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O
M  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \
M]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#.
M &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +,
M_P"O /\ I0#_ )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2
M -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T
MM0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0">
M /\ F #_ )( _P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L
M%@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!;
M )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\
MB@#_ (4 _P"" /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A
M !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P
M6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_
M '@ _P!V /\ U@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0
MB@ < (H (P"( "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z
M %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L
M_P!I /\ P    *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7
M '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0
M: !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!=
M /\ K    )D   "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &<
M& !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5
M %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\
MG0   (L   !\    <0   &D   !D    8    %X !0!<  L 6P / %L % !:
M !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X
M6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D
M 'X   !P    9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4
M3@ : $X ( !- "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!#
M %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#
M  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6
M $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D
M. !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@
M"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L
M%P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@
M "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@
M4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S
M !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@
M:P G 7H )@&, "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$
M $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0
M*P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @
M!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3
M   Z$P  -1(  #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6
M "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D
M& R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W
M%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,
M&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"-
M !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P
M+Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8
M$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3
MG@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@
M "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@
M$A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )
M%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49
M   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<
M  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH
M QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @
M&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<
M'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]
M   =V   '>P 6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'
M&QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $
M(20  B(L  $B-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   A
MUP  (>T 51T  $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT
M !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$
M "<I   G,@  )ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@
M)>T 42   $4A   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@
M   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF
M   M+P  +3D  "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX
M32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /
M)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S
M*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224
M #XF   T)P  +2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+
M"BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P
M.C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI
M   Q*0  *RD  "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34
M  $W    .0(  #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX
M $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O
M+   *BL  "4J   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _
M    00   $,"  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT
M  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P
M*"T  "(O   ;,0  %30  ! W   -.@  "#T   )     0P   $8   !(
M2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7
M/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(
M !TU   6.   $3P   Q    '1    $<   !*    30   %    !3    50
M %<   !9    6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-
M940  &17  !D:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]
M   10@  #$8   9*    3P   %,   !6    60   %P   !?    80   &0
M  !E    9P   &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT
M '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,
M30  !5(   !7    7    &    !D    :    &L   !N    <0   ',   !U
M    =P   'H   !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%
M  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@
M &$   !F    :P   &\   !T    >0   'T   "     @P   (4   "'
MB@   (P   "/    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?
M4   G6<  )J!  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '
M  !W    ?0   ((   "&    BP   (\   "3    E0   )<   ":    G0
M *    "C    I@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10
MM5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")
M    D    )4   ":    GP   *,   "F    J    *L   "N    L    +,
M  "V    N@   +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$
M ,UH  #+@0  RI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M
M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0
M:0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_
M )0 _P"/ /\ ]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "
MS  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K
M &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@
M_P"$ /\ Z    -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B
M *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &(
ME0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X
M /\ V0   /_B?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?
MG  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"(
M $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8
MX !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $
M (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0
M=0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E
M /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '
M" !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!#
M &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H
M5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@
M  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8
M0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z
M $H _P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  <
M4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!)
M $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $
M_P!  /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P *
M $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X
M/0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V
M /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T
M"P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !!
M #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\
M<P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T
M  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L
M10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08
M %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H
M+  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B
M $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,
M  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+
M "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D
M&P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)
M#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'
M#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92
M !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$
M/!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9
M"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,
M7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,
M #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L
M$PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +
M#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4
M   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,
M  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH
M!A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G
M%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2
M#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z
M   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P
M(18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (
M%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9
MC   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@
M !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X
M AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@
M'*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9
M   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0
M   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\
M ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6
M&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F
M$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T
M   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'
M$1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$
M+14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   J
MT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$
M  TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(
M #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0
M,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI
M   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4
M   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T
M-R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P
M,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)
M%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H
M "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /
M #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P
M5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL
M   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D
M  !,    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4
M &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B
M,   &C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M    6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08
M  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.
M%#P   Y!   '1P   $P   !1    50   %D   !=    80   &4   !H
M:P   &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")
M'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@
M  A.    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0
M (    ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P
MH"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M    8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),
M  "6    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<
M +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L
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M__________________________________________________\
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M]O?X^?K[_/W^_VUF=#$      P0A   !                     0
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MT]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\
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M@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MGH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W.;%"Q/QQA$O\L074NK
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
MG=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT?^X% [_N!TG_[4I1O>P-6G>J$&0QYQAL<2<<;;"FWZY
MOYV&O;V:B<&[EXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N
M@*+4K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
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M@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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MCK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,*
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MRO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_
MF+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]
MK9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_
M" 7UP@\9]L(6-N[(%5#-W QFM=H/B*+)-J":OE:PE[=JN96U=KR4M'Z^E+.$
MOY"RA<"-L8;!BK&&P8BQA\*&L(C"A+")PH.PBL.!L(O#@*^-PWZOC\-^KX_#
M?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/P]G"!P7D
MQPL8[\@0--':"T6ZZ0YHIMX8@IC1-Y61R%.AC\)EJ8Z^<JZ-O'NRC+J!M8FX
M@K>'N(2XA;>%N8.VAKJ"MH>Z@;6(NX"UB;M^M8J\?;2,O'RTC;U\M(V]?+2-
MO7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O=3$!P36RPD5
MT]0+)[WB#$FI]!1EF>8E>([<.8:(U$^0AL]@EX3,;9R#R76@?\=XHGW&>Z1Z
MQ7VF><2 IW?#@:AVPH.I=<*$JG3!AJMSP8>K<L")K'&_BZUQOXNM<;^+K7&_
MBZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K<_&!P+0S0D2P-D)
M+*SW#TB;^AY<C^\Q:X;G0G: XE!^?MU?A7O9:8IWU6Z/=--SDG'1=Y1PT'J6
M;L]]EVW.?YELS8&9:\V#FFK,A9MIS(><:,N)G6?*C)UGRHR=9\J,G6?*C)UG
MRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G<K(" '"T@<3KN8)+9W_
M%4&1_RA0A_HY7('S2&9\[51N=^A>=7'D97IMX6M^:M]P@6C>=81FW'B%9=M[
MAV/:?HABVH&)8=F#BF#9A8I@V(>+7MB*C%[6C8U>UHV-7M:-C5[6C8U>UHV-
M7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C<3*!P.QV@05G_\-*)+_'3>)
M_RY#@O\]3GS]2U=W^%9?;_-=96CP8FID[6EN8>MO<5_I<W-=Z'=U7.=[=EOF
M?G=:YH!X6>6#>5CEA7I8Y(AZ5^2+>U;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..
M?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?/^J' 7_JB<7_Z<V+_^B1$KZG5)E
MZI=??MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]
M@)O!O7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=?
M?MR3;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!
MO7Z>P;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3
M;I//DGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>
MP;Q]H<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//
MDGBEQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]
MH<*\>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBE
MQI*"M,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\
M>Z3"O'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPO^J' 7_JB<7_Z<V+_^B1$KZG5)EZI=??MR3;I//DGBEQI*"
MM,22B;;#D8ZXP8Z0NL"*DKR_AY2]OH26O[Z"F<"]@)O!O7Z>P;Q]H<*\>Z3"
MO'JHP[QYK<.X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPO^J&P7_JB<7_Z<U+_^C1$KZG5%EZ9=>?MN4;93/DG>FQ9*!M,23
MB+;#DHVXP8^/NL"+D;R_B).^OH66O[V"F,&\@)O"O'Z>PKQ]H<.[>Z3$NWJI
MQ+IYK<2U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#
MM7FNP_^K&P7_JR87_Z@T+_^D0TKYGE!EZ9A=?]J5:97-E'2HQ91^M,25AK;"
ME8RYP9&.N[^-D+V^B9*_O8:4P;R#E\.[@9K$NGZ=Q;I]H<:Z>Z7&N7JJQK5Z
MK,:Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JM
MQ/^K&@7_JR47_ZDT+_^D0DKYGT]FZ)E<@-J69I;,E7&IQ95\M,26@[?"EXNZ
MP).,O+Z/CK^]BY#!O(>3P[J$EL6Y@9G&N7^=Q[A]H<BX?*;)M7JJR;![J\>L
M>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ?^L
M&07_K"06_ZDS+_^E04KYGT]FZ)E;@=F88Y;,EF^JQ99YM,.7@;?!F(FZOY6+
MO;Z1C<"\C8_"NHB2Q;F%E<>X@IC)MW^=RK9]HLNV?*C+L'NIRJQ\JLBH?:S%
MJ'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ?^L&07_
MK"06_ZHR+_^E04OYH$YGYYI9@=F989?+EVVKQ9=WM,.9?[?!FH>[OY>*OKV3
MC,&[CH[$N8J0Q[B&D\FV@IC+M7^=S;1^H\ZQ?*;.K'VHRZA]JLFE?JS&I7ZL
MQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQO^L&07_K2,6
M_ZHR+_^F0$OXH$UGYYQ7@=F:7I?+F&JLQ9ETM,.:?;?!FX6[OIF)O[R5BL*Z
MD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ&
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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M@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV
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MUJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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ML+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]J*3.?J2HRW^?JLF
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M)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!=JJ)OGVOA;R
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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M:_-KDW#P:9ES[F>?=^QEI7GK9*I[ZF*O?>EAM7[H8+U_Z%_%@.A>T('B7]J
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MZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_
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M&A[_G!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@
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MA^1Y<H?D>7*'Y'ERA^1Y<H?D>?]M$P'_=A,!_X@2 ?^8$P#_IQD![[,6 >+
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M=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X) ,O,"0#$TQ<
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M."[_[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0
MHKT  )3*  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/4O\]$TS_119(
M_TP90_]3&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I_Z<I)_^Y*R;_
MTBPE_^\L)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8
M (;3  !YX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V"D'_/0P]_T0.
M.?]+$#;_41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;'_^F'!W_MQT<
M_\H>'/_F'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>
M  !K]   8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O]
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M:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T XZD, -FU# #/N1H
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M24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP
MOZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@? G[H+09VZ#@.;NA!%F;G2AU?
MYU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z0^B@/$#ILCX_ZLL^/NCO/CWF
M_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P
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M'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW
M9^D  %__!@!8_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N
M_U )*_]7"BC_7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_
M^A07__H4%__Z%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4
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M67YR^UE^<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL
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M5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@
MTI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%U
MO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ
M_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<
M +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C
M9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%
MN?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G
M  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9
M(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_]
M0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@
MM   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@
M7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_
M-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP
MB<4  '[/ @!TV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2[$@/3>Q1$TKM6A9&
M[6,90^UM'$#M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O\R8T[/\F,NO_*#+G
M_RLSY/\L,^3_+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T
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M"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8  $?U  !!_P
M//\) #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<_SL"&?]" Q;_20,3
M_U$#$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_T 4'_^,%!__C!0?_
MXP4'_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\"
M "K_"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"
M!_]) @/_4P( _UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0,
M_[4# /^U _\Y)P+_,S("_S4T _\X-@/_.#L$_S9#!?\S3@?_,5L)_R]H#?\M
M=A'_*X04_RF1%O\IFQC_**09_RBM&O\HM1O_)[X<_R?('/\GU!W_)^0=_R?O
M'O\G^1[_)_\>_R?_'O\G_QW_*/\=_RO_'O\M_Q_\+_\?_"__'_PO_Q_\+_\?
M_"__'_\Z)P+_-#$"_S@Q _\[- /_.SD$_SI!!?\W2P?_-5@*_S-E#O\Q<Q+_
M+X$5_RV.%_\MF!G_+*$;_RRJ'/\KLAW_*[L>_RO$'_\KT!__*N$@_RKM(/\J
M]R#_*O\@_RO_(/\K_Q__+/\?_R__(?PQ_R+W,_\B]S/_(O<S_R+W,_\B]S/_
M(O\[)@+_-3 "_SLO O\^,0/_/S8$_SX]!?\\2 ?_.U4+_SEB#_\W;Q/_-7T7
M_S.*&?\RE1O_,9X=_S"G'O\PKQ__,+<@_R_ (?\ORR+_+]PB_R_J(_\O]2/_
M+_XC_R__(O\P_R+_,/\C^S/_)?4U_R7P-_\F\#?_)O W_R;P-_\F\#?_)O\\
M)@+_.2T"_S\L O]#+0/_1#($_T,Y!?]#10?_0E(+_T!?$/\^:Q7_.W@8_SF%
M&_\WD![_-YH@_S:C(?\UJR+_-;,C_S2\)/\TQB7_--0E_S3F)O\T\2;_-/LF
M_S7_)?XU_R;Z-O\H\SC_*>PZ_RGF//\JYCS_*N8\_RKF//\JYCS_*O\])0+_
M/2H"_T,H O]'*0/_22T$_THV!?]*00?_24T,_T=:$?]%9Q;_0G0:_T" '?\^
MC"#_/94B_SR>)/\[IB;_.ZXG_SJW*/\ZP2C_.LTI_SKA*?XZ[BG[.ODI]SO_
M*?8Z_ROP._\MZ#W_+N$__R[;0?\NVT'_+MM!_R[;0?\NVT'_+O\^)0+_028"
M_T@D O],)0+_3RD#_U(S!?]1/@?_44D,_T]6$O],8A?_2F\<_T=[(/]%AB/_
M0Y$E_T*:)_]!HBG_0:HJ_4"R*_Q O"S[/\@M^#_;+?1 ZRWP0/<M[4#_+^L_
M_S'D0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_] ) +_12,"_TP@
M O]2(0+_5B8#_UDO!/]9.@?_648,_U91$O]471C_46H=_DYU(?Q,@27Y2HLH
M]TF5*_5'G2SS1Z8N\D:N+_!%N##O1<0Q[473,>A&Z#'E1O8RXD7_-=]$_S;3
M1_\WRDC_.,1*_SB_2_\WOTO_-[]+_S>_2_\WOTO_-_]!(P'_21\!_U$< ?]7
M' +_7","_V L _]@-@;_8$$+_UY-$?U;6!CX6&0=]%5P(_%3?"?N4(8KZT^0
M+NE-F3#G3*$RY4RJ,^-+M#3B2\ UX$O/-=M+YC;52O0XT4K_.LY*_SS$3/\\
MO4W_/+A/_SRT3_\[M$__.[1/_SNT3_\[M$__._]"(@'_3!P!_U48 ?]<&0'_
M8R "_V8H _]H,@7_:#T)^F9($/1C4Q?N8%\=ZEUK(^9:=BCB5X$MWU6+,-Q3
ME#/949TVU5"F.--/KSK03[L[SD[)/,M/X3W'3_(^PT__0,!/_T&W4?]!L5+_
M0*U3_T"J5/\_JE3_/ZI4_S^J5/\_JE3_/_]&'P'_4!D!_UD5 ?]B%P'_:!T!
M_VPD O]O+@/Y;S@'\6Y$#NMK3A7E:%L<WV1G(]I@<2K477LOT%N%-,Q8CCC)
M5Y<[QU6@/<14J3_"4[1!OU/"0KU3UD.Y4^U$ME/]1;-4_T6L5O]$IU?_1*18
M_T.A6/]"H5C_0J%8_T*A6/]"H5C_0O]('0'_4Q8!_UT2 ?]F% '_;1D!_W(A
M ?MU*0+R=C,%Z78^"^)S2A+;;U<:TFMB(\UG;"O(9'8QQ&%_-\!>B3N]7)(^
MNEN:0;=9I$2U6*Y&LE>[1[!7S4BM6.A(JECZ2:=9_TBA6O](G5O_1YM<_T:9
M7/]%F5S_19E<_T697/]%F5S_1?]+&@'_5Q,!_V$0 /]K$@#_<A8 _W@< ?5[
M) 'K?2T#XGXY!]E[1A#0=E,:R7%>),-M:"R^:G$SNF=[.+9D@SVR8HQ!KV"5
M1:Q>GT>I7:E*IERV2Z1<QTRB7.)-GUWW3)Q>_TR87_]*E6#_29-@_TB18/]'
MD6#_1Y%@_T?_XGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0.
M /]O$ #_=A, _'T7 .^!'@'DA"<"VX0T!="!0P_(?$\9P7A:([MS9"RU<&TS
ML6QV.JUJ?S^I9XA#I6611Z)CFTJ?8J5-G&&Q3YE@P5"78-Q0E6'S3Y-B_TZ0
M8_],CF3_2XQD_TJ+9/](BV3_2(MD_TB+9/](BV3_2/]0%@'_7!  _V@- /]R
M#@#_>A  ]H$2 .F&%P#>BB !THHP!,F&0 [!@DT9NGU7([1Y82RN=6HTJ7)R
M.J1O>T"@;(1$G6J-2)EHETR59Z%/DF:M49!EO5*.9=13C&;P48MG_U"(9_].
MAVC_3(9H_TN%9_])A6?_285G_TF%9_])A6?_2?]2% '_7PX _VL+ /]U# #Y
M?@T \(4. ..+$ #6CQH S(XN!,.+/0V[ATH8M(-5(JU^7BNG>V<SHG=O.IUT
M>$"9<H!%E6^)29%MDTV-;)Y0BFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_
M38!K_TR :_]*@&O_2H!K_TJ :_]*@&O_2O]4$@'_80P _VX* /UX"0#H@@@
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M3&QY_TQL>?],;'G_3/]># #_; $ YGH  -:&  #+CP( Q)<$ +Z=! "XH@X
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M+S_']3 ]Q/\S.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0
MLI\  *6G  ":KP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17
MV$8)4]A0#4_861%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6
M\B,WU/\G-M+_*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4
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M"1K__PD9__\)&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT
M6]H  $[@  !#Y0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A
M_S\"'_]& AS_3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_
M]@4.__\%#O__!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$
M $#G   W\P  ,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!
M$O\X 1#_0 $._T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0,
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M/)%;_SN/6_\ZCUO_.H];_SJ/6_\ZCUO_.O],$@#_5@T _V ) /]H"@#Z;PP
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M8_\]@F/_/()C_SR"8_\\@F/_//]0#P#_6P< _V8# .QO @#<=@, U'P' -&
M"0#*@A0 PH,H KJ!.0>S?D80K'M1&:9W6B&A=&,HG')K+IAO<S.4;7PWD6N$
M.XUJCC^*:)A"AF>C1(1FL4:!9L-'?V;A1W]G^$5^:/]#?FC_07UG_S]\9_\^
M?&?_/7QG_SU\9_\]?&?_/?]2#@#_70, _6D  .%R  #6>@( SG\% ,J#" #%
MAA( O(<F ;6&-@:N@T,/IX!.&*%\6"";>6 GEG=I+9)T<#..<GDWBG"!/(9N
MBS^#;95#?VRA17QKKD=Z:[](>&O=2'AL]D9X;/]$=VS_0G=K_T!W:O\_=VK_
M/G=J_SYW:O\^=VK_/O]4# #_7P  \FP  -UV  #0?0( R8,$ ,2'!@"_BA
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M  #D<0  SWX  ,.(  "YD0  L)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ%
M#8"?2A5YG5,<=)M:(V^98BAJF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!
M4I+)0E*1ZT%2D/] 4H__/U6+_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #=
M=@  R8,  +V-  "SE0  J9L  *"@  "6IP  CZD/ (NJ(0&%J3 $?Z@\"GBG
M1Q)SI5 8;:-8'FBB8"1DH6<I7Z!P+EN>>3)7G80V4YR1.5"<GSM.F[ ]3)S'
M/4R;ZCQ,F?\\3)C_/$V5_SQ/D?\[4(__.U"/_SM0C_\[4(__.^MM  #3?
MPXD  +>3  "LF@  HI\  )FE  ".JP  A; + (&Q&P!\L2L"=[ X!W&O0PUK
MKDT49JU5&6&L71Y=JV4C6:IN)U6I=RM1J((O3:>/,DJGGC5(IZ\V1Z?&-D:F
MZ39%I/XW1:/_-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\
M +"8  "EG@  FZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.
M7K=2$UJV6AA6MF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U
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M'3'*_Q\PR?\A+\C_(2_(_R$OR/\A+\C_(;Z/  "OF@  HJ$  ):I  "*L
M?;@  '&_  !FQ@  6\P" %#2!P!'V@P 1MP8 $7<)P!$W34!0=U  C_>2P,]
MWE4$.M]?!CC?:0<UWW8),^"$"S'@E POX:8-+N&\#BWBX XMWO@/*]W_$BK<
M_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<
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M @?__P('__\"!___ I&M  ""N   <\(  &3,  !6U0  2-T  #OB   PYP
M)^X  "/_   @_P0 '/\, !G_$0 6_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '
M_SX !/](  #_5   _V(! /]S 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_
M\P$ __,! /_S 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T
M !C_   5_P  $?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX
M /\W  #_00  _TT  /]<  #_;0  _X(  /^6  #_J   _[H  /_#  #_PP
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M)ZY&_R>J1_\FITC_)J=(_R:G2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$
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M+X5;_R^%6_\OA5O_+_]+# #_5   ^UX  .)E  #8:P$ SVX% ,QP" #&<A(
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M.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A:@
MS74  ,!^  "VA@  KHL  *6.  ";D0  E9,1 )"4(@&+DS$#A9(]"7^12 ]Z
MCU$6=8U9&W&,8"!LBF@E:(EP*62'>2UAAH,Q786/-%J$G#97@ZPX58._.56#
MX3A5@ODW5H+_-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH
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M*T*<_RQ"F_\L1)?_*T27_RM$E_\K1)?_*]=R  ##@   MHP  *J4  "?F0
ME)X  (FC  !^J   <*X  &JP#@!HL1T 9;$L 6&Q. -=L$,&6;!,"E6O5 Y2
MKUT13JYE%4NN;QA(K7D;1:V&'D*LE2 _K*4B/JVY(SVMV"(]J_4C/*G_)3NG
M_R8[IO\F.Z3_)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0
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M#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0  (:L  !YM   ;+L  &#"  !4Q@
M2,L  #[0   UU00 +=T* "SA$P KXA\ *>,J "CD-0 GY#\ )N5* "3F50 C
MYF$!(>=N 2#G?@(>Z) "'>FD AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC
M_P48X_\%&./_!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,
M #+:   JWP  )>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5(
M$_9? !+V;@$1]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-
M\_\!#?/_ 9FC  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B
M   ?Z@  '/L& !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].
M  ;_7  $_VP  O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\
M /__ (VK  !]M0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5
M^0  $O\  !#_"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_
M20  _U<  /]I  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z
M ("U  !POP  8<D  %+3  !#VP  ->$  "GF   >Z@  %>X  !#X   ._P
M"_\   C_   $_P8  /\*  #_#@  _Q$  /\5  #_&P  _R,  /\K  #_-@
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M#](L_Q#1+/\0SRS_$,XM_Q#.+?\0SBW_$/\R&0#_-Q0 _SH1 /\\$@#_/QD
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M'II'_QZ:1_\>FD?_'O] #0#_1@0 _TP  /A2 @#H500 X54( .)5#0#551D
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M,6EGW#!I9_4N:6?_+&EG_RIJ9_\I:F;_*&IF_R=J9O\G:F;_)_]0  #G6P
MTV8  ,5N  "[<P  LW<  *MY  "D> , G7H4 )A[)0&3>S0#CGI !XEX2@V$
M=E,2@'5;%WQS8AMX<FH?=7%R(G)O>R9O;H4I;&V0+&ELG"YF;*HP9&R\,6-L
MV3!C;/0O8VS_+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD
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M*U)\_RE3>_\H5'K_)U1Z_R=4>O\G5'K_)^A>  #0:P  P'8  +1^  "KA0
MH8D  )>+  ")C0  @X\( 'Z0%P![D2<!=I$T W*0/P9MCTD+:8Y1#V6-61-B
MC& 77HMH&UN*<1Y7B7LA5(B&)%&'E"=/AJ(I38:T*DN&S"I+A>XI3(3_*4R#
M_RA,@_\G38'_)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX
M )&1  "$DP  >I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T3
M6)-E%U63;AI1DG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&
MB_\D1HK_)$:*_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6
M  !^F@  <)T  &N?#@!HGQP 9J J 6*@-P)?GT$%6Y]*"%B>4@M4GEH.49UB
M$DZ<:Q5+G'482)N!&D6;CQU"FI\?0)JP(#^:R" _F>L?/YC_(#Z6_R$^E?\A
M/Y3_(3^4_R$_E/\A/Y3_(<UP  "\?0  L(@  *2/  "9E   CI@  (.=  !W
MH   ::0  &"G" !=J!0 6ZDD %FI,0%6J3P"4ZE%!%"H3@9-J%<)2JA?#$>G
M: Y$IW,10:9_%#ZFC18\IIT7.J:O&#FFQQ@YI>H8.*/_&C>A_QLWH/\<-Y__
M'#>?_QPWG_\<-Y__',1X  "UA0  J8\  )V5  "2F@  AI\  'JC  !NJ
M8JP  %6P  !0L@X 3K(; $VS* !+LS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\
MLV\*.K-[##>SB@XULIH/,[.M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L
M_Q8OK/\6+ZS_%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0
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M IZ:  "2H0  A*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0
M'-L  !7?!0 4Z0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )
M\'0 "/&)  ?RH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A
M  "&J0  >+(  &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0
M  _P 0 -^0H "_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$
M /UU  #\C   _*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !Y
ML@  :KL  %S$  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]
M   %_P,  ?\)  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?
M  #_=0  _XT  /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO
M7<8  $[/   _U@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_
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M ?\"GP'_ :4 _P&L /\!L@#_ ;H _P'$ /\!T0#_ .0 _P#Q /\ _ #\ ?\
M_ +_ /P#_P#\!/\!_ 7_ ?P%_P'\!?\!_ 7_ ?\?)@#_(2( _R A /\>(P#_
M&"< _Q,P /\1/ '_#DH!_PU7 ?\+8P'_"F\!_PIZ ?\*A '_"HT!_PJ4 ?\*
MFP'_"J(!_PJH ?\*KP'_"K<!_PK  /\*S #_"N  ^PKO /<*^@#U"_\!]0S_
M ?0-_P'T#?\"] W_ O0-_P+T#?\"] W_ O\B(@#_)!T _R0< /\B'0#_'B(
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M#+LL_PR[+/\,NRS_#/\Q$0#_-0P _S8' /\Z"P#_/!  _SL5 /@Y'P#O-RL
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M2[,>BTO%'HE+XAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]
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M(WA5UR-W5?(B=E;_('96_Q]V5O\==E;_''96_QMV5O\;=E;_&_]%  #L3@
MVE@  ,E>  "_8@  MV0  +%C  "K80@ I&,7 )]D* ":93<"EF1#!9%C30B.
M854,BF!=$(=?91.$7FP6@5UT&7Y<?1Q\6X8>>5J1('=:G2)T6:HD<EFZ)7%9
MTB5P6O C;UK_(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL
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M(U]G_R%?9O\?8&;_'F!F_QY@9O\>8&;_'N]/  #:7   QF4  +IM  "P<@
MIW4  )UT  "4<P  C70- (EV' "%=RL!@7<X WQV0P9X=4P)='14#7%S6Q%N
M<F,4:W%K%VAP<QIE;WP=8FZ'(%]ME")=;*(D6FRR)5ELQR58;.@E66S](UEK
M_R%::_\?6VO_'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD
M )EY  "-=P  AWD+ (-[& !_?"@ >WPU G=[0 5S>DD(;WE1#&QX60]H=V$3
M979H%F)U<!E?='H<7'2%'UISD2%7<J C57*P)%-RQ213<N<D4W'\(E1Q_R!4
M</\?57#_'E5O_QU5;_\=56__'>57  #-9   OFT  +)U  "H>P  GWX  )-]
M  "'?0  @'\' 'R %0!X@20 =8(R 7&!/01M@$8':8!/"F9_5@UC?EX18'UF
M%%U\;A=:>W<:5WJ"'51ZCQ]1>9TA3WFN(DYYPR)->.4B37?[(4YW_Q].=O\>
M3W7_'4]U_QU/=?\=3W7_'=]<  #(:   N7(  *YZ  "E@   FH(  (Z"  "
M@P  >84" '2&$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$
M:Q14@W4748* &DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_
M'$E\_QQ)?/\<27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0
M<(P  &N.#0!HCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-
MC'(32HM]%DB*BAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$
M_QI"A/\:0H3_&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0
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M#;6   "HBP  G)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@
M-K4+ #2U%0 SMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(G
MN8T");F? R2YM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*
M  "@D0  E9<  (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X#
M "3"#  BPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4
M&<>9 !C(K@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8
MF   BYX  'VE  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,
M!  3T H $=(1 !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-
M  O8I  *V+X "=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP
M@*8  '*M  !DM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,
MVP4 "-X+  ;?$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #F
MD@  YJH  .?(  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\
M &6W  !7O@  2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0
M .D&  #I#0  Z1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@
M])<  /6P  #VT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!
M  !*R   .\P  "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0
M  #U!0  ]0L  /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$
M /^:  #_L@  _\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [
MT0  +=@  "'=   6X@  #N8   CJ    [0   /    #X    _P   /\   #_
M    _P   /\&  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!
M  #_F0  _Z\  /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT
M_P U /\ 00#_ $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_
M *0 _P"J /\ L #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P
M /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *
M_P"F /\ K0#_ +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X
M /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'
M.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C
M /X J0#\ +  ^@"Y /< Q #U -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\
M[P#_ /  _P#P /\ \ #_ /\>'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_
M#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&
MI@#T!JT \@:U / %P #M!<X ZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_
M >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP
M_Q%) /\050#\#F$ ^0YK /8.=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J
M#JH Z ZS .8/O0#E#\P X0_C -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3
M_P+2$_\"TA/_ O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E#
M /083P#O%UL [!=F .D7< #F%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z<
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M"/\O" #_,0  _S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D
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M50.D1%X%H41F!Y]#;@B=0W8*FT)^"YE"A@V708\.E4&9#Y-!I!&10; 2D$'
M$HY!V1*+0?$2B4+_$HA"_Q&(0O\0AT+_$(="_P^'0O\/AT+_#_\X  #S/0
MXT<  -),  #(3@  P$T  +M* @"V1PX L$D= *M++0"F3#L!HDQ' IY+402;
M2UH&F4IB")9):@J427$,DDAY#H](@@^-1XL1BT>5$HE&H!2'1JP5A4:[%H1&
MT1:"1^X6@$?_%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P
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M&6I5_Q=J5?\6:E7_%6M5_Q1K5?\4:U7_%/)#  #?3P  RU@  +U=  "S80
MJV(  *)@  ";7   E5X0 )!@'P",82X B&$Z H1@102!8$X&?E]6"7M>70MX
M764.=EQL$'-<=!-P6WT5;EJ(%VM:E!EI6:$;9UFP'&59PQQD6>,<9%GZ&F19
M_QAD6?\795G_%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8
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M%E9E_Q569?\55F7_%>)1  #*70  NV8  *]L  "F<0  F7   (YO  "#;@
M?7 % 'AR$@!U<R$ <G,O 6]S.@)L<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;
M;W036&Y_%55NBQ=3;9D946VH&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J
M_Q50:O\54&K_%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4
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M$<5F  "U<0  JGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\
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M R>EK00FI<8#)J3K!"6B_P4EH/\&))__!B2>_P<DGO\'))[_!Z]^  "CB
MEXX  (V3  !^E0  <)@  &.;  !7GP  3*(  $*F   XJ0  +ZP# "JN#@ I
MKA@ **\C ">O+0 FL#< );!! "2P2P CL58 (K%C "&Q<0 ?L8( 'K*4 1RR
MJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90
M (2:  !VGP  :*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX
M%[L6 !>\(  6O"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .
MP+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA
M  !KIP  7JP  %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-
M  G*%  (RAT !\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L
M ,W(  #,[0  S/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@
ML   4K8  $6Y   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4
M#@  U14  -8>  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T
M  #>V0  W_<  -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@
M1;\  #C"   LQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0
MX@X  .03  #E&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #P
MO   \.,  ._Y  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@
M "K,   ?T   %=4   [:   'W@   .(   #F    Z0   .H   #L    [@4
M .\,  #Q$   \Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@
M_\   /_A  #_]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8
M   3W0  #.(   /F    Z0   .P   #P    \P   /0   #V    ^    /H
M  #]!P  _PT  /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8
M /^Z  #_T0  _]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\
MJP#_ +( _P"Z /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_
M /X _P#^ /\ _@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^
M *X _0"V /P P #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4
M_P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H
M] "R /( NP#Q ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J
M /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\
M5P#_ &( _ !L /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N
M .< MP#F ,, Y #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\
MW0#_ /\;$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W
M EP \@)F .X"< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$
MM #8!<  U@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_
M /\?$ #_'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8
MY0QA .(,:@#>#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+
M#K\ R@_0 ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B
M# #_(00 _R   /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1:
M - 59 #-%FT RQ9U ,D7?0#'%X4 Q1B, ,08E #"&9P P!FE +X9KP"]&KL
MNQK+ +@;Y0&T'/8!LAW_ K =_P*O'?\"KAW_ JX=_P*N'?\"KAW_ O\F!@#_
M)0  _R8  /LG  #Q)0, \"$+ .@<$@#>&1T U!LM ,T=/ #('TD Q2!5 ,$A
M7P"_(F@ O")P +HC> "Y(W\!MR.' ;4CCP&T))<!LB2@ ;$DJ@*O)+8"K27&
M JLEWP*H)O,#I2;_ Z,F_P.B)O\$H2;_ Z$F_P.A)O\#H2;_ _\I  #_*
M]BT  .<P  #?+P  V2L$ -8B"@#.(Q8 QB8G , H-@"[*D0 N"M/ +4L60"R
M+&(!L"QJ :XM<@&L+7H"JBV! JDMB@*G+9(#I2V; Z0MI02B+;$$H"W !)\M
MV 2<+N\%F2[_!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4
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M#7E"_PQX0O\+>$+_"WA"_PIX0?\*>$'_"O8V  #F0   T4@  ,--  "Y3@
ML4T  *E)  "D108 GT83 )I((P"623( DDH^ 8]*2 *,2E$#BDE9!(=)8 6%
M26@'@TAO"(%(=PI_1X +?4>*#7I'E0YX1J(/=D:P$'5&PA!S1N 0<D?W#W%'
M_PYQ1_\-<4?_#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(
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M#E]3_PU?4_\-7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6
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M#=%4  "^7@  L6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!<
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M"CE^K LW?L,+-WWF"S=[_ LW>O\+-WG_"CAX_PHX>/\*.'C_"KYD  "P;P
MI7@  )9Y  "'>0  >WD  '!Z  !D?   6(   %"#  !+A0H 2(84 $>'( !%
MB"L 1(@U $.(/@!!B4<!0(E/ 3Z(6 (\B&$#.HAL!#>(> 4UB(<&,XB8!S*'
MJ@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\
M )!^  ""?@  =G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2,
M.9$M #B2-P WDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,H
MDKT$*)+A R>0^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$
M  !]A   ;X4  &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD
M "N<+@ JG3@ *9U! "B=2P GGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!
M'I[= 1Z<^ (>FO\"'IG_ QZ7_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !U
MBP  :(X  %N1  !0E0  1ID  #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH
M)  <J"T &Z@W !JI00 9J4P &*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3
M !*H]0 3I_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !ME0
M8)@  %2<  !(H   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU%P .
MM2$ #;4K  VU-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%  :V
MZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0
M $NH  ! K   -;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D
M ,$B  #"*P  PC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@
MQ/8  ,/_  ##_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U
M   UMP  *;H  !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8
M  #.(0  T"H  -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND
M -;]  #6_P  UO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   H
MP0  '<0  !3'   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?
M%0  X1T  .,G  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO
M  #K_@  Z_\  .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP
M$L\   O3   "V    -T   #A    Y    .4   #G    Z0   .L'  #M#0
M[Q$  /$9  #T)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #]
M[0  _?0  /WT '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T
M  #A    Y0   .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@
M /X.  #_%0  _R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@
M_]0  /_4 /\+( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\
M8@#_ &T _P!V /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U
M /\ O@#_ ,L _P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\
M^0#_ /\-'0#_"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_
M &@ _P!R /\ >@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D
MN0#X ,8 ]@#9 /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_
M /\0&0#_#A4 _P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &,
M_@!M /P =0#Z 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M
M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2
M% #_$!  _PP/ /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G
M /$ < #O '@ [0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H
MW0#) -L X #8 /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_
M$@P _PX) /\+# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4
M:@#B '( X !Z -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$
M ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04
M_Q   /\0!@#_#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2
M VP SP-T ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(
MU0"[">P N O] +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<
M /\6  #[$P8 ^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6<
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M I H_P*/*/\"CB?_ HXG_P*.)_\"CB?_ O\F  #R*0  XS$  -(T  #(-
MP#   +LI @"X(PX L28< *PH*P"H*C@ I"M$ *$L3@"?+5< G2U? )LM9P&9
M+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./+J8#C2ZS XPNQ0.*+^$$AR_V!(4O
M_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD
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M!FI!_P9J0?\%:D'_!>TW  #60@  Q$D  +=-  "K30  H$H  )A'  "30@
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M!]I&  ##4   M5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L
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M"D9BJ@M$8K\+1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7
MJV0  )MD  ",8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6
M:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!H
MJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD
M )9H  "'9P  >V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X
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M !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P
MB8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6
MH P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VC
MD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@
M '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0
M"JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP
MKIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2
M  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)
M  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$
M +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5
MHP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%
M"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;
M  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@
M/K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0
MTP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #E
MI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\
M "/#   7QP  #\H   ?.    T0   -8   #<    WP   .    #B    Y
M .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP
M^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.
M   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O    \0   /,
M  #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD
M /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_
M $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\
MH0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_
M /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $(
M_P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y
M *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X
M_P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!)
M /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\
M[ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A
M /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8
M3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A
M -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\
MS #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E
M %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@
MI0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_
M /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P
MSP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X
M *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4
M  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0
M +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@
MJ@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_
M$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.
M4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S
M )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0
MY2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B
M&58 H!I= )X;90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >
MOP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT
M ,HP  "^+@  M2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$
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M!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$  +-#  "E00
MFSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4 >CQ- '@\50%W
M/%P!=3QC 7,\:@)Q/',"<#Q\ VX[AP-L.Y0$:CNA!&@[L05G/,4%93SE!60\
M^@1D//\#8SO_ V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,
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M!%))_P-22/\#4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX  'Y,  !X2
M<DH  &Y+#0!K31@ :$XD &9.+P!D3SD 8D]" &%020%?4%$!75!8 EM/8 )9
M3V@#5T]R!%5/?0533XH%4DZ8!E!.J =.3KL'34[9!TU.]09-3O\%34W_!$U-
M_P1.3/\#3DS_ \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\
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M \%0  "Q6@  H5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T
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M BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A  "D:0
MD&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8* #1W$@ S
M>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8 )GJ' 25Z
MF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT
M 'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0
M)H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :
MA*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q
M  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5
M !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0
M#H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D
M>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:
M%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ
M  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0
M4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$
MI18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "F
MPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$
M #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$
M +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@
MM=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D
M   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0
M  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<
M ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @
MMP  %KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0
M#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9
M  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@
M#,8   /)    S    -    #5    V0   -H   #<    W@   .    #B!0
MY L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #T
MWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(
M  #7    W    .    #E    YP   .D   #K    [0   .\   #Q    \P
M /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@
M_]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\
M6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K
M /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\
MYP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_
M &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0
MK@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_
M /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H
M^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D
M +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'
M#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!=
M .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T
MS0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_
M 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0
M7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S
M +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!
M_P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#
M &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P
MO0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D
M .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L
ML !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"=
M \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5
M  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E<
M *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P
MD [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_
M'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )82
M7@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G
M ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@
MJB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")
M'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B
M^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H
M )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP
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M 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)   "5/@  BSP  (0Y  !_-@
M>S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI# &HZ2P!H.U( 9SM9 &4[80%C
M.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#6#O2 U<[\0)6._\"5CO_ E8Z
M_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H
M '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7 %] 7@%=0&8!
M7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/\"4#__ E __P)1
M/O\!43[_ <\[  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\  &M
M# !G014 94(A &-#*P!A0S4 7T0^ %Y$10!=14T 6T54 %E%7 %8160!5D5M
M 51%> )2184"4423 T]$HP--1;0#3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"
M3$+_ LH_  "Y2   IDH  )5)  "'2   ?4<  '5%  !N0@  :4,  &5$"0!B
M11, 7T8> %U'* !<2#( 6D@[ %E)0P!724H 5DE2 %1)60%326$!44EK 4])
M=@)-28("2TF1 TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_
M L9#  "V3   HDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A
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M CI7FP(X5ZT"-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@
ME54  (54  !X5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$
M6R4 0ULN $)<-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=
MF0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@
M (!8  !S5P  :5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82
M.V(I #IB,@ Y8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L
M8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;
M  !O6P  95L  %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD
M #)I+0 Q:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z<
M(VN] ")JX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J
M7P  86   %=@  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ
M)@ G<B\ )G(W "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y
M !ESW  :<?< &G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9
M760  %)F  !(:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;
M>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]
MU0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH
M $QM  !#<   .70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\
M$(<H  Z',0 .ASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &
MA>P !X3_  B#_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U
M   \>0  ,GT  "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@
M  &2*0  DC,  ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4
M )#Z  "/_P  C_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    T
MA   *XD  "*-   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">
M(@  GRL  )\U  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV
M  "=_P  G/\  )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0
M(Y8  !J:   2G@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0
MK2(  *XK  "O-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M
M_P  K?\  *W_ (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0
M !*H   ,K   !*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@
M +TA  "^*P  P#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0
MP/\  ,#_ 'F-  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX
M   "NP   +X   #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5
M  #0'P  TRL  -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L
M -C_ '"9  !@G@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%
MR    ,L   #/    T@   -,   #6    V    -L   #=    WP<  .(-  #E
M$P  Z!T  .PJ  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T
M &>F  !8K0  2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@
M -P   #@    XP   .0   #F    Z    .L   #M    [P   /("  #U"@
M^!$  /P<  #_+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\
M% #_ !( _P 2 /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H
M /\ < #_ '@ _P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D
M^@#( /D X@#X /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_
M  X _P . /\ #P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X
M:P#\ ', ^@!Y /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#!
M .L U@#J .X Z0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H
M_P ( /\ "0#_ !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N
M &T [ !T .L >@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H
MR@#7 .8 U #X -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P
M /\  P#_  T _  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &<
MVP!M -D = #5 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@##
M -P P0#Q +\ _P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\
M  #V  @ [@ 1 .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G
M ,0 ;0#" ', P !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X
ML #J *\ _ "M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H
M    W@ , -, %0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0
M9P"R &T L !T *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C
M )\ ]@"> /\ G@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5
MRP & ,, #P"] !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D
M &@ H@!N *$ =0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )(
M\@"1 /\ D #_ )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<
M +< "@"Q !( K  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6,
ME@)I )0"< "3 W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$
M"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-
M  "F!PT H@46 )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE
M (D-; "(#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\
M=Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9
M$00 F X0 ),0&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6
M: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_
M &T:_P!M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'
MC!<, (@8%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S
M'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B
M_P!D(O\ 9"'_ . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B (
M 'X@$@![(AX >",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@
M:2AQ &<H>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<
M*?\ 7"C_ -@L  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G
M$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N
M %\O> !>+X0 7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\
M52[_ - Q  "].@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K
M+Q8 :3 A &8Q*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU
M=0!7-8( 5360 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_
M <LV  "X/0  HSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1,
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M0P  FD(  (I"  !]00  <T   &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5
M(@!302L 4D$T %!"/ !/0D, 3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.)
M 4-#F0%"0ZL!0$/  3]#X0$_0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10
MED4  (9%  !Y1   ;T0  &="  !@/P  6T$  %="  !40PT 4405 $]%'P!.
M12@ 3$8Q $M&.0!*1T$ 24=( $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(
MEP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<
M ()'  !V1P  :T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4
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M "E7U@ I5O4 *57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4
M8%   %A1  !.4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q
M6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=
MT@ B7/, (EO_ "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0
M %15  !*5@  0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX
M)V,V "9C/@ E8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :
M8_$ &V'_ !M@_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9
M  !'6P  /EX  #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP
M !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\
M$FG_ !-H_P 3:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"
M80  .60  #)G   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U
M,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]
M  MQ_P ,<?\ #'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:
M,VP  "MO   D<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &
M?S0 !7\_  1_2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\
M_P  >_\  'O_ (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4
M "1Y   =?   %H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP
M (LW  "+0P  BU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P
MA_\  (?_ ()M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$
M   5B   $(P   N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N
M  "9.0  F4<  )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\
M )7_ 'MT  !O<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .
ME@  "9D   &<    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H
M+P  J#T  *E,  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_
M '=[  !H>P  67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I
M *@   "K    K@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)
MNC$  +I   "Z4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#
M  !?A@  48L  $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<
M  "[    O@   +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20
M ,XS  #/1   T%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7
ME   29H  #NA   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+
M    S0   ,X   #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D
M  #G-@  Z$D  .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I
M0JL  #2R   FN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;
MWP   .    #B    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\
M)0  _3D  /Y/  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P /
M /\ $0#_ !8 _P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ',
M_P!Z /\ @ #_ (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U
M /$ ] #_ /, _P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\
M"P#_ !$ _P = /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T
M /4 >@#T (  \@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D
MY #[ ., _P#B /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_
M  X _P 8 /\ ) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8
M= #D 'H X@"  .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T
M ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L
M]P 3 /$ '@#M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#.
M ', S !Z ,H @ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D
M_@"X /\ N #_ +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 .
M -X & #8 ", T@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T
MN0!S +< >@"U ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F
M /\ I@#_ *4 _P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@
M$@#" !T O@ H +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M
M *< <P"E 'H I "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\
ME@#_ )< _P"7 /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S
M !8 KP A *L + "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@
M;@"7 '4 E0!] )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_
M (@ _P"( /\ B #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !
MH@ : )X )0"; #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"*
M '  B !X (< @0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$
M_P![!/\ >P3_ /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3
M ), '@"0 2D C0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P
M?0AT 'P(?@!Z"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O
M#?\ ;PW_ .@6  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+
M%P"&#", @PTM ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q
M '$1>P!P$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\
M91/_ -\>  #&)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\
M$AT >10H '84,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9
M=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_
M -4E  "]*@  J"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@
M;QPC &T=+0!K'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=
M(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK
M  "V+@  HBX  )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,?
M &4D*0!C)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P
M5"B* %,IF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P
M,@  G#(  (PR  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ
M)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ(
M $POEP!++Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0
MES4  (<U  ![-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6
M,"L 53$S %,Q.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<T
ME0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@
M (,X  !W.   ;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@
M3S8P $XV. !,-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP!
M.:0 /CFX #TYTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[
M  !S.P  :CH  &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM
M $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:,
M.3VV #@]T0 W/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O
M/@  9CT  %X]  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_
M,@!"0#H 04!! $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T
M #)"S@ R0?  ,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00
M8D   %M   !4/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \
M1#< .T4^ #I%1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&
MS  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,
M %=#  !00P  2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230
M-4H[ #1*0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G
M2^T )TK_ "A)_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&
M  !,1P  1$@  #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X
M "Y/0  L4$@ *U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L
M(4__ ")._P B3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)
M2P  0$P  #M.   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95
M/  E5D4 )%9. ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_
M !M4_P ;4_\ '%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P
M/%$  #93   Q50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <
M74  &UU* !I=50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:
M_P 36O\ %%G_ )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8
M #)9   K6P  )5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H
M$F5$ !%E4  095T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -
M8?\ #6'_ (U5  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?
M   F8@  'V4  !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^
M  AN2@ ';E< !FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\
M VK_ (5:  !T6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?
M:@  &6T  !-Q   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X
M0P  >%   'A>  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_
M 'Y?  !N7P  8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=
M$G<   U[   (?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P
MA$@  (17  "$:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E
M  !I9   7V,  %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,
M  :'    B@   (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\
M )).  "27P  DG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F
M:@  6&L  $MM   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5
M    F    )D   ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$
M  "C50  HVD  **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@
M474  $1Y   W?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D
MIP   *@   "I    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T
M2@  M5T  +5S  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(
M #R'   OC@  (Y0  !B:   0GP  ":0   "I    K0   +    "T    MP
M +@   "Y    NP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0
MRE   ,IF  #*?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8
M   GGP  &Z4  !&K   )L    +4   "Y    O0   ,$   #&    R    ,D
M  #+    S    ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(
M .17  #E;P  YHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?
ML   $[8   N\    P0   ,4   #)    S0   -(   #6    V@   -L   #>
M    X    .(   #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(
M  #[7P  _'H  /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !,
M_P > /\ *@#_ #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_
M ($ _0"' /P C0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\
M_P#O /\ XP#_ -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9
M /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H
M[P"! .X AP#L (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#=
M /\ U #_ ,D _P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T
M( #Z "L ]P V /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z
M -H @0#8 (@ U "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\
MQ #_ +L _P"V /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G
M "4 Y  P .$ .P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,,
M>@#! ($ OP") +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_
M *X _P"J /\ IP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\
MR@ J ,< - #$ #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N
M 'H K "" *H BP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\
M_P"= /\ FP#_ /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C
M +, +@"P #< K0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ',
MFP![ )H A "8 (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P".
M /\ CP#_ /P   #O    VP   ,D   "]    M0 " *X # "I !, I0 = *(
M)P"@ #$ G0 Z )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U
M (L ?@") (D B "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\
M@ #_ /0"  #@"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2
M "H CP S (T / "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X
M>0!\ (0 >P"0 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_
M .D-  #/$   N1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0
M@P N ($ -@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q
M 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4
M  ##%P  KA<  )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H
M '<(, !U"#@ <PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X
M9@R+ &0-F0!B#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y
M'0  I!X  )4=  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/
M*P!L$#, :A [ &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.(
M %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@
MG2,  (TC  "!(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C
M%B\ 81<W & 7/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;
ME !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<
M (<H  ![)P  <B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL
M6AXS %@?.@!7'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)
M(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L
M  !V*P  ;2H  &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P
M %(E-P!0)3X 3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**
M02BR $ HRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q
M+P  :"X  &$M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ
M- !**SL 22M" $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP
M #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@
M9#(  %TQ  !8+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%
M,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4R
MQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4
M %DT  !4,P  4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38
M/C4] #TU1  \-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O
M-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W
M  !0-@  2S0  $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ
M #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8
M*CK] "HZ_P K.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-
M.@  1C@  $(Z   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_
M/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\
M "4^_P F/?\ )CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0
M0CT  #P^   Y/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K
M1$0 *D1- "A$6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#
M_P @0O\ (4'_ )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$
M #A#   T10  ,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$
M(TI* ")*50 @2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :
M1_\ &D?_ )5"  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'
M   P20  *TL  "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!'
M !I040 94%T %U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\
M%$W_ (]%  ![1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K
M3@  )E   "!3 P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)7
M30 15UD $%=H  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_
M (A)  !V2@  9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5
M(58  !M9   57 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *
M7E0 "%YB  =><P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.
M  !P3@  8DX  %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT
M !5@   08P, #&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX
M &=<  !G;0  9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J
M4P  75(  %12  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H
M   ,:P$ !FX)  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6
M  !Q9@  <7D  '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P
M6E<  %%6  !&5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $
M=@   '@%  !X"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]
M7@  ?7(  'V(  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP
M $M=  ! 7P  -6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@
M (,!  "$!@  A0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@
MBVD  (N   "+F0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E
M   X:0  +FX  "1S   :>   $WT   V!   &A0   (D   "-    D    )(
M  "2    E 4  )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\
M )QV  ";D0  FZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P
M=@  )7P  !N!   2AP  #(P   21    E0   )D   "=    H    *$   "B
M    I    *4!  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K
M  "NA0  KJ$  *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0
M'8P  !.2   ,F    YT   "B    I@   *H   "N    L    +$   "S
MM    +8   "X    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%
M=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T
M  VC   #J0   *X   "R    MP   +L   "_    P@   ,(   #%    Q@
M ,@   #*    S0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:
MX(0  .&A  #AO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U
M    N@   +\   #$    R    ,X   #1    U    -4   #8    V@   -T
M  #?    X@   .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(
M /F0  #YJP  ^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_
M #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L
MB #Y (\ ]P"7 /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_
M ,X _P#& /\ P@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P
M_P X /\ 0P#] $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H
M (D YP"1 .0 F@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$
M_P"[ /\ MP#_ /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R
M /  / #L $8 Z !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 ((
MS0"* ,L DP#( )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N
M /\ JP#_ /\   #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L
M-@#3 #\ S@!( ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N ""
M +8 BP"T )8 L@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\
MGP#_ /\   #_    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\
M #@ N !! +4 2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *,
MA "A (X GP": )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_
M /\   #V    Y    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #(
MI0 Z *( 0@"@ $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0
M (< C@"3 (P H0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@
M  #E    S0   +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T
M )( / "0 $, C@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($
M?P"- 'X FP!\ *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1
M @  NP(  *P!  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0
M-@"" #T @ !# 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"(
M '$ E@!O *4 ;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#
MK@P  )X,  "3"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V
M #@ =  ^ ', 1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4
MD@!D *$ 8P"R &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(
M ),2  "($0  @ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3,
M:@(Y &D#0 !G T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:
M!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8
M  !_%P  =A8  '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU
M & ,/ !?#$( 7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\
M4 ZQ $X.R !-$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W
M'0  ;QP  &D:  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2
M. !7$CX 5A)% %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N
M $85Q0!%%>@ 11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@
M:"$  &(?  !?'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/
M&#L 3AE" $T92 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;
MP@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4
M %TD  !9(@  5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S<
M1Q\^ $8@10!%($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W
M(N, -R+[ #<B_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H
M  !4)@  42,  $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[
M $ E0P _)4H /293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$
M,2?Y #(F_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0
M*@  3"@  $HF  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ
M0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX
M "PK_P M*O\ +2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@
M2"P  $4K  !!*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T
M+T4 ,R]. #$P6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O
M_P H+_\ *"[_ )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#
M $ O   \,   .C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$,
M+31, "PT5@ J-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C
M,_\ (S+_ )@Q  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS
M   W-   -#4& #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E)
M "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\
M'C?_ ),T  !_-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R
M.0  +SH" "P["P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^
M4  ?/EP '3]I !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_
M (XW  !Z.   :CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@
M*4   "9!"  D0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 8
M1%D %T1G !5$=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[
M  !V/   9CT  %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40
M "%& P =2 P &TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8
M$$ID  ]*=  .2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q
M/P  8D   %9   !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+
M   63@< $U . !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?
M  E1;P '4($ !5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P
M740  %)$  !*1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   2
M5 , #E<*  M8$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8
M:0  6'P  %B1  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@
M $]'  !'1P  0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P(
M"5X)  1?#@  7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P
M8'8  &"+  !?H@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+
M  !$2P  .TP  #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'
M  !G#   9P\  &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\
M &J%  !JG0  :;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _
M4   -5,  "U6   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P
M"   <0T  '(0  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^
M  !VEP  =;$  '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6
M+UL  "9?   =8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P
M?@@  '\,  "!$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%
MCP  A*D  (/)  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8
M !YK   5<   #G4   EY   !?@   ($   "%    B    (H   "+    C0$
M (X&  "0"P  D0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@
ME:(  )3!  "3Z@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y
M   .?P  !X0   ")    C@   )(   "6    F    )H   ";    G0   )\
M  "A P  HP@  *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D
M *BU  "GW0  I_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   '
MD    )8   ":    GP   *,   "G    J@   *L   "M    KP   +$   "S
M    M0   +@%  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH
M  "^R0  O>\  +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@
M *<   "L    L    +4   "Y    O    +T   "_    P0   ,,   #&
MR    ,H   #- @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;
MM0  V]D  -OR $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D
M  "^    P@   ,@   #+    S@   ,\   #2    U    -8   #:    W0
M -\   #B    Y@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0
M];\  /7= /\ !@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\
M1 #_ $T _P!5 /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2
M /, FP#P *8 [@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\
MNP#_ /\   #_    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\
M $< ^ !/ /0 5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\
ME0#< )\ V0"K -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_
M /\   #_    _P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $
MX@!) -\ 4 #; %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#"
M )@ P "D +T L@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\
M  #_    _P   /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !"
M ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )
MJ@"< *@ J@"F +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^
M    [P   -\   #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T
M0P"K $D J !/ *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4
M )8 H@"4 +( D@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L
MV0   ,<   "Z    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8
M $, E@!) )0 3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0
MF@"" *H @0"^ (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@
M +,   "H    H    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T
MA0!# (0 20"" $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T
M *, <@"U '( SP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(
M  "7    D0   (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ]
M '8 0P!T $D <P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T
M90"O &4 Q@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")
M!P  @@,  'X   ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H
M/@!I $0 9P!) &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J
M %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@
M=@T  '$*  !O!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!?
M #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %
MNP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(
M &<0  !E#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL
M50=" %0'2 !3"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&
M"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6
M  !<$P  6A$  %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^
M $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P
M/1'V #T1_P ]$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5
M&0  4Q8  %(3  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $43
M0@!$$TD 0Q12 $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U
M #86_P V%O\ -Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@
M31L  $P9  !+%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]
M&48 /!I/ #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;
M_P P&_\ ,!O_ )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"
M $8=  !%' ( 0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0
M-A], #0@5@ S(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J
M(/\ *R#_ )DB  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A
M   _(0  /2$) #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1*
M "\E4P M)5X *R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\
M)23_ )0E  " )P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z
M)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI
M40 H*EP )BII "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_
M ) H  !\*@  ;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@
M,BL# # K#  N+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C
M+EH (2]G !\O=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK
M  !X+0  :"X  %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\
M "LP"@ I,1  )S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U<
M&S-D !HT=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T
M+P  93$  %@Q  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U
M!@ C-@T (382 " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB
M !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@
M830  %4T  !+-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =
M.PL &SP0 !D]%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^
M;P ./H$ ##Z5  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<
M %$W  !(-P  03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008
M%$,- !)#$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '
M1'P !D20  1#I0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ
M  !%.@  /CH  #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*
M  U*#P ,2A0 "TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<
M $J+  !*H0  2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"
M/0  /#T  #8]   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0
M#0 #41$  %$7  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'
M  !1G0  4;4  %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0
M.4   #)!   J0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#
M6!   %@3  !9&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9
MF0  6;$  %C1  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44
M "U'   E2@  'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T
M &$0  !B%0  8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP
M8ZT  &+,  !A\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/
M   ?4@  &%4  !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-
M  !M$0  ;A8  ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<
M &[&  !M[P  ;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   8
M7   $6    QD   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z
M#0  ?!   'T6  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^
M  !\Z0  >_\  'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:
M"VT   -R    =@   'H   !]    @    (,   "$    A@   (<"  ")!P
MBPP  (T0  "0%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".
MX0  C/L  (S_ %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT
M  ""    A@   (L   ".    D0   ),   "5    EP   )D   ";    G00
M )\*  "B#P  I!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT
MH/4  )__ $YA  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3
M    F    )T   "A    I    *4   "G    J0   *L   "M    L    +(
M  "U"   N X  +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H
M +?\ $9K   Y<   *W<  !]_   3A@  "XX   &5    FP   *$   "F
MJP   +    "S    MP   +<   "Z    O    +\   #!    Q    ,<   #*
M    S04  -$.  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R
M #YY   Q@   (X@  !>1   -F0   Z    "G    K@   +,   "X    O0
M ,(   #&    R@   ,H   #-    SP   -(   #5    V0   -T   #?
MXP   .<%  #K#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\
M  #_    _P $ /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0
M /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *(
MZP"O .@ P #F .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_
M    _P   /\   #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /(
M4@#N %@ ZP!> .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G
M ,X M@#+ ,X _^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0
M_P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H
M .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8
MP@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@
M /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D
M*P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V
M *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\
MD #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N
M "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0
M=P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_
M /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "<
ME@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"
M 'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8
M  #+    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I
M (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ',
M;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X
M    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P =  C ',
M*P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X
M &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0
MF ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E
M "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4
M@0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L
M 'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "<
M60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!*
M (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40
M  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I
M $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL
M0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D
M%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)
M*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R<
M #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&
M5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* !
M#BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0
ML  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P
M $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL
M.!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G
M%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>
M  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O
M #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4
M(!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _
M(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>
M,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G
M !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P
M.",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E
M(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D
M_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28
M #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8
M'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3
M*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH
M   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\
M !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\
M$"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F
M+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S
M0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_
M '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,
M'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,
M.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N
M  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8
M !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8
M SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=
M,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]
M   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.
M  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P
M3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -
M10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,
M5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L
M $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3
M D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@
M5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^
M   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92    5    %<"
M  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET
M %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R
M0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;    7@   &    !B
M @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ
M  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@
M(TT  !M1   350  #ED   A=   !80   &0   !G    :@   &P   !N
M<    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y
M>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@
M !-<   -80  !F8   !J    ;P   '(   !V    >0   'P   !]    ?P
M ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P
MBHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ
M   %<    '8   ![    ?P   (,   "'    B@   (T   ".    D0   ),
M  "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($
M )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[
M@0   (<   "-    D@   )8   ":    G0   )\   "A    I    *8   "H
M    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27
M  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E
M )H   "@    I0   *H   "N    L0   +(   "U    MP   +H   "\
MOP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*
MJP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T
M  "S    N0   +X   #"    Q0   ,8   #)    S    ,X   #2    U0
M -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0
MZ[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\
M.@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0")
M .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\
MK0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W
M #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -(
MB@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_
M /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8
MU@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W
M (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\
M  #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W
M +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0
MG0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L
M    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\
M. "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"(
M (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7
MP0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0")
M #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4
MC@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K
M )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$
M=0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D
M )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T
M  "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q
M &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )
M5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U
M    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H
M,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"<
M $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"
M8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!.
M #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $
MJP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T
M %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\
M10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W
M +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0
M  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q
M #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L
M+@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$
M$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+
M-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S=
M "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0
M/!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O
M$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1
M]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@
M #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S<
M)Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9
M%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:
M   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD]
M " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\
M%1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K
M'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>
M1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_
M 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(
M)!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4
M(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?
M  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",
M !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H
M#BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@
M)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH
M   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2
M  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P
M3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3
M+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R
M7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L
M $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@(
M#C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6
M.&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO
M   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'
M  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0
M #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T
M,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!
M"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S
M  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-
M+3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P
M2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.
MA0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<
M "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<
M %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P
M5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!
M   51   $$@   M+   %3@   %$   !4    5P   %D   !;    70(  %X&
M  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),
M &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   0
M3@  "E(   -6    6@   %T   !@    8P   &4   !G    :0   &L!  !M
M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I
M  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@
M 5\   !C    :    &L   !O    <@   '4   !W    >0   'L   !]
M@ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""
MP@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\
M  !T    >    'P   "!    A    (<   "(    BP   (X   "0    DP
M )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0
MEN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&
M    BP   )    "4    EP   )D   "<    GP   *$   "D    IP   *H
M  "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\
M *WU #=<   K80  'F@  !-P   +>    (    "'    C@   )4   ":
MGP   *0   "H    K    *T   "P    LP   +4   "X    NP   +\   ##
M    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I
M "]I   C<   %GD   V!   !BP   ),   ";    H@   *@   "N    M
M +@   "]    P    ,(   #%    R    ,L   #.    T0   -8   #;
MWP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\
M  #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!'
M /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D
MY@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_
M    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P
M2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP">
M ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z
M]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #(
M $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L
MI "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP
M -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $
MJP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2
M *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\
M  "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _
M )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *,
M? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=
M    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T
M/0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N
M &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")
M@@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J
M #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H
MO@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0
M &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #<
M6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !-
M -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K    9    &
M  !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W
M $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D
M0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2
M    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0
M. !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H
M #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@
M1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z
M #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\
M^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH
M #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #<
M,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G
M /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-
M   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\
M "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX
M'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P
M#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,
M0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_
M 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@
M*A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =
M$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3
M  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0!
M "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H
M%A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A
M&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6
M 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4
M ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@
M4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :
M&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>
M7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X
M $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P(
M$R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %
M(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A
M   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'
M  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8
M "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T
M)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ
M"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV
M   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@
M*R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $
M, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   Q
MB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@
M "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P
M #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0
M-Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I
M   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-
M   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL
M #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :
M+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&
M#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T
M  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0
M$3@   T[   (/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P
M40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0
MUP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$
M  =$    2    $H   !-    4    %,   !5    5P   %@"  !;!@  70L
M %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S
M6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/
M    4P   %8   !9    7    %\   !A    8P   &4   !G 0  :@4  &T*
M  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$
M &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=
M80   &4   !H    :P   &X   !Q    <P   '4   !X    >P   'X#  "!
M"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_
M #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M    <0
M '8   !Z    ?@   ($   "#    A@   (D   "+    C@   )(   "5 0
MF0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+
M   L3@  (%,  !59   -8    V<   !N    =    'H   "     A    (H
M  ".    D@   )4   "7    F@   )T   "@    HP   *<   "K    KP
M +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D
M6P  &&$   YI   %<0   'D   "!    B    (\   "4    F@   )\   "D
M    J    *D   "L    KP   +,   "U    N0   +T   #!    Q@   ,L
M  #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0
M$7$   =[    A    (T   "5    G0   *,   "I    KP   +0   "Y
MO    +X   #"    Q0   ,@   #,    T    -0   #:    WP   .0   #J
M    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P
M /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %
M^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#;
M -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,
M  #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/
M -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$
MN #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G
M    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P
M3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8
M )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&
MOP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"?
M $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@
M[P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0
M )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4
MAP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R
M /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4
M  ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!#
M '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8
M8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O
M  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &
M0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_
M %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,   !@
M70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1
M $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4
M_P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3    40 "
M $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T
M1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [
M /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)    1P   $4
M!0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _
M #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\
M,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [
M  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #
M0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_
M ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8
M,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H
M $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)
M  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08(
M "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48
M(0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D
M#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*
M"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/
M !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$
M41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A
M# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-
M7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,
M $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@
M&P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -
M$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6
M   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(*
M !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&<
M!Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T
M&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6
M#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU
M  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@
M*QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,
M&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <
MB   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P
M ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX
M!B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@
M()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=
M   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00
M   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P
M "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   =
M'@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K
M$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU
M   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(
M%R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P
M,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   P
MW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0
M !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A
M #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP
M-OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL
M   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41
M  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H
M #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $
M-P   #H    \    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0
M$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_
M #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0
M $0   !'    20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@
M7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV
M   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)    3    %
M  !3    5@   %D   !;    70   &    !B    90   &@%  !K"P  ;Q
M &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R
M-P  *#D  !X[   5/P  #D0   =)    30   %(   !6    6@   %X   !B
M    90   &@   !K    ;0   '    !S    =@   'D   !]!   @0L  (41
M  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@
M(D$  !=&   /2P  !U$   !7    7    &(   !F    :P   &\   !T
M>    'L   !^    @    (,   "&    B@   (T   "1    E@,  )L,  "=
M$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT
M !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")    C0
M )$   "3    E@   )D   "=    H    *0   "H    K    +(#  "W#0
MMQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB
M    :@   ',   ![    @@   (D   ".    E    )H   "?    I    *8
M  "I    K0   +    "S    MP   +L   #     Q0   ,L   #1!   U0X
M -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T
M?0   (<   "0    EP   )X   "D    JP   +$   "V    N@   +P   #
M    Q    ,@   #+    SP   -0   #:    X    .8   #K    \08  / 3
M  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4
M]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U
M %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$
M_P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  %
M /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8
MT !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"=
M /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;    W    -@
M!P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5
M +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\
M@@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O
M  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4
M4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_
M &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0   "1  8
MD  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\
M %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &
M_P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z  $ >  )
M '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H
M9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2
M /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F    90 $ &,
M"P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+
M %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\
M1P#_ *(   "-    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3
M  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $<
M3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_
M )0   !_    ;P   &,   !9    40   $T   !*    2    $< ! !'  H
M1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z
M %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@
M  !T    90   %@   !/    2    $,    _    /0   #P  @ \  < .P ,
M #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L
M+P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L
M    70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #(
M#0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1
M "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!
M5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I
M  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\
M6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H
M $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P
M(@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7
M &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-
M   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4-
M !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V,
M$0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U
M#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)
M#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES
M  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0
M*Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2
M#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-
MA@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(
M ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X
M#@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A
M$)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3
M   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1
M  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL
M !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :
M%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86
M$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T
M   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@
M%A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0
M&A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9
MVP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18!
M !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,
M " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP
M'?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7
M @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86
M   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL
M "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -
M'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N
M&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_
M $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0
M!R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P
M-A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D
M   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH
M   M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H
M $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P
M*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V
M    .    #L    ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?
M  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P
M)RD  ",G   ;*   %"H   XM   *,   !#,    W    .@   #T   !
M0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:
M)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP
M !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,    3P
M %(   !5    6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@
M:RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU
M   1.0  "CT   )"    1P   $P   !0    5    %@   !;    7P   &(
M  !E    :    &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0
M 'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +
M10   DL   !1    5@   %L   !@    90   &D   !N    <@   '8   !Y
M    ?    'X   ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K
M  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5
M %L   !A    :    &X   !S    >0   'X   "#    B    (P   "/
MD@   )4   "9    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R
M-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T
M  !U    ?    (,   ")    CP   )4   ";    H    *,   "F    J0
M *T   "Q    M0   +D   "^    Q    ,H   #2    V@H  -86  #2*0
MSD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(
M    D    )@   "?    I0   *T   "S    N    +H   "^    P@   ,8
M  #*    S@   -,   #:    X    .<   #M    \P   /0.  #R'@  [S8
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M____________________________________________
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M^_S]_O]M9G0Q      ,$(0   0                    $
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M#/^D-Q3_L#\<_[I(*O_#4#O[R%A0]<M?9NG/9GS<R6N2SL-OIL&Z<K6VLG;
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M45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU',RPD
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MXTDSS^M.2<;M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04
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MHWJ=P9N I[B4A["QCXZVJXJ5NZ:'G;ZBA:7 GX2OP99^L,&4?[:XDX"[LI.
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M95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI67_K1
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
M&?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW
M[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?3
M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY &?^3
M22+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN
M>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?38-J'
MTV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY &?^322+_
ME54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NIL
MLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?38-J'TV#:
MA]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY &?^322+_E54M
M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI
M:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@
MVH?38-J'TV#:A]-@VH?_@QP#_X G!_]],@S_B#<1_Y _&/^522+_EU0M_Y9?
M.?^3:T7_CG=1_XB"6_J$C&3U?Y1K\7J;<NYVHG?K<J=[Z6^M?^=LLH+E:KB$
MY&F_A^)HQXG@9L^*UF/6C,]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BL]BV(K/
M8MB*SV+8BL]BV(K_A!L#_X$G!_^ ,0S_BS81_Y,^&/^91R+_G%(M_YI=.O^8
M:4?_DW13_HY^7_>(B6GQ@I%R[7V8>>EXGW_E=*2$XW"JB.!ML(S>:[>/W6J_
MD=MIR)/59L^5RV31D\9EU([&9=2.QF74CL9EU([&9=2.QF74CL9EU([&9=2.
MQF74CL9EU([_A1L#_X(F!_^", S_CC40_Y8]&/^<1B'_H% M_Y];._^<9DC_
MF'%6^Y-\8O2-AFWNAXYWZ("5@.1ZG(?@=:*,W7*HD=IOKY78;;>9U6O G-)I
MR9[)9<F>PF?-F+YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1
MD[YIT9/_AAL#_X,F!_^%+PO_D#00_YD]%_^?1B'_HT\M_Z-:._^@9$G_G6]8
M^IAY9?&2@W'JBXQ\Y(.2AM]]F8[:>*"5UG2GFM-PKI_1;;:CSVO I<=FPJ?
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M<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S4>G5<U'IU7/_F! !_ZX. -3!"0#)SPD
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M@UFVW8-9MMV#6;;=@UFVW8-9MMV#6;;=@UFVW8/_@18"_Y44 ?^G%@']N!<
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M^[(@ >V_)0+AS"H#U-$R#<?,01^ZQTPQKL%40J.\7%"9MV)<D+-I9H>P;VZ
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MS3"[L0  K+P  )_)  "3V0  B?P+ 8#_%P)V_R %;/\H"63_, U=_S@05_]
M$U'_1Q9-_TX82O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^ 'SO_B" Z_Y$A
M./^;(C?_I"(V_ZTC-?^X(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2.M
MM@  G\0  )+2  "$X0  ??\- 7+_$P)H_QL$7_\C!EC_*PE1_S,+3/\Z#4?_
M00]#_T@10/].$CW_5!,[_UH4.?]?%#?_914U_VL6,_]R%C'_>A<O_X(7+O^+
M&"S_DQ@K_YP9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQFAOP
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M-?];L3?_6KDX_UK!.O]9RSO_6-4\_U??/?]6YC[_5>L^_53P/_E3]3_V4OE
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M:E>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP<
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M_U*F:?]2IFG_4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1
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M9FB3]F!HDO=?:)+W7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P
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M55"Z_E50NOY54+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH
MH-T5 )G=* 20VS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4
MSH1-4,Z/4$W.FU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*
M_TU*RO]-2LK_34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4:
M 8WE*P:$Y#4->^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5
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M,P8Z_SD'-O] "#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^
M#1[_C X=_Y<.'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O
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M8/] NF#_0+I@_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O.
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M6WB"_E9Y@?]1>8'_47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X
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M4F&8_U)AF/]289C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00
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M(3CXM2(W^<@B-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@
MJ:X  )RY  "0Q   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*
M_T *1O](#$/_3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__
MJ1<N_[<8+?_(&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4
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M_V$4 ?]L$@'_=A<!_WT< ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW
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M3HET_TF)=/]$B'3_0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\
M_8P0 .V4$@#@FA4 TYPD LB9-@F_E$,5MH]/(*Z*6"NGAF$SH8)H.YQ_<$&7
M?'=&DWE^2X]WAD^+=8]2B'.85H1RHEB!<:Y:?W&\7'UQT%Q_<^Q6@7;[3X-X
M_TJ#>/]%@GC_1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\-
M .>8#0#;GPX SI\B <2=- BZF$(4LI--'ZJ/5BJCBE\RG(9F.I>#;4"2@'5%
MC7Y\2HE\A$Z%>HQ2@GB55GYWH%E[=JM;>76Z7'=VS5QX=^I8>WKZ47U\_TM]
M?/]&?7S_17U\_T5]?/]%?7S_17U\_T7_81 !_V\+ /]]"P#UB H WY,( -B;
M"@#3H@P R:,? ;^@,@>VG$ 3K9=+'J635"B>CUTQF(MD.9*(:S^-A7)%B(-Z
M2H2 @4Z ?XI2?'V357A\G5AU>ZE;<GJX7'%ZREQR?.A8=7[Y47> _TQW@/]'
M=X#_1G> _T9W@/]&=X#_1G> _T;_9 \ _W() /]_" #EC 4 V)8' -&>"0#.
MI0H Q*8= ;JD+P:QH#X1J)Q)':"84R>9E%LPDY!B.(V-:3Z(BG!$@XAX27Z&
M?TUZA(A1=H*157*!FUAO@*=:;'^U7&N R%QK@>59;H/W4G&$_TURA/](<H3_
M1W*$_T=RA/]'<H3_1W*$_T?_9@T _W4' /:#!0#<CP, TI@& ,RA!P#(J @
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M/$3%P3Q#Q=\\1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP
MQ9H  +>D  "KK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ EC
MUD807M90%5G56!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5
MPC$_U>$P/]/R,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$
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M$2?_X1$F__(1)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0
M<-,  &3>  !8YP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P
M_T8%+?]-!2O_5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_
MP L:_]8+&O_?"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X
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M,+MB?36X8(4XM5Z-/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9
MHU[_.Z-?_S>C8/\SHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_
M<!( _W<6 /M\' 'N?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G
M>3:O98 ZJV.(/:AAD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_
M/IIC_SF;9?\VFV7_,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!
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M.H!U_SJ =?\Z@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H
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M1U&;ND=0F]%'49ON1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=
MV8,  ,B0  "^F@  LZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%W
ML$P8<:Y4'VRM6R5GJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NE
MND)+IM%"2Z7M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD
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M)3O,^R4[R_\E.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@
MD;8  (6_  !YQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)
MWU<,1M]?#T/?:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>
M^1HTW?\;--S_&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X
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M!A/_Z083_^D&$__I!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@
M//4  #?_!  S_PT +_\3 "O_&@ H_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6
M_T8"%/]- A'_5@(0_V "#O]L @S_>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_
MP@,(_\(#"/_" PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\
M "S_   G_P< (_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!
M"O\^ 0C_1@$%_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@(
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M1((5]D.,%_1"E!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^)
M]![?0/X=W4'_&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@:
M ?].& '_4AL!_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8
MZTB&&^E'CQWG1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R30
M1?XBS4;_(,Q'_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2
M% '_6!@!_UT? ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!
M']Q,BB+92Y(DU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPH
MP$O_);],_R*^3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_
M7A4 _V(< ?]E) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2
MA";*4(PHQT^4*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_
M*K-1_R>S4O\DLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A(
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M+(YE_RR.9?\LCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP
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M_S'_7P( ]VP  -YW  #0@0  QX@! ,"- P"YD0, LI,1 *N3(P&CD3,&G(Y
M#96+2A6/B%,<B89;(H2#8BB @6DM?']P,7A^=S5T?( X<7N)/&YZDS]K>9Y"
M:'BK1&9XNT5D>-%%9GGN0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_
M80  ZF\  -EZ  #,A   PXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"0
M2!2*CE$;A(M9(7^)8"=[AV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI
M0V!^N41??L]$8'_L0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9
MY7(  --^  #'AP  OH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%
ME$\9?Y%7'WJ/7B5UCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%
MMT)9A<Q"6H7J/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8
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M-4F@^3)*G_\P2Y__+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@
MIJ   )RF  "1K   AK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<
ML5L:6+!C'E6O:R%1KW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K
M^2U$J_\K1*K_*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4
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M$R_4_Q,OU/\3+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0
M7,\  %+5 P!(W @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600R
MZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F
M_PHFYO\*)N;_"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<
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M 0#_R@&&MP  =\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P
M&_\% !?_#  4_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0
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M0),6X#^;%]\_HAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,=
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M'J)2_QVB4O\=HE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@
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M.6YJN3IM:LXZ;6OK-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60
MZV4  -MP  #->   Q'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.
M?5$5B7M9&H1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AO
MMSIG;\LZ9W#I-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@
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M7'KE-UY[^#)?>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  #
M@P  MXD  *^.  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*
M6AMQB&$?;8=H(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB LC=6@,4W5H#C
M-EB!]S%9@?\M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP
MLXX  *F2  "@E0  EI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEK
MD%X=:(YE(62-;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(
M]C!3B/\L5(C_*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(
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M(4"D_R! I/\@0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K
M=[$  &JV  !CN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'
MMFL31+5U%D*U@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP
M_QLYL/\;.;#_&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@
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M!1_@_P6DG@  F*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW
M+^4' "WM$  K[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9
M\W$!&/.! 1?TD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P
M_P*:I   C:T  '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0%
M "3[#0 A_!, 'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$
M#/]O 0S_@ $*_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/
MK   @+8  '*_  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_
M"0 6_PX %/\3 !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<
M  #_:P  _WT  /^0  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0
M<[\  &3)  !6TP  1]L  #K@   NY0  (^D  !KM   5_0  $O\  !#_ @ .
M_PD "_\-  C_$  $_Q,  ?\8  #_'@  _R0  /\K  #_,P  _ST  /])  #_
M5@  _V8  /]X  #_B@  _YL  /^H  #_L0  _[$  /^Q  #_L0#_)2L!_R@I
M ?\I*0'_*"P!_R,R ?\>.P+_&D<"_Q=5 _\58@/_$W #_Q)\ _\2AP/_$I$#
M_Q*9 _\2H /_$J<#_Q*M _\1M /_$;L#_Q'$ _\1S@/_$=\#_Q'K O\2]@+_
M$OX"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_*"D!_RLF ?\L
M)@'_*RD!_R@O ?\B. +_($0"_QU2 _\;7P/_&&P#_Q=Y!/\7A 3_%XX$_Q>6
M!/\6G03_%J0$_Q:J!/\6L03_%K@$_Q;  _\6R@/_%ML#_Q;H _\7] /_%_T#
M_!?_ OL7_P/[%_\#^A?_ _H7_P/Z%_\#^A?_ _H7_P/_*B8!_RXC ?\O(@'_
M+R4!_RPK ?\J-0+_)T$"_R1. _\B6P/_(&@$_QYT!/\=@ 3_'8H$_QV2!?\=
MF@7_':$%_QVG!?\=K07_';0$_QV]!/\=QP3_'=0$_AWF!/L=\@3W'OL#]1[_
M!/0>_P3S'O\$\Q[_!/(>_P3R'O\$\A[_!/(>_P3_+B(!_S(? ?\T'@'_,R !
M_S(F ?\R,@'_+SX"_RQ* _\J5P/_)V0$_R9P!?\E>P7_)(4%_R2.!O\DE@;_
M))T&_R2C!O\DJ@;])+$&_"2Y!OLDPP;Y),\&]B3C!O(D\ 7N)?H%[27_!NLE
M_P;J)?\&Z27_!NDE_P;I)?\&Z27_!NDE_P;_,AX!_S8; /\X&0#_.!L!_SHC
M ?\Y+0'_.#H"_S5& _\R4@3_,%\$_RYK!?\M=@;]+( '^BR)!_DKD0?W*YD(
M]2N?"/0KI@CS*ZT(\2NU"/ KOPCN*\L(ZRO?".<L[@CD+/H(XBS_"> L_PG>
M+/\(WBS_"-TL_PC=+/\(W2S_"-TL_PC_-1H _SH6 /\]% #_/Q< _T$? /]!
M*0'_0#0!_SU! O\Z30/\.%H%^#9E!O0U<0?Q-'L([S.$">TSC0GK,I0*Z3*;
M"N@RH@OF,JH+Y#*R#.,RNPSA,L@,WS+<#-HR[ W5,_@-TC/_#= S_PS.,_\,
MS33_"\PT_PO,-/\+S#3_"\PT_PO_.18 _SX2 /]!$ #_11, _T@; /]() #_
M1R\!_D0[ O="1P/Q/U0%[#Y@!N@\:PCE.W8)XCM_"^ ZB S=.9 -VSF7#MDX
MG@_6.*80U#BN$=(XMQ'0.,,2SCC3$LHXZ!+'.?<2Q#G_$<(Z_Q#!.O\/P#K_
M#K\Z_PZ_.O\.OSK_#K\Z_P[_/1, _T(/ /]&#0#_2Q  _TX6 /]/'P#]3BD!
M]$PT >Q(00+F1TX$X$5;!MM$9@G60G ,TD%Y#L] @A#-0(H1RC^1$\D_F13'
M/J 5Q3ZH%L,^L1?!/KP7P#[+&+T^XABZ/O(7MS__%K5 _Q2T0/\3LT'_$;-!
M_Q"S0?\0LT'_$+-!_Q#_0!  _T8, /]+"@#_40T _U,1 /]4& #S5"( Z5(M
M >%0.P':3TD#TDU5!\Q+8 O(26H.Q4AS$<)'>Q._1H,5O46+%[M%DQBY1)H9
MMT.B&K5#JQNT0[8<LD/$';!#V1ZM0^T=JT7\&JE%_QBH1O\6J$;_%:='_Q.G
M1_\3IT?_$Z='_Q/_1 X _TH( /]0!@#_50H _U@- /=9$0#J6!@ WU<D -17
M-0',540$QE10",%26PR]4&40N4YM$[9-=A:T3'T8L4N%&J]*C1NM294=JTF=
M'JE(IB"G2+ AI4B](J1(SR*A2.@BH$GX'I]+_QN>2_\9G4S_%YU,_Q:=3/\6
MG4S_%IU,_Q;_1PL _TT" /]4 @#W6@0 ZUT' .=="P#A7!  TUT> ,I=, '#
M7#\$O5I,"+=85PRS5F 1KU1I%*Q3<1>I47@:IU" '*1/AQZB3X\@H$Z8(9Y-
MH2.<3:LDFDVX)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_
M&)11_QC_20@ _U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#
MM&!("*]=4PRJ6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G262
M4:<GD%&S*(Y1PRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6
M_QK_3 0 _U,  .Q<  #?8@  U&8! ,YH!0#+9P@ PF<6 +IH* &S9S@#K65%
M!ZAC4 RC85D1GU]A%9M=:!B87' ;E5IW'I-9?R&06(<CCE>/)8Q7F2>)5J,I
MAU:O*H55ORN$5M4L@U?O*8-8_B2#6?\@A%K_'H1:_QR$6O\<A%K_'(1:_QS_
M3@$ _U<  .5?  #89@  SFH  ,=L P##:P4 O&P2 +1M)0"M;#4#IVI"!Z%G
M30R<9581F&->%91B91B18&P;CE]T'HQ>>R&)78,DAER,)H1;E2B!6J J?UJL
M+'U:NRU\6L\N>UOL*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4
M]5D  .%C  #2:@  R6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7
M:E,0DFA;%(YF8AB+96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>
MN"YU7LPO=%[I+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P
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M+V1L]BIF;?\F9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@
MN7P  +%_  "I@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V
M=V 9<W9G''!T;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q
M]2I@<?\F87+_(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8
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M(D&6[R!"E?X>0I7_'4.4_QQ#E/\<0Y3_'$.4_QS,=0  O($  +&,  "FD@
MFY<  )&;  "%GP  >:,  &JG  !EIPX 8Z@< &"H*P%=J#8"6:= !%:G2093
MIE$)4*99#$VE8 Y*I6D11Z1R%$2D?19"HXD8/Z.7&CVCIQL\H[D<.Z/2&SNB
M[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P
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M!R/'_P<CQ_\'(\?_!R/'_P>IE@  GIT  )*C  "%JP  >+(  &NX  !?O@
M4L(  $?&   ]R@  -,\$ "O4"0 FV0\ )=D9 "7:)0 DVC  (]L[ "/;10 B
MW%  (=U; "#=:  >WG8 '=Z' 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:
M_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH
M #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT,
M%.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,
MZ_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8
M   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_
M  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T
M /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9
MY0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_
M.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E
M  #_Y0!_M   <+T  &''  !3T   0]8  #;=   JX@  '^8  !;J   0[0
M#/H   G_   &_P   O\$  #_"0  _PT  /\0  #_%   _QH  /\A  #_*0
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M ?\-[P'^#?H!^@W_ ?D._P'Y#O\!^0[_ ?@._P'X#O\!^ [_ ?@._P'_)B,
M_R@@ /\H( #_)B( _R(H ?\@,@'_'#\!_QE, ?\760+_%64"_Q-Q O\3? +_
M$X8"_Q.. O\2E@+_$IT"_Q*C O\2J0+_$K "_Q*W O\2P0+_$LP!_1+? ?D3
M[0'U$_@!\Q/_ ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP<
M /\L&P#_*QT _RDD /\H+P'_)3L!_R)( ?\?5 +_'6$"_QMM O\:=P+_&H$"
M_QJ* O\:D@+_&ID"_1J? OP:I@+[&JP"^1JT O@:O0+V&L@"\QK; N\:Z@+L
M&_<"Z1O_ N@;_P/G'/\#YAS_ ^4<_P/E&_\#Y1O_ ^4;_P/_+1L _S 7 /\Q
M%0#_,!8 _S$@ /\P*@#_+C8!_RM# ?\H3P+_)EP"_R1G OPC<@/Y(WP#]R*%
M _4BC0/S(I4#\B*; _ BH@/O(JD#[2*Q ^PBN0/J(L4#Z"+5 ^0CZ0/@(_8$
MWB/_!-LD_P39)/\$V"3_!-<D_P36)/\$UB3_!-8D_P3_,18 _S02 /\V$0#_
M-Q, _SD; /\X)0#_-C$!_S,] ?TQ2@'X+E8"]"UB _ L;0/M*W<#ZBN !.@J
MB 3F*I $Y2J7!.,JG@7A*J4%X"JM!=XJM@7<*L(%VBK2!M4KYP;0*_4'S2S_
M!\LL_P?)+/\'R"S_!\<L_P;'+/\&QRS_!L<L_P;_-1( _SD. /\Z#0#_/A
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M$9A&_Q"71O\0ET;_$)=&_Q#_0@4 _T<  /=/  #E4P  W54! -=5!@#54@L
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M)&9BKB5E8K\F9&+:)F1C\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E_QCP4P
MW5\  ,MH  "_;P  MG,  *YU  "F=0  G7,% )9S% "1="0 BW,R H9R/@2!
M<$<(?6]/"WEM5PYV;%X1<VMD%'!J;!=M:G,::VE\'&AHAA]F9Y$B8V>>)&%F
MK"5@9KTF7V?6)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(
M ,=K  "\<@  LW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'
M>'1-"G1R50YQ<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5:
M:[LF66S3)EIL[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O
M  "X=@  KWL  *9^  "=?@  D7P  (I\#P"%?1X @7TM 7Q\.0-W>D,&<WE+
M"7!X4PQL=UH0:79A$V9U:!9C=&\887-X&UYR@AY;<HT@67&:(E=QJ"15<;DE
M5''0)51Q[B)6<?X>5W'_'%=Q_QI8<?\96''_&5AQ_QGC7@  S6D  +]S  "T
M>@  JW\  **"  "8@P  BX$  (2!#0!_@AH >X(I 7:!-@)R@4 %;G])"&I^
M4 MG?5<.9'Q>$6%[9A1>>FT76WIV&5EY@!Q6>(L?4WB8(5%WIB)0=[<C3W?.
M(T]W["%0=_T>47?_&U)W_QE2=_\94G?_&5)W_QG>8@  R&X  +MW  "P?P
MIX0  )V'  "2AP  A(<  'V'"0!XB!8 =(@F '"(,@)LAST$:(9&!F6%3@EA
MA54,7H1<#UN#8Q)9@FL55H%T%U. ?AI0@(D<3G^6'DQ_I2!*?[8A27_,(4E^
MZQ]*?OP<2W[_&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD
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M$C:9_Q$WF?\1-YG_$3>9_Q&^>P  L8<  *6/  ";E   D)@  (2<  !WH
M:Z0  %^G  !2J@  3:L. $NK&@!*JR< 2*LS $:K/0%$JT8!0JM. D"K5@,^
MJU\%.ZMH!CFJ<P@WJH )-*J/"S*JGPPQJK ,,*K'##"IYPPOI_H-+Z;_#2^E
M_PTOI?\-+Z7_#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP
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M 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS
M)-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )
MYUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F
M_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L
M !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP
M /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'
MJ0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH
M   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)
M  #^6@  _FT  /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@
M;+L  %W$  !/S0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T
M_P   /\   #_    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_
M1@  _U@  /]K  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD
M /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H
M_P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_
M /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>
M(0#_&2, _Q,I /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./
M /\"E@#_ IP _P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8
M^ #_ /<"_P#W _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_
M'A\ _Q@D /\5+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+
MD@'_"ID!_PJ? /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_
M .\+_P#N#/\ [0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@
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M!;0L_P6T+/\%M"S_!;0L_P7_- P _S8% /\Y P#_/ @ _SP- /T[$P#Q.!T
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M#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43(
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M&711KQMS4< ;<5';''%2\AEQ4_\5<53_$W)4_Q%R5/\0<E3_$')4_Q#S2
MXU,  -!;  #$8   NF,  +-C  "L80  I%X) )U?%P"87R< DU\U 8Y>0 .*
M74H%AEQ2!X-;60J 6F ,?5EG#GM8;A!X6'42=E=^%'16B!=R5I,8;U:?&FY5
MK!ML5;T<:U;5'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8
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M'5IBZAQ;8_P87&/_%EQC_Q1=8_\376/_$UUC_Q/F50  SU\  ,%H  "V;@
MK'(  *1T  ":<P  CF\  (=O#0"";QL ?7 I 'EO-0%U;C\#<FU(!6YL4 =K
M;%<*:6M>#&9J90YD:6P186EU$U]H?Q9<:(H86F>6&EAGI!Q69[0=56?*'55G
MZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78
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M%$9X_Q)'>/\11WC_$4=X_Q'-90  O7   +%Y  "G@   G(0  )*&  "&A@
M=X8  &N&  !FAPT 8X<9 &"()P!>B#,!6X@\ EB'10-6ATT$4X94!E"&6PA.
MA6,*2X1L#$F$=@]&@X$11(./$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D"
M_Q% @/\00(#_$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX
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M""F?_PBQ@@  I8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP
M/*T  #6O#  SL!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$G
ML70!)K&# 22QE (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L
M_P2JBP  G9$  ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<
M "JZ P DO T (KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP
M&;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*A
MD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$
M   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP
M  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F
MC9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1
MT0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #>
M<P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8
M '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0
M ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@
M[78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W
M  !9OP  2\8  #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L
M  #K    [04  .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,
M /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,
MR@  /,\  "[4   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V
M    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B
M  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0
M_P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_
M )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T
M_P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE
M /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@
M_P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T
M /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,
M+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@";
M /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\
MZ@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_
M$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&
MG0#Q!J, [P:J .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_
M -T,_P#<#/\ W S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\
M_Q0[ /\220#\$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F
M#J  Y ZG .(.KP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3
M_P'*$_\!RA+_ <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU
M /4:0@#O&$\ ZA=: .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP
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M!*(L_P3_,@  _S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL
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M#8D^LPV(/L0.AC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/
MZT,  -Q*  #,3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&8
M2$X"E$=7 Y)'7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#
MKQ!^0\ 0?$3:$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@
M --/  #'5   O54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"
MC4U3!(I,6@6'2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U
M2+P2=$G2$W-)[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3
M  #!6   N%H  +!9  "I5@  HE(' )M2%0"64R0 D5,R (U3/@&)4D<"AE%0
M!(-15P6 4%X&?D]E"'M/; EY3G,+=TY[#75-A0YS39 0<4V<$F]-J1-N3;D4
M;$W.%&Q-ZQ-L3OT0;$__#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]
M7   M%X  *Q>  "D6P  G%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ5
M5 5Z5%L&=U1B"'53: ES4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+
M%652Z11E4OL19E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P
ML&(  *AB  "?7P  EEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T
M6%@&<5A?!V]79@EM5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5
MYQ5@5OH28%;_#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68
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M$%)B_PY28O\-4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0
M?VL  'AK!0!R:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9
M:64)5VEM"U5I=PU3:((/4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG
M_PY-9_\-36?_#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$
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M"SIZ_PO :0  LG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$
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M B>>D (FGJ$"))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0
MH(@  )6.  "+D@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 I
MJ0\ **D8 ">J(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VK
MBP ;JYT &JNQ !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\
M (^4  "#F0  =9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08
M&;</ !BW%P 7MR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /
MN9< #KFL  VYQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;
M  !YH   :Z8  %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&
M  O&#@ *Q14 "<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL
M ,:@  #%M@  QM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !M
MJ0  8*\  %.T  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0
M"@  T!   - 6  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2
M  #6IP  UK\  -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@
M5+D  $:]   YP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P
MW0H  -X/  #?%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #I
MF   Z:T  .G%  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(
M #G&   LR@  (,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $
M .H'  #K#0  [1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA
M^IL  /JO  #ZP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0
M   ?U   %-H   W?   %XP   .8   #I    [0   .\   #Q    \P   /4
M  #V @  ^ D  /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4
M /^:  #_JP  _[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_
M #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\
MI #_ *H _P"P /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_
M /H _P#Z /\ ^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H
M_P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #]
M *8 _ "L /L M #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /
M_P#P /\ \ #_ /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!#
M /\ 4 #_ %P _P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *(
M\P"H /$ L #P +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E
M /\ Y0#_ .4 _P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\
M2P#_ %< _@!B /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D
M .8 K #D +0 X@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\
MU0+_ -4"_P#_'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X
M!E$ ] 1< .X$9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%
MJ #5!;$ T@6[ - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_
M ,4,_P#_(0P _R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH
MY0U6 .$-8 #=#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(
M#JX Q@^Y ,00R #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83
M_P'_)08 _R,  /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/
M ,X560#+%6, R!9K ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D
MMQFT +4:P@"T&M8 L!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_
M*   _R<  /XJ  #O*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@
M4P"\(5T N2%E +<B;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O
M :<CO &F),X!HR3H J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+
M_RT  .TR  #B-   VC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O
M*U< K"M@ *HK9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHK
MM@.9+,<#ERSB Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,
M .0Z  #6/0  S#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U(
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M2@  O$L  +5)  "O0P  J3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M
M60*)0& #AT!G X4_;02#/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-
M"G4_Z@IT0/P(=$#_!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P
MME   *Y/  "G2@  H$0' )I%% "51B( D$8P (Q'/ ")1D4!AD9. 8-&50*!
M15P#?D5C!'Q$:@1Z1'$%>41Y!G=$@@AU0XT)<T.9"G%#I@MP0[4,;D3)#&U$
MYPQM1?H*;$7_"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54
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M"EM2_PE;4?\(6U'_"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@
MB%<  (!6"@!Z5Q4 =E<B '-8+@!P5SD ;5=! 6I720)H5E "9E97 V167@1B
M564%8%5M!UY5=PA<58(*6E6.#%E5G U75:L.5E6^#U55VP]55?,-557_"U95
M_PE65?\)5E7_"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP
M 'M;!@!U6Q( <5L? &Y<*P!K7#8 :%L_ 65;1P%C6TX"85I5 U]:7 1=6F,%
M6UIK!EE9=0A768 *55F,"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9_PI1
M6?\)45G_"%%9_PC440  PEH  +1A  "J9@  H&@  )=I  ",9P  ?6   '5?
M P!O7Q  :U\< &A@* !F8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%5UYI
M!E5><PA37GX)45V*"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)
M3%W_"$Q=_PC/5   OEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I
M9 X 9609 &)D)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G!5!C
M<0=.8WL)3&.("DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_
M"$=B_PC*6   NF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L
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M!3AXD08W>*$'-7BS!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:
MK7$  *)Y  "8?@  C8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#
M@1X 0H(I $&",@! @CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!
MC@0P@9\$+H&Q!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@
M )U_  "2@P  B(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ<
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M !&EOP 0I.( $:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0
M<9H  &2>  !8H0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0
ML1@ #K$B  ZQ*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2P
MM0 $L-  !+#O  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(
M %JG  !.JP  0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(
M ;T9  "^(@  OBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@
MOL(  +WD  "]]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P
M  !"LP  -;8  "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2
M  #*&0  RR(  ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,
M ,_.  #/ZP  SO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   U
MO   *;\  !["   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9
M$0  VQ8  -P?  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z
M  #EU   Y>H  .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@
M',D  !/-   ,T0  !-4   #:    W@   .$   #B    Y    .4#  #G"0
MZ0X  .L2  #M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #W
MO   ]\X  /??  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4
M  K;    WP   .(   #E    Z0   .P   #M    \    /$   #S    ]00
M /<*  #Z$   _!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J
M_[8  /^_  #_OP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\
M5@#_ &, _P!M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L
M /\ M #_ +T _P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\
M^@#_ /H _P#_$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_
M %X _P!I /\ <@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D
MKP#X +@ ]@## /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_
M .X _P#_$A0 _P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D
M_P!D /T ;0#[ '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L
M +, Z@"] .@ RP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .
M_P#_%!  _Q$. /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!>
M /( : #P '  [0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X
MW "X -H Q0#6 -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_
M%PP _Q0( /\/!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8
M8@#C &H X !R -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S
M ,D OP#& -  Q0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8
M_Q<  /\4  #_$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2
M!&0 SP5L ,P%<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'
MO "Y",T N KE +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL
M /\;  #Z&@  ]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX
MP0YF +\.;0"]#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M
M$<H JA+E *<4]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C
M  #F)   X"$  -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@
M + 89P"N&&X K!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4
MGAS? )H=\P&8'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:
M+P  SRT  ,HG  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C
M8@"A(VD H"-O )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276
M 8XF[P&,)_\"BR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.
MQ#<  +XR  "Z*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6
M*V, E"MJ 9(K<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,N
MZ@.!+OP#@"[_ G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\
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M!69 _P1F0/\$9C__!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@
MD40  (I!#0"$0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M
M0V<":T-O VE#>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$
M_P5?1/\$8$3_!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD
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M!5!0_P702P  OU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX
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M!41=D 9#7J '05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@
MM%\  *AF  ">:@  E6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!2
M8R4 4&,O $YD. !-9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]C
MC@4]8YX&/&.P!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,
M *5J  ";;P  D7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$
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M B=[OP(F>^$")GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P
MA((  'B#  !LA   7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  L
MA2T *X4U "J%/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&
MO $>AMX 'H3U 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@
M '&*  !EBP  6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4
M()$N !^1-@ >D4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3
MD=@ $X_T !2._P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1
M  !=DP  4)4  $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD
M !*=+0 1GC< $9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P
M"9SL  J;_@ +FO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4
MG   2)\  #R@   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J
M)  %JBX !*HX  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD
M  "H]@  I_\  *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@
M/:@  #&J   FJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0
MMR4  +<O  "X.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V
M[P  MOP  +;_  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$
M ":S   <M@  $[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P
M ,4D  #&+@  R#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y
MR/0  ,C]  #(_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]
M   1P   "\,   /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49
M  #7(@  VBT  -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8
M -_T  #?] !YH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )
MS    ,\   #3    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H
M%@  ZB   .TK  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A
M  #SX0!MJ@  7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@
M -X   #B    Y@   .D   #J    [    .X   #P    \@   /0&  #V#
M^1(  /P<  #_*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_
MP0#_!QD _P$7 /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J
M /\ <P#_ 'L _P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@
M_P#$ /X U0#\ .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_
M"Q4 _P43 /\ $P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\
M;@#_ '8 _P!^ /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^
M /, S #Q ., [P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$
M_PD0 /\ #P#_ !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X
M '$ ]@!Y /0 ?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4
MQ0#C -H X0#M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+
M /\#"0#_  P _P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L
MZ0!S .< >@#E (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0
M ,X S@#F ,P ]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'
M  #_!0@ _P . /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M
M -4 <P#2 'H T "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,<
MO0#? +P \0"[ /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_
M#   _P<) /@!$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4
M;0## '0 P0!Z +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8
M *X"[0"L _L JP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0
MY@X  .4&" #= Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U
M!VX LP=U +$(>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-
M[0"?#OX G0[_ )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H
M - 3 @#.# L QPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@
MIA%O *01=@"B$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2
M%OT D!?_ (\7_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A
M  "]&04 N1(0 +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II
M )<;< "5&W< E!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H
MA"#_ 8,@_P&#(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P
M)0  K!T, *8>& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD
M:P"))'( B"1Z (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_
M 7@H_P%X*/\!>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P
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M ED^_P+6/P  PT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$
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M TY*CP-,2Y\$2TNP!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20
MN%$  *Q7  "A6P  F%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:
M32@ 6$TQ %9-.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/
MC0-'3YT$1D^N!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54
M *E;  "?7@  E6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424
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M S5>O0,T7]T#-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;
MC&X  (%N  !V;   9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^
M8S4 /60] #QD10 [9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]E
MNP(N9=H"+F3T BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',
M 'US  !R<@  9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$
M-6LY #1K00 S;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G
M;=8!)VOR 2=J_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY
M  !M>   8'<  %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T
M "QT/  K=$0 *71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==(
M'W3Q !]S_P$?<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G
M?P  6G\  $U^  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^
M-@ A?C\ 'W]( !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O
M !9\_P 6>_\ %GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP
M5(<  $B(   \B   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5
MBC< %(I! !.*3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'
M_  .A_\ #H;_  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)
M $&2   TD@  *I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\
M"I<Y  F71  (EU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]
MD_\  9+_  &2_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;
M   LG   (IT  !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q
M  "D/   I$@  *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L
M *#_  "@_P"1B@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   C
MI@  &:@  !&J   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q
M,@  LCX  +),  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__
M  "O_P",D   ?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L
M$+,   JU   "N    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P
MP3(  ,)   ##3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!
M_@"!EP  <YT  &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X
M  #!    Q0   ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8
M -8R  #800  V%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !V
MGP  9Z8  %FL  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.
M    T@   -4   #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD
M  #L,@  [4,  .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ
M6Z\  $RV   ^O   +\   "#$   4R   #,P   +0    U    -D   #>
MX@   .4   #F    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\
M(P  _S,  /]&  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4
M /\ % #_ !< _P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '<
M_P!^ /\ A0#_ (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[
M .8 ^0#V /@ _P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\
M$ #_ !$ _P 7 /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y
M /T @ #\ (8 ^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X
M[0#P .L _@#J /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_
M  P _P 3 /\ 'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$
M>@#O ($ [@"' .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I
M -H ^0#9 /\ UP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D
M_P 0 /\ &0#[ "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@
M 'L W@"! -P AP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8
M\P#% /\ PP#_ ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P +
M /, $@#N !\ Z@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0
MR@![ ,@ @0#& (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S
M /L LP#_ +( _P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .<
M#0#@ !@ V@ E -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T
M +@ >P"V ($ M "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /<
MI #_ *, _P"B /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0
M !$ R0 = ,0 *@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D
M=0"H 'L I@"# *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_
M )4)_P"4"?\ E G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH
MO0,4 +<$(0"R!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";
M"W8 F0Q^ )<,A@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1
M_P"'$?\ AQ'_ (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T.
M *H.&0"E#R< H1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W
MC!-X (L3@0")%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\
M&?\ >QG_ 'L9_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6
M$P"9%R$ E!DM )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS
M '\=? !]'88 ?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\
M<2'_ '$A_P#H*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-
M(!L B2$G (8B,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E
M=P!S)8$ <2:- &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_
M 6@H_P'A+@  RS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8
M?R@B 'PI+0!Y*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I
M+'T :"R) &8ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N
M_P':-   Q3P  +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX>
M ',O*0!Q,#, ;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD
M8#*% 5\RD@%=,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2
M.   P$   +-%  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT
M)0!I-2\ 9S4W &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>"
M 5@XCP%6.)X!53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/
MO$0  *])  "D3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C
M.BL 8#HT %XZ/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\
MC0%0/9P!3SVL DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@
M *Q-  "A4   EU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@
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M C]*NP(^2]@"/DKS CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P
MD%T  (9<  ![60  ;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'
M2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/
MN0(Y3]0".4_R 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$
M (-A  !X7@  :5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4
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M 2=>_P$G7?\!*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@
M8&L  %1I  !)9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K
M94( *F5* "AE5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E
M_@ @9/\ (&/_ 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(
M $]Q  !$;P  .FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T
M(6Y& "!N4  >;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8
M;/\ &&O_ !AK_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY
M   _>   -7@  "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA
M !5X2@ 4>%8 $WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\
M$'7_ !!T_P"?<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X
M@@  +H(  "2"   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#
M1  ,@U  "X-=  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__
M  9__P":>0  D'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC
M)HP  !V-   5C@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0
MD$D  (]6  "/90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+
M_P"4@   BX4  (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<
M !68   /F@  "IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4
M )U.  "=7   G6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".
MB   AHP  'B0  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD
M   (I@   *@   "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$
M  "L4P  K&,  *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@
M>Y,  &V7  !?G   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P
ML@   +4   "U    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]
M1P  O5@  +UK  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L
M &*@  !3I0  1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP
M ,(   #"    PP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@
MT4L  -%>  #2<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I
M  !'KP  .;,  "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\
M  #0    T@   -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P
M .E/  #I9   ZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [
MN0  *[P  !W    1Q   "<@   #,    SP   -,   #9    W0   .    #A
M    XP   .4   #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^
M  #^4P  _FH  /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !,
M_P 9 /\ )@#_ #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_
M (< _P"- /\ DP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\
M_ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_
M  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\
M9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T
M .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L
M_P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R
M &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T
MN0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P
M /\   #_  0 _P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &(
MWP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#%
M ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\
M  #_    ]  ' .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C
M ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D
ML0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N
M    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +<
M8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0##
M )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@
MU00  ,X !0#& !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F
M &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$
MTP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$
M +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP
MEP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$
M"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7
M  "L$   J D- *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U=
M (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P
M=A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@
M'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P4
M7@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\
M &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@
MD!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P
M'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B
M_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@
M ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L
M921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9
M*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ
M P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I?
M %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\
M4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K
M+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P
M9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_
M $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D
M8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!-
M-6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W
M_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80
M %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD
M1SIU $4[@P!$.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^
M0@  KTD  *-.  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[
M%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S
M $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10
MK$P  *%1  "75   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)
M0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#
M?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5
M )Y5  "46   BUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D
M0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U
M2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9
M  "27   B%T  'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D>
M #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L
M+DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/
M80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/
M(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.:
M "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@
M@V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M
M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9
MJP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP
M '5L  !J:P  76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B,
M)%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 7
M8,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R
M  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E
M !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T
M#FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@
M=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q
M)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2
M  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@
M37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '
M?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !Y
MZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<
M #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",
M (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@
MA/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1
M   DD0  &I(  !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D
M  "6+@  ECD  )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4
M )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;
MG   $IT   R?   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E
M)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\
M  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP
M"JD   &K    K0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P
MM20  +<P  "W/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U
M_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0
M  "W    N@   +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD
M ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!P
MFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$
M    R    ,L   #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8
M  #B)   XS4  .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI
M5:H  $:P   XM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4
MV    -P   #=    WP   .$   #C    Y0   .@   #J    [08  /$.  #U
M%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P .
M /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X
M_P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W
M -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\
M" #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P
M /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T
MY@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_
M  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H
M<0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #>
M ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_
M^P + /8 $P#Q "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2
M '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L
MZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ %
M .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H
MO0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G
M /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0
M"P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I
M *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X
ME0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^
M  X N  7 +, (P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L
M:0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y
M (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @
MJP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P",
M &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%
M_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4,
M )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V,
M?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M
M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+
M#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E
M ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\
M8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]
M$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46
M:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_
M %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X
M;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;
M'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B
M_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3
M &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H
M425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##
M-   LSL  *<_  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF
M&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS
M $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.
ML#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2
M+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P
M?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,
M *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P
M2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]
M-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+
M  "430  BDX  (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A
M $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D
M-SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "2
M40  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY
M)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9
M # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50
MAE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W
M/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#
MJ@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH
M 'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"<
M,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D
M2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>
M  !K7   7U@  %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK
M "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L
M'4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I
M80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0
M+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9
M !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P
M660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :
M6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9
M\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H
M $AH   ^9@  ,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X
M$6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )
M8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P
M   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR
M  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@
M &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q
M>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U
M-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_
M  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@
M'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P
M@CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]
M_P"-?   A($  'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP
M !"-   )C@   H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(
M ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(
MA   @(@  '*+  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9
M    FP   )T   "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U
M  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP
M=8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F
MJ    *H   "J    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q
M.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8
M %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0
M +<   "W    N    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P
MQ3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D
M  !!J   ,JP  "2O   6L0  #;0   .W    N@   +T   #     Q    ,8
M  #&    R    ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT
M -]   #@5   X6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   T
ML@  );4  !>Y   -O    ;\   ##    QP   ,H   #/    TP   -8   #7
M    V@   -P   #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q
M  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X
M_P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_
M 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$
M_@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0
M /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@
M\@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#>
M /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\
M%@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W
M -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\
MQ0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K
M !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@
M=P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_
M +  _P"P /\ K #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8
MT0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S
M '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X
M_P"> /\ G@#_ )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ;
M +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '
MH !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"-
M /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L
M( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P
M (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\
M?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9
M ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($
M<0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_
M '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L
MB0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R
M 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)
M_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8>
M 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W
M90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-
M(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.
M(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V
M %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*
MMBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A
M%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8
M?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30
M *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$
M5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !'
M'XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\
M  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E
M $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@
M/R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "4
M0@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F
M* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7
M #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@
MAT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _
M*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,P
MIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H
M 'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD
M."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L
M-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-
M  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M
M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D
M)CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L
M3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY
M,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4
M "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P
M74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G
M/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"
M\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0
M %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0
M($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 6
M1_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8
M  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX
M !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\
M$4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _
M6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2
M/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_
M  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@
M,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )
M6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9
M_P"79   CFL  (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD
M "%G   89@  $68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$
M &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3
M;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ
M   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'
M  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P
MA7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -
M?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![
M3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\
M 'B"  !K@P  784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0
M (H   "*    B08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@
MB58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(
M  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<
M  "8    EP   )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T
M )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6
MDP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E
M    I0   *4   "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3
M  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G
M/)\  "VB   @HP  $Z4   NG   !J0   *L   "N    L0   +(   "R
MLP   +0   "U    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  #
M6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD
M "&K   3K0  "[    "S    M0   +@   "\    OP   ,$   #!    PP
M ,0   #&    QP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30
MVV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U
M   *N    +L   "_    PP   ,8   #+    S@   -$   #1    U    -8
M  #9    VP   -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4
M /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_
M "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L
MA #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_
M .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ",
M_P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J
M (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\
M_P#$ /\ O0#_ +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J
M /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X
MT@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V
M /\ L #_ *T _P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X
M+P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^
M +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\
MHP#_ *  _P#_    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#"
M #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D
M?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_
M ), _P#]    \0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P
MK0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6
M (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8
M_P#S    XP   -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O
M )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D
MA "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G
M!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L
M,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!]
M '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$
MQA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![
M #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &<
M@P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T
M + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L
M;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:
M!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH
M  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM
M & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH
M3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9
M+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80
M+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7
M $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0
MBS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,
M%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:
MI@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH
M 'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT
M0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V
M(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\
M  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P
M #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8
M+R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N
M/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E
M,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/
M "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@
M83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O
M*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O
M[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(
M %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4
M*2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?
M,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#
M  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z
M "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\
M&S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'
M10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY
M00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_
M !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P
M.D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5
M/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !!
M_P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX
M "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4
M#T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":
M50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2
M   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-
M  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P
MC6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :
M6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !6
M5P  5F4  %5W  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@
M (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@
M#F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P
M7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR
M  !U=   :G4  %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP
M  )K!@  :PL  &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P
M &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P
M>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W
M @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H
M  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0
M6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%
MA ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""
M=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H
M $*+   UC0  )XT  !N-   1C@  "HX   "/    D0   )(   "2    D@
M )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P
MDX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5
M   IE@  ')<  !&8   )F0   )L   "<    G@   *    "@    H    *
M  "A    H00  *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@
M *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =
MH   $:$   BC    I0   *<   "I    K    *X   "N    K@   *\   "P
M    L0   +(   "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%
M  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@
M!ZP   "O    L0   +0   "X    NP   +P   "\    O@   +\   #
MP@   ,0   #&    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4
MD@  U:L  -7$  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@
M  "[    O@   ,(   #'    R@   ,P   #,    S@   -    #2    U0
M -@   #;    WP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@
M\)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\
M/ #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0",
M /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\
MP@#_ +T _P#_    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z
M $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$
MC@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_
M +( _P#_    _P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L
MXP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#'
M )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4
M_P#_    _P   /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^
M ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@
ML0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_
M    ^P   /    #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0
M0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+
M )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y
MZP   -T   #/    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"?
M $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H
MCP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@
M ,D   "^    M@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H
MC0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X
M )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+
M  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z
M 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\
M:0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G
M$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\
M.@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8
M %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'
ME1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B
M #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !
MI0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(
M (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34
M5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%
M"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F
M  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV
M $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8
M.Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R
M*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1
M-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7-
M #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@
M92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y
M%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;
M[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\
M %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C<
M,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G
M(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P
M  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [
M "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T
M(B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*
M,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E
M00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_
M !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P
M/C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?
M*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM
M_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@
M #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8
M&"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">
M10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z
M   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/
M !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20
MD4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D
M/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[
M60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0
M (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1
M&$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &
M064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->
M  !Y8   <&   &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H
M  Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(
M $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W
M90  ;F8  &5F  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2
M!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O
M  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;
M;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@
M6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8
M?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(
M %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D
M &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@
M8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W
M  !%=P  .'8  "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*
M  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL
M &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \
M?P  +X   ")_   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^
M"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<
M  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0
M)(D  !B)   /B0  !XH   "+    C    (T   "-    C    (P   ", P
MC @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+
MK@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,
M  Z4   &E0   )8   "8    F@   )L   ";    FP   )L   ";    G
M )T%  "="P  GA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0
MGL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?
M    H0   *,   "E    J    *D   "I    J0   *H   "K    K    *T
M  "N 0  L D  +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0
M +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K
MK0   +    "T    M@   +@   "X    N0   +H   "\    O0   +\   #
M    PP   ,4'  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"
M  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@
M +X   ##    Q@   ,@   #(    R@   ,L   #-    SP   -(   #5
MV0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #L
MP@#_    _P   /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!,
M /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )<
MZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_
M    _P   /\   #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T
M3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U ";
M -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_
M_P   /\   #_    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3
M %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P
MGP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P
M /D   #O    Y@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H
MNP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E
M *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H
M  #=    SP   ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!)
M *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T
MD "L (X OP", .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(
M    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0
M20"2 $X D !3 (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D
M 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X
MKP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@""
M $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T
MK@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@
M )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$
M<@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!>
M +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(
M  "(    @@ % 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!!
M &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4
M40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_
M#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@
M00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#'
M $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0
M;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!,
M $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%
MY0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@
M &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T
M00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S
M#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:
M  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_
M #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H
M+!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/
M&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 1
M0P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_
M "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@
M0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H
M%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :
M_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",
M #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T<
M(1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A
M.   E3T  (M!  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D
M   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/
M !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/
MDT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J
M)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E
M60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44
M (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0
M("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0
M*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,
M  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 %
M !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&,
M"C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z
M4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T
M"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q
M  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6
M;UD  &58  !;50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +
M.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \
M@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X
M &-=  !:7   3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP
M T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@
M0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C
M  !780  25T  #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.
M  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I
M $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !0
M9@  0V0  #=A   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5
M$   514  %0;  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D
M  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;
M/6L  #!I   E:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@
M7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;
MN0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,
M "AR   =<   $V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX
M &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0
M9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][
M   4>@  #7H   1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.
M  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X
M '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -
MA0   X4   "&    AP   (@   "(    AP   (<   "'    AP0  (<)  "'
M#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L
M  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0
M )(   "3    E0   )8   "6    E@   )8   "6    EP   )<   "7!P
MF T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6
M^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\
M  "A    I    *4   "D    I0   *4   "F    IP   *@   "I    J@0
M *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!A
MD0  4Y4  $28   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P
M    L@   +0   "S    M    +4   "W    N    +D   "[    O0   +\!
M  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0
M1YT  #BB   II@  &:@   VK    K0   +$   "T    MP   +H   "_
MP0   ,0   ##    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;
M    X P  .$8  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P
M /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %<
M]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B
M +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\
M  #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8
M .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\
MQ0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[
M    \P ! .T # #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8
M5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W
M *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I
MX    -4 " #. !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O
M %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D
MPP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R
M +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %
MFP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "%
M -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X
M  "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!.
M (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,<
M<@#L '$ _P!P /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9
M  , DP , (X $@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@
M30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A
M &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-
MA@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H
M $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4
M\@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P "
M '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8
M6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!)
M /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L
M!@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!'
M $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@
M/@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !<
M 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $,
M20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_
M #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $
M3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X
M TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(
M_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$
M $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D
M+@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D
M*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0
M!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0
M "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P
ME3,  (HV  " -P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P
M$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X2
M6@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<
M (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4
M)A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7
M%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^
M  !\/P  <S\  &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD)
M !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V,
M$1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![
M1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=
M#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q
M  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2
M<$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2
M(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F
M@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP
M &5+  !;2   4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T
M#2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P
M*Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0
M  !:30  3TH  $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0
M  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$
M #&G   POP  ,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !8
M4P  3E   $5-   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V
M$P  -AD  #8@   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E
M   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760
M3%8  $!2   U3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0
M/A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \
MNP  /-X  #OU   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL
M #I7   O50  )5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0
M $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N
M0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>
M   I7   'UH  !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6
M  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@
M $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B
M9   &&(  !!@   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9
M&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T
M  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;
M$6L   EJ    :@   &D   !I    :    &<#  !F"   9@P  &8/  !E%
M91P  &4G  !D-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>
M_P!]=   =W<  &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4
M  !U    =0   '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4
M '(@  !R+   <CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![
M>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""
M    @P   (,   "#    @@   ((   ""    @@   ((%  """@  @@\  ((7
M  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@
M:(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+    C    (T   "/
MD0   )(   "1    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4
M&0  E"<  )0X  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H
M $V-   _D   ,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP
M *    "@    H    *    "A    H@   *,   "D    I0   *8'  "H$
MJ!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6
M   SF0  (YP  !2=   *GP   *$   "C    I@   *@   "L    K@   *\
M  "O    L    +    "R    LP   +0   "V    MP   +H   "]!P  OQ
M +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   F
MHP  %J4   NG    J@   *T   "P    LP   +8   "[    O0   ,    "_
M    P0   ,(   #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3
M  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_
M_P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M
M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -(
MZ #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P "
M /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X
MT@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y
M /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .<
M"@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!=
M +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T
MH@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&
M  X P0 5 +T '@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4
M6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[
M (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H
MK  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0
M %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L
M_P!Z /\ =P#_ '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP -
M )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %,
M?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I
M /\ :0#_ &< _P#3    PP   +4   "K    HP   )L   "2    C  * (<
M$ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3
M &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\
M6@#_ %H _P#%    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U
M !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X
M4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_
M $T _P"["@  K T  * -  "5#   C @  (,"  !\    =0   &X " !I  X
M90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0
M %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $(
M_P"R$0  I10  )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P /
M %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %
M0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L
M%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T
M$ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4
M #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@
MFB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!!
M !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X
M6P M &< *P!V "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/
M1DE,10 1$B4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5
M  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T
M "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^<
M'0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'
M%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)
M-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY
M !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0
M/!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :
M#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0
M_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\
M #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H
M$Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7
M-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A
M   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"
M  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.
MBCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G
M(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;
M3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$
M ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@
M'24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #
M(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(
M  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L
M !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4
M "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S
M3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N
M P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB
M   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5
M:%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &
M,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R
M<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED
M %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @
M #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P
M.(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?
M  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*
M  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($
M #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+
M80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,
M#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6
M  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@
M-V0  "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"
M5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1
MJP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP
M ")J   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@
M &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP
M6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES
M   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(
M  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X
M &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '
M?0   'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\
M!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?
M  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B
M (D   "*    C    (T   "-    C    (P   ",    C    (P   "-
MC00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*
M\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<
M  "9    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP
M *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<
MC0  39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
M    J@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0
M  "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0
M09@  #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W
MN0   +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
M    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P
M /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X
MZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/
M *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\
M  #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!.
M ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *,
MM@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
M    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@
M30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K
M )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<
MS@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A
M $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L
MM0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@
M +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4
MC0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V
M ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$
M  ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$
M 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@
M9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
M    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H
M0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+
M %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!
M>0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !;
M $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@
MZ !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P
M &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P
M30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \
M /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &
M 0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \
M $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$
M,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1
M  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8
M/@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^
M "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P
M1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K
M $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\
M_P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL
M #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X
M(@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":
M)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0-
M @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$
M !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P
MC"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I
M#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+
M30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,
M '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P
M(! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,
M#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ
M  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8!
M !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4
M!A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S
M/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8:
M @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B
M   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P
M:$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -
M&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =
M<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@
M %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D
M!2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<
M(H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+
M  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,
M   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(
M ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !3
M3P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N
M#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7
M   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350
M1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0
M-0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   R
MK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8
M #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X
M #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP
M.<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8
M   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/
M  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8
M $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =
M70  $EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0
M$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ
M  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490
M#60   -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0
M6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3
M_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T
M  !M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X
M &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W
M>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M    >@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.
M  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@
M8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&
MB    (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")
M$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8
M $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP
M )@   "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P
MG1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1
M   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<
M  "F    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD
M +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @
MG0  $9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
M    MP   +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,
M  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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ME)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM
M[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
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M_________ZQ3$       %VW6____________________________^X Q
M    "6',____________________________TEH"         %W,________
M____________________J#4          %S3________________________
M____?0T          %36___________________________N?44
M $34___________________________\JF0O @  !"(W25C.____________
M________________Z:1K02@_8W^5I[K:____________________________
M___5LJRRS.3Z________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________ENY=W8LC_____
M____________________________VYYG-@H  HS_____________________
M___________(?S\%     %[/_____________________________]F!.0
M     #RJ_____________________________YY,         ".0________
M____________________W&\:         !!]^?______________________
M____KT@           !O[O__________________________A!,
M  !DYO_________________________L40            !7WO__________
M______________^X%0            !(UO________________________]T
M%              XS_________________________FB6A,            C
MQ?_________________________?FUPL           -NO______________
M____________[[%]53DB$0<! A$BLO______________________________
MW[^EF9B:H*R]VO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________X[Z=@'S[________________________________\K>$
M5S . !VL_______________________________2BDP5      !R\_______
M_____________________]9_-@        !+R?______________________
M____^I$^           OJ___________________________P%H
M   :E?__________________________C20            (A/__________
M_______________G7@              =_________________________^T
M)0              :O________________________]]
M6_3_______________________TK                3.O_____________
M_________Z4                 /.'______________________S ,
M            +=G_____________________F8IA)P              )]?_
M_____________________^V^B54G            )=S_________________
M_________LJ==EU*/#(M+# Y1][_______________________________WF
MW=;2T-/9Y/__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________OU+O6________
M_________________________^>XCVI++Q5O________________________
M_______DH6<T!P     \R?___________________________]:".P
M   2E___________________________[84Q            ;___________
M________________ID(             4.'________________________L
M:0              -\G_______________________^S+P
M(K;_______________________]Y                $*?_____________
M__________(T                 )G______________________ZD
M             (S______________________T8                  '__
M____________________WP                   '3_________________
M____EP                   &K_____________________S@
M         &/______________________RDB 0               &'_____
M_________________[FC@%<W%P           &C_____________________
M______K3KI2&?'5Q<')W@93_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________V[J=
M@FEIT_______________________________R)-E/1D    =GO__________
M_________________]N.3!,         ;O__________________________
MVWPL            1=?_________________________BRH
M(K3________________________"1                Y?_____________
M__________]] 0               '_______________________^<V
M             &K______________________YT                  %C_
M_____________________T8                  $?X________________
M____Z0                   #7I____________________E@
M         "7;____________________O                    !C.____
M________________ZP                    _"____________________
M_P                    JY_____________________R<
M      JU_____________________W                    VY________
M_____________^"<C'!50C,F&Q0/#0X2&B:_________________________
M____^>38TL[,R\S/UN#\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z].\X___________________________
M_____]*IA65(+!(!A?____________________________&K<3P/
M3^#_________________________U7\U            '[+_____________
M___________C=1T              (G_______________________^0(P
M             &?______________________]5#                 $CV
M_____________________XH                  "[=________________
M_____S@                  !?(____________________O@
M          2V____________________G                     "E____
M________________N@                    "3____________________
MW                     ""_____________________P
M      !T_____________________Q,                   !H________
M_____________T(                   !@_____________________WH
M                  !=_____________________]$
M  !A______________________\D                  !F____________
M___________)K)F)?79Q;&EG9F=K<'J,____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________XL6JD7EA=_______________
M_______________=IG=0+ P     ,<3_________________________X)).
M$P           (_________________________2<!T              &#_
M_____________________^YO#P               #?B________________
M_____Y8<                 !3 _____________________T
M          "C____________________K@                    ")____
M________________G@                    !R____________________
MO                     !?____________________V@
M      !-____________________^@                     [________
M_____________PX                    J^?___________________S,
M                   ;Z?___________________UX
M   /V____________________X\                    &T/__________
M_________]                      RO____________________\K
M                R/____________________^
MR______________________W%@$%!0,!       !!@T8R_______________
M_________.OAV,_,S<_0TM37W.+J________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________':QO______________________________\<:CA&A-,A@ %:O_
M_________________________[E\1A@          ''_________________
M_______7?"\              #OC_____________________]]D"0
M          RU_____________________W0#                  "-____
M________________Q14                   !J____________________
MF0                    !+____________________M@
M       P_?__________________UP                     9Y_______
M____________]@                     %T____________________PX
M                    P?___________________R\
M    K____________________U(                     GO__________
M_________WD                     CO___________________Z4
M                @/___________________]@
M=/____________________\V                    ;?______________
M______]\                    :?_____________________7#0
M            :/______________________<                   8?__
M_____________________U \1DY465UA9&AL<'9^B?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________[]6[HXMS6I7___________________________B_CF1!
M(04      %+\_______________________WG588             !?!____
M_________________^5L%@                "-____________________
M_V,                   !>____________________G0
M       U_/__________________H0                     1V?______
M____________R@                      N___________________[@
M                    H?___________________PP
M    BO___________________RT                     =O__________
M_________TT                     9/___________________V\
M                4O___________________Y0
M0/___________________[P                     ,/______________
M_____^H.                    (O____________________]$
M            %?____________________^!                    "_7_
M___________________("P                   NS_________________
M____7@                   .7_____________________R1P
M         -K______________________YT!              <.%\7_____
M___________________5N;S!Q\[5V^'F[?3[________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________XW\______
M________________________[,:EB&U4.R$' #+>____________________
M____UY)9*0            "@______________________^)-@
M      !G_____________________V8                    R]O______
M____________E0                     #R/__________________IP
M                    H/__________________UP
M    ?/___________________P                      7O__________
M_________R4                     0____________________T@
M                +/___________________VH
M&/___________________XL                     !?/_____________
M_____Z\                      .'__________________]4
M             ,____________________\D                     +[_
M__________________]4                     *[_________________
M__^+                     )_____________________+#@
M         )+_____________________5P                   (;_____
M________________J@H                  'G_____________________
M_VT                  &;_______________________=5
M     $7_________________________:B,K-3]*56!J=7Z'D9S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^C/
MMIV#:4ZY_________________________^RR@UPZ'0(       ![________
M_______________%;2D               ! _____________________X,;
M                   'R___________________D@
M    F/__________________I                       :O__________
M________W0                      0?___________________PX
M                '?___________________SD
M .C__________________V                       ,[_____________
M_____X4                      +?__________________Z@
M             */__________________\L                      )#_
M_________________^\6                     'W_________________
M__\^                     &S___________________]I
M         %K___________________^9                     $G_____
M_______________2%@                   #G_____________________
M6                    "G_____________________H@
M     !G_____________________]58                   3_________
M_____________[LO                  #X______________________^K
M*0                #/________________________R4<     !Q,@+CY2
M:(3M________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________]-7)________________________
M____^M*PDG==0B@,  !*________________________Q7U%%P
M   1V/___________________\10                    G___________
M________H@P                     :/__________________E
M                -O__________________V@
M!^S__________________Q4                      ,3_____________
M_____T@                      *+__________________W4
M             (/__________________YT                      &G_
M_________________\,                      %+_________________
M_^</                     #[___________________\S
M         "O___________________]8                     !C_____
M______________^!                      7___________________^L
M                      #____________________>(@
M      #R____________________7                     #?________
M____________GP                    #,____________________Z$H
M                  "W_____________________Z 6
M  "<______________________]Z @                !W____________
M____________>@L               5,_________________________Z)7
M:'2 C9RKO-#G________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^WC____________
M_______________2HWI8.BDC'!8.!@  G_____________________^L4@X
M                :?__________________Y$,
M-/__________________>0                       ./_____________
M____S0                       ++__________________Q,
M             (7__________________T\                      %W_
M_________________X,                      #K_________________
M_[(                      !S__________________]L#
M          +___________________\J                      #[____
M______________]/                      #G__________________]T
M                      #4__________________^;
M      # ___________________$!P                    "M________
M___________P,P                    ":____________________9P
M                  "&____________________HP
M  !R____________________XT0                   !<____________
M_________Y$&                  !!_____________________^M?
M               =_______________________*2P
M________________________RU<   P8)#$_3F!TBZ?'________________
M___________7Y_+_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________KU,W'PKZZM[.PK:FHI?______________
M_____]U^4S\P(QD1"0(          -O_________________=@
M             *?_________________N@                       '7_
M_________________P<                      $;_________________
M_TX                      !K__________________XP
M          #]_________________\$                       #;____
M______________$9                      "^__________________]$
M                      "D__________________]K
M      "-__________________^1                      !Y________
M__________^W                      !F___________________>(0
M                  !3____________________2@
M   _____________________=P                     K____________
M________K H                    6____________________YT4
M                _____________________XH
M_____________________]9-                    _?______________
M______^G+@                  U?______________________F"H
M      88+45@X/_______________________ZAC=(&/G*N[S>+Z________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^(S@$E#0U]04D]&24Q% !(2____________________
M___________________________________________GR[>IG96.B82 ?'AT
M<&QH99#_________________O&I(+1D*                 #'_________
M_________P                        /__________________T(
M                  #<_________________XX
M  "R_________________\X                       "-____________
M______\I                      !K__________________]:
M              !.__________________^&                       T
M__________________^N                       >________________
M___4%P                     *___________________Z/0
M            ____________________90                      ____
M________________C@                      ____________________
MO!D                     [___________________\4X
M        V/___________________XL                     O_______
M_____________\Q#                    H?____________________^1
M&0                  >O_____________________R= H
M   17_______________________Z'03'RPX15-B<H6;M-+U____________
M_______________7Z/3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M
M*"/$_________________TLE"P                    "2____________
M_____X@                       !F_________________]<
M               ]__________________\S                       8
M__________________]L                        ________________
M__^=                        ___________________)#
M            ]O_________________Q-0                      W___
M________________6P                      R___________________
M@@                      M___________________J08
M        H___________________TR\                     C?______
M_____________UX                     =____________________Y,'
M                    7O___________________\U#
M    0/____________________^'$                   '/__________
M___________87@                   /______________________OTX
M      X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^[AU\_)
MP[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4
M_________________]<%                        ________________
M__\T                        ]O________________]V
M            TO________________^P                        LO__
M_______________A)                       EO__________________
M40                      ?/__________________>0
M        9O__________________H                       4?______
M____________QR,                     //__________________[DL
M                    )____________________W0
M    $/___________________Z,6                     /__________
M_________]A,                     /____________________^(#P
M                 /_____________________+4P
M /______________________I3@           D=-$YKC/______________
M_________YDY0U%?;GV.H+7+Y?_____________________________K^?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KS+FLH9F1BX:!
M?'AT<&MH9F9H\?________________]A13(C& X&                GO__
M______________]^                        =?_________________#
M                        4O_________________[-P
M        ,O__________________:@                      %O______
M____________E@                       /__________________OQL
M                     /__________________YD(
M     /___________________VD                      /__________
M_________Y "                     /___________________[DL
M                 /3__________________^A<
M -G___________________^1&                    +S_____________
M_______*4P                   )W_____________________F"X
M        $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____
M_____________________^>@JKG(V.G\____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#
M/CHV,B\N,?_________________2)1$#                     /______
M____________0@                       /__________________?0
M                     /__________________L L
M     /;_________________W3D                      -S_________
M_________V(                      ,7__________________XD
M                 *___________________Z\B
M )G__________________]9(                     (+_____________
M______]R                     &G___________________^A*
M             $[____________________37                    #/_
M____________________EBX              !4R4G?_________________
M____X'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##
MV.__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^>#2
MR,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,.
M"00  -3_________________D@                       *W_________
M________S!X                      (O_________________^U(
M                 &W__________________X
M %'__________________ZD;                     #K_____________
M_____]!"                     "/___________________5H
M              S___________________^/%                     #_
M__________________^X/@                    #_________________
M___E;0,                   #_____________________GS<
M     ! O4'3_____________________W7(4      87*D%:=92VVO______
M_________________[Q81%1D=8::K\CC____________________________
M___2S>'Q____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________\^_K[_?______________________[KFHG9:/
MBH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"
M "/__________________VD                       #_____________
M_____YL*                      #__________________\@Y
M              #___________________!C                      #_
M__________________^*#@                    #_________________
M__^P-                     #____________________56P
M          #_____________________A1H                   /L____
M________________L4D              !@Y78'_____________________
MY7L>       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-
M[?____________________________^SGK3%U^O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD
M85Y;65A75UE>97'__________________[\Q'Q80"@4               #_
M_________________^U6                      #H________________
M__^"!                     #,__________________^K+P
M          "S___________________25P                    ";____
M_______________W?!                    "%____________________
MHC<                 !2N4____________________RV$"
M#"Q0=I[1____________________]8TP       -(SM7=IF^Y?__________
M_____________\-C&"H[3%]TC:?&Y_____________________________^H
M?Y:HN]#G_____________________________________?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___=SL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*
M2$=&2$M066:A__________________^G)@X' @                !6____
M_______________.4                      Z___________________T
M>0L                    A____________________GS(
M       .____________________Q%@                (,5J$________
M____________Z7\?           &)TMQFL+I_____________________Z=)
M      (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___
M__________________________^N<H68K,+;]O______________________
M____________W^______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MO[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"
M0T=.66E]____________________GBX&                    ________
M____________PU8                  !5!____________________YWL:
M              DT8(NT_____________________Y\_          0E2G&9
MPNO______________________\9F#P   !,J1&*#I\WU________________
M_________^N.-2L^46B!G;S>______________________________^^=G^4
MJ<'<^?__________________________________TMCS________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________V\O#O[^_Q\_C]____________________________^+"?
MFI>6EI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%:
M:(.I_____________________Z9! 0          !S9CC[KA____________
M_________\9E"@      !"=,<YS$[/_______________________^6(+P
M$RI$8H*FS/3___________________________^K4#9*87N6M-;Z________
M_______________________2AWR8L<OI____________________________
M________U,[M________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MY>/CY.;H[?'Y______________________________VQE)*2
ME9F=HZFRO-#M__________________________^=4T=)35%68'.*K];\____
M______________________^R5@ :-5!MBZ[2]_______________________
M_______-;SY?>YFWU_G________________________________NGX.FPN'_
M____________________________________X\[K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________
M
M
M                      #_____________________________________
M____________________________________________________________
M____________________________________________________________
M_____________P   /_N  Y!9&]B90!D@     #_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,#
M P,# P,# P/_P  4" %F!1\$ 1$  A$  Q$ !!$ _\0 AP !  (" @,! 0
M          D*!P@&"P,$!0(!$  !! (! P("!0,+#0D+!PT  0(#! 4&!Q$2
M"!,)(10Q02(5"C(C%E&UU7:V%[<X6'@Y87%",R25-M8W=Y<8&8%BLU2T)357
MF)&AP=%2DC24=2:'L>%RTM-5A5:&EO!#4V.#1-1%94?_V@ .! $  @ #  0
M #\ O\%_@O\ !?X
M
M
M                                                          !6
M\_$P?Q4>!?YPL7\&^\  I9        O3?ASOZ/\ S7\X;D;]S''@ )Z@
M
M
M
M
M
M           5O/Q,'\5'@7^<+%_!OO  *60       +TWX<[^C_S7\X;D;]S
M''@ )Z@
M
M
M
M
M                      5O/Q,'\5'@7^<+%_!OO  *60       +TWX<[^
MC_S7\X;D;]S''@ )Z@
M
M                      8[VGEKC?3%DCV/<<+1LQ*J24(K*Y'*,5/J?B\8
MRYD&=?H171HG4U9YC\V_$_@)]JMRKSQQ_KN6I/?';UJGE5VG<*TD:*JML:?J
M4.=V>OU5.B+)4:U7(J=>J* 8#SOF9Q]1<^+!8+9,^]JKTFECIXBC(GPZ+'+/
M/9O?'X]>ZLWI_5^J-'DCW\?&#7)9JG'''/*_)5B%SD;D+=7!:-KMIJ*B,?5N
M9'(Y;8?M?'JDV*A5$Z=.O54:!BK)>;.S2JOW/H^"HMZ_!,ED\AE51.CO@JU8
ML,BKU5/J3X(OZOPTQVW\0ARW<>Y=$\=N.=<C55[&[;MVS;J]K>V5$1S\/3T%
M'*CU8O5&I\&N3I]I%:!Q.;S'Y7E?W,H:97;T1/3AQ&3<Q%3Z5ZV,Y/)U7_Z7
M0PI>]^7S3MSK-7UK@+&1JUK4JT='W"2!%:GQ>CLER-D;7<_Z^LBM_41 #U8O
M+_ER/N[TU:?N<KD67"S)V(O]@WT,A"BM3_?=7?U3XU+WT?.&JDR3LX;R2RS.
ME8Z[H%^-:['(G2O#]W;10:Z%G3X+(DDGQ^+E /MT?-#D>%6)?U[3;L;>U'+#
M5S-*=_1?M*Z3[YLPHY4^"=(D1/U%,A:][_7E91="S9.+N!=@K1I&V1]##;[@
M,C8Z/ZRNDM+OV6H,D>SX)V5&M:OQ[5^@ R'AO-JB]6,V'0K==$1/4LX;-0W%
M<OUJRE=I4>Q$_46P[^N;1Z'^(4UR=T%?D_QJS>,:U&I:RNA\@4<ZZ5RJO>^#
M7]AU[74@1J?0UV3DZ_\ E( 9JUKR@X>V-8XW[!/KMJ7IVUMEH34$;^KZF0KK
M=P\7;_OK*=?JZ_$D"XF]X3P2Y4=5J6.3\CQ;F+?;Z>(Y9UR]K38^J=7_ #6S
M8Q^?T6GZ:]$7U<JSJJ_9[D150#.V/R6/RU6*]B[]+)49DZPW,?:@N594_5BL
M5WR0R)_6522#6-KU;=<+3V/3=DP&VZ]D&J^AGM8S&.SV%O,3Z7T\IBK-NC9:
MG7Z62.0 ]T^^
M
M
M    5O/Q,'\5'@7^<+%_!OO  *60       +TWX<[^C_ ,U_.&Y&_<QQX ">
MH
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M<[VKZ,TB?$ YT;&@
M
M
M   %;S\3!_%1X%_G"Q?P;[P "ED       "]-^'._H_\U_.&Y&_<QQX ">H
M
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M,S9:<^4JK8?8VO-0+&U_SN1?,Z.57+797C=Z2 8D-(@
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MCKL++-*_C[]22:K=I6Z\C9(I8WNCD8Y'-545% /,>^
M
M
M                          5O/Q,'\5'@7^<+%_!OO  *60       +TW
MX<[^C_S7\X;D;]S''@ )Z@
M
M                :C<]>2=71EM:EI$M;([=VK%D,FJ1V<?KBN1R.C1O5T=S
M,Q_!?2<BQ0K_ &SN<BQD'GN5>[/A_'5^7X1\>;>*VCG%(WT]GVUS:N7U?BI\
ML<C)*B0JZ:IG=^K+VN^3D:^G0<J?-))(UU4 C5R.2R&7O6LGE;MG(Y&],^Q<
MNW)I+%JS/(O5\LTTKG/>]?ZJ_1\"I5M6U[-O.QYG;]RSV6VC:=BOSY3.[#G;
M]G)Y?+9&R[NGMW[UN26Q8F>OPZN<O1$1$Z(B( >D<?
M           -@>%^?MBXKM18RWZ^;TN>?NMX5\OY_'^JY5FNX.655;7F1SE>
M^!52&=>O7L>[U6R>> /N:<I>&69I:EG%R'(? &0R*R9O0+%Q%R6K?.2N==S_
M !W<MN=%B[[)9'6)\<]S,?D7]R.6O-)\W&!*AK&T8+<<)1V'7,A#DL3D(^^"
MQ%U1S7-7ME@L1/1LM:U ]%;)&]$>QR=%0N8<0<P\<\\\>Z]RCQ3L]';=*V:L
MMC'92DKXY(IHW>G<QN3I3MBN8K,8VPBQ6:MAD<\$C5:YJ?#J!]\R8
M
M
M                                   5O/Q,'\5'@7^<+%_!OO  *60
M      +TWX<[^C_S7\X;D;]S''@ )Z@
M
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MLU:S$^*1J/:J 'VS(8
M
M                                                         !6\
M_$P?Q4>!?YPL7\&^\  I9        O3?ASOZ/_-?SAN1OW,<>  GJ
M
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M^P^M2V;Y:/,:9E)&N1K&XW;\++D->LS2-<UWH?,-LL:].^-BKT .!FMP
M      !LIXZ<U2\:[ W!YNRY=)S]J-E_U%<YN#OR=L46:A;\>V#HC66VM^+H
MD1Z=71M:Z6KVJ_<"N^)7)T7'7(>6F?X]\F9>M!L:67R2P\=[-92.E2W^A%U=
MZ..5J1PYJ*-.Z6FULZ(^6K''(!*TQ[)6,EB>R2.1C7QR,<CV/8]$<Q['M56N
M8YJ]45/@J%TBO8KW*\%NI/#:JVH8K%:S7E9/7L5YV-EAG@FB<Z.:&:-R.:YJ
MJUS5147H ?H\P
M
M                                                  !6\_$P?Q4>
M!?YPL7\&^\  I9        O3?ASOZ/\ S7\X;D;]S''@ )Z@
M
M                                    ?$V38,7JF!RNQYJPVMB\-2FO
M6Y5Z=W9$W[,4355/4L6)%;'$Q/M/D<UJ?%4,?<K\GZ?POQONG*V_Y./$:?H>
MOW]BSEUW:LJUZ4?6*E2B<YJV\IE+;HZM.NU?4L6IHXF(KGHB@0P<A[SE>1=N
MR^UY9SFRWY^VG4[U?%C<;#U91QT'7HB1UH>G<J(WU)%=(J=SU*!7E'Y%;GY4
M\W[OS3NTDD5O9<@L6"P:67V*6IZE05U?7-6QJN;&Q*V*H(GJO8R/YJV^:R]J
M23/50.$FOH        !L;Q!XX;7R8D&8R3I-9U!ZM>W*V8%=>RT?5>K<+2>K
M/6B=TZ+9D5L+>O5OJJUS"5CP7]J/FCRY;C=\VN2UQ%P9,^.>+<\MC7S;#NE5
M%<KX^/\  6'5TNU)%8D:Y6TZ.A&KE="EM\<D" 20:#Q9I'&U)*NK86"O9=&D
M=O,6D;:S5_Z%=\UD7L27TW.3KZ4:1P-7XM8A:]\:?#3QX\3, W#\-Z!C\5E9
MJS:V:WK+MBS/(&R(G8LBYG:;$#;GRLLK$D^2JI6QT3U58J\?50#(9M&
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M]0-RR>X
M
M                                             K>?B8/XJ/ O\X6+
M^#?>  4L@       7IOPYW]'_FOYPW(W[F./  3U
M
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M\6J ?;,A
M
M                                            %;S\3!_%1X%_G"Q?
MP;[P "ED       "]-^'._H_\U_.&Y&_<QQX ">H
M
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M&5855$CI83:K%6Y\$5739N55Z(B &\!8C
M
M
M         *WGXF#^*CP+_.%B_@WW@ %+(       %Z;\.=_1_P":_G#<C?N8
MX\ !/4
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M%Y,S_(&P2/F;C*EVPM;6M7I32.E^Z=1UBIZ6%UO%,<[KZ56&/O=U<]7O5SE
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M: 93,H   &6>#MM=I?*6HY=TJQ4I\G%A\I\>D:XW,K]WSOF3^RCJ.G;/T_\
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MS%]E:>W\E2^;HUH)+4D%9ZL8KT=(Y$:U%<K6J -U0
M    :?\ +GG[X9\#;SD^,^7_ ")XYT+?<-7QMK+:KFLE93+8V#,4(,IC'7H*
ME.TVL^[C;45B-CU1ZPRL?T[7-50!C3_:P>W-_*YXF_OAE/V*  _VL'MS?RN>
M)O[X93]B@ /]K![<W\KGB;^^&4_8H #_ &L'MS?RN>)O[X93]B@ ;><0<T<7
M<^Z12Y)X<W/%;_HF1NY''X_:,(EM<5>MXFRZEDHJ<]NM56RE*Y&Z&1[$<Q)6
M.9U[FN1 !D\         &&^9_(?@SQVU[]*.<>6-%XNPKV2OJ3;?L./Q5S*N
M@6-LL&"Q,LJY?8+<:RMZPTH+$R(O7MZ  A'YV_$>^(N@S7L9PGQ_R7S[DZKW
MMKY=\4'%>B9!&J]K%KYG9JF4W6/N<U%7U=;8B,<BHJKU:@ BOY*_$E^8FQRS
MP<;<6\&\9XR1_=!->QFU[YLM=J-<WTURE_8\+K\S%5W<O7#H[JU.BHG<C@!I
MGLGO;>YOLL_J2>2]S"P)U]*EK?&W$>$@A[H8HI/[HJZ&F2L=ZQ]_YZ>7L>YW
M9VHO1 !C+_:P>XS_ "N>6?[X8O\ 8H ')\#[QON7:XZ)V/\ *[<K"Q323,^_
MM:XXVIJODC]-S96[/IF8;-"C?BV-Z.C8[[341WQ !LSH7XA?W#]1DKKLF4X>
MY2BCZ).S=>,X,6^RWTDB<Y9.-LOH+8IE7K(BM;V))]+59]@ $BG#GXFW 3.K
M4O(+QAR^.:BM^<V;AS<*6:=(URHCTK:/NT&!2%8D3JBNV&3OZ].C.G5P F?\
M=O=:\#O)N2CC-!Y[UG ;=?6&*+0^3_5XVVN2[/\ &/&XV':4HX?9L@K?CZ>'
MNY#X=?C\%Z "1(                   %;S\3!_%1X%_G"Q?P;[P "ED
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M]DL3WQR1O:^.1CE8]CV*CF/8]JHYKVN3JBI\44 VFXP\A[F.=7PF^2RW\?\
M9AK["C72WZ:?DM3),:BOOUT^'65$6=OTKZG7X;0<:>0-O'NKX7>I);U#[,4&
M?1JR7Z:?0U,BQB*^] GPZRHGK-^E?4Z_ #<ZG<J9"K7O4;,-NG:B9/6M5Y&S
M03PR)W,DBD8JM>QR+]**;BU+E6_5@NT;$-NG:B9-7LUY&303Q/3JR2*1BJQ[
M')]:* >RB]/BGP5/BBI]1[2*K51S55KFJBM<BJBHJ+U145/BBHH!-]QYL*[7
MHNH[&]W=-E]?Q=NVO7KTO/J1MOLZ_7V76R-Z_P!0[#[Q<Y0=S3XX\(<J3R^M
M?WCC'3\YFG=R/[=BFPM2+98>]%7O^7S\-F/K\%7MZJB+\$ YD9Y
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M=1Q>KT)Y(V0V<K9JQ++F-AR$<;G1)E=ES4]C(6^W["V;,BM1$5$ !F,
M&"O(3R7X-\5]!M\E<\\BX#C[5X/5BI.RD[I<QL.0BC]7[FU37J;+&;V?,OC^
MU\M2@FD9'UD>C8VN>T 5-_-/\1-S'R%:R>F>'&O_ +RVE(^S47DW:Z.(V'E/
M/UU<Z-MG%8>W%D]3T2M8KN<BM5N5OM7MEBM5I$[$ %=K>=_WKD[9LENG(^Y;
M1ONWYB3U<IL^XY[*;)G\@_JJM6WELQ:N7IT9W*C4<]4:GP1$0 '$0
M        2/\ B3[K7FAX>3XW&Z-R?=W7CFE)$DO$_*3[FY:5\G&C6?)X1UNW
M%L.FQM8BJUN'O4H5D7NDCE3JU0!;<\$_>P\7?,*7#:)MUA. .<LBL%.#1MWR
MU675=KR<KG1LKZ!OSXJ&.RMJR]8VQX_(0XW)2S2^E6AM(Q95 $RH
M       *WGXF#^*CP+_.%B_@WW@ %+(       %Z;\.=_1_YK^<-R-^YCCP
M$]0   *L?XGG_ ;P_P#VV<R?K/QX "H6       "_P#^PG_1G<._MMY?_A-V
M8 $R(                 *%GX@[^D9V7_--Q;^M=X $(0       .V0
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M7Z',>G]B]B_!4^I0 1N>0'^5S;?_ ,!_<SA213@G_)5JW_XY^Z/+@&&S+@
M    !(QXY9UV8XTI597J^; 9&_AG*YW5ZPHZ/(U>J+\4CCKY!L;?JZ1]/J4C
M]\@L*F)Y%N68V(R'.X^CEFHU.C/55K\?9^*)T]22>@Z1WU]9.OUH 9X,(@
M&8^*N7<KQ[=CI6G39'5;,R+=QJN[I*:O5>^[BN]R-AG17=SX^J1S(G1>UW1[
M<O\ %O+.4T"XRG9=-D-7LS(MW&J[NDIJ]5[[N+[W(V*=%7N?'U1DR)T7H[H]
MH$AF)RV-SN-J9?$6X;V.O0MGJVH'=62,7JBHJ*B/CDC>BM>QR(]CT5KD145"
M0'%97'9S'5,MB;<5['WHFS5K,+NK)&+U145%1'1R1N16O8Y$<QR*UR(J*@!+
M=XGY9V2X;Q-9SG/=@\OG,2JN=W*C77%RT;>O3JC61Y5$1%5>B(B)\.B)=B]E
M+=I-M\"]*Q,LTD\O'>\<B:2Y\LOJO;')GG;M6AZJU'LC@J;G&QC7*[MC:U$5
M&]K6@;)DLP                     !@;R/\E^&?$_B[.<O<X;A2U/4\/&Y
ME:)>VSGMFR[HW/I:UJ6$8]MO.[!DGM[8H8^C(V]TT[XJ\<LK !19]Q7W>.>?
M.?*Y73,)8R/$GCC%;<S$\6X;(JW([96K3J^IEN4<U3])VPWIW,;,W&,5,31>
MUB-9//%\Y* (C@                       ;:>(OFUY"^$O($.]\&[G9QE
M>U8JNVS1,LZQD>/]\HUE<B4-KUQ+$$-E[89'LAN0.@R%/O<M>>)7.Z@"]M[>
MGN;\&>X!ISOT:FCT/FG7Z$5G?.&,WDHK&9QT?5L4FP:ED'0TF[EIS[+NSYN&
M*.Q3>YC+D%=98%F $DP     *TWXBWPT_?"XAU'S#TS%>MMG"_RVE\G_ "D/
M=9R?%6PY5?N++S]B/EF_0;<LDK>UK?LU,U8FD<D=9.@ ID        LL_ATO
M,O\ >]Y>V[P]W/*^CJ?-'S.Y\8_-S=M;&<JZ]BD^_,1!WN9%#^G.FXU'=SG*
MKK>%K0QM62RO4 7-P                   54?Q(/F++CL1Q[X3Z=DG,EV"
M/'<M<S.JS?!V&IWK,''&GV_3<]CFW,S0L9JU7D1DD:TL9*WJR7X@"HZ
M  "T_P#AP/#J7*[/OWFMN&-<F.U:/(\5\.?-0]$L[%E*<+N0]LIK(UDC6XC
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MPVJEACXIHXY6.8@ R            "MY^)@_BH\"_P X6+^#?>  4L@
M  7IOPYW]'_FOYPW(W[F./  3U    JQ_B>?\!O#_P#;9S)^L_'@ *A8
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MDD;T1?H5$4_=FK9I3RU;E>>I9@<K)JUF*2">%Z?%62PRM;)&Y$7Z%1% / >
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MECYK'U.9*^QTYXEB?3F9LVAZQ42:O*SK)(LL6ML5W7[/;V]OQ5P!NJ3]
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M6KV0R%ZU)+:NWKMJ5TDLLCG222.5SE5550 >B
M    "1?V\?<BYF]O_D>/)ZS9M;;P[LN2IR<G<07[CF8C8*K$2O+G-=EE;*S6
MMVI5%_,786HRQZ;(K;)H6M:P =@9X\>0_$_E+Q/K'-'"^SU]HTG:*_6.1.R#
M*X/*P,C^\]9V;&>I)-A=DPLTB1V:TBKTZMDC=)#)%*\ 9M         !6\_$
MP?Q4>!?YPL7\&^\  I9        O3?ASOZ/_ #7\X;D;]S''@ )Z@   58_Q
M//\ @-X?_MLYD_6?CP %0L       %__ -A/^C.X=_;;R_\ PF[, "9$
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MR(B]K51J(B 1G\]?Y8N0/_;\W_ 0%*;W*OX]WD[_ )S+_P"M^. ,1&CH
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MUC:?(5*AD(9=0MR/<B,J[71E9\BJJG3(Q-@8CW6T[ +&Y=G
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MNVMC.5=>Q2??F(@[W,BA_3G3<:CNYSE5UO"UH8VK)97J +FX
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M.*N%L]4@MXGBZK,R&YB-LWG'V(Y(KW)#VJV:K0D18L$BM=*UV0^S1 G7+5
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M+3G-DBAJ\[?:!XD\CJF7Y X0J8'AWFYR6+TK*53[OX[W^X]7S21;1B,;7>W
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M%WN)4V/C3:[^ EN)"^O!F\4G9=UW9J,4CG/9C=HUZW5R%9'+W)!98CNCNJ
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MEAVN9*M!Q[0G9)UD:^GAJST>J+U^RSM $F. US7M4QD&%U? X;6\/6Z_+8G
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MMO+_ /";LP )D0                 4+/Q!W](SLO\ FFXM_6N\ "$(
M   ';(  ^3G\U0UK!9K8\I)Z6,P&)R6:R,O="STZ&*IS7K<G?8E@KL[*\#EZ
MR/8Q.GVG(G50 =5AO>WY3D+>-RW[./63-[QM>Q;?F)'2.E=)E-ER]S-9![I7
MHCY5=;NO57*B*[Z5 !Q0     %M;\/E[>FD9?4'^<W+6O4=ES4^R97 \ XG+
MU$MXS7HM7M28O8N2HZ\_?5N9^38HK&-QKWL5<:_'SSL59I8GP "UT
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M_'\:;HR:=L-&AE+UU4T3:9ED?' QV$V*U\M+-(Y&08[(VW_%40 O3EW,
M          BG]X7S8D\+_$;8K^IY1*',G,$ESC/BET,WIY##6\A0D=M.^56M
M7U&NTG!2+)7E1',CRUFBCT5CU10!UY#G.<Y7.57.<JN<YRJKG.5>JJJK\555
M !_      ;$>+/B_RQY@<T:MP?P]AOO+9=BF=/D,K;;9CU[3];J.C7,;?MF0
MKP6%QF Q$4C>]_:Z2>>2*O R2Q-#$\ =@]X(>W[P=X#\9,T[C7',S>\9RO3E
MY)Y9S-&JS;MZRL,;%?&Z6-)'X34J-GO7'8>&5\%1KE>]\]F2>S, -Z@
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M>QS[3M_Z-4YHG97*S(J1PQNM6+3L7@<?WO\ DL536OBZ'JR?+5XO5D[@!G\
M                 $&'O8\KOQ^F\.\)XZS7[]FSV8Y&V>."\^/(5L=JM-,!
MJ].]18]&SX;8,CLF0G:Y[53YK"-5JHK%ZU7/Q2OD5+J? ' WC+AK\<=WE_?,
MKR-N$$%ER6TU'BZG5IX7'WZS5[%QF=VS;([43GIU=8P7V?R7@%=XH]
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MC+V:SV?R=#"X3#8RM+=R66R^5M14<;C,?3KM?/;O7[L[(HHF-5\DCT:B*J@
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MP[^VWE_^$W9@ 3(@                 H6?B#OZ1G9?\TW%OZUW@ 0A
M    [9  ' .5]07D'BWDK0D;&]=WT#<=01DS6OB<NRZ[D<,C96.FKM=&[YWH
MY%D8BI_9-^E !U64T,M>66">*2">"1\,T,S'1RPRQN5DD4L;T:^.2-[51S51
M%14Z* #Q@     M(^P=[EVK\<56>$/.>?IZ]KN6SV2S7 VZ9J[#1PN*S>?LO
MOY[C++7;<T53'0;!F99<AAY7=K9,E:M5WO=)8JL !;_
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MG+]K*YO.9*]F,QE+TKI[N2RF3M2W<A?MSO57S6KEN=\DCU^+GN55 !\T
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M*G$_,\M.%>YMR&.6QQIMEYL37*Y+%2.WAK-J3M:ST,; BJKVH@ JB
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MY/:8KXJ.UZK?94V/5[[T:JMBO58'2-3N9W,5'* ,_@
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MS8S/ZOM/.G*&P:[G,;83ML8_,87+;3;QN3HSHG1\4T3XW)]** #6P
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M:-@CVJ.>-J+9L\=;=8QNO;]C&HLD;/3K668O+O>O<YD.*D:Q.LB@ HI
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M3^BI1QV/OW)L-M=M&.1RMPE_)M:WKU<G:[H )"P
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M$D_U77JFJ:]B=>I?&#&5&0+)T[5L3JJRV[3F]5[7VK4CY%3Z$5W1/@ <=.0
M  &>_%7;9-"\G?'?=8Y%C35N;^*\[,J+T22IC=XP=F[!)UL5$=!9J1OCD:LL
M:.8Y45S47JF=/%_:WZ+Y*>/VY,>L?Z,<T\89R7HO1)*N.W7"V;D$GY^JCH;-
M6-\;VK+&CF.5%<U%ZH!V0IV(@         !5A_$\;;+5TGQ!T1DS_0SNU<P;
M;:@:]OII+J>)T##T)IF>HCT>K-TLMB7L5%1)/BG3HH J&@
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M<E\MR7Y/_>^D-]"3I:Q'%5&"M^^9E'=JN[/OVID:V"8R1J)-!D[+XW=]9>@
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MQ_B>?\!O#_\ ;9S)^L_'@ *A8       +_\ ["?]&=P[^VWE_P#A-V8 $R(
M                *%GX@[^D9V7_ #3<6_K7> !"$       #MD    ?QS6O
M:YKFHYKD5KFN1%:YJIT5KD7JBHJ+\4 !2P]XSV=LOP9E]F\I/%S6+65X/RMJ
M[G>2>-=?QRS6N&;4RR7,AG\#C:$/5_%3U[Y)&,9_[O\ Q[O[AZ.K "M^
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MA[>/O3XR_1R556I:Q]RM>K*]J/8D]29D\*O8OP>U)(TZI]: '9Z'96@
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MZ)IHO;,YH9'+)&RQM/#\-AC'N8V>%O*>J6&Q3-:J)+&D\#'HUW5.]C5^E$4
M'7^        N]_AL]<CQOA#R;L#XXTM[-Y*[=VS,D>YS\9AN.N+J52&:-41D
M4D61DNN3MZ]62-55^I !85                           !U?_F1@8M5\
MO?*K5X$A2#6_)'G+ PI7:YD"18?D[:,=&D+'JKVPHRNG:BJJHG3J #6\
M $U_X?S(UJ7N0:/6G5Z2Y?C3E;'4T:Q7-6S%K+\LY)%Z_FV?)XN5>O\ Y2(G
MU@ OP@   K>?B8/XJ/ O\X6+^#?>  4L@       7IOPYW]'_FOYPW(W[F./
M  3U    JQ_B>?\  ;P__;9S)^L_'@ *A8       +__ +"?]&=P[^VWE_\
MA-V8 $R(                 *%GX@[^D9V7_--Q;^M=X $(0       .V0
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M<YIXA8^OC:/(KI'Y'E[0ZBK'#'-?NVYD7D? 4VIW217'IEXV.<Z.U.D<=1P
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M?]2W+/\ HYW#]A@ /WA.=/\ J6Y9_P!'.X?L, !^\)SI_P!2W+/^CG</V&
M_>$YT_ZEN6?]'.X?L, !^\)SI_U+<L_Z.=P_88 #]X3G3_J6Y9_T<[A^PP '
M[PG.G_4MRS_HYW#]A@ /WA.=/^I;EG_1SN'[#  ?O"<Z?]2W+/\ HYW#]A@
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M32U\CQ_Q9E:MU\/IL=7CEDM30M3J]'+7<[K\5:T 6!P
M          =7AY9[(S<O*GR8V^.PVW'M7D#S+LC+36,B;99G.1MDR;;#8XOS
M4;9FVNY&M^RG7HGP !K\     ";W\/CC/G_<9UJU\G\U]R\3<IY/U_2]3[N]
M7%TL-\YW]%]#O^]OE^[X=?7[?[( %],   %;S\3!_%1X%_G"Q?P;[P "ED
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M+%37'T,1Y&<LVL)27O7Y?6\_N.5V/6(T<]SGO;^CV7JJCE7JY%1?K ,*FEP
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MX66_*/@BY8Z6+%;1N6]=J=Z?:AIRY'3MSL>FOQ^R^_@6]R?J]%^H %M$
M                     &&/(SE>EP3P%S/S+?EABAXQXQW;=HDF6-&V;^OZ
M]?R&+Q\:2HK)+&3R<,->)BHOJ2RM;T7J #JV[%B>W/-:M336;-F:2Q8L6)'S
M3V)YGNDFFFFD<Z26:61RN<YRJKE555>H /$     "QU^&ETF3*^6?-V_OK/E
MIZ=P%8U]LZQJL-7*[MONH6:;_41.C+$N-U"\QB*OVF+)\%Z=4 %U8   %;S\
M3!_%1X%_G"Q?P;[P "ED       "]-^'._H_\U_.&Y&_<QQX ">H   %6/\
M$\_X#>'_ .VSF3]9^/  5"P       7_ /V$_P"C.X=_;;R__";LP )D0
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M8O';G/.XW";A#?GZ8W1-UN>CBM;Y*JK*]L..@CE]&CFY.K628M6S2=[J-=J
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M+4WN941JLABXUQ^0Y 2:5SU1C&I-K3&HJKU5[FM;U<K44#L"2^>
M 0A_B"N,9M_]N[8MEK5%LS\.\I<<<CN6)'.GAI7+F0XTO2,;&Y'R011<AI),
MWHYC8XUE<B)'WM %"L       '9*>U_Y$P>3W@UP%R/+<;;V;&Z=3X[WWN>Y
MUEF[<=,9JF8MW.K6HR?8(L=#E6M;U1(;[/C]2 #?P
M                          %*W\1/X=1\7<YZIY8Z?C4KZ?SVW]'=^;5A
M5E7&<N:UC&>A?D5C600KO6HTVS-8U%?+<Q-Z>15=* "N"
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MT10!V1<<D<L;)8GLDBD8V2.2-R/CDC>B.8]CVJK7L>U>J*GP5  ?L
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M;U:>#R/'VI5&](OS#M9XJT?%92'OCC8Z3_GZ"V_J]7/;W]O7HU$0 16
M ]S'4+.5R%'%TF))<R5RK0J1N>R-LEFY.RO Q9)%:QB/ED1.KE1$^E0 =L(
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M/(O2.M5A[NLDLBMCC;\7*B&1>*.)>1.<-\P/&G%FJY3<-RV.W'5Q^)Q<"O\
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ML+IFG:]52IA]>P%**ACJ<2*KGO2.-.Z>U8D59)IY5?-/*YSY'N>Y7*!\LYD
M:L<Y[(ES*TM;K2(Z'%,^;O(U>J+D+3/S4;D_\JM47K__ #E3ZBIW[\WDO#NW
M+FC^-6MY%MC"<14?TLWEM>;OAEY#VNDS[KQMEB-5BSZQI\C)&O:[X.S,T;D1
MT:@'B\==H76^3\1!)(K:>R1RZ[:3NZ-66ZK),:[L7[+I%R<$+$7X*C9'=/I5
M%@%;^4@!)X>8     L&?AZ.(I-D\B.7>9;=99,9Q=QK5U>A,Y.UL6S\DYAJU
MIH7+T622'7-1R43T;U1K;35=T[F]9[O8&XGDV+R Y8Y?M5EDQO&?'-;6J,SD
M[6Q;+R+EFK6FA<O19'PZ]J>2C>C>J-2RU7=.K>H%O0ME          &"?*#A
MNGY"^.G-O"-Q(V_OG\9;?J-"Q+V=M#-Y3#6HM>RJ>I^;]3$9Y*UIG=]GOA3K
M\  =7CD<=>Q&0OXG*5)Z&2Q=RUCLC1M1NBLT[U*=]:W4L1.Z.CGKV(G,>U?B
MCD5  >F     "R-^'5\QJ?&'-6X^)FZ91U75^>%CV7CA]B1C:-#EG7,;(R_C
M.KD8V&3>M0II&DCWKWV\/4KQM5]@ %TH
M                 &H_G1XLX'S*\7>5.!<NE2OE-EP;\CHF;MLZLUKD7 *N
M4TO.+*QCYX:D>8@97O>ETDFQMBQ"B])5 !UH.R:YG-/V+/ZEL^,M879=6S65
MUS8<->8D=W$YS"7I\9EL9;C1SD9:H7ZLD4B(JHCV+\0 ?%           !_6
MM<YR-:BN<Y4:UK457.<J]$1$3XJJJ #L5O:1\-F^&7AUI&KY_%I1Y8Y*2+E'
MEQTT2,OT]DV*E67%ZE85R.DB32-<CK4)84>Z),@RW-'T]=W4 2<@
M Z_#WR/'F?@CW N3,S3I+6U3G>KC^;-=F;"C(9,ALZS4M\B=-&B12W5W[%9&
MV]O1KVPW(E>BJY'O $/P       +V?L6>?U'R:\?:7CYON9C=SGX\Z_C\,QM
MVRUV0WKB6@L&)U7:Z[9.V>Y=U>-]?#99WYUZ/;4LS/62]T0 3N@
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M-<L1T/'W1YU@GF?M;&Y?D*Y3E17K]VZ+C[+'8ZPWM[)&9BWC)HE<CDBDZ*T
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MJUMCYOS-[EBXV5BMGAU[)U:>)TF#O7IWU+>LXJ')Q?#X?>3OI )="5\
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MXI(<;R;Q?<R=2YL.B[&V-OJ(K8UBL9'5LJY'2XO)^C$RW#U:YD5B*>"( ;S
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MO7>C8LKXV\AT+K58QRR58]VXORC&-<Y%6-4NXV%W<WHO1JI]"J@ +S0
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M=ST?+31J]<+N&O+-+9Q5Q%8_TI462I;:Q9*TTT?VP ;.@
MTF]PWQ+Q?FIXG<G\(RPU&[;9QR;7Q;E+:QQMPO*&L16+FJ6%LR]64JF7?)-B
M;TW1SF8W(V.U.[H #K6<OB<I@,ME,%F\?;Q.:PN1NXG+XN_!)5OXW*8VS+3O
MX^[6E:V6O;IVX7QR1N1',>U45.J  ^<         #L+O9J\.)/$+PUU./9L:
M^CROS2^KRQR3'9C6.[B7YK'P-U#3YV/1)8'ZOJ_HI9@<G6+*6;G3X*@ )8@
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M3<DDL1.3NBRN0NMZJU&= !+:     "MY^)@_BH\"_P X6+^#?>  4L@
M  7IOPYW]'_FOYPW(W[F./  3U    XSNFI83?\ 3MLT39:[K>N;KK.>U+/U
M&JUKK6$V3%VL-E:[7/9*QKIJ-V1J*K7(G7XHOT  ZN3FOBO8.#>8.3^&]J8K
M=AXOWS:=%RLGIK'':LZSF;F)^\*R=ST=2R4=9MB![7.9)#*US55JHJ@#&
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M<K+*@%@PGO              /XYK7M<US4<UR*US7(BM<U4Z*UR+U145%^*
M Z_SWF/;ZL^%WD7;V_1<*M?QZYOOY39>/7T*LC<7I&PND^:V?C"=[46&HF)L
M3K;Q+%[6R8F9D;%DDJ67- $.8       .7:)OV[<7[=@]]XYVS8-'W76;K<A
M@-IU?*W,+G,3;:QT:RT\A1EAL1)+#(Z.1G=V2Q/<QZ.8YS5 %I;P;_$7)!!A
MN//.?6YYO2CAHP\^\>XA)9I.UT;&V^0^.\=&Q7*D?>^:]@&.<Y48QF+55?*
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M%606Q [0.);5_$7LKC9>YC:>W[ZZ5NU;"V2L]T=F""3'XNVUR^I2^CH (C
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M\,O*N^X71-:DG8B.FUSC''7+>0R5)Z.7^Y,CLFYSU7]>BK-BE^'1$50!9A
M   !XYIH:\,MBQ+'!!!&^:>>9[8H888FJ^2661ZM9''&QJJYRJB(B=5 !\;&
M[3K&9L+4Q&QX'*VTC=,M7&Y?'WK"0L5K7RK#5L2R)&QST17=.B*J?J@ ^Z
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MZOS7&^PHD2=W6I9UW*^HU9%C:L3</G,@]ZNZ=W;T[VM7JY$^)O1K'XB7VO\
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M>JHC54NI000UH8:U:&*O7KQ1P0001LBA@AB8D<4,,4:-9'%&QJ-:UJ(B(G1
M#LJSR@'P-HVS5M(P=[9MTV7 :AK>,C27);#M&9QV P>/B<Y&-DO9;*V:E"I&
MY[D1%DD:BJO0^#LVTZQI>%N[)N.QX'4]=QL:2Y'/[-E\?@<+CXG.1C9+N5RE
MBK1JQJ]41%DD:G5>@!!UY:>^_P  \3Q9+5_&_%KSYO<<<L$>RRK=P?$^&M]J
MM;+)DI(Z^=W%:\G15AQ\=>I.S\C(-4A4\JO?$X(XLBR.L^.^,7G7=V1R0LV2
M5;F$XLQ%KM5K99,B^.#.;<M>3HJPT(Z]2=GY%]J@%'KW3/)[FKRNY2TWD?F_
M<[>UYY,5GJ.)I,BAQVOZQATNX^:'"ZS@:;8Z.)QT;WJKNUKI[$G66>269SI'
M5B?(KR=YM\I=T=O/-6[Y':LC%Z\>%Q2=M#6-6HSNC5V-U?7:GIXW#U7-AC25
M[&+8M.C22Q+-+U>H$7!K\       2.>*O^3&?]M&5_Y)C#S,_)3_ '?_ )5
M)G?;:\),YYL^06)U>W5N5N(M'EH;1S'L4"N@2MK;;#UI:O0M].UFP[K:JOJ5
MD15?#7;8M(U[:SF.W[]NKPPS7F;SWBM9MUKE?BC2I*.S<O;! KH4K:ZVP_Y/
M6:-KIVLS^Y6:SJE9$57PP-L6D:]*SFJ!?FP^'Q6O8C%8#!8ZEA\)@\;1P^&Q
M..KQ4\?B\5C*T5+'XZA4@:R&K2I5(&111L1&L8U&HB(A>NQ&(Q> Q.+P6#Q]
M/$X7"8ZEB,1BL?7BJ8_&8O&UHJ>/Q]&K"UD-:G2J0LCBC8B-8QJ(B(B 'T3Z
M(               !KAY9>+O&?F+P5N? _*E)TF"VBJRQB<Y5BA?F]+VS'I)
M)KVY:Y-,G2OF,):>J]O5([562:K,CJ\\S' #KCO+#Q:Y3\.>;]MX,Y:QGRN=
MUVPMC#9RJR7[AW;5+<LR8'<]9LR(GS.&S=>%51J])JMADM:=L=B"6-@ UO
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M9]Y;1L]J"*+.[[N=V"O'G-QV"2-TBNO9)]=C(84>^.E3BAJQ+Z4+$ !M$
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MT31<'2U[6,!CFN2MC\;19VL1TDCI)[=NS*YTUBQ,Y\]FQ(^65[Y'N<H YT
M     "MY^)@_BH\"_P X6+^#?>  4L@       7IOPYW]'_FOYPW(W[F./
M3U      UC\QO&'3_,3QSY*X W-65*^YX97:]GO226QJ>Z8F1N2U':*R(B2N
M^Z<W7B=8B8YBVJ;IJZN1DS@ =:GS!Q-O7!/)^\\/<F86;7]ZX\V&_K6QXR7O
M5C+E)Z>E<HSO9&EW$Y6H^.U2LM3T[52:.9G5CVJH QN         #E>G;WO'
M'F7CV#0-RVO1L]$G;%F].V++ZSEXVHO5&QY+"W*5QB=?CT1Z  WAU+W8?<9T
MJI'2PWEQRQ=ABCCB:_;;^*W^VK8NWM62_O>)V2]-(O8G<]\CGO\ CW*O5>H
MR;>][OW0\C5EIV/*.W'#-V=[Z/$G V+M)Z<C)6^E>QG%M2]!U<Q$=V2-[F]6
MKU:JHH U<Y4\]/-#FRI;QO)WD]S1L^%OI(V]K:[WF\-JEQLO<CFVM4U^SBM<
ML(C7N:U'U5[6N5K>B*J  U)           !9T_#W> %G=]ZF\W^3\%UTGC^S
MD,)P73R,".AV3D)OK8W.[S#!/&Z*SB]$KNEJ4Y416KFI721N9-CEZ@"XX
M"EA[[G/_ +@FA<]Y_AO=^2,KJ_C+N^/GRW%&-XQJWM,U?>=-E=%#D<+O.4JW
M+.8VO:-?M.96R]*W>=0<[T;<-*M#;B8 "M\       #Z.)R^6P&4Q^;P64R.
M%S6)MP7\7E\3=LXW*8V_5D;+6NX^_3EAMT[=>5J.CDC>U['(BHJ* "8/Q_\
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MOV.LV.-N/+4LR8W'XZ*=]*??-Z=3F@N5-3HW(WQ5X(WQ6<O;B?! ^-D5JS5
M%%[R.\R?)?RQV*]L/._+VX;K%9O2WJ.J2Y6U1T+7N^171U]:T>C)!K6&AKL1
MK$?%7]>1&(Z6223J]0!K?0OWL7<K9'&7;>.R%.9EBG>H69J=RI/&O5DU:U7?
M'/!,Q?BCFN14_5 !.[[=_OD\\^.&R8#C_P E-CV/G3@"U/6QMK([!:ESG*/'
M%5\L<*9G7=ENODRNU8C'0?VW#Y&:95B8UM.:MVK', +L\7*_&T_%J\W0;KK\
MW$C=&FY,=R#%?BDUA-!KX-^R6-K7(LZQIAX,%$ZT^3^QB:JJB*BH #((
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M6SB+:44D:Z:K4N2KE*,>6NPM<V%?E9&1N7U'1N8U6J!"?L7E-G-NS60V+8\
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MCV]%=2UEMB14Z=4=>R=]J1N7N7[2,IH[IVIT1R+U7K\/$]?BB?J?^$ U2/P
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MU-&DEFS(B=>C8XVQPQQ1, &;0         5O/Q,'\5'@7^<+%_!OO  *60
M     +TWX<[^C_S7\X;D;]S''@ )Z@       0)>]5[7$OEYI+/(+@[!LE\D
M.-,&ZIDM?H1-;/S)HE!9++=?1G>QDN\:PDDLN(E1/5O0O?0?ZBK2^6 %&.U5
MLTK-BG<KSU+E2>6K;J6HI(+-6S!(Z*>O8@E:R6&>&5BM>QR(YKD5%3J #P
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MRR8C8L/++*W$[7J^0DBA;E]9SU>+U:MAK6KT[HY6QSQRQ, &#P
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M"OLDCY\ENO$M%K*]38%D?9M7]BT5KGMAJ9_O>BS8AJ,@NLZNJ>G9:E>Y5_\
M>']AS$>14^T>3WAQB<7K/.]EUS.\C<1Q+7Q>L\R7'])[FP:S-+-!CM6Y(L*U
M[[,;D90SDSO5D=7N++-; KT7*=O'7+>/R%6S1OX^U8HWZ-R"6K<I7:<SZ]NG
M;K3M9-6M5;$;HY(WM:]CVJUR(J*A1TV?5]DTG8LUJ.XX#,:MM6MY*WA]@US8
M,=;Q&;PN6HRN@N8[*8R_%!<HW:LS%:^.1C7-5/B@!ZQ\(
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M4\3T?7QUJ+"0=%ZHGW/!'2M(B_0J.OQS.3I\/C_NGA<O55_J?  P^?D
M^AB\5?S5^OC<96DMW+3T9%#&G_G/>Y>C8XHV_%SW*C6M3JJ]#(?%7%/('-N_
M:YQCQ?K.1VW==JO,H8C#XZ-%<JK]JQ=NV9%95QN)Q\".FM6YWQUZT#'22/:Q
MJJ =FY["'A%H/BWX)</\AMQ++?,?.FE1;MNVWW&M?9;KFR9O([%J>L8!%BB=
MCM=BPMNI9E3HLMVT[U9GN9'6B@NW^WQ[?VB^$''KVK+3VKFC<*-3]\C?V1/2
M%48YMEFH:DRPQD]'4L7:^/<YK+&2L,2Q.C4;!7K 3B$AP
M        !IQYI^#/!'G5QA-QYS%@ECRN.2Q:T3D7",@K;MQ_FI8E8E["Y!['
M-MXVS\$NXRTDM&XQ&JYC9HX)H0!0_P#.[VU?(KP*VR:MR#A9-LXKR%]:VF\U
MZQC[;M,V!DJR.IT<PU769--VM\$:K)B[LBN<YCUJS6X6^NX 1[
M                E_\ ;S]G7R#\W+N(WC9:V1X8\=WS5[-GDK8,6]N9W+']
M62R5>,-=N.K39WYN%>QN6F[,3 KE<U]J6)U9P O%^,OBSPCXA\8XWB?@O3:F
MJZY3].SE+[^RWLNW9I((X+&R;AG711V<YG+C8T[GN1L4+.D4$<,#&1- &PP
M                    (X/=7\/U\S_#?D/C[!4&7.3M.8WD[B/MACDM6-VU
M.I<D77*SG-[T?NF LW<2Q.]D;;-N&5ZJV+H #KD9(Y(I'Q2L?'+&]T<D<C59
M)'(Q5:]CV.1',>QR=%1?BB@ _  +[GL2>'SO&OP[Q_)&TX=*'*'DK/CN1\TZ
MQ$L>1QW'T526+B[7I^Y&JR-<1>L9E6*B2,DS3HW_ !B1&@";0
M            $,_N6>SMQ#YQU<CR3H<N*XC\E8:K5CW>#'K^C'(GRD/IU<5R
M9C*#6SV+2Q1L@@S==K\A5B1K967(8HH& "D+Y'>+W.?B;R%=XRYYT#,:/LD"
MS2XV>U&EG7]HQL4B1MS>H[%567$[%AY>]OYVM*]87KZ4S8IFOC: , @
M                  G(]MGV5.8/+^U@>4N:X<_PUXX2/JY&#(6::4>0.4<>
MKFRI!H6,R<#TQ6#O0?1G;L#ZRL>UU2&Y]I8P!=ZX=X9XO\?^/-=XIX<TO#:%
MH.K5&U,1K^%A>V-J]K4GOY"[8DGR.9S-][?4MWKDT]RW,JR32O>JN4 9.
M        !6\_$P?Q4>!?YPL7\&^\  I9        O3?ASOZ/_-?SAN1OW,<>
M  GJ         !7)]VKV5<=Y$2[%Y(^*.)QN!YWG6SF.0.-6S5L3KG+TC())
MK.:P+GLBH8+DVY*Q/665\-#,/<LD[X+2R3V0!2^V+7=@U'.Y?5]KPF6UK9=?
MR-O$9W7\]CK>(S6&RM&9U>[C<IB[\,%VA>J3L5DD4K&O8Y%1410 ?&
M               !*?[<'M6\T>?.UU,X^#)<=>.^&R20[ER[>QZ]N36K+_=F
MK<<5;B1P[-M,O8L<LS>^AB>OJ6G.D]&K9 %]W@/@#B7QDXOUWA_A73\=I>C:
MW"OR]"FU9+F3R,S(FW\_L&3E[KN=V+*NA:ZS<L/?-)VM;U1C&,: ,R
M  CW]P_V\.)_<!XG?JVTLKZOREJ]>[:XIY6JTF3Y75,K.Q'OQ658Q8YLUI6:
MFC8V_0<]/H2>!8[$;'H .O\ _)WQ7YL\0>4LMQ)SEJ-G6MBH/GFQ.3A2:UJ^
MY81EF2O5VC3,X^O7BS> OK'U8_LCGA=UBL103LDB8 -=P
M    64/9_P#9ESG,F3U'RD\K-<?A^&*%FMG^.>)\_1?'E^6K%:2*QC-@VS$W
MZW;3XND>B2002IZV>:U%5C<>YK[@ N>0PPUX8J]>*."""-D,$$+&Q0PPQ-1D
M<44;$:R..-C41K41$1$Z( #R      ZI;=M3RNA[GMVC9V":KG-,V?/:GF:U
MB+T)Z^5UW*V\/D8)H.^3T9H;=-[7,[G=JHJ=5^D '&      3Z>T!J&3E\0O
M>(WYR6(L/1\*]VU")5<K:EW)Y7C'F3-3HUO8K9K&+JX:/N7N18VW$^"]_5 !
M><        !'UY?^W?Q%Y2QW-II-BXYY@]%GH[WA:$+JNQ/KQ)#7J[WAXU@9
MGF)78V%EYCXLC R.)OJRP0MK.BE]QKVB/&CW#L'9S>PT&\8\^4<>E76><=3Q
MM=V8D2M&K*6)W[#))3J[YKL2(C6LGDAOU6(B5;4+%>R0"LOY >+O-/C-L7W#
MRMJ-G&5+5F># [;CEDR6F;0V!9'++@<^R*.&698(_6=4G;7R$$3FNGKQ=R(M
M#/SA]LWRP\ ]FFH<TZ)->T.U>6IK/,FFQW<WQCLW>LJUHHLXM2O-@<S-%"YR
MX[)Q4[J(U7-C?'TD<!KX1^@        'W,/A'YCUTBLPPR0=BN9(URJYC^J(
M]O;]*(K>B_J=4_5 !]O]![G_ !VM_P"9+_X@ /T'N?\ ':W_ )DO_B  _0>Y
M_P =K?\ F2_^( #]![G_ !VM_P"9+_X@ /T'N?\ ':W_ )DO_B  _0>Y_P =
MK?\ F2_^( 'JW=53&U9KV0S&-HTJS%DL6[;UKUX8T^E\LTJLC8W^NI[-.E<R
M-F&E0JV+MRP](X*M6&2>>9Z_0V.*)KGO=_60 TAYOY3VVY0LZYPQG,/C+4R/
M@M[OE*%JQ)78J*UR:]C)8O3]=>OPM645&_'LA55;(FUG'7CL]5@R^^JC6IVR
MPZY7EZN=]:?>MN%_1J?JPQ.55_LGI\6*!%SD?%3<\O?N93*[[C\EDLA8EMWL
MA?AREN[<M3O62:S:LSR233SRO<JN<YRN55^)MC6IUZ=>&K4AAK5:\;(:]>O$
MR&"&*-J-9%%%&C61QL:G1$1$1$ /33Q#V/Z]PPG3Z^E"\O\ WNY.IYO3_J_]
M[_YP#GNK^)FMX^Q'9VK/W=A;&_O^[J5;[FI2(G_[.S,VU;O3,7Z5]-]=WU=?
MA\?ZC$^M>O\ N &U..QN/Q%&MC,73K8_'TXDAJTZD+(*\$:*J]L<4:-:WJY5
M5?K5RJJ_%5/V >Z   #B6];17TS4<_LUA6?\UX^66M&]41L]^7I7QU9>JI_Z
M1>EC8OU]%ZG\5>B*H!$#//-9GFLV)'S3V)9)YY7KW/EFE>LDDCW+\5>][E55
M_54\ !X@   <FU?4LUMUY*6)K]S6*U;5V;N93I1NZ]'V)D:[HJ]%[6-1SW=/
M@GP7IM!XK^('-WF#O;-*XAUMUFK2DK/VO=LOZ]'2M)H67N1EW8<RR"?MFF;&
M]:].NR>]:['>E"]K)', W>XIXG;6RF#U'5:<F7VO;,MB=?J3.8B6\KE\O>@H
M8^C U.[Y>":]88UD;57XJBN5SOB70?";P,X=\)-*DQ.EPNV;D//4ZT6^\IYF
MG##G]EEB<V=V/QU9DEF/6M4@M)WP8Z"63\EC[$UF9J3 ':W\5:#C.*>+^-^+
ML*C$P_&^A:?H.)2-B1L3&:?KV.UZ@C(VM8UC$JXYG1$1$1/J0W? .>@
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M3X "=R&&&O#%7KQ1P001LA@@A8V*&&&)J,CBBC8C61QQL:B-:B(B(G1  >0
M                        % ?WQO#Z3Q@\R]@W37,2RAQ7Y&_>/*.H+4@6
M''8W:YK,+>3M7B^*1,FI;+<;DV11-9#!2S%:)B=&*B #6OVP_$:SYG^8?&7%
MM['27>/,'=3D3EZ;I(E:#C?4;=.SE<=9EB_.0NVW)3U,)$]OVF39)K_@UCE0
M =D-7KP5((*M6"&M5K0QUZU:O&R&"O!"QL<,$$,;6QQ0Q1M1K6M1&M:B(B=
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M5&314*L[&N: )Y6M:QK6M:C6M1&M:U$1K6HG1&M1.B(B(GP0 ']
M    !6\_$P?Q4>!?YPL7\&^\  I9        O3?ASOZ/_-?SAN1OW,<>  GJ
M           !&CYZ^U?XV>>N,ES&W8Z3CSFBG0^3P'->G4:OZ0MCAA;%1QVY
MXE\E6COVOU/28C(+<D5RO$U8ZERJDDG> *9/F7[4'F!X76\GEMOT2QR%Q33?
M))6YBXSK7MBU%E%&^HDVTTXJZ9[19HF.:R5<I6@IK.JLKV;")WJ (TP
M          9/XCX5Y;YZW"EH/#/'6W<E[??5OI8/4,+<R]F"!ST8Z_DI:\:U
M</BH%7K-<MR0U8&(KI)&M150 6DO O\ #NU,3:PO)?G5EJF8LP>C?I^/VF9=
MTN*CLM<JL@Y(WG%3M^]&1?!7X_!RMKN>C5=D)HED@< +2>LZQK>EZ_AM3T_
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M'HYT,>P1V[6<<Z-R)8KY&HDC>ZNWH )W0
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MN-H5X:=''T*T-.E2J5V-BKU:E2NR."M7@B:C6,8UK6M1$1$0 'M@
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M=<Q>NTK$S&JU;E]N-K0/R61E[E=)9L.EL2O<KGO<Y550!DL
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MUB_9KMK9;;;*39O>,XS[#I&97;<O)<S4E26=GJ_)Q2Q48I%58H(T^ !R0V9
M  +KWX<WQ:EXU\<-Y\E]DQOR^Q^0.?CQ&H2686_,U^,>/K>1QT=NNZ2-MFHS
M9MSL9!TK.O98KXVG,G5%:H +&0
M                                                    /'###7AB
MKUXHX(((V0P00L;%###$U&1Q11L1K(XXV-1&M1$1$3H@ /(
M
M
M                                                       "C%[_
M -X9VN"?*)OD1JN*6+C'R7DM9O(35HV)4P?,&.BB_3;&SI&BK NV0.ASD4DJ
MHZU;LWT8G;7=T $!@       /:I7;N,NU,CCK=K'Y#'VJ]VA?I6):MVE=JRL
MGJVZEJ!\<]:U6GC:^.1CFO8]J*BHJ  NS^T;[R^O>1^+UOQT\H=BQVN>1%-E
M;"Z;O&2=!C<%S;%'&D5*O8L=(:&(Y.<C$CDJKZ4.8E5KZG]T2.JM %A\
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M'/Z(Z:9M:LU9)'?;ED57N57.50 <R
M
M
M
M
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MLUE_3>&'RU\IB^K9(&6*F2Y&O0P9.RSO>W[OK8[X1R>NP %A4
M
M
M
M
M                              %<GWV?;-L\^:=-Y=<'ZZZ[S)QO@D@Y
M0UC$5))<GR;QWB(F_+YBC5KM<[(;CH5-CU1J-6>_B$6%KGR5*D#P!2E
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M7?5@ %\^...*-D43&1Q1L;'''&U&1QQL1&L8QC41K&,:G1$3X(@ /V
M
M
M
M
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MM3ODL6[4TDTKW2/<Y0!DD
M
M
M
M
M      'CFAAL0RU[$4<\$\;X9X)F-EAFAE:K)(I8WHYDD<C'*CFJBHJ+T4 %
M1;W7O8UNX*?8O([PBU6:_@)7V,SR#X]8*O)/D,'+(^S;R>R<44FO=)=P:]4=
M+KL+73TUZKCVOKJVI6 %5^2.2*1\4K'QRQO=')'(U621R,56O8]CD1S'L<G1
M47XHH /P                             "6+VUO:BYA\]]GI;3E(LKQO
MXV8;))'MG*EFHV&WL:T[217]4XNKWH)8,[L;UCDBFO.CEQF)5KG6%DF2*G8
M%]+@O@OB[QNXNU7ASAS5:.H:'J%%*F,QE1.^Q:L/_.7\SF;\G6UF,_F+2NGN
M7)W.FL3.5SE^A$ &7
M
M
M
M
M         0A>X[[*7"_F._.<J<22XGA3R,MLFNW,W6HR,T#DK(='2(W?\)CF
M*_'YFY,JH_.T(G7%5ZOM07E;&C !2U\E/%#G_P 1MZDX^Y]XYS>BYF1;,F%R
M%B-EW6-LH5I6QORNH[/1=/AM@Q_YQBO6"5TM=7HR=D4O6- !KL
M             #D&JZGM.];%B-0TG6\[M^U[!=CQV"UG6,3?SN?S-^5%6*EB
M\1BX+5^_:>C55(XHW.5$5>G1  6E_;P_#XW[$^$Y;\\.RG19\KD\'X[X#*^I
M>MN[V31+RML^+E]*C6[&+W8;$SR32)(WYB[ YDM1P M@:[KFOZA@<1JVJ8/$
MZUK6OXZIB,%K^!QU3$87#8JC"VO2QN+QE"*"E0HU(&(R.*)C6,:B(B(@ /L@
M
M
M
M
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MGN3-C^7S_)VT0ND9-+'F-LFJP3049IHF/=0H14<:CV-<VLUR=0 ;E@
M
M
M
M
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M!>1EQE9>][.V9-'X!W.1RHUJ._-MD3M<GQZ]40 ;D<;>*WM[6WUIN7_=)T[
M1M:K[F-XV\4_*/;WS.1Z(E>MF]GX^TAM9KHE[O6?CY>CD[?25%[D $HG G&7
MX;[0<GB_TK\B]XYRSTMB%L4G+.K<^ZOJ,%Y9&^G*^CJG$>@8>OCFJW[;,M<N
M5NBKZBJWHB "T7XQ_P"JA^][!_JA?O&?O;]E/O\ WB?T,^XO7]%_H??7Z'?9
M^^NWU/5^=_NSU?4]7\YW@ V.
M
M
M
M
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1a05.jpg
<TEXT>
begin 644 image1a05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M>%_#+_@H%\(OB5XOT[P_HOBW[;K&JRB"UM_[+O8_-<@G&YX0HZ=20*N>/_\
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MM)RTT6H!8%MPKQN2FWRE"%0 ".H))-9U(<T9+NFOR^[S^6]C2G/EE&3Z._\
M7?ROY]V?%/CWP5<?L&?!O7=(TWPY\,;'Q7KWP]U6:Q\2>"/#(T*_TQ;*.U$W
MGW#SS2W6?/603_NSO@!9"7!3V;X<?";P_P#LX_MB>$/#_@31K70=$\1>!]1G
MUFVL<10WDUI<V"V]Y,B\27!%S,K3$>8X?YF8*,>G^!/V5O _P\%Z+73=1U3[
M?8MI<G]OZU?:[LLVQOMH_MLTWE0OA=T<>U'V)N!VKB?X0_LS>"_@7J%Q>>'-
M-O(KRXM8K#[3?ZK=ZG/!:1$F.UBDNI9&AMT+$K#&5C!.0N:Z.?\ >*;\_G=3
M27HN9/S:OOJ<_+:GR+^M8N_K[K7S[71\QVWQ&\3Z5^WY\2O".EWDW@_0_%GB
MW3(KSQ6([:=UG30;22+3;>.42*L]P$D)EFB,81"B;I9$V='\'OV4OA?\5O"/
MQ4USQ-X/\+MKA\:^(L^)3I\,>KZ?Y=W)LFBO0HFB>+ 9'5P4*@@C%>\>*/V8
M_ _C./Q0NI:']H/C&^M-3U5Q>7$<DUU:)$EM-&ZN&ADC$$6UHBA!3/4DGG]7
M_89^'.NZAJTUU9^*);77KV74-2TS_A,-872;^65]\OFV NA:R)(V=\;1%'!(
M*D$BN=4WR<O7D<;]4_W>ORY6M+:6>[DWT2DM/5/[E-?CS)ZI]>EDOGS3/VB_
M'_C[X$^ ?[-\6?$K_A-I? =GJ]]I?A'PSIEQ())HIBFH:A?:HIM$B<096W1X
MIV+.1Y@(\OZB_94^)&I?&+]F/X>^+-8^S_VMXF\.6&IWGD)Y<9FFMTD?:N3@
M;F.!GBJOCW]DKP#\2O$BZIJNC77VAK*'3;F&RU:\L+/4K2)G,=M=VT$J07<*
M^9(!'.DB;9'7&UB#UGPV^'.C?"'P#I/A?P[9_P!GZ'H5LEG8VWG23?9X4&%3
M?(S.0!QR2:Z)33=1_P SNO)7DW]]XZ>7:R6/+\-NBMZZ1_)IV\GWNWN5Y#\3
MOA!\6O$^J7TGAGXQVOA>UN'9K>!_!]M?M:#.54,TJ[L=#N&3[5Z]1691\X_L
MR>#/%?PR_:0UG1_B'XF_X6%XNNO#D=W;>)1"M@OV,73(UM]BC7RH?WA#;E9R
MW<\<_1U>3?\ -]/_ '(G_N0KUF@ KR7]L?\ Y)II_P#V%8__ $5-7K5>2_MC
M_P#)--/_ .PK'_Z*FKS\V_W.IZ'5@?X\?4\&TO\ U=7ZH:7_ *NK]?FDMS[(
M****0'L7[)O7Q!_V[?\ M6O8J\=_9-Z^(/\ MV_]JU[%7Z+D/^XP^?\ Z4SY
M+,_]YE\OR1X3^VG_ *[PO_V]_P#M&O)M._U:UZS^VG_KO"__ &]_^T:\FT[_
M %:U\GGW^^S^7Y(]W*_]WC\_S9;HHHKQCT KV+]DWKX@_P"W;_VK7CM>Q?LF
M]?$'_;M_[5KU\A_WZ'S_ /26<&9_[M+Y?FCV*BBBOT4^2"BBB@ HHHH *\F\
M'?\ )]/Q&_[$3PK_ .G#Q'7K->3>#O\ D^GXC?\ 8B>%?_3AXCH ]9H;[IZ_
MA10V=IV_>[9J9?"P/BCXWV?A/4/AQK$/P_C_ &J)O'$@0:-#+<?$&VM9[KS%
MVQS2W3I;QP,?ED=G0+&7*LK!2/M2W#+;QAAA@HR,[L'Z]Z^ DUCXN:3K'B32
M9(_C9=?$C5= LEAE$&I-H$?B1-0E??%.%.FPZ>(/(+JI57@!1U:<NE??T.[R
ME\S;YF!NV],]\5I'6DI=V_31VT];7\TT^K"I_%<>WWZV>OY>JEV'4445(!11
M10 4444 %%%% !1110 4444 >3?\WT_]R)_[D*]9KR;_ )OI_P"Y$_\ <A7K
M- !7DO[8_P#R333_ /L*Q_\ HJ:O6J\E_;'_ .2::?\ ]A6/_P!%35Y^;?[G
M4]#JP/\ 'CZG@VE_ZNK]4-+_ -75^OS26Y]D%%%%(#V+]DWKX@_[=O\ VK7L
M5>._LF]?$'_;M_[5KV*OT7(?]QA\_P#TIGR69_[S+Y?DCPG]M/\ UWA?_M[_
M /:->3:=_JUKUG]M/_7>%_\ M[_]HUY-IW^K6OD\^_WV?R_)'NY7_N\?G^;+
M=%%%>,>@%>Q?LF]?$'_;M_[5KQVO8OV3>OB#_MV_]JUZ^0_[]#Y_^DLX,S_W
M:7R_-'L5?$7C7]I7QYHG[(?QR%KX3^)FHS:7JGBZ"R\6VNK::EOIJ17MVL3(
M9+]+Q%MU"J D.5$>$! &?MVO-[O]EWP_>?!+QIX":\U@:/XZGU:XOYA+']IA
M;49I99_*;R]H"M,P3<K8 &=W)/Z*OB;\FOG>+_),^7IR2<;]))OT2E?\UH>(
M>/OV[O%UOX\\96?A71[R^L_A_<QZ<^FKX U_7+CQ/<+;Q7$R1ZA9*;:Q)$HB
M7S4F.X;V"HR@Q?M:?M[>)/@HOB#4M!UCP/(WA[2H-7?PB_AW5=9USR?+BEE.
MHS6LBQZ-N679&;F*1#MWE\%D3U_Q-^R#8ZIXRUK5M%\:^/O!</BCR&U[3]!O
MK>WM]8DB18A,7D@>>WF:%4C:6TE@=EC0[MRAAD?$[]@K0_BA!XTT^;QE\0-*
M\-?$ M+KFAZ??6T=K=SFUCMO/\Y[=[M6VPPL4$XB=H\/&ZO(CD=+-_T^OR>M
MKW2T7*KW65&*5E+;KZ:?BMG:U[M\ST1S_C7]LCQ-X7U[Q;X233]"/C:/Q5HN
MD>&(7BE-O>6&IJCI<RKY@9C"D6H[RC*#]CX"YK0\#_M7^)O$NL^'_"=QI^C1
M>.'\;ZCX>UN%8)5M[?3[)7N3>1H9-X\VU>QVEF8![Q>"!BNZU7]E3POKGQT\
M'_$2Z;4IO$G@O39=,M',RB*[5T9%DG4+\\D:R3A""H7[3-Q\W'-_"GX%2S_M
M@>.?BMJ&A7OA^6^TV#PYI]O=7$,KW:Q.6GOPL,LB(LZI:(H8K+MM1O5> *C9
M22?2_P"%N6_>_+[VWQOI$CWN37>R^]WYK=%:]U_@2^U8]NKR;P=_R?3\1O\
ML1/"O_IP\1T^X_:"\9F>2&W^!?Q++*Q"RSZGX=C@8#N2NINX!'3Y,Y(R!R0_
MX,^#O%5[\9?%GCSQ1I.G>'6\0:+I.B6FE0:C]OFBCLI]2F,TT@C1%=SJ&WRT
M+A1%G>=V%DL]3K@_VF_$_@#P7\"_$.K?%&'1;CP'80K-JL6JV(OK611(NP-
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M>OB#_MV_]JUZ^0_[]#Y_^DLX,S_W:7R_-'L5%%%?HI\D%%%% !1110 4444
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M>F8U+>7_ *2CY!_X*V>-KW2O"G@S089I([+6KJYN;I%.!-Y A"!O4 S$XZ9
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M^LX'_P"1W0_[>_\ 2)'A\2?\BZI\O_2D?3-%%%?T(?E84444 %%%% !1110
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M>\9?]N7_ +<5]9P/_P CNA_V]_Z1(\/B3_D75/E_Z4CZ9HHHK^A#\K"BBB@
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M_#O_ (\E^E=:.E<E\._^/)?I76CI7\W5OC9^MT_A"BBBLRSZ7_X)U?>\9?\
M;E_[<5],U\S?\$ZOO>,O^W+_ -N*^F:_H3@?_D24/^WO_2Y'Y7Q)_P C&I\O
M_24?%/\ P5^_X_OAK_W$_P#VSKP7P1_R#E_W17O7_!7[_C^^&O\ W$__ &SK
MP7P1_P @Y?\ =%?F/'?_ "-:O_;O_I,3[+AG_<H?/_TIG04445\2?1!7TO\
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M $ENZ^HZ^7/^"M7_ ";OH/\ V,T'_I+=UXG$G_(LK?X3TLH_WRGZGR+\._\
MCR7Z5UHZ5R7P[_X\E^E=:.E?S=6^-GZW3^$****S+/I?_@G5][QE_P!N7_MQ
M7TS7S-_P3J^]XR_[<O\ VXKZ9K^A.!_^1)0_[>_]+D?E?$G_ ",:GR_])1\4
M_P#!7[_C^^&O_<3_ /;.O!?!'_(.7_=%>]?\%?O^/[X:_P#<3_\ ;.O!?!'_
M "#E_P!T5^8\=_\ (UJ_]N_^DQ/LN&?]RA\__2F=!1117Q)]$%?2_P#P3J^]
MXR_[<O\ VXKYHKZ7_P""=7WO&7_;E_[<5]9P/_R.Z'_;W_I$CP^)/^1=4^7_
M *4CZ9HHHK^A#\K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \F_P";Z?\ N1/_ '(5ZS7DW_-]/_<B?^Y"O6: "OES_@K5
M_P F[Z#_ -C-!_Z2W=?4=?+G_!6K_DW?0?\ L9H/_26[KQ.)/^196_PGI91_
MOE/U/D7X=_\ 'DOTKK1TKDOAW_QY+]*ZT=*_FZM\;/UNG\(4445F6?2__!.K
M[WC+_MR_]N*^F:^9O^"=7WO&7_;E_P"W%?3-?T)P/_R)*'_;W_I<C\KXD_Y&
M-3Y?^DH^*?\ @K]_Q_?#7_N)_P#MG7@O@C_D'+_NBO>O^"OW_']\-?\ N)_^
MV=>"^"/^0<O^Z*_,>._^1K5_[=_])B?9<,_[E#Y_^E,Z"BBBOB3Z(*^E_P#@
MG5][QE_VY?\ MQ7S17TO_P $ZOO>,O\ MR_]N*^LX'_Y'=#_ +>_](D>'Q)_
MR+JGR_\ 2D?3-%%%?T(?E84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'DW_ #?3_P!R)_[D*]9KR;_F^G_N1/\ W(5ZS0 5
M\N?\%:O^3=]!_P"QF@_]);NOJ.OES_@K4?\ C'?0?^QF@_\ 26[KQ.)/^196
M_P )Z64?[Y3]3Y%^'?\ QY+]*ZT=*Y+X=G_0U^E=:.E?S=6^-GZW3^$****S
M+/I?_@G5][QE_P!N7_MQ7TS7S-_P3J^]XR_[<O\ VXKZ9K^A.!_^1)0_[>_]
M+D?E?$G_ ",:GR_])1\4_P#!7[_C^^&O_<3_ /;.O!?!'_(.7_=%>]?\%?O^
M/[X:_P#<3_\ ;.O!?!'_ "#U_P!T5^8\=_\ (TJ_]N_^DQ/LN&?]RA\__2F=
M!1117Q)]$%?2_P#P3J^]XR_[<O\ VXKYHKZ7_P""=7WO&7_;E_[<5]9P/_R.
MZ'_;W_I$CP^)/^1=4^7_ *4CZ9HHHK^A#\K"BBB@ HHHH **** "BBB@ HHH
MH **** "O)?$O[;7@+P;XDM=+U9?'6F7%]JD>BVTMUX#UV*TN;N23RXXX[AK
M,0OO;[K*Y5AR"1S7K5>'Q6S?%[]NJZ^U_O-'^$.BP264)!VG5=2$H><Y&"T5
MI&$4CH+R7N>"/QI/;K\E?\;66CU:Z7"7P-K?I^7X7N_),ZX_M/\ A-OB5=>$
MX%\67VK6-\FG7,EEX2U:[T^UN'1'"27L5LUJF%E0L6E 0-\Q'-,A_:Q\ W'Q
M._X1%=<D.K?V@=($ITZZ&G/?B/S#9+?>7]E:Z"@DP"4RC!&W(('SI>Z]X2\$
M>*M8_P"$$\7>,;?XT7WCO<_@_6?$TDD_ESZG&+MO[&AG^SM9-9M+,EPT3.L+
M)*9 R@KE:9XEL?\ A3NE_"./481\6+?XL+>W.CK%_P 3)84\1G4GU%H<;A;-
M9_O1<$>40RINW';11]Y4[_:LG\^2[7DN9Z^7;5E7W>>W2]O1*5K^O*O^'T/L
MC6/B5HN@^/\ 1?"]W>^3KOB*WNKO3[;R9&^T16WE>>V\*47;YT?#$$[N,X..
M:^)/[3_A+X4^-H_#FI_\)1>:W)9+J/V31?"NJZV\=NSM&LCFSMY0@+HX&X@G
M::\$_P""B_A3Q=XT^/OPTL/!6I3:;K+>&?$\C+;Y2ZU"!#IC2VEO,&'V::=0
M8EGPQCWE@NX!EJ_!_P#:*^"_PS^/^DZG8^(O!?P]\$ZK\-;!-&MM2O;?1XXR
MNI7OFP!)&7$T;EA(O+!]V[G)J:;YN6^EW+\%4:^_D2Z]=%[MZFN6#EZ?^E17
MY2;Z=-];?4_PR^*6@?&/PC#KGAO4H]3TV9WBWA'CD@E1BLD,L3A9(I48%7CD
M571@0R@@BN@KX&^(GC/0[[P_XU\17VB^$]0^'OQ2^(L<F@WOC._FT[PI'Y&C
M(AU2\ 4I=6TUQ;-Y44FV*X<1.LBDQR5Z7_P2JFLK'0_BWI.F7NAW6DZ?XV:;
M35T/29M)T@6T^G64RR65K)++Y5M([22(4D:.3<9$)1UK2FN>_2T5+YM0NO)K
MG_#O=*9^[;K=M?+WM?/X;>OE9OZNHHKQOXA_L&_#SXH:SJVH:K_PG/VS69'E
MN3;>.=;MX=S==D"78A1?1%0*.@&.*D"T'4_MULN1N7P&"1GD Z@<?G@_D:]:
MKYS_ &:O@;HW[*7[26M>"_"S3-H.N>'4UZ87D<$MX+E;IH<M="-;B<%&_P"7
MB24C:-I49!^C* "OEW_@K9;23?LV:3(B,RV_B.WDD(_A7[/<KG\V _&OJ*O.
M_P!K#4? ^D?L^>)KKXC3QVOA&"UW7LI_UB'</+\O ),OF;0@ )+$#!KS<YH*
MM@:M-M1O%ZO1+KJ^W<[,OJ.GB832OJM%O\C\Q? _BR.TA56;'XUUR>-+=A]Y
M?SKR+1;S2?'.M7$GAB35H]&:1OLS:E$BW&S/R[Q&Q7.,9P<9KID\ 7&WG4/_
M "%_]E7\HX[B?):%9TZM>S7:,G^*BT?N&%R7,:E-3A3T?G%?FSN?^$R@_O+^
M=!\9P#^)?SKA_P#A +C_ *"'_D+_ .RJ?3OA\&O(_M>I3I;Y^<PVX9\>P+@?
MK7)'B[(6[?6/_)9__(F[R',TK^R_&/\ F?:__!,[51JZ^-I$_P!6IL5#=B?]
M(R/Y?G7U17D/[$^@>"] ^"=NG@N2YFMY)2U_+=@"[>YP-PEQP,#;@#C;C&<D
MGUZOZHX1I4Z>3T%1FIQ:NI1=TU)N6C^9^)9].<L?4=2+BT[-/1JR2_0^)O\
M@L1NCD^&\NUMBMJ2ENP)^R8_D?RKYN\%>*8TM55FZ>M?;G_!4(> ;']F:XU/
MQUJDVC_V?=+_ &1/;0B>YENV!"PQQDKOWJ&R"R@!=Q("YK\W_AX9O%]HLT+M
M;QMRNX9;'O@_UK\F\2L9@\!F#JXRHHJ:36[:LDM4DVMM#[K@_#XC%850P\&^
M5M=%UOHW;N>TCQ/ ?XOUI?\ A)H?[WZUPB^#KL#_ )"!_P"_7_UZ7_A#[O\
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MA\8?V9O 'BK5A_Q-/$/A^RO[PB,1AYI($9V"C@ L20!Q@BKY?B_NM?BY)?\
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MFIMWNWYVL[6;WN[7UMHUH9RTJ<JTM^-TG=+:RVZW=]>ZT445)04444 %%%%
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M"J)"I."P4 D'&1S1'5-KI_P?\OR[HJ6C2?7]+?YK^DS:HHHH **** "BBB@
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M*^<XN_Y$V(_PL];(?^1A2]3XQ_9F_P"0##]!7L@Z5XW^S-_R 8?H*]D'2O\
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M* "BBB@ HHHH **** /)O^;Z?^Y$_P#<A7K->3?\WT_]R)_[D*]9H *^#?\
M@X9_Y,W\(?\ 8]6G_I!J%?>5?!O_  <,_P#)F_A#_L>K3_T@U"OG.+O^1-B/
M\+/6R'_D84O4^,?V9O\ D P_05[(.E>-_LS?\@&'Z"O9!TK_ #LS_P#WV?J?
MUEEG^[Q"BBBO%/0/JS_@F%]_QS_VX?\ MS7UA7R?_P $POO^.?\ MP_]N:^L
M*_OWP5_Y(S!?]Q/_ $[,_EWQ%_Y*'$?]N?\ I$3\Q/\ @XN_Y#_P-^NN?^XV
MO%_@)_R+</\ NBO:/^#B[_D/_ WZZY_[C:\7^ G_ "+</^Z*_#/'7_D:U/\
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M_DD/Q6_\).__ /C5+_PJ_P"/O_1(OBO_ .$I?_\ QJOQ'_B&N9_\^Y?^ O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image2a04.jpg
<TEXT>
begin 644 image2a04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MY_Y1-1_^1Z_&VBC_ (CAGO\ SZH_^ S_ /E@?\2O<*_]!&(_\#I__*C]DO\
MAZO\ _\ H?/_ "B:C_\ (]'_  ]7^ ?_ $/G_E$U'_Y'K\;:*/\ B.&>_P#/
MJC_X#/\ ^6!_Q*]PK_T$8C_P.G_\J/V2_P"'J_P#_P"A\_\ *)J/_P CT?\
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MC_AZO\ _^A\_\HFH_P#R/7XVT4?\1PSW_GU1_P# 9_\ RP/^)7N%?^@C$?\
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MP#_Z'S_RB:C_ /(]?C;11_Q'#/?^?5'_ ,!G_P#+ _XE>X5_Z",1_P"!T_\
MY4?LE_P]7^ ?_0^?^434?_D>C_AZO\ _^A\_\HFH_P#R/7XVT4?\1PSW_GU1
M_P# 9_\ RP/^)7N%?^@C$?\ @=/_ .5'[)?\/5_@'_T/G_E$U'_Y'H_X>K_
M/_H?/_*)J/\ \CU^-M%'_$<,]_Y]4?\ P&?_ ,L#_B5[A7_H(Q'_ ('3_P#E
M1^R7_#U?X!_]#Y_Y1-1_^1Z/^'J_P#_Z'S_RB:C_ /(]?C;11_Q'#/?^?5'_
M ,!G_P#+ _XE>X5_Z",1_P"!T_\ Y4?LE_P]7^ ?_0^?^434?_D>C_AZO\ _
M^A\_\HFH_P#R/7XVT4?\1PSW_GU1_P# 9_\ RP/^)7N%?^@C$?\ @=/_ .5'
M[)?\/5_@'_T/G_E$U'_Y'H_X>K_ /_H?/_*)J/\ \CU^-M%'_$<,]_Y]4?\
MP&?_ ,L#_B5[A7_H(Q'_ ('3_P#E1^R7_#U?X!_]#Y_Y1-1_^1Z/^'J_P#_Z
M'S_RB:C_ /(]?C;11_Q'#/?^?5'_ ,!G_P#+ _XE>X5_Z",1_P"!T_\ Y4?L
ME_P]7^ ?_0^?^434?_D>C_AZO\ _^A\_\HFH_P#R/7XVT4?\1PSW_GU1_P#
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MCAH4%CKRWGQ0\4V^LZ4\D,0CMX4O$F*SD2$J^T$80.,]\<U]#_M:_M$_"_\
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MF_\ NN"_Z]/_ -/5CY7A[_?\S_Z_Q_\ 4;#A1117A'U04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^R7_  2H_P"3!_ ?_<0_].-U
M7T-7SS_P2H_Y,'\!_P#<0_\ 3C=5]#5_=7"/_(BP7_7FG_Z1$_RO\0O^2JS/
M_L(K?^G)!17&_M"Z_>>%_@KXCU#3[B2UO;6T,D,R?>C;(Y%?$?\ PU+\0O\
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M?7&O9Q<?X>]YSG?X]/CMUVOU/+R_Z357"U\37_LY/VTU.WM6K6ITZ=OX>O\
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MK^@>BC_B \/^@U_^"_\ [</^)K*O_0L7_@Y__*S^?C_A$-6_Z!>H_P#@,_\
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M_0L7_@Y__*S^?C_A$-6_Z!>H_P#@,_\ A1_PB&K?] O4?_ 9_P#"OZ!Z*/\
MB \/^@U_^"__ +</^)K*O_0L7_@Y_P#RL^??^"65G-8?L'^!89XI(95_M#<D
MBE6&=0N3R#7T%6!X<F9_&WB-69F5'M]H)X7,0Z5OU^Y93@/J.!HX)2YO9PC"
M]K7Y8I7MK:]MKG\N\09L\TS3$YFX\OMJDZG+>]N>3E:]E>U[7LK]C@?VH_\
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MLUS ;B\FAM+JT5;HB$*Z&.[D)$:QG<J'( (/0_M)_LE:3^T=K'A375\0^*/
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M';7_ /P1_P#VRO-J*/\ 63"?]"ZA_P"5_P#Y<']DU_\ H*J?^4__ )6>D_\
M"&_"_P#Z';7_ /P1_P#VRC_A#?A?_P!#MK__ ((__ME>;44?ZR83_H74/_*_
M_P N#^R:_P#T%5/_ "G_ /*STG_A#?A?_P!#MK__ ((__ME'_"&_"_\ Z';7
M_P#P1_\ VRO-J*/]9,)_T+J'_E?_ .7!_9-?_H*J?^4__E9Z3_PAOPO_ .AV
MU_\ \$?_ -LH_P"$-^%__0[:_P#^"/\ ^V5YM11_K)A/^A=0_P#*_P#\N#^R
M:_\ T%5/_*?_ ,K/2?\ A#?A?_T.VO\ _@C_ /ME'_"&_"__ *';7_\ P1__
M &RO-J*/]9,)_P!"ZA_Y7_\ EP?V37_Z"JG_ )3_ /E9Z3_PAOPO_P"AVU__
M ,$?_P!LKN?V;/#'@&Q^-_A^;2?%6L7^HI*YAMYM)\E)#Y3YR^\XXR>G:OGV
MO2/V0_\ DX[PO_UWD_\ 1,E?3<%\086IQ#@(1P%&+=:DKKVUU><=5>LU=;JZ
M:[IGD\0976CE>)D\34=J<]'[.S]UZ.T$_N:/T$HHHK_30_D,**** "BBB@ H
MHHH **** "BBB@ HHHH **** .5\<3W5OXS\/M9P1W%P$NMJ/)L4_*F><&K'
M]K^)/^@/8_\ @;_]C2^(/^2@^'?]RZ_] 2NAH YW^U_$G_0'L?\ P-_^QH_M
M?Q)_T!['_P #?_L:Z*B@#G?[7\2?] >Q_P# W_[&C^U_$G_0'L?_  -_^QKH
MJ* .=_M?Q)_T!['_ ,#?_L:/[7\2?] >Q_\  W_[&NBHH YW^U_$G_0'L?\
MP-_^QH_M?Q)_T!['_P #?_L:Z*B@#G?[7\2?] >Q_P# W_[&C^U_$G_0'L?_
M  -_^QKHJ* .=_M?Q)_T!['_ ,#?_L:/[7\2?] >Q_\  W_[&NBHH YW^U_$
MG_0'L?\ P-_^QH_M?Q)_T!['_P #?_L:Z*B@#G?[7\2?] >Q_P# W_[&C^U_
M$G_0'L?_  -_^QKHJ* .=_M?Q)_T!['_ ,#?_L:/[7\2?] >Q_\  W_[&NBH
MH YW^U_$G_0'L?\ P-_^QH_M?Q)_T!['_P #?_L:Z*B@#G?[7\2?] >Q_P#
MW_[&C^U_$G_0'L?_  -_^QKHJ* .=_M?Q)_T!['_ ,#?_L:/[7\2?] >Q_\
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MR)XO$G_(IQ7_ %[G_P"DL_02BBBO]6C^+0HHHH **** "BBB@ HHHH ****
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M96=P/+GAAC4Y)0\J"WJ/XQQS7C7AWXE>(_"%BUKI/B#6M+M6<R&&TOI88RQ
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M_5H_BT**** "BBB@ HHHH **** "BBB@ HHHH **** .>\0?\E!\._[EU_Z
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MWHR3VUYO::[6TY]+)-VU;NQT9^RE&44O=<6NRMR:>CY-KVVT]W7\T_"GQ/\
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MV%??\^=U_P!^6_PH_L*^_P"?.Z_[\M_A1]7J_P K^YA[:'=?>5:*M?V%??\
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MJ%9X62Z)1NAPJ$5=_P"%::#_ - NU_(_XU%X@_Y*#X=_W+K_ - 2NAH P_\
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M'_"M-!_Z!=K^1_QK<HH P_\ A6F@_P#0+M?R/^-'_"M-!_Z!=K^1_P :W**
M,/\ X5IH/_0+M?R/^-'_  K30?\ H%VOY'_&MRB@##_X5IH/_0+M?R/^-'_"
MM-!_Z!=K^1_QK<HH P_^%::#_P! NU_(_P"-'_"M-!_Z!=K^1_QK<HH P_\
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MRCCCO(98S$94M5@:6T1_*\N1X3^BWA+1;GPWX6TW3[S5]0\07=C;1P3:G?I
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MFT[[W=]Q1]V]NJ2^47=)=K/56VZ'Q_\ M3_\$\O#OQ _9W^%W[/V@>!=7O\
MP)IOB.PUF^UVXU."2+2HK.[6ZNFNGFG^V7-S?J]S$62*4.US*TKH#EOKG4-/
MCU'39K5MRQ7$31'9P0",<5/11*TX2ISU4FY/S;23_"*01]V491^RDEY)-O\
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M3_P54_\ D3S:BO2?^$-^%_\ T.VO_P#@C_\ ME'_  AOPO\ ^AVU_P#\$?\
M]LH_U/Q?_/ZA_P"%%#_Y8']NT/\ GW4_\%5/_D3S:BO2?^$-^%__ $.VO_\
M@C_^V4?\(;\+_P#H=M?_ /!'_P#;*/\ 4_%_\_J'_A10_P#E@?V[0_Y]U/\
MP54_^1/-J*])_P"$-^%__0[:_P#^"/\ ^V4?\(;\+_\ H=M?_P#!'_\ ;*/]
M3\7_ ,_J'_A10_\ E@?V[0_Y]U/_  54_P#D3S:BO2?^$-^%_P#T.VO_ /@C
M_P#ME'_"&_"__H=M?_\ !'_]LH_U/Q?_ #^H?^%%#_Y8']NT/^?=3_P54_\
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M_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\
M0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*B
MN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #
M?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?
M_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M
M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:
M/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_
M .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_
MT!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\
M2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH
M Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['
M_P #?_L:/[7\2?\ 0'L?_ W_ .QH Z*BN=_M?Q)_T!['_P #?_L:/[7\2?\
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M^@)70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '/>&?^1Y\3?[]M_Z)%=#7/>&?^1Y\3?[]M_Z)%=#0!P/[4?_ ";YXK_Z
M\6_F*_/&OT._:C_Y-\\5_P#7BW\Q7YXU_#/TIO\ D?X3_KS_ .WS/Z,\&_\
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M-[-Y-O#[N^#M'OBOLKP]XVNE^+'@KPJT-G+H^L>#HY+V*2W1S=$1OM#L1DJ
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MES)2YKMN"BW>/*DD^;1\SU6W4\;HHHK\R/L HHHH **** "BBB@ KTC]D/\
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M_CA^T[\-?V9-,L;WXD_$+P/\/;/5)6@LI_$NO6NDQ7DBC<R1M<.@=@""0N2
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M;>UK'Z)P=Q_+(<-/#*A[3FES7YN6VB5OA?8_+W^PK[_GSNO^_+?X4?V%??\
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M;_T*7AG_ ,%<'_Q- '345S/_  I;P;_T*7AG_P %<'_Q-'_"EO!O_0I>&?\
MP5P?_$T 2^(/^2@^'?\ <NO_ $!*Z&N9_P"%+>#?^A2\,_\ @K@_^)H_X4MX
M-_Z%+PS_ ."N#_XF@#IJ*YG_ (4MX-_Z%+PS_P""N#_XFC_A2W@W_H4O#/\
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MW_H4O#/_ (*X/_B:/^%+>#?^A2\,_P#@K@_^)H Z:BN9_P"%+>#?^A2\,_\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image34.jpg
<TEXT>
begin 644 image34.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M_P#T+_Q#_P# "S_^2J_+"BC_ (C'Q'_-#_P!!_Q+CP;_ "5/_!C_ ,C]3_\
MA^#\)_\ H7_B'_X 6?\ \E4?\/P?A/\ ]"_\0_\ P L__DJORPHH_P"(Q\1_
MS0_\ 0?\2X\&_P E3_P8_P#(_4__ (?@_"?_ *%_XA_^ %G_ /)5'_#\'X3_
M /0O_$/_ , +/_Y*K\L**/\ B,?$?\T/_ $'_$N/!O\ )4_\&/\ R/U/_P"'
MX/PG_P"A?^(?_@!9_P#R51_P_!^$_P#T+_Q#_P# "S_^2J_+"BC_ (C'Q'_-
M#_P!!_Q+CP;_ "5/_!C_ ,C]3_\ A^#\)_\ H7_B'_X 6?\ \E4?\/P?A/\
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M"_\ $/\ \ +/_P"2J_+"BL_^(Q\1_P T/_ $;?\ $N/!O\E3_P &/_(_4_\
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M3XQ^*WBSX2QZMXCUOQO=7\D=AJEL'6>>YN;65FGC A*-L1GDED#"0*>?L?\
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M#HPP=!UI0<G9.%DW!QBY1J.":N_BA4A5INTJ;;.[\*>%_">@_P#!/;Q5I_Q
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MT+X7\/\ QM^/G[+.G_V';:/X9\0:-:2_V1"V^*WMVD63[/NP-PV_*6P"V2<
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M17YD?\)UKG_08U7_ ,"Y/\:/^$ZUS_H,:K_X%R?XT?\ $UF$_P"A=+_P:O\
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M7_@LE_PH_P"&'?C#_P!$U\9?^"R7_"OW$HH_X@7EO_034^Z/^0?\339U_P!
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M%Z=-4U9ZIJSV,TW=QEHUNNUTFM>NC6JT84445!04444 %%%% !1110 4444
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M](\975_K]Y)\-=7TI;B\62TTUY9#H<\JPQ0""'2RU^LL,@F4;+O'J'_!2/\
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M>Q?L)?\ )Q.G_P#7K<?^BS7W7AC_ ,E;EO\ U_I_^E(^<XP_Y$>+_P"O<_\
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MMW?)=M:V34K)M,N--RBH1VE9:?XHJ/HG*R3TOM=I-%?]K_\ 8-\4_M9>#/C
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M2GP#\9?;-%_LOX5^#M:\/:M%YTOVBXN+V/2UB: >7M:,&REW%V0C<F <G;]
M445I4J2FW*7=O_P*3D_Q;,J=-0A&G'9))?(****S+"BBB@ KGKC_ )*E:_\
M8,D_]&+70USUQ_R5*U_[!DG_ *,6@#H:*** .!_:C_Y-\\5_]>+?S%?GC7Z'
M?M1_\F^>*_\ KQ;^8K\\:_AGZ4W_ "/\)_UY_P#;YG]&>#?_ "*Z_P#U\_\
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M_F*_/&OT._:C_P"3?/%?_7BW\Q7YXU_#/TIO^1_A/^O/_M\S^C/!O_D5U_\
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M1110 4444 %<]<?\E2M?^P9)_P"C%KH:YZX_Y*E:_P#8,D_]&+0!T-%%% '
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MY<,(094A_O#B/VMOV;/^&I?A_H&A?VU_87]A^+]!\5>?]C^U>?\ V7J=O?\
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M1^U'_P F^>*_^O%OYBOSQK^'_I.UO9<2X&K:_+23^ZI)G]&>#:OE==?]//\
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M*** "N>N/^2I6O\ V#)/_1BUT-<]<?\ )4K7_L&2?^C%H Z&BBB@#@?VH_\
MDWSQ7_UXM_,5^>-?H=^U'_R;YXK_ .O%OYBOSQK^&?I3?\C_  G_ %Y_]OF?
MT9X-_P#(KK_]?/\ VV(4445_,)^P!1110 4444 %%%% !1110 4444 %%%%
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M_A33?_&J/^%D?#C_ *)G=?\ A33?_&J_G+_5W ?]#2A_X#B?_F<_5?[4Q/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N>N/^2I6O\ V#)/_1BUT-<]<?\ )4K7_L&2?^C%H Z&BBB@#@?VH_\
MDWSQ7_UXM_,5^>-?H=^U'_R;YXK_ .O%OYBOSQK^&?I3?\C_  G_ %Y_]OF?
MT9X-_P#(KK_]?/\ VV(4445_,)^P!1110 4444 %%%% !1110 4444 %%%%
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MC42TDD]>EW97[7>GKH?95%?GK\5/^"B-C^T3^S9\8/$W@>S\7>%]2U#]F?\
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M*\4E_9R^!\/A:UUQ[[2ET2^NXK"VU!M?Q:W%S+.+:.%)?,VM(\Y$2H"6:0A
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MM;U#P_X;\=6C^%[LSR1R"\G%G&C6\%M<RV]VZ)+:M.989E?R8OCS\>/%6F_
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MGXZ)/K.BW'BN^N%OK"7X=7%U;-):2SLBV[WD<VQ@BH39QHIVVD2Q3> /VCO
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MZ?>:]<M9Z9;W-@L4NHSK%),T4*M.#(XBBED*KDA(W;&%)&E_8'BK_H9-,_\
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M1IGW5X;U#5/&,%U)H_CCPWJL=C=RV%R]G8+.MO<Q,4EA<K.=LB,"K(<,I&"
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MN6,E@K< ]1;_ +8?PCN_@G+\2XOBE\.9/AQ!)Y,GBI/$MDVB1OY@BV&\\SR
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M?A_J?CCP?IWCS7K9KS3/#=UK-O#J^HP*)"TL-JSB:1 (I2652!Y3\_*<?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>slide4.jpg
<TEXT>
begin 644 slide4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /UX_;?_
M &Y_^&,[K0VGT'^VK76E<#RY_+DC=3[C&,?CG]? _P#A^KI__0A7G_@<O^%5
M_P#@NG_QZ^ _]^?^0K\[Z_GGQ"\1,ZRG.JF"P4XJ"46KQ3W2;U9_8'A!X.\-
M<0<,TLSS.G*564IIM3DE:,FEHO(_1C_A^KI__0A7G_@<O^%'_#]73_\ H0KS
M_P #E_PK\YZ*^)_XC!Q+_P _(_\ @$3]._XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
MB,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=
M/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_Y\S_ /!DO\S]&/\ A^KI
M_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\ B,'$O_/R/_@$0_XEVX*_
MY\S_ /!DO\S]&/\ A^KI_P#T(5Y_X'+_ (4?\/U=/_Z$*\_\#E_PK\YZ*/\
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MP4N^'>I_\%&;[QG?2:CIG@Z+PE)X4M-4:V>7[0ZW8NA<O"J^9'&Y#HH"L_\
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M45^,G])!1110!]1_\$>O^3V-+_[!E[_Z+K]=:_(K_@CU_P GL:7_ -@R]_\
M1=?KK7]<>#G_ "3D?\<_S1_GO]([_DLI_P#7NG^3/SW_ ."Z?_'KX#_WY_Y"
MOSOK]GOVL?"/AGQAX[T6'Q1X9TWQ-:PV$KPPWN[;"_F(-PP1SCBO,O\ A2'P
MC_Z)+X3_ /(G^-?FGB=DV'Q&?U*M3$Q@[1T<9M_"NL8M?B?H7A'XL87(N&J6
M75<+4J.,IN\7"VLF_M23_ _*ZBOU1_X4A\(_^B2^$_\ R)_C1_PI#X1_]$E\
M)_\ D3_&OS[_ %;PG_0;#_P&I_\ ('Z9_P 1ZP/_ $ U?OI__)GY745^J/\
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M/C;XJ_9_\:Q^(O!^LW&B:LD+VYFC5)%EC<?,CQN&1UR <,I 9588901^D_\
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M"?\ Y$_QH_U;PG_0;#_P&I_\@'_$>L#_ - -7[Z?_P F?E=17ZH_\*0^$?\
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M]6W&K_\ (#I^.V74X*G3P%5)*R2=)));)+GV1^5U%?JC_P *0^$?_1)?"?\
MY$_QH_X4A\(_^B2^$_\ R)_C4_ZMX3_H-A_X#4_^0+_XCU@?^@&K]]/_ .3/
MRNHK]4?^%(?"/_HDOA/_ ,B?XT?\*0^$?_1)?"?_ )$_QH_U;PG_ $&P_P#
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M$]*UV^ALT9+>*>ZLXIY%C5F9@@9R%#,Q  R2>:]"KB_V;?A!_P ,]?LZ^ ?
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MK7^T$LO+NDN4BFDWR21Q'%E->#;*Q7YL@;PA'SW\-_\ @ES\8O&G_!%'XX>
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M[=+7U6CN4Z*N?\(QKG_0O>(/_!=+_A1_PC&N?]"]X@_\%TO^%?(_ZIYU_P!
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M_P "7^93HJY_PC&N?]"]X@_\%TO^%'_",:Y_T+WB#_P72_X4?ZIYU_T"5/\
MP"7^0?VO@?\ G]'_ ,"7^93HJY_PC&N?]"]X@_\ !=+_ (4?\(QKG_0O>(/_
M  72_P"%'^J>=?\ 0)4_\ E_D']KX'_G]'_P)?YE.BKG_",:Y_T+WB#_ ,%T
MO^%'_",:Y_T+WB#_ ,%TO^%'^J>=?] E3_P"7^0?VO@?^?T?_ E_F4Z*N?\
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M**^^/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^ T__P >H_X>+>-O^@7X5_\  :?_ ./4?\3(<&?SU/\ P6_\P_XA1G_\L?\
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MHNB:+:16&GZ?86Z6UK86\2!(H8HD 2.-$555% "@   "@#^>'QM\)[CX/?\
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M<+\02RK 2G*FH1E>;3E>2UUC&*MVT"BBBOM#\T"BBB@ HHHH **** "BBB@
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M-LY9)WL[?4+EKAK^Z@3419RNJ.&CF!B/U_\ \$=?V7/'?[-W@3X[:OX_T/\
MX174/C)\:O$_Q'TW1)KVWN[_ $G3K^2!+>*\:VDEMA<%;<N5@FF0+(@W[MRJ
M ?7]<'X>_P"3GO&'_8KZ'_Z5ZQ77^(O#>G>+]%N--U;3[+5-.N@%FM;N!9X9
M@"" R,"K<@'D=0*\Y^%?@#0?AS^T5XSL?#VBZ3H-E+X<T2=[?3K..UB>0W.K
MJ7*H "Q"J,]<*/04 >IT444 %%%% !7@?_!1;_DB>E_]AR+_ -$7%>^5X'_P
M46_Y(GI?_8<B_P#1%Q7YMXP?\D9F/_7M_FCZS@7_ )'^%_QK\F?%]%%%?YB'
M]@!1110 4444 %%%% !1110 4444 ?J91117^PA_"84444 %%%% !1110 44
M44 %%%% 'XV_\%5_^3^/'G_</_\ 3=:U\\U]#?\ !5?_ )/X\>?]P_\ ]-UK
M7SS7\*\7?\CW&_\ 7ZI_Z7(_U0\/?^25RS_L'H_^FXA1117SI]@%%%% !111
M0 4444 %%%% 'V3_ ,$/O^3K_$'_ &*5S_Z665?J?7Y8?\$/O^3K_$'_ &*5
MS_Z665?J?7]<>#G_ "3D?\<_S1_GO]([_DLI_P#7NG^3"BBBOU0_!PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *X/P]_P G/>,/^Q7T/_TKUBN\K@_#
MW_)SWC#_ +%?0_\ TKUB@#O**** "BBB@ KP/_@HM_R1/2_^PY%_Z(N*]\KP
M/_@HM_R1/2_^PY%_Z(N*_-O&#_DC,Q_Z]O\ -'UG O\ R/\ "_XU^3/B^BBB
MO\Q#^P HHHH **** "BBB@ HHHH **** /U,HHHK_80_A,**** "BBB@ HHH
MH **** "BBB@#\;?^"J__)_'CS_N'_\ INM:^>:^AO\ @JO_ ,G\>//^X?\
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M@Y_R3D?\<_S1_GO]([_DLI_]>Z?Y,****_5#\'"BBB@ HHHH **** "BBB@
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M6M)UZRB\.:) ]QIUY'=1)(+G5V*%D) 8!E..N&'J* /4Z*** "BBB@ KP/\
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MV+X8(GT!10 5P?A[_DY[QA_V*^A_^E>L5WE<'X>_Y.>\8?\ 8KZ'_P"E>L4
M=Y1110 4444 %>!_\%%O^2)Z7_V'(O\ T1<5[Y7@?_!1;_DB>E_]AR+_ -$7
M%?FWC!_R1F8_]>W^:/K.!?\ D?X7_&OR9\7T445_F(?V %%%% !1110 4444
M %%%% !1110!^IE%%%?["'\)A1110 4444 %%%% !1110 4444 ?C;_P57_Y
M/X\>?]P__P!-UK7SS7T-_P %5_\ D_CQY_W#_P#TW6M?/-?PKQ=_R/<;_P!?
MJG_I<C_5#P]_Y)7+/^P>C_Z;B%%%%?.GV 4444 %%%% !1110 4444 ?9/\
MP0^_Y.O\0?\ 8I7/_I995^I]?EA_P0^_Y.O\0?\ 8I7/_I995^I]?UQX.?\
M).1_QS_-'^>_TCO^2RG_ ->Z?Y,****_5#\'"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K@_#W_ "<]XP_[%?0__2O6*[RN#\/?\G/>,/\ L5]#_P#2
MO6* .\HHHH **** "O _^"BW_)$]+_[#D7_HBXKWRO _^"BW_)$]+_[#D7_H
MBXK\V\8/^2,S'_KV_P T?6<"_P#(_P +_C7Y,^+Z***_S$/[ "BBB@ HHHH
M**** "BBB@ HHHH _4RBBBO]A#^$PHHHH **** "BBB@ HHHH **** /QM_X
M*K_\G\>//^X?_P"FZUKYYKZ&_P""J_\ R?QX\_[A_P#Z;K6OGFOX5XN_Y'N-
M_P"OU3_TN1_JAX>_\DKEG_8/1_\ 3<0HHHKYT^P"BBB@ HHHH **** "BBB@
M#[)_X(??\G7^(/\ L4KG_P!++*OU/K\L/^"'W_)U_B#_ +%*Y_\ 2RRK]3Z_
MKCP<_P"2<C_CG^:/\]_I'?\ )93_ .O=/\F%%%%?JA^#A1110 4444 %%%%
M!1110 5^8/[</C#_ (*":#_POSXX^'_&/P_^"_PR^!GGZAX4^'VH:39>(?\
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M*5S_ .EEE7ZGU_7'@Y_R3D?\<_S1_GO]([_DLI_]>Z?Y,****_5#\'"BBB@
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M_:/L_P#8W]D>1_:/]H;^?LOV?SO+_>[/*^>OH"@ K@_#W_)SWC#_ +%?0_\
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M&L_#CQ)80ZE_:=@=1TV1 \MG=&*"2:W>.6)@TD$+ABZE,*'?@/\ ARI\*_\
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ME4?\,D?%?_HG^I_^#33/_DJOT,HH_P");^#/Y*G_ (,?^0?\17S_ /FC_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'_PP\;SP16<=OK-A=1^5X6F,$8C,DMG*DUM)<F.2:2&>)9+J1E2'ZR_8O\
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MYW\Y( #Z^\"_\%4_A'\3_C+\&?"GAW4M0UK3?V@O#^HZ[X!\46<4<VC:Z^G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>slide6.jpg
<TEXT>
begin 644 slide6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M2_VE/@%XX^'.NW&H6FB>/_#]_P"&]0GL'2.ZAM[RVDMY7B9U=%D"2,5+(P!
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M],\]LAOL<,/R,R#",RGZ H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#@_VJ/^38?B/_V*^I_^DDM=Y7!_M4?\FP_$?_L5]3_])):[R@ HHHH
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M/%Y>?#5_A5JG@A_%-MX6NM-3^U/[4CU6.\NE>&:,D/ \.$D4M$RF16?RN?\
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MGU7Q%XHA59=6&YY8_LUO9>9%;^6;:03O)YL=R44QT ?4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '!_M4?\FP_$?_L5]3_])):[RN#_ &J/^38?B/\ ]BOJ
M?_I)+7>4 %%%% !7Q?\ \%%O^2V:7_V XO\ T?<5]H5\7_\ !1;_ )+9I?\
MV XO_1]Q7X-](_\ Y(R?_7RG^;/TKPG_ .1_'_!+\CP.BBBO\]#^H@HHHH *
M*** "BBB@".3_@JG\0OV;G_X0O0]'\&W6EZ+_J);ZTN9+AO-_?-N*3HIPTC
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M0O\ R6#6/^V/_HB.N+KM/VA?^2P:Q_VQ_P#1$=<77[3E7^Y4?\$?R1^]9/\
M[A0_P1_])04445WGI!1110 4444 %?LK_P $I?\ DP;P%_W$/_3C=5^-5?LK
M_P $I?\ DP;P%_W$/_3C=5^R>!__ "/:O_7F7_I=,_G+Z3W_ "2V'_["(?\
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MVAOY^R_9_.\O][L\KYZ /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME8!YV'I7M%<'^U1_R;#\1_\ L5]3_P#226N\H **** "OB__ (*+?\ELTO\
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M+#<[*2WV6ZDDGAR?W4KLZ;6)- '[/5\O_P##Y_\ 9?\ ^&R?^% ?\+?\/_\
M"UO[5_L+^R?LUU]F_M';G[']N\K[']HW?NO*\[?Y_P"XQYW[NN@_X)._\HLO
MV:?^R5>%_P#TT6M?C#_PJ?PK_P 0.?\ ;'_",^'_ .UO[5_MW[=_9T/VG^T?
M^$S_ +.^V>9MW?:/L/\ HOFYW^1^ZSL^6@#]GOC=_P %1_@3^SG\4]6\'>,/
M'7]EZMX:_LO_ (2&XBT74+S2O"G]IS>38?VMJ,$#V>F>>V"OVR:'Y&5SA&5C
MZ!X=_:C\">+_ -H[Q%\)=)US^U/'O@_2K;6=>L+2RN)X=$@N6(MDNKI8S;07
M$J@R1VTDBSO$#*L9C^>OSA_X*K?\$IO&WBO_ (;/\5?\)=\/]%^$7[1.E>#M
M;\7>(M5GOUU7X>6?A7$M[+;Z;;VDXU7?:VWF(OVFU;>QCP=H=OF__@F1_P %
M=/&7[)WP:_:6^-GQ(^%FG^*M;N?$'A7XD?%36O[>%GK-CI?B@PQZ'IVC0^7>
M?VA9V>GM%<0Q7E]9F 7LEL$4Q-+( ?O=1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%?)__  7%_:]\9?L(?\$K_BU\4OA[-I]IXR\.VEC;Z9=7EJ+J.R>\U&UL
M6G$;'8TD:7+2('#1^8B;TD3<C?BC;?MX?$?_ ()^Z/\ M,2>&_V[/^%X>(/@
M=XK\ >(/!=SKOB9M8L/B?9W-KJ%OJ^EV]K)J,V^WC_M.)[@V\DC(VFQ/^YE6
M.6$ _I>HHHH **** "BBB@ HHHH X/\ :H_Y-A^(_P#V*^I_^DDM=Y7!_M4?
M\FP_$?\ [%?4_P#TDEKO* "BBB@ KXO_ ."BW_);-+_[ <7_ */N*^T*^+_^
M"BW_ "6S2_\ L!Q?^C[BOP;Z1_\ R1D_^OE/\V?I7A/_ ,C^/^"7Y'@=%%%?
MYZ']1!1110 4444 %%%% 'S'^T+_ ,E@UC_MC_Z(CKBZ[3]H7_DL&L?]L?\
MT1'7%U^TY5_N5'_!'\D?O63_ .X4/\$?_24%%%%=YZ04444 %%%% !7[*_\
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M 4444 %%%% '!_M4?\FP_$?_ +%?4_\ TDEKO*X/]JC_ )-A^(__ &*^I_\
MI)+7>4 %%%% !7Q?_P %%O\ DMFE_P#8#B_]'W%?:%?%_P#P46_Y+9I?_8#B
M_P#1]Q7X-](__DC)_P#7RG^;/TKPG_Y'\?\ !+\CP.BBBO\ /0_J(**** "B
MBB@ HHHH ^8_VA?^2P:Q_P!L?_1$=<77:?M"_P#)8-8_[8_^B(ZXNOVG*O\
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MU>ZEDE!7[5=1S>7;/:V\ENL!#&?>LE?4%?@#^RKK7BK]C?XN^"_A#X)^('Q
ML_B-X'_:_A^'%GX&;7)HYKKX7IIN9+^?PU"8[%K>: O>RZJMBK22RR71G\QC
M)7[_ % '!_M4?\FP_$?_ +%?4_\ TDEKO*\7_:L^'>L2? OXC:@/'GBQ+/\
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MZ<;JOV3P/_Y'M7_KS+_TNF?SE])[_DEL/_V$0_\ 3=4^AZ***_J@_A0****
M"BBB@ HHHH _-WXY_P#);/&/_8<O?_1[URM=5\<_^2V>,?\ L.7O_H]ZY6O\
MD^(O^1KB?^OD_P#TIG]NY5_N5'_!'\D%%%%>.=X4444 %%%% !7R3\2/^2B:
M]_V$;C_T:U?6U?)/Q(_Y*)KW_81N/_1K5]IP7_'J>B_,^]X"_P!XJ_X5^9BT
M445^B'Z>%%%% !1110 4444 ?T.4445_H8?Y#A1110 4444 %%%% '*_'/\
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MA:_%#3]"L)M1DLXKBXLU%S;F-KBUDD:&:*.61XF1?,$9D5:_8CX,^_Z*^?\
M_@IU_P %"_"O_!+_ /8V\4?%SQ3:_P!K?V3Y5GI&B1WT-I<^(-1F;9!:Q-(?
M]Z60HLCQP0SR".3RRI] _9.^.G_#4'[+'PT^)G]E_P!A_P#"Q/"NE^)_[-^T
M_:O[/^VVD5SY'F[$\S9YNW?L7=MSM7.  >@45\8?M>?\%1/B)\.OVN)O@K\
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M.?\ R6SQC_V'+W_T>]<K75?'/_DMGC'_ +#E[_Z/>N5K_)/B+_D:XG_KY/\
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M^1UA/^OM/_TM'P-1117^59_9P4444 %%%% !1110![Y_P3I_Y+9JG_8#E_\
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M*7?LV^/?"NI:%KOBK3]:T36K26PU#3[_ ,.7US:W]O*A26&6)[8I)&Z,RLC
MA@2""#7/^)?VU?V1/&GP:C^'.L2>#]6^'L-I;6$?AB\\%W,^C);VQC-O"+1K
M0PB.(Q1%$"80QIM VC!_K=D7_0;1_P#!D/\ Y(/^(?<4_P#0MQ'_ ()J?_(G
MP1^T/\)O#VG_ /!=[]J#2OB[^U5XP_9/\*?$?P_X0\8^'6\-^+;+PK=>-DL]
M/;2_.;5I=XACMITOHS8/LDN3,LX4I:AC]/\ [!WPA\3?\%9OV#/V4_V@OBYK
M7C#X<_'[P/::M?Z/XH\-V-I873V][]HT]YFLK^VN;)X[^QCM;DN+;&65[<PQ
MOL/I/QT_:I_8O_:@_LO_ (698_#_ .(G]A^;_9O_  D_@.;5_P"S_-V>;Y/V
MBS?R]_E1[MN-WEIG.T8Z_P 6?\%+OV;?'OA74M"UWQ5I^M:)K5I+8:AI]_X<
MOKFUO[>5"DL,L3VQ22-T9E9&!# D$$&C_6[(O^@VC_X,A_\ )!_Q#[BG_H6X
MC_P34_\ D3\:/^"8WPGN/ '_  45^!^H_!/QAXP\ ?!W]H*[\8?#[P!KHN8-
M:U]/"?A>R%U->6QU*&:UMH]9UPSWL]K+ID4MO) PA:..=_,_7[_@AU^U[XR_
M;O\ ^"5_PE^*7Q"FT^[\9>(K2^M]3NK.U%K'>O9ZC=6*SF-3L621+99'"!8_
M,=]B1IM1<GQ_^U3^Q?\ %?X6:+X%\4V/P_\ $O@GPUY']D>'M5\!S7FE:5Y$
M+00?9[:2S:*+RX6:--BC:C%1@$BO8OV8OVK/@[\4VM? WPNU/3_(\-Z2GV32
M+#1KC3K73K"#RX$CB1H8XTC0-$BQIC P ,#C?#\39/B*BHT,72E*6B2J0;;\
MDG=G-C."N(<)1EB<5@*T(15W*5*<8I=VW%)+U/9****]L^9"BBB@ HHHH ^$
M/^"TO[;G['.A?#/Q!^S=^U%\0=0\*Q_$CP_!J9M+#2=5GNH[?[6YM;R*>TM9
MHEDCN[(NJ2;@3 !)&\;%6_&#X8^#/V-;GXRZAK'Q@_X*8_%#XM^#?&-W8W'C
M[PX_@'Q;ILGC]+ 9L8+^\:2=Y(X76,*61I$C5EB>%RLJ?M__ ,%N/^"<<?[<
MW[$OQ)7P)\//A?KWQXN/#\>F>&M<\0Z#IUQJ$5NER)9[.VO+J&0V\DD#W:0O
MNC$4UP)!)"<S)^.'B7X7?%3]NKX6?"7X(_#O_@EWX?\ @#\0--U71Y'^)VN^
M$;NWTJT^PPDSS7;7E@OFV\FTM)%J,^H^<A:,Q75R\4@ /Z7J*** "BBB@ HH
MHH **** .#_:H_Y-A^(__8KZG_Z22UWE<'^U1_R;#\1_^Q7U/_TDEKO* "BB
MB@ KXO\ ^"BW_);-+_[ <7_H^XK[0KXO_P""BW_);-+_ .P'%_Z/N*_!OI'_
M /)&3_Z^4_S9^E>$_P#R/X_X)?D>!T445_GH?U$%%%% !1110 4444 ?,?[0
MO_)8-8_[8_\ HB.N+KM/VA?^2P:Q_P!L?_1$=<77[3E7^Y4?\$?R1^]9/_N%
M#_!'_P!)04445WGI!1110 4444 %?LK_ ,$I?^3!O 7_ '$/_3C=5^-5?LK_
M ,$I?^3!O 7_ '$/_3C=5^R>!_\ R/:O_7F7_I=,_G+Z3W_)+8?_ +"(?^FZ
MI]#T445_5!_"@4444 %%%% !1110!^;OQS_Y+9XQ_P"PY>_^CWKE:ZKXY_\
M);/&/_8<O?\ T>]<K7^2?$7_ "-<3_U\G_Z4S^W<J_W*C_@C^2"BBBO'.\**
M** "BBB@ KY)^)'_ "437O\ L(W'_HUJ^MJ^2?B1_P E$U[_ +"-Q_Z-:OM.
M"_X]3T7YGWO 7^\5?\*_,Q:***_1#]/"BBB@ HHHH **** /Z'****_T,/\
M(<**** "BBB@ HHHH Y7XY_\D3\8_P#8#O?_ $0]?F[7Z1?'/_DB?C'_ + =
M[_Z(>OS=K^)?I4_\C7 _]>Y?^E']"^#'^Y8G_&OR"BBBOY5/V<**** "BBB@
M K%^)'_).]>_[!UQ_P"BFK:K%^)'_).]>_[!UQ_Z*:NC"_QX>J_,Z<'_ +Q#
M_$OS/DFBBBOW _H,**** "BBB@ HHHH ^A_^"4O_ "?SX"_[B'_INNJ_96OQ
MJ_X)2_\ )_/@+_N(?^FZZK]E:_JCP/\ ^1%5_P"OTO\ TBF?PI])[_DJ</\
M]@\/_3E4****_9#^<@HHHH **** "O+/VU?^39O$W_;K_P"E<->IUY9^VK_R
M;-XF_P"W7_TKAKX_Q$_Y)7,_^P>M_P"FY'O<+?\ (ZPG_7VG_P"EH^!J***_
MRK/[."BBB@ HHHH **** /,?VKO^2=V?_813_P!%2U\^U]!?M7?\D[L_^PBG
M_HJ6OGVOU+A/_D7KU9^P<%_\BU?XF%%%%?3'U@4444 %%%% !7V5_P $._\
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M'_PKO^S_ .TO^$GL;2U\_P"V_:O*\G[/<S[L?9)-V[;C<F-V3CZ_H **\O\
MVT/VO?!O[!?[,'C#XN?$";4(?"G@NT2XNUL+4W-U<O)*D$$$2 @&26>6*)2[
M+&ID!=T0,Z_$'_!+3_@IA\;?$?\ P3;_ &LOBY^T!8Z?K7Q"^ WC7QA;S^&K
M 6VGVNG)I&EVUVVCQ3P+*#''.9XEG=KB0@@F2; ) /TOHK\@?@W^VG^V3^S[
M_P ,G?''XL_$[X?_ !,^&7[6_BO2O#%U\/M/\.1:/_P@?_"0_P"E:3/8WR1&
M>Z^SVZMYJ7+'&#$&G9Q>19_BS_@KG\8? 7Q,U+XEZ[\3-/T7P)HO[94O[/\
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M>'O_ "4>#_QK\F?G/B[_ ,D=F'_7M_FC]4J***_MH_S-"BBB@ HHHH ^3_\
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M57_K]+_TBF?PI])[_DJ</_V#P_\ 3E4****_9#^<@HHHH **** "O+/VU?\
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M++*OLO#W_DH\'_C7Y,_.?%W_ )([,/\ KV_S1^J5%%%?VT?YFA1110 4444
M?+_[:O\ P1F_9L_X*)?%/3_&WQB^&_\ PF'B;2]*CT2UO/\ A(-4T_RK..::
M9(O+M;F*,XDN)FW%2QWX)P !Y!_Q"X_L)_\ 1#?_ "\_$'_R=7W_ $4 %%%%
M !1110 4444 %%%% '!_M4?\FP_$?_L5]3_])):[RN#_ &J/^38?B/\ ]BOJ
M?_I)+7>4 %%%% !7Q?\ \%%O^2V:7_V XO\ T?<5]H5\7_\ !1;_ )+9I?\
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M &$;C_T:U?:<%_QZGHOS/O> O]XJ_P"%?F8M%%%?HA^GA1110 4444 %%%%
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MS^%/I/?\E3A_^P>'_IRJ%%%%?LA_.04444 %%%% !7EG[:O_ ";-XF_[=?\
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M?)/Q(_Y*)KW_ &$;C_T:U?6U?)/Q(_Y*)KW_ &$;C_T:U?:<%_QZGHOS/O>
MO]XJ_P"%?F8M%%%?HA^GA1110 4444 %%%% ']#E%%%?Z&'^0X4444 %%%%
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M^X']!A1110 4444 %%%% 'T/_P $I?\ D_GP%_W$/_3==5^RM?C5_P $I?\
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M.O+/VU?^39O$W_;K_P"E<-?'^(G_ "2N9_\ 8/6_]-R/>X6_Y'6$_P"OM/\
M]+1\#4445_E6?V<%%%% !1110 4444 >8_M7?\D[L_\ L(I_Z*EKY]KZ"_:N
M_P"2=V?_ &$4_P#14M?/M?J7"?\ R+UZL_8."_\ D6K_ !,****^F/K HHHH
M **** "OLK_@AW_R=AXA_P"Q2N?_ $LLJ^-:^RO^"'?_ "=AXA_[%*Y_]++*
MOLO#W_DH\'_C7Y,_.?%W_DCLP_Z]O\T?JE1117]M'^9H4444 %%%% !1110
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M/!_XU^3/SGQ=_P"2.S#_ *]O\T?JE1117]M'^9H4444 %%%% !1110 4444
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MN?\ 1,?'G_@BN?\ XBC_ %1SW_H"K?\ @N?_ ,B'_$0N%O\ H98?_P '4_\
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M - _QY_X0^M?_(E '>45P?\ PT=X?_Z!_CS_ ,(?6O\ Y$H_X:.\/_\ 0/\
M'G_A#ZU_\B4 ?#/QS_Y+9XQ_[#E[_P"CWKE:[;XK>$_$7B7XH^)-2L?!OCR:
MSU#5;JYMY/\ A%M17S(WF9E.#"",@@X(!KG_ /A7'BS_ *$GQY_X3&H?_&:_
MS!SW@#BBIF6(J4\MQ#3J3::HU&FG)V:?+JF?V%EO$V3QPE*,L72348W7M(=E
MYF316M_PKCQ9_P!"3X\_\)C4/_C-'_"N/%G_ $)/CS_PF-0_^,UY/_$/.*O^
MA9B/_!-3_P"1.S_6G)?^@NE_X,A_F9-%:W_"N/%G_0D^//\ PF-0_P#C-'_"
MN/%G_0D^//\ PF-0_P#C-'_$/.*O^A9B/_!-3_Y$/]:<E_Z"Z7_@R'^9DT5K
M?\*X\6?]"3X\_P#"8U#_ .,T?\*X\6?]"3X\_P#"8U#_ .,T?\0\XJ_Z%F(_
M\$U/_D0_UIR7_H+I?^#(?YF37R3\2/\ DHFO?]A&X_\ 1K5]F?\ "N/%G_0D
M^//_  F-0_\ C-?._C;]D3XK:OXSU>[M_AKX\DM[J]FFB?\ L&Z&Y6=B#@ID
M9![U]=PCP+Q+1K5'6R^O&Z6]&HNOG$^VX)XTX?H5ZCKXZC%-+>K!=?.1Y#17
MI7_#&?Q<_P"B8^//_!%<_P#Q%'_#&?Q<_P"B8^//_!%<_P#Q%?>?ZHY[_P!
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M  F-0_\ C-'_  KCQ9_T)/CS_P )C4/_ (S1_P 0\XJ_Z%F(_P#!-3_Y$/\
M6G)?^@NE_P"#(?YF316M_P *X\6?]"3X\_\ "8U#_P",T?\ "N/%G_0D^//_
M  F-0_\ C-'_ !#SBK_H68C_ ,$U/_D0_P!:<E_Z"Z7_ (,A_F9-%:W_  KC
MQ9_T)/CS_P )C4/_ (S1_P *X\6?]"3X\_\ "8U#_P",T?\ $/.*O^A9B/\
MP34_^1#_ %IR7_H+I?\ @R'^9XW^U=_R3NS_ .PBG_HJ6OGVOJS]H/X#^/O'
M'@RUM-+\ >/+JXCO4F9/^$<O4PH20$Y:(#JP_.O'?^&,_BY_T3'QY_X(KG_X
MBOTCAC@KB&E@5"K@*T7=Z.E-/\8GZIPCQUPW1R]0K9A0B[O1U::?XR/-:*]*
M_P"&,_BY_P!$Q\>?^"*Y_P#B*/\ AC/XN?\ 1,?'G_@BN?\ XBOHO]4<]_Z
MJW_@N?\ \B?3_P#$0N%O^AEA_P#P=3_^2/-:*]*_X8S^+G_1,?'G_@BN?_B*
M/^&,_BY_T3'QY_X(KG_XBC_5'/?^@*M_X+G_ /(A_P 1"X6_Z&6'_P#!U/\
M^2/-:*]*_P"&,_BY_P!$Q\>?^"*Y_P#B*/\ AC/XN?\ 1,?'G_@BN?\ XBC_
M %1SW_H"K?\ @N?_ ,B'_$0N%O\ H98?_P '4_\ Y(\UK[*_X(=_\G8>(?\
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MA),;O# D;%20#M)4D9 ..PHKI:* "BBB@ HHHH **** "BBB@ HHHH ****
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M6_$5HEA?:@^HWNIW36Z/O\F.6\FF>&-GVLZ1%1(8XBX8QQ[<_P#X<P?LO_\
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MQ39W26D9)(CC,\[R.$"F0K%O+>3%L_2^O/\ ]J/]ESP)^VE\"=<^&?Q,T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9=]_:O_  E&?MWV#S\_9_L_]C?Z3NV8W_)YV_\ =5^<'Q<^.WPX_8K\"?\
M!13]G7XM_#/Q _QV_:,^(&NZW\.=,A\(+JTWQ L]9D:/P]+9W$8=9/L=\9+D
M*[*T,LCK 'NEEA3Z _8H_P",3?\ @N'^S'\,_B!_Q(/&UQ^Q7HG@F/3?^/K=
MK%G?O<W-MYL&^+Y(=.O&\POY;>3A7)= P!]O?\/G_P!E_P#X;)_X4!_PM_P_
M_P +6_M7^PO[)^S77V;^T=N?L?V[ROL?VC=^Z\KSM_G_ +C'G?NZ[#7O^"D/
MP2\)>%?B]K&M>/M/T&S^ UV+/QW'JUI<Z?=:"[HKVY-O-&DTT=R&46LD"21W
M9(6W:9N*_!'_ (27PK_PY*_X=W_\*E\0?\-O?\+ ^Q_\(G_PB\/VG^T?[3^W
M_P!O?VAG[/\ 9_[&_P!%^V>=O\CG'V+_ $BOK#_@I]J_AGXM?MY_$;XQ>&_A
M/J'CKX&_LSW>D6'[15GI.K7:VOQBN(]DEM"+&V5[#4Y/#.Y;FZ2_DC(&;><)
M!$CD _9[PGXFM_&GA73=8LX]0AL]6M(KR"._L)["Z1)$#J);>=$FAD (#1RH
MLB'*LJL"!H5G^$_%FE^/?"NFZ[H6I:?K6B:U:17^GZA87"7-K?V\J!XIHI4)
M22-T965U)# @@D&M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>slide7.jpg
<TEXT>
begin 644 slide7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'PG_ .$/^,/Q2_9)N_$+ZMX2FG_LBU\5V_B24_VA'97L\BI%):I+(D4DZJ)
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M5]<_]*]'KO* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P G/>#_ /L5]<_]*]'KO*X/Q#_R<]X/_P"Q7US_ -*]'KO* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7H]=Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^'!X7D\<:WJ4]C_PEFL6T,26D]S&='MSI?E-'<V]_'DVSN_[L_N=10!\ ?\
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M]E76?A'HUUX8U[24^RZC?7;7EI?3/>W=M%)I\T-RI6:VDG?]VY,8!0O\?_\
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MQI:^%;$7&LZ=H*W)OKBZMI)&6UM9%EL[>/[1>'[,@F/F%0P=?G#]A?X:Z#\
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MVK\3/^AF_P#*=:?_ !JC_B:+A7_H'Q'_ (!3_P#EH?\ $'<Z_P"?M+_P*?\
M\@??-%? W_#:OQ,_Z&;_ ,IUI_\ &J/^&U?B9_T,W_E.M/\ XU1_Q-%PK_T#
MXC_P"G_\M#_B#N=?\_:7_@4__D#[YHKX&_X;5^)G_0S?^4ZT_P#C5'_#:OQ,
M_P"AF_\ *=:?_&J/^)HN%?\ H'Q'_@%/_P"6A_Q!W.O^?M+_ ,"G_P#('WS1
M7P-_PVK\3/\ H9O_ "G6G_QJC_AM7XF?]#-_Y3K3_P"-4?\ $T7"O_0/B/\
MP"G_ /+0_P"(.YU_S]I?^!3_ /D#[YHKX&_X;5^)G_0S?^4ZT_\ C5'_  VK
M\3/^AF_\IUI_\:H_XFBX5_Z!\1_X!3_^6A_Q!W.O^?M+_P "G_\ ('WS17P-
M_P -J_$S_H9O_*=:?_&J/^&U?B9_T,W_ )3K3_XU1_Q-%PK_ - ^(_\  *?_
M ,M#_B#N=?\ /VE_X%/_ .0/OFBOD7]E_P#:@\=?$3XYZ'H^L:Y]LTV\\_SH
M?L=O'OVV\KK\RQAAAE!X/:OKJOUS@+CW+^+<OGF66PG&$9N#4U%.ZC&5URRD
MK6DNM[WT/B.)>&L5D>*CA,7*,I2BI>ZVU9MKJEKH^@4445]L?/!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ%G:">66;^BZOY\=-_X)P_\ !1G]A+XR_ W0OA;\)OA?\5O"G[)=WXH3X?\
MB9]3M;"/Q/;^( [7,E_;3ZI#,LD8F*K'&(Q'(C#?<(%D< _8[_@ECX!^#?PP
M_P""??POT7]G[6O^$D^$5KI1DT'56O&NIM1\V:26YFG9@I2X:Z><RQ%(_)E,
MD7E1;/+3Z KY?_X(S_LF_P##"_\ P39^&_PFD\7>'_'&H>"O[3L]4U71'WV
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MB+BOB^O\]/I'_P#)9S_Z]T_R9_47A/\ \B"/^.7YA1117X,?I04444 %%%%
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M>IT445_>1_-84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=0\0:IX9\'_;/L=UK<\,]_+]IO)[R3S'ABBC.)+AP-L:X4*#DY)]@H ****
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M $Y2/R?QC_Y$M+_K['_TB9ZG1117]Y'\UA1110 4444 %%%% !1110 4444
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M35]\U_>7T7?^25Q'_81/_P!-TC^:_&/_ )'5+_KU'_TN84445_21^3A1110
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MGJ=%%%?WD?S6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&EG=WN@^&?[;MX]/TNY$-P?MGV?;Y?G2;6Q(K(@9Y;>*7]7J* /RQ_X)H>
M/!O_  5;_:'_ &[OBEK'@/4/$7[-7[15WX7\/>'+KQ#8FSC\6IHEA<6-Y=6T
M987$<:7"Q20W $<B2 ;3'<02I%\7_P#!6W]ES3O%'Q3_ &B_BI^SSH?B"/\
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MHO+L6M4$#8:!56)DC,91?K^@ HHHH **** "BBB@#@_$/_)SW@__ +%?7/\
MTKT>N\K@_$/_ "<]X/\ ^Q7US_TKT>N\H **** "BBB@ HHHH **** "BBB@
M#P/_ (*+?\D3TO\ [#D7_HBXKXOK[0_X*+?\D3TO_L.1?^B+BOB^O\]/I'_\
MEG/_ *]T_P F?U%X3_\ (@C_ (Y?F%%%%?@Q^E!1110 4444 %%%% !1110
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M %%%% !1110 4444 >!_\%%O^2)Z7_V'(O\ T1<5\7U]H?\ !1;_ )(GI?\
MV'(O_1%Q7Q?7^>GTC_\ DLY_]>Z?Y,_J+PG_ .1!'_'+\PHHHK\&/TH****
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M^E<U? U??/[%7_)LWAG_ +>O_2N:OZ2^B[_R56(_[!Y_^G*1^3^,?_(EI?\
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M?^DG[/X,?[[B?\"_,Y6BBBOXE/Z%"BBB@ HHHH **** "BBB@ HHHH ****
M"OOG]BK_ )-F\,_]O7_I7-7P-7WS^Q5_R;-X9_[>O_2N:OZ2^B[_ ,E5B/\
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MA_Y.>\'_ /8KZY_Z5Z/7>5P?B'_DY[P?_P!BOKG_ *5Z/7>4 %%%% !1110
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M3WLL_D7$,L4^^&RDM]C*-OVGS V8PK<_^VK\$/VK/V<_^"#6GQZ7^T1CXZ?
M_2H_&7B?Q;]A$G_"46>E":]ETWSI$:1]L:0IY\L9:^^Q;+E52\N-H![?_P $
M.OV0_&7["'_!*_X2_"WXA0Z?:^,O#MI?7&IVMG="ZCLGO-1NKY8#(HV-)&ER
ML;E"T?F(^QY$VNWUA7R__P $8/VQ=>_;Y_X)@?"#XJ>*8?+\3>(-*EM-7EWQ
MG[?>6-U/83W>(XXHX_M$EJT_E(@6/SM@+!0Q^H* "BBB@ HHHH **** .#\0
M_P#)SW@__L5]<_\ 2O1Z[RN#\0_\G/>#_P#L5]<_]*]'KO* "BBB@ HHHH *
M*** "BBB@ HHHH \#_X*+?\ )$]+_P"PY%_Z(N*^+Z^T/^"BW_)$]+_[#D7_
M *(N*^+Z_P ]/I'_ /)9S_Z]T_R9_47A/_R((_XY?F%%%%?@Q^E!1110 444
M4 %%%% !1110 4444 %%%% 'J?[%7_)S/AG_ +>O_22:OOFO@;]BK_DYGPS_
M -O7_I)-7WS7]Y?1=_Y)7$?]A$__ $W2/YK\8_\ D=4O^O4?_2YA1117])'Y
M.%%%% '/_%+XL^%?@=X$OO%/C;Q-X?\ !_AG2_+^V:OK>HPZ?86GF2+%'YD\
MS+&FZ1T0;B,LZ@<D"N@K\H?^#L#]DW_A9'_!/'XC?%7Q!XO\07VD_#O2M$B\
M*>#X7^RZ5INL7&O6]O>:S.4(:[N'L;A;6%)<QVZ-=,JL]QNC_5Z@#S_Q_P#M
M8_"SX4?%/1? OBGXE_#_ ,->-O$OD?V1X>U7Q#:6>JZKY\S00?9[:2199?,F
M5HTV*=SJ5&2"*/CI^UC\+/V7_P"R_P#A9GQ+^'_P[_MSS?[-_P"$G\0VFD?V
MAY6SS?)^T2)YFSS8]VW.WS$SC<,_G#_P54_X)B_LX_#;X6?&B/5/"_B#XT?M
M-?M=:K>1^ 8=7N$U3Q-%K"P[K.'2Y/W/]GZ/IG[N6>5G6..TC$5Q++&((#G_
M +4'_!.3]HK0O%2ZZOAG4/C5K?BK]C6Z_9_UC4-'\161NH_%3.KOJ-W+JUQ:
M/+9SO([>>AEG)20O"I*[@#]3O$7Q9\*^$/'?AWPMJWB;P_I?B;QA]I_L'2+O
M488+_6_LT8EN?LL#,))_*C(>3RPVQ2"V!S705^ /_!)3]O>S_9[_ &COB-XR
M\?\ @WQ!\3-6^#7P5M/!7A6[\ 7%K=6%EX$\),MIK.NV]U?2:=;:CI^H:M$9
MK=X#=72M;74.(TC3SOW>^$_Q2T'XX_"SPSXV\+7W]J>&?&&E6NMZ1>>3)!]K
ML[F%)H)?+D59$W1NK;756&<$ Y% '04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YN_'/_ )+9XQ_[
M#E[_ .CWK](J_-WXY_\ );/&/_8<O?\ T>]?RK]*G_D58'_KY+_TD_9_!C_?
M<3_@7YG*T445_$I_0H4444 %%%% !1110 4444 %%%% !1110 5]\_L5?\FS
M>&?^WK_TKFKX&K[Y_8J_Y-F\,_\ ;U_Z5S5_27T7?^2JQ'_8//\ ].4C\G\8
M_P#D2TO^OL?_ $B9ZG1117]Y'\UA1110 5Y?\%OVT/A?^T7\9?B5\/\ P/XP
MT_Q-XK^$%W:V'B^TLXY6CT>XN!,8X3.4$,D@,$R.D3N8I(G20(X*UV'Q8\ _
M\+7^%GB;PM_;7B#PU_PDNE76E?VOH5Y]CU72O/A>+[3:3X;RKB/=OCDP=KJI
MP<8K\\/^".7P!\&_LM?\%<_V]/A[\/?#VG^%?!OA6T^&EEIFF6:D1VZ?V!<L
MQ+,2\DCNS.\CEI))'=W9G9F(!]__ !^^/W@W]EKX->(?B%\0O$.G^%?!OA6T
M-YJ>IWC$1VZ9"J J@O)([LJ)&@:221T1%9V53Y_^S-_P4H^ O[8?P:UCX@?#
MOXJ^#]>\*>&;1[_7;M[S[#)X>MT,X,U_!<".:RC(MIW5[A(PT<3.I*?-78?'
MW_A5G_%%?\+2_P"%?_\ (UV/_"(_\)5]D_Y&']Y]B^P?:/\ F(?ZWRO)_???
MV=Z_-']FSX*>/O&/[;7[9_P%^/=QX/T?X\?M:?!^T\23>(? #W-_X1TK1K>V
MN/#,*K:7JPW:WD<DQF8&>6.=7 #6YC_>@'W=\"_^"H_P)_:(_M3_ (1_QU_9
M_P#8_A6+QW/_ ,)/HNH>%_,\/2[]NLP_VG!;^?IX\MMUU%OA3*;G7>F[U#X
M_'?PS^T[\&O#WQ \&76H7WA3Q7:"_P!)N[S2KO2Y+RW8D),(+J**81R ;T=D
M DC9'0LCJQ_ '_@JW^RM\:/V3?"OPNTGQ+XB\'^&=;\0? JT^!MY8>!K^^US
M4]2\'>&T?7?$VO137,>E6\$B6]I:P_V=)++]KAO+F(2 \U^I_P#P3;_X*;_\
M+W^*?@GX.ZE\(_#_ ,+?[?\ @KHWQ<\&VOAC7_[6TJU\/7$RV<=C,C6-E]DN
M(=UN%AACFAV;P)%V*' /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R_P#;0_9#\&_MZ?LP>,/A'\0(=0F\*>-+1+>[:PNC;75L
M\<J3P3Q. 0)(IXHI5#JT;&,!T="R-^:/_$*UXJ\5?\4/XQ_;:_: \2_L]Q?Z
M';_#WSYH_)TZ#G3K7SI;N:S_ -&:.V.18!#Y'R1PDJ8_U^HH Y_X3_"W0?@=
M\+/#/@GPM8_V7X9\'Z5:Z)I%GYTD_P!DL[:%(8(O,D9I'VQHJ[G9F.,DDY-=
M!110 445\O\ _!2;_@I-_P ,)?\ "O/"WA;X>>(/C!\9/C!JLFE>"?!.E3?8
MO[4^S^4][<W%ZT;Q6MO;PRJ[R.#C<"0L2S30@'U!17YX1_\ !P)I7@[]B7]H
M'X@?$+X0>,/ GQ8_9JN[73?&7PUN+Q)Y(;C4+D6^E2PZCY:0S6=R65S.B$K&
MLCI'-&8'N-#Q]_P7._X47H_[0F@^//A=M^+OP-U7PYH6G^$O"GB3^VH?'VH^
M(;59M)L]-GFM;6YDN&83>?$MF[QQ0/)&+C!10#[_ **S_"=SJMYX5TV;7;/3
M]-UN6TB?4+2PO'O;6UN"@,L<4[Q0O-&K[@LC11E@ 2B$[1H4 <'XA_Y.>\'_
M /8KZY_Z5Z/7>5P?B'_DY[P?_P!BOKG_ *5Z/7>4 %%%% !1110 4444 %%%
M% !1110!X'_P46_Y(GI?_8<B_P#1%Q7Q?7VA_P %%O\ DB>E_P#8<B_]$7%?
M%]?YZ?2/_P"2SG_U[I_DS^HO"?\ Y$$?\<OS"BBBOP8_2@HHHH **** "BBB
M@ HHHH **** "BBB@#U/]BK_ ).9\,_]O7_I)-7WS7P-^Q5_R<SX9_[>O_22
M:OOFO[R^B[_R2N(_[")_^FZ1_-?C'_R.J7_7J/\ Z7,****_I(_)PHHHH ^?
M_P#@J/\ L,?\/*/V$_'7P4_X2C_A"_\ A-/L'_$Y_LW^T?L?V74+:]_U'FQ;
M]WV?9_K%QOW<XVGT#X^_#OQW\0O^$*_X07XB_P#"N_[#\5V.K^(?^)!;ZO\
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MQ/\ ^AP\!_\ A(7?_P LZ[RB@#@_^$>^)_\ T.'@/_PD+O\ ^6='_"/?$_\
MZ'#P'_X2%W_\LZ[RB@#@_P#A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</
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M')\OK_6<%AXPG9JZWL]SR<Z\0.(LWPSP>98N=2FVGRMJUUL]NAP?_"/?$_\
MZ'#P'_X2%W_\LZ/^$>^)_P#T.'@/_P )"[_^6==Y17T1\><'_P (]\3_ /H<
M/ ?_ (2%W_\ +.C_ (1[XG_]#AX#_P#"0N__ )9UWE% '!_\(]\3_P#H</ ?
M_A(7?_RSH_X1[XG_ /0X> __  D+O_Y9UWE% '!_\(]\3_\ H</ ?_A(7?\
M\LZ/^$>^)_\ T.'@/_PD+O\ ^6==Y10!P?\ PCWQ/_Z'#P'_ .$A=_\ RSH_
MX1[XG_\ 0X> _P#PD+O_ .6==Y10!P?_  CWQ/\ ^AP\!_\ A(7?_P LZ/AQ
MXG\3?\+-\0^&_$E]H.I-IFEZ?J5O<Z;IDMA_Q\RWL;(Z27$^<?9%(8,/OD8X
MS7>51M_#=C:^);O6(X NI7UM!9SS;C^\BA:9XEQG VM/*<@9._G.!@ O4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?]N?\*[\*ZIXG_LW[3]E_M#[%:2W/D>;L?R]_E;=^QMN[.UL8/Y@_!O]M/\
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MC[-W]D[OL_\ R$/X_)\OS/+^7R_M/^B5] ?LP?$;XC_M$?\ !37XL?ME:E\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGN(Y-1WQQW$?V6$(R^1N\PEU2O;_ (U_\$UX_P!I3_@N5;_$[XC?"KP?X_\
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MKJJ*RKT8UJ4J4]I)I^C5CHPN)GAZT,13^*+37JG='Y6_\.._BQ_T,/P[_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>slide8.jpg
<TEXT>
begin 644 slide8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M\._] IO^_4E'_#Z[P[_T"F_[]25^9]%'_$:N(.U/_P !?_R0?\2S\(_S5O\
MP./_ ,@?IA_P^N\._P#0*;_OU)1_P^N\._\ 0*;_ +]25^9]%'_$:N(.U/\
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M\._] IO^_4E'_#Z[P[_T"F_[]25^9]%'_$:N(.U/_P !?_R0?\2S\(_S5O\
MP./_ ,@?IA_P^N\._P#0*;_OU)1_P^N\._\ 0*;_ +]25^9]%'_$:N(.U/\
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M?^BS_P B?&_]?8_^DH****_##^I0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#]1OV4/%'Q0\)_P#!,;X;W'PG\.:-XG\1/J-['<VNIRK'
M#':&\ORT@+3PC<)!$,;CPQ^4]1YK^T-^VA\>?@_X^^&-Y\6O"'AWPGI=CXB&
MKQ/HHBNKN\AAC:WNXE#74R#=;WCJ-VP[G4JP*DC8_9[UOP_\0O\ @G+\/O"-
MO\>-&^$/B+2]1N[VZFCUF.WO3']JO<0/&+F%U5Q+')R<':IP<@CPK]N7X06G
MA;X>Z1K#_M'6_P :+Z'4?L4.FMJ NYK".6-WDG7_ $N<JNZ&-6PH!+)D\ ']
M^SC,L;1R+#UL#4FN2C0>E6DJ:<5!N]-_O6U;H][=+G\D\.9/EF(XIQF&S2C2
M;JXG$KWJ&(=5J<IJ-JJ_<*+O]I?#=;M,[O\ :1_8YMM?_P""M.D^%Q!I_P#8
M?CZ[A\2SVS74X\RVQ)+?H[@;TDE>VNRH0[1YL8#(.$\C_P""F_QCD^,G[97B
MR3S+@V/AF;_A'K..>*.-H5MBRS ;,[E:Y-PZLQ+;7&=N J_6'[/_ .VIX*T#
M]BS0?&FH>*/#MI\1?ASX2U'PO8:%)*5^U2%K86NZWSYTN\6=D6DB81CS)\E=
MI\OXU_9)_;A\6?L:?\)!_P (OI_AV_\ ^$D^S?:?[4@FEV>1YNS9Y<L>,^<V
M<YZ#&.<_/<2RRJ-.-"G64*>,FZ\W%*3A'D]R#BFKVG*:LW&UKVT/L."HY_.M
M/$UL,ZM;+J2PM.,Y."J3]I:I54Y1E:]*%)W2ES7:YM;GMW[$>J2?L\?\$]_B
M]\7_  ZMNOC:/48- M;JZMXYEL8"]F"T8(SN+79<ABR,T$&Y"%(;U/XH_!GP
M_P#M'?M2?LO^,?$&GV\=]\3=#;4]?M+:",6=Y)96,5[&&1U<NKM)Y+B1G)AC
M1 1MW'A/AC^U3I_[;GP)^-'@GQMXA\&_#WQ1XPN[/7+&^O+AK73+EX8[.+R1
MYK'R\?88,GS'<_:'98R(B#I?%?\ ;!\%?!;]IO\ 9[T;3=8T_P 6^'_@_I(T
MO5-?L9RUO+]JM([.1U6-9 WDQ1K,1&TFXN8LJR$U[^%Q.6T\MH0G5C+"1]BE
M>RO46)DZDG"[E%NE=RZ<KM=Z'RF/P>=5LZQ56GAYPQ\OK+?+>5J4L%!4HJK9
M1E%5[**5GSJ_*G<[+QU\3-0_;'^&G[5WA7QE#I[Z?\*[N:\\.R6MJJ7%F]J+
MP(-[[OO?8OF8 .1<W"AE5D5#_@E#X,^$O@'Q9;0^'?$&H^*/B=K'A)=1UIU7
M;I^B0L]K*UHF,*TFZ>%6.Z4AK63/DDF-N=^)'BKP)^R_\-/VD-<T_P")'@WQ
MUJ/QHNY+?2M)TC4(Y;BU2Y%SO>0QM)CR_M<YY 1A;I\ZM,$3R/\ X([?$;P_
M\,?VF=<O_$FO:-X>L9O#%Q;QW.IWL=I"\ANK1@@:1@"Q56.,YPI/8UO#-H4>
M(<!]<Y)UWSJ<Y-2<(NK4<&FGRWY+)7NXQV2NF<E3(*N)X/S;^S?:4L+'V;IT
MX1<%4FJ%)5$XRCSN/M+N25E.:=V[-/Y/K[:_9RTC_AL'P-H.D^+/V==1UVWT
MW26L+/QMX<G_ +'N'MK>WBLXF+W#I;WMPCPH/WDQ50&VQ81U;XEK]!++P8OQ
MP^ O@NPU3]KCPKX/TF/PQ9V+>&K1K:T6UC:RABDMKG%\CSMA"'$P(#-(%5%8
MH/SC@6A*K6JJW/%)7A^Y2EKU=;W4EWBG)-Z6W/V;Q4Q4*&'P[YO9R<I6JVQ#
ME#W?LQPRYI-Z:2E&#2=[Z(^5_P!M?]GSP_\ LT?&VX\-^&_%MOXNL5A::21#
M&TVER>?-&;.<QLP,T:QKN.$.7^XO KN_V8OVL_%W@[X::+\,_@SX3_LOXBZ]
MJPFO]>MVAO;C74 FV0O#/"R0QQHZ'=O"((I'.WS)#7FG[5'P/\/_  !^(5GH
M_AOQ]HWQ%L;G3DO9-2TP1B&"1I)4,!\N:4;@L:M]X'$@XZ$_3W_!.71_"?PA
M_9V\3^,[/X@?#S1/BUXJM+G2]&36O$T-FFBVV]5#S0LCD2&6,S89)%=(X "@
M>0UTY'A<0^(:M+#-85)2YN249.$-&XTYMOWGI&+B[ZVORW1Q<48_"+@^A7QB
M>.;<%#VD)0C4J.ZC*M327[N.LI1G%KW4[<RBSS3_ (*\:1X5T3]LK4(?#5K;
MV=V^G6]QK\<$;QJVHREY&<@C;N>%[=V*<,S$G+ES7OW_  2_UOQKX=_X)Y^-
M[SX=Z/I^O>,8?%K_ -GV-\X2WGS#IXEW$R1#B(R,/G7E1UZ'X<_:'^&EW\,?
MB$T-_P"-/"OCR^U:'^T[G5=!U<ZI"\DDD@82S,H)F+*78')PZG)S7T-^SQ\=
M+3X8_P#!*SXE6&E^,;?P]XVF\3QW&G6UKJPM-5>,MIJN\2JXE*E%E!*C&%<'
M@&O2R'-XPXEQN85X^Q]RM*T7%->ZVE%ZQY^SLTY:VZ'C<6</SJ<%9;E&%G]8
M_>X:'-.,G&7OI-SBFI*GW5TU#3FZGLO[;:>*OB%_P3WU_7?CAX5\*^&?'^BZ
MY##X86RN$W&.1[8/Y;+<2EF>/[5NCW8*P*Y3,:N/ M"_X)HVUG9>&=*\8?%#
MP[X.^(7CBT^UZ!X9NM/G=Y-\2M%%=RML-K(TI:+:T;9="J&5P4'SSX]^+OBS
MXJ?9?^$H\4>(O$GV#?\ 9O[4U&:\^S[]N_9YC-MW;5SC&=HST%?=7Q&\8_#O
M]K+X[?"_XX'XH^#?"=GX+M+.;Q#H.HS.-3MIK.0WWDVT;*CW>YY3#N1 /DRG
MFL3&.F..RSB'%3Q-6GS3A&E!*I-1E./-+VE24HNFG**:2Z))-II-''/+,[X0
MP%+!4*W)3JRKU).C2<X4Y*$?8T81FJK4)R4F]+N3<8M2DF_*_P!GC]GKXB?#
M[P-^TMX?A\8_\(C_ ,(7I+1>(-/&B)>)XCA6WOBH268))#&\:N4D5<LEPK8X
M%5Y?^";_ (5\+_#WX<^)/%WQGT;PG8_$33H+FVCN]&=YH;B:."18P%FP8565
M_,N',:1D19'[W*^J>$_VKO!_Q/OOVPM>?6M&T>'Q=H<=CH,-Y?+!-K"P:?>V
MJ/"DH1V:0+&_EA=RF95.3@GRO_@H-\1O#_C3]F;]F^PT?7M&U:^T/PPUOJ5M
M9WL<\VGR?9=.79,JL3&VY'&& .48=C6F,P.24,J==)5U2C/D4JD[-?6G%-)3
M5KPU:25_B>NICEV:<3XK/HX23>%=>5/VLH4J=TU@8U&G*5.7-RU5RIR<K? G
M9)'KG["O[!>G_ G]NW7M%\;7&GZUJGAG28]=\+)]F9H[^%[CRAJ'WBL4D#*$
M\J0,1)+O0D1+(?A7XK>'- \(^/K_ $_POXD_X2[0[?R_LVK?V?)I_P!KW1JS
M_N9"73:Y9.3SLR."*_3:]_:?^'-A_P %.[/69/''A5M%OOAL=)CU*/4XI+);
ML:B\_DO.K&.-O+1F^=ESE1U90?S)^*WP]_X57X^O]!_MSP[XD^P>7_Q,="O/
MMFGW&^-9/W<N%W;=VUN!AE8=J\_CO!8#"9?2PN71BXPK5DY*5Y*_(XI^]9IK
M1-INT(V:O+F]3PJS/-LPSBOCLXG-3JX;#M0<>6#LZBFXWC=.,M6E)+FJ2O%I
M14/LB\\!?\+4_P""6'[/?A?[5]@_X23XAII?VGRO-^S^?=ZI%OV97=MW9QD9
MQC(ZUSVH_P#!)2VNOB7K_@/0_BUX=U3QYI-I'J<&DS:5/"ALR8%:2YF1I%MY
M TK8B D9D\I_E63Y.A^''Q=\)V/[$W[-.DS>*/#L.J:#\3K._P!3LWU&%;C3
MK9;^_=IID+;HXPKHQ=@% =3G!%=W\(_CIX)TW_@KE\4O$EQXQ\*V_AW4/#$-
MO:ZK)JT"V5S((]+!1)B^QF!CDX!)^1O0U])'+\EQL,&\;&,I2CAJ;?.TXQ="
M3D[*25U)+5II/1]CXV><<2Y;4S%99*=.,)8RLHJG&2G-8J*BFY0;M*,GI%IM
M:IK=?+'Q:_8;C\'_ +/]Q\0O"/CK1O'^D^']1_L?Q*UC:R6T.EW?[E?]'DD.
M+R'S)D42H%R'C8*5+F/U3Q=_P2B\*_#[XPZ+X+U[XY:-INK>)X4;1[9]"<W-
MW)ND5E=?/V0J2J+$SR9F<R(J[D^;G?A'\1O#^F_\$C?BEX;N->T:W\1:AXGA
MN+72I+V-;VYC$FEDND);>R@1R<@$?(WH:^G_ -LGX.^&?%7[?7PW\7ZQ\3/!
MO@__ (0^TL+Z_P!.UJX%I<3PPWMQ/ UNSE8YO,D26-QN4PA%<A]ZJ>'+N&\H
MQ&'6+I8>,W*.';BZDE&//.K&=GSIWY81E9R=G=VY;H]3..,N(<)BWE]?&3IQ
MC/%Q4U1A*4U2IT)TFU[*4;<]24+QBE)6BWSVD?(_P4_X)LZM\3-?^+6CZYXH
MT_P=JGPJV+.]]:/]AO-ZW#+,TSM&T-N5@5Q*8VS'('VX&#G> OV'='^-OQ8N
MM*\!?$K3];\':#I*:OK_ (JU'1KG2;32$\YEDB*R9#2")3*N]XT=4D&Y=C&O
M?O"?[5W@_P")]]^V%KSZUHVCP^+M#CL=!AO+Y8)M86#3[VU1X4E".S2!8W\L
M+N4S*IR<$^-?\$XOC;X5\':3\4/A_P"+M9M_"]C\4M#&E6VMW"O)#97!$UNJ
MNBC&TK=NY=WC11 06&[*^;_9/#T:^$PT5&4*CK7J.<DVH3J*DOB48J:44VUL
MTTUJW[7]O<7SPN88V<IQJ48X;EI*G!J+J4J4J\O@<YNFY5)1BI;IQ:EHERWQ
MP_8OMO WP5M_B5X&\;Z?\1O S7:Z==W=MIT]E=Z=<DN")X&W>5&,1 /(ZLS7
M$>$PRLW4Z[_P3GM-/_:]\#_"^P\?V^K6/CC0SKEMK]OI@:%8_+NY%V1K.1(K
M+; AQ( 1(#@XYZ'XD^*_"O[+O_!/?6OA';^-?"OCSQ=XVUR+5;K_ (1ZZ>YL
MM+MP\1#"X"%)6S8Q@H3&X^T9VE5#/Z9\"?VU/#OAW]@VU\47GBC[-\3OAWX>
MU/P?I%@9;);B?[3+:?99X[5CNECA6&T!<CI#<%ED(!.F%R7()XOV.)48-4Z=
M6:4VU%QD_:TD^?>4+-7E*46K)IF..XFXLIY?]8P4IU(RK5J%.3IQC*:G!>PK
MR7LK<L*JE%VC&,DU)IQL?//PV_86T_Q;IOQ$\4:U\0-/T'X8^ =6DT9?$\.G
MMJ7]JS">.*-HK>&0MY;++$Y<,P'FH%WC>R;+?\$U+N3]H7X=^%K?Q?;WGA'X
MHZ=+J>@^)H].*M-'%9_:7#V;R*Z-@QC!?&V53G<'C7T/_@F_^T5IOAS]E3QY
MX T[Q_HWPU\?S:BVMZ/JVN+ NGR*4M8S'OFRFXF%D8%2RK,'19"C!=KPI\?F
MMOV^/A(OCCXV^'?'T?AFTU&:_P!3AL;/3=%T::YTYP88KQ"JW.YE0%F50#L
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ME;\>6>E;_P!Q'E__  5$_P"35M5_W9O_ $FFK\<Z_:[]NJ'3;CX3V<>L:?\
MVMI+Z@%O++SV@^UQ&&7?'YB_,FY<C<O(SD5\>_\ "*_ /_HAW_EY:C_C7F>.
M5?+J>8898W%PHOD=E*-5MKFW7LZ4U][3\CS/H^\80R;+<52EAJM7FJ)WI^RL
MO=M9^TJP=_1->9\)T5]V?\(K\ _^B'?^7EJ/^-'_  BOP#_Z(=_Y>6H_XU^'
M?7,@_P"AI1_\ Q/_ ,SG] _\15I?]"[$?^6__P T'PG17W9_PBOP#_Z(=_Y>
M6H_XT?\ "*_ /_HAW_EY:C_C1]<R#_H:4?\ P#$__,X?\15I?]"[$?\ EO\
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M?=G_  BOP#_Z(=_Y>6H_XT?\(K\ _P#HAW_EY:C_ (T?7,@_Z&E'_P  Q/\
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M+_S1](?BJ&=2P#CAZE'D]K_$]GK?V>WLZE3:VM[;JU];<9^WM_R1NW_Z_?\
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M3J7_ %]2_P#H9K/KP,9_O$_\3_,]+#_PH^B_(****YC8**** "BBB@ HHHH
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M0_S/+**]3_X8J^)G_0L_^5&T_P#CM'_#%7Q,_P"A9_\ *C:?_':/^(><5?\
M0LQ'_@FI_P#(A_K3DO\ T%TO_!D/\SRRBO4_^&*OB9_T+/\ Y4;3_P".T?\
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M_P"-,-H-U:K+J?\ ;$9B$OG0):I*\D&QHR9E4QCS8@6!D0-YD<GQ[]G:A/\
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MY_<?<%%?-T__  5W_9TMOC/:_#MOB79'QM>>+)O!$>CKI=\UPNK13Q6[0.!
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MX?I7NO[,G_)#=!_W)?\ T=)7A3_</TKW7]F3_DAN@_[DO_HZ2OW3P9^'%_\
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M_P _I_\ @3_S.D_X4=X7_P"@7_Y,S?\ Q5'_  H[PO\ ] O_ ,F9O_BJXO\
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M,W_Q5'_"CO"__0+_ /)F;_XJNLHH_P!5\F_Z!*7_ (+A_D']JXW_ )_3_P#
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MG)_\*.\+_P#0+_\ )F;_ .*H_P"%'>%_^@7_ .3,W_Q5=911_JODW_0)2_\
M!</\@_M7&_\ /Z?_ ($_\SD_^%'>%_\ H%_^3,W_ ,51_P *.\+_ /0+_P#)
MF;_XJNLHH_U7R;_H$I?^"X?Y!_:N-_Y_3_\  G_F<G_PH[PO_P! O_R9F_\
MBJLZ1\)?#^@ZE#>6NG^5<0'<C^?(VT].A8BNCHJJ?#>4TYJ<,+333NFH1336
MS3MN*69XR2<959-/^\_\SE9O@IX9N)FD;3-S.2S'[1+R3_P*F_\ "CO"_P#T
M"_\ R9F_^*KK**E\,Y.W=X2E_P""X?Y!_:F-_P"?TO\ P)_YG)_\*.\+_P#0
M+_\ )F;_ .*H_P"%'>%_^@7_ .3,W_Q5=911_JODW_0)2_\ !</\A_VKC?\
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MY,+35U9VA%73W6VS[$RS+%R^*K+_ ,"?^9R?_"CO"_\ T"__ "9F_P#BJ/\
MA1WA?_H%_P#DS-_\57645'^J^3?] E+_ ,%P_P BO[5QO_/Z?_@3_P SD_\
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M;:]DKVNS"OBJU:WMIN5MKMO\R/X[?\?_ ('_ .QEM?Y/7H%>?_';_C_\#_\
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MXP\"?$+X07>GV_BCPUXDCLFNK%-0M!=V4ZSV-S=6DL<T>_ 2<R(8F#HF4+>
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M\5=<^)O_ "#?L7]D?VEY'^A?ZV3SO*\G_6_)OW?ZM<<^ ?MJ?\$D?CM^V_\
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M.R:ZL4U"T%W93K/8W-U:2QS1[\!)S(AB8.B90M[A7S?^Q?\ L'ZK^SA^T/\
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MX2&9C-_:U\;J6*\\F&21%^SVEGN<JYP%,;??] !1110 4444 %%%% !1110
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M_P"@Y_Y)7'_QNO0** //_P#AJ3P)_P!!S_R2N/\ XW1_PU)X$_Z#G_DE<?\
MQNO0** //_\ AJ3P)_T'/_)*X_\ C='_  U)X$_Z#G_DE<?_ !NO0** //\
M_AJ3P)_T'/\ R2N/_C='_#4G@3_H.?\ DE<?_&Z] HH \_\ ^&I/ G_0<_\
M)*X_^-T?\-2>!/\ H.?^25Q_\;KT"B@#S_\ X:D\"?\ 0<_\DKC_ .-T?\-2
M>!/^@Y_Y)7'_ ,;KT"B@#S__ (:D\"?]!S_R2N/_ (W1_P -2>!/^@Y_Y)7'
M_P ;KT"B@#S_ /X:D\"?]!S_ ,DKC_XW1_PU)X$_Z#G_ ))7'_QNO0** //_
M /AJ3P)_T'/_ "2N/_C='_#4G@3_ *#G_DE<?_&Z] HH \__ .&I/ G_ $'/
M_)*X_P#C='_#4G@3_H.?^25Q_P#&Z] HH \__P"&I/ G_0<_\DKC_P"-T?\
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M^25Q_P#&Z] HH \__P"&I/ G_0<_\DKC_P"-T?\ #4G@3_H.?^25Q_\ &Z]
MHH \_P#^&I/ G_0<_P#)*X_^-T?\-2>!/^@Y_P"25Q_\;KT"B@#S_P#X:D\"
M?]!S_P DKC_XW1_PU)X$_P"@Y_Y)7'_QNO0** //_P#AJ3P)_P!!S_R2N/\
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M@"Q15?\ M:U_Y^K?_OX*/[6M?^?JW_[^"@"Q15?^UK7_ )^K?_OX*/[6M?\
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MJC/+.'.#\PC4G@\#0DJ<YTY?N8*TX/EDM8*]FK75T^C:.]_X:>\>?]#%<_\
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M^8O_ (FN"HH_UHSK_H+J_P#@R?\ F'^HO#7_ $+Z'_@FG_\ (G>_\-/>//\
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M_P#R)WO_  T]X\_Z&*Y_[\Q?_$T?\-/>//\ H8KG_OS%_P#$UP5%'^M&=?\
M075_\&3_ ,P_U%X:_P"A?0_\$T__ )$[W_AI[QY_T,5S_P!^8O\ XFC_ (:>
M\>?]#%<_]^8O_B:X*BC_ %HSK_H+J_\ @R?^8?ZB\-?]"^A_X)I__(G>_P##
M3WCS_H8KG_OS%_\ $T?\-/>//^ABN?\ OS%_\37!44?ZT9U_T%U?_!D_\P_U
M%X:_Z%]#_P $T_\ Y$[W_AI[QY_T,5S_ -^8O_B:/^&GO'G_ $,5S_WYB_\
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M'X>_MI^,/A[I/Q1MTBT;5)OB]#+'KUU>6S><&D%P'DA$3HB,3=2'!4J"%PH
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M'EGI6_\ <1P'_!1?PIJ'CK]GZ31=)MFO-4U:=[2T@5@K32O;S*J@D@#)(')
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MR?QAXITW2;5HH[G5+J*SB:4D1J\CA%+$ G&2,X!..U9]6M"M+6_UNS@OKO\
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MK,HIU\-5DE=6NDGK9J255*2;6JDFG;8^8Z*^G/\ A6WPQ_Z%'4/_  ;RT?\
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MHI7?2[2[M'FYSQMAZV7UZ2H5$Y0DKM0LKQ:UM-O\#Y/\5_\ (TZE_P!?4O\
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MC^UO^$=U_1=>_L'4IM'U/^SKZ*Z_LZ^AQYMK-Y;'RYTW+NC;#+N&0,BOS/\
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MO*0AGV [%()P.:_/?_@IQ^W=X[\&_M37?PY\!_'#_A"O$&CZ;:W&E^"?A_\
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M[,G_ "0W0?\ <E_]'25X4_W#]*]U_9D_Y(;H/^Y+_P"CI*_=/!GX<7_W#_\
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M96VO"7[;;6K7"998=CM$\JES)+)<-^@W_"F_$W_0*F_[^)_\51_PIOQ-_P!
MJ;_OXG_Q5>A3H\1P<G&A4]Y1B[TKJT(\L&DXM*44K*2M):N]VSGE4RV5KU(Z
M-OX[?$[O9ZIO=/3R/A/XR?\ !+_QQXG_ &M?'_Q'^'?[0?BCX5:3\7[;2[7Q
MQI&G>'K.\OK]+*W:T4V.H2$26#FV8A)$1WCE9I-S#9&G+_!__@C+K'P0T+]E
M6WT/XP?9[W]FC4M=N9+K_A%$?_A*+75KL2W5ML>Y86N;<RV_F#S6'F^8NQE
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MI?%3Q!>*@^()N;?0--\/Z;IT]YK&JW%U'-"D$=F@MI'+2%VC:3RXI6&%\_\
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M6>18[=I)&*",*9&5&\@^&_[??@W_ (+/?\%B_P!D7QG\!=+\8>(/"GP&\/\
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M_H=-/_\ !0G^-%% !_PAGQ!_Z'33_P#P4)_C1_PAGQ!_Z'33_P#P4)_C110
M?\(9\0?^ATT__P %"?XT?\(9\0?^ATT__P %"?XT44 '_"&?$'_H=-/_ /!0
MG^-'_"&?$'_H=-/_ /!0G^-%% !_PAGQ!_Z'33__  4)_C1_PAGQ!_Z'33__
M  4)_C110 ?\(9\0?^ATT_\ \%"?XT?\(9\0?^ATT_\ \%"?XT44 '_"&?$'
M_H=-/_\ !0G^-'_"&?$'_H=-/_\ !0G^-%% !_PAGQ!_Z'33_P#P4)_C1_PA
MGQ!_Z'33_P#P4)_C110 ?\(9\0?^ATT__P %"?XT?\(9\0?^ATT__P %"?XT
M44 '_"&?$'_H=-/_ /!0G^-'_"&?$'_H=-/_ /!0G^-%% !_PAGQ!_Z'33__
M  4)_C1_PAGQ!_Z'33__  4)_C110 ?\(9\0?^ATT_\ \%"?XT?\(9\0?^AT
MT_\ \%"?XT44 '_"&?$'_H=-/_\ !0G^-'_"&?$'_H=-/_\ !0G^-%% !_PA
MGQ!_Z'33_P#P4)_C1_PAGQ!_Z'33_P#P4)_C110 ?\(9\0?^ATT__P %"?XT
M?\(9\0?^ATT__P %"?XT44 '_"&?$'_H=-/_ /!0G^-'_"&?$'_H=-/_ /!0
MG^-%% !_PAGQ!_Z'33__  4)_C1_PAGQ!_Z'33__  4)_C110 ?\(9\0?^AT
MT_\ \%"?XT?\(9\0?^ATT_\ \%"?XT44 '_"&?$'_H=-/_\ !0G^-'_"&?$'
M_H=-/_\ !0G^-%% !_PAGQ!_Z'33_P#P4)_C1_PAGQ!_Z'33_P#P4)_C110
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,(SCCV#8_"BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>slide11.jpg
<TEXT>
begin 644 slide11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W$^-'Q
M^T3X%0:?)K$6H3?VDT@A6UC1B-FW<3N90/OKWSS7 _\ #PCP3_SX^(O^_,'_
M ,>KEO\ @I+_ ,>7A+_M\_G;U\I5_._BYXU8WA#.*>6X;#0J*=*-2\FT[N<X
MVTZ>[?YGZGP/X?X?/<#/%U:LH.,W&R2>T8N^OJ?:W_#PCP3_ ,^/B+_OS!_\
M>H_X>$>"?^?'Q%_WY@_^/5\4T5^6_P#$U.:_] -/_P "D?9?\08P7_03/[D?
M:W_#PCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X]7Q311_Q-3FO_0#3
M_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\ OS!_\>H_X>$>"?\ GQ\1?]^8
M/_CU?%-%'_$U.:_] -/_ ,"D'_$&,%_T$S^Y'VM_P\(\$_\ /CXB_P"_,'_Q
MZC_AX1X)_P"?'Q%_WY@_^/5\4T4?\34YK_T T_\ P*0?\08P7_03/[D?:W_#
MPCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X]7Q311_Q-3FO_0#3_P#
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M$7_?F#_X]7Q311_Q-3FO_0#3_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\
MOS!_\>H_X>$>"?\ GQ\1?]^8/_CU?%-%'_$U.:_] -/_ ,"D'_$&,%_T$S^Y
M'VM_P\(\$_\ /CXB_P"_,'_QZC_AX1X)_P"?'Q%_WY@_^/5\4T4?\34YK_T
MT_\ P*0?\08P7_03/[D?:W_#PCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?
MF#_X]7Q311_Q-3FO_0#3_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\ OS!_
M\>H_X>$>"?\ GQ\1?]^8/_CU?%-%'_$U.:_] -/_ ,"D'_$&,%_T$S^Y'VM_
MP\(\$_\ /CXB_P"_,'_QZC_AX1X)_P"?'Q%_WY@_^/5\4T4?\34YK_T T_\
MP*0?\08P7_03/[D?:W_#PCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X
M]7Q311_Q-3FO_0#3_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\ OS!_\>H_
MX>$>"?\ GQ\1?]^8/_CU?%-%'_$U.:_] -/_ ,"D'_$&,%_T$S^Y'VM_P\(\
M$_\ /CXB_P"_,'_QZC_AX1X)_P"?'Q%_WY@_^/5\4T4?\34YK_T T_\ P*0?
M\08P7_03/[D?:W_#PCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X]7Q3
M11_Q-3FO_0#3_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\ OS!_\>H_X>$>
M"?\ GQ\1?]^8/_CU?%-%'_$U.:_] -/_ ,"D'_$&,%_T$S^Y'VM_P\(\$_\
M/CXB_P"_,'_QZC_AX1X)_P"?'Q%_WY@_^/5\4T4?\34YK_T T_\ P*0?\08P
M7_03/[D?:W_#PCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X]7Q311_Q
M-3FO_0#3_P# I!_Q!C!?]!,_N1]K?\/"/!/_ #X^(O\ OS!_\>H_X>$>"?\
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MPCP3_P ^/B+_ +\P?_'J/^'A'@G_ )\?$7_?F#_X]7Q311_Q-3FO_0#3_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J2U_X^8_]X?SJ.I+7_CYC_P!X?SKV.'?^
M1KA?^OD/_2D<.:?[E6_PR_)GZ1?!;_DCGA/_ + UG_Z(2BCX+?\ )'/"?_8&
ML_\ T0E%?ZV'\0G@W_!27_CR\)?]OG\[>OE*OJ[_ (*1J7M/"(4%C_IG 'O;
MU\J_99/^><G_ 'R:_AOZ3&58W$\44*F&HSFOJ\%>,6U?VE72Z3UU1_17A'C<
M/1R>I&K.,7[66C:7V(=R.BI/LLG_ #SD_P"^31]ED_YYR?\ ?)K^=_\ 5W-?
M^@:I_P" 2_R/U3^U,%_S^C_X$O\ ,CHJ3[+)_P \Y/\ ODT?99/^><G_ 'R:
M/]7<U_Z!JG_@$O\ (/[4P7_/Z/\ X$O\R.BI/LLG_/.3_ODT?99/^><G_?)H
M_P!7<U_Z!JG_ (!+_(/[4P7_ #^C_P"!+_,CHJ3[+)_SSD_[Y-'V63_GG)_W
MR:/]7<U_Z!JG_@$O\@_M3!?\_H_^!+_,CHJ3[+)_SSD_[Y-'V63_ )YR?]\F
MC_5W-?\ H&J?^ 2_R#^U,%_S^C_X$O\ ,CHJ3[+)_P \Y/\ ODT?99/^><G_
M 'R:/]7<U_Z!JG_@$O\ (/[4P7_/Z/\ X$O\R.BI/LLG_/.3_ODT?99/^><G
M_?)H_P!7<U_Z!JG_ (!+_(/[4P7_ #^C_P"!+_,CHJ3[+)_SSD_[Y-'V63_G
MG)_WR:/]7<U_Z!JG_@$O\@_M3!?\_H_^!+_,CHJ3[+)_SSD_[Y-'V63_ )YR
M?]\FC_5W-?\ H&J?^ 2_R#^U,%_S^C_X$O\ ,CHJ3[+)_P \Y/\ ODT?99/^
M><G_ 'R:/]7<U_Z!JG_@$O\ (/[4P7_/Z/\ X$O\R.BI/LLG_/.3_ODT?99/
M^><G_?)H_P!7<U_Z!JG_ (!+_(/[4P7_ #^C_P"!+_,CHJ3[+)_SSD_[Y-'V
M63_GG)_WR:/]7<U_Z!JG_@$O\@_M3!?\_H_^!+_,CHJ3[+)_SSD_[Y-'V63_
M )YR?]\FC_5W-?\ H&J?^ 2_R#^U,%_S^C_X$O\ ,CHJ3[+)_P \Y/\ ODT?
M99/^><G_ 'R:/]7<U_Z!JG_@$O\ (/[4P7_/Z/\ X$O\R.BI/LLG_/.3_ODT
M?99/^><G_?)H_P!7<U_Z!JG_ (!+_(/[4P7_ #^C_P"!+_,CHJ3[+)_SSD_[
MY-'V63_GG)_WR:/]7<U_Z!JG_@$O\@_M3!?\_H_^!+_,CHJ3[+)_SSD_[Y-'
MV63_ )YR?]\FC_5W-?\ H&J?^ 2_R#^U,%_S^C_X$O\ ,CHJ3[+)_P \Y/\
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MCHJ3[+)_SSD_[Y-'V63_ )YR?]\FC_5W-?\ H&J?^ 2_R#^U,%_S^C_X$O\
M,CHJ3[+)_P \Y/\ ODT?99/^><G_ 'R:/]7<U_Z!JG_@$O\ (/[4P7_/Z/\
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M,%_S^C_X$O\ ,CHJ3[+)_P \Y/\ ODT?99/^><G_ 'R:/]7<U_Z!JG_@$O\
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MZ!JG_@$O\@_M3!?\_H_^!+_,CHJ3[+)_SSD_[Y-'V63_ )YR?]\FC_5W-?\
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M-_Z%+PS_ ."N#_XFC_A2W@W_ *%+PS_X*X/_ (FNFHH YG_A2W@W_H4O#/\
MX*X/_B:/^%+>#?\ H4O#/_@K@_\ B:Z:B@#F?^%+>#?^A2\,_P#@K@_^)H_X
M4MX-_P"A2\,_^"N#_P")KIJ* .9_X4MX-_Z%+PS_ ."N#_XFC_A2W@W_ *%+
MPS_X*X/_ (FNFHH YG_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#/_@K@_\
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MC_A2W@W_ *%+PS_X*X/_ (FNFHH YG_A2W@W_H4O#/\ X*X/_B:/^%+>#?\
MH4O#/_@K@_\ B:Z:B@#F?^%+>#?^A2\,_P#@K@_^)H_X4MX-_P"A2\,_^"N#
M_P")KIJ* .9_X4MX-_Z%+PS_ ."N#_XFC_A2W@W_ *%+PS_X*X/_ (FNFHH
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M-_Z%+PS_ ."N#_XFC_A2W@W_ *%+PS_X*X/_ (FNFHH YG_A2W@W_H4O#/\
MX*X/_B:/^%+>#?\ H4O#/_@K@_\ B:Z:B@#F?^%+>#?^A2\,_P#@K@_^)H_X
M4MX-_P"A2\,_^"N#_P")KIJ* .9_X4MX-_Z%+PS_ ."N#_XFC_A2W@W_ *%+
MPS_X*X/_ (FNFHH YG_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#/_@K@_\
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MO^%6?8]$U'PI=>&[SPQ?^%XFM4DLHFTN\@MY[>W>WV^2WE")U1@A/EL%]@H
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MQ_P4>_X-$[KX"?"?7_!^O?%BQM)[B[\/'6X$NK%T\77.I007*@DVTEU!:R"
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M>;Y/VB1/,V>;'NVYV^8F<;AGT"@ HKS_ ,?_ +6/PL^%'Q3T7P+XI^)?P_\
M#7C;Q+Y']D>'M5\0VEGJNJ^?,T$'V>VDD667S)E:--BG<ZE1D@BCXZ?M8_"S
M]E_^R_\ A9GQ+^'_ ,._[<\W^S?^$G\0VFD?VAY6SS?)^T2)YFSS8]VW.WS$
MSC<,@'H%%<_XB^+/A7PAX[\.^%M6\3>']+\3>,/M/]@Z1=ZC#!?ZW]FC$MS]
ME@9A)/Y49#R>6&V*06P.:Z"@#YO_ &WO G[4;>*M#\3?LW>./A?')':/I>L>
M#OB5ILS:!."_FIJ=O=6""_CO$V^287D>WDCEW!8Y(LR_.'_#D+Q5_P .P/\
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M\IUW_P#&J/\ AM7X9_\ 0S?^4Z[_ /C5'_$1.%?^AGA__!U/_P"2#_5;.O\
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M?_" Z?!_PG>CK<7$DFD?8U?RK#S(9+>+[3"3(OV;>!F1L=)B?ECIO[%_PO\
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M\**OOV?]5@UKPDFM1WVC74_VA]1B6UN=/$6J//)<RRSOYL<TD^XPJP8O]O\
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MM_$WQ-U;Q";SQ[J3M;/:VTYU-DRLEE RI:A4$<.P,$+O(S^!_P##^;_JE/\
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M!]/O/+\K1-$\16TUA9;8U0^6U[:7-R=[*7/F3/\ ,[!=J[54 ^_M-^%OP/\
MV._BGK/C:WL?A_\ #'Q-\:M5L-$O[SSH-(_X3'5O.O9K6+RRR1W&H2R7=XVY
M5-Q/NPQ<1H%]@KX _86_X-G?V4_V#O'>B^+])\,^(/'GC;PUJIU?1]>\8:J;
MR;3)1&J1A+:!(+-O*8&6-Y+=Y8Y6WK("D6S[_H **** "BBB@ HKY/\ VWO^
M"D7B;X#_ !]T/X-?!KX.ZA\>OC1J7A]_&E]X;3Q):>&+72/#Z7/V/[=)?7BF
M*21[MEB2WB#/A97<QA8Q+P'BS_@O%X-\%_L&:E\4KSP'XPF^)>D^-9?A)/\
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M_P <OS"BBBOP8_2@HHHH ^?_ -JO_DH=G_V#D_\ 1LM>9UZ9^U7_ ,E#L_\
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MEU2N\H **** "BBB@ HHHH **** "BBB@ HHHH **** / _^"BW_ "1/2_\
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M?]OW_MM7%X^?\D'CO^X7_IZF?!>&?_)28;_M_P#]-S/EFBBBO\W#^L0HHHH
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M 7G_ ,E4?\/P?BQ_T+_P\_\  "\_^2J^-J*/^(A<1_\ 09/[U_D'_$(.#?\
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M5E2EO%M/Y.P4445TF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!^ZO[(O_ ":A\,/^Q2TK_P!(XJ]#KSS]D7_DU#X8?]BEI7_I'%7H=?WWD_\
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MF2>ZGU06-@TLZL]Y=GRS UJH'F*,QM\@SN;[OH **** "BBB@ HHHH ****
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M_P# _P#TJ)QE%%%?I9^N!1110 5_0Q7\\]?T,5_0W@+_ ,QW_<+_ -R'\?\
MTKO^97_W'_\ <(5ROQS_ .2)^,?^P'>_^B'KJJY7XY_\D3\8_P#8#O?_ $0]
M?MW$7_(JQ/\ U[G_ .DL_D[*O]]H_P"./YH_-VBBBO\ ),_MT**** "O,_VJ
M_P#DGEG_ -A%/_14M>F5YG^U7_R3RS_["*?^BI:];(?^1A2]3W.&_P#D9T?\
M1\_T445^Q'[P%%%% !7Z&?\ !!G_ )JM_P!PC_V^K\\Z_0S_ ((,_P#-5O\
MN$?^WU?H?A3_ ,E3A?\ M_\ ]-S/Q_Q[_P"2$QW_ '"_]/4S]#****_LD_S?
M/B__ (*+?\ELTO\ [ <7_H^XKP.O?/\ @HM_R6S2_P#L!Q?^C[BO Z_S$\8/
M^2SS'_KX_P D?V!P+_R(,+_@7YL****_-CZP**** /J/]MK]M;_AW;_P2/\
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M/$FLVVE6LUPR.ZPK+.Z(TA2.1@@.2(V.,*<:'_"V?"O_  JS_A.O^$F\/_\
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M@\2W$C-?^'M0T^$@:-J:G;+/"D;'+#"JQ)&2 0"1[!0 4444 %%%% !1110
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M8?\ !#[_ ).O\0?]BE<_^EEE7ZGU_7'@Y_R3D?\ '/\ -'^>_P!([_DLI_\
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MI:],KS/]JO\ Y)Y9_P#813_T5+7K9#_R,*7J>YPW_P C.C_B/G^BBBOV(_>
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M?MYQN/B'[3?[;W[27Q9_;S\4_ W]D_0_@?>2?"/P_8:I\0_$'Q*FU1;6QO\
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MHK^^S_)<_$']M[QA^R%\,M'_ &M/A/X__9U\/_#[]J3XCZKXHE^'\%]X9O\
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M]NXB_P"15B?^O<__ $EG\G95_OM'_''\T?F[1117^29_;H4444 %>9_M5_\
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M?^WU?GG7Z&?\$&?^:K?]PC_V^K]#\*?^2IPO_;__ *;F?C_CW_R0F._[A?\
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M#(! )!]@H _-WXY_\EL\8_\ 8<O?_1[URM=5\<_^2V>,?^PY>_\ H]ZY6O\
M)/B+_D:XG_KY/_TIG]NY5_N5'_!'\D%%%%>.=X5B_$?_ ))YKW_8.N/_ $4U
M;58OQ'_Y)YKW_8.N/_135T87^/#U7YG5@O\ >*?^)?F?)M%%%?N!_104444
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M?\C7$_\ 7R?_ *4PK\LZ_4RORSK^3OI8?\RO_N/_ .X3]>\%/^8S_N'_ .Y
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MC_B/G^BBBOV(_> HHHH *_0S_@@S_P U6_[A'_M]7YYU^AG_  09_P":K?\
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MP"UCXC?#G1_&&BZ)HOB";PW/!XDM;:VNGN(K:VN&=5@GF0QE+J, EP<AOE
M)^D*^;_^"7_Q+_:7^*GP"UC4/VJ/A[X/^&OQ"A\036^GZ9X;N4GM9]+%M;-%
M.S)>78\PSM=*1YBG$:_(,[F^D* "BBB@ HHHH **** "BBB@ HHHH X/XO\
M_)0?A7_V-$__ *9=4KO*X/XO_P#)0?A7_P!C1/\ ^F75*[R@#\W?CG_R6SQC
M_P!AR]_]'O7*UU7QS_Y+9XQ_[#E[_P"CWKE:_P D^(O^1KB?^OD__2F?V[E7
M^Y4?\$?R04445XYWA6+\1_\ DGFO?]@ZX_\ 135M5B_$?_DGFO?]@ZX_]%-7
M1A?X\/5?F=6"_P!XI_XE^9\FT445^X']%!1110 5]#?\$J/^3^/ ?_<0_P#3
M==5\\U]#?\$J/^3^/ ?_ '$/_3==5]%PC_R/<%_U^I_^EQ/C_$+_ ))7,_\
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M?\"_-A1117YL?6!1110!\F_$?_DH>O?]A&X_]&M6+6U\1_\ DH>O?]A&X_\
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MAQJ-G=Z5H=G96EF$M)$M;V\CMKB&1YHVMR\;1I'$#$H(+?7] !1110 4444
M%%%% !1110 4444 <'\7_P#DH/PK_P"QHG_],NJ5WE<'\7_^2@_"O_L:)_\
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M_P#I*/\ )?B+_D:XG_KY/_TIA7Y9U^IE?EG7\G?2P_YE?_<?_P!PGZ]X*?\
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M_<A_'_TKO^97_P!Q_P#W"%<K\<_^2)^,?^P'>_\ HAZZJN5^.?\ R1/QC_V
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MU?\ DV;Q-_VZ_P#I7#7P-7\&_2B_Y*K#_P#8/#_TY5/Z4\'/^1+5_P"OLO\
MTB 4445_-I^L!1110!XS^US_ ,R__P!O/_M*O&:]F_:Y_P"9?_[>?_:5>,U^
MM<,_\BVG_P!O?^E,_;^#_P#D44O^WO\ TJ04445[Q]*%%%% 'ZG_ /!#[_DU
M#Q!_V-MS_P"D=E7V37QM_P $/O\ DU#Q!_V-MS_Z1V5?9-?VUX>_\DY@_P#
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M_ _SB?<< _\ (PG_ ('_ .E1.,HHHK]+/UP**** "OZ&*_GGK^ABOZ&\!?\
MF._[A?\ N0_C_P"E=_S*_P#N/_[A"N5^.?\ R1/QC_V [W_T0]=57*_'/_DB
M?C'_ + =[_Z(>OV[B+_D58G_ *]S_P#26?R=E7^^T?\ ''\T?F[1117^29_;
MH4444 %>9_M5_P#)/+/_ +"*?^BI:],KS/\ :K_Y)Y9_]A%/_14M>MD/_(PI
M>I[G#?\ R,Z/^(^?Z***_8C]X"BBB@ K]#/^"#/_ #5;_N$?^WU?GG7Z&?\
M!!G_ )JM_P!PC_V^K]#\*?\ DJ<+_P!O_P#IN9^/^/?_ "0F._[A?^GJ9^AE
M%%%?V2?YOGQ?_P %%O\ DMFE_P#8#B_]'W%>!U[Y_P %%O\ DMFE_P#8#B_]
M'W%>!U_F)XP?\EGF/_7Q_DC^P.!?^1!A?\"_-A1117YL?6!1110!\F_$?_DH
M>O?]A&X_]&M6+6U\1_\ DH>O?]A&X_\ 1K5BU^X87^!#T7Y']%8+_=Z?^%?D
M%%%%=!U!7H?[(O\ R=?\,/\ L;=*_P#2R*O/*]#_ &1?^3K_ (8?]C;I7_I9
M%7HY/_O]#_''_P!*1X_$7_(JQ/\ U[G_ .DL_=6BBBO[[/\ )<\L_;5_Y-F\
M3?\ ;K_Z5PU\#5]\_MJ_\FS>)O\ MU_]*X:^!J_@WZ47_)58?_L'A_Z<JG]*
M>#G_ "):O_7V7_I$ HHHK^;3]8"BBB@#QG]KG_F7_P#MY_\ :5>,U[-^US_S
M+_\ V\_^TJ\9K]:X9_Y%M/\ [>_]*9^W\'_\BBE_V]_Z5(****]X^E"BBB@#
M]3_^"'W_ ":AX@_[&VY_]([*OLFOC;_@A]_R:AX@_P"QMN?_ $CLJ^R:_MKP
M]_Y)S!_X%^;/\Q_%_P#Y++,?^OC_ "04445]D?FX4444 %%%% !1110 5^,.
MM_LL_P#!03_@EY^W#^T%K7[,?PP^#_QI\!?'SQ7+X[?5=;6RT^_TN>XGN96T
M^1GU"SN7\EIF #//!M*RQB"2>YCK]GJ_F1_:9M_V2_VOO^"HW[4=S^VU^TY\
M4-,UOP9XUG\->"(O"^C7#:99Z-;S7"BQ1_[.N'$EJ_[F6,6\$9F669)[TW+R
MH ?L?_P0"_X)Z^._^"=/[#VH:+\3KKP^/'OQ%\5WGCO6M*T2QM[2P\.3WD%K
M%_9\:VP6V/EK;*2+=$@C:1HH@T<:2/\ ;]?BC_P;A_\ !:/X/?#/]F#PI\"_
MB-\?=0\4>,M2\:R>&OAOI>I^&-374[31I98+32K&ZDB@FM89&E\QUC%Y<1V\
M,\,7GA(@D?[74 %%%% !1110!\W_ +;W[0W@']CKQ5H?BZS^'NG^/OVB/'UH
M_@OP%H6DVEM'XH\6A7^U/8B\9=]MI<#D7-U<2M]GMD!D8%VC23\\?VY_V3?^
M'<W[./[-FM?$;Q=X?D\3?$#]M7P_\6?B)JL+_8?#>BZC?+=RWB6;3GS(]/MX
MX% DN7+L$>5C&&$<?W]^VK_P1F_9L_X*)?%/3_&WQB^&_P#PF'B;2]*CT2UO
M/^$@U33_ "K..::9(O+M;F*,XDN)FW%2QWX)P !H?"?_ ()&?LZ_!/\ 9'\8
M? CP[\,]/A^$_CZ[EO\ 7?#]YJ-[J,=Y<21P1F82W$TDT4BBUMV1XG4Q20I(
MA20;J /E'XV> ?"O[6__  <7_$[X6WFM>9I_B#]D"]\&^)/[(O(3?Z1]NUY=
M\9R'$-Q]EO(ID61#\LT3E65AGX?_ ."Q'_!/;7O@=_P@/@&\^)?_  LOQ-HO
MP5AT'Q#I'A?P['X<MK3X8^$/-UBYFU*>:;59K;4+Z_M=.@L[Q(8K4SV\L3JP
M<I7[7?L0_P#!-[X)?\$X?"NN:/\ !?P#I_@JS\37:7NJ2)=W-]=7SQILC$EQ
M=22S&.,%RD>_RT,LK*H:1RW077[%_P +]5^,OC;X@:IX/T_7O%?Q#\/Q^$]=
MN]:DEU2.XT9 P.F107#R0V]G(79Y;>!(XYY#OE61_FH ^4/^";?_  4X^*G[
M0'[4_@GX9_$RT^'^I?\ "RO@!HWQTTW4O#&D7>C_ -B?;+M;:72YHKB\O/M6
M/-C9;A7@QY;@Q-O!3[_KP_\ 9?\ ^"<GP>_8Z\5-KO@/PSJ%KK:^'[7PG;:A
MK'B+4_$%UINC6KL\&F6DNH7$[VEFKMN^SP&.-BL9*DQIM]PH \?\9:IXOO?B
MU\,8]>T/PWINGKXEN#%-8:Y->S._]C:G@-&]I"%!7<20Y(( P<Y'L%<'\7_^
M2@_"O_L:)_\ TRZI7>4 ?F[\<_\ DMGC'_L.7O\ Z/>N5KJOCG_R6SQC_P!A
MR]_]'O7*U_DGQ%_R-<3_ -?)_P#I3/[=RK_<J/\ @C^2"BBBO'.\*Q?B/_R3
MS7O^P=<?^BFK:K%^(_\ R3S7O^P=<?\ HIJZ,+_'AZK\SJP7^\4_\2_,^3:*
M**_<#^B@HHHH *^AO^"5'_)_'@/_ +B'_INNJ^>:^AO^"5'_ "?QX#_[B'_I
MNNJ^BX1_Y'N"_P"OU/\ ]+B?'^(7_)*YG_V#UO\ TW(_9*BBBO[J/\KSP/\
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M?_[>?_:5>,U^M<,_\BVG_P!O?^E,_;^#_P#D44O^WO\ TJ04445[Q]*%%%%
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MK@_B_P#\E!^%?_8T3_\ IEU2N\H _-WXY_\ );/&/_8<O?\ T>]<K75?'/\
MY+9XQ_[#E[_Z/>N5K_)/B+_D:XG_ *^3_P#2F?V[E7^Y4?\ !'\D%%%%>.=X
M5B_$?_DGFO?]@ZX_]%-6U6+\1_\ DGFO?]@ZX_\ 135T87^/#U7YG5@O]XI_
MXE^9\FT445^X']%!1110 5]#?\$J/^3^/ ?_ '$/_3==5\\U]#?\$J/^3^/
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M?+-%%%?YN']8A1110 5\S?M!_P#)7M7_ .V/_HF.OIFOF;]H/_DKVK_]L?\
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MX'7^8GC!_P EGF/_ %\?Y(_L#@7_ )$&%_P+\V%%%%?FQ]8%%%% 'R;\1_\
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MOLFO[:\/?^2<P?\ @7YL_P Q_%__ )++,?\ KX_R04445]D?FX4444 %%%%
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M7S[2U?RW>>2,8C(S WS$Y"_2% !1110 4444 %%%% !1110 4444 <'\7_\
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MD=E7V37QM_P0^_Y-0\0?]C;<_P#I'95]DU_;7A[_ ,DY@_\  OS9_F/XO_\
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MS3$RCAJC3J3^Q+^9^1_:&5YG@U@Z2=6/PQ^TNR\S3HK,_P"$UT?_ *"VF?\
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MT?\ P)?YFG169_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C1_J[FO_0-4_\
M )?Y!_:F"_Y_1_\  E_F<_\ M!_\DAU?_MC_ .CHZ^9J^C/CEXCT_5_A;JEO
M:W]G=7$GE;8HIU=VQ,A. #DX )_"OGG^S;C_ )]YO^^#7Z-PADF8PP<E/#S7
MO/>$NT?(_5N!<\RVG@)J>(@GSO><5]F/F0T5-_9MQ_S[S?\ ?!H_LVX_Y]YO
M^^#7U?\ 9&/_ .?$_P#P&7^1]I_K%E7_ $$T_P#P./\ F0T5-_9MQ_S[S?\
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MMIG_ (%)_C1_PFNC_P#06TS_ ,"D_P :/]7<U_Z!JG_@$O\ (/[4P7_/Z/\
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M1C_^?$__  &7^1]%_K%E7_033_\  X_YD-%3?V;<?\^\W_?!H_LVX_Y]YO\
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M/XC>%[[Q!XP\ W=K")+?0]>EO;QMX7RHFTR_MPV"<M^\GB&!D_-GH"1UE%%
M!1110 4444 %%%>'_MO?\%(?@E_P3A\*Z'K'QH\?:?X*L_$UV]GI<;VES?75
M\\:;Y#';VL<LQCC!0/)L\M#+$K,&D0, >X45Q_P!^/W@W]J7X->'OB%\/?$.
MG^*O!OBJT%YIFIV;$QW"9*L"K /'(CJR/&X62.1'1U5U91V% !1110 4444
M%<G\%O"]]X0\'WEIJ$(AN)M>UF]50X;,5QJ=U<1-D$CYHY4..HS@X((KK**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OE_\ ;5TS]GW]DCXIZ?\ M5?$3PM_:GQ4T72H_ 7A.>RBFU+7
MM7EN9IFM](TBPW^7)J%Q)//&C1HLOERS!Y4@\TCZ@KY _;W_ ."-WA7_ (*
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M>)_C_;Z5J']G^)+O4=)FL-5N8+2XLH+BVBUB1;.1)WU"&1P7MRR]:/@GX_\
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MO')U>ZT![.5YX)].<0H(9!.8I6#K)'(;:$.C(&1@#X _8%^(OQM^"G_!8O\
M9TT=M1_;/T;X._&FT\4V<5G^T#XXMM8U/Q&FG:4;ES_8PB$FD26]Y&A61W:2
MXA>-D9(Y)4?P_P 0?#GXC_%?_@U5\=?M"?$SX^_&#XEZMXLTJ#0;#PWK>LM/
MHFE6<7CNR FD1]\MWJ'G6T^+R63<MO<K;A=D*&OU?_9]_P""#GPX^!'[6/P_
M^-]]\4/V@/B9\3?AW_:,-AK7CSQBNN375G=V<EJ+&7? ,6\'GW4T2P^6WFW<
MID:5=B)T'_#E3X6?\.GO^&.?[?\ B!_PK+_H)_;K3^WO^0Q_:_\ K?LWD?\
M'Q\O^H_U?'WOGH ^</VB?^"BOB'_ ((P_&7]JS0?B1XLU#6M$\8>'[SXN? _
M5?%L][JEO-JDH2SNO"F_='^[AU![.2"RLD(M[*XDFFG0'<OV]_P37^#?C+X
M_L&?"KPK\1M?\8>)OB%8^'X+CQ/>^*-;&M:F-4N,W-W ]V"PEC@GFD@B(9P(
M88EWOC>?D#_@IQ\)KC_@J!_P45^!_P #9O@'XP/A3X+^-;?QYXL^)_B7PK!+
MX7O=+ALH[AM$L996Q>QW\\UO;7,893&]J&,%PD+M%^E] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMX\^-5E\+?&MA?:+KHL%:>:XD6QTP0B=EU"6Q-C+'-<2&S5I)1)(A&Q?C_\
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MMZ;)'A\F%Q-(9P^88BTRQQR2E!%&\B_DC\7/CM\./V*_ G_!13]G7XM_#/Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_^.G[)WPL_:@_LO\
MX69\-/A_\1/[#\W^S?\ A)_#UIJ_]G^;L\WR?M$;^7O\J/=MQN\M,YVC'H%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPO\ CQ\2K14\3_$?X>:_J+2?:+/4;JYTN2#SC"5CC@F2&:.%+<S1O,A<%EE
M!P'_  2/^!/PC_X)M_MYZ+X#U3]E;QA^SS\0OB;X?U/0? 'BS6_B)'XNNOB-
M9:=]GN]0%];64\EII=XT<5I=%43R21/''*NU$F^+_P#A07_&BC_AY/\ \)K\
M0/\ AL?_ (2O_A*O^$Z_MC_J8/[ _LW['L^R_P!G_9.?(\K_ *8[OLO^BU^I
M_P !OV(?VDOCI^VU\,_C1^U1KGP/L[SX#VFL)X(TOX50ZIY>I7&L6R6EY)J4
MFHY(CB@B7RHX%!:24LSJL6R7YP_X<(?M'?\ "B?^&0_^%R?#_P#X8E_X2O\
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MX1__ (3;^RK7_A(?["\[^RO[1\E/M/V3SOWOV?SM_E^9\^S;NYS704 %%%%
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M=0:G^\D8/;K:HJ>6\[(7',!Y>NO_ &F/V!OVO-?U'XP_#;X>_%;X7^(O@/\
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M_!;?P#\9/B!^QM8Q_!W6OB!I/]D^*],U7QQ#X O%M/&6J^%X6=M0MM%D8?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>slide12.jpg
<TEXT>
begin 644 slide12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'?^WG_TJFHH_8\_Y-S\._\ ;S_Z5345_L(?PF<K_P %"/\ DB=C_P!A>/\
M]$7%?%-?:W_!0C_DB=C_ -A>/_T1<5\4U_$OTJ?^1K@?^O<O_2C^A?!C_<L3
M_C7Y!1117\JG[.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!^@'['G_ ";GX=_[>?\ TJFHH_8\_P"3
M<_#O_;S_ .E4U%?["'\)G8>/OASHOQ0T5-/UVR%]9QS"=8S*\>UP" <H0>C$
M=>]<?_PQY\.?^A=_\G[K_P".5Z910!YG_P ,>?#G_H7?_)^Z_P#CE'_#'GPY
M_P"A=_\ )^Z_^.5Z910!YG_PQY\.?^A=_P#)^Z_^.4?\,>?#G_H7?_)^Z_\
MCE>F44 >9_\ #'GPY_Z%W_R?NO\ XY1_PQY\.?\ H7?_ "?NO_CE>F44 >9_
M\,>?#G_H7?\ R?NO_CE'_#'GPY_Z%W_R?NO_ (Y7IE% 'F?_  QY\.?^A=_\
MG[K_ ..4?\,>?#G_ *%W_P G[K_XY7IE% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQ
MY\.?^A=_\G[K_P".5Z910!YG_P ,>?#G_H7?_)^Z_P#CE'_#'GPY_P"A=_\
M)^Z_^.5Z910!YG_PQY\.?^A=_P#)^Z_^.4?\,>?#G_H7?_)^Z_\ CE>F44 >
M9_\ #'GPY_Z%W_R?NO\ XY1_PQY\.?\ H7?_ "?NO_CE>F44 >9_\,>?#G_H
M7?\ R?NO_CE'_#'GPY_Z%W_R?NO_ (Y7IE% 'F?_  QY\.?^A=_\G[K_ ..4
M?\,>?#G_ *%W_P G[K_XY7IE% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQY\.?^A=_
M\G[K_P".5Z910!YG_P ,>?#G_H7?_)^Z_P#CE'_#'GPY_P"A=_\ )^Z_^.5Z
M910!YG_PQY\.?^A=_P#)^Z_^.4?\,>?#G_H7?_)^Z_\ CE>F44 >9_\ #'GP
MY_Z%W_R?NO\ XY1_PQY\.?\ H7?_ "?NO_CE>F44 >9_\,>?#G_H7?\ R?NO
M_CE'_#'GPY_Z%W_R?NO_ (Y7IE% 'F?_  QY\.?^A=_\G[K_ ..4?\,>?#G_
M *%W_P G[K_XY7IE% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQY\.?^A=_\G[K_P".
M5Z910!YG_P ,>?#G_H7?_)^Z_P#CE'_#'GPY_P"A=_\ )^Z_^.5Z910!YG_P
MQY\.?^A=_P#)^Z_^.4?\,>?#G_H7?_)^Z_\ CE>F44 >9_\ #'GPY_Z%W_R?
MNO\ XY1_PQY\.?\ H7?_ "?NO_CE>F44 >9_\,>?#G_H7?\ R?NO_CE'_#'G
MPY_Z%W_R?NO_ (Y7IE% 'F?_  QY\.?^A=_\G[K_ ..4?\,>?#G_ *%W_P G
M[K_XY7IE% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQY\.?^A=_\G[K_P".5Z910!YG
M_P ,>?#G_H7?_)^Z_P#CE'_#'GPY_P"A=_\ )^Z_^.5Z910!YG_PQY\.?^A=
M_P#)^Z_^.4?\,>?#G_H7?_)^Z_\ CE>F44 >9_\ #'GPY_Z%W_R?NO\ XY1_
MPQY\.?\ H7?_ "?NO_CE>F44 >9_\,>?#G_H7?\ R?NO_CE'_#'GPY_Z%W_R
M?NO_ (Y7IE% 'F?_  QY\.?^A=_\G[K_ ..4?\,>?#G_ *%W_P G[K_XY7IE
M% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQY\.?^A=_\G[K_P".5Z910!YG_P ,>?#G
M_H7?_)^Z_P#CE'_#'GPY_P"A=_\ )^Z_^.5Z910!YG_PQY\.?^A=_P#)^Z_^
M.4?\,>?#G_H7?_)^Z_\ CE>F44 >9_\ #'GPY_Z%W_R?NO\ XY1_PQY\.?\
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M^.5Z910!YG_PQY\.?^A=_P#)^Z_^.4?\,>?#G_H7?_)^Z_\ CE>F44 >9_\
M#'GPY_Z%W_R?NO\ XY1_PQY\.?\ H7?_ "?NO_CE>F44 >9_\,>?#G_H7?\
MR?NO_CE'_#'GPY_Z%W_R?NO_ (Y7IE% 'F?_  QY\.?^A=_\G[K_ ..4?\,>
M?#G_ *%W_P G[K_XY7IE% 'F?_#'GPY_Z%W_ ,G[K_XY1_PQY\.?^A=_\G[K
M_P".5Z910!F^$/"&G> O#MOI.DVWV33[3=Y46]GV;F+'EB2<LQ/)[T5I44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/!:_9[B5',%E]G::6<RLQ=2]>0?!+X?:E\<?AM_P3/\ VA/@;H_B#XR?#GX
M^%=;\,ZM96J6.A>)+OSM"311.MKJ%W#:+Y-Y82QS(+QL%E,+7$>9*^C_ -IO
M_@EW\1-=_:?\4_%S]G?]H34/V>?%?Q-M+"W\?J_@NP\76OB=].B:#3YXTO64
MV<D4$DD3B)O+E B.Q75WD]O_ &7/V.M!_87_ &-M#^#OPCF_L?3_  CI5Q::
M)>ZZDFK8O)6EF:[NXUD@,V^ZE>:2**2!3O9(S"NT( ?AC_P21\=^)OV7/V\_
M@1\(?B5X'U#Q]K?[.OA_Q)X.\":#X(U*TO&N?&.I^9KGB"9=0G>STTR:;I=P
MFFWMI-?2^5<&!H(Y#*\D7[O?L7_M>^#?V]/V8/!_Q<^'\VH3>%/&EH]Q:+?V
MIMKJV>.5X)X)4)($D4\4L3%&:-C&2CNA5V^4/ /_  0Q_P"%%Z/^SWKW@/XH
M[?B[\#=5\1Z[J'BWQ7X;_MJ'Q]J/B&U:'5KS4H(;JUN9+AF$/D2M>.\<4"1R
M&XP'7Z/_ .";W[$.E_\ !.']B7P#\%]'US4/$UGX*M)DDU2\A2&2^N+BYFN[
MB01KD1QF>>79&6<I'L5GD8%V .?_ ."N?[//@']JW_@G5\3/A_\ $[XA:?\
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M/U+6XK25]/M+^\>RM;JX"$Q1RSI%,\,;/M#2+%(5!)".1M/X^_\ #U?X^?\
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M QRH(9%B;:RIY;,_X;5^&?\ T,W_ )3KO_XU1_PVK\,_^AF_\IUW_P#&J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?^+'_"5?\ "K/$W_""_P#"/_\ ";?V5=?\(]_;OG?V5_:/DO\
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MUW_\:KX&HK\E_P")HN*O^@?#_P#@%3_Y:?<?\0=R7_G[5_\  H?_ "!]\_\
M#:OPS_Z&;_RG7?\ \:H_X;5^&?\ T,W_ )3KO_XU7P-11_Q-%Q5_T#X?_P
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M9:_0/#//\7D^=QQN":4U&2U5U9[Z'3A>$\OXCJ?V9F:;IOWO==G=;:GZ!_\
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M]M;6X* RQQ3O%"\T:ON"R-%&6 !*(3M !H4444 %%%% !1110 4444 %%%%
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MK*7CMX-TTTC,L<:  MODC1^/^#__  5Y^#?Q'_9Q\>_$CQ)>^(/A##\)]O\
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M*T445_$I_0H4444 8OQ'_P"2>:]_V#KC_P!%-7R;7UE\1_\ DGFO?]@ZX_\
M135\FU^B<%_P*GJOR/U3P_\ ]WJ_XE^04445]H?H 4444 ?0W_!*C_D_CP'_
M -Q#_P!-UU7[)5^-O_!*C_D_CP'_ -Q#_P!-UU7[)5_5'@?_ ,B*K_U^E_Z1
M3/X/^E!_R56'_P"P>'_IRJ%>!_\ !1;_ )(GI?\ V'(O_1%Q7OE>!_\ !1;_
M )(GI?\ V'(O_1%Q7M^,'_)&9C_U[?YH_&^!?^1_A?\ &OR9\7T445_F(?V
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M_MK_ (1;PSX?\-?\)+JL^NZO_96G0V?]JZC/M\^\N/+5?-N)-J[Y7R[;1DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME5F?_816_P#3D@K\W?CG_P EL\8_]AR]_P#1[U^D5?F[\<_^2V>,?^PY>_\
MH]Z_G?Z5/_(JP/\ U\E_Z2?;^#'^^XG_  +\SE:***_B4_H4**** ,7XC_\
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M?V7@O^?,?_ 5_D=5_P +S\;?]#AXJ_\ !M/_ /%T?\+S\;?]#AXJ_P#!M/\
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M2*.&/?@I )',K%W?"!?<***_H@_CP**** "BBB@ HHHH **^;_\ @H[_ ,%
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M+_X5UXF\4:5#JMYX8:]FO)M#\Y?,CMIWFM[:07"1L@EC:%?+E\Q 7"!V] H
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M4445^TG]!!1110 5]D_\$/O^3K_$'_8I7/\ Z665?&U?9/\ P0^_Y.O\0?\
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M-BY_T60):_:-,:S_ '=OY7EY^Y'+OKX _P""QW_!.OPK\+/'?ACX7^$O%7Q
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M/-DV[L[?,?&-QSZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Y0_MZ_LV?MS?LQ?\%5_%?[0W[,?AGX?_'#2?BAX5L_
M#DVC^+'MHIO T5F(,VUM+<7MM*EO/,LESMMIA%)+/.9[<O%;SO\ J]7\Z/\
MP5N\#_LE_&/_ (+O?'?2?VOOC7\4/"NFZ7X?\-MX.E\+)<75KH _L^-KK2KE
M)-/N7221YDO8A:(UOBZG,DJSL8@ ?I?_ ,$)_P!CK]H+X#?\+R^*'[1$WA_P
MWXP^/?BM?$;> /#R0KI7A66+SHY;D"VD>V^T7:M#YC(9)9$M8))[B:=Y!']_
MU^8/_!M[\&_V-OA)_P +F_X9)^+'Q ^*']H?V)_PE?\ PD]G+;_V9L_M#['Y
M._3K//F;[K=CS,>4GW,_-^GU !1110 4444 %%%% !1110 4444 <'^T=_R3
M[3_^QH\._P#IZL:[RN#_ &CO^2?:?_V-'AW_ -/5C7>4 %%>/_"W_@H3\ OC
MCX[L?"W@GXX?!_QAXFU3S/L>D:)XRT[4+^[\N-I9/+@AF:1]L:.YV@X5&)X!
M-=!X_P#VL?A9\*/BGHO@7Q3\2_A_X:\;>)?(_LCP]JOB&TL]5U7SYF@@^SVT
MDBRR^9,K1IL4[G4J,D$4 >@445Y__P -8_"S_A>W_"K?^%E_#_\ X6;_ -"C
M_P )#:?V]_Q[_:O^/+S//_X]_P!]]S_5_/\ =YH ] HKS_Q_^UC\+/A1\4]%
M\"^*?B7\/_#7C;Q+Y']D>'M5\0VEGJNJ^?,T$'V>VDD667S)E:--BG<ZE1D@
MBN@_X6SX5_X6G_P@O_"3>'_^$V_LK^W?^$>_M&'^U?[.\[R/MGV;=YOV?SOW
M?F[=F_Y<YXH Z"BBB@ HHHH **** "BBB@#RS]M7_DV;Q-_VZ_\ I7#7P-7W
MS^VK_P FS>)O^W7_ -*X:^!J_@WZ47_)58?_ +!X?^G*I_2G@Y_R):O_ %]E
M_P"D0"BBBOYM/U@**** /&?VN?\ F7_^WG_VE7C->S?M<_\ ,O\ _;S_ .TJ
M\9K]:X9_Y%M/_M[_ -*9^W\'_P#(HI?]O?\ I4@HHHKWCZ4**** /V2_X)4?
M\F#^ _\ N(?^G&ZKZ&KYY_X)4?\ )@_@/_N(?^G&ZKZ&K^ZN$?\ D18+_KS3
M_P#2(G^5_B%_R569_P#816_].2"OS=^.?_);/&/_ &'+W_T>]?I%7YN_'/\
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M3?\ !2W_ )DK_M^_]MJ^6:_S<\?/^2\QW_<+_P!,TS^L?#/_ ))O#?\ ;_\
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MOXATKP]:6>JZKY\RSS_:+F.-99?,F59'WL=SJ&.2 :^,_P#@@S_S5;_N$?\
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M$OBGI_C;XQ6?_"8>)M+TJ/1+6\\WQ+I_E6<<TTR1>7:F*,XDN)FW%2QWX)P
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MO_I7#7P-7WS^VK_R;-XF_P"W7_TKAKX&K^#?I1?\E5A_^P>'_IRJ?TIX.?\
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M36O$5C?Z?J%A<)<VM_;RV%V\4T4J$I)&Z,K*ZDA@002#7Y@5_(_C'_R4<O\
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M@_@/_N(?^G&ZKZ&KYY_X)4?\F#^ _P#N(?\ IQNJ^AJ_NKA'_D18+_KS3_\
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MBFQ_M3PSXPTJZT35[/SI(/M=G<PO#/%YD;+(FZ-V7<C*PSD$'!KH**_T,/\
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M^NYYH9)A<P.49(28XX'PZ21M7Z'U^6/_  ;5_LE^/OAAXJ_:2^-'BOX+:?\
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M:?$NP^._@8ZS<W-KX.M].N6CT:&YT!G:U\.1PRI;00);VUF "L*@HY1OW.H
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M_!*C_DP?P'_W$/\ TXW5?0U?W5PC_P B+!?]>:?_ *1$_P K_$+_ )*K,_\
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M7_D?X7_&OR9\7T445_F(?V %%%% !7S_ /M5_P#)0[/_ +!R?^C9:^@*^?\
M]JO_ )*'9_\ 8.3_ -&RU]-PG_R,%Z,^NX(_Y&:_PL\SHHHK]2/V8**** "O
MW5_9%_Y-0^&'_8I:5_Z1Q5^%5?NK^R+_ ,FH?##_ +%+2O\ TCBK]U\"_P#?
M\5_@7_I1_*_TJ/\ D58'_KY+_P!)/0Z***_I<_B<_+.BBBO\>S^[ HHHH *X
MS]H/_DD.K_\ ;'_T='79UQG[0?\ R2'5_P#MC_Z.CKORK_?:/^./YH]+)?\
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M?_813_T5+7S_ %^A<-XJOB,$JF(FYRN]9-M_>S]OX#HTZ65*%**BN:6B5E^
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ML/\ ]@\/_3E4*\#_ ."BW_)$]+_[#D7_ *(N*]\KP/\ X*+?\D3TO_L.1?\
MHBXKV_&#_DC,Q_Z]O\T?C? O_(_PO^-?DSXOHHHK_,0_L **** "OG_]JO\
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MQ?\ ^2-S'_KV_P T?J?1117]M'^8Y\L_\%+?^9*_[?O_ &VKY9KZF_X*6_\
M,E?]OW_MM7RS7^;GCY_R7F._[A?^F:9_6/AG_P DWAO^W_\ TY,****_'C[L
M**** /F;]H/_ )*]J_\ VQ_]$QUQE=G^T'_R5[5_^V/_ *)CKC*_:<J_W*C_
M ((_DC^@LE_Y%]#_  1_])04445WGI!1110!_0Q1117^AA_C^<K\<_\ DB?C
M'_L!WO\ Z(>OS=K](OCG_P D3\8_]@.]_P#1#U^;M?Q+]*G_ )&N!_Z]R_\
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MO_)J'PP_[%+2O_2.*OPJK]U?V1?^34/AA_V*6E?^D<5?NO@7_O\ BO\  O\
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M$/7YNU_$OTJ?^1K@?^O<O_2C^A?!C_<L3_C7Y!1117\JG[.%%%% 'F?[5?\
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MOXZ^(+"?PO\ #Q$N;>ZT*WL7U 2-);3J'@C=[L;%VQ!BDK16]O;FW4_J=7Y
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MOVU?^3F?$W_;K_Z20UY97J?[:O\ R<SXF_[=?_22&O+*_P J_$3_ )*K,_\
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MB_\ 1%Q7M^,'_)&9C_U[?YH_&^!?^1_A?\:_)GQ?1117^8A_8 4444 %?/\
M^U7_ ,E#L_\ L')_Z-EKZ KY_P#VJ_\ DH=G_P!@Y/\ T;+7TW"?_(P7HSZ[
M@C_D9K_"SS.BBBOU(_9@HHHH *_=7]D7_DU#X8?]BEI7_I'%7X55^ZO[(O\
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MF:BBBOVD_H(**** "OLG_@A]_P G7^(/^Q2N?_2RRKXVK[)_X(??\G7^(/\
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MR_\ 2(!1117\VGZP%%%% 'C/[7/_ #+_ /V\_P#M*O&:]F_:Y_YE_P#[>?\
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MZ7/XG/RSHHHK_'L_NP**** "N,_:#_Y)#J__ &Q_]'1UV=<9^T'_ ,DAU?\
M[8_^CHZ[\J_WVC_CC^:/2R7_ )&%#_''_P!*1\S4445^TG]!!1110 5]D_\
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M?3+J\M1=1V3WFHVMBTXC8[&DC2Y:1 X:/S$3>DB;D8 ^L**_+'X*_##XN?\
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MT?\ #*_PP_Z)QX#_ /"?M/\ XW7>44 <'_PRO\,/^B<> _\ PG[3_P"-T?\
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M YH P_\ AE?X8?\ 1./ ?_A/VG_QNC_AE?X8?]$X\!_^$_:?_&Z[RB@#@_\
MAE?X8?\ 1./ ?_A/VG_QNC_AE?X8?]$X\!_^$_:?_&Z[RB@#@_\ AE?X8?\
M1./ ?_A/VG_QNC_AE?X8?]$X\!_^$_:?_&Z[RB@#Q;X+?LJ^!4\'WG]L?#CP
MC]K_ +>UDQ_:] MC)]G_ +3NOL^-T>?+\CRMG;9MQQBNM_X97^&'_1./ ?\
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MF98TW2.B#<1EG4#D@4 8?_#*_P ,/^B<> __  G[3_XW1_PRO\,/^B<> _\
MPG[3_P"-UN?"WXL^%?CCX$L?%/@GQ-X?\8>&=4\S['J^B:C#J%A=^7(T4GES
MPLT;[9$=#M)PR,#R"*Z"@#@_^&5_AA_T3CP'_P"$_:?_ !NC_AE?X8?]$X\!
M_P#A/VG_ ,;KO** .#_X97^&'_1./ ?_ (3]I_\ &Z/^&5_AA_T3CP'_ .$_
M:?\ QNN\HH \6UG]E7P*?CIX<:'X<>$?[%&@ZJ+O9H%M]F^T?:--\C?^[V^9
ML^T;,\X\S'&ZNM_X97^&'_1./ ?_ (3]I_\ &Z[RB@#@_P#AE?X8?]$X\!_^
M$_:?_&Z/^&5_AA_T3CP'_P"$_:?_ !NN\HH X/\ X97^&'_1./ ?_A/VG_QN
MC_AE?X8?]$X\!_\ A/VG_P ;KO** .#_ .&5_AA_T3CP'_X3]I_\;H_X97^&
M'_1./ ?_ (3]I_\ &ZZSQ9XLTOP%X5U+7==U+3]%T31;26_U#4+^X2VM;"WB
M0O+-+*Y"1QHBLS.Q 4 DD 5S_P %/VA? /[2GA6XUWX<^./!_C_1+2[:PGU#
MPWK-MJMK#<*B.T+2P.Z+($DC8H3D"13C##(!3_X97^&'_1./ ?\ X3]I_P#&
MZ/\ AE?X8?\ 1./ ?_A/VG_QNH_ '[6/PL^*_P 4]:\"^%OB7\/_ !+XV\->
M?_:_A[2O$-I>:KI7D3+!/]HMHY&EB\N9EC?>HVNP4X) KT"@#@_^&5_AA_T3
MCP'_ .$_:?\ QNC_ (97^&'_ $3CP'_X3]I_\;KO** .#_X97^&'_1./ ?\
MX3]I_P#&Z/\ AE?X8?\ 1./ ?_A/VG_QNN\HH X/_AE?X8?]$X\!_P#A/VG_
M ,;KDO@)^RKX%3X%^"UUSX<>$?[:70;$:A]MT"V-S]H^SQ^;YNZ/=YF_=NW<
MYSGFO::* .#_ .&5_AA_T3CP'_X3]I_\;H_X97^&'_1./ ?_ (3]I_\ &Z[R
MB@#@_P#AE?X8?]$X\!_^$_:?_&Z/^&5_AA_T3CP'_P"$_:?_ !NN\HH X/\
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MT"V^S?:/M&I>?L_=[?,V?9]^.<>7GC;7M-% '!_\,K_##_HG'@/_ ,)^T_\
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M@B@##_X97^&'_1./ ?\ X3]I_P#&Z/\ AE?X8?\ 1./ ?_A/VG_QNN+\6?\
M!3;]FWP%XJU+0M=_:#^!^BZWHMW+8:AI]_XZTNVNK"XB<I+#+$\X>.1'5E9&
M *D$$ BN@^"G[;OP7_:4\57&A?#GXO?"_P ?ZW:6C7\^G^&_%5CJMU#;JZ(T
MS102NZQAY(U+D8!D49RPR :G_#*_PP_Z)QX#_P#"?M/_ (W1_P ,K_##_HG'
M@/\ \)^T_P#C==Y6?XL\6:7X"\*ZEKNNZEI^BZ)HMI+?ZAJ%_<);6MA;Q(7E
MFEE<A(XT169G8@* 22 * .3_ .&5_AA_T3CP'_X3]I_\;H_X97^&'_1./ ?_
M (3]I_\ &ZZSPGXLTOQ[X5TW7="U+3]:T36K2*_T_4+"X2YM;^WE0/%-%*A*
M21NC*RNI(8$$$@UH4 <'_P ,K_##_HG'@/\ \)^T_P#C=<G\>?V5_ O_  HW
MQI_8/PY\(KKG]A7W]G&QT&W%T+C[._E>45CW>9OV[=O.<8YKVBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OF__ (* ?L"?"/\ ;%U'P#XP^-NJ:A)X$^"-W>^*KC0+_5H[7PCJ
M3B 8N]8AD79-':)'(Z%G2-5EN%D$D4LD;?2%?('_  5W_P"":GCO_@IMX$\%
M^%O#?QN_X53X9\/:K_;.N:1-X.M_$EAXNGAD@ELDO()IXHY;>"2*1S;2B6"9
MI$,D9,,9 !Y?_P $*_@#;^"_B9^TA\4OASX>U#P+^S/\:O$&EZS\+/#=TL]B
MKI#:21ZCK5OILA(LK/4)VCDM@1'(]O#!^YAA6W4_H?7S_P#L,?L\?';X"?\
M"4?\+J_:*_X7]_:WV3^QO^*!T_PK_87E^?Y__'H[>?YV^'[^-GD<9WM7T!0
M4444 %%%% !1110 4444 %%%% !1110!^6/[5'[#?P+^+O\ P5>^#?[-/@SX
M%? _P?HFB^'W^,GQ$O[3X?:/;7NLZ7::A':Z;I5I/]FD_=S:@F;V)HXC):C8
MDX#RQ/\ J=7S_P#!G]AC_A6?_!03XT?'S5O%'_"5:A\3M*T/0M!L+O3?WW@;
M3K"%Q<V=K=-*Y^SW=TPNI(HTA3S5#,)&^<?0% !1110 4444 %%%% !1110
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M!_P"^)G[6/P7^(6D_#?X/^%?#/PQ_MS^WO!]I\.].^P>.?M]FEO;?:BH2/\
MT213-'YD4WS,=OEGYB ?;]%%% !1110 4444 %%%% !1110 4444 ? '_!:/
M_@GK9_%[X)_$3Q/\//V:?#_[0/QM^*&E?\(:+_Q!XAM8IO!-G]@OHX-2TXZH
MSP6OV>XE1S!9?9VFEG,K,74O7R@EM\+_ -N76_\ @D-\/X;S4/B1\#=0\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"T\S0[J63RX(56--TCNYV@99V)Y)-?H_0 4444 %%%% !1110 4444 %%%%
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M%HOBS4O$MO'X5NO+L+7[%J37%O,;JWM[:[TN*ZE^U6\7[EH]R2?OHD /M_\
M;!_X*M_\,Y_\%'/@+^S1X5\!?\+"\;?&+S-0U7_B=_V3_P (IH\;MNU#]Y;O
M%=_N;;4I/(25)/\ 0-N,S1Y^0/@7_P '1_CO]J#^U/$WPS_8S^('Q$^&6A^*
MXM U*^\,>*[?5_%6GVLN^2*[FT&WMGGCWV\4C*6E%JTT;PB[+*6'/_\ !K-X
M!^*G[7?COQA^V+\8M:\0:CJ%YX5T_P"$?@_[;>7<RZAIVGQVOVZ^/VH.9/-N
MK6%C-#/L>\?5B\:L1CY_^.G_  2J_;F^*?[9.E_%3PC^SE\/_@G\?;#X@2ZA
M=?%KP!X_MK/PKJ]G(J6[W=QHMU<7-R=[++/+)&B-<PW5PEQ8SRR$T ?I_P#\
M''GQ9\5? [_@C'\9/%/@GQ-X@\'^)M+_ +$^QZOHFHS:??VGF:YI\4GESPLL
MB;HW=#M(RKL#P2*_"'PE_P %$OB=^SOH_P %OB%\'OV[_C!^T1\;=6U72X=2
M^#6MZ#XCN[".6[M7^T6,CW-P\&H[;ADM L"K*[3++ T;HK+^_P!_P7J_9<\=
M_MI?\$GOBM\,_AGH?_"2>-O$O]D?V;IOVVWL_M/D:Q8W,O[VXDCB7;##(WS.
M,[<#)(!O_P#!-#_@FA\-?V6OV:O@GJ&H?!/X7^%?C1X5\%:59:WK=GX<TT:S
M;ZI_9L=O?DW\"%Y)'=IU>19&$@=_F8,20#R#]O'_ (+P:K^SU^VU>_L^?!+X
M ^,/VC/B7X6\/S^)/%UEI>H/I4?A^W6VCNXT1C:SFYD:"2,X55!DN+6"-IKB
M8PIR'C__ (.@OAQH/_!(_1?VH/#_ (!\0>(-0U+Q7!X#O/!\E\ME_9&N&V:\
MN(9;YHF#VZVJ-+'/%"YD\V!6CA9I1!Q_[7_[$?[6G['_ /P6C\<_M6_LV_#[
MP?\ &^S^,7@I_#>HZ-JFK6^CR>%[B&SL((7<SW4(GC,^GVD^8VR\8NH&6!O)
MN6X_]GO_ ()!_M'?L-?\$ =>^$6@?#_X/_&CXC?$[Q7_ ,)%XO\  'BR5_L%
MKIUU:6]LUE;74=W;QMJ%M):6ES]H%Q$D;+/Y#R2102R@'J'C'_@MC^T5XU_9
M'_:'U"#]D_QA\,_%?@CX:MXT\(^+;;Q-9>(O".IV\D<+R7UOJXMAI]S):VMT
ME_';PM<"Z6TN(B8W4*W7_P#!K_\ M.?&3]I7_@FSH%U\5/#_ (@O-/T[[1_8
M/Q"UOQ@NN7_CW?JFI"Y\R%LW-K]C:.*W'GNWF*%*85<5\P?\$R/^"1?[4'PW
MT?\ ;&\"R>!_^% _ OXU?#_6-*\)?#_Q#X^M?%<.G>(=0M?LT-REU9QR2+;P
MQB:.21U69XI+-6%X\'FI]?\ _!NC\'_CM^RC^PGIWP4^-7P=_P"%:_\ "M?,
M_L;6?^$LT_6/^$J^W:AJ%[/^XM&?[+]G\V%/GD;S?,W#;M90 ?GA_P '&'[,
MW[27_!-_PKK/QZT+]M3XX7VB?$;XE3V&G^"[#5M4TFU\-6]ZFH7T4,4J:BZ-
M';I;K"J+!&""" @78?I#XH>/?BI_P:]?LL:]\3/B9\8/B!^VE_PLKQ7HWAC3
M=-\3ZQ=Z/_PB^RTU:YEGAEN)M1W>;Y<:LBI'GRT)9MH ]?\ ^#H#]@KXL?\
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M^RK\.?%<'AC6/B8OC.QTV_;=)91R3P:)/&+E\M?0F)&D3>LD9D:W;S5B[_\
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M"Z\:V']EV;Q:[+*@WPR7;R2LT$Q:9"I+L2U?G#K/_!$W]HKQQ\*?^"HFA?\
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MH/$7PG\*^+_'?AWQ3JWAGP_JGB;P?]I_L'5[O3H9[_1/M,8BN?LL[*9(/-C
M23RRN]0 V1Q7044 <_X=^$_A7PAX[\1>*=)\,^']+\3>,/LW]O:O::=#!?ZW
M]FC,5M]JG51)/Y49*1^86V*2%P.*Z"BB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'Q"^ _Q*\;G4&FU>3[+>/I&EVD\MG9.\6+6S>=)O*2.!(XA+E85^Y7I_C/\
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M\0^&_ 7@_P )3?9O"[6_A=/MSOJ=FSLFH27J.$<RX"/N++/!Y=I'[AJ/P/\
MVO?V^_'?[/?@#XW_  G\/_#S2?V>OB!HGQ"UKXJ0^-;'6H?B'>:)'+#ML])M
MH();7^T)IO/!F$2V\6_*%U2%_/\ XR?L6?MD_L^_\-8_ [X3?#'X?_$SX9?M
M;^*]5\3VOQ!U#Q'%H_\ P@?_  D/^BZM!?6+RF>Z^SVZKY3VRG&!*5G9S9Q
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MW=:9X@O_ #I_.EMXM1-K>26<LZ(S[MET;8R,1YIH _6ZBO#_ /@FO'\4+/\
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M^TI\5;WXF_\ "!_VUI\G_".?:/$&GR_8O[1\\6MSMM+#[1YNZ+/F^7Y8=<,
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M!<7/@[XJ>(I].\(^,W6 S:I!#X:-O%=6UFT4LLL1MXYXX%A:.-T>,7%O[_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>slide13.jpg
<TEXT>
begin 644 slide13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( P0#[P,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M'DB"/YL,6 ^;/7BMWG&(OT^XB.08.VS^\_0J'_@K/\.)A_R!O&J>FZSMN?\
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MG_\ )5?E]+<JELW\*XQ7-ZRWV7:QV[6..:U7$&*MNON(7#>#;M9_>?JK<?\
M!?GX-VV=WASXE';UQI]E_P#)=4;G_@X8^"]INW>&?BA\HR/^)=8_-]/],K\E
M[\9,F45AT(S7)>*%CE#,VYH6^4;?X35QSW%-[K[@J<-X.*ND_O/UPU3_ (.:
MO@/I#*LWA#XO;B<872].X_\ )ZLS6O\ @Z5_9_T2.%Y/!OQDF6;[IBTG36_/
M_3QBOP]^(NHS"7SAM\H':RXP5'K7*BT>[TIIH5:2%FW,0?FSV!_4\=<UZF'S
M*O-:V^X\?$93AX?#?[S^LK]C[]J?P_\ MK_LW>%_BAX5L]9T_0/%D,L]I;ZM
M%%%>1".>2%A(L<DB [HF(VNW!'?@<W^T?_P4?^"?[(_Q'T_PC\1O'ECX9\1Z
MM9)J5I936=U,\UN\DD:R9BB90"\4@Y(/RGVKR_\ X(**$_X)'?!<*BQ_\2Z\
M^4=!_P 3"ZK\^?\ @Y2EATS]OKPO=K$9;UOA]9Q1\?<']HZD<_J:]3%8J=*@
MJL=]#QL+A85<0Z4M%K^!^DDO_!:']F*&5HV^+&DAE."/[/ON/_(%.'_!9K]F
M4E?^+KZ3\W3_ (E][S_Y!K^=E-7?;'"H:XN)L;B/6NMT?3F$:M=,K3 < =5^
MM>&\]KIVLOQ_S/HH\.X9J[E+\/\ (_H*M?\ @K=^SK>1AHOB=ICJ>F+"\_\
MC-64_P""J_[/TC!5^)&FY/3_ $&[_P#C5?A/X7GDAMU^;)'3BNITPL9!)]['
M3':N:IQ'B([*/X_YF\>&,,_M2^]?Y'[;M_P5 ^ ZXS\1--Y_Z<[K_P"-4+_P
M5"^ K/M'Q$T[=Z?8KO\ ^-5^,$9)7YFW,_/TJS;6;)*&:0,6/%82XHQ/2,?Q
M_P S:/"F%>\I?>O\C]G8/^"E_P #;F15C^(&GLS=/]#NN?\ R%2G_@I=\#1*
MJ?\ "P-/W-T'V.Z_^-5^/]M=K8VX9>67OZ4VROC#*9&/?C-.7$^)2^&/X_YB
MCPKA6_BE]Z_R/V&/_!2+X(@_\C]I_)Q_QZ7/_P :J2+_ (*-?!6=B%\>6!QU
M_P!$N?\ XW7Y!VT\CRJ_4-^E78;EA:M&OWL]14?ZTXK^6/W/_,T_U3PG\\OO
M7^1^ML/_  4;^"MPVU/'EBQSC_CTN?\ XW5K_AX'\'2/^1WL?_ 6X_\ C=?D
MKH\HMI5$@VLP_P FMI)-_P H.X,>.:Z*?$F)DKN,?Q_S,Y<*X5?:E]Z_R/U0
M7_@H%\'F/'C:R_\  6Y_^-TY?V__ (/MT\;6/7'_ !ZW'_QNORSE+PE?E^8]
M3GM2Q"1I@%;*U?\ K%B?Y8_<_P#,/]5<+_-+[U_D?J='^WM\(I4W+XTLBH.W
M/V6XZ_\ ?NIH?VY_A1<(S)XPLV5>I%M<<?\ D.OS L-V0LG"J=WUKI+2(06B
ME?E1_O ]JVCGF(?V5^/^9G/A?"K:4OO7^1^D2_MJ?"]X]P\66I7U%M/_ /$5
M'_PV[\*]Q7_A+[/<HR1]FGX'_?%?G;!?S:?:7"XP/O $?PT,8;FY5FS&DMON
M8CJ_I5?VY7_E7X_YDKAG#?S2_#_(_11/VVOA;(&V^+K/Y<9_T>?C/3^"FG]M
M_P"%85F_X2^SPHR?]&G_ /B*_.U]LEI'R RI^\(/7^[5.VOVM[KY%WPQYS[T
MO[<K]E^/^97^J^&_FE^'^1^D'_#;GPL _P"1OL^F?^/>?_XBJ_\ PW=\)2^W
M_A,K/=Z?9;C_ .-U^=,:&:-=RG=RV/8UF3:3YMUE9-@!YP>:SEQ!B%]F/X_Y
MA3X7PLMY2^]?Y'Z4?\-X_"7./^$SLO\ P&N/_C=.'[=GPF)_Y'*SZ9_X]KC_
M .-U^:#V0AO$C=BS9W<]Q5A+A?-,@_>1*<,!Z5/^L&([1_'_ #-/]5<+_-+[
MU_D?I/\ \-V?";R]W_"966WU^S7'_P ;I#^W=\)5CW?\)G9;?7[-<?\ QNOS
M5GN#$N[Y?);[JXZ55E>1#M&V16Y)%$N(<0OLQ_'_ ##_ %5PO\TOO7^1^F7_
M  WK\(\#_BM++YNG^C7'_P ;H_X;U^$>[;_PFEGD?].MQ_\ &Z_,N*-@5;^^
M<#VH6=EF*9#,K8K/_63$?RQ_'_,K_5/"_P TOO7^1^F;?M[?"-%W'QI9X_Z]
M;C_XW0O[>WPC9=P\:6>"<?\ 'K<?_&Z_-!Y5?*GGTQV-1QJ[1LJEO0"A\28B
MWPQ_'_,TCPCA&K\TOO7^1^FA_;S^$8&?^$TL^N/^/6X_^-T1?MY_".;[OC.S
M/_;K<?\ QNOS1AMA+:X^?='W]Z? (X8_O'=GD5G_ *S8K^6/W/\ S*_U/P=K
M\\OO7^1^EZ_MU?"=CQXRL^/^G:X_^-TL7[<_PHF4%?&%FP;H?LUQ_P#&Z_-=
M9B%=57[HSGVJ>TE"1Q0;FPVUBV/NXK:/$6(:^&/X_P"9C+A/"+:4OO7^1^D'
M_#=?PGQ_R.5GTS_QZW'_ ,;IS?MR_"E!D^,+/G_IVG_^-U^;K2%)X_W9VRG'
M(_A]:DO-+^S6ZM')YFY\(1V-:1S_ !#Z1_'_ #(_U5PO\TOO7^1^C;?MV_"5
M2P/C*RRG)'V:XX_\AU*G[;_PK=01XPLOFZ?Z//\ _$5^:MK9 7,TA99)$<''
MK5ZSNECFF,FQEF/#=L^E.&?8A[J/X_YBEPMA4KJ4OO7^1^CC_MO?"N.+>WC"
MSVYQG[//UZ?W*=-^VU\+;8_O/%UFN#CFWG_^(K\ZY3:Q-:Q2*O*EG*G[K=14
M.H)%<3V\C2%MRL64'H1TJO[>K]E^/^9E_JSAOYI?A_D?HD_[=WPEC9E/C.RR
MC;3_ *-<<'_OW4+_ +?OP@C4%O&MF W _P!%N?\ XW7YR7?DHLGR_+(BL">[
M=ZR=33[3(\:KY?DKD8[UE+B'$+I'\?\ ,TAPOAG]J7WK_(_3%?V_O@^YP/&U
MB>-W_'K<=/\ OW0/V_?@^Q;'C:Q^7K_HUQQ_Y#K\QY)X[27;&P96B W8[U%Y
ML=H9O,QF09!%9_ZR8CM'\?\ ,O\ U5PO\TOO7^1^G<W_  4$^#L#;6\;V2G_
M *]+G_XW3#_P4*^#:]?'%C_X"7/_ ,;K\PKI#*D;*,C'>J=]^[+;N588QZ5F
MN)L4[^['[G_F/_5/"_S2^]?Y'ZC-_P %$_@NB;CXZL=OK]DN?_C=0_\ #R'X
M)#_F?;#_ ,!+K_XU7Y2Y8'RU.Z'/)JM?V!4,R?ZO&2*S_P!:,5_+'[G_ )B?
M"N%7VI?>O\C]8U_X*1?!)^GCVP/_ &YW7_QJ@_\ !2+X)#;_ ,5[8_-T_P!#
MNO\ XU7Y*VK[(=V?ES\OM4%U=H(X]K,K*3DGM1_K3BOY8_C_ )A'A7"/[4OO
M7^1^MI_X*6_ X?\ -0-/ZX_X\[K_ .-4#_@I?\#3_P U T_KC_CSNO\ XU7Y
M V:9#JTC;@=V#Z4^8;+9<C<N_J*/]:<5_+'[G_F7+A/"+:4OO7^1^O4G_!3#
MX&Q-M;X@:>#_ ->=U_\ &J8/^"F_P*+[?^%A:?N]/L=U_P#&J_'F2X2.9VW9
M':JB3B]W-&S1L#S[TO\ 6K%?RQ^Y_P"9/^J>&_FE^'^1^QDG_!43X"P_>^(F
MG#G'_'E=_P#QJJ%[_P %:_V=]-!\_P")NF1XZYL;S_XS7X]ZG#]GC5EW,S=0
M>]</XWL'U.SE,>.A!%7'BC%-_#'[G_F)\*X7^:7WK_(_;2/_ (+ _LW2IN7X
MI:4R^HL+S_XS4;?\%C/V:E;:?BII.>G_ !X7O_QFOY_=.U:X\/%X6C,UNSE6
M(_@J'7S]KM!)!,,QC(.?N_6NVCGV(GO%?C_F<=;AW#P5U)_>O\C^@2\_X+*?
MLSV'^N^*VDI_W#[T_P#M&L6]_P""['[)NG;O.^,FCQ[#ALZ9J''_ ) K^?.X
M\7OKD4D8^6:U.QE[L>S5YUXKE-K>3PW&-DW1O2O2I9E5ENE^/^9Y4LKI+J_P
M_P C^D>]_P""^/[(FG6K33?&G14B5BA;^R]0/(&?^?>O=/V4?VQ?AK^W#\,I
MO&7PK\56OB_PS;W\NER7T%O/ JW,2HSQ[9D1L@2(<XQ\W6OY$_'Q;3]$M[-5
MY\LRL2>I.?Z 5^^O_!H]*\W_  2WUEG78?\ A8.JX'J/(LZ[\/B)3E9HX,5A
M84XWBSRK_@X>DCM_VV_#4G_+3_A![,#Z?VAJ%?$GA:*2*3+?=FDW >E?9_\
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M.,;65ES:^6FGFTCYL$JSH\BRQ<XP >AKI?#TK6UH&W+[FOT;_8S^$6@_MA?
M+QDWCKX,^$_!EU#,]OIMWI^D"SDEB:/>LB,0&!0G;D=<5Y;_ ,$C?V;?!?Q<
MU3Q=J?B:ST_7=4T-Q!I^E7A#P["#^^:/^+G"Y.0,>M<]'*9\\(Q>DTVGJMO(
MZ*V>4U"I*47>FTFM'OMJ?)NF74<L[JI#;>E3!?M$FY0493EL]#7UE^T+XM?X
M6_#/QGX>^(_P3\.>'-;U"-XO#VN:+IJ+:J^<A5EQSM&,'@G.*] ^$/[)%O\
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MM8\(^&;K5/#L-[;P7[:?&;B0)"75V;&2X)Z^PKC_ /@E9#X>^*OB_7/"^O\
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MC],_V"/@Y8_\$^CXF\8_$OQMX3T];^S6Q@M+'4ENE<!@Y?C!+$KM  []:?\
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ME:%^DC?O%VL$P3GU'3^9KD=5O7LV59.-K$_*?X37)B+[G13BI(OWNMQJ-O\
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MG/7.:[#3-3CUQ(Y-OEN&&Y?2FMC"M&43@?$=JME'RO\ $5K(L#YC_+78>/\
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M(DW#A4[#\Z\TT?Q*]W*I69C+TCF(RNWN&]*ED\1P>&_,A:99K>ZR8QC&UQU
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MWBS0W,C37DFQ2%PN.YKXCM_B;K5I_J[S;[^4F?SQ6O8_M#^,=.C58=:E55&
M#%&<#\5J_P"RI+JB/]9*7\K_  _S/MW4?'MKI.F/#ND8Q\3.W\35S.K>,8FB
M#2/MN+KY2 ?N+7R'<?'SQ;=!A)K$K!NH,:8_E4,_QJ\37+!GU21BHP/W:?X4
M?V3+N5_K)2_E?X?YGUY;^/+6"ZFN&/\ H\*[8_K62WQ/^VN\KR%EB^55!QNK
MY3E^+GB*<8;4I2/3:O\ A4'_  LK7-N/[0E_(?X52RE]63+B2GTBSZZ'Q*6W
M12&W;AT5L;:LVWCN.:?[1)<1^8O +<X%?':_$;6E/_'])_WRO^%2#XIZ\ O_
M !,)/EZ?(O'Z4O[)?=!'B2"^RS[6C^*UO;.JK_I$BD$%SC=GTJ]I'Q7F>9EA
M$F2W()^4?2OEWX:^.+S5]'6:[E,UR)67S" ,#C XKT[PUJ[7<J"8Y&.JFN"M
M@5&^NQ[F&S15(J7<]UTWQW)JMU UQ+MV97&:ZF#5&U)%\P>5&HX<=37D/AS4
MD1UC55;GOUKLKGQ)]FTM=TFUI!M!':O/E3L>O'$)1N<O\3+^3QCXYMM/A^:S
MLW&]O[QKW;X;2)HVBP(S?=.-H[5XSX=6UAUII%99$ZAVZUZAX<UI8;=?+;<?
M6CELK#P\WNSU[1M64:=%(?,5?K6U87XFPRLS 'N.E><Z1KGVJ2"-NF<UZ!X<
MO$GM]@X\L]:YY16QU:K5=35NV\J%6QUYK&US34U_3)H9HU,,HZ_W?>MG4K_,
M:Q^69![5F7[-;0EH5^\#P3TK&45:QCR]6?,/Q4TC4_A7/)Y@:ZTV20NK_P!R
MH_ OQRCAMY+>1T9!C&3TKW#QYX._X3+29H+H[H9H]I -?+'Q<_9QD\%3/=:6
MUQMDR0 >E=&'A&7NR=C.I6:CKJ>P)\7[6259FD;C'E8/"GWKG_''Q1BU/4F:
M3<(U7DI]V5^WZ5\P:AX@\1:?=-;RS2'_ 'JAF\;ZU-%Y9E5?<]Z[XX!/6YY,
MLR4=;'K'B/XC[4DC2>/+$ELM]SVKA]0^)#/NC^T;DZ$@\BN#NKJXNIF\YFW=
M<D\&O,?B+JEU:>++F..ZN$10N%60@#Y1VKT,-EZ;M<\S'9PZ<.>WXGM.J>-8
MQN5?M$J9Y^M4+OXCSP8D2)=JKMZUX3_;5Y_S]W7_ '];_&FG5[L_\O5Q_P!_
M#_C7I1P*1XDL\;Z/[SV:7XGW,L>W+1L.F*JR?%.YBB9D51(O0D]:\A;4+A_O
M3S'ZN:;]KE_YZ2?]]&M?JD#E>;5.AZAJWQEU1VXF6W;'(3O6'<_%W7';Y+IB
M.^!VKB3*S=6;\Z!*R]&8?C6D</32V,)YC6EU.F;X@ZE),6EE,F>SL1BM#3OB
MG=6"Q_N%9H6W9!SFN),C$_>;\Z!*R]&;\Z/J\.B(^O5>K/9K/]I180RMHT<T
M<A!<.$!'T.*=;?M&3:%?-<:9'?6_VAL["R[4'H.*\7\]_P"\WYTOVB3C]X_'
M3GI4_5H!''55U/H6Q_;C\4:9E8K=&C4X7)P:L/\ MT^*;J&968;[A=BD8'E'
MUKYS:[E?[TDAR<G+'DTT3R#^-OSJ/J5)OWD5_:5?HSZ,LOVX_%!N$:22ZD@B
M41!5=1N(ZUV'A_\ ;S=V"WGVB%L=3*.?TKY$6XD7I(XSUP:#<2'^-_SK&IE6
M&E]DZ:>=8F.[/M_2/VP+3Q2WDK<P[&ZF0D%:[33?'2:]I@>.1;B.48R_:OSM
M2[EB;<LDBD="&(J]!XSUBV4+'JVI1J.@6Z<8_6N6IDT7\#M\CMI\0-?'&_S_
M . ?H!'8&X.T,_F9R/L_)-5KC0)M2U)FNH[CRUQN# @YKX0A^(WB&W;='KVL
MHWJM[(/ZU*GQ/\2RW"%_$.N-R!DWTIX_[ZKG_L.HG\:^XU_U@IM_ _O_ . ?
M:.MSV\FI>2+<"-1@9Z&H;1V%VL$$?SYX ZUL.#KEU;QP0#RVB4DX[X&376^%
M_#EA86ZR*/,NLX:0]5]OI7C5&DM3ZBA%-W3+/A7P]_85BC.6%Y, 03S@5U&G
MP!0[>GRCWJMIUF<>6P5E;UI5E:XNUAA7Y8_XJ\VI)-Z'MTNQ_03_ ,$;1M_X
M)H?"H?\ 3C=?^EMQ7P)_P<*6^_\ ;H\*O_U(]H,_]O\ J%??G_!&]2G_  32
M^%08[C]AN<G_ +?;BO@__@X+BW?MJ^&VSAAX(M-OU^WZA7U>8?\ (LAZ1_(_
M/<!&^<54N\_S9\1)$L\L2_=.#S5FVM3<7&3\NTX'O4<<#1QJW^R"3Z4XSLJ!
MUYYQFOE([GUTHM(Z2UA4PXQGBK&FQ_:H-R[N#M'M5&*;R O/WE&/K5[2KS[)
M<2QR9^[D'TI52:<67H)_[)&=W/<U#?7$^MPE\_NR, _WJIS:A'=!5C$DA)YS
M6AI=Q%;RB+9PW05S1@V=J]W<I:;X<F8JOEAES7:Z+X66QV^9MP^"J8JQH-K&
MB_='/-7[\2K-&BJQW]''\%=\**6YS5*S;TV)D\-QIS'GIG';-7X8)8XUW0Q^
M_/451&J_8D^_NV\$YJU9:_&8]WWLC %:\L3.3>YFZM')=6LJQ^9&V<C#5R[R
M75HPCY4]_EZUW;7<<Z_="\=*Q-6TTKN9=Q7/:N>I!W]TVHU%;4Y+4]7N+.#=
MN\U>F,_=KF-2^(=Q9C]W,T2YY&W(KNKGPZLK-(T;,K<8(KD?$GA".)F7R_E8
MY)[?2I4)=3JIRIO0RT^(&J) UQ]J:56; $?05/8?&5C.K31RS+G;O*XYKG-1
M\)^7<,+=FA9CGR@?E/TKG[F"Z5YHUD>UGBYVG[CTI4V;\B2N>T6/Q321_P!Y
MRJC'[OTK8L/B/;7I0^8/,SM"D]!7S#>ZWJUG=_Z',%G R\3-UK9TGXAW5YY.
M]$BF3[QQ@YK.=%M:@DNA]0S>);?]VS-E\<\59/B.WO6BVS+Z;1]*^>-#^)MY
M)(-S,6Z#?QN%=5;>/?L4*S7"I&K' &[H?6N>5.Q?LWNSV:VUE(8/]9M;. !4
MJ7[76-I[]?2O.M+\2QR6BR+(KJ>22W2M;1/%RNQ5I!][@9[5SR=M67:Z.VGE
M$-PJGE<9S3C>JN%S][I7.G7O/;R693'UW ]/QITNID[6'S*G04XS3V,_9LWF
M<L,=!5)IUA9OF_BQ52YU7<NWG=]:I^;ND96;YFYS18U-:_N52S;9][';O1I<
MJVL$.YMI<9Q6/;:D)+H1M\P4@#WK2N GVD,K?+C@>E!#-8WBR2C#<U7$C"1F
M#8(.:AMDS)G=G'6I%"R6^?XLU.I2V,W7];_LVR:ZDW-SR.U+8ZF=5TN&==RA
MO2I;[2UNH65@&4_PGI57$>GV:P0C:%Y JHW-X\O+KN:EBYVXR ::TZQ3\':%
M[GO6?O9 9-Q"X_6F/=-<6ZLS<?SJ]#+E9NB_%Q#E6Z^E4DU3[*Y3[WJ#69%J
MD<-RR#@ 5%<WL<ETJ_WAUS6L-'=F$HMFTUTEZJKG[K9(QVJR-JH2I]QQ6#9Z
MI]DD'S*P9<&C4O%>Q-H^51QFM.=(YY:&Q]L9!MW85C56\U^.W4*NUFR0>:X_
M6O% L8VD^T;N/XFQL]\5Q^I>,9&C#>9(5F)Z=_?V%5[1/8<8-L[G6_'K6TC*
MK9*C!R>&/K7):U\7%%SY+7$*L.H#9KSW6_&,FI3NJL6CC.PON^5#Z>]<_/$W
ME27%SN+*?DV\;A19FSI11V&L_'J6:5H5>..$ E7(PS?A7/WGQ:U#7I([2S^6
M.3[S@?,3_A7%:E833:CF+$FQ< MUK?\ !>D-H\'FR*\D\AX;/W:[.6!ARLZ)
MYM0$<=K"R+,W+NE:^G>%YE!:1FN)) %8L:K:4C6C-)*/WDA&".M=18-(+I>
MRXZ5A*G;4V]HTK(U/"WAE--"S3 M)C&3_#75:,I:Y69N.< >HK-M)PMNI9D
M[#UI%UY+1]JMC'/-9Z7,92E)V.ZTC45 ^8*H).34][XHA@&%<#'H*\TO/'ZV
M;;5DPV>@/6LZ\\>+&I:X;:K=@>M7[2VQC*BV[R.]U#QIAF>3"@=.>M9&J^-(
MX;=GDDVY[9KSV^\3R7LOG3EHX4^XH/WJKP7<GB61CDB!?3^*CVC97LXQ.A7Q
M5-K6H;44XS@'V[5VOA:T9'C7JP_UI/\ "/6N5\(Z-!86VY\M)V4=0*W-1\:1
M^'-/\N)EDDD//J*PE%[LF7))61VFJWL,MOY-NP8?=C']_P!S6#XAF%O8;5 D
M/1B:SM!UQD+W$TB[V7( Z*/:L/Q!XR\V21A@=0.:REJC*--J5S \<O')!+&N
MT+M+?0US6@![6PMUE;_6-DD5+JFK-?7302$$S'BKD!B:1 %^6W&%/O0HNUCK
MEK9$\7[V>3YN%Z9I?-\^W9O[O&/6JLMWFX^3C<>:D,RR2A%^]U-92T.V,?=.
M3^(4(FTF9<;<# ]J_6S_ (-?+/[#_P $[_$2=/\ BX&JD?\ ?FTK\F?&T3W5
MM(J\,U?KM_P;06DEG_P3[UY9%VL?'>IGCO\ N;6OJ^&9_O.7R9\?Q=3?L>?S
M1\U_\'&3E/VT?#.W[S>"+0#_ ,#]0KX(BE9(O,C1]RC!4GY,U][_ /!QFH;]
ML[PS_>7P1:X_\#M0KX'T*\^QP1O+MD\E\^61PWUK7'?[Q/U)RS_=*?H0W-\T
M<&[<K$]5K,OM0"1*LS+\YYP>M7/$ZK;S374:QM#)\V%X"$_X5YCXT\0R6\B^
M7,ISSG^[^%$8IG3*4EN=#K7B>/18)?E/DK]U<X)KYH_;9\>+XF\%:3:K(S>3
MJ#2["V2O[LBNQUXZGXE=MMY,YSM!"8'/IS7EG[3_ ,/W\)^!M+NIBTD]Q>E"
M['DCRR:]'!TTJD6SR\TJ-X>:\O\ (\.HHHKZ ^)"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ]"^&*[O#Z@\*TK9/Y5Z)X=#*R^7(>#P:\]^&:N
M_AB/;U69_P"E=EH5Q<0W6ZW:,,.S]*\VM3YI-'T6&ERTHM=CT#2M6U>S/[EH
MV!'?@G\:U)+OQ3J4216]ON7/0#?4/A76KS$3-9+<;>24YKU#P1XD^T7*^=IT
MD'N4KR:T8Q=F?3824IP.>^'_ ,&O$6OW*R23^6T;89,<5[OX-^!6I:=:_-=^
M<R\G*\5V'PSOK6>WA/V>)FZ':,-^->K6(MX+8,DRQQ@892,FO-E+F.[VE1;'
MC]OX.OM-!9?+EV\KCCGTK8T=;ZSM&CDFCCD;DEOY5Z%JEMIYM85D6.4!_,1Q
M'MQGL6_^M5.?3([<M]E3S(V.YF+AA^'&:YY15]3NH8B323,'2]3N)(6!N[==
MG;!.:KSRR2R_N1+(W0E>E;K_ &B63"BSA5?[_P#^JH)HC,G%YN8'YE@BQGUY
MK&4ET-IR3,[3[2<0NOEICK@US_BGP_%?12+)&&&",D=*WKN5;-I$W2?-]T#K
M6)KE\P5F;<O'3-3S6=SEDN8^:_BY\.K>&[D:*%<+T;'->(^*M)73G*!68^PZ
M5]8>--#FUUG\I RL#EO2O$/&7@=)KVX5[JULQ$<;I3C=]!7O8.M>-CP\=AX*
M6AX]/9+(1PRCJ<]Z\C^*<7D^-[M?9/\ T$5]$:CX;D!VKY5TO0-%)^O-?/\
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ML8QP>*UK'Q3<6%OF:;:%.TX;M7Y^W?\ P4?\=7C[FL?#8^;=Q:..?^^Z5O\
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M%+-1N 7..!7RD?V_O!MW.SS1Z]TZ+;)_\75N7_@H3X),4,<:^(E6/KFU0_\
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M<W%O&)+A_.4>9ST.:F7PLUQ.1)(VZ3ABC<C%6]0UG^QF5E7EN"156Q\7"_\
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M%4]#[UT1SO&/>7X+_(Y)\-X%?8_%_P"9^<*?\$7/$EU.T=MXVT6XD4X;;8S
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MN&%5\K VM$3QR/3WK7@D6*.<)E6D7A"/O+US46A7K:5/)"LZR+(3Y1(Y)QD
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M=HQ_Q_WG_P BUQ_V7B_Y&=W]LX'_ )^H^.WCWVBO& LF<2 GI4.F^(8WU"2
M L(>#D<$U]F-_P $.OBWM7'B'X==<G-_><_^2M4S_P $*OB^9V;_ (2+X;[7
M.3_I][_\B5G++<6G=4V7'.,O:LZJ/DF^OH[HJJJ%9N ,]320Z6VS$F64\[O[
MM?7L'_!"KXKP2>8OB+X>&0?=S?WG'_DK5U/^"(7Q9*L)/$7P].X=K^\_^1:O
M^S,4]739/]LX&*M&JCY,L]0>UAB\ME)Q]VK5IJI>=?,W/-U5%_AKZDE_X(>?
M%J,Q^3XB^'BX^]NU"\_3_1:VM,_X(J_$RS12^N^ VD7^(7MWS_Y+54<OQCT]
MFT3+-LOM?VB/D]Q\OF%EN)V.2@/W1Z5%JU]#9P1R1LL;9RPST/I^-?6X_P""
M+'Q,^W%O[>\!B'!P!?788M[_ .C4V?\ X(J?$F\M LNN> ]ZKA<7MWC/O_HU
M)97BK6<&1_;&"V]HCY-L-:ANT$TSL9&'"#^&I-5UOR[9<1R-"3V%?4NF?\$3
M/B=I]S)+_;O@!F8_*/MUY@#_ ,!JLO\ \$7OBG(_F-X@\!NV<;3?784#_P !
MNM5'+<6OL,'FV7_\_$?'NH3A44R;D\SE%'0_[U6+34XUFC55D7:/O@?*:^NI
M?^"+OQ2N"3)KW@!CT'^FW? _\!JC7_@BQ\4DM1&OB#P#E5(_X_KO&?\ P&IP
MRW%):P8?VME]_P"(CXS\9:[-J2-8Q,%DN#@,.YIMO!';1K;B3]VN$/NV.:^N
M'_X(??%UI5;_ (23X=_+_P!/UYD?^2M:%K_P1$^)EO N[7O 4DV223?7>/\
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M[0D_X(9_%PM\OB+X<C@C_C_O/_D6LR]_X(-_&2[D8_\ "3?#;:QR =1ON/\
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M@?\ GXCX/UJVQ#C.<\UCVT+6;LR?Q$*W.-HSUK[SNO\ @A!\8+M-K^)/AO\
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M[(Q?_/MG7_;67_\ /U'R@FBPVDN]UVX8;EQ]ZMF"P40R2P'Y<;MOI7U9;_\
M!'_XH218N=;\ LR\*5O+O\,_Z-4=O_P1[^*5O=><->\!JPX %[=[2/0_Z-6T
M<JQ=K>S9BLYP-W^]1\KQ.T4L;2,,=4?T^M:!E696:.7;+C[N/OU]0R?\$?OB
M0"6CUSP/NDY=6O+K;GV_T>EN/^"0/Q)GC7_B>>!_,7D-]LNAC_R7JGE>,6U-
MB_MC /5U$?*-PD=Y%\K-%-GFJ-_>F&)@T?W>,@=:^LY?^"/?Q0FC(;7? 89N
MK"]N^?\ R6JM)_P1S^*TA7.O?#]E0;>;Z[Y_\EJF65XQ_P#+MC6<9??^*CXU
MNW^T*VY0JMW!K(N(W$N(VW?[U?9\O_!%/XJ2AA_PD'P_VL<X^W7?'_DM4%S_
M ,$1OBG,OR^(/A^I_P"OZ\_^1:Y_['QO_/MF\<\R]?\ +U'Q/?QR-RRJ<=<&
MJB3#81MVJO&#7VS<?\$/OBU(,+X@^'8^M_><_P#DK5*;_@A7\7)I%;_A(OAS
M\O\ T_WO/_DK1_8^-_Y]LV_MW+FOXJ/C' D/I]:&C5=IK[0'_!"SXM'&[Q#\
M.<@YXO[S_P"1:=)_P0N^+,C?\C#\.AGK_I]Y_P#(M']CXU_\NV/_ %@R]+^*
MCX=U;YVPM8.LS;4"\KQ7WC<?\$'OC!)&RKXD^&_)XSJ%[_\ (E9.H?\ ! +X
MSW9&WQ+\,>/74;[_ .0ZG^P\<_L,UAQ)ET=?:(_/S5[@*FS<V[V%<GK[$N/Y
M5^BFI_\ !O#\<+N3,?B;X4^V[4[_ /\ D*N?N_\ @V[^/EQ=>9_PE'P@QZ'5
M=1_^0:Z:.0XS[42*G%67+[5SX?\ A_"TE_N9?EB^8$CO7[@?\$#+C[3^Q%J3
M<_\ (V7_ %_ZY6]?%.A?\&[?[0FA;]OB#X,R>8V3NUK4^!_X 5^CG_!*W]DG
MQA^Q=^S3>>$?'%UX;N]8FUZZU)'T.[GN;80R)$J M-#$V_*-D;<#CD]O?RG+
M<11Q'M*BLK/J?&Y]FF&Q&&Y*<[NZZ'G_ .U-_P %U_A'^R1^TKX@^%?B#PW\
M2-2\0>&1;&]N-*T^SELE$]M%<H0\EU&_"3(#E!SG&1@GC+;_ (.2_@;=,VWP
MG\6/+SA9#IFGA7^G^FY_2OSC_P""Z6J0Z9_P5.^*T8CW3W']DD(#M,A&CV0!
M)]O3VKY/\'W$M]K4?FL3M!/E#MBML1F5:%248VT;Z&.#R;#U:<92OJD]_(_=
MVV_X.)/@K=2K&GA7XJ%B,_\ (-L./_)RKUI_P<#?!F]9@OAOXFC:.=VG6/\
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M?^#=5DM=2TN^T^X4[?(N[=HY$/?J/Y58M[AIT">6W[MQN9N^:_5GX&:II_\
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M( Z_2J,<4C#=_P \\L3]T-Z?6HE)IFD8I[FD;M8/]8LC>< WTI!#);W/WB)
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M_P#PNS6M+_X*J7*3:I>R60U$Z-]D64^7Y!C^4;<XX9MV<9KC?^"HW@R/P?\
MM(RS:?'!:P^(=/CGG6-<9E4D,Y]SQ^556P]*-)U:=_=ERN_YCP^,JSKJC52]
MZ*DK?D_\SYLU.[FE$\ZX5Y"3^?\ ^JLW0O,;:+@[BA.2*N72D/M63*&%0,_W
MQTJW'IL.GW05?F9U&\GD;^]>+*[=SZ".BL+;7<J:G&EOPK'//I6TACF19)3\
MS*>E9".4\EN/.16#$<"ET]C);[FR5CSCFNB,E;4Q<'<T) EG:21[5"W'+;>W
MI0MZ$C4^6TG/S!NW%5;V^6.1T\L*I(;/O3;J^BFO6D>9A^Y+[5Z9'%4^6URH
MQ:9&)1+;.\<?EGS0,@^]17BJM])N\S"X)J&RE(#2?-Y:L&X;&3FG&>XFENF\
MK<'P.O2N7VRD[1-G!I7+>QHI V8VW#<GJ![T10MY_G-Q(R$?K5/^T_L'E)Y*
M[IEVY/48]Z'NY+."-9&W-DX]A6G,B>5E^TGD22.U_C9<D^E.>1FBGN"RB6)L
M$>HK.CUUM/OG9!&QD3:=PS@>U6+34(]59\QK&[=<# -2ZB0^5EB[F6^N%;;P
MS$#'O3;<XO\ YOEAWY;W%56.V9GW?NX&&X+Q\PJ198YD&5DSG/7J*/:)Z!RL
MN/<M!/,T#?N@A(SZU#;3_P"EEI&4^6F]?<T&\\B;RU12K#H1UJ.$()QOC5=O
M(_\ KU,I);C]FRY%,L+0S1R8,V=P]*5M4:WB*G$B^9D^U95K,D;EL?=)VXZ#
M-27+_:+4;6559^<=:I35A<K)B5AN+ABVQ9),_I5>.19]/9^%6/.:;++_ &C;
M-#T96R#ZUFN/LX^SQ>9ME^]N.:4I7V+BNY>L]2C$D*PQ^8&SEJ=$?**E3_%D
MBJMO"]EM:-2JK\HSTS2V\@A.V0EGY(YJ;A*UC7M;E;<3,R_ZP<5/&'2UBED;
MY9/W87]:K"ZP^PJNT)NZ412+=RV\GV@;5?<BXX!]ZNYCRLOK<M,_R1J9-^Y6
M/\.!5OR(WCN(UNI%N) ID&/E('-8J2M#?R$,S*2$)7CWXK0@1-*FAD9I)8\$
M,"V2<^IHC*^B)EIN"WRMY>XF0J&&:PUO!-*(67Y)E/Z&MJ:YBLD6*15"R!W0
MXY&36'?2QJMNL7R-",9;G.>34U-AQUU(=2MHX[J1TZ%57]*P7:2UF:/^&%#&
M1]:W+Z)FM?W:_P ?4]\5S^L++%J5S(P.)"';'J*XY;FT96+>E2PQRQJT?S0H
M03^%8S&2';C[JBKGVB0V]Q<*OR2 *OK5>V;REF9HV:-.,$\UG+49/IC_ &CR
MQM4B3.[=_2DN4627R<.D8;)(HM+9FMUX"S1G*CMSZU/J$$D,2!@S&3J4.,4U
M%J)G?WC%NYHWADW22#RVVK[BLJ]N887D;S'95 P*N:_=L+A8?+Z=<"LR2Q#S
M3\MM8 [<^U9\KN;1DD4K>]S%M$C%78D!A5JW0K(%\N-O?TINDZ;]I@W2E048
M[ 5Z5I6WDM/]W=)T.#Q2Y6:<Z$F@^9-R"1O[]0&#$)9FW-SS5B_D";F#$;?N
MC-5Q<38V!%V]2<=:<I6W".YGS76YBK?*/6JJ7,8D^]^8JU=#[0S"';N49((Z
MBLU_W&XR1J6?[N#]VL^:^J.A,6_B#_</RU%;1M#MQTW9-2VJXMV9?7G-(TZ@
M?+][J<TPEJB+4'$MP[,>%&*_5_\ X(#QB+]CWQ-COXSNC_Y(V%?D;J4S#S"K
M=3\V:_6__@@!(9/V./$V?^ASNA_Y(V%?2<,_[XO1GRO%47]1;\T?F#_P76U*
M/P__ ,%2/BQ=L-TC#244_P#/,?V199(KY0TR1I@J^6S1IM8,1]_/-?2G_!>9
M&N/^"M/Q4#*'@C_LC.>@/]CV/'T/I7SKILY,4:M&JKP-J]CZ#VKTL=_%EZO\
MSDRM_NH>B_)'KG[*JR2_'OP>VQ4V:U:KM]1O%?IE_P ' TXA\3_#?YU5FM[@
M ;N3SV%?FG^S1\8]2_9_^+.E^,-,TS1]0U3227MX-5MC<6JOC"R; R_,O4'/
M!K[#N_\ @M'\4OB#+'_;'ASX9:A-;?ZF2YT%IVA_W=\AQ7#3K45AIT:C:<FN
ME]OF=];"XB6+IXFE%-036KMO\F?7/_!-+0YOV0_^">OBCQIXPAETVVU,S:NE
MK,/*F\M8_+08;^*0J"HZG<*^=OV*?V,X?B+^S)XQ^)'B_P 9>+M%^'</VJZN
M-&\/SE)]2$()D>13\C="H4J2<=17B7QQ_:^^(G[3D C\9>()KS389/.@T^!1
M#:P-[1KUQQC<3CM75?LT_MY>/_V7O!VH^'_#[Z+?:'?.9C9ZM:FXBC8C#;0&
M7 ;N#D&CZ]AI5(0DGR0BTN]WU:OMY7,(Y?C%"=6$E[2<DWVY5?1-K?SL?;O[
M .I^#?$G[ /CJY\&>$]8\,Z+-'>J#JEW]JDU'$3#S=VU5QCC &!7S5_P1O\
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M 3VH^)W_  4=^)?Q5TBZTG6HO"-[8W%N8I6ET1#)$&&"4<L2K>A'2L7]GO\
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M1_+L /-8N3A\)K[1$NH7&V6 Q?-AB&I+.874LSYPV[!I+6V:1?F;;M)/UJ)
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ML5VMGDGC'OBL8RTNS1I7L7KJ95N7V_>]*IVUZ(0R$MC.1_LU*CXO&F9M^T$
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M\%E/C N?D4Z+V_Z@FGUX5IZ;[>,AD=2/<5[=_P %Z$W_ /!9WXQ+-N>/.BE
M#C'_ !)-/_K7BFDQ'[%"W\6!^(KT\R5ZK]6>1E,K4(^B_(Z?PK+Y7WL@-]WT
MKO=)G98H_F7&.WK7!Z1 J%& ;J 5/3-=MHKB(;6P<CCVKQYQ5['TE.3Y4SLO
M#K*DGS?-N&3Z9K>TV1E,C1[NG1CP*Y+0[UHI57Y=I'ZUUNC$RAE91N(XP*YY
M15S3F9LHRM:<L!Y@&<=0?:E@/DI"&;=(#S@]138&^S11LY5EQ@ CH:)>)5=E
MVMG.!Z5G*5EH$=7J7H)I)KQ96V84X(/-6()-]NS1MN9IBN[."HP:HVUY':2,
MS-AFYQVK/;56FN6C3<6/.U?F&?PK/ZQ;<N-.\O(VC$SL&W?-"0O7[Q^E3+>*
M9%CQY;*<DA?F_"H]/EW3QMY916 W9')-3)#Y>HKMRQS\VX;6YZ<'DU<9\VI#
MT=D;$&JK/\JA%6,8R%^5O_KU8CM5$]K.N651N.1U^E9^DG=:&%0TBK(3NZ8Y
M[YK3#;]37S!YS*1LQPJKCFM8[$M:W)?-:W0W"REO.EW*F<,!GHU:HT^)(Y)'
M976XD4&)!MV$UG-8_:O+C4;?+<GY?X@?>M.)TN'S)L5(W&X#J2!6L;-:DROT
M'QV4=K:R31MAH;@)ECT'?%36=YY6HQLT8EAWEESU)JE;ZA##,6*[]DNYDZJP
M/2IH$%O=PR;M^UB611Q@],5:TT0KV^(T%OIKQMJB&WCE=G0$8"8'./>M.">2
M:U69?W;2VR;W(VDC)&16?I,T=E?%&C6=;?<R$\X+"M)[A6L(8]N-R[!NY"'/
M:MHF5220VTDGF8,V?+M.B_W_ $YJ2#5U,\[,/^!8ZU.EEYL<G'EB*([AGG.>
MM5O]18M"6CWXR3BB5^A,;29-JTXN+.--VU552ON>]55U9;:(,T;?,< !_P"=
M59YMD"LS;O*'%9ES=>;+M$B-QNP!TK&3<=6=7)IH;%]%'/&TR_=7GD\9K/NY
M_)ME^N6/84V*>1+7'5>C _TJE)=JMJT>_<,]#ZUC4J:&E.GJ3Q7T8;.PL5&
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MFC^7@,1_":PXWDLW5MS$+R3C!Q2W.JR-;-Y+;L'+%>C5T<Q/*=!A!%#M4,S
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M5SFA+I^H32I"9.7*8'L:6[N/LT\8F7YAU8]JKO>1Q/ .K$]!UJ:\B-Q=G<<
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M0N_LR+A D/\ $>N:X/Q8(WU+Y$^5CD 'K7;:Y&OV"1?M321X^4L.<UYY>/\
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M,^9XJ_W)^J/SA_X+?N(O^"F?Q,D^;>ATH#CM_9-G7Q\<VK-+U;/RX]Z^Q?\
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MF/5=5;<O[MLEQGK[4XT)=0=;4ZS18V@MX2'/;> X&% ^]5O5=1*W+K'EX[P
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M.TEXTTN1+_"OOBNATRT1Y(S)-YB]#L7G%;>R*NC95D,2W!NO]+V[58MYF/\
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M=D**9ATXQ7RQ_P -+>-3C_B=/\K;A^XBZ_\ ?-3C]J?QV)0_]N-N'?[-%_\
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M_%]GPCD=ANK\Y+;]I[QU:8V>(KKY3D;D1OYBK3_M<?$*08/B.XVYS@0Q8_\
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M(VE>&V8G/-J__P 74-S^W9XJNKOSFTSPZLF"N5MG7@_\#KQ.BG_9V&_D1/\
M;&-?_+QGL47[;'B>$-_Q+?#[;QM.ZV9N/Q>HG_;-\3,)@+#05^T##_Z,W/\
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M5-5_:E9*SFSG_L?#M^["-O0^:M/_ ."0_P )9 OVB/Q5",99WU(+^GEU+/\
M\$@_A#C,!\33+GAEU1=N/^_=?2XL)IF\^ZF,\;#&5.%_+K5Y(8[6..3$:0YZ
M#C=4?VEB/YW]YI_9&%M=TU]Q\J+_ ,$DO@^)U$T?BJ&/NYU,%3]/W?2ENO\
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M84444 %%%% !1110 4444 %%%% !1110 4444 %=E\ =W_"U--VKN.). /\
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M'6K>ZO;?RR5E2,Q ^F!SC\Z\3_X*%PW$7P%NH_+N/*ANK8.TS[C]\XYP*]#
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M."N?!B7K2&^G:1E&42)LKGWQ45MHJV,!W1QQD'@*.,5VWBD2/?&18U'D@+L
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M,9%^RG<OG$2'_9)YQ7USXB_X)G?'+4]+DA'@4R9V;%_MK3P1@DD9\^N1O?\
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M?\O-7&_X(D?M(+:R-'X!RSJH\N37M,.#SG!^TXKT;XA;0E]S//K2P3?\2/\
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M66US3<M_Y,?SJ2U_X)"_M#6)CEC\!R^<2&D UW3,'U'_ !\UE*CBGO"7W/\
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M_P#(TEF&"ZU8_P#@2_S/F+<T$+?:I/F;!V,.1^';/I4EC'<7=R@:)HU)Y"9
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MQ4ZD8OJT>7W'_!9K]FNU=5D^)!5FZ#_A'M5_^1J7_A\Q^S9C_DI'_EOZI_\
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M+_P5<^ ,)^;Q[C_N":C_ /(]?CVY8V+/A7VGK67>QQW#M,)%R1C92_UHQ?\
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M)^2>E_S/1/AQ^P#\2OB3\(=;\<+I\.A^']%LI;\3ZF6A:^2-2S") "Q.!P6
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MCQ-FK']6E%%%?J1^*A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KRG]NTX_8@^,G_8C:W_Z03UZM7E/
M[=HS^P_\9/\ L1M;_P#2">LZW\.7HS;#_P 6/JOS/YM=-C\OYNOS9KJM'O#
M%9ONOP!7.Z>!GYMN>U;.E3,6"_Q+]W%?F;W/UZ-34Z>$[4W!?O=_2M)';/EA
MUZ C%8]B&:%N!G'.:V-*5HHOF&,@8KFF;*=]"2VC%S.ZLOS+WJP(_M*,N[;L
M[U7NE#RKM9EY^;;W%7DC0IB/[N.<]S69O'8<;4%(R3AB,?6BU0+)YD?(3AA4
MEO$S3Q>8%48ZU+):-%N*MNR>M',(3$<VYEXP=P^E2?ZU=R_P\GZ4^*R+,H_N
MK5G2P)&=)/3RQ^-:F8EK&ODF2,-NDY&>U/"LL:Q[_E!S@CG/>KD%NCP-G^$X
M3Z4DMOLG55^7..?2M)?"9QGJ0:;HZQ7$R;EW;<G/I5N39;QJGG+NA/E+]#3)
MF^RWTC<,4QN;UI\.GI<37#MG[PD%9FM[ZES1RUE*OF+F,YCW>E7(+V.VFEC=
MF\E1D'N:I13LDC':7VR*Y [@]:N:VHFU9I84Q'+&%"D\ U4=B);EI=4EL TT
M>]I ,,IZ,*B-S'/=_>*MLW8'2EBL)-T?G$*NPGCO67EMH8%E56K.J53-B2^$
M"#<,)(/UI\$OG+&V"&QPQK.,;/%+'(WR]5IUG)( 2RMM0XW9ZU$;=2I&Q-;*
M8U?=E@>,=S39;IAMS&#(>OH!56[+K&OE,WJQSVJ)+@:A;,JJRM&V!D]:<I12
MT"*NS?@EB:W78JNIZ@\$&H;QU+,V)/+'R[>U4X-25$^8_-C;39=5S^[ SY=9
M^TOH5R6U*5_RX"OM53D@U6N+_P ^T<JWW5(Z=:-0<S32;>XY%4[']]!)#)\O
M<8K"/Q'1+8H>%;U8[J0?PMU%;NDI)J<5PDTBK'$<J>YKE[:5M.\020JRJTR_
M>VUJ*\C,J[LX/6G3J7*JT_?+5QY2Z@7:3]],<A<<&I"J^;RS''3;T)]*:\^V
M<94?(",YY/%-C#+8HR+N#KT)Y%0^6XO>*^IG:-R[@W1@>U5[:=,^6WWNHITT
MWG!E#D-&<'/:L\W .H;2OS*,[O6GIT-HWMJ;$%LUU*F[/##@&M"SG:S><9^7
M/0]ZQ=,F=IV5N$/>M*:!AM"MG;S51,,1&Y+JEPI:X=F[ BJFG:AEE\P$K)[5
M7\07P@M$ ^]N -31W0.S:OW*TC*QGRVB=!IP9FC7E5YJ:4-')$L;J6!/'8UG
MKJJR6?R_N^>0.]3:;=K<^9YB'[ORL>]-R;1S3-73I?M<:JS,& Y /RY%6)K]
MIHE+?, <9]*H6T@AM8V95..^.:AU"]WQ2;?O?3%;\UE<48W=C1BO=VT+A@K9
MQCI4]U=J8\#.<<UDZ4\B*K,VW^M6-4U-5B8*?FQ6<JEU8B5/4Y_7M4::Y$.[
M:O9O6LVX@6^U&!9)=L*\G'>I?$8S<,W1B :S(?,\V3YNE0=D:?N%Z:UBGOL?
M\LU^Z<]*@U"?[+(&&#M;+@^E):?N7R_S;ZCOH&:16QYG_+,K]:9! -MW>+(O
MS0]56K4NG'9YC/Y:]2,=:LZ9;QI;R%D^91E1_=J:+3Y+FZMS,S'SFW +UXJH
M;DSGH0VUJ)XHU7_4AOG/?%3:BXMF\F/=M9@3(#]T"KUE:;YI%8JL4@*@8Y)J
M-]+2X#L^UE5@O^[BM*FQC%WE<IQ.T5](1(WS#D_[%%N?[3GVGS/)4_*YZ&DN
M[=M\L>T;NS#TK1TB'RDA\P[O+_A]3VK)%S(;NP7S\J_RQ_+MQUK+GGA>X;R_
M]7'P_M6YXAC\R+S(V_>-PP_NFN?:"1I^F%_C']ZCFL90W*-PN^XPOW<]:KHJ
MO?\ S,=HXP16C<62+>"3^*I(K96N3(WTI<USIZ%06:J,?(WN:IWL>TJOR]>U
M:EULC9=K;?4^M8^HSB>3<JG@X/- HF?JJM"?EZ,.3Z5Q_B7'ER?O@6],5UFI
M3[F9>>5[FN3\3PJ--X;:WM3CN:+<X/4/DDW%6XSS6/J+,Y/,FVMK6\LCJK,S
M8!Q6.C>?;[&KLI[&$S^L*BBBOU,_% HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;(V?F '05O:;<7#2Y^4AN@!^:M*9G)\IT,$*B-_EYZ9J.ST_]Q,ZLWF YY'
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M-VMQ!(,L&7N?6DTVX\^'!;;G&<FLJ:5R[WC8Z:WE6'C=C:!G!ZU=@G%VN58
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M8^)$\J-)N6WA7Y7).7?Z"J^D>(+[5[IFC9K>S X;;\Q/M6?<68N!')Y*.R]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ(S_ -JWWV6V#[HQSG[M4]'U:\\5W:PVJ[DZ/)VKKM'\.3:8IC$:H&8;YAU
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M'PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8MRJ%V]SBFNJ!2V-V.WK7EGM>S/ZA****_4#\7"BBB@ HHHH **** "BBB@
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MRUHK]4?#_P"SMX UNSA\SP'X3,G(81V*#CL<^M4=<_9=\"Z=<--;^#O#;(V
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M<*M-_"-O]:U)=(CG&R2%5Y()QR#]:/[<Q?\ -^"_R#^P\N>B@_O?^9^;Z_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>slide14.jpg
<TEXT>
begin 644 slide14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP#_SYM_X$M_\:K\J**/^(Y9U_P ^:7W3_P#DP_XE=X:_Z":_WT__ )6?JO\
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M .3#_B5WAK_H)K_?3_\ E9^J_P#P^1\ _P#/FW_@2W_QJC_A\CX!_P"?-O\
MP);_ .-5^5%%'_$<LZ_Y\TONG_\ )A_Q*[PU_P!!-?[Z?_RL_5?_ (?(^ ?^
M?-O_  );_P"-4?\ #Y'P#_SYM_X$M_\ &J_*BBC_ (CEG7_/FE]T_P#Y,/\
MB5WAK_H)K_?3_P#E9^J__#Y'P#_SYM_X$M_\:H_X?(^ ?^?-O_ EO_C5?E11
M1_Q'+.O^?-+[I_\ R8?\2N\-?]!-?[Z?_P K/U7_ .'R/@'_ )\V_P# EO\
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MD$95B RLIPRD#[:\0Z1:?#W]A#]JN;0+6WT.9?B3>:0)-/C%LPLEO;*-;7*
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MYS@JV(S"E&G4IUJM/EB[V5.3BDW=J4ELY*R;U22T"BBBOF3[8**** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q;_ ,%J/^2*:3_VV_\
M1]G7Y<U^HW_!:C_DBFD_]MO_ $?9U^7-?ROXX?\ (]I?]>8_^EU#^\/HO_\
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MK^UC_,T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT<G_ .A;3_\  ZO_ ,F'_$0.,?\ H9S_ /!='_Y6>,_\.;?!/_18/_*;%_\
M'J/^'-O@G_HL'_E-B_\ CU>S44?VCD__ $+:?_@=7_Y,/^(@<8_]#.?_ (+H
M_P#RL\9_X<V^"?\ HL'_ )38O_CU'_#FWP3_ -%@_P#*;%_\>KV:BC^T<G_Z
M%M/_ ,#J_P#R8?\ $0.,?^AG/_P71_\ E9XS_P .;?!/_18/_*;%_P#'J/\
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M=5@LGM_LB0^4NX/ORKMGE0,8[UZ#4>F_\E.\%?\ 8;@_K7TW!>.RR>=X>-'
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M .">OQN\%Z?XH\2>&[SQ9>ZQ;:79Z:6UJZ>VU/1EFLH[?<!)=":&2%55RCR
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MIZ][V:/H2BBBOA#WSJ?@K_R4[2_]Z3_T6]<S<?\ 'Q)_O&NF^"O_ "4[2_\
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M.V\MDGK8[\GR^OAJ2Q,(Q;<$N57C>]G>3=]4O+OL'_!3SX^^(O"WPZT?X/\
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M^$?CM_P6+_;K^!OQ%^(OP-UKX"_"WX"ZE<ZPJZQ?NFL:KJ:O:W$:)'/;QR-
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MIC]FCX)_V+XH^(.DR:TWC3QAX'\.:3-=ZKK&G12+%&UNT860N;9-97;%,A4
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M3?\ Q5'_ !!F?_06O_ /_MP_UV7_ #Y_\F_X!Q7P5_Y*=I?^])_Z+>N9N/\
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MZ]_PQQX#_P"@???^#";_ .*H_P"&./ ?_0/OO_!A-_\ %4?\09G_ -!:_P#
M/_MP_P!=E_SY_P#)O^ >0UUGQG_Y')?^O2#_ - %=E_PQQX#_P"@???^#";_
M .*IS_L>>!9&RUC?L?4ZA,?_ &:N^CX2SAA*F%^M+WY1=^3;EYNG-UYOP.>7
M%ZE6C5]E\*:^+O;R\CQ^BO7O^&./ ?\ T#[[_P &$W_Q5'_#''@/_H'WW_@P
MF_\ BJX/^(,S_P"@M?\ @'_VYT?Z[+_GS_Y-_P  \AHKU[_ACCP'_P! ^^_\
M&$W_ ,51_P ,<> _^@???^#";_XJC_B#,_\ H+7_ (!_]N'^NR_Y\_\ DW_
M/(:*]>_X8X\!_P#0/OO_  83?_%4?\,<> _^@???^#";_P"*H_X@S/\ Z"U_
MX!_]N'^NR_Y\_P#DW_ /(:*]>_X8X\!_] ^^_P#!A-_\51_PQQX#_P"@???^
M#";_ .*H_P"(,S_Z"U_X!_\ ;A_KLO\ GS_Y-_P#R&BO7O\ ACCP'_T#[[_P
M83?_ !5'_#''@/\ Z!]]_P"#";_XJC_B#,_^@M?^ ?\ VX?Z[+_GS_Y-_P
M\AHKU[_ACCP'_P! ^^_\&$W_ ,51_P ,<> _^@???^#";_XJC_B#,_\ H+7_
M (!_]N'^NR_Y\_\ DW_ /(:*]>_X8X\!_P#0/OO_  83?_%4?\,<> _^@???
M^#";_P"*H_X@S/\ Z"U_X!_]N'^NR_Y\_P#DW_ /(:ZS4O\ DC.F_P#82E_]
M %=E_P ,<> _^@???^#";_XJG']CSP*4V_8;_:#G']H38_\ 0J[\%X2SP\:L
M?K2?/%Q^#:[3O\7D<]?B]5'!^R^%W^+R:[>9X_17KW_#''@/_H'WW_@PF_\
MBJ/^&./ ?_0/OO\ P83?_%5P?\09G_T%K_P#_P"W.C_79?\ /G_R;_@'D-%>
MO?\ #''@/_H'WW_@PF_^*H_X8X\!_P#0/OO_  83?_%4?\09G_T%K_P#_P"W
M#_79?\^?_)O^ >0T5Z]_PQQX#_Z!]]_X,)O_ (JC_ACCP'_T#[[_ ,&$W_Q5
M'_$&9_\ 06O_  #_ .W#_79?\^?_ ";_ (!Y#17KW_#''@/_ *!]]_X,)O\
MXJC_ (8X\!_] ^^_\&$W_P 51_Q!F?\ T%K_ , _^W#_ %V7_/G_ ,F_X!Y#
M17KW_#''@/\ Z!]]_P"#";_XJC_ACCP'_P! ^^_\&$W_ ,51_P 09G_T%K_P
M#_[</]=E_P ^?_)O^ >0T5Z]_P ,<> _^@???^#";_XJC_ACCP'_ - ^^_\
M!A-_\51_Q!F?_06O_ /_ +</]=E_SY_\F_X!Y#17KW_#''@/_H'WW_@PF_\
MBJ/^&./ ?_0/OO\ P83?_%4?\09G_P!!:_\  /\ [</]=E_SY_\ )O\ @'D-
M1Z;_ ,E.\%?]AN#^M>Q?\,<> _\ H'WW_@PF_P#BJY/XA_ 7PU\+_&O@&[T>
MUN(9KCQ%;Q.9+J24%1ENC$]U%>QD'A;/+<PI8YXE2Y'>W):^C6_,_P CBS#B
MM8K#2H>RMS+>]_T/?J***_7CXX^?_P#@HA_R2K2?^PC_ .TI*\;_ &8?V=-$
M^*_AG5M8\376JZ?IMO?6NFV4UE)&/-N)7"%&4H[?>E@ . /G//!Q[)_P40_Y
M)5I/_81_]I25D^&?A/I^F?LI^%-)NO&VG^!;[6;I/$+W9N]OVPXW1@!Y(^45
MK8G;PKQ*>3AJ_G/Q.X=IYEQ;1Q%>A&M##X6<^2<HQC*3FX0C)R<5\4N;64?A
MWOH_U;@_-)83)*E*G4=.56M&/-%-R24>:322;V5MGOMU7D/AK]GRUNOVKY/
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M,V6! P.2,5]-_LW^+X_BGXF^,OBB2/59);N!%M);*%%U2&V*7 2.';TEV1Q
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M:2:_\5:Y=+(;2PC*(_E[_*D8N58A48(DLICAD\@_9<_X*T^._$_[9.A_ O\
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MH)K?0?$.G:K;O>Z9<0P7$LD]M<"W4I<6[23(DB;HYY%?;& ?4%%%% !1110
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M\4OCC::7<>-O .DV]HN@6%NO_$JTS0@7$B2QHE^L-U.QG!C4A5NFC::Z\/\
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M_P!$[U7_ ,'TG^%>:LCI+#O"+.*'LW)2<;XGE<DFE+E]A;F2;2=KI-KJ=?\
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MU\-/C5XF^#_VW_A'=2_L[^T?+^T?Z/%-YFS=M_UBMC&]NF.OTKJ?^%A?"O\
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M/5+9=#FOAO\ 'GQ;\([&YM?#VLRZ?;7CB66(PQS1EP,;@LBL%)& 2N"0%SG
MQ@^*?%.H>-O$-WJVK74M]J%\_F332'YG/0<=     ,      "O0_^%A?"O\
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M_P"#Z3_"C_A87PK_ .B=ZK_X/I/\*^4_U7P7_0TP_P!V(_\ F<]G^V,1_P!
M=7_RE_\ +3RRBO4_^%A?"O\ Z)WJO_@^D_PH_P"%A?"O_HG>J_\ @^D_PH_U
M7P7_ $-,/]V(_P#F</[8Q'_0'5_\I?\ RT\LHKU/_A87PK_Z)WJO_@^D_P *
M/^%A?"O_ *)WJO\ X/I/\*/]5\%_T-,/]V(_^9P_MC$?] =7_P I?_+3RRBO
M4_\ A87PK_Z)WJO_ (/I/\*/^%A?"O\ Z)WJO_@^D_PH_P!5\%_T-,/]V(_^
M9P_MC$?] =7_ ,I?_+3RRBO4_P#A87PK_P"B=ZK_ .#Z3_"C_A87PK_Z)WJO
M_@^D_P */]5\%_T-,/\ =B/_ )G#^V,1_P! =7_RE_\ +3RRBO4_^%A?"O\
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M\*^#?"MH++3-,LU(CMTR68EF)>21W9G>1RTDDCN[LSLS'L** "BBB@ HHHH
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M*\^%XOM-I/AO*N(]V^.3!VNJG!QBOSP^"G_!L-X!_9K\*W&A?#G]IS]L_P
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M0^"+73?@KXRNOA/X_P!0U+0X;4_VOH]Y:QM)("I$L@:18S$# 6.53+F(@,2
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MX62.1'1U5U90 =A1110 4444 %%%% !7E_P6_;0^%_[1?QE^)7P_\#^,-/\
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M^*O!OBJT%YIFIV;$QW"9*L"K /'(CJR/&X62.1'1U5U91^>/[>_Q@U[X1?\
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MFRUGPMJD!"W6EZC:L=]M>0.=KQMD$%71GC='8 ]0HHHH *\S_:$_Y&/X=_\
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MC49=1*27D4T4D11E\LC.#$2[;F)A]78UB_"[]I;_ (5K\;/$7C'^Q?MO]O\
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MT+<JYU:>G*E\6J5G=71C@<^X)P>(6)PU9QDFWO6:O*]_==XZW?3?7<X?X/\
MCU_AA\3]#UY6E6/3[I7G$2*\CP'Y954-QEHV=1R,$]0>1T'[57AR'P_\==<D
MLVEFT_5W75;6X8AH[I+A1*SQL  T?F,ZJ1D87&2036Q_PQ5XZ_Z!4W_?4?\
M\71_PQ5XZ_Z!4W_?4?\ \77CT_"?CQ9+/)IY<W%U8U8OVE+W6HN$E;GU4TXW
MV:<%N=TN-N&O[0CCXXI)\C@UR3U5U):\OV7>V_Q,FT#]H[2_!OQ'\!S:?8ZA
M)X8\$VLENL4FR.XN9;A&%U<[<MM+,^X1F1E^0 %-QP:KJ_AWXSZ[\-_ ?AFS
M\2?V+I=U+#+/>>4;UTN9UDF($8*@1HK-N/&,Y&%RT/\ PQ5XZ_Z!4W_?4?\
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M[>.]Y'X6MXXX[2*["S+,;N2T@'G)!,<7,D"122Q+(TR:'_"TO%G_ $3W4/\
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M_9'VO^WO^/=O[1_M3S?W'_'QL\C[/_RSSO\ FQ1_PM+Q9_T3W4/_  8PT?\
M"TO%G_1/=0_\&,- 'C_[/O[%7BK3/^"CGQ@_:*^)&H>'[S5M>TJT\!_#W3=*
MGFF_X1OPO;O]IF%Q*8H%EN+V^)N'C:*4VVP1QW,J,0N!^WO_ ,$^_&WC_P#:
M.\&_M'? 'Q!X?\-?M"> ]*E\,"W\5W-^?"?C#0YVE+V&I16CB4>1-.UW \8(
M,T:"1' BD@]__P"%I>+/^B>ZA_X,8:/^%I>+/^B>ZA_X,8: / /V"/\ @GWX
MV\ ?M'>,OVCOC]X@\/\ B7]H3QYI47A@V_A2YOQX3\'Z' T12PTV*[<RGSYH
M%NYWD  FD<1H@,LD_K__  SWKWC+]LG_ (61XIU[S_#/@_2O[+\$^%8?+GL[
M6\G7-[K\Y:!9$U!HW:PA5'=8+473"0G49H8>@_X6EXL_Z)[J'_@QAH_X6EXL
M_P"B>ZA_X,8: /A#XW_\$2_'WQ!T[XV?!?2?%G@^']G']I'XE1?%#QAJEX;G
M_A-M"N))X[O4=-T^-8C931S7-CI_D7,S*;:*2Y5X+MA&Y_2^O/\ _A:7BS_H
MGNH?^#&&C_A:7BS_ *)[J'_@QAH ] HKS_\ X6EXL_Z)[J'_ (,8:/\ A:7B
MS_HGNH?^#&&@#T"BO/\ _A:7BS_HGNH?^#&&C_A:7BS_ *)[J'_@QAH ] HK
MS_\ X6EXL_Z)[J'_ (,8:/\ A:7BS_HGNH?^#&&@#T"BO/\ _A:7BS_HGNH?
M^#&&C_A:7BS_ *)[J'_@QAH _/'Q_P#\$U/V]A\&O'G[.^A_M!?"_P 7? ?Q
MO=W&F)XW\?QZEJWQ,TSP_?%/MEFQ\O[)=2)&]U$KRN'=9"4DM!Y*6WV=X2_9
MH\5?L;_LX_!;X6_L\6GP_L_#/@?5=+TKQ%_PED4T<UUX>17_ +1N;;["D<;:
MQ-(5F\R1%ADEEG=QEJ] _P"%I>+/^B>ZA_X,8:/^%I>+/^B>ZA_X,8: /D#]
MH+]@C]IKX)?\%!/B!\>?V5?&7P?F_P"%W:5IUIX[\+_%*VO380WFF0QVUA=V
M,VGQ^?\ \>_FHT4CJJL\C$R[XUML_P" _P#P1+U7XO?!K]I5OVKO%FG^,OB%
M^UC=Z>_BV+P27T_1O#=OI)9=&CTUY(EF>2W'E.9+A6#F**.1)MLLMS]G_P#"
MTO%G_1/=0_\ !C#1_P +2\6?]$]U#_P8PT ?"&I?\$M/VGOVQ/"OA+X(_M0?
M$CX7^(OV<? MW9W%S=>#[C7K7QI\3TTY#%9P:Y)<3M"D=P=EW=&)Y9//@01.
MK;;B/[?_ &O/A1XR^/'P:F\%^#/&&H?#N3Q-=PV>L^*-*N1#K.BZ7DO='3MT
M,B?;)D3[*DC&,VPNFN49Y+=(9=#_ (6EXL_Z)[J'_@QAH_X6EXL_Z)[J'_@Q
MAH \/_;*_P""?NJ^+_B9^SQ\3O@U'X/T7QE^S-=WEMX;\+:L'T[POJ6C:C:1
M:??6!:UA>6RDCM(U-K+%%+'$\85X)$<&/H/^"8W[$.J_L1_!KQ<OBK7-/U[X
MA?%KQKJGQ*\:2Z5"\.C6FLZF8VN+;3DDS,+.(11HC3,TCE6D.S>(H_4/^%I>
M+/\ HGNH?^#&&C_A:7BS_HGNH?\ @QAH ] HKS__ (6EXL_Z)[J'_@QAH_X6
MEXL_Z)[J'_@QAH ] KS/]H3_ )&/X=_]C-!_Z"]7/^%I>+/^B>ZA_P"#&&N=
M\97'BGXC>*?"'G>#[W2[?2=:AO9IFNHY@$&5/"], YS[4 >Q4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>slide17.jpg
<TEXT>
begin 644 slide17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( )X#"P,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1^Z7_#0'@C_H:M#_ / M/\:/^&@/!'_0U:'_ .!:?XU^%O\ PGFN?]!G5O\
MP+D_QH_X3S7/^@SJW_@7)_C1_P 1VPG_ $"2_P# E_D'_$JV8?\ 0PA_X!+_
M .2/W2_X: \$?]#5H?\ X%I_C1_PT!X(_P"AJT/_ ,"T_P :_"W_ (3S7/\
MH,ZM_P"!<G^-'_">:Y_T&=6_\"Y/\:/^([83_H$E_P"!+_(/^)5LP_Z&$/\
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MX$O\@_XE6S#_ *&$/_ )?_)'[I?\- >"/^AJT/\ \"T_QH_X: \$?]#5H?\
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M^([83_H$E_X$O\@_XE6S#_H80_\  )?_ "1^Z7_#0'@C_H:M#_\  M/\:/\
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M'_TO>OHN%_\ ?9?]>J__ *8J'Q_'/_(LA_U_PO\ ZE43YYHHHKYT^P"BBB@
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M\1O^PLW_ *"M?14_^1%4_P"OT/\ TBH?'UO^2JH_]@]7_P!.43QNBBBOG3[
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M=@<PQ.:UJ<*E>K5E4C-TX\]-.$8\BF[RLN5NZ<?B:MNW^I_[1?P(\%?M$?\
M!47P_H'CD?:-.C^'GVNTL?MIM?[1N5OKD"+*E9&VQM++MC8-^YR255@<;X[6
M&J7W_!.7XP:'<>#? O@WQ%8ZC;ZC<>$_"!AFGT:R-U:R1R7RP$KYQAADD,H"
MJT,:MA=K*OYDT5]37\1J-3ZS)811E7]HI-25[5(\J3?L[MPWCJHV;3C=J2^#
MPO@WB*/U&,LP<H87V+C%PE;FI5'-M+VO+%5%92O&4KQBU.R<7^BG[5GP1U3]
MN_XP_#_XL> /$^C:/X+M=#@75M>;588[GP;) TEZ[7"I)E)DCN$PJ/E70[VB
M7$AS_P#@G3JD>N?L:_%+X?\ A5? OCGQM9:Y)JUIHFNV\DFFZS:*+-%F$<PC
M+*S0/LW[/+D,)D\L,#7Y]T5Q1XZIQS)YFL/[]1353W]^>*B^3W;0M:^JG=NS
M=K)>I+PKK2R99)+&+V=*5-T?W2]WV<Y32J-3YJE[\ONRII))I<S;?Z2^#_''
MC?4/^"@/P(\+>.H_AGI>I>&-.U-XM"\)+.&T&.?2FVV]R&+0JP6) B0NP"C/
MW&C9M'X'_"#5/V4?VIOCM\;O%5QHS> /)U9[6[LM1AFDOY)=068V\:E@%FCD
MA:W9)"A\\JB[QEA^9-%=-#Q"C"7M:E!RG&HZD&ZFS]G&G%2]SWDE%-VY;NR7
M*E9\>*\'YU(>PHXJ-.G.C&C4BJ/Q15:=:;@_:>XY.;BK^TY5=OFDTU]M> _#
M%S^V-_P3"\,_#GP-)I][XY\"^(IM0N]%N;^"WN[RV,EP3- K/S&/[0B!>38N
MZ.1020H?G?\ @J'XOTG3O"?P:^&MKJFGZQKGPU\/-I^M3Z=<I<6D-R$M[9H0
MP.\2(]G(61T1@KQ\9) ^1Z*\7&<7>WR]X/V5IRITZ<I<UTX4FG&T>71NRN^9
MIVT2UO\ 29?X??5<XCF+Q%Z<*M:M"')9JI734[SYGS15Y.*Y$TWJW96****^
M-/T@*^AOV8?^3)_VC?\ KTT'_P!+WKYYKZ&_9A_Y,G_:-_Z]-!_]+WKZ+A?_
M 'V7_7JO_P"F*A\?QS_R+(?]?\+_ .I5$^>:***^=/L HHHH ]#_ &1?^3K_
M (8?]C;I7_I9%7Z?_M _##]I[Q%\7=6O/AW\1O!N@^#IO)_L^QOK:-[B#$,8
MEW$V4IYE$C#YVX8=.@_'VBON.&>,8Y5@JF#G3F^::ES4ZKI/1-6;C%MIWO:^
M]NQ^7<;>',\^S*EF5.M2BZ=.4.6KAXUXOFDI<R4IQ2DK63LW9O74_3:U^,_P
MI^"__!6W6)K'4-&TFUUSPQ-IFNWR3I!8VNM?:/M$IGDD98U8QVZ(QCSF=\,/
M,,A'GGPU^$&J?\$\_P!E3X\P_$FXT:QOO'6G'1/#]C:ZC#+=:N42>W-S%&64
MM"&OHG/_ "T5%<M&ORAO@RBNVIQ_SSE7>'2FI5I4[2M&'MH\LN:/*^?35.\=
M6VTUH>;2\)?9TX8:.,DZ4H8>-92CS2J?5IN<'&?,O9IMV:<9^ZDDT]3[B_;U
M\ :I\2?V"?@#XNT&&WU3P[X-\,);ZQ>P7<)6RDDCT^V5"N[<S":-XV" E&0A
MMN*],^,_PWN?VN_VHOA#\<?!^I>'9/A[X?M+"[U^\NM6@C?P[]CG;4)8KM59
M@DGE3*NU2VQP=Y1,.?S1HJ)<<49UZE2IAVXU%1<ESV]^BK1:?)I%K>+3>]I+
M2VL/"_$4L+2HT,8E*B\2H2=)O]WB7S3C)>T5YQ>L9IQ6B3IO7F^_/A]=0_&[
M_@J%X^^,6CZM_9_P_P#AEF\UG5T>*8RPP:>]J1"BK-YL<WV>9@R#)A#$,DAC
M%<'_ ,%2[*3XY6W@OXZ:!>7&H> _%6G1Z/;K=K'#<Z5=Q27#/;&,*"5++,=^
MZ7YTE^<(80?C^BN7&<9?6<OKX"K1_C3E5DU)K]Y*2::5K<JBN5QU;;YN9627
M=E_AO]2S?"YK0Q'^[4H4(1<$_P!S&#3BY<UW.4VI*:LHI<G([N3****^'/U
M**** .B^$7_)6/"__86M/_1R5Z%_P4)_Y/3^(W_86;_T%:\]^$7_ "5CPO\
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M^!1/N?\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\
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M_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\
MB:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W
M_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\
MB#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_
M-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_
M (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ
M3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#
M2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*
MO^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/
M#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-
M_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5
M)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75
MX-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI
M)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_X
MJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&
MI_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\
MX-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@
MF/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_ST
MD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z
M&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT
M:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A
M=7@W_H;/#/\ X-(/_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%
M$/\ B#&-_P"@F/W,_2+_ (75X-_Z&SPS_P"#2#_XJC_A=7@W_H;/#/\ X-(/
M_BJ_-W[5)_STD_[Z-'VJ3_GI)_WT:/\ B:G*O^@&I_X%$/\ B#&-_P"@F/W,
M\K_;E\*:IXM_:+UJ^TG3=0U.REDD*7%I;O-$^9I2,,H(/!!_$5Y!_P *O\3?
M]"[KO_@!+_\ $U^P_P"Q[\-?#GB;X":3>:EX?T74+R22<//<V,4TC8E8#+,I
M)P.*]._X4MX-_P"A2\,_^"N#_P")K[S$>%>!SZ?]M.O.'UA*IRV3MS).U_*Y
M]7DGT@LRX>P-/(X82G-8=>SYG*2;Y7:]O,_"K_A5_B;_ *%W7?\ P E_^)H_
MX5?XF_Z%W7?_   E_P#B:_=7_A2W@W_H4O#/_@K@_P#B:/\ A2W@W_H4O#/_
M (*X/_B:P_X@5@/^@J?W1/5_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FC_A5_B;_H7==_\ )?_B:_=7_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#
M/_@K@_\ B:/^(%8#_H*G]T0_XFHS7_H!I_\ @4C\*O\ A5_B;_H7==_\ )?_
M (FO=?V=?#NH:)^R%\?--O;&\L]2UBUT5;"TGA:.>^,=ZS2")"-TFU>3M!P.
M37ZP?\*6\&_]"EX9_P#!7!_\31_PI;P;_P!"EX9_\%<'_P 37?EO@S@L'6=:
M.)D[QG'9?;A*#?R4KGE9S])+,LQPZP\\'3BE.G.ZE+>G4A42^;@D_)GX5?\
M"K_$W_0NZ[_X 2__ !-'_"K_ !-_T+NN_P#@!+_\37[J_P#"EO!O_0I>&?\
MP5P?_$T?\*6\&_\ 0I>&?_!7!_\ $UP?\0*P'_05/[HGJ_\ $U&:_P#0#3_\
M"D?A5_PJ_P 3?]"[KO\ X 2__$T?\*O\3?\ 0NZ[_P" $O\ \37[J_\ "EO!
MO_0I>&?_  5P?_$T?\*6\&_]"EX9_P#!7!_\31_Q K ?]!4_NB'_ !-1FO\
MT T__ I'X5?\*O\ $W_0NZ[_ . $O_Q-'_"K_$W_ $+NN_\ @!+_ /$U^ZO_
M  I;P;_T*7AG_P %<'_Q-'_"EO!O_0I>&?\ P5P?_$T?\0*P'_05/[HA_P 3
M49K_ - -/_P*1^%7_"K_ !-_T+NN_P#@!+_\31_PJ_Q-_P!"[KO_ ( 2_P#Q
M-?NK_P *6\&_]"EX9_\ !7!_\31_PI;P;_T*7AG_ ,%<'_Q-'_$"L!_T%3^Z
M(?\ $U&:_P#0#3_\"D?A5_PJ_P 3?]"[KO\ X 2__$T?\*O\3?\ 0NZ[_P"
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M . $O_Q-?NK_ ,*6\&_]"EX9_P#!7!_\31_PI;P;_P!"EX9_\%<'_P 31_Q
MK ?]!4_NB'_$U&:_] -/_P "D?A5_P *O\3?]"[KO_@!+_\ $T?\*O\ $W_0
MNZ[_ . $O_Q-?NK_ ,*6\&_]"EX9_P#!7!_\31_PI;P;_P!"EX9_\%<'_P 3
M1_Q K ?]!4_NB'_$U&:_] -/_P "D?A5_P *O\3?]"[KO_@!+_\ $T?\*O\
M$W_0NZ[_ . $O_Q-?NK_ ,*6\&_]"EX9_P#!7!_\31_PI;P;_P!"EX9_\%<'
M_P 31_Q K ?]!4_NB'_$U&:_] -/_P "D?A5_P *O\3?]"[KO_@!+_\ $T?\
M*O\ $W_0NZ[_ . $O_Q-?NK_ ,*6\&_]"EX9_P#!7!_\31_PI;P;_P!"EX9_
M\%<'_P 31_Q K ?]!4_NB'_$U&:_] -/_P "D?A5_P *O\3?]"[KO_@!+_\
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M3#Y8^4DF;CT/Y[PSD,\YS*GE\)J',I-R>T8PC*<I/JTHQ;LM7;2[/J,XS*.
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M8<;2<8P<'!)5@-3]D70K'Q+^T-X?L=2L[74+.;[3YEO<Q++%)BVE895@0<$
M\]P*SPG"V-GG5#(\3%TJM6=."YEM[1I1EIO&TDTUHUL56SG#QR^IF-%\\(1E
M+3KRIMKR>EM=GN>;T5];>*_%\/A_Q3J5A:_LZQ:E;6-U+;Q7<6ECR[I$<JLB
MXM",, ",$C!ZGK7@^I_"Z^\=^!?%'Q&L8M+TO0;757C.GK(WFV_F21E4C"H$
M*+YZ#JO"G@<"OH^(O#UY?)TL#B/K$XJ<IQ5*K3Y8TU><KU(Q4E'KRM]]F>3E
M7%'UI<^(I>RBW%1;G"5Y3=HJT&VF_-(X&BN^UW]F[Q+H]OX.:%+75+CQQ!]H
MTZWLW9I579&Y\S<JJN%D!)R5 5B2 ,UH>-?V5->\(^'M5U"WU3PWXA707V:G
M;Z1>FXN-/'S M*A12H4HP/<8)(PK$>#_ *DY[RU9?59VII.6FR<%4^?N-3:5
MVHM-V1Z?^L.6W@O;1]^Z6N]I<OR][W5>UWHCS&BO7M+_ &,?$NI:)H&I/JWA
M6QL_$D$4MI)=WS19DE5&B@P4RTKAB0J!A^[;D?+NZG]F[]E/R/CQJ6E^-+>U
M?_A'8%NXK)I<IJ>Y\),JD?O;<8.[IABBL.62O9RSPMXCQ>,P^$GAY4U6DHJ<
ME:*YH\Z;:OIRIM=79I7:L<&,XRRJAAZM>-53]FFW%;NSY;)>MD^U[O0^>**[
M[0/V=M7\5>.M4T;3=2T"\M=%@%S?:U%>;M*MHS'ORT^WZK@#.5?^%685?BA\
M"]7^%FF:?J4USI>L:-JFY;?4]*N/M-FTBE@8R^!AQM)QC!P<$E6 ^?J<)YQ3
MPL\=/#R]E!M2E:Z7+)1D]-XJ347)7CS:7N>I#.\#*M'#QJKGDDTNNJNOFUK9
MZVUM8XNBN^_9H^$G_"YOB[I^ES)NTVWS>ZASC-NA&5X96^=BL>5.5W[L<&O1
M/AS%I_B.Z^+7B;0O"FB^*+G3;JUCT*Q?2/,M_LTMRZ?+:H%Y\I%.=H8;22>7
MSZW#_ V)S.A2Q+FJ<:DJJC=-N2HTG5J.,5K*R48JR=YRM=6.',^(Z.$JSHJ+
MDX*#>J23J34()MZ*[NW?:*O9W/GVBOHSX@?#G0?AE\4OB=X@DTC3X=%T6UCM
M-(MI81)$=4NH(W7RXI/W4@CW2.T9R$5E(3 &/,?V9%TB]^-&DZ;KUO:W.D:U
MYFG3QSV_F[FE1EB"G!:-_-\L"1"K+G[P&:O,.!*^"S:CD^)K1C4JU94[Z\L5
M&JZ2G)NS493C)[745S:WL3A>)*>(P53'T:;<80C.W5W@IN*M?51:ZZMVTW.!
MHK?^*7P_NOA9\0=6\/WC>9+ILYC63 'G1D!HY, MMW(RMMR2-V#R#6!7QN,P
M=;"8B>%Q,7&I3DXR3W4HNS3\TU8][#XBG7I1K4G>,DFGW35T_F@HHHKF-@HH
MHH **** "BBB@ HHHH **** "BBB@#[R_8A_Y-ST;_KK<?\ HUJ]:KR7]B'_
M )-ST;_KK<?^C6KUJO\ 6;A7_D28/_KU3_\ 2$?Q+G7_ ",*_P#CE_Z4PHHH
MKWCS0HHKX@_:C^'?[;7[37[9.N:!\,_B+X?_ &8_@EX+TJW_ +-\5_V!IGC'
M5?B%J-PL4DO^AW!'V*WM<21?,8W9QO'GI,/LH!]OT5^<'_!/[_@I9^T%^U1_
MP2H^*?B3PQX3^'_QG_:$^$/BN^^'%A<:)KL-MX;\?WEH;,#6XY7\B);<PW?V
M@QH\2W MV\HVXG2.'@/VXO'W[<W_  2S^!+?M.>-/VA/A_\ %CPSX5U6PN_&
M7PFMO EMHFE)9W]PEK)::;JRB6^D^SSW4*P2W 1F2,2RB0JUO, ?J]117Y@_
MM5? ?]L+]C?]G'QI\4O&W_!2#['X9\#Z5-JMYM^!/AF.:ZV+^[MH/.N8XVN)
MI"D,4;.OF2RQH#EA0!^GU%?F#X)_:P_:@TSX6?L,? _XA>+O^$7^-O[3?]N:
MWXP\<1Z#:C5?#>G:;#_:XTZ+39[2.UAU"6TFM[*22:!TMGBG/DW#E9%Z_P#9
M<_X*8?%SX@_LC^.O#,=CX/\ &G[1'@GXP:O\ _#FHZB)-'T;QMJFG1_:'UR\
MAA5_L4<>GQW=[/;1.1*;"6.!D>X@A4 _0^BL_P )Z-<>'/"NFZ?>:MJ&O7EA
M:16\^IWZ0)=:BZ(%:>58(XH1)(06811QQ@L=J*N%&A0 4444 %%%% !1110
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M@_X1R7GPU?XE>(/B'JFC?\)!J=C;C5/L45MI]A(4M6D,L861K@L##=.R>7)
MOF\_\,/^"AWQ0_8EU']HKX1_'O5=/^+7Q"^!OPUG^,'A/Q-;Z?%X=D^)?A](
M)FN1-;6PGM["2UOXC9!R0\L;QR"W.QY)0#]#Z*_-#]CS]NSXV^%OVA_V0K/X
MD>.-/^)>B?MN>"M4\4KIJ>'[;1(_AK>VM@NM)#820AI;JS:TO(K-H[QY9O,M
M%N!< 2/;U]?_ +$/Q;\9?M)>%=<^)^NMI]CX'\:W:7'PWTRQF$RS>&E3=9ZQ
M<L\$<T=YJ(D:X:!F*V]O]BB,<=PETT@![A1110 4444 %%%% !1110 4444
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MSR<K?*Y]IEF#6#P=+")W]G&,;]^5)?H%%%%>2=P4444 %%%% !1110 4444
M%%%% !1110!]Y?L0_P#)N>C?]=;C_P!&M7K5>2_L0_\ )N>C?]=;C_T:U>M5
M_K-PK_R),'_UZI_^D(_B7.O^1A7_ ,<O_2F%%%%>\>:%?$'[:?[;G[*?QU^*
M?Q._9%_:4N/^$*T^'2M*UN9O&^H'POH/C.S::&YCETW4EN(C+Y%U%&CKOB9I
M(9E02K#.4^WZ\_\ CI^R=\+/VH/[+_X69\-/A_\ $3^P_-_LW_A)_#UIJ_\
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M32FOU8M=6]O8JDD*LL0A6\:(0Q%7!/\ @MEX!_X>)?\ !(7]HCP+\(=:\/\
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MQM_T.'BK_P &T_\ \71_PO/QM_T.'BK_ ,&T_P#\71_QBO\ U$?^4P_X6O\
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M_P#\71_PO/QM_P!#AXJ_\&T__P 71_QBO_41_P"4P_X6O^G7_DX?\*,\;?\
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M /Q='_&*_P#41_Y3#_A:_P"G7_DX?\*,\;?]"=XJ_P#!3/\ _$4?\*,\;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"UY9R^5'/',WG::8+W:85:..;# ;&->W_MA_MV?&WQ3^T/\ M>V?PW\<:?\
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MY,G':K_P1^">M?#_ /:H\9:YJ3:?'8ZTEW+8!;E6ENTEN8I2RQ_> CRJN6
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MHV^==4DSZP\9^$-(\>Q?L]Z1KLGEZ7>Z4ZRCSO)\UA:6K)'N_P!MPJ8&&.[
M()!KKX?#;Z#X.^)GANU\-^&]!:31YX=%T_3G6;5M4MDAEB6YF"DM('=@$)&X
M,SJV3AF^(**]'"^,N'HUZN*_L]>TJ63DJD5+E6'C0Y7)TG)KW74BDXI2E:2E
M9,Y:W 56=.%'ZT^6-W;E=KNJZMTN=*^JB[IMI:-7/HS]I?PQ>>+?V9_ACKFF
MQQ7FDZ!HZQ7]Q'.A6W=UM80N,Y)\Q64A02I4YQ7KWC[7=>\2^(=#\7>"-/\
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MO3H=0L+ORY%EC\R"96C?;(B.-P.&12.0#1X_^$_A7XK_ -B_\)3X9\/^)?\
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M3K=A*&AANV0S1QD3S@HK@$32<?.V0#L**** "BBB@ HHHH **** "BBB@#X
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M* %    % &A1110 4444 <S%_P E?F_[!(_]&UTU<S%_R5^;_L$C_P!&UTU
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MW_H&C][/S=_L6\_Y]+K_ +]-_A1_8MY_SZ77_?IO\*_2+_A4WA7_ *%GP_\
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MWG_/I=?]^F_PK](O^%3>%?\ H6?#_P#X+H?_ (FC_A4WA7_H6?#_ /X+H?\
MXFC_ (E6RK_H.J?^ Q#_ (C/C?\ H&C][/S=_L6\_P"?2Z_[]-_A1_8MY_SZ
M77_?IO\ "OTB_P"%3>%?^A9\/_\ @NA_^)H_X5-X5_Z%GP__ ."Z'_XFC_B5
M;*O^@ZI_X#$/^(SXW_H&C][/S=_L6\_Y]+K_ +]-_A1_8MY_SZ77_?IO\*_2
M+_A4WA7_ *%GP_\ ^"Z'_P")H_X5-X5_Z%GP_P#^"Z'_ .)H_P")5LJ_Z#JG
M_@,0_P"(SXW_ *!H_>S\W?[%O/\ GTNO^_3?X4?V+>?\^EU_WZ;_  K](O\
MA4WA7_H6?#__ (+H?_B:/^%3>%?^A9\/_P#@NA_^)H_XE6RK_H.J?^ Q#_B,
M^-_Z!H_>SS']CWQUHGAGX":39ZEK&EZ?>1R3EX+F[CAD7,K$95B",CFO3O\
MA;/A7_H9O#__ (,8?_BJ;'\(O"L0('AK0>23S81-UY[K^G:G?\*F\*_]"SX?
M_P#!=#_\37].9;@HX/!TL'%W5.,8I]^5)7_ _'\7B'7KSKM6<FW][N'_  MG
MPK_T,WA__P &,/\ \51_PMGPK_T,WA__ ,&,/_Q5'_"IO"O_ $+/A_\ \%T/
M_P 31_PJ;PK_ -"SX?\ _!=#_P#$UW'.'_"V?"O_ $,WA_\ \&,/_P 51_PM
MGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\
MP70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\
M"IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\
M\&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"
MIO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\
M_!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V
M?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__
M  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PM
MGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\
MP70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\
M"IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\
M\&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"
MIO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\
M_!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V
M?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__
M  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PM
MGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\
MP70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\
M"IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\
M\&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"
MIO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\
M_!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V
M?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__
M  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PM
MGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\
MP70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\
M"IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\
M\&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"
MIO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\
M_!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V
M?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__
M  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PM
MGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\
MP70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\
M"IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\
M\&,/_P 51_PMGPK_ -#-X?\ _!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"
MIO"O_0L^'_\ P70__$T '_"V?"O_ $,WA_\ \&,/_P 51_PMGPK_ -#-X?\
M_!C#_P#%4?\ "IO"O_0L^'__  70_P#Q-'_"IO"O_0L^'_\ P70__$T 97A_
MQ5I?B3XNSMIVI6&H*NDC)MKA)<8E&?ND^H_,5VM9>B>"-%\-733Z;H^EZ?,Z
5[&DMK5(F9<@X)4 XR <>PK4H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>slide42.jpg
<TEXT>
begin 644 slide42.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M%U^>5O$[BZC+DK8AQ>]G3II_C _7\+X(^'F)CSX;"1FMKQK56K]KJJS]#/\
MA_-_U2G_ ,N;_P"Y*/\ A_-_U2G_ ,N;_P"Y*_/.BL?^(K<4_P#05_Y)3_\
MD#I_X@)P)_T _P#E6M_\L/T,_P"'\W_5*?\ RYO_ +DH_P"'\W_5*?\ RYO_
M +DK\\Z*/^(K<4_]!7_DE/\ ^0#_ (@)P)_T _\ E6M_\L/T,_X?S?\ 5*?_
M "YO_N2C_A_-_P!4I_\ +F_^Y*^!?"?@_5_'NO0Z5H6EZEK6J7.XPV=A;/<W
M$NU2S;40%CA02<#@ FNB\2_LV_$7P7H=QJFL> ?&FDZ;9J&GN[S0[F""$$@
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M0_U%S_\ Z!9_A_F>^45X'_P\6\$_] OQ5_X#0?\ QZC_ (>+>"?^@7XJ_P#
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M  R+\6/^B8?$/_PG+S_XW7[JT4?\0*P'_05/[HA_Q-1FO_0#3_\  I'X5?\
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M/^)5LJ_Z#JG_ (#$/^(SXW_H&C][/S=_X49XV_Z$[Q5_X*9__B*/^%&>-O\
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MIT$.J1W&AS1P7+W.F7-M!(SQ+*I@FDC6.X4*X!>%G56#(Q#JRCYA_P""6O\
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M9^"M8\2:_J%OI.AZ!93:CJ-[<-MBL[>%#)+*Y[*J*S'V%?)O[1?C#6?V0/\
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M!97L^!'N*@0N3R!G(P>Q(/%?).O^&M2\*:A]DU33[[3;K:'\FZ@:&3:>AVL
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M%7_)LWAG_MZ_]*YJ]3KRS]BK_DV;PS_V]?\ I7-7J=?ZJ>'?_)*Y9_V#T?\
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M&?\ MZ_]*YJ]3K_53P[_ .25RS_L'H_^FXG\8\4_\CK%_P#7VI_Z6PHHHK[
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MC_A8?CK_ *)W_P"5ZW_PKOZ* . _X6'XZ_Z)W_Y7K?\ PH_X6'XZ_P"B=_\
ME>M_\*[^B@#@/^%A^.O^B=_^5ZW_ ,*=X8U_7->^)NGMK7A_^P6CTN]$2_;H
M[KS@9;/)R@&W''7KFN]K+N]&FG\;:?J"[/L]K8W5N^3\VZ22W9<#TQ$V?PH
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M^@?X@_[\0_\ QV@#UZBO(?\ AM/PM_T#_$'_ 'XA_P#CM'_#:?A;_H'^(/\
MOQ#_ /': /7J*\A_X;3\+?\ 0/\ $'_?B'_X[1_PVGX6_P"@?X@_[\0__':
M/7J*\A_X;3\+?] _Q!_WXA_^.T?\-I^%O^@?X@_[\0__ !V@#0_9P^-6J?&#
M^V?[2M]/@_L[R/+^RHZ[M_F9SN9O[@QC'>O3J^4OV</C5I?P?_MG^TK?4)_[
M1\CR_LJ(VW9YF<[F7^^,8SWKT_\ X;3\+?\ 0/\ $'_?B'_X[0!Z]17D/_#:
M?A;_ *!_B#_OQ#_\=H_X;3\+?] _Q!_WXA_^.T >O45Y#_PVGX6_Z!_B#_OQ
M#_\ ':/^&T_"W_0/\0?]^(?_ ([0!Z]17D/_  VGX6_Z!_B#_OQ#_P#':/\
MAM/PM_T#_$'_ 'XA_P#CM 'IEKK<D_C"^TTHHCM;.VN5?^)C*\ZD'V'E#\S6
ME7AMI^USX;@\9ZAJ+6.N>3=65M;(HABW!HWN&8G]YC&)5QSV/3C.I_PVGX6_
MZ!_B#_OQ#_\ ': /7J*\A_X;3\+?] _Q!_WXA_\ CM'_  VGX6_Z!_B#_OQ#
M_P#': /7J*\A_P"&T_"W_0/\0?\ ?B'_ ..T?\-I^%O^@?X@_P"_$/\ \=H
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M:UJ-CH^CZ3;27M]?WMPEO;64$:EY)99'(5$5069F(  )) I-I*[&DV[(S?\
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M%U"ZADDC=259&4@A@2"""*%JKK8):/E>_P#7^9;HHHH **** "BBB@ HHHH
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M*>E*,7]E127;EBD]>JT7*]'9-M*]D5-:CDNKDWYW=UIT:UNM=TDW:[=1110
M4444 %?"WA?]FO3_ (+_ /!<[P[XF/B+QCXL\1^//A;XIGO[_P 0:G]I^S6\
M.L:&;:QM8(UCM[:V@$TH5(HU9C(SR-+(Q<_=-<%K/[.^BZY^TSX?^*TUUJB^
M(O#?AS4?#%M;I)&+*2VO;BSN)7=2A<R![&(*0X4!GRK$@K5%\F(A5>R4T_\
MMZG**_\ )G$*GO494^_*U\IQ?Y)GYW>-88=<_P""+'[7'CJ^$*^,H_&_C/Q%
M_:3&)KJVU/2=8ECTN428XDMTL;)(CU58T QQ7ZA>';N;4/#]C<7">7<36\<D
MJ9#;6*@D9'!P?2OG[QG_ ,$S_"?C7Q[KUY-XN\?V?@?Q=KD7B7Q#\/[:[LU\
M-ZYJ,9C8SRAK9KQ%DDAADE@ANHX)GC)DC<22B3Z-I4W:C"'51BK=N6"B[>3M
MIUY5&]G=(J^]6<UMS3?JISYDG_A7RO*5N[****0!1110 5\+?M@_LUZ?X?\
M^"J7[+/Q.O/$7C'7]>U;QKJFD6-GJ.IYTKPY9'PMJKRP65I$J1+YLL,<DDTH
MDG8HJ^;Y:JB_=-<%\6/V=]%^,7Q*^&WBK4[K5(-0^%NM7&NZ5':R1K#<3S:?
M=6#+.&1BR"*[D8!"AWJAR0"IJF^6:GV_7?\ #3T;6S82UISAWC)?-Q:7XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>slide91.jpg
<TEXT>
begin 644 slide91.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /V8_:X_
M:)UCX PZ"VDV>FW1U5K@2_:T=MOE^7C;M9>N\YSGH*\7_P"'C'C+_H$>&?\
MOS/_ /':ZK_@I7_Q[>#?]Z\_E!7RK7\;^-GBMQ3D'$T\ORG%>SI*$';DIRU:
MUUE"3_$_>O#W@O)LSRA8K&T>:?-)7YIK1;:*27X'T!_P\8\9?] CPS_WYG_^
M.T?\/&/&7_0(\,_]^9__ ([7S_17Y)_Q'SCS_H._\I4?_E9]O_Q#/AO_ *!O
M_)ZG_P F?0'_  \8\9?] CPS_P!^9_\ X[1_P\8\9?\ 0(\,_P#?F?\ ^.U\
M_P!%'_$?.//^@[_RE1_^5A_Q#/AO_H&_\GJ?_)GT!_P\8\9?] CPS_WYG_\
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M_P#)ZG_R9] ?\/&/&7_0(\,_]^9__CM'_#QCQE_T"/#/_?F?_P".U\_T4?\
M$?.//^@[_P I4?\ Y6'_ !#/AO\ Z!O_ ">I_P#)GT!_P\8\9?\ 0(\,_P#?
MF?\ ^.T?\/&/&7_0(\,_]^9__CM?/]%'_$?.//\ H._\I4?_ )6'_$,^&_\
MH&_\GJ?_ "9] ?\ #QCQE_T"/#/_ 'YG_P#CM'_#QCQE_P! CPS_ -^9_P#X
M[7S_ $4?\1\X\_Z#O_*5'_Y6'_$,^&_^@;_R>I_\F?0'_#QCQE_T"/#/_?F?
M_P".T?\ #QCQE_T"/#/_ 'YG_P#CM?/]%'_$?.//^@[_ ,I4?_E8?\0SX;_Z
M!O\ R>I_\F?0'_#QCQE_T"/#/_?F?_X[1_P\8\9?] CPS_WYG_\ CM?/]%'_
M !'SCS_H._\ *5'_ .5A_P 0SX;_ .@;_P GJ?\ R9] ?\/&/&7_ $"/#/\
MWYG_ /CM'_#QCQE_T"/#/_?F?_X[7S_11_Q'SCS_ *#O_*5'_P"5A_Q#/AO_
M *!O_)ZG_P F?0'_  \8\9?] CPS_P!^9_\ X[1_P\8\9?\ 0(\,_P#?F?\
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MS_11_P 1\X\_Z#O_ "E1_P#E8?\ $,^&_P#H&_\ )ZG_ ,F?0'_#QCQE_P!
MCPS_ -^9_P#X[1_P\8\9?] CPS_WYG_^.U\_T4?\1\X\_P"@[_RE1_\ E8?\
M0SX;_P"@;_R>I_\ )GT!_P /&/&7_0(\,_\ ?F?_ ..T?\/&/&7_ $"/#/\
MWYG_ /CM?/\ 11_Q'SCS_H._\I4?_E8?\0SX;_Z!O_)ZG_R9] ?\/&/&7_0(
M\,_]^9__ ([1_P /&/&7_0(\,_\ ?F?_ ..U\_T4?\1\X\_Z#O\ RE1_^5A_
MQ#/AO_H&_P#)ZG_R9] ?\/&/&7_0(\,_]^9__CM'_#QCQE_T"/#/_?F?_P".
MU\_T4?\ $?.//^@[_P I4?\ Y6'_ !#/AO\ Z!O_ ">I_P#)GT!_P\8\9?\
M0(\,_P#?F?\ ^.T?\/&/&7_0(\,_]^9__CM?/]%'_$?.//\ H._\I4?_ )6'
M_$,^&_\ H&_\GJ?_ "9] ?\ #QCQE_T"/#/_ 'YG_P#CM'_#QCQE_P! CPS_
M -^9_P#X[7S_ $4?\1\X\_Z#O_*5'_Y6'_$,^&_^@;_R>I_\F?0'_#QCQE_T
M"/#/_?F?_P".T?\ #QCQE_T"/#/_ 'YG_P#CM?/]%'_$?.//^@[_ ,I4?_E8
M?\0SX;_Z!O\ R>I_\F?0'_#QCQE_T"/#/_?F?_X[1_P\8\9?] CPS_WYG_\
MCM?/]%'_ !'SCS_H._\ *5'_ .5A_P 0SX;_ .@;_P GJ?\ R9] ?\/&/&7_
M $"/#/\ WYG_ /CM'_#QCQE_T"/#/_?F?_X[7S_11_Q'SCS_ *#O_*5'_P"5
MA_Q#/AO_ *!O_)ZG_P F?0'_  \8\9?] CPS_P!^9_\ X[1_P\8\9?\ 0(\,
M_P#?F?\ ^.U\_P!%'_$?.//^@[_RE1_^5A_Q#/AO_H&_\GJ?_)GT!_P\8\9?
M] CPS_WYG_\ CM'_  \8\9?] CPS_P!^9_\ X[7S_11_Q'SCS_H._P#*5'_Y
M6'_$,^&_^@;_ ,GJ?_)GT!_P\8\9?] CPS_WYG_^.T?\/&/&7_0(\,_]^9__
M ([7S_11_P 1\X\_Z#O_ "E1_P#E8?\ $,^&_P#H&_\ )ZG_ ,F?0'_#QCQE
M_P! CPS_ -^9_P#X[1_P\8\9?] CPS_WYG_^.U\_T4?\1\X\_P"@[_RE1_\
ME8?\0SX;_P"@;_R>I_\ )GT!_P /&/&7_0(\,_\ ?F?_ ..T?\/&/&7_ $"/
M#/\ WYG_ /CM?/\ 11_Q'SCS_H._\I4?_E8?\0SX;_Z!O_)ZG_R9] ?\/&/&
M7_0(\,_]^9__ ([1_P /&/&7_0(\,_\ ?F?_ ..U\_T4?\1\X\_Z#O\ RE1_
M^5A_Q#/AO_H&_P#)ZG_R9] ?\/&/&7_0(\,_]^9__CM'_#QCQE_T"/#/_?F?
M_P".U\_T4?\ $?.//^@[_P I4?\ Y6'_ !#/AO\ Z!O_ ">I_P#)GT!_P\8\
M9?\ 0(\,_P#?F?\ ^.T?\/&/&7_0(\,_]^9__CM?/]%'_$?.//\ H._\I4?_
M )6'_$,^&_\ H&_\GJ?_ "9] ?\ #QCQE_T"/#/_ 'YG_P#CM'_#QCQE_P!
MCPS_ -^9_P#X[7S_ $4?\1\X\_Z#O_*5'_Y6'_$,^&_^@;_R>I_\F?0'_#QC
MQE_T"/#/_?F?_P".T?\ #QCQE_T"/#/_ 'YG_P#CM?/]%'_$?.//^@[_ ,I4
M?_E8?\0SX;_Z!O\ R>I_\F?0'_#QCQE_T"/#/_?F?_X[1_P\8\9?] CPS_WY
MG_\ CM?/]%'_ !'SCS_H._\ *5'_ .5A_P 0SX;_ .@;_P GJ?\ R9] ?\/&
M/&7_ $"/#/\ WYG_ /CM'_#QCQE_T"/#/_?F?_X[7S_11_Q'SCS_ *#O_*5'
M_P"5A_Q#/AO_ *!O_)ZG_P F?0'_  \8\9?] CPS_P!^9_\ X[1_P\8\9?\
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MWP_X1UW6+*V^!7B"\L]/DECCU)-2U#R9$7.)1\A7;@9^\1CO7"_$+X>:/=?
M;P7XHT&Q^SW-U-)IFJJLLDGFW(QL;#,0N0K' P/F'%=YX]\7^'?&/B/5KR'X
M\>(+"QU*:1UT]-+U!H88W)_= ;P"H!Q]T#':N<_9C^*WAGPUH.K:%XNO&M]+
M6^M=7L7%N\VZ>&0$KA5;&]549.!C/-?M688?)\9F4\KQ4\/3I5X34*J^I)4Y
M0G&:?-AOA4H*4%[5IRYK*[3/SG 5,=1P<<7!595*;@Y1?UAN2:<9*U71M-\W
MN:)Q3[&!^TQX*T'X:>)=)\/:3;A-0TW3H3J\_FR.9[IU#'AB0N!@X4 ?/CM6
M[\(_ 7A'0?A#:^+/%>CW&O\ ]L:XFD6]NEY););)C+2Y0@LW#?*>#@=,YKD;
M7XY3V_Q(USQ'<:%X=UR;6I7<P:Q9_:XK<,^X;!D8( "Y]*] \)?&'PC\3/ O
M]B^*[BU\&_8==CUFW&FZ;(UG(@0(T*1IDH3\QR<C+9YZ5X_#=;A_%YWB<P3H
MP<U/V5*I"$:4+3BH\SJ?NF_8J7Q+6;O\=CU,PAF='+Z6'J*I))Q=2<)2<W?6
M22C[]E)]-HJVQ:O/V??#/PFU3XB:IKMC>>(-)\*26T5A8FZ:W-P;C:07D3YO
MEWJ,@8/)QVK"^)?P(\-:+\7[&%=87PYX4U;2HM;62YW32P1N<>1$.6D?., \
MA22=VTYW;S]H+PS\6=4^(FEZ[?7GA_2?%<EM+87QM6N#;FWV@!XT^;YMBG .
M!R,]ZX3]I#XG:9\1?'^G_P!C//)HV@V$&F6LTJE6N%C)S)M/(!SP#S@#(!X'
MI<1UN$Z67*IE].C4IJK'V<;I5'^]Q/.JC35;V?L_8_$U&W+[-J7,S@R>GG4\
M7&&+E4C)P]YZ\B7LZ5G&Z<.?VG/>R;WNN6P?M5> -)^&?Q<FTK0[9K6PCM()
M%1I6D8LR DDL2<D\^GIBO-Z](_:J\>Z3\2?BY-JFBW7VVQ:T@B$OE/'EE0!A
MAP#P?:O-Z_)^-OJ?^L.._L_E]C[:IR<EN3DYWR\O+[O+:UK:6VT/L^'?K']E
MX?ZU?VG)'FYK\U[:WOK?O<****^7/:"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J2U_X^8_]X?SJ.I+7_CYC_WA_.O8X=_Y
M&N%_Z^0_]*1PYI_N5;_#+\F?J11117^MA_$)\N_\%*_^/;P;_O7G\H*^5:^J
MO^"E?_'MX-_WKS^4%?*M?YZ?2/\ ^2SG_P!>Z?Y,_J+PG_Y$$?\ '+\PHHHK
M\&/TH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV_\ CE'_  Q+\2O^A?C_ /!A;?\ QROO:BC_ (EOX,_DJ?\ @Q_Y!_Q%?/\
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M_P ,2_$K_H7X_P#P86W_ ,<K[VHH_P");^#/Y*G_ (,?^0?\17S_ /FC_P"
MH^"?^&)?B5_T+\?_ (,+;_XY1_PQ+\2O^A?C_P#!A;?_ !ROO:BC_B6_@S^2
MI_X,?^0?\17S_P#FC_X"CX)_X8E^)7_0OQ_^#"V_^.4?\,2_$K_H7X__  86
MW_QROO:BC_B6_@S^2I_X,?\ D'_$5\__ )H_^ H^"?\ AB7XE?\ 0OQ_^#"V
M_P#CE'_#$OQ*_P"A?C_\&%M_\<K[VHH_XEOX,_DJ?^#'_D'_ !%?/_YH_P#@
M*/@G_AB7XE?]"_'_ .#"V_\ CE'_  Q+\2O^A?C_ /!A;?\ QROO:BC_ (EO
MX,_DJ?\ @Q_Y!_Q%?/\ ^:/_ ("CX)_X8E^)7_0OQ_\ @PMO_CE'_#$OQ*_Z
M%^/_ ,&%M_\ '*^]J*/^);^#/Y*G_@Q_Y!_Q%?/_ .:/_@*/@G_AB7XE?]"_
M'_X,+;_XY1_PQ+\2O^A?C_\ !A;?_'*^]J*/^);^#/Y*G_@Q_P"0?\17S_\
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MV_\ CE'_  Q+\2O^A?C_ /!A;?\ QROO:BC_ (EOX,_DJ?\ @Q_Y!_Q%?/\
M^:/_ ("CX)_X8E^)7_0OQ_\ @PMO_CE'_#$OQ*_Z%^/_ ,&%M_\ '*^]J*/^
M);^#/Y*G_@Q_Y!_Q%?/_ .:/_@*/@G_AB7XE?]"_'_X,+;_XY1_PQ+\2O^A?
MC_\ !A;?_'*^]J*/^);^#/Y*G_@Q_P"0?\17S_\ FC_X"CX)_P"&)?B5_P!"
M_'_X,+;_ ..4?\,2_$K_ *%^/_P86W_QROO:BC_B6_@S^2I_X,?^0?\ $5\_
M_FC_ . H^"?^&)?B5_T+\?\ X,+;_P".4?\ #$OQ*_Z%^/\ \&%M_P#'*^]J
M*/\ B6_@S^2I_P"#'_D'_$5\_P#YH_\ @*/@G_AB7XE?]"_'_P"#"V_^.4?\
M,2_$K_H7X_\ P86W_P <K[VHH_XEOX,_DJ?^#'_D'_$5\_\ YH_^ H^"?^&)
M?B5_T+\?_@PMO_CE'_#$OQ*_Z%^/_P &%M_\<K[VHH_XEOX,_DJ?^#'_ )!_
MQ%?/_P":/_@*/@G_ (8E^)7_ $+\?_@PMO\ XY1_PQ+\2O\ H7X__!A;?_'*
M^]J*/^);^#/Y*G_@Q_Y!_P 17S_^:/\ X"CX)_X8E^)7_0OQ_P#@PMO_ (Y1
M_P ,2_$K_H7X_P#P86W_ ,<K[VHH_P");^#/Y*G_ (,?^0?\17S_ /FC_P"
MH^"?^&)?B5_T+\?_ (,+;_XY1_PQ+\2O^A?C_P#!A;?_ !ROO:BC_B6_@S^2
MI_X,?^0?\17S_P#FC_X"CX)_X8E^)7_0OQ_^#"V_^.4^#]B?XE),C'P_'A6!
M/_$PMO\ XY7WG16^%^CSP?AZ\,13A4YH-27[Q[IW70RK>*6>U:<J4Y1M)-/W
M5L] HHHK]R/SH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\K@_#W_)SWC#_L5]#_\ 2O6*[R@ HHHH **** "BBB@ HHHH **** "BBB@
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M.;!1110 4444 %%%% !1110!P?A[_DY[QA_V*^A_^E>L5WE<'X>_Y.>\8?\
M8KZ'_P"E>L5WE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/
M?QQ_Y*CJG_;+_P!$I7T)7SW\<?\ DJ.J?]LO_1*5^4^,'_(FI?\ 7V/_ *1,
M^MX-_P!]E_@?YQ.3KS+]M;_DS;XM?]B9K'_I#-7IM>9?MK?\F;?%K_L3-8_]
M(9J_G?#?QH^J_,_6\H_WZC_CC_Z4C^>2BBBOUX_O@_8S_@TQ_P":_?\ <N_^
MY2OV,K\<_P#@TQ_YK]_W+O\ [E*_8ROV#A;_ )%=+_M[_P!*9_F_X]_\EWCO
M^X7_ *9IA1117T!^/A1110 5D^/?^1&UK_KPG_\ 1;5K5D^/?^1&UK_KPG_]
M%M7#FG^YU?\ #+\F=&%_CP]5^9\RT445_%)^X'YE_P#!Q=_S1W_N-?\ N/K\
MRZ_33_@XN_YH[_W&O_<?7YEU^E\/_P"X4_G_ .E,_L;PK_Y);"_]O_\ IR85
M_5K_ ,$[/^4?GP+_ .R>Z!_Z;;>OY2J_JU_X)V?\H_/@7_V3W0/_ $VV]?J/
M _\ 'J^B_,_&?I4?\BK _P#7R7_I)['1117Z0?Q.%%%% !1110!XC^TG_P C
MS:_]>"?^C)*\]KT+]I/_ )'FU_Z\$_\ 1DE>>U_(W''_ "/L5_B_1'[%D/\
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MK>#?]]E_@?YQ.3KS+]M;_DS;XM?]B9K'_I#-7IM>9?MK?\F;?%K_ +$S6/\
MTAFK^=\-_&CZK\S];RC_ 'ZC_CC_ .E(_GDHHHK]>/[X/V,_X-,?^:_?]R[_
M .Y2OV,K\<_^#3'_ )K]_P!R[_[E*_8ROV#A;_D5TO\ M[_TIG^;_CW_ ,EW
MCO\ N%_Z9IA1117T!^/A1110 5D^/?\ D1M:_P"O"?\ ]%M6M63X]_Y$;6O^
MO"?_ -%M7#FG^YU?\,OR9T87^/#U7YGS+1117\4G[@?F7_P<7?\ -'?^XU_[
MCZ_,NOTT_P"#B[_FCO\ W&O_ ''U^9=?I?#_ /N%/Y_^E,_L;PK_ .26PO\
MV_\ ^G)A7]6O_!.S_E'Y\"_^R>Z!_P"FVWK^4JOZM?\ @G9_RC\^!?\ V3W0
M/_3;;U^H\#_QZOHOS/QGZ5'_ "*L#_U\E_Z2>QT445^D'\3A1110 4444 >(
M_M)_\CS:_P#7@G_HR2O/:]"_:3_Y'FU_Z\$_]&25Y[7\C<<?\C[%?XOT1^Q9
M#_R+Z7H%?S+U_317\R];\(_\O?\ MW_VX_IKP'_YCO\ N%_[D"OTI_X-:/\
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M74DMT+E7M-=DE\VUS/\ -1VT:;U3/F'_ (>G^/=6^ WQX\8?\(OX=\(I\/\
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MT/C#\6/[0U)]2_M;XC^)/[>U2VW11Q_9XYO+CVP#R]P3!PTCG/S<>PU\>_\
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M .!I>[>4K-W2MO\ .[_39=M5=JR11114@%%%% !1110 4444 %%%% !1110
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MUBC555551@ #  IU0[7T(CS<JYMPHHHI%!1110 4444 %%%% !1110 4444
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M-8_](9J_G?#?QH^J_,_6\H_WZC_CC_Z4C^>2BBBOUX_O@_8S_@TQ_P":_?\
M<N_^Y2OV,K\<_P#@TQ_YK]_W+O\ [E*_8ROV#A;_ )%=+_M[_P!*9_F_X]_\
MEWCO^X7_ *9IA1117T!^/A1110 5D^/?^1&UK_KPG_\ 1;5K5D^/?^1&UK_K
MPG_]%M7#FG^YU?\ #+\F=&%_CP]5^9\RT445_%)^X'YE_P#!Q=_S1W_N-?\
MN/K\RZ_33_@XN_YH[_W&O_<?7YEU^E\/_P"X4_G_ .E,_L;PK_Y);"_]O_\
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M/^1#+_%'\SZ;A/\ Y&"]&>>T445_,1^I'\_7_#Q/]H+_ *+I\8__  M-2_\
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MI;3<_>RBOY2O^'B?[07_ $73XQ_^%IJ7_P >H_X>)_M!?]%T^,?_ (6FI?\
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MXX4444 %>(_M)_\ (\VO_7@G_HR2O;J\1_:3_P"1YM?^O!/_ $9)7YQXJ?\
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M^,/^R>WO_IRTROS6K]*?^#6C_E('XP_[)[>_^G+3*_2N'_\ D8TO4^\\7_\
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M"BBB@ KQ']I/_D>;7_KP3_T9)7MU>(_M)_\ (\VO_7@G_HR2OSCQ4_Y$,O\
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MI_VR_P#1R5\]U]"?''_DEVJ?]LO_ $<E?/=?SCXP?\CFE_UZC_Z7,_2^#?\
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MPO\ V_\ ^G)A7]6O_!.S_E'Y\"_^R>Z!_P"FVWK^4JOZM?\ @G9_RC\^!?\
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MS_V.=K_Z0W]?C]7[ _\ !P)_R9MX9_['.U_](;^OQ^K]$X:_W)>K/ZV\'?\
MDG(_XY_F%?TI?\$!/^42/PF_[C'_ *>;ZOYK:_I2_P"" G_*)'X3?]QC_P!/
M-]7ZAP3_ +]/_ _SB? _2@_Y)7#_ /81#_TW5/L:BBBOU _@\**** "BBB@
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M110!P?A[_DY[QA_V*^A_^E>L5WE<'X>_Y.>\8?\ 8KZ'_P"E>L5WE !1110
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M  O\S]$X+_@5/5?D%?F7_P '%W_-'?\ N-?^X^OTTK\R_P#@XN_YH[_W&O\
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MGO7BGS66BYOBMTO;H<U.ZYD]&I25NUI/W;O?E^&_6UPHHHK$T"BBB@ HHHH
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MIK7=]I%Q+NV1&':WF!R-FT[L8-;N26_K\N_XH\A1;V]/GV.@HKC_ (*_M#^
M/VD_#%QK?PY\<^#_ !]HMI<M93W_ (<UFVU6UAG"JYB:2!W59 KHQ4G(#J<8
M(K!^+_[;'P9_9[\8VOAWQ]\6_ACX'\07L*7-OIGB#Q38Z9>3Q.S(DB0S2J[*
MS*RA@,$J0.0:KE::B]WMYBW3:V1Z=7B/[2?_ "/-K_UX)_Z,DKT)/CWX%D^+
MW_"O5\:>$V\??8?[3_X1H:O;_P!L?9.GVC[)O\[RO]O;M]Z\O^./BC3/&'BB
MVO-)U&QU2S6W>V,]I<)/&)8;B:*6/<I(WI(CHR]59&4X((K\W\5/^1!)_P!Z
M/YM?F?2\)_\ (P7H_P K_EJ<71117\Q'ZF?S+T445^R'^A!]C?\ ! 3_ )2W
M?";_ +C'_IFOJ_I2K^:W_@@)_P I;OA-_P!QC_TS7U?TI5^H<$_[C/\ QO\
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M6TMS:QDKQOIS*]]=+)W]VYI&JJ=*I-]%?=I:2B[2MT=K=[M-)NR.)_X(D?\
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M'@_4I-0L(;N;3[J*YLKC3[W3KJ%MLMM=6MPD=Q;3H<9BFC1P&4[<,">0U_\
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M@II8*,U]K6W17Z+LET05_,O7]-%?S+T^$?\ E[_V[_[<?T]X#_\ ,=_W"_\
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MR2QJ[1/]Z,D9*G'<=*FHHK^&GJ]#]TBFHI-W?<^&/^#@3_DS;PS_ -CG:_\
MI#?U^/U?L#_P<"?\F;>&?^QSM?\ TAOZ_'ZOT/AK_<EZL_KCP=_Y)R/^.?YA
M7]*7_! 3_E$C\)O^XQ_Z>;ZOYK:_I2_X("?\HD?A-_W&/_3S?5^H<$_[]/\
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M^*TY0B[737,G=IM/=)I\J8?\/6O@'_T/O_E$U'_Y'H_X>M? /_H??_*)J/\
M\CU^-5%?S7_Q'#/?^?5'_P !G_\ +#^S?^)8>%O^@C$?^!T__E1^OGB+]H+P
MC^TC>KKG@O5O[:TNU06,L_V6:WVS*2Y7;*B,<+(AR!CGKD'&?7SO_P $SO\
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M_P $SO\ DA&K?]AZ;_TGMJ_+N(O%3^WL&\O^J^SNT[\_-MY<D?S/L<Y\"O\
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M\'%W_-'?^XU_[CZ_,NOTOA__ '"G\_\ TIG]C>%?_)+87_M__P!.3"OZM?\
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MMK^E+_@@)_RB1^$W_<8_]/-]7ZAP3_OT_P# _P XGP/TH/\ DE</_P!A$/\
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M'P?^PE\%(_!/@Z37-0AFO9]6U76==OS?ZQXAU"=MT]]>W! \V>1@"S *.
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M_A/VG_QNOYM_XE/_ .II_P"4/_NQ^L?\1K_Z@_\ RI_]S/PY^)'_ "437O\
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M'_1./ ?_ (3]I_\ &Z/^&5_AA_T3CP'_ .$_:?\ QNO4P_@A[)-?7;_]P_\
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M]C0A1^IWY4E?VF]E;^0_+O\ :%_Y(_K'_;'_ -'QU\QU^\'_  RO\,/^B<>
M_P#PG[3_ .-T?\,K_##_ *)QX#_\)^T_^-U[63?1Q^H4'1_M'FN[W]C;HE_S
M]?8^TR'Z27]FX=T/[.YKR;O[:W1*W\)]C\'Z^Y/^"9W_ "0C5O\ L/3?^D]M
M7WY_PRO\,/\ HG'@/_PG[3_XW1_PRO\ ##_HG'@/_P )^T_^-U[F'\"_9SYO
MKM_^X7_W0X>,/I#?V[ESP']G^SNT[^UYMO+V:_,\+HKW3_AE?X8?]$X\!_\
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M3I=4N)]\+VDR+JEW;V$MJNR82QR-YF]H&3(5UK.I>VG]=NCZZ;?=NJA:^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNM%3Q+I=AXKM+2.36M+9UC-U UI<W"+L=XUD@F:.XB\V/?$H=29A[SM'M?\
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M]3\5?#^X\<?#7XC>(O"NFR7LJ>,?A[?:TGB3P?>M$L<<8@T3;J;VMU$TR2/
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>slide101.jpg
<TEXT>
begin 644 slide101.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MM?%E%'_$T7%7_0/A_P#P"I_\M#_B#N2_\_:O_@4/_D#[3_X>(>!_^@?XF_\
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MK_H'P_\ X!4_^6A_Q!W)?^?M7_P*'_R!]I_\/$/ _P#T#_$W_@+#_P#':/\
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MHH_XFBXJ_P"@?#_^ 5/_ ):'_$'<E_Y^U?\ P*'_ ,@?:?\ P\0\#_\ 0/\
M$W_@+#_\=H_X>(>!_P#H'^)O_ 6'_P".U\644?\ $T7%7_0/A_\ P"I_\M#_
M (@[DO\ S]J_^!0_^0/M/_AXAX'_ .@?XF_\!8?_ ([1_P /$/ __0/\3?\
M@+#_ /':^+**/^)HN*O^@?#_ /@%3_Y:'_$'<E_Y^U?_  *'_P @?:?_  \0
M\#_] _Q-_P" L/\ \=H_X>(>!_\ H'^)O_ 6'_X[7Q911_Q-%Q5_T#X?_P
MJ?\ RT/^(.Y+_P _:O\ X%#_ .0/M/\ X>(>!_\ H'^)O_ 6'_X[1_P\0\#_
M /0/\3?^ L/_ ,=KXLHH_P")HN*O^@?#_P#@%3_Y:'_$'<E_Y^U?_ H?_('V
MG_P\0\#_ /0/\3?^ L/_ ,=H_P"'B'@?_H'^)O\ P%A_^.U\644?\31<5?\
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M_@+#_P#':^+**/\ B:+BK_H'P_\ X!4_^6A_Q!W)?^?M7_P*'_R!]I_\/$/
M_P#T#_$W_@+#_P#':/\ AXAX'_Z!_B;_ ,!8?_CM?%E%'_$T7%7_ $#X?_P"
MI_\ +0_X@[DO_/VK_P"!0_\ D#[3_P"'B'@?_H'^)O\ P%A_^.T?\/$/ _\
MT#_$W_@+#_\ ':^+**/^)HN*O^@?#_\ @%3_ .6A_P 0=R7_ )^U?_ H?_('
MVG_P\0\#_P#0/\3?^ L/_P =H_X>(>!_^@?XF_\  6'_ ..U\644?\31<5?]
M ^'_ / *G_RT/^(.Y+_S]J_^!0_^0/M/_AXAX'_Z!_B;_P !8?\ X[1_P\0\
M#_\ 0/\ $W_@+#_\=KXLHH_XFBXJ_P"@?#_^ 5/_ ):'_$'<E_Y^U?\ P*'_
M ,@?:?\ P\0\#_\ 0/\ $W_@+#_\=H_X>(>!_P#H'^)O_ 6'_P".U\644?\
M$T7%7_0/A_\ P"I_\M#_ (@[DO\ S]J_^!0_^0/M/_AXAX'_ .@?XF_\!8?_
M ([1_P /$/ __0/\3?\ @+#_ /':^+**/^)HN*O^@?#_ /@%3_Y:'_$'<E_Y
M^U?_  *'_P @?:?_  \0\#_] _Q-_P" L/\ \=H_X>(>!_\ H'^)O_ 6'_X[
M7Q911_Q-%Q5_T#X?_P  J?\ RT/^(.Y+_P _:O\ X%#_ .0/M/\ X>(>!_\
MH'^)O_ 6'_X[1_P\0\#_ /0/\3?^ L/_ ,=KXLHH_P")HN*O^@?#_P#@%3_Y
M:'_$'<E_Y^U?_ H?_('VG_P\0\#_ /0/\3?^ L/_ ,=H_P"'B'@?_H'^)O\
MP%A_^.U\644?\31<5?\ 0/A__ *G_P M#_B#N2_\_:O_ (%#_P"0/M/_ (>(
M>!_^@?XF_P# 6'_X[1_P\0\#_P#0/\3?^ L/_P =KXLHH_XFBXJ_Z!\/_P"
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M #]J_P#@4/\ Y ^T_P#AXAX'_P"@?XF_\!8?_CM'_#Q#P/\ ] _Q-_X"P_\
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M#HK_ ,A^I%%%%?W&?SJ?+O\ P4K_ ./;P;_O7G\H*^5:^JO^"E?_ ![>#?\
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M]ESZQLD[.VJ/SG <28B&#CF%3$>TC!P]HN:E*T9)K:G"+C:33M)WLFNYY?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_YYR?\ ?)H^RR?\\Y/^^37ZD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\
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M'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y-?J111_Q*ME7_0=4_P#
M8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^^37ZD44?\2K95_T'5/\
MP&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3_ODU^I%%'_$JV5?]!U3_
M ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y-?J111_Q*ME7_0=4
M_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^^37ZD44?\2K95_T'
M5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3_ODU^I%%'_$JV5?]
M!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y-?J111_Q*ME7
M_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^^37ZD44?\2K9
M5_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3_ODU^I%%'_$J
MV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y-?J111_Q
M*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^^37ZD44?
M\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3_ODU^I%%
M'_$JV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y-?J1
M11_Q*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^^37Z
MD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3_ODU
M^I%%'_$JV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SSD_[Y
M-?J111_Q*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\\Y/^
M^37ZD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG_/.3
M_ODU^I%%'_$JV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+)_SS
MD_[Y-?J111_Q*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^RR?\
M\Y/^^37ZD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:/LLG
M_/.3_ODU^I%%'_$JV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\FC[+
M)_SSD_[Y-?J111_Q*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\ ?)H^
MRR?\\Y/^^37ZD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\ 99/^><G_ 'R:
M/LLG_/.3_ODU^I%%'_$JV5?]!U3_ ,!B'_$9\;_T#1^]GY;_ &63_GG)_P!\
MFC[+)_SSD_[Y-?J111_Q*ME7_0=4_P# 8A_Q&?&_] T?O9^6_P!ED_YYR?\
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MD_YYR?\ ?)H^RR?\\Y/^^37ZD44?\2K95_T'5/\ P&(?\1GQO_0-'[V?EO\
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MN6.MFG^AAB?&#&5J,J+P\?>36[ZJP4445_3Y^/!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_I7K%=Y7!^'O^3GO&'_8KZ'_ .E>L5WE !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBOL#^;PHHHH **** /F7Q[_ ,CSK7_7_/\ ^C&K)K6\>_\ (\ZU_P!?\_\
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M444 <'X>_P"3GO&'_8KZ'_Z5ZQ7>5P?A[_DY[QA_V*^A_P#I7K%=Y0 4444
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M@?\ KY+_ -)/8Z***_2#^)PHHHH **** /)_VG_^8'_VW_\ :5>3UZQ^T_\
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MWK]*X'_CU?1?F?A/TJ/^15@?^ODO_23V.BBBOT@_B<**** "BBB@#R?]I_\
MY@?_ &W_ /:5>3UZQ^T__P P/_MO_P"TJ\GK^5/$G_DH\1_VY_Z;B?K7#/\
MR+:?_;W_ *4PK\,?^"Q?_*1WXC?]PS_TUVE?N=7X8_\ !8O_ )2._$;_ +AG
M_IKM*\SA7_>Y?X7^:/Z!\$?^1[5_Z\R_]+IGS+7L?_!.S_E('\"_^RA:!_Z<
MK>O'*]C_ ."=G_*0/X%_]E"T#_TY6]?HV$_CP]5^9_1O$7_(JQ/_ %[G_P"D
ML_JUHHHK]X/\EPHHHH **** "O$?VD_^1YM?^O!/_1DE>W5XC^TG_P CS:_]
M>"?^C)*_./%3_D0R_P 4?S/IN$_^1@O1GGM%%%?S$?J1_,O1117[(?Z$'V-_
MP0$_Y2W?";_N,?\ IFOJ_I2K^:W_ (("?\I;OA-_W&/_ $S7U?TI5^H<$_[C
M/_&_RB?P?]*#_DJL/_V#P_\ 3E4****^P/YO"BBB@ HHHH ^9?'O_(\ZU_U_
MS_\ HQJR:UO'O_(\ZU_U_P __HQJR:_BG-/]\J_XI?FS]PPO\"'HOR/,OVUO
M^3-OBU_V)FL?^D,U?SR5_0W^VM_R9M\6O^Q,UC_TAFK^>2OJN$_X-3U7Y'].
M>!G^XXK_ !K_ -)"OV,_X-,?^:_?]R[_ .Y2OQSK]C/^#3'_ )K]_P!R[_[E
M*_3.%O\ D:4O^WO_ $EGJ>/?_)"8[_N%_P"GJ9^QE%%%?L!_F^%%%% !1110
M 5\GU]85\GU^&^-'_,'_ -Q/_;#[S@G_ )??]N_^W!7PQ_P<"?\ )FWAG_L<
M[7_TAOZ^YZ^&/^#@3_DS;PS_ -CG:_\ I#?U^/Y/_OM/U/V[P^_Y*/"?XU^3
M/Q^HHHK]2/[6/WO_ .#6C_E'YXP_[*%>_P#IMTROTIK\UO\ @UH_Y1^>,/\
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MIM76BM>3V26KC\2_6_\ X)]?M$:!^U)^R!X,\7>&_"Z>!]->";26\.1F%H=
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M5[_Z;=,K]*:_:.'_ /D74O0_S'\7_P#DLLQ_Z^/\D%%%%>P?FX4444 %%%%
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MDW&Q](M[A$T>,-;<?9X@;C>/)/WWJ"7$EA,MK)##=-&PADEC,D:/CY2RAE+
M'!(#*2.,CK4U%$I)Q2MLK?U>^GE?396226:BEMV7S>MWVN_)):7W;;\L^%=G
MKUC^T5XS7Q#J6DZI>GPYHA273M-DL(EC^TZOA2CSS$MG<=V\ @@;1@D^IUP?
MA[_DY[QA_P!BOH?_ *5ZQ7>5)04444 %%%% &3X]_P"1&UK_ *\)_P#T6U?,
MM?37CW_D1M:_Z\)__1;5\RU_/_C)_OF'_P +_,_1."_X%3U7Y!7PQ_P<"?\
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MU%%%?J1_:Q^]_P#P:T?\H_/&'_90KW_TVZ97Z4U^:W_!K1_RC\\8?]E"O?\
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MHHH \G_:?_Y@?_;?_P!I5Y/7K'[3_P#S _\ MO\ ^TJ\GK^5/$G_ )*/$?\
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M&[#P5HBVVB?V7]CT;2WG>T6Z_?S?:KT_;9?-N%$*/M7;!'\V[MZ_EOQ-Y?\
M67$\FWN?^FX^;_-VVN]W^L<,JV706ZUL^^K_ %NNE[7LKV17X8_\%B_^4COQ
M&_[AG_IKM*_<ZOPQ_P""Q?\ RD=^(W_<,_\ 37:5Y/"O^]R_PO\ -'] ^"/_
M "/:O_7F7_I=,^9:]C_X)V?\I _@7_V4+0/_ $Y6]>.5['_P3L_Y2!_ O_LH
M6@?^G*WK]&PG\>'JOS/Z-XB_Y%6)_P"O<_\ TEG]6M%%%?O!_DN%%?)W[:,W
MQ6\/_M6_ O4[3X@6NB?#6\\>VND2>&=*TZ2*]UMI=.O)'>_O6F(>!&B.RVCA
M4$X=Y'(5$Y3_ (*'_L\:?\1_C=X'\%^$_&'QE\-?$3XNZLUS>ZCH?Q3\2Z=:
M^'-#L$B?4;V"PAOULHY&4V]K&! 4\Z]61D?:^9IRYU=?SN'S2C*_I:5WV2N^
MJ537*[/^52^5Y*WK>-DNK=ETO]N45POQP^%NN?$;X*WWA/POXPU+P3?7T<%F
M=<AC:\U"WM0Z"<0NTBLMQ)")$2X+,T;N),.R@'XAL-+^*^H>&OCI\,O"*_%[
MP_=V=[X:UW0_!WB/QP]]XQFT)KI4U9[/79+ZX6,7B6MU% G]HB2VD4LSVHFC
M =_>Y5\OO5V]]$G=VN[*3M97)BGRJ3^?E?;[WIK97:5[NQ^C%>(_M)_\CS:_
M]>"?^C)*^7?@#^UE<?L\S>#]'^.'C;Q?X?M_ 4^MM+92SWOB2_=I;AY;:#6+
MRQ%PK0Z1I%W8BZNKF22W$]["[W+/")&^H/VD)%E\;6;*RLK:>A!!R"/,DK\[
M\5H_\($I+;GC^?W>>^S1])PF_P#A12?:7SMH[>7R3Z-)Z'G]%%%?S ?JA_,O
M1117[(?Z$'V-_P $!/\ E+=\)O\ N,?^F:^K^E*OYK?^" G_ "EN^$W_ '&/
M_3-?5_2E7ZAP3_N,_P#&_P HG\'_ $H/^2JP_P#V#P_].53)\=^/M"^%O@[4
MO$7B;6M)\.^']'@:YO\ 4]3NX[2SLHE^])++(0B*.[,0!7D/P=_;TT+]I?\
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M7XYU^QG_  :8_P#-?O\ N7?_ '*5^F<+?\C2E_V]_P"DL]3Q[_Y(3'?]PO\
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M;QF"QM?*M7"E$_2WXP7+WOP>O)I(9+>2:.!VB?&Z(F2,E3CC(Z5V5<G\<?\
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MNWV2YG[J9[;^RW_PM7_A1VB_\+L_X5]_PLK,_P#:W_"$?;/[#QYS^3Y'VO\
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MRA7O_IMTROTIK\UO^#6C_E'YXP_[*%>_^FW3*_2FOVCA_P#Y%U+T/\Q_%_\
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M:::C=-/5-:IGZ'4445L?R$?F7_P<7?\ -'?^XU_[CZ_,NOTT_P"#B[_FCO\
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M\B+&_P#7FI_Z1(_0ZBBBOHS^&#\R_P#@XN_YH[_W&O\ W'U^9=?II_P<7?\
M-'?^XU_[CZ_,NOTOA_\ W"G\_P#TIG]C>%?_ "2V%_[?_P#3DPK^E+_@@)_R
MB1^$W_<8_P#3S?5_-;7]*7_! 3_E$C\)O^XQ_P"GF^K])X)_WZ?^!_G$_,?I
M0?\ )*X?_L(A_P"FZI]C4445^H'\'A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <'X>_P"3GO&'_8KZ'_Z5ZQ7BO_!2W_F2O^W[_P!MJ]J\/?\
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M_<8_]/-]7V-7[AE/^XT?\$?R1_E?XA?\E5F?_816_P#3DCX&_;5_Y.9\3?\
M;K_Z20UY97J?[:O_ "<SXF_[=?\ TDAKRRO\N_$3_DJLS_["*W_IR1_3W"W_
M ")<)_UZI_\ I""OC.OLROC.NS@G_E]_V[_[<?M'AY_S$?\ ;G_MP5ZU^PQ_
MR=-X7_[>_P#TDGKR6O6OV&/^3IO"_P#V]_\ I)/7Z#0_B1]4?4\7?\B+&_\
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M,N1U&Y2,CD$<54H^ZI+JO^'_ *Z;.S32QCS+26]D_OZ>3ZM>::NFF^)\/?\
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MI?V:?^>7CS_P>C_XU7V?^I.._GA][_\ D3^AO^)H>%?^@?$?^ 4__EIWG_!
M3_E$C\)O^XQ_Z>;ZOL:O$?@!^Q#9?LN?"32? O@7Q]X\T/PKH?G?8;'&EW7D
M>;-)/)^\FLGD;,DKM\S'&[ P  -3PC\._&NK>(/%%OJ'Q(\>6MIIFJ);:9)_
M9^CI]KMS96LK29-@0V)Y9TRN!^[QC*DG]&P-&5'#4Z,MXQ2=O))'\6\59I2S
M/.L9F-!-0K5:DXIVNE.;DD[-J]GK9M7ZL^8/VU?^3F?$W_;K_P"DD->65]I>
M-?V -&^(GB:ZUC6/''CR\U*\V^=-G38]^U%1?E6S"C"J!P.U9/\ P[+\)_\
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M_P 5X3(L15JXN,I*<4ERI/9WUNT?'%8OQ'_Y)YKW_8.N/_135]K?\.R_"?\
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M$_\ H;O'G_?W3_\ Y$H_X=E^$_\ H;O'G_?W3_\ Y$K^#?\ B5WBK_H(P_\
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M_P#!Z/\ XU7WW^I.._GA][_^1/ZE_P")H>%?^@?$?^ 4_P#Y:?E?_P $!/\
ME+=\)O\ N,?^F:^K^E*OB[X ?\$(_@O^RY\6])\=>!=1\>:'XJT/SOL-]_:<
M%UY'FPR02?NYH'C;,<KK\RG&[(P0"/=_B+\._&OA_P /V]QH_P 2/'E]=R:I
MI]M)&=/T>3;;RWL$5Q)A; 'Y('E?/1=F2" 0?LN'<KJX##2HUFFW)O2_9+JE
MV/YI\9./,OXMSJEF.6PG&$:48-344[J<Y77+*2M:2ZWO?0G_ &U?^39O$W_;
MK_Z5PU\#5]]^-?V:[[XB>&;K1]8^)7CR\TV\V^=#Y&CQ[]KJZ_,M@&&&4'@]
MJX#_ (=E^$_^AN\>?]_=/_\ D2OP7QF\&<ZXMSJEF66U:481I1@U.4T[J<Y7
M7+"2M:2ZWO?0K@'C[+\CR^>$Q<)RE*;E[JBU9QBNLEKH^A\AUXS^US_S+_\
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M)\'T5]>?\.R_"?\ T-WCS_O[I_\ \B4?\.R_"?\ T-WCS_O[I_\ \B5_'?\
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M*2M>HGL^VY_/37]*7_! 3_E$C\)O^XQ_Z>;ZN#_XAI?V:?\ GEX\_P#!Z/\
MXU7TI\ /V(;+]ESX2:3X%\"^/O'FA^%=#\[[#8XTNZ\CS9I)Y/WDUD\C9DE=
MOF8XW8&  !]=P[P[B<!B95JTHM.+6C?=/JEV/CO&3QDR7BW):679;2JQG&K&
M;<XP2LH3C9<LY.]Y+I:U]3VZBN3^"LNN/X$,?B*XOKO4K74]2M1<7D$<$US;
MQ7UQ';2,L:(GS0+$V510P(8#FNLK[(_FD**** "BBB@ HHHH **** "BBB@
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MR9K2V7CG_A85BKM;1+>Z=\.O$6L::TMS*(8(1>65C-;F:25E18A)O+.B[<L
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MYCI,]Q\0?V'M)CU:]U&X?4/A!\';.:X2\EANO+_X3B[B&V:-ED1@@ #JP9<
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M6TT'1+"%;>PT:";0](O)8;:%0$AC:XN9Y=B *&E8@#-?6=#C[L)+[48R_P#
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MSXU:-HVN7LUA"D%]I6HV\<7VVWAN;>265[<1PPM#/$[32,L<>XAV0JP'P7X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% ')_"SX#>!O@8-8'@GP7X3\'CQ#>OJ>J
MC0](M]/_ +3NW^]<3^2B^;*W=WRQ]:ZRBBCR **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.#1Y?UW_ "#;?^M;?GIZFY1110 4444 %%%% !1106VC)X ZFANVK **\;\
M?\%%/V??BQXZL?"_A7XZ?!OQ-XFU.4P6>D:5XTTV\OKN0 L4CACF9W8!6)"@
MG /I7J7ACQCI'C:SN+C1=4TW5[>TNY[">6RN4N$AN8)&BGA8H2%DCD1D=#\R
MLI4@$$46=K_U_6J!Z.S_ *W_ ,G]S-*BBB@ HK+B\<:+<>-+CPW'K&EOXBM;
M*/4IM+6ZC-[#:R.\<<[0YWK$SQR*KD;2T; $E2!J4=+_ -=@ZV_KO^04444
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MYGO8/.:=##+#NG=J2?-?722=MO*VY\:_MT?8O^&//V??L/V/_A9'_"8>#/\
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M)\/> O%3Z]JWBB2_:V+QM=:C:Z3;P1QBU4K'(SK(\@8O%Y0W_0'_  HGP/\
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' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>slide151.jpg
<TEXT>
begin 644 slide151.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M'X5^*_%'A5O NL^))M3L)H?B!X@>]FO+KQA(()W9DLM/AO;LRWRQ3GSQ#M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBM9E1H@$E5-R_HO7;4DO9PC%Z6;WONW;7R22>D?>3O%.YR03YGS;K3:W1?\
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M](Y:_"JOYI\=?]^PO^"7_I1_;'T5_P#D58[_ *^1_P#20HHHK\)/ZH"BBB@
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MPY%_Z(N*_-O&#_DC,Q_Z]O\ -'UG O\ R/\ "_XU^3/B^BBBO\Q#^P HHHH
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M2K:_9K6-9%W(TC^83M'E8ZL*^H*_*#_@AM_PK#_AN7XA?\,@?\)U_P ,A_\
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M-$'_ *9=+KO*X/X0?\E!^*G_ &-$'_IETNN\J2@KP/\ X*+?\D3TO_L.1?\
MHBXKWRO _P#@HM_R1/2_^PY%_P"B+BOS;Q@_Y(S,?^O;_-'UG O_ "/\+_C7
MY,^+Z***_P Q#^P HHHH **** "BBB@ HHHH ^T/^"=/_)$]4_[#DO\ Z(MZ
M]\KP/_@G3_R1/5/^PY+_ .B+>O?*_P!//!__ )(S+O\ KVOS9_'_ !U_R/\
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M'@_\:_)GYOXO_P#)&YC_ ->W^:/U/HHHK^VC_,<**** "BBB@ HHHH ****
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MX/\ QK\F?F_B_P#\D;F/_7M_FC]3Z***_MH_S'"BBB@ HHHH **** "BBB@
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M^P HHHH **** "BBB@ HHHH ^T/^"=/_ "1/5/\ L.2_^B+>O?*\#_X)T_\
M)$]4_P"PY+_Z(MZ]\K_3SP?_ .2,R[_KVOS9_'_'7_(_Q7^+]$%%%%?I!\F%
M%%% 'GG[77_)J'Q/_P"Q2U7_ -(Y:_"JOW5_:Z_Y-0^)_P#V*6J_^D<M?A57
M\T^.O^_87_!+_P!*/[8^BO\ \BK'?]?(_P#I(4445^$G]4!1110 4444 %%%
M% !7V3_P0^_Y.O\ $'_8I7/_ *665?&U?9/_  0^_P"3K_$'_8I7/_I995]E
MX>_\E'@_\:_)GYOXO_\ )&YC_P!>W^:/U/HHHK^VC_,<**** "BBB@ HHHH
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MFWC!_P D9F/_ %[?YH^LX%_Y'^%_QK\F?%]%%%?YB']@!1110 4444 %%%%
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MT<*6%Y,AM89),MYD4*+,Z'+.T9V_M%;HT<"+(_F2*H#/C;N/<X[9KX2_8.^
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M$GCV3Q5X:\._#W4=%BM],T%M/O/#GP\TZ5;_ %07,GVF7[;>7*QV&GK,BVX
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M** "BBB@ HHHH ^T/^"=/_)$]4_[#DO_ *(MZ]\KP/\ X)T_\D3U3_L.2_\
MHBWKWRO]//!__DC,N_Z]K\V?Q_QU_P C_%?XOT04445^D'R84444 >>?M=?\
MFH?$_P#[%+5?_2.6OPJK]U?VNO\ DU#XG_\ 8I:K_P"D<M?A57\T^.O^_87_
M  2_]*/[8^BO_P BK'?]?(_^DA1117X2?U0%%%% !1110 4444 %?9/_  0^
M_P"3K_$'_8I7/_I995\;5]D_\$/O^3K_ !!_V*5S_P"EEE7V7A[_ ,E'@_\
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M2%%%%?A)_5 4444 %%%% !1110 5]D_\$/O^3K_$'_8I7/\ Z665?&U?9/\
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M_DC,Q_Z]O\T?6<"_\C_"_P"-?DSXOHHHK_,0_L **** "BBB@ HHHH ****
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M+@_+Z=6+C)4U=-6:U>Z9_)?&]2,\]Q,X--.6ZU6R.\HK@_\ AJCX8?\ 11_
M?_A06G_QRC_AJCX8?]%'\!_^%!:?_'*_1#Y4[RBN#_X:H^&'_11_ ?\ X4%I
M_P#'*/\ AJCX8?\ 11_ ?_A06G_QR@"#]KK_ )-0^)__ &*6J_\ I'+7X55^
MT/[4?[2/P[\0?LS?$6PL/'O@N^OK[PQJ5O;6UOK=M)-<2/:RJJ(JN2S,Q
MR20*_&3^S;C_ )]YO^^#7\Y>-V"Q%?'89T:<I6@]DWU\C^ROHQ9G@\+E>-CB
M:L8-U(VYI)7]WS:(:*F_LVX_Y]YO^^#1_9MQ_P ^\W_?!K\1_LC'_P#/B?\
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M/_PH+3_XY0!S?B;]H'6=&\2:A9Q6NF-':7,D*%XWW$*Q S\_7BJ/_#2>N_\
M/KI/_?J3_P"+KRKQK\<_!-WXRU:6+QAX6DCDO9G1TU:!E<%V((._D&LS_A=?
M@W_H;?#/_@T@_P#BJ_E_'<1<41Q-2-.I5LI.VCVOIT/U3#Y;E3I1<HQO9=?+
MU/:/^&D]=_Y]=)_[]2?_ !='_#2>N_\ /KI/_?J3_P"+KQ?_ (77X-_Z&WPS
M_P"#2#_XJC_A=?@W_H;?#/\ X-(/_BJY/]9.*O\ GY5^Y_Y&W]F93_+#[_\
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M92DY*2MS*VENFB/C>)\/A:-6"PJ25G>WJ=Y17!_\-4?##_HH_@/_ ,*"T_\
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M$^(O#7A;PIXQUFSM96L;"/PE=#489;ELE8A= O NX@G(7+\BNQO?V?O&;?\
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145)04444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>slide161.jpg
<TEXT>
begin 644 slide161.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M//FQRL2GZ%R-H_B9?Q\^)7Q+USXO^-]0\1>(M0GU36-4E,L\\IZ]@JCHJJ,
M*,    8K\C\1O$B&3Q> RYIXE[O1JFN[6SD^B>V[TLG_ $)X-^"]3B.:S;.(
MN.#B]%JG5:Z)JS4%UDM7M%WNX_=__#^;_JE/_ES?_<E'_#^;_JE/_ES?_<E?
MGG17XE_Q%;BG_H*_\DI__('].?\ $!.!/^@'_P JUO\ Y8?H9_P_F_ZI3_Y<
MW_W)1_P_F_ZI3_Y<W_W)7YYT4?\ $5N*?^@K_P DI_\ R ?\0$X$_P"@'_RK
M6_\ EA^AG_#^;_JE/_ES?_<E'_#^;_JE/_ES?_<E?GG11_Q%;BG_ *"O_)*?
M_P @'_$!.!/^@'_RK6_^6'Z&?\/YO^J4_P#ES?\ W)1_P_F_ZI3_ .7-_P#<
ME?GG11_Q%;BG_H*_\DI__(!_Q 3@3_H!_P#*M;_Y8?H9_P /YO\ JE/_ )<W
M_P!R4?\ #^;_ *I3_P"7-_\ <E?GG11_Q%;BG_H*_P#)*?\ \@'_ ! 3@3_H
M!_\ *M;_ .6'Z&?\/YO^J4_^7-_]R4?\/YO^J4_^7-_]R5^>=%'_ !%;BG_H
M*_\ )*?_ ,@'_$!.!/\ H!_\JUO_ )8?H9_P_F_ZI3_Y<W_W)1_P_F_ZI3_Y
M<W_W)7YYT4?\16XI_P"@K_R2G_\ (!_Q 3@3_H!_\JUO_EA^AG_#^;_JE/\
MY<W_ -R4?\/YO^J4_P#ES?\ W)7YYT4?\16XI_Z"O_)*?_R ?\0$X$_Z ?\
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M !'SCS_H._\ *5'_ .5A_P 0SX;_ .@;_P GJ?\ R9]3?\/+?^I*_P#*Q_\
M:*/^'EO_ %)7_E8_^T5\LT4?\1\X\_Z#O_*5'_Y6'_$,^&_^@;_R>I_\F?4W
M_#RW_J2O_*Q_]HH_X>6_]25_Y6/_ +17RS11_P 1\X\_Z#O_ "E1_P#E8?\
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M=]X>_P""<OA7P-XK^,5E\1/$.OQZ=\,;6RU*VO='2)6U"VG$CG,4BM^\94"
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M<FK;FU66<[I+V2<0 "4L%(_=G;F3!&_Y?F&[:)[J1H$DCA+DQI(X=E7/ +
M$@=P!GT'2ODN*JV55'1_LOETC:=HRC>?62YOL2TY%HXV=TKZ_H'!.'SVG6Q3
MSE2Y92O2YIPERT^:5HOE^VM'*6J<7!*3<9-QT445\D??GZ/_ +:O_)S/B;_M
MU_\ 22&O+*]3_;5_Y.9\3?\ ;K_Z20UY97YOXB?\E5F?_816_P#3DC^3>%O^
M1+A/^O5/_P!(1]A:YKOBS2?AOX#7P]X]\'^$;=M!MS+!K%Q#').VP?.HDB<[
M<<<$<UY9\%/@QI_QXNM2U;Q!-XHU75-0U)T8:+:)%#&3\\D\L\J"  D\(IW=
M,*<@#@OBM\6O^%G:7X9MO[/^P_\ ".:8FF[O/\S[1M_CQM&W/IS]:Z#X>?M(
MP>#OAE;^';_PS::T--U#^T]/FDO)(4AG'W6D1/\ 6@$G@L!CCL#7ZMBN..'\
MWXBYLVJ.6#I1?(JDJTX2DU37NT[2]DU%3L^1Q;M=+24?CZ/#N8X++I/!Q2KS
MEJXJFI*/-)W<KKG7PNW,G;9]'I>-?V;M+\.P_$*QL[^^N]:\&2V]S"C% EQ9
M2JK,2NW.^/=RP(!XX&:O0?LOZ&/&BZ==:EJ5K:^'_#\>L^)92R/)%(5#F&%=
MORD+SEMW7\#A#]IK9\>]2\:+H8:TUBW-K>Z7+>;UFC,2QE?,V#'**WW3C&*H
M^%_VD-2T'XJ:]XCN;.'4[;Q-YL6HZ?/(=DT#G/EANVU0%!P<#M7C1S'@98B#
M]FK.K.+]VHXJG!U72J/3F:GST5.*]_EI3O&\TGV+"\1NC;F?-[-2WC?VCC",
MH=M+3DG\/-):V6F_-\ O"_BS3O#.O^%K[7I/#NJ:U%HFH0:BL2WMK(S#YU9!
ML*E2.QP2.N2%V'_9Y^'NI?&N'P+I^L>)EU.&\87EQ<>0+=XEC9S%%@!C-]U=
MS#;PYP> >5U;]I.VB_X1RQ\/^&;?P_X=T#4TU9]/2]>XDO;A6SN>9ESC;P!@
MX]P% QI?C3#<?&V]\77'A_2]0MM0N'EFTN_5;F(HW50S+PPZAMO![$9!N><\
M&4:E*,*-*I>K2]J^6JH\BIQ]HZ=US1A*HGHX\ZUM!1?*$,#GU2,FYSBE"IR+
MF@Y<S?N*=G9M*_7EV3E?4Z']I/X#Z/\ "/2]-N--7Q19W%S*T4UIJ\"28&"0
MZ3PCR3T^X&+#() Z4S]B'_DY/0O^N=S_ .D\E0?&C]I/_A:7@JQ\/V.CS:3I
MEG<_:V%SJLVI3.X4JH$DO*H 3\HR.F,<YYGX(?%'_A37Q)L?$7V'^TOL2RK]
MG\[R=^^-D^]M;&-V>G:O-CG'#N!X\PV99=-1P=.I2DY*,TE91YVDXJ3UO=J$
M;N_+"*LCLI8+-*_#M?"XQ-UY0J))N-W=-15TVE\Y2LMY'LGP6^-&N?'[XDW7
M@KQE);Z]HFJ17"JLEI%&UFZ*S+(C(JD,,$9.2"1C%7-#\)_\+K^'/PED;_2)
M-"UJ31[UP<_ND_>\\]/+A7_OKWKS]/VDM!\)0WUQX-\"6OAO7+Z)H#J4NJS7
MSPH_WC&C@!6/]X?D15/X*?M,W7P:\"Z]HL>F_;O[5W/:S&X\O[!*T;1F0+L;
M<<%>,C[N.]?6Y1QQE%-4<#G^-^M^[)U*J567,X5:5:C3YJD(U96]G4C>4>6*
MJVO9,\'%</8[EGB<MP_L6G#DA>"U<9PG.T9."NIIZ.\N357L>TW,5O\ M$?$
M_P"'OBR&-/)L]8O;*Z8C*A;=FN+<'CN@SSZ_G-X5^(6N>+/A#XFUW0?$^A>%
M[J_\7SM'?:M+'' 8/*0+'ET<;MH3'&?E/->'_!G]IBZ^#W@#7]#BTU;UM6#-
M:W!N?+-A*T1C+A=IW?PG@K]WKSQ@K\6=OP*;P5_9_P![5_[5^V>?_P!,PGE^
M7M_'.[\*ZH>*F6TL/]9IU9>WK4ISJ\O/3;Q#C0II1G%75U2G4YD[+VC5UL92
MX,Q4I_5^1>RIRA&%^62]GS2G)N+>MFXQL]^79GH?[35XOQ,E\)Z;87%EXR\;
MVMK+_:UYH-OYT=R/E* &-?GV@-G P.>%S@8?P4^#\FA>*IM<\::7?Z;H_ASR
MIY+:[@:"2]G=ML$*JP!(9QDG&,*<]:\ST+Q#J'A?45O-,OKS3KR,%5GM9FAD
M4$8(#*0>17;^$/VJO'W@UF$'B2^N(YI5EF^UA+J23&!C?*KL!@8P#@=<5\%E
M_%F18S/_ .WL\A.-3F4K1C&I!.,5&#DI3C*;32E4;E[[NVO>:/IZN2YCALO_
M +/RZ47&SUDW&7O2;DHN,6HJS:C9>[IV/;_$>I:7X=_;>\1ZMJVK6&C0Z7HP
MDAN+EE.V5K>-%V(3F1@&8[5R3C'>I/#OA/5/'?QH\$ZUKWB2S\>>')+2[NM+
MNCIJ6>)8U&5>(*.C;2,D\H>!BO-];_;6U+7_ (E76JW6CV]SH-]8-ILVC33!
ME,+@;P)E16R6!.2#@,1Z$9<_[5MUIGB_PQ=Z!HEKHNB^%$DCM-+,[7 =9>)M
M\K ,2V>#C@\\G.?TS_B(/"\:U2;Q,I4WBYUE%1K1;<\1S\\X<SHU*<:>L>:*
MK*<8^[%71\='A?.'2A%4E&HJ"IW;@TDJ<HV4K*I&;DU?E;A9N[=D;GQ@\27'
MQD_9?TKQ=K7V:77K/79-/%RL2QO);LC.(_E !"G&/H3U))\)KT+XM_'.W\?>
M%=/\/Z+X?M_#.@V-Q)>FU2Z:Z:6X?=ER[ ' #$!<<9/., >>U^'\>9MA\PS.
M->A4]JU3I1G4M)>TJ1IQC.?OI3=VOBFE*5KM:GZ'PU@:N%PDJ=2'LTYR<873
MY(MW4?=;CYV3:5["H[1L&4E64Y!':OMO]B?XW:[\5?"5U9:U:W-PVCA8TU4_
M=N1VC<]Y ,'(SD8)P>6^;OV</V<-1^//B+)\RST&S<?;+S'7OY<>>"Y'X*#D
M]@?N_P (^$=.\">';72=)M8[.QLTV11(.GJ2>I)/))Y).:_?OHV\&Y['%O/_
M &CHX1IQY?\ G\^FC^S%Z\^][QCO*WYGXLY]ESH++.53KIWO_P ^_GW:^SVU
M?0TJ***_M(_G\**** "BBB@ HHHH **** "BL#XH?$:Q^$W@6^\0:E%=36>G
M^7YB6RJTK;Y%C& S*.KCJ1QFO(O^'BW@G_H%^*O_  &@_P#CU?(Y]QYP_DF(
M6%S7%0I5)14DI-W<6VD]MKIKY'N9;PWF>84G6P5&4XIV;7>R=ON:/?**\#_X
M>+>"?^@7XJ_\!H/_ (]1_P /%O!/_0+\5?\ @-!_\>KQ?^(P<&?]#&G][_R/
M0_U%S_\ Z!9_A_F>^45X'_P\6\$_] OQ5_X#0?\ QZC_ (>+>"?^@7XJ_P#
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M5HK\P_X@5@/^@J?W1/W+_B:C-?\ H!I_^!2/PJ_X9%^+'_1,/B'_ .$Y>?\
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M_ 8A_P 1GQO_ $#1^]GYN_\ "C/&W_0G>*O_  4S_P#Q%'_"C/&W_0G>*O\
MP4S_ /Q%?I%11_Q*ME7_ $'5/_ 8A_Q&?&_] T?O9^;O_"C/&W_0G>*O_!3/
M_P#$4?\ "C/&W_0G>*O_  4S_P#Q%?I%11_Q*ME7_0=4_P# 8A_Q&?&_] T?
MO9^;O_"C/&W_ $)WBK_P4S__ !%'_"C/&W_0G>*O_!3/_P#$5^D5%'_$JV5?
M]!U3_P !B'_$9\;_ - T?O9^;O\ PHSQM_T)WBK_ ,%,_P#\178_!+]D/Q-\
M2/%JP:QIFJ>'])M\/=7%W:O [K_<B#@;F/KR%ZGL#]XT5WY9]%_(\/BJ=?$X
MFI5A%W<&DE*W1M:V?6VMM+K<Y<9XQ9C5HRIT:,82:LI7;:\TGI?M<S?"/A'3
MO GAVUTG2;6.SL;--D42#IZDGJ23R2>23FM*BBOZ6H4*="G&C1BHQBDDDK))
M:))+1)+9'Y)4J3J3=2HVVW=MZMM]6%%%%:D!1110 4444 %%%% !1110!Y9^
MVK_R;-XF_P"W7_TKAKX&K[Y_;5_Y-F\3?]NO_I7#7P-7\&_2B_Y*K#_]@\/_
M $Y5/Z4\'/\ D2U?^OLO_2(!113[>+[1<1QYV[V"Y],U_.-.G*I-4X;MV7JS
M]8VU&45ZQ\7_ -E.^^$OQ#\/Z/)J7V[3_$4\=O#J"VOEB-V<(RE-QY7<&QNY
M![<XY3QS\(]0\-?%74O"NF1WFOWFGRF-?LMHQDF 4,2(U+$8!]3TKZ+-.#<Y
MRZ<Z6,P[C*%3V35TWSN/,DDFV[QU35XM;,\?!9_E^+C&>'JIJ47-/5+E3LV[
MI6LW9IV?D<E16L/ >N'Q+_8O]BZM_;&,_8?LDGVG&W=_J\;ON\].G--UCP-K
M?A[2[>^U#1]4L;*Z($%Q<6DD44V1D;68 -D<\'I7BRR[%J$JCI2Y8MIOE=DT
MTFF[:--I.^S:/0^M46U%35WJM5K?:W>YET445QG0%=5\#/\ DMG@[_L.67_H
M]*Y6NJ^!G_);/!W_ &'++_T>E>QP[_R-<+_U\A_Z4CAS3_<JW^&7Y,_2*BBB
MO];#^(0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P""J5]\ -.;5OCE\-U^'/A_5/!>H^.M GTOQ"-=NI[:P2&6YL;V(V]NEKJ
MCN8"D<,MS"Y$P\\>6"_*_#/_ (+=^&_%S>)K*\/P=UG7=/\ !FJ>--(L? 'Q
M4M?%PN(]/@$T]G?M':PM8W!5D*E4N(6"S8E)C"OM^%O^"9VN?M'_  WTF/\
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M9^S]X,T*Q^&?Q=M/#.JR> ].\ >*K^^\)?VDNKV]BLJVM_9Q?:XQ97T:W%P
MTC74)#H'AD\L$XU(SEAI+[;22]>6=VWTU<;J.S2LVKG13E"->3TY;IJ_;FU7
MG:.S>_6*>_E/P]_X+;Q^#_@1\'](\0:]\(;OXFZI\+M \;>*[OXA_$.T\ V]
MW)?VV52R'V29;BY=XIG:-8X88E:+,B^8JCUJS_X*?ZM^TAX<CN?V?_ MGX\A
MA\$6WC76;C5/$2Z/-ID-[YXM+2T5;>YAO+YC:W1,;RP6X\N/-QME#+)\*O\
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M +#EE_Z/2O@N'?\ D:X7_KY#_P!*1]/FG^Y5O\,OR9^D5%%%?ZV'\0A1110
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MI6;;;Y)72;O*VI_PL'0?^@YH_P#X&1_XT?\ "P=!_P"@YH__ (&1_P"-9_\
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MKHXNNJ^!G_);/!W_ &'++_T>E<K75? S_DMG@[_L.67_ */2OB.'?^1KA?\
MKY#_ -*1]#FG^Y5O\,OR9^D5%%%?ZV'\0A1110 4444 %%%% !1110 4444
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M.20E0G4C^]DWJGLX0:Z/^?1V=DD[C+*RATVSBM[>*."WA0)''&H544<  #@
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M1V,2M&PB8@@A<@@\Y%=W398EGB9'571P596&0P/4$4 8/_"J/"W_ $+7A_\
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M.%Z%201W!(KNZ;)$LR[656&0V",\@Y!_ @&@#!_X51X6_P"A:\/_ /@NA_\
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MC[Q!\/WUF\(:\U6#3KUHK:>X8*H><V[0AW ^=E+'YF(KYBU[Q)XR_: _8_\
MVFOVD;?XD?$/0?&_PS\0>*!X'M-*\47UIH&D6GAR:5(K>?2T=;.]%R]K,9VN
MX979;@JK($CV?7/[&G[-WC+]D;X,Z/H,S>&?%GB+Q5XGU/Q1X\U3[=/IL-O=
M:C//>7#6$/D3-<+'-)'"B320DQ+O,@8>6?%O'_\ P3[^,>E_#3XU?!GP-J'P
M]3X3_'+6M2U.?Q%JNJWT>O\ A"#6'SJUO!8);/!?$EKAX)'N[8*UP Z.(LR3
M555R]U^_[/E4NGM?W5Y>2TF^:UK7CUY75.5)23DOW?M>9JW_ "Z_>6C;T<%R
M[WL[:7/L'X&_$<?&+X*>#_%RQ1P#Q5HEEK C0DK']H@27:,@' WXY -=36=X
M0\+V?@?PGI>BZ?&8[#1[2*QMD/\ #%$@1!^"J*T:Z,1*#JR=)6C=V]+Z?@<N
M'C-4HJKK*ROZVU_$****Q-@HHKF?BW\%O!OQ_P#!<WAOQYX2\,^-O#MQ(DTN
MEZ]I<&I64KH=R,T,RLA93R"1D'D4G?H"MU/F7_@J$?'?B?XH? OPOX9\,_&S
MQ)X4O-:U/5O%EO\ #;5Y=!O;RWMM/>.WM9M36]L([9'N+I)=LEW'YOV4JHD8
M!:]0_8.\:>"_$7PRUS2?"8^(6GWWA76YM,\1Z)XY\1WVO:]X?U'RXI&MI[F[
MN[PLIBDAD0P7$D#+(&C8[B:H^*/V=_%7[.MOX57]F_0?A?X9\*Z*][_:WP\>
MTA\,:)K;7 CV7:WEG8W$MM/ Z$[4@9)A*P?:51Q1_9H_9I\:?L[6GQ(\9&R\
M)ZU\2OC%XO@\2Z_IW]MW%MI&D0B"ULOLUM=?8WDN#!:V^Y7>VA-Q(2&$"L"C
MHZ.4>C7H^;F@DO./+=WU2:3;B[Q%6NU&75.W=<MIMO\ Q<S2[M-JS237DMCX
M6U;_ (*!?M<_M*:3JOC[XD>$])^#UQ8>$?"5OX1\6ZAX?2PO9M+BO[C4IUM7
MC6\F\RYA5$NA/ JV^!$?,DW^U?\ !+?]I36OVOO^"?'PH^(WB22VF\1^)-#1
MM5FMXO*CN+N)W@FD5  %WR1,VU1M&[ X KB?'/[,?QG^"_[0OQ;\8?!1?AOK
M%G\;+6TN-2A\7:U?Z:_AC6+:T%DE] MO:W(O(9(5A+V[-;,&M^)L2_N_:OV/
MOV;M/_8^_9<\!_##3+Z;5+/P/HMOI0OIHA%)?/&@\R=D!(4R/N?:"<;L9/6C
M#Z4;/M#_ ,"2G[1KM>33OI=./\MHNI9U+^<O_ 7R\J;ZV6GDU)Z<WO>D4444
M %%%% !1110 5Y/^WA\?;S]E?]BKXK?$C3HK>?4O _A34=:LXYP3$\\%N[QA
M@!DKO"Y'I7K%<=^T-\%-+_:2^ WC/X>ZY)<1:/XWT2\T.\D@;;+'%<PO$S*?
M[P#Y'N*Y\9&I*A.-+XFG;IK;37IJ=&%E"->$JOPW5^NE]=.I\37&F^)/V(-7
M_9/\:1?$CXC^*]2^+WB>R\'>/H/$GBF^U;3M<EU33KBY%U;V<SO;Z?)#=P*8
MULH[>,1R/&RE-NS]"J^-? '['OQL^(OBWX%:;\6KKX:P>$OV?[S^UK?4/#NI
MWM[J/C?4(+&6PLIY[6>UBCTY%CGEGDC2>\)EV*KJJEF^RJ]"O*#<N39SDX]+
M0?+RJVEM>9VZ)K;9>?0C-1@I[J$5+K>:<KN_7W7%7ZV"BBBN<Z HHHH ****
M !FVJ3SQSQ7YH?L7^,Y_"B^%_'O[0'AG]J[PGKGC+QK=O:>)/$7CO4['PI;W
M-]JL_P#9>F/H<6L%[>$(\%LHNM,B@9E7<=LB%_TMG1I8757:-F4@.H&5/J,Y
M''N*^//&_P"R+\</VE_!/A/X9?%W5/ >L>#O"OB73/$.H>-M.U*:/7O%XTV^
M2\MX9=)2PBM;%I7CB$LD5Y* (VV(/,'EE/2O%^<4_*+DN=I]TM5W>REJ@J:T
M91\FUYR47RIKLV[/IU;6C.U_X*P?'_Q)^SG^Q3K>K>#]2&B^*-=U;1_"VF:G
MY:R-IDNIZE;6)N45E93)$L[.H=2NY5R".#Y[H.EWG[#?_!2/X/\ PYT+QC\0
M/$7@GXS>%==2^T_Q?XLU'Q--;ZGI M9XKV">^DFEA:6&XF26))%A;9&PC5ER
MWKG[8O[-'B#]M3]GSQ[\/]3DT?P>9KVROO".MV=]-J,JW-G+!>6US=VQA@$>
MR[A"F&.64/&N?,1FVIR_PL_9W^+'Q2_:]\+_ !<^,EK\//#<OP[\,7N@^']#
M\(ZW>:W%<W>H20->W\]Q=6=H8@([6&..!(G(#RLTS?*H,/I.[[MOMRNFU%6Z
MM3N[6NFXM_#>)6LXV^7GS*2NT^BY;:]4I*[YK/Z>HHHH **** "BBB@ HHHH
M ^)_VK/'?QL\-?\ !4W]FNQF\4:'H/P=\0>)-5TV'0-':X;4/$4B>';^X-QJ
M<S;$6.*5 (K6-9%) F>0L(TBHV/A;5O^"@7[7/[2FDZKX^^)'A/2?@]<6'A'
MPE;^$?%NH>'TL+V;2XK^XU*=;5XUO)O,N851+H3P*MO@1'S)-_NG[3'[,^O?
M&;]IO]GOQII=WI-OI?PG\1ZGJ^KQ74LBW%S%<Z/>6,:VX5&5G$MPA(=D 4,0
M2<*?/_'/[,?QG^"_[0OQ;\8?!1?AOK%G\;+6TN-2A\7:U?Z:_AC6+:T%DE]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
